PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Carey, JR; Liedo, P; Muller, HG; Wang, JL; Vaupel, JW				Carey, JR; Liedo, P; Muller, HG; Wang, JL; Vaupel, JW			Dual modes of aging in Mediterranean fruit fly females	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; LIFE; MORTALITY; FLIES; RATS; DIET; AGE	The life history of medflies is characterized by two physiological modes with different demographic schedules of fertility and survival: a waiting mode in which both mortality and reproduction are low and a reproductive mode in which mortality is very low at the onset of egg laying but accelerates as eggs are laid. Medflies stay in waiting mode when they are fed only sugar. When fed protein, a scarce resource in the wild, medflies switch to reproductive mode. Medflies that switch from waiting to reproductive mode survive longer than medflies kept in either mode exclusively. An understanding of the physiological shift that occurs between the waiting and reproductive modes may yield information about the fundamental processes that determine longevity.	Univ Calif Davis, Dept Entomol, Livermore, CA 95616 USA; Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA; Colegio Frontera Sur, Tapachula 30700, Chiapas, Mexico; Univ Calif Davis, Div Stat, Livermore, CA 95616 USA; Max Planck Inst Demog Res, D-18057 Rostock, Germany; Odense Univ, Sch Med, DK-5000 Odense C, Denmark; Duke Univ, Sanford Inst, Durham, NC 27706 USA; Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; El Colegio de la Frontera Sur (ECOSUR); University of California System; University of California Davis; Max Planck Society; University of Southern Denmark; Duke University; University of Southern California	Carey, JR (corresponding author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Livermore, CA 95616 USA.	jrcarey@ucdavis.edu	Liedo, Pablo/E-9313-2010	Liedo, Pablo/0000-0002-0004-1721; Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [AG-08761] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIGAKI T, 1984, EXP GERONTOL, V19, P267, DOI 10.1016/0531-5565(84)90022-6; Audesirk T., 1996, BIOL LIFE EARTH; BALL ZB, 1947, AM J PHYSIOL, V150, P511, DOI 10.1152/ajplegacy.1947.150.3.511; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BOULETREAU J, 1978, OECOLOGIA, V35, P319, DOI 10.1007/BF00345140; Carey JR, 1998, FUNCT ECOL, V12, P359, DOI 10.1046/j.1365-2435.1998.00197.x; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CAREY JR, 1986, ENTOMOL EXP APPL, V42, P159, DOI 10.1007/BF00343543; CAREY JR, 1997, ZEUS SALMON BIODEMOG, P127; CAREY JR, 1985, OIKOS, V44, P257; DEPAOLA LV, 1994, MODULATION AGING PRO, pCH10; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Finch CE, 1990, LONGEVITY SENESCENCE; HOLEHAN AM, 1985, MECH AGEING DEV, V33, P19, DOI 10.1016/0047-6374(85)90106-X; HOLLIDAY R, 1989, BIOESSAYS, V10, P4; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; Lotka AJ, 1907, SCIENCE, V26, P21, DOI 10.1126/science.26.653.21-a; Masoro EJ, 1996, J GERONTOL A-BIOL, V51, pB387, DOI 10.1093/gerona/51A.6.B387; MASORO EJ, 1988, J GERONTOL, V43, pB59, DOI 10.1093/geronj/43.3.B59; MERRY BJ, 1979, J REPROD FERTIL, V57, P253, DOI 10.1530/jrf.0.0570253; Muller HG, 1997, P NATL ACAD SCI USA, V94, P2762, DOI 10.1073/pnas.94.6.2762; Muller HG, 1997, BIOMETRIKA, V84, P881, DOI 10.1093/biomet/84.4.881; Partridge L., 1986, P45; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; ROITBERG BD, 1989, EVOL ECOL, V3, P183, DOI 10.1007/BF02270920; TATAR M, 1995, ECOLOGY, V76, P2066, DOI 10.2307/1941681; TULJAPURKAR S, 1989, THEOR POPUL BIOL, V35, P227, DOI 10.1016/0040-5809(89)90001-4; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; VISSCHER MB, 1952, AM J PHYSIOL, V170, P72, DOI 10.1152/ajplegacy.1952.170.1.72; Wachter K. W., 1997, ZEUS SALMON BIODEMOG, P1; Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	33	126	131	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					996	998		10.1126/science.281.5379.996	http://dx.doi.org/10.1126/science.281.5379.996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703516				2022-12-24	WOS:000075412700049
J	Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N				Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N		DECODE Study Grp	Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; MEN; PREVALENCE; POPULATION; FINLAND; NIDDM	Objective: To evaluate the impact of the revised diagnostic criteria far diabetes mellitus adopted by the American Diabetes Association on prevalence of diabetes and on classification of patients. For epidemiological purposes the American criteria use a fasting plasma glucose concentration greater than or equal to 7.0 mmol/l in contrast with the current World Health Organisation criteria of 2 hour glucose concentration greater than or equal to 11.1 mmol/l. Design: Data were collected from 13 populations and three occupational based studies from eight European countries. Ail studies used a 75 g oral glucose tolerance test to measure fasting and 2 hour glucose concentrations. Subjects: 17 881 men; 8309 women; age range 17-92 years. Main outcome measures: Classification of diabetes according to both sets of criteria. Results: The application of the American criteria on European populations induced changes in prevalence of diabetes ranging from a reduction of 4.0% to an increase of 13.2%. A total of 1517 previously undiagnosed individuals had diabetes according to either the WHO or the American criteria. Among 1044 with diabetes according to American criteria, only 45% had 2 hour values fulfilling the WHO criteria. The risk of disagreement of classification decreased with increasing body mass index (P < 0.00001) and increasing age (P < 0.0001); the impact of sex was not significant (P = 0.08). Conclusions: This shift in strategy from using 2 hour to fasting plasma glucose will cause an increase in the prevalence of diabetes in some European populations. A high degree of disagreement in the classification was observed between the two recommendations. Prospective data are needed to evaluate whether the WHO or the American criteria best identify individuals at risk of developing microvascular complications and cardiovascular disease. Wider implementation of revised diagnostic criteria should await prospective data.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Steno Diabetes Center	Borch-Johnsen, K (corresponding author), Steno Diabet Ctr, Steensens Vej 2, DK-2820 Gentofte, Denmark.	kbjo@novo.dk		Eriksson, Johan/0000-0002-2516-2060				[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; FESKENS EJM, 1994, ARTERIOSCLER THROMB, V14, P1641, DOI 10.1161/01.ATV.14.10.1641; FONTBONNE A, 1992, DIABETES, V41, P1385, DOI 10.2337/diabetes.41.11.1385; GARANCINI MP, 1995, DIABETOLOGIA, V38, P306, DOI 10.1007/BF00400635; Gavin JR, 1997, DIABETES CARE, V20, P1183; HAGERUP L, 1987, SYGDOM SUNDHED BEFOL; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HITUNEN L, 1994, DIABETIC MED, V11, P241; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; Kangas T, 1996, DIABETES CARE, V19, P494, DOI 10.2337/diacare.19.5.494; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; Lindberg O, 1997, J AM GERIATR SOC, V45, P407, DOI 10.1111/j.1532-5415.1997.tb05163.x; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; MOOY JM, 1995, DIABETES CARE, V18, P1270, DOI 10.2337/diacare.18.9.1270; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pajak Andrzej, 1995, European Heart Journal, V16, P143; PYRALA K, 1979, J CHRON DIS, V32, P45; RAJALA U, 1995, SCAND J PRIM HEALTH, V13, P222, DOI 10.3109/02813439508996765; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; STENGARD JH, 1993, DIABETES METAB, V19, P121; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; World Health Organization, 1980, WHO TECHN REP SER, V646, P1; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	31	346	351	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1998	317	7155					371	375						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694750				2022-12-24	WOS:000075409600021
J	Scolding, N; Franklin, R				Scolding, N; Franklin, R			Axon loss in multiple sclerosis.	LANCET			English	Editorial Material							RETINAL GANGLION-CELLS; DISABILITY; LESIONS; CULTURE; MRI		Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England; MRC, Cambridge Ctr Brain Repair, London W1N 4AL, England; Univ Cambridge, Dept Vet Med, Cambridge CB2 1TN, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Scolding, N (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England.			Franklin, Robin/0000-0001-6522-2104				BARNES D, 1991, BRAIN, V114, P1271, DOI 10.1093/brain/114.3.1271; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FRIESEN L, 1974, ARCH OPHTHALMOL-CHIC, V92, P91; Greenfield JG, 1936, BRAIN, V59, P445, DOI 10.1093/brain/59.4.445; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; MATTHEWS WB, 1979, J NEUROL SCI, V40, P11, DOI 10.1016/0022-510X(79)90004-2; MCDONALD W I, 1986, P112; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; RAINE CS, 1989, LAB INVEST, V60, P714; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; Scolding N, 1997, CURR OPIN NEUROL, V10, P193, DOI 10.1097/00019052-199706000-00005; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380510	17	57	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					340	341		10.1016/S0140-6736(05)60463-1	http://dx.doi.org/10.1016/S0140-6736(05)60463-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717917				2022-12-24	WOS:000075110500005
J	Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK				Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK			A viral mechanism for inhibition of the cellular phosphatase calcineurin	SCIENCE			English	Article							SWINE FEVER VIRUS; TRANSCRIPTION FACTOR NFAT1; NF-KAPPA-B; CONSTRUCTION	The transcription factor NFAT (nuclear factor of activated T cells) controls the expression of many immunomodulatory proteins. African swine Fever virus inhibits proinflammatory cytokine expression in infected macrophages, and a viral protein A238L was found to display the activity of the immunosuppressive drug cyclosporin A by inhibiting NFAT-regulated gene transcription in vivo. This it does by binding the catalytic subunit of calcineurin and inhibiting calcineurin phosphatase activity.	AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Dixon, LK (corresponding author), AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England.		Goatley, Lynnette/ABI-1426-2020; Dixon, Linda K/B-9063-2019	Goatley, Lynnette/0000-0001-6792-2235; Dixon, Linda/0000-0003-3845-3016				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; DavisPoynter NJ, 1996, IMMUNOL CELL BIOL, V74, P513, DOI 10.1038/icb.1996.84; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HARPER JW, 1993, CELL, V75, P805; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MISKIN JE, UNPUB; Neilan JG, 1997, VIROLOGY, V235, P377, DOI 10.1006/viro.1997.8693; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RODRIGUEZ JM, 1992, VIROLOGY, V188, P67, DOI 10.1016/0042-6822(92)90735-8; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	17	112	118	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					562	565		10.1126/science.281.5376.562	http://dx.doi.org/10.1126/science.281.5376.562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677199				2022-12-24	WOS:000075012300041
J	Gordon, LK; Levin, LA				Gordon, LK; Levin, LA			Visual loss in giant cell arteritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; BIOPSY FINDINGS; PROGNOSIS; DIAGNOSIS		Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Levin, LA (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 600 Highland Ave, Madison, WI 53792 USA.							ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALBERT DM, 1976, ARCH OPHTHALMOL-CHIC, V94, P2072; Boehme MWJ, 1996, AM J MED, V101, P387, DOI 10.1016/S0002-9343(96)00230-6; Cornblath WT, 1997, OPHTHALMOLOGY, V104, P854, DOI 10.1016/S0161-6420(97)30222-X; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; Fineman MS, 1996, AM J OPHTHALMOL, V122, P428, DOI 10.1016/S0002-9394(14)72073-2; Font C, 1997, BRIT J RHEUMATOL, V36, P251; Ghanchi FD, 1997, SURV OPHTHALMOL, V42, P99, DOI 10.1016/S0039-6257(97)00052-0; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; JONASSON F, 1979, SCOT MED J, V24, P111, DOI 10.1177/003693307902400203; Lauwerys BR, 1997, J RHEUMATOL, V24, P1570; Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; MELBERG NS, 1995, OPHTHALMOLOGY, V102, P1611; Myklebust G, 1996, BRIT J RHEUMATOL, V35, P1161; RodriguezValverde V, 1997, AM J MED, V102, P331, DOI 10.1016/S0002-9343(97)00117-4; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; Schmidt WA, 1997, NEW ENGL J MED, V337, P1336, DOI 10.1056/NEJM199711063371902; SLAVIN ML, 1994, AM J OPHTHALMOL, V117, P81, DOI 10.1016/S0002-9394(14)73018-1; Sorbi D, 1996, ARTHRITIS RHEUM-US, V39, P1747, DOI 10.1002/art.1780391019; Sudlow C, 1997, BRIT MED J, V315, P549, DOI 10.1136/bmj.315.7107.549; Wagner AD, 1996, AM J PATHOL, V148, P1925; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105	25	36	37	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					385	386		10.1001/jama.280.4.385	http://dx.doi.org/10.1001/jama.280.4.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686559				2022-12-24	WOS:000074804200044
J	Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L				Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L			Survival in treated hypertension: follow up study after two decades	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PREVENTION; GOTEBORG; SWEDEN; LIPIDS; DEATH; TRIAL; MEN	Objective: To compare survival and cause specific mortality in hypertensive men with non-hypertensive men derived from the same random population, and to study mortality aid morbidity from cardiovascular diseases in the hypertensive men in relation to effects on cardiovascular risk factors during 22-23 years of follow up. Design: Prospective, population based observational study. Subjects and methods: 686 hypertensive men aged 47-55 at screening compared with 6810 non-hypertensive men. The hypertensive men were having stepped care treatment with either beta adrenergic blocking drugs, thiazide diuretics, or combination treatment. Mortality, morbidity and adverse effects were registered at yearly examinations and from death certificates. Main outcome measures: All cause mortality and cause specific mortality. Results: Treated hypertensive men had significantly impaired probability of total survival as well as survival from coronary heart disease and stroke. All cause mortality as well as coronary heart disease and stroke mortality were very similar in hypertensive men and normotensive men during the first decade, but increased steadily thereafter despite continuous good blood pressure control. Smoking, signs of target organ damage, and high serum cholesterol levels, but not blood pressure at screening, were significantly related to the incidence of coronary heart disease during follow up. In time dependent Cox's regression analysis, the incidence of coronary heart disease was significantly related only to serum cholesterol concentrations in the study. Cancer mortality was almost similar in treated hypertensive men (61/686, 8.9%) and non-hypertensive men (732/6810, 10.8%). Conclusion: Treated hypertensive men had impaired survival and increased mortality from cardiovascular disease compared with non-hypertensive men of similar age. These differences were observed during the second decade of follow up. During an observation period of 22-23 years-about 15 000 patient years-hypertensive men receiving diuretics and beta blockers had no increased risk of cancer or non-cardiovascular disease.	Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Heart & Lung Dis, Sect Prevent Cardiol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Andersson, OK (corresponding author), Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; ANDERSSON O, 1978, ACTA MED SCAND, V203, P391; BERGLUND G, 1976, ACTA MED SCAND, V200, P163; BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; BULPITT CJ, 1979, LANCET, V2, P134; Chobanian AV, 1996, CIRCULATION, V93, P638, DOI 10.1161/01.CIR.93.4.638; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAY JL, 1982, BRIT MED J, V284, P1145, DOI 10.1136/bmj.284.6323.1145; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; ELMFELDT D, 1975, J CHRON DIS, V28, P173, DOI 10.1016/0021-9681(75)90005-3; ERIKSSON H, 1992, J INTERN MED, V232, P389, DOI 10.1111/j.1365-2796.1992.tb00604.x; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; HARMSEN P, 1972, ACTA MED SCAND, V191, P463; LEREN P, 1980, LANCET, V2, P4; PEDERSEN TR, 1994, LANCET, V344, P1383; RAY AA, 1982, SAS USERS GUIDE BASI; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rose GA, 1968, WHO MONOGRAPHY SERIE, V56, P98; Samuelsson O, 1996, BMJ-BRIT MED J, V313, P660; *SAS I, 1991, SAS STAT SOFTWARE PH; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMIRK FH, 1972, AM HEART J, V83, P825, DOI 10.1016/0002-8703(72)90216-5; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	26	163	167	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1998	317	7152					167	171		10.1136/bmj.317.7152.167	http://dx.doi.org/10.1136/bmj.317.7152.167			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665894	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075047800018
J	Kros, CJ; Ruppersberg, JP; Rusch, A				Kros, CJ; Ruppersberg, JP; Rusch, A			Expression of a potassium current in inner hair cells during development of hearing in mice	NATURE			English	Article							GUINEA-PIG; COCHLEA; CALCIUM; SODIUM; CHICK; NERVE	Excitable cells use ion channels to tailor their biophysical properties to the functional demands made upon them(1). During development, these demands may alter considerably, often associated with a change in the cells' complement of ion channels(2-4). Here we present evidence for such a change in inner hair cells, the primary sensory receptors in the mammalian cochlea. In mice, responses to sound can first be recorded from the auditory nerve and observed behaviourally from 10-12 days after birth; these responses mature rapidly over the next 4 days(5-8). Before this time, mouse inner hair cells have slow voltage responses and fire spontaneous and evoked action potentials. During development of auditory responsiveness a large, fast potassium conductance is expressed, greatly speeding up the membrane time constant and preventing action potentials. This change in potassium channel expression turns the inner hair cell from a regenerative, spiking pacemaker into a high-frequency signal transducer.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, ENT Hosp, Div Sensory Biophys, D-72076 Tubingen, Germany	University of Bristol; University of Sussex; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Kros, CJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.		Huisman, Jeroen/B-7859-2009					Appenrodt P, 1997, J PHYSIOL-LONDON, V501P, pP147; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; Ehret G, 1983, DEV AUDITORY VESTIBU, P211; EVANS MG, 1987, BIOPHYS J, V52, P649, DOI 10.1016/S0006-3495(87)83256-3; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1988, J NEUROSCI, V8, P2460; Geleoc GSG, 1997, P ROY SOC B-BIOL SCI, V264, P611, DOI 10.1098/rspb.1997.0087; GUMMER AW, 1994, NEUROREPORT, V5, P685, DOI 10.1097/00001756-199402000-00006; Hille B., 1992, IONIC CHANNELS EXCIT; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KETTNER RE, 1985, J NEUROSCI, V5, P275; Kirkwood NK, 1997, J PHYSIOL-LONDON, V504P, pP127; KROS CJ, 1990, J PHYSIOL-LONDON, V421, P263, DOI 10.1113/jphysiol.1990.sp017944; KROS CJ, 1993, J PHYSIOL-LONDON, V473, pP231; Kros CJ, 1996, COCHLEA, P318; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; Mikaelian D, 1965, ACTA OTO-LARYNGOL, V59, P451, DOI [10.3109/00016486509124579, DOI 10.3109/00016486509124579]; Mu MY, 1997, DEV BRAIN RES, V99, P29, DOI 10.1016/S0165-3806(96)00194-0; ODOWD DK, 1988, J NEUROSCI, V8, P792; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; PUJOL R, 1998, DEV AUDITORY SYSTEM, P146; Romand R., 1983, DEV AUDITORY VESTIBU, P47; RUBSAMEN R, 1998, DEV AUDITORY SYSTEM, P193; RUSSELL IJ, 1987, HEARING RES, V31, P9, DOI 10.1016/0378-5955(87)90210-3; SHNERSON A, 1982, DEV BRAIN RES, V2, P65; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SUGIHARA I, 1989, J NEUROPHYSIOL, V62, P1330, DOI 10.1152/jn.1989.62.6.1330; Walsh Edward J., 1992, P161	29	301	306	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					281	284		10.1038/28401	http://dx.doi.org/10.1038/28401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685158				2022-12-24	WOS:000074851900049
J	Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ				Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ			Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study	BRITISH MEDICAL JOURNAL			English	Article								Objectives:To determine the demands on healthcare resources caused by different types of illnesses and variation with age and sex. Design: Information on healthcare use was obtained from all 22 healthcare sectors in the Netherlands. Most important sectors (hospitals, nursing homes, inpatient psychiatric care, institutions for mentally disabled people) have national registries. Total expenditures for each sector were subdivided into 21 age groups, sex, and 34 diagnostic groups. Setting: Netherlands, 1994. Main outcome measures: Proportion of healthcare budget spent on each category of disease and cost of health care per person at various ages. Results: After the first year of life, costs per person for children were lowest Costs rose slowly throughout adult life and increased exponentially from age 50 onwards till the oldest age group (greater than or equal to 95). The top five areas of healthcare costs were mental retardation, musculoskeletal disease (predominantly joint disease and dorsopathy), dementia, a heterogeneous group of other mental disorders, and ill defined conditions. Stroke, all cancers combined, and coronary heart disease ranked 7, 8, and 10, respectively Conclusions: The main determinants of healthcare use in the Netherlands are old age and disabling conditions, particularly mental disability. A large share of the healthcare budget is spent on long term nursing care, and this cost will inevitably increase further in an ageing population, Non-specific cost containment measures may endanger the quality of care for old and mentally disabled people.	Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Dept Hlth Policy & Management, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Meerding, WJ (corresponding author), Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands.	meerding@mgz.fgg.eur.nl						AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; *AUSTR I HLTH WELF, 1996, AUSTR HLTH 1996; *EX NHS, 1996, BURD DIS DISC DOC; GROENENBOOPM GKC, 1995, ELDERLY CARE EC PERS; Koopmanschap M, 1994, EUR J PUB HLTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COSTS DIS NETHERLAND; LINDGREN B, 1990, KLIN PHARM, V4, P12; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; *MIN HLTH, 1996, ANN OV HLTH CAR 1997; MOORE R, 1997, EC BURDEN ILLNESS CA; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL., 1996, GLOBAL BURDEN DIS, P201; Polder JJ, 1997, COSTS DIS NETHERLAND; World Health Organization, 1977, INT CLASS DIS	14	213	218	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					111	+		10.1136/bmj.317.7151.111	http://dx.doi.org/10.1136/bmj.317.7151.111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657785	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000075081700020
J	Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW				Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW			Double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; BIOLOGICAL CLOCK; NERVOUS-SYSTEM; NUCLEAR ENTRY; MUTANTS; MELANOGASTER; EXPRESSION; MUTATION; REVEALS; BRAIN	We have isolated three alleles of a novel Drosophila clock gene, double-time (dbt). Short- (dbts) and long-period (dbt(L)) mutants after both behavioral rhythmicity and molecular oscillations from previously identified clock genes, period and timeless. A third allele, dbf(P), causes pupal lethality and eliminates circadian cycling of per and tim gene products in larvae. In dbt(P) mutants, PER proteins constitutively accumulate, remain hypophosphorylated, and no longer depend on TIM proteins for their accumulation. We propose that the normal function of DOUBLETIME protein is to reduce the stability and thus the level of accumulation of monomeric PER proteins. This would promote a delay between per/tim transcription and PER/TIM complex function, which is essential for molecular rhythmicity.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Sci & Technol Ctr Biol Timing, New York, NY 10021 USA	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University	Blau, J (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Kloss, Brian/0000-0003-0130-8739; Rothenfluh, Adrian/0000-0002-3813-5723	NIGMS NIH HHS [GM 54339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BRUCE VG, 1972, GENETICS, V70, P537; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; KUNES S, 1993, J NEUROSCI, V13, P752; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Myers MP, 1997, NUCLEIC ACIDS RES, V25, P4710, DOI 10.1093/nar/25.23.4710; PITTENDRIGH CS, 1967, P NATL ACAD SCI USA, V58, P1762, DOI 10.1073/pnas.58.4.1762; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Stanewsky R, 1997, J NEUROSCI, V17, P676; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	651	670	2	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					83	95		10.1016/S0092-8674(00)81224-6	http://dx.doi.org/10.1016/S0092-8674(00)81224-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674430	Bronze			2022-12-24	WOS:000074790800012
J	Zhang, GY; Darst, SA				Zhang, GY; Darst, SA			Structure of the Escherichia coli RNA polymerase alpha subunit amino-terminal domain	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; FUNCTIONAL MAP; ASSEMBLY DOMAIN; TRANSCRIPTION ACTIVATION; ASSOCIATION; PREDICTION; PROMOTERS; ERRORS; GENE	The 2.5 angstrom resolution x-ray crystal structure of the Escherichia coli RNA polymerase (RNAP) alpha subunit amino-terminal domain (alpha NTD), which is necessary and sufficient to dimerize and assemble the other RNAP subunits into a transcriptionally active enzyme and contains all of the sequence elements conserved among eukaryotic alpha homologs, has been determined. The alpha NTD monomer comprises two distinct, flexibly linked domains, only one of which participates in the dimer interface. In the alpha NTD dimer, a pair of helices from one monomer interact with the cognate helices of the other to form an extensive hydrophobic core. ALL of the determinants for interactions with the other RNAP subunits lie on one face of the aNTD dimer. Sequence alignments, combined with secondary-structure predictions, support proposals that a heterodimer of the eukaryotic RNAP subunits related to Saccharomyces cerevisiae Rpb3 and Rpb11 plays the role of the alpha NTD dimer in prokaryotic RNAP.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19441-01, GM53759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ishihama A, 1981, Adv Biophys, V14, P1; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KIMURA M, 1995, J MOL BIOL, V254, P342, DOI 10.1006/jmbi.1995.0621; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; ZILLIG W, 1976, RNA POLYMERASE, P101	34	91	95	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					262	266		10.1126/science.281.5374.262	http://dx.doi.org/10.1126/science.281.5374.262			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657722				2022-12-24	WOS:000074714200051
J	Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK				Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK			Visualization of specific B and T lymphocyte interactions in the lymph node	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; GERMINAL-CENTERS; CELLS; ANTIGEN; (4-HYDROXY-3-NITROPHENYL)ACETYL; IMMUNOGLOBULIN; TOLERANCE; INDUCTION; FOLLICLES; INSITU	Early events in the humoral immune response were visualized in Lymph nodes by simultaneous tracking of antigen-specific CD4 T and B cells after immunization. The T cells were initially activated in the T cell areas when the B cells were still randomly dispersed in the B cell-rich follicles. Both populations then migrated to the edges of the follicles and interacted there, resulting in CD154-dependent B cell proliferation and germinal center formation. These results provide visual documentation of cognate T-B cell interactions and Localize them to the follicular border.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA; Dartmouth Med Coll, Dept Microbiol, Lebanon, NH USA	University of Minnesota System; University of Minnesota Twin Cities; University of Glasgow; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College	Jenkins, MK (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Garside, Paul/A-4227-2009; Jenkins, Marc K/G-1063-2012	Jenkins, Marc K/0000-0001-8009-7655	NIAID NIH HHS [AI27998, AI39614, AI35296] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027998, R01AI027998, P01AI035296, R01AI039614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAUN J, 1982, J IMMUNOL, V128, P1198; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FULLER KA, 1993, J IMMUNOL, V151, P4505; GARSIDE P, UNPUB; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Liu CP, 1996, J EXP MED, V184, P1619, DOI 10.1084/jem.184.5.1619; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; Luther SA, 1997, J EXP MED, V185, P551, DOI 10.1084/jem.185.3.551; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Raff M C, 1970, Nature, V226, P1257, DOI 10.1038/2261257a0; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; Vora KA, 1998, J IMMUNOL, V160, P728; ZHDNG B, 1996, J EXP MED, V1874, P1083	29	591	610	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					96	99		10.1126/science.281.5373.96	http://dx.doi.org/10.1126/science.281.5373.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651253				2022-12-24	WOS:000074685800045
J	Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I				Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I			Seasonal variation in coronary artery disease mortality in Hawaii: observational study	BRITISH MEDICAL JOURNAL			English	Article									Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, New England Med Ctr, Hlth Inst, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Seto, TB (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA.	tseto@bidmc.harvard.edu		Mittleman, Murray/0000-0001-9788-7274				DEPASQUALE N, 1961, AM J MED SCI, V242, P468, DOI 10.1097/00000441-196110000-00012; DOUGLAS AS, 1990, AUST NZ J MED, V20, P669, DOI 10.1111/j.1445-5994.1990.tb00397.x; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; FAMIGHETTI R, 1993, WORLD ALMANAC BOOK F, P407; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2	5	33	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1946	1947		10.1136/bmj.316.7149.1946	http://dx.doi.org/10.1136/bmj.316.7149.1946			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641932	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000074636700027
J	Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G				Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G			The late elongated hypocotyl mutation of Arabidopsis disrupts circadian rhythms and the photoperiodic control of flowering	CELL			English	Article							DNA-BINDING DOMAIN; PROTEIN; PERIOD; CLOCK; EXPRESSION; TIMELESS; MYB; AUTOREGULATION; INSERTION; MUTANT	The dominant late elongated hypocotyl (lhy) mutation of Arabidopsis disrupted circadian clock regulation of gene expression and leaf movements and caused flowering to occur independently of photoperiod. LHY was shown to encode a MYB DNA-binding protein. In wild-type plants, the LHY mRNA showed a circadian pattern of expression with a peak around dawn but in the mutant was expressed constantly at high levels. Increased LHY expression from a transgene caused the endogenous gene to be expressed at a constant level, suggesting that LHY was part of a feedback circuit that regulated its own expression. Thus, constant expression of LHY disrupts several distinct circadian rhythms in Arabidopsis, and LHY may be closely associated with the central oscillator of the circadian clock.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Warwick	Coupland, G (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Schaffer, Robert J/D-1018-2011; CARRE, Isabelle A/D-8802-2011; Coupland, George/AAP-8609-2020	CARRE, Isabelle A/0000-0002-0548-7378; Coupland, George/0000-0001-6988-4172; Schaffer, Robert/0000-0003-1272-667X				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Edmunds LN, 1988, CELLULAR MOL BASES B; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; Feldbrugge M, 1997, PLANT J, V11, P1079, DOI 10.1046/j.1365-313X.1997.11051079.x; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FOLLET BK, 1985, REPROD MAMMALS; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; HALL JC, 1995, TRENDS NEUROSCI, V18, P218; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kreps JA, 1997, PLANT CELL, V9, P297, DOI 10.1105/tpc.9.3.297; LOGEMANN J, 1987, ANAL BIOCHEM, V141, P329; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; RIKIN A, 1984, PLANT PHYSIOL, V75, P493, DOI 10.1104/pp.75.2.493; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SCHAFFER R, 1997, THESIS U E ANGLIA NO; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wilson K, 1996, PLANT CELL, V8, P659, DOI 10.1105/tpc.8.4.659	39	677	739	8	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1219	1229		10.1016/S0092-8674(00)81465-8	http://dx.doi.org/10.1016/S0092-8674(00)81465-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657154	Bronze			2022-12-24	WOS:000074491100016
J	Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K				Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K			Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization	NATURE			English	Article							PROTEIN-KINASE; STRESS FIBERS; ZINC-FINGER; IDENTIFICATION; RHO; GTPASES; FAMILY; CDC42; MOTIF	Rac is a small GTPase of the Rho family that mediates stimulus-induced actin cytoskeletal reorganization to generate lamellipodia(1-5). Little is known about the signalling pathways that link pac activation to changes in actin filament dynamics. Cofilin is known to be a potent regulator of actin filament dynamics(6-10), and its ability to bind and depolymerize actin is abolished by phosphorylation of serine residue at 3 (refs 11, 12); however, the kinases responsible for this phosphorylation have not been identified. Here we show that LIM-kinase 1 (LIMK-1), a serine/threonine kinase containing LIM and PDZ domains(13-16), phosphorylates cofilin at Ser3, both in vitro and in vivo. When expressed in cultured cells, LIMK-1 induces actin reorganization and reverses cofilin-induced actin depolymerization. Expression of an inactive form of LIMK-1 suppresses lamellipodium formation induced by pac or insulin. Furthermore, insulin and an active form of Rac increase the activity of LIMK-1. Taken together, our results indicate that LIMK-1 participates in,Rac-mediated actin cytoskeletal reorganization, probably by phosphorylating cofilin.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto 6190237, Japan	Kyushu University; Kyoto University; National Cerebral & Cardiovascular Center - Japan; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.		Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	21	1026	1050	2	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					809	812		10.1038/31735	http://dx.doi.org/10.1038/31735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655398				2022-12-24	WOS:000074433100055
J	Patton, BL; Chiu, AY; Sanes, JR				Patton, BL; Chiu, AY; Sanes, JR			Synaptic laminin prevents glial entry into the synaptic cleft	NATURE			English	Article							PROTEIN S-LAMININ; NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; NEURONS; REGENERATION; AXOTOMY	Presynaptic and postsynaptic membranes directly oppose each other at chemical synapses, minimizing the delay in transmitting information across the synaptic cleft. Extrasynaptic neuronal surfaces, in contrast, are almost entirely covered by processes from glial cells(1). The exclusion of glial cells from the synaptic deft, and the long-term stability of synapses, presumably result in large part from the tight adhesion between presynaptic and postsynaptic elements(2,3). Here we show that there is another requirement for synaptic maintenance: glial cells of the skeletal neuromuscular synapse, Schwann cells, are actively inhibited from entering the synaptic deft between the motor nerve terminal and the muscle fibre. One inhibitory component is laminin 11, a heterotrimeric glycoprotein that is concentrated in the synaptic cleft(4). Regulation of an inhibitory interaction between glial cells and synaptic deft components may contribute to synaptic rearrangements, and loss of this inhibition may underlie the loss of synapses that results from injury to the postsynaptic cell(5-12).	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA	Washington University (WUSTL); City of Hope; Beckman Research Institute of City of Hope	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.							ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; Bargmann C, 1998, NATURE, V391, P435, DOI 10.1038/35020; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; DUCHEN LW, 1974, J NEUROL SCI, V21, P391, DOI 10.1016/0022-510X(74)90041-0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; Kreutzberg Georg W., 1995, P355; MATTHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91, DOI 10.1113/jphysiol.1975.sp010837; MILEDI R, 1968, PROC R SOC SER B-BIO, V169, P289, DOI 10.1098/rspb.1968.0012; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Peters A, 1991, FINE STRUCTURE NERVO; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; Son YJ, 1996, TRENDS NEUROSCI, V19, P280, DOI 10.1016/S0166-2236(96)10032-1; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; WINLOW W, 1975, J NEUROCYTOL, V4, P377, DOI 10.1007/BF01261371	29	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					698	701		10.1038/31502	http://dx.doi.org/10.1038/31502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641682				2022-12-24	WOS:000074289600057
J	Cachero, TG; Morielli, AD; Peralta, EG				Cachero, TG; Morielli, AD; Peralta, EG			The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C3 ADP-RIBOSYLTRANSFERASE; SERINE-THREONINE KINASE; TYROSINE KINASE; ACETYLCHOLINE-RECEPTOR; PUTATIVE TARGET; FOCAL ADHESIONS; FAMILY GTPASES; K+ CHANNELS; CELLS	Tyrosine kinases activated by G protein-coupled receptors can phosphorylate and thereby suppress the activity of the delayed rectifier potassium channel Kv1.2. Using a yeast two-hybrid screen, we identified the small GTP-binding protein RhoA as a necessary component in this process. Coimmunoprecipitation experiments confirmed that RhoA associates with Kv1.2. Electrophysiological analyses revealed that overexpression of RhoA markedly reduced the basal current generated by Kv1.2 expressed in Xenopus oocytes. Furthermore, in 293 cells expressing Kv1.2 and m1 muscarinic acetylcholine receptors, inactivating RhoA using C3 exoenzyme blocked the ability of mi receptors to suppress Kv1.2 current. Therefore, these results demonstrate that RhoA regulates Kv1.2 activity and is a central component in the mechanism of receptor-mediated tyrosine kinase-dependent suppression of Kv1.2.	Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University	Peralta, EG (corresponding author), Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA.							AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BARRY ST, 1994, J CELL SCI, V107, P2033; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; CARROLL RC, 1995, CURR BIOL, V5, P536, DOI 10.1016/S0960-9822(95)00106-0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZGERALD EM, 1995, BIOCHEM SOC T, V23, pS193, DOI 10.1042/bst023193s; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hille B., 1992, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; YAMAGISHI T, 1995, EUR J PHARMACOL, V281, P151, DOI 10.1016/0014-2999(95)00240-L; YATANI A, 1991, J BIOL CHEM, V266, P22222; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	57	82	90	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1077	1085		10.1016/S0092-8674(00)81212-X	http://dx.doi.org/10.1016/S0092-8674(00)81212-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635436	Bronze			2022-12-24	WOS:000074205700018
J	Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D				Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D			GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; DORSOVENTRAL AXIS; SPEMANN ORGANIZER; WINGLESS SIGNAL; LAEVIS EMBRYOS; PROTEIN; LITHIUM; TAU	Dorsal accumulation of beta-catenin in early Xenopus embryos is required for body axis formation. Recent evidence indicates that beta-catenin is dorsally stabilized by the localized inhibition of the kinase Xgsk-3, utilizing a novel Wnt ligand-independent mechanism. Using a two-hybrid screen, we identified GBP, a maternal Xgsk-3-binding protein that is homologous to a T cell protooncogene in three well-conserved domains. GBP inhibits in vivo phosphorylation by Xgsk-3, and ectopic GBP expression induces an axis by stabilizing beta-catenin within Xenopus embryos. Importantly, antisense oligonucleotide depletion of the maternal GBP mRNA demonstrates that GBP is required for the establishment of the dorsal-ventral axis in Xenopus embryos. Our results define a family of GSK-3-binding proteins with roles in development and cell proliferation.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.			Pierce, Sarah/0000-0001-6739-7135	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HDO7183, HD27262] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BYSTROFF C, 1998, IN PRESS J MOL BIOL; Carnac G, 1996, DEVELOPMENT, V122, P3055; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fagotto F, 1997, DEVELOPMENT, V124, P453; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GERHART J, 1991, BOD MAR LAB, P57; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KUCHARZ EJ, 1988, INT J IMMUNOPHARMACO, V10, P253, DOI 10.1016/0192-0561(88)90056-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1998, IN PRESS BIOESSAYS; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PIERCE SB, 1995, DEVELOPMENT, V121, P755; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sorensen AB, 1996, J VIROL, V70, P4063; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WU YY, 1991, P SOC EXP BIOL MED, V198, P620; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; [No title captured]	66	283	292	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1031	1041		10.1016/S0092-8674(00)81208-8	http://dx.doi.org/10.1016/S0092-8674(00)81208-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635432	Bronze			2022-12-24	WOS:000074205700014
J	Costanzi, C; Pehrson, JR				Costanzi, C; Pehrson, JR			Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals	NATURE			English	Article							DOSAGE COMPENSATION; XIST GENE; MOUSE; MAINTENANCE; EXPRESSION; NUCLEUS; REGION; RNA	In female mammals one of the X chromosomes is rendered almost completely transcriptionally inactive(1,2) to equalize expression of X-linked genes in males and females. The inactive X chromosome is distinguished from its active counterpart by its condensed appearance in interphase nuclei(3), late replication(4), altered DNA methylation(2), hypoacetylation of histone H4 (ref. 5), and by transcription of a large cis-acting nuclear RNA called Xist(6-10). Although it is believed that the inactivation process involves the association of specific protein(s) with the chromatin of the inactive X, no such proteins have been identified(11). We discovered a new gene family encoding a core histone which we called macroH2A (mH2A)(12,13). The amino-terminal third of mH2A proteins is similar to a full-length histone H2A, but the remaining two-thirds is unrelated to any known histones. Here we show that an mH2A1 subtype is preferentially concentrated in the inactive X chromosome of female mammals. Our results link X inactivation with a major alteration of the nucleosome, the primary structural unit of chromatin.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pehrson, JR (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.							BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRENEMAN JW, 1993, CHROMOSOMA, V102, P591, DOI 10.1007/BF00352306; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; EVANS EP, 1982, NATURE, V300, P433; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; HWA TC, 1965, HEREDITAS, V52, P320; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KASLOW DC, 1987, P NATL ACAD SCI USA, V84, P6210, DOI 10.1073/pnas.84.17.6210; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MIGEON BR, 1985, P NATL ACAD SCI USA, V82, P3390, DOI 10.1073/pnas.82.10.3390; MONESTIER M, 1994, J IMMUNOL, V152, P667; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; Willard H, 1997, NATURE, V386, P228, DOI 10.1038/386228a0	25	463	477	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					599	601		10.1038/31275	http://dx.doi.org/10.1038/31275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634239				2022-12-24	WOS:000074150100058
J	Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B				Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B			Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPSTEIN-BARR-VIRUS; QUANTITATIVE-ANALYSIS; IMMUNE-RESPONSES; HIGH-FREQUENCY; LYMPHOCYTES-T; HIV-1; INDIVIDUALS; INFECTION; EXPANSION	Background DNA vaccination is known to generate immune responses against HIV-1 in animal models. We aimed to assess the efficacy of DNA vaccination in induction of immune responses in HIV-1-infected human beings. Methods Nine symptom-free HIV-1-infected patients were immunised with DNA constructs encoding the nef, rev, or tat regulatory genes of HIV-1. The patients were selected for having no or low antibody reactivities to these antigens. HIV-1-specific cytotoxic T-lymphocytes (CTLs), precursor frequencies, and antigen-specific proliferative responses were measured before, during, and after three immunisations over 6 months. Findings Cellular immune reactivities against the HIV-1 regulatory proteins were absent or low before DNA immunisation. DNA vaccination induced detectable memory cells in all patients and specific cytotoxicity in eight patients. CTLs were MHC-class-I restricted and mainly of CD8+ origin. In three patients the cellular activity was transient, decreasing after an initial response. Interpretation DNA immunisation with HIV-1 genes can induce specific cellular responses in human beings with no apparent side-effects. It is theoretically possible that HIV-1-specific cytotoxic responses to regulatory proteins could lead to infected cells being eliminated before they have released new viral particles. However, it is possible that the patients we selected responded less than would nonselected or non-infected individuals. The small number of patients presented here does not allow generalisation of our findings.	Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden; South Hosp, Dept Dermatovenereol, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control	Wahren, B (corresponding author), Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden.		Hinkula, Jorma/P-6849-2018	Hinkula, Jorma/0000-0003-1908-5609				Asakura Y, 1996, AM J HEMATOL, V53, P116, DOI 10.1002/(SICI)1096-8652(199610)53:2&lt;116::AID-AJH9&gt;3.0.CO;2-2; BOYER JD, 1997, NAT MED, V3, P525; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Geretti AM, 1996, J INFECT DIS, V174, P34, DOI 10.1093/infdis/174.1.34; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5; Hinkula J, 1997, J VIROL, V71, P5528, DOI 10.1128/JVI.71.7.5528-5539.1997; HYDENBURGFULLER D, 1994, AIDS RES HUM RETROV, V10, P1433; Johnson R P, 1994, Curr Top Microbiol Immunol, V189, P35; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; LEANDERSSON AC, IN PRESS AIDS; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LUBAKI MN, 1994, AIDS RES HUM RETROV, V10, P1427, DOI 10.1089/aid.1994.10.1427; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Ratto S, 1996, J ACQ IMMUN DEF SYND, V11, P128, DOI 10.1097/00042560-199602010-00003; Riviere Y, 1994, Curr Top Microbiol Immunol, V189, P65; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004; WAHREN B, 1994, J ACQ IMMUN DEF SYND, V7, P220; Wahren B, 1995, ANN NY ACAD SCI, V772, P278, DOI 10.1111/j.1749-6632.1995.tb44759.x; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996; Zhong Q, 1997, VACCINE, V15, P497, DOI 10.1016/S0264-410X(97)00223-5	35	335	357	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1320	1325		10.1016/S0140-6736(97)09440-3	http://dx.doi.org/10.1016/S0140-6736(97)09440-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643795				2022-12-24	WOS:000073439400010
J	Celentano, DD; Vlahov, D; Cohn, S; Shadle, VM; Obasanjo, O; Moore, RD				Celentano, DD; Vlahov, D; Cohn, S; Shadle, VM; Obasanjo, O; Moore, RD			Self-reported antiretroviral therapy in injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-The US Public Health Service and the International AIDS Society-USA recently published recommendations for antiretroviral therapy (ART) for persons infected with human immunodeficiency virus (HIV); however, anecdotal evidence suggests that HIV-infected injection drug users (IDUs) may not be receiving optimal care as defined by the recommendations. Objective.-To assess ART use in HIV-infected IDUs. Design.-A cross-sectional survey of self-reported ART use between July 1996 and June 1997 in IDUs. Setting.-A community-based clinic affiliated with Johns Hopkins University, Baltimore, Md. Participants.-A total of 404 HIV-infected IDUs with CD4(+) cell counts less than 0.50 x 10(9)/L recruited into a longitudinal study in 1988 and 1989. Main Outcome Measure.-Self-reported ART use was assessed: no current therapy, monotherapy, or combination therapy with or without a protease inhibitor. Results.-One half (199/404 [49%]) of patients reported no recent ART. A total of 14% (58/404) had monotherapy, 23% (90/404) were receiving combination therapy without a protease inhibitor, and 14% (57/404) had triple-combination therapy with a protease inhibitor. A multivariate analysis of factors associated with ART showed that care continuity and recent HIV-related outpatient visit (odds ratio [OR], 4.30; 95% confidence interval [CI], 2.36-7.81 and OR, 2.84; 95% CI, 1.66-4.88, respectively), CD4(+) cell count of less than 0.20 x 10(9) (OR, 2.41,95% CI, 1.51-3.84), no current drug use and being in drug treatment (OR, 2.16; 95% CI, 1.34-3.47; OR, 2.12; 95% CI, 1.23-3.66, respectively), and unemployment (OR, 2.31;95% CI, 1.21-4.40) were associated with reporting ART use. In other analysis, less likely to receive protease inhibitors were current drug injectors (OR, 0.5; 95% CI, 0.3-1.0) and those recently incarcerated (OR, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to receive protease inhibitors (OR, 2.0; 95% CI, 0.9-4.6). Protease inhibitor use doubled (P<.01) from July and December 1996 to January and June 1997 (7.7% and 14.8%, respectively). Conclusions.-Those IDUs infected with HIV who were not receiving ART tended to be active drug users without clinical disease who have less contact with health care providers. Although we do not have information on clinical judgment regarding treatment decisions or whether persons were prescribed therapy not taken, the proportion of subjects reporting receiving ART suggests that strategies for improving treatment in this population are indicated. Expanding simultaneous treatment services for HIV infection and substance abuse would enhance the response to these related epidemics.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Program Infect Dis, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Celentano, DD (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Program Infect Dis, 615 N Wolfe St,E-7132, Baltimore, MD 21205 USA.	dcelenta@jhsph.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04334] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DeGruttola V, 1997, J INFECT DIS, V175, P237, DOI 10.1093/infdis/175.2.237; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Freeman RC, 1996, AIDS EDUC PREV, V8, P58; GULICK RM, 1996, 11 INT C AIDS JUL 7; HIRSCH M, 1997, 4 C RETR OPP INF JAN; HO DD, 1997, 4 C RETR OPP INF JAN; Kasl S V, 1975, J Human Stress, V1, P5; Mehta S, 1997, AIDS, V11, P1665, DOI 10.1097/00002030-199714000-00002; MOORE RD, 1994, NEW ENGL J MED, V20, P1412; SCHAUB AF, 1993, CLIN EXP HYPERTENS, V15, P1121, DOI 10.3109/10641969309037099; STRATHDEE SA, 1998, 5 C RETR OPP INF CHI; Vlahov D, 1991, NIDA Res Monogr, V109, P75; WONG JK, 1997, 4 C RETR OPP INF JAN	18	225	228	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					544	546		10.1001/jama.280.6.544	http://dx.doi.org/10.1001/jama.280.6.544			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707145				2022-12-24	WOS:000075244900031
J	Manabe, T; Noda, Y; Mamiya, T; Katagiri, H; Houtani, T; Nishi, M; Noda, T; Takahashi, T; Sugimoto, T; Nabeshima, T; Takeshima, H				Manabe, T; Noda, Y; Mamiya, T; Katagiri, H; Houtani, T; Nishi, M; Noda, T; Takahashi, T; Sugimoto, T; Nabeshima, T; Takeshima, H			Facilitation of long-term potentiation and memory in mice lacking nociception receptors	NATURE			English	Article							HIPPOCAMPAL CA1 REGION; SYNAPTIC TRANSMISSION; CALCIUM CHANNELS; ORPHANIN-FQ; NEURONS; LTP; MODULATION; CELLS	The peptide nociceptin (also named orphanin FQ) acts in the brain to produce various pharmacological effects, including hyperalgesia and hypolocomotion(1,2). The nociceptin receptor uses guanine-nucleotide-binding proteins to mediate the inhibition of adenylyl cyclase, the activation of potassium channels and inhibition of calcium channels(3). It has been shown using knockout mice that the nociceptin receptor is not required for regulation of nociceptive responses or locomotion activity, but modulates the auditory function(4). Here we show that mice lacking the nociceptin receptor possess greater learning ability and have better memory than control mice. Histological analysis revealed the expression of both the nociceptin precursor and the nociceptin receptor in the hippocampus, thought to take part in aspects of learning and memory. Moreover, the receptor-deficient mice showed larger long-term potentiation in the hippocampal CAI region than control mice, without apparent changes in presynaptic or postsynaptic electrophysiological properties. These results show that the loss of the nociceptin receptor results in a gain-of-function mutation in both the memory process and the long-term potentiation mechanism in CA1, perhaps as a result of altered intracellular signal transduction systems in neurons.	Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138654, Japan; Univ Tokyo, Fac Med, Dept Neurophysiol, Bunkyo Ku, Tokyo 1138654, Japan; Nagoya Univ, Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Hosp Pharm, Nagoya, Aichi 4668560, Japan; Kansai Med Univ, Dept Anat, Osaka 5708506, Japan; Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; University of Tokyo; Nagoya University; Nagoya University; Kansai Medical University	Takeshima, H (corresponding author), Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138654, Japan.		Noda, Tetsuo/B-1667-2016	Takeshima, Hiroshi/0000-0003-4525-3725				BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Fukuda K, 1997, FEBS LETT, V412, P290, DOI 10.1016/S0014-5793(97)00815-6; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; Ikeda K, 1997, MOL BRAIN RES, V45, P117, DOI 10.1016/S0169-328X(96)00252-5; Knoflach F, 1996, J NEUROSCI, V16, P6657; Lou LG, 1997, BIOCHEM BIOPH RES CO, V240, P304, DOI 10.1006/bbrc.1997.7654; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mamiya T, 1998, BRAIN RES, V783, P236, DOI 10.1016/S0006-8993(97)01406-6; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NABESHIMA T, 1993, METHODS NEUROSCIENCE, V14, P217; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sandin J, 1997, EUR J NEUROSCI, V9, P194, DOI 10.1111/j.1460-9568.1997.tb01367.x; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460; Yu TP, 1997, HIPPOCAMPUS, V7, P88, DOI 10.1002/(SICI)1098-1063(1997)7:1<88::AID-HIPO9>3.0.CO;2-3	28	282	319	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					577	581		10.1038/29073	http://dx.doi.org/10.1038/29073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707118				2022-12-24	WOS:000075238700048
J	Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO				Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO			Delivery of epitopes by the Salmonella type III secretion system for vaccine development	SCIENCE			English	Article							LYMPHOCYTES-T; TYPHIMURIUM; CELLS; IDENTIFICATION; IMMUNIZATION; RESPONSES; CARRIERS; VECTORS; STRAINS; GENE	Avirulent strains of Salmonella typhimurium are being considered as antigen delivery vectors. During its intracellular stage in the host, S. typhimurium resides within a membrane-bound compartment and is not an efficient inducer of class I-restricted immune responses. Viral epitopes were successfully delivered to the host-cell cytosol by using the type III protein secretion system of S. typhimurium. This resulted in class I-restricted immune responses that protected vaccinated animals against lethal infection. This approach may allow the efficient use of S. typhimurium as an antigen delivery system to control infections by pathogens that require this type of immune response for protection.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Nebraska System; University of Nebraska Lincoln	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	galan@asterix.bio.sunysb.edu						ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; CURTISS R, 1994, DEV BIOL STAND, V82, P23; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DECKHUT AM, 1993, J IMMUNOL, V151, P2658; Fu YX, 1998, J BACTERIOL, V180, P3393, DOI 10.1128/JB.180.13.3393-3399.1998; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GALAN JE, 1990, GENE, V94, P29, DOI 10.1016/0378-1119(90)90464-3; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, CELLULAR MOL BIOL, P2757; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; Hackett Jim, 1993, Current Opinion in Biotechnology, V4, P611, DOI 10.1016/0958-1669(93)90085-B; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; KAREM KL, 1997, J GEN VIROL, V78, P27; Katz SL, 1997, LANCET, V350, P1767, DOI 10.1016/S0140-6736(97)05358-0; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; Lambert PH, 1996, DEV BIOL STAND, V87, P45; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; OSSEVOORT MA, 1995, J IMMUNOTHER, V18, P86, DOI 10.1097/00002371-199508000-00002; Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349; Ringrose JH, 1996, CLIN RHEUMATOL, V15, P79, DOI 10.1007/BF03342653; Rolph MS, 1997, CURR OPIN IMMUNOL, V9, P517, DOI 10.1016/S0952-7915(97)80104-5; Schlom J, 1996, BREAST CANCER RES TR, V38, P27, DOI 10.1007/BF01803781; Schmidt W, 1997, P NATL ACAD SCI USA, V94, P3262, DOI 10.1073/pnas.94.7.3262; SCHODEL F, 1995, DEV BIOL STAND, V84, P245; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; Vitiello A, 1996, J IMMUNOL, V157, P5555; Weiskirch LM, 1997, IMMUNOL REV, V158, P159, DOI 10.1111/j.1600-065X.1997.tb01002.x; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WUNDERLICH J, 1991, CURRENT PROTOCOLS IM; YANG DM, 1990, J IMMUNOL, V145, P2281; 1997, WHOVRDGEN9701	35	227	260	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					565	568		10.1126/science.281.5376.565	http://dx.doi.org/10.1126/science.281.5376.565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677200				2022-12-24	WOS:000075012300042
J	Torigoe, C; Inman, JK; Metzger, H				Torigoe, C; Inman, JK; Metzger, H			An unusual mechanism for ligand antagonism	SCIENCE			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; RECEPTOR LIGANDS; LEUKEMIA-CELLS; IGE; ANTIGEN; PHOSPHORYLATION; AGGREGATION; COMPLEXES; KINASE	The ratio of late to early events stimulated by the mast cell receptor for immunoglobulin E (IgE) correlated with the affinity of a ligand for the receptor-bound IgE. Because excess receptors clustered by a weakly binding ligand could hoard a critical initiating kinase, they prevented the outnumbered clusters engendered by the high-affinity ligands from launching the more complete cascade. A similar mechanism could explain the antagonistic action of some peptides on the activation of T cells.	NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Torigoe, C (corresponding author), NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA.							ALBER G, 1992, J IMMUNOL, V149, P2428; ASHMAN RF, 1969, J BIOL CHEM, V244, P3405; BARSUMIAN EL, 1985, CELL IMMUNOL, V90, P131, DOI 10.1016/0008-8749(85)90175-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547, DOI 10.1159/000237098; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; ELIOT CW, 1985, FOLKLORE FABLES, P27; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HABA S, 1991, J IMMUNOL METHODS, V138, P15, DOI 10.1016/0022-1759(91)90059-O; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; LIU FT, 1980, J IMMUNOL, V124, P2728; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; METZGER H, 1982, MOL IMMUNOL, V19, P1071, DOI 10.1016/0161-5890(82)90316-9; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; RACIOPPI L, 1995, CHEM IMMUNOL, V60, P79; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN KE, 1980, J IMMUNOL METHODS, V37, P83, DOI 10.1016/0022-1759(80)90183-0; SUBRAMANIAN K, 1995, THESIS CORNELL U ITH; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; TORIGOE C, UNPUB; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; WOFSY C, 1997, J IMMUNOL, V159, P5985; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	39	134	137	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					568	572		10.1126/science.281.5376.568	http://dx.doi.org/10.1126/science.281.5376.568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677201				2022-12-24	WOS:000075012300043
J	Young, A; Willatts, S				Young, A; Willatts, S			Controversies in management of acute brain trauma	LANCET			English	Editorial Material							CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; METABOLISM		Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary	Young, A (corresponding author), Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England.		Young, Amber/H-2988-2018	Young, Amber/0000-0001-7205-492X				ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 1995, MAN SEV HEAD INJ; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DeWitt D S, 1995, New Horiz, V3, P376; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031	20	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					164	166		10.1016/S0140-6736(05)77803-X	http://dx.doi.org/10.1016/S0140-6736(05)77803-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683202				2022-12-24	WOS:000074859800006
J	Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY				Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY			Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OPEN READING FRAME; PRODUCTIVE INFECTION; MUTATIONAL ANALYSIS; RHESUS-MONKEYS; TYPE-1; GENE; PROTEIN; MACROPHAGES; LYMPHOCYTES	Expression of human immunodeficiency virus-type 1 (HIV-1) Vpr after productive infection of T cells induces cell cycle arrest in the G(2) phase of the cell cycle. In the absence of de novo expression, HIV-1 Vpr packaged into virions still induced cell cycle arrest. Naturally noninfectious virus or virus rendered defective for infection by reverse transcriptase or protease inhibitors were capable of inducing Vpr-mediated cell cycle arrest. These results suggest a model whereby both infectious and noninfectious virions in vivo, such as those surrounding follicular dendritic cells, participate in immune suppression.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, AIDS Inst, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Chen, ISY (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA.		Stewart, Sheila A/C-5213-2012		NATIONAL CANCER INSTITUTE [R01CA070018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [CA70018] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; PHS HHS [T32/A107388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BALOTTO CP, 1993, J EXP MED, V176, P1099; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOCH J, 1995, J VIROL, V69, P4807, DOI 10.1128/JVI.69.8.4807-4813.1995; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NALDINI L, 1996, P NATL ACAD SCI USA, V93, P11383; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; POON B, UNPUB; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Sambrook J., 1989, MOL CLONING; SHEARER GM, 1986, J IMMUNOL, V137, P2515; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; TENNERRACZ K, 1989, PROGR AIDS PATHOLOGY, P29; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265	50	165	166	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					266	269		10.1126/science.281.5374.266	http://dx.doi.org/10.1126/science.281.5374.266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657723				2022-12-24	WOS:000074714200052
J	Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H				Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H			Inhibitory long-term potentiation underlies auditory conditioning of goldfish escape behaviour	NATURE			English	Article							MAUTHNER CELL; STARTLE REFLEX; TRANSMISSION; SYNAPSES; RESPONSES; NETWORK	Long-term potentiation (LTP), the increase in synaptic strength evoked by high-frequency stimulation, is often considered to be a cellular model for learning and memory. The validity of this model depends on the assumptions that physiological stimuli can induce LTP in vivo and that the resulting: synaptic modifications correlate with behavioural changes. However, modifiable synapses are generally embedded deep in complex circuits. In contrast, the goldfish Mauthner (M)-cell and its afferent synapses are easily accessible for electrophysiological studies, and firing of this neuron is sufficient to trigger fast escape behaviour in response to sudden stimuli(1,2). We have previously shown that tetanic stimulation can induce LTP of the feedforward inhibitory synapses that control the excitability of the M-ceIl(3,4). Here we report that natural sensory stimulation can induce potentiation of this inhibitory connection that resembles the LTP induced by afferent tetanization. Furthermore, comparable acoustic stimulation produced a parallel decrease in the probability of the sound-evoked escape reflex Thus we demonstrate for the first time, to our knowledge, a behavioural role for the long-term synaptic strengthening of inhibitory synapses.	Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Osaka 5608531, Japan; Inst Pasteur, INSERM, U261, Biol Cellulaire & Mol Lab, F-75724 Paris, France	Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Oda, Y (corresponding author), Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Machikaneyama 1-3, Osaka 5608531, Japan.							ALJURE E, 1980, BRAIN RES, V188, P261, DOI 10.1016/0006-8993(80)90574-0; Blaxter J.H.S., 1988, P203; Brunskill R.W, 1978, ILLUSTRATED HDB VERN; Canfield JG, 1996, BRAIN BEHAV EVOLUT, V48, P137, DOI 10.1159/000113193; EATON RC, 1991, J EXP BIOL, V161, P469; EATON RC, 1988, J NEUROSCI, V8, P2758; FABER DS, 1975, BRAIN RES, V96, P349, DOI 10.1016/0006-8993(75)90746-5; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FAY RR, 1995, BRAIN BEHAV EVOLUT, V46, P141, DOI 10.1159/000113267; FETCHO JR, 1991, BRAIN BEHAV EVOLUT, V37, P298, DOI 10.1159/000114367; FISHER TM, 1995, J NEUROSCI, V15, P762; FURUKAWA T, 1967, J NEUROPHYSIOL, V30, P1377, DOI 10.1152/jn.1967.30.6.1377; FURUKAWA T, 1963, J NEUROPHYSIOL, V26, P140, DOI 10.1152/jn.1963.26.1.140; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; KANDEL ER, 1978, GRASS LECT MONOGR J; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; ODA Y, 1995, J NEUROPHYSIOL, V74, P1056, DOI 10.1152/jn.1995.74.3.1056; RODGERS WL, 1963, J COMP PHYSIOL PSYCH, V56, P917, DOI 10.1037/h0039700; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; VU ET, 1993, J NEUROSCI, V13, P4379; Wilson MA, 1997, TRENDS NEUROSCI, V20, P102, DOI 10.1016/S0166-2236(96)01023-5; YANG XD, 1990, NATURE, V348, P542, DOI 10.1038/348542a0; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZOTTOLI SJ, 1977, J EXP BIOL, V66, P243	27	69	69	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					182	185		10.1038/28172	http://dx.doi.org/10.1038/28172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671301				2022-12-24	WOS:000074705900054
J	Kaelin, WG				Kaelin, WG			Carcinogenesis - Another p53 Doppelganger?	SCIENCE			English	Editorial Material									Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA.	William_Kaelin@dfci.harvard.edu						COLBRINIK D, 1996, GENE DEV, V10, P1633; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LECOUTER JE, COMMUNICATION; MARIN MC, COMMUNICATION; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; YANG A, COMMUNICATION	11	30	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					57	58		10.1126/science.281.5373.57	http://dx.doi.org/10.1126/science.281.5373.57			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9679018				2022-12-24	WOS:000074685800034
J	Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM				Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM			Covalently functionalized nanotubes as nanometre-sized probes in chemistry and biology	NATURE			English	Article							FORCE MICROSCOPY; CARBON NANOTUBES	Carbon nanotubes combine a range of properties that make them well suited for use as probe tips in applications such as atomic force microscopy (AFM)(1-3), Their high aspect ratio, for example, opens up the possibility of probing the deep crevices(4) that occur in microelectronic circuits, and the small effective radius of nanotube tips significantly improves the lateral resolution beyond what can be achieved using commercial silicon tips(5). Another characteristic feature of nanotubes is their ability to buckle elastically(4,6), which makes them very robust while limiting the maximum force that is applied to delicate organic and biological samples, Earlier investigations into the performance of nanotubes as scanning probe microscopy tips have focused on topographical imaging, but a potentially more significant issue is the question of whether nanotubes can be modified to create probes that can sense and manipulate matter at the molecular level(7), Here we demonstrate that nanotube tips with the capability of chemical and biological discrimination can be created with acidic functionality and by coupling basic or hydrophobic functionalities or biomolecular probes to the carboxyl groups that are present at the open tip ends. We have used these modified nanotubes as AFM tips to titrate the acid and base groups, to image patterned samples based on molecular interactions, and to measure the binding force between single protein-ligand pairs. As carboxyl groups are readily derivatized by a variety of reactions(8), the preparation of a wide range of functionalized nanotube tips should be possible, thus creating molecular probes with potential applications in many areas of chemistry and biology.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833; Joselevich, Ernesto/0000-0002-9919-0734				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Bodanszky M., 1994, PRACTICE PEPTIDE SYN; Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; EVANS JF, 1977, J ELECTROANAL CHEM, V80, P409, DOI 10.1016/S0022-0728(77)80064-8; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; GILES MA, 1990, ANAL BIOCHEM, V184, P244; HIURA H, 1995, ADV MATER, V7, P275, DOI 10.1002/adma.19950070304; Keller D, 1996, NATURE, V384, P111, DOI 10.1038/384111a0; KUMARAMANICKAVEL G, 1994, NAT GENET, V8, P10, DOI 10.1038/ng0994-10; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; March J., 1992, ADV ORG CHEM, V4th; Marti A, 1995, LANGMUIR, V11, P4632, DOI 10.1021/la00012a009; McKendry R, 1998, NATURE, V391, P566, DOI 10.1038/35339; Noy A, 1998, LANGMUIR, V14, P1508, DOI 10.1021/la970948f; Noy A, 1997, ANNU REV MATER SCI, V27, P381, DOI 10.1146/annurev.matsci.27.1.381; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Vezenov DV, 1997, J AM CHEM SOC, V119, P2006, DOI 10.1021/ja963375m; WANDASS JH, 1987, J ELECTROCHEM SOC, V134, P2734, DOI 10.1149/1.2100278; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; WONG SS, UNPUB J AM CHEM SOC	24	1342	1418	4	342	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					52	55		10.1038/27873	http://dx.doi.org/10.1038/27873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665127	Green Published			2022-12-24	WOS:000074579600044
J	McGarry, TJ; Kirschner, MW				McGarry, TJ; Kirschner, MW			Geminin, an inhibitor of DNA replication, is degraded during mitosis	CELL			English	Article							SISTER-CHROMATID SEPARATION; CELL-FREE-EXTRACTS; S-PHASE; LICENSING SYSTEM; MITOTIC CYCLINS; FISSION YEAST; XENOPUS; PROTEOLYSIS; PROTEIN; DESTRUCTION	We describe a novel 25 kDa protein, geminin, which inhibits DNA replication and is degraded during the mitotic phase of the cell cycle. Geminin has a destruction box sequence and is ubiquitinated anaphase-promoting complex (APC) in vitro. In synchronized HeLa cells, geminin is absent during G1 phase, accumulates during S, G2, and M phases, and disappears at the time of the metaphase-anaphase transition. Geminin inhibits DNA replication by preventing the incorporation of MCM complex into prereplication complex (preRC). We propose that geminin inhibits DNA replication during S, G2, and M phases and that geminin destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							AMON A, 1994, CELL, V77, P4037; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harlow E, 1988, ANTIBODIES LAB MANUA; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUTCHISON CJ, 1993, CELL CYCLE PRACTICAL, P177; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kay BK., 1991, XENOPUS LAEVIS PRACT, V36; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG A, 1997, SCIENCE, V283, P83; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rowles A, 1997, CURR OPIN GENET DEV, V7, P152, DOI 10.1016/S0959-437X(97)80123-2; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Stern B, 1996, TRENDS GENET, V12, P345; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	42	708	725	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1043	1053		10.1016/S0092-8674(00)81209-X	http://dx.doi.org/10.1016/S0092-8674(00)81209-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635433	Bronze			2022-12-24	WOS:000074205700015
J	Henry, PD; Pacifico, A				Henry, PD; Pacifico, A			Altering molecular mechanisms to prevent sudden arrhythmic death	LANCET			English	Article							PLATELET-ACTIVATING-FACTOR; LEFT-VENTRICULAR DYSFUNCTION; ISCHEMIC-HEART-DISEASE; MYOCARDIAL REPERFUSION; ALPHA; ATHEROSCLEROSIS; INFLAMMATION; INFARCTION; RECEPTOR; BLOOD	Trials of drug treatment for prevention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with arrhythmic agents fails to address the mechanisms leading; to electrophysiological failure. We propose that preventive treatment should pay more attention to molecular mechanisms responsible for the progression of cardiac disease to electrophysiological failure. Most sudden cardiac deaths occur in people with atherogenic dyslipidaemias. Our hypothesis is that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis. Proinflammatory-prothrombotic lipid-derived mediators that may play a part in arrhythmogenesis include phospholipids and leucotrienes acting through the platelet-activating-factor and peroxisome proliferator-activated-receptor pathways. There are drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiological failure.	Texas Arrhythmia Inst, Houston, TX 77030 USA		Henry, PD (corresponding author), Texas Arrhythmia Inst, Houston, TX 77030 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; ASAI K, 1993, ARTERIOSCLER THROMB, V13, P892, DOI 10.1161/01.ATV.13.6.892; Becker L, 1996, CARDIAC ARREST SCI P, P28; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FORNES P, 1994, ARCH MAL COEUR VAISS, V87, P319; Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HERTUALLA SYY, 1993, P NATL ACAD SCI USA, V88, P5252; Hoffman BF, 1996, J CARDIOVASC ELECTR, V7, P120, DOI 10.1111/j.1540-8167.1996.tb00507.x; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KLUFT C, 1988, THROMB HAEMOSTASIS, V59, P329; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Matsumori A, 1997, CIRCULATION, V96, P1386, DOI 10.1161/01.CIR.96.5.1386; Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17, DOI 10.1152/ajpheart.1997.272.1.H17; PEDERSEN TR, 1994, LANCET, V344, P1383; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Prescott SM, 1996, JPN CIRC J, V60, P137, DOI 10.1253/jcj.60.137; RIALS SJ, 1995, CIRCULATION, V91, P426, DOI 10.1161/01.CIR.91.2.426; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sakai A, 1997, ARTERIOSCL THROM VAS, V17, P310, DOI 10.1161/01.ATV.17.2.310; Schoonjans K, 1996, J LIPID RES, V37, P907; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; TAMURA K, 1994, CORONARY ARTERY DIS, V5, P267; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; ZOLBE RG, 1997, CIRCADIAN RHYTHMS CA, P1	35	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 25	1998	351	9111					1276	1278		10.1016/S0140-6736(97)10049-6	http://dx.doi.org/10.1016/S0140-6736(97)10049-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643764				2022-12-24	WOS:000073283600043
J	Kaplan, EH				Kaplan, EH			Israel's ban on use of Ethiopians' blood: how many infectious donations were prevented?	LANCET			English	Editorial Material									Yale Univ, Sch Management, New Haven, CT 06520 USA	Yale University	Kaplan, EH (corresponding author), Yale Univ, Sch Management, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH056826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009531] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA09531] Funding Source: Medline; NIMH NIH HHS [P01-MH/DA-56826] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*CENT BUR STAT, 1995, STAT ABSTR ISR; Kaplan E H, 1995, Public Health Rev, V23, P215; KAPLAN EH, 1998, IN PRESS J ACQ IMM D; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Litvak E, 1997, MED DECIS MAKING, V17, P455, DOI 10.1177/0272989X9701700411; NAVON Y, 1996, SUMMONING CLARIFY BL; POLLACK S, 1993, ISRAEL J MED SCI, V29, P19; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; SCHMEMANN S, 1996, NY TIMES        0129; SIEGEL J, 1996, JERUSALEM POST  0318; Siegel Judy, 1996, JERUSALEM POST  0206, P12; SLATER PE, 1993, ISRAEL J MED SCI, V29, P2; Vikhanski L, 1996, NAT MED, V2, P260, DOI 10.1038/nm0396-260; 1996, JERUSALEM POST  0129	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1127	1128		10.1016/S0140-6736(97)10356-7	http://dx.doi.org/10.1016/S0140-6736(97)10356-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660600				2022-12-24	WOS:000073090200047
J	della Rovere, GQ; Bird, PA				della Rovere, GQ; Bird, PA			Sentinel-lymph-node biopsy in breast cancer	LANCET			English	Editorial Material									Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	della Rovere, GQ (corresponding author), Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England.							Abati A, 1996, CANCER, V78, P1; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; Cox CE, 1998, ANN SURG, V227, P645, DOI 10.1097/00000658-199805000-00005; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; HADDAD FF, 1997, REF GYNECOL OBSTET, V5, P2; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; O'Hea BJ, 1998, J AM COLL SURGEONS, V186, P423, DOI 10.1016/S1072-7515(98)00060-X; Rodier JF, 1997, ONCOL REP, V4, P281; ROSEN PP, 1983, ANN SURG, V197, P276, DOI 10.1097/00000658-198303000-00006; Roumen RMH, 1997, EUR J SURG ONCOL, V23, P495, DOI 10.1016/S0748-7983(97)92885-7; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0	13	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					421	422		10.1016/S0140-6736(05)79184-4	http://dx.doi.org/10.1016/S0140-6736(05)79184-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708748				2022-12-24	WOS:000075252000007
J	Springer, S; Schekman, R				Springer, S; Schekman, R			Nucleation of COPII vesicular coat complex by endoplasmic reticulum to Golgi vesicle SNAREs	SCIENCE			English	Article							TRANSPORT VESICLES; SORTING SIGNALS; PROTEINS; RECEPTORS; GLYCOPROTEIN; FUSION; YEAST	Protein trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus involves specific uptake into coat protein complex II (COPII)-coated vesicles of secretory and of vesicle targeting (V-SNARE) proteins. Here, two ER to Golgi v-SNAREs, Bet1p and Bos1p, were shown to interact specifically with Sar1p, Sec23p, and Sec24p, components of the COPII coat, in a guanine nucleotide-dependent fashion. Other v-SNAREs, Sec22p and Ykt6p, might interact more weakly with the COPII coat or interact indirectly by binding to Bet1p or Bos1p. The data suggest that transmembrane proteins can be taken up into COPII vesicles by direct interactions with the coat proteins and may play a structural role in the assembly of the COPII coat complex.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	schekman@uclink4.berkeley.edu	Springer, Sebastian/AAJ-7036-2021	Springer, Sebastian/0000-0002-5527-6149				Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SPRINGER S, UNPUB; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	32	172	178	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					698	700		10.1126/science.281.5377.698	http://dx.doi.org/10.1126/science.281.5377.698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685263				2022-12-24	WOS:000075107900042
J	Utley, RT; Ikeda, K; Grant, PA; Cote, J; Steger, DJ; Eberharter, A; John, S; Workman, JL				Utley, RT; Ikeda, K; Grant, PA; Cote, J; Steger, DJ; Eberharter, A; John, S; Workman, JL			Transcriptional activators direct histone acetyltransferase complexes to nucleosomes	NATURE			English	Article							TATA-BINDING PROTEIN; BASAL TRANSCRIPTION; VP16; ADA2; DOMAINS; ADAPTER; INVITRO; GENE; CBP	Transcriptional co-activators were originally identified as proteins that act as intermediaries between upstream activators and the basal transcription machinery. The discovery that co-activators such as Tetrahymena and yeast Gcn5( >)(1,2), as well as human p300/CBP3,4, pCAF(5), Src-1(6), ACTR(7) and TAFII250(8), can acetylate histones suggests that activators may be involved in targeting acetylation activity to promoters. Several histone deacetylases have been linked to transcriptional co-repressor proteins(9), suggesting that the action of both acetylases and deacetylases is important in the regulation of many genes. Here we demonstrate the binding of two native yeast histone acetyltransferase (HAT) complexes to the herpesvirus VP16 activation domain and the yeast transcriptional activator Gcn4 and show that it is their interaction with the VP16 activation domain that targets Gal4-VP16-bound nucleosomes for acetylation. We find that Gal4-VP16-driven transcription from chromatin templates is stimulated by both HAT complexes in an acetyl CoA-dependent reaction. Our results demonstrate the targeting of native HAT complexes by a transcription-activation domain to nucleosomes in order to activate transcription.	Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Ctr Gene Regulat, Althouse Lab 306, University Pk, PA 16802 USA; Jichi Med Sch, Dept Biol, Minami Kawachi, Tochigi 32904, Japan; Univ Laval, Hotel Dieu Quebec, Ctr Canc Res, Quebec City, PQ G1R 2J6, Canada	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Jichi Medical University; Laval University	Workman, JL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA.	jlw10@psu.edu	Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STEGER DJ, UNPUB P NATL ACAD SC; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Utley RT, 1996, METHOD ENZYMOL, V274, P276; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	31	428	439	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					498	502		10.1038/28886	http://dx.doi.org/10.1038/28886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697775				2022-12-24	WOS:000075080400057
J	Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J				Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J			Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha	CELL			English	Article							AMINO-ACID MOTIF; LARGE-T-ANTIGEN; LOCATION SEQUENCE; PORE COMPLEXES; PROTEIN IMPORT; IDENTIFICATION; BINDING; TRANSPORT; BETA; SUBSTRATE	Selective nuclear import is mediated by nuclear localization signals (NLSs) and cognate transport factors known as karyopherins or importins. Karyopherin alpha recognizes "classical" monopartite and bipartite NLSs. We report the crystal structure of a 50 kDa fragment of the 60 kDa yeast karyopherin alpha, in the absence and presence of a monopartite NLS peptide at 2.2 Angstrom and 2.8 Angstrom resolution, respectively. The structure shows a tandem array of ten armadillo repeats, organized in a right-handed superhelix of helices. Binding of the NLS peptide occurs at two sites within a helical surface groove that is lined by conserved residues. The structure reveals the determinants of NLS specificity and suggests a model for the recognition of bipartite NLSs.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Conti, Elena/0000-0003-1254-5588				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1998, CRYSTALLOGRAPHIC NMR; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WOZNIAK RW, 1998, IN PRESS TRENDS CELL; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	50	651	669	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					193	204		10.1016/S0092-8674(00)81419-1	http://dx.doi.org/10.1016/S0092-8674(00)81419-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695948	Bronze			2022-12-24	WOS:000075020100008
J	Rees, K; Wright, A; Keeling, JW; Douglas, NJ				Rees, K; Wright, A; Keeling, JW; Douglas, NJ			Facial structure in the sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article							SLEEP-APNEA		Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Med, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Paediat Pathol, Edinburgh EH8 9YL, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Douglas, NJ (corresponding author), Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland.	n.j.douglas@ed.ac.uk	Douglas, Neil/B-1491-2013	Rees, Karen/0000-0003-1832-3679				KAHN A, 1992, SLEEP, V15, P287, DOI 10.1093/sleep/15.4.287; MATHUR R, 1995, ANN INTERN MED, V122, P174, DOI 10.7326/0003-4819-122-3-199502010-00003; MATHUR R, 1994, LANCET, V344, P819, DOI 10.1016/S0140-6736(94)92375-2; SKATVEDT O, 1994, ARCH DIS CHILD, V71, P133; Tishler PV, 1996, AM J RESP CRIT CARE, V153, P1857, DOI 10.1164/ajrccm.153.6.8665046	5	20	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					179	180		10.1136/bmj.317.7152.179	http://dx.doi.org/10.1136/bmj.317.7152.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665897	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075047800024
J	Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F				Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F			IgD can largely substitute for loss of IgM function in B cells	NATURE			English	Article							IMMUNOGLOBULIN MU-CHAIN; DEFICIENT MICE; GENE; ANTIGEN; TERMINATION; LYMPHOCYTES; EXPRESSION; DISRUPTION; DIFFERENTIATION; RECOMBINATION	The mu and delta heavy chains of IgM and IgD, the first antibody isotypes expressed during bone-marrow B-cell development, are encoded by a common transcription unit. Expression of the mu chain on the surface of late pre-B cells allows their further development to immature B cells. Coexpression of the delta chain and emigration of the immature B cells to the periphery eventually leads to the development of naive mature IgM/IgD double-positive cells. Although IgM is important in driving B-cell development(1), the contribution of IgD is not clear. Here we investigate the function of IgD. We generated mice deficient in IgM (IgM(-/-) mice) by deleting the mu. region in embryonic stem cells. IgM-/- mice showed normal B-cell development and maturation, with IgD replacing membrane-bound and secretory IgM. Moreover, specific B-cell responses and isotype class switches occurred during immunization or infection. In contrast to mice deficient in B cells, IgM(-/-) mice survived infection with vesicular stomatitis virus by developing neutralizing immunoglobulins, but they were more susceptible than wild-type controls with delayed specific immunoglobulin responses. These data lead us to conclude that IgD is largely able to substitute for IgM functions.	Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Novartis Pharma Inc Res, Basel, Switzerland; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, Plan Les Ouates, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	Max Planck Society; Novartis; GlaxoSmithKline; University of Zurich; University of Cape Town	Brombacher, F (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-7800 Freiburg, Germany.	fbrombac@uctgshl.uct.ac.za		Ochsenbein, Adrian/0000-0003-1773-5436				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; COICO RF, 1983, J IMMUNOL, V131, P2254; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FREER G, 1994, J VIROL, V68, P3650, DOI 10.1128/JVI.68.6.3650-3655.1994; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IGLESIAS A, 1987, NATURE, V330, P482, DOI 10.1038/330482a0; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LEIST TP, 1987, J IMMUNOL, V138, P2278; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; WEISS EA, 1991, MOL IMMUNOL, V28, P687, DOI 10.1016/0161-5890(91)90110-6; Yuan D, 1996, J IMMUNOL, V157, P2073	30	113	120	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					797	801		10.1038/31716	http://dx.doi.org/10.1038/31716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655395				2022-12-24	WOS:000074433100052
J	Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA				Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA			An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA				TERM-CARE FACILITIES; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; UNITED-STATES; RISK-FACTORS; POLYSACCHARIDE VACCINE; ANTIBIOTIC-THERAPY; HOSPITAL OUTBREAK; CHILDREN; INFECTIONS	Background Outbreaks of pneumococcal disease are uncommon and have occurred mainly in institutional settings. Epidemic, invasive, drug-resistant pneumococcal disease has not been seen among adults in the United States. In February 1996, there was an outbreak of multidrug-resistant pneumococcal pneumonia among the residents of a nursing home in rural Oklahoma. Methods We obtained nasopharyngeai swabs for culture from residents and employees. Streptococcus pneumoniae isolates were serotyped and compared by pulsed-field gel electrophoresis. A retrospective cohort study was conducted to identify factors associated with colonization and disease. Results Pneumonia developed in 11 of 84 residents (13 percent), 3 of whom died. Multidrug-resistant S. pneumoniae, serotype 23F, was isolated from blood and sputum from 7 of the 11 residents with pneumonia (64 percent) and from nasopharyngeal specimens from 17 of the 74 residents tested (23 percent) and 2 of the 69 employees tested (3 percent). All the serotype 23F isolates were identical according to pulsed-field gel electrophoresis. Recent use of antibiotics was associated with both colonization (relative risk, 2.3; 95 percent confidence interval, 1.3 to 4.2) and disease (relative risk, 3.6; 95 percent confidence interval, 1.2 to 10.8). Only three residents (4 percent) had undergone pneumococcal vaccination. After residents received pneumococcal vaccine and prophylactic antibiotics, there were no additional cases of pneumonia, and the rates of carriage decreased substantially. Conclusions In this outbreak a single pneumococcal strain was disseminated among the residents and employees of a nursing home. The high prevalence of colonization with a virulent organism in an unvaccinated population contributed to the high attack rate. Clusters of pneumococcal disease may be underrecognized in nursing homes, and wider use of pneumococcal vaccine is important to prevent institutional outbreaks of drug-resistant S. pneumoniae infection. (N Engl J Med 1998;338:1861-8.) (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Oklahoma State Dept Hlth, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Oklahoma System; University of Oklahoma Health Sciences Center	Butler, JC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, MS C-23,1600 Clifton Rd, Atlanta, GA 30333 USA.							[Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; BECKSAGUE C, 1994, INFECT CONT HOSP EP, V15, P494; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARTER R, 1997, 37 INT C ANT AG CHEM, P55; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; CRAIG AS, 1997, 35 ANNM SAN FRANC SE, P77; Dean A.G., 1994, EPI INFO VERSION 6 W; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FENOLL A, 1991, REV INFECT DIS, V13, P56; Finland M, 1942, MEDICINE, V21, P307, DOI 10.1097/00005792-194209010-00003; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Herrmann KL, 1995, DIAGNOSTIC PROCEDURE, V7th, P121; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JONES SR, 1987, AM J MED, V83, P499, DOI 10.1016/0002-9343(87)90761-3; KATZ PR, 1990, ARCH INTERN MED, V150, P1465, DOI 10.1001/archinte.150.7.1465; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P320; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MANDIGERS CMPW, 1994, EUR RESPIR J, V7, P1635, DOI 10.1183/09031936.94.07091635; Mannheimer SB, 1996, J INFECT DIS, V174, P513, DOI 10.1093/infdis/174.3.513; Marrie TJ, 1996, DRUG AGING, V8, P338, DOI 10.2165/00002512-199608050-00003; MCDOUGAL LK, 1995, ANTIMICROB AGENTS CH, V39, P2282, DOI 10.1128/AAC.39.10.2282; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MILLAR MR, 1994, J HOSP INFECT, V27, P99, DOI 10.1016/0195-6701(94)90002-7; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1993, CLIN INFECT DIS, V17, P66, DOI 10.1093/clinids/17.1.66; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; *NCCLS, 1993, M7A3 NCCLS; Nicolle LE, 1996, INFECT CONT HOSP EP, V17, P119; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Reichler MR, 1996, J INFECT DIS, V173, P374, DOI 10.1093/infdis/173.2.374; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHARTZ JS, 1988, ANN INTERN MED, V109, P762; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Snow R, 1995, PUBLIC HEALTH REP, V110, P720; STRAHAN GW, 1997, ADV DATA VITAL HLTH, V280; Strausbaugh LJ, 1996, INFECT CONT HOSP EP, V17, P129; TAN TQ, 1993, PEDIATRICS, V92, P761; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; ZIMMER JG, 1986, J AM GERIATR SOC, V34, P703, DOI 10.1111/j.1532-5415.1986.tb04301.x; 1996, MMWR MORB MORTAL WKL, V45, P853; 1997, MMWR MORB MORTAL WKL, V46, P60; 1995, MMWR MORB MORTAL WKL, V43, P949; 1996, MMWR MORTAL WKLY REP, V45, P1; 1994, MMWR MORB MORTAL WKL, V43, P23; 1995, MMWR MORB MORTAL WKL, V44, P97	78	190	193	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1861	1868		10.1056/NEJM199806253382601	http://dx.doi.org/10.1056/NEJM199806253382601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637804	Bronze			2022-12-24	WOS:000074352800001
J	Borgstein, J				Borgstein, J			The poetry of genetics: or reading a genetic sequence - a literary model for cellular mechanisms	LANCET			English	Article											Borgstein, J (corresponding author), Hercules 9,Col Credito Constructor, Mexico City 03940, DF, Mexico.							Blake William, 1968, AUGURIES INNOCENCE; KIPLING R, 1987, JUST SO STORIES ELEP	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1353	1354		10.1016/S0140-6736(97)12036-0	http://dx.doi.org/10.1016/S0140-6736(97)12036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643814				2022-12-24	WOS:000073439400043
J	Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N				Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N			Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people	LANCET			English	Article							MEDICATION USE; NURSING-HOME; FALLS; WOMEN; EPIDEMIOLOGY; OSTEOPOROSIS; METAANALYSIS; DEPRESSION; THERAPY	Background Tricyclic antidepressants (TCAs) are associated with an increased risk of falls and hip fractures in elderly people. Selective serotonin-reuptake inhibitors (SSRIs) are reported to be better tolerated than TCAs. We investigated the risk of hip fractures associated with SSRIs and TCAs. Methods This case-control study used administrative healthcare data from the province of Ontario, Canada. 8239 cases-patients aged 66 years or older, treated in hospital between April, 1994, and March, 1995, for hip fracture-were each matched for age and sex to five controls. Logistic regression was used to calculate the odds ratio for hip fracture with adjustment for potential confounding effects produced by concomitant drug use and comorbidity. Findings With participants who had no exposure to antidepressants as the reference category, the adjusted odds ratio for hip fracture was 2.4 (95% CI 2.0-2.7) for exposure to SSRIs, 2.2 (1.8-2.8) for exposure to secondary-amine TCAs, and 1.5 (1.3-1.7) for exposure to tertiary-amine TCAs, For all types of antidepressants, current use was associated with a higher risk of hip fracture than former use, The odds ratios for hip fracture were higher for new current users than for continuous current users in all three drug classes. The proportion of current use in the low-dose range was 22% for SSRIs, 50% for secondary-amine TCAs, and 58% for tertiary-amine TCAs. Interpretation Exposure to any of the three classes of antidepressants is associated with a significant increase in the risk of hip fracture. Despite differences in dose distribution, this analysis suggests that SSRIs do not offer an advantage over TCAs in terms of risk of hip fracture.	Sunnybrook Hlth Sci Ctr, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Clin Res Unit, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Div Geriatr Med, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Toronto, ON, Canada; Univ Toronto, Fac Med, Inst Clin & Evaluat Sci Ontario, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Hlth Adm, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Pharmacol & Drug Safety Res, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Baycrest; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Liu, B (corresponding author), 2075 Bayview Ave,Room E240, Toronto, ON M4N 3M5, Canada.							ANDERSON G, 1996, PATTERNS HLTH CARE O, P323; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; CAMPBELL A J, 1991, Drugs and Aging, V1, P289, DOI 10.2165/00002512-199101040-00005; CLAYER MT, 1989, J TRAUMA, V29, P1673, DOI 10.1097/00005373-198912000-00016; *COMM PROF HOSP AC, 1978, INT CLASS DIS; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; de Jonghe F, 1992, Drugs, V43 Suppl 2, P40; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532-5415.1995.tb05557.x; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; LEONARD BE, 1993, J CLIN PSYCHIAT, V54, P3; LEVINSON ML, 1991, DICP ANN PHARMAC, V25, P657; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; LORD SR, 1995, BRIT J CLIN PHARMACO, V39, P227, DOI 10.1111/j.1365-2125.1995.tb04441.x; Macdonald J B, 1985, Clin Geriatr Med, V1, P621; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; Mittmann N, 1997, J AFFECT DISORDERS, V46, P191, DOI 10.1016/S0165-0327(97)00107-9; NEVITT MC, 1994, RHEUM DIS CLIN N AM, V20, P535; PRESKORN SH, 1993, AM J MED, V94, pS2; PRESKORN SH, 1995, INT CLIN PSYCHOPHARM, V10, P129, DOI 10.1097/00004850-199510030-00001; RAY WA, 1990, AM J EPIDEMIOL, V131, P502, DOI 10.1093/oxfordjournals.aje.a115524; RAY WA, 1991, ARCH INTERN MED, V151, P754, DOI 10.1001/archinte.151.4.754; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; RUTHAZER R, 1993, AM J PUBLIC HEALTH, V83, P746, DOI 10.2105/AJPH.83.5.746; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; SULSER F, 1983, J CLIN PSYCHIAT, V44, P14; THRONGREN KG, 1993, CLIN ORTHOP RELAT R, V287, P76; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; *WHO COLL CTR DRUG, 1991, ATC IND; Williams J. I., 1996, PATTERNS HLTH CARE O, P339	34	286	291	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1303	1307		10.1016/S0140-6736(97)09528-7	http://dx.doi.org/10.1016/S0140-6736(97)09528-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643791				2022-12-24	WOS:000073439400006
J	Jones, EM; MacGowan, AP				Jones, EM; MacGowan, AP			Back to basics in management of Clostridium difficile infections	LANCET			English	Editorial Material							DIARRHEA		Southmead Gen Hosp, Dept Med Microbiol, Bristol BS10 5NB, Avon, England	Southmead Hospital	MacGowan, AP (corresponding author), Southmead Gen Hosp, Dept Med Microbiol, Bristol BS10 5NB, Avon, England.		MacGowan, Alasdair/AAM-1582-2020	MacGowan, Alasdair/0000-0002-6720-5268				CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; *DEP HLTH PUBL HLT, 1994, PREV MAN CLOSTR DIFF; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; Jones EM, 1997, LANCET, V349, P1176, DOI 10.1016/S0140-6736(05)63056-5; McNulty C, 1997, J ANTIMICROB CHEMOTH, V40, P707, DOI 10.1093/jac/40.5.707; Wilcox MH, 1998, J HOSP INFECT, V38, P93, DOI 10.1016/S0195-6701(98)90062-7; Wilcox MH, 1996, J HOSP INFECT, V34, P23, DOI 10.1016/S0195-6701(96)90122-X	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					505	506		10.1016/S0140-6736(05)79246-1	http://dx.doi.org/10.1016/S0140-6736(05)79246-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716052				2022-12-24	WOS:000075435300006
J	Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y				Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y			Callosal window between prefrontal cortices: Cognitive interaction to retrieve long-term memory	SCIENCE			English	Article							CORPUS-CALLOSUM; MONKEYS; CORTEX; COMMISSUROTOMY; ASSOCIATION; ACTIVATION; NEURONS; RETINA	A perceptual image can be recalled from memory without sensory stimulation. However, the neural origin of memory retrieval remains unsettled. To examine whether memory retrieval can be regulated by top-down processes originating from the prefrontal cortex, a visual associative memory task was introduced into the partial split-brain paradigm in monkeys. Long-term memory acquired through stimulus-stimulus association did not transfer via the anterior corpus callosum, a key part interconnecting prefrontal cortices. Nonetheless, when a visual cue was presented to one hemisphere, the anterior callosum could instruct the other hemisphere to retrieve the correct stimulus specified by the cue. Thus, although visual Long-term memory is stored in the temporal cortex, memory retrieval is under the executive control of the prefrontal cortex.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 444, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Hasegawa, I (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Miyashita, Yasushi/B-7171-2019; Hasegawa, Isao/AAW-5682-2021	Miyashita, Yasushi/0000-0003-3496-8637; Hasegawa, Isao/0000-0002-8633-2502				BLACK P, 1964, SCIENCE, V146, P799, DOI 10.1126/science.146.3645.799; Buckner RL, 1996, J NEUROSCI, V16, P6219; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1990, BEHAV BRAIN RES, V38, P109, DOI 10.1016/0166-4328(90)90009-4; FENDRICH R, 1989, NEUROPSYCHOLOGIA, V27, P273, DOI 10.1016/0028-3932(89)90018-3; Fuster JM, 1995, MEMORY CEREBRAL CORT; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; GAZZANIGA MS, 1969, EXP NEUROL, V23, P11, DOI 10.1016/0014-4886(69)90029-6; GAZZANIGA MS, 1966, NEUROPSYCHOLOGIA, V4, P183, DOI 10.1016/0028-3932(66)90047-9; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; HALSBAND U, 1985, BEHAV BRAIN RES, V18, P269, DOI 10.1016/0166-4328(85)90035-X; HAMILTON CR, 1986, 2 HEMISPHERES ONE BR, P315; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; HOLTZMAN JD, 1984, VISION RES, V24, P801, DOI 10.1016/0042-6989(84)90151-2; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MATSUDA K, 1996, NEUROSCI RES       S, V20, pS270; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; NOBLE J, 1973, BRAIN RES, V50, P147, DOI 10.1016/0006-8993(73)90601-X; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PETRIDES M, 1987, FRONTAL LOBES REVISI, P91; SAKAI K, 1995, MAGNET RESON MED, V33, P736, DOI 10.1002/mrm.1910330521; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673; STONE J, 1973, J COMP NEUROL, V150, P333, DOI 10.1002/cne.901500306; STUSS DT, 1989, FRONTAL LOBES; SUGISHITA M, 1978, NEUROPSYCHOLOGIA, V16, P417, DOI 10.1016/0028-3932(78)90065-9; SUGISHITA M, 1994, NEUROPSYCHOLOGIA, V32, P399, DOI 10.1016/0028-3932(94)90086-8; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; ZEKI SM, 1973, J COMP NEUROL, V148, P167, DOI 10.1002/cne.901480204	34	114	117	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					814	818		10.1126/science.281.5378.814	http://dx.doi.org/10.1126/science.281.5378.814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694651				2022-12-24	WOS:000075295600047
J	Krug, EG; Ikeda, RM; Qualls, ML; Anderson, MA; Rosenberg, ML; Jackson, RJ				Krug, EG; Ikeda, RM; Qualls, ML; Anderson, MA; Rosenberg, ML; Jackson, RJ			Preventing land mine-related injury and disability - A public health perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIPERSONNEL MINES; MOZAMBIQUE; CAMBODIA		Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Krug, EG (corresponding author), CDC, Div Violence Prevent & Control, 4770 Buford Hwy,Mailstop K-6, Atlanta, GA 30341 USA.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P37; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P724; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Forjuoh S N, 1993, J Public Health Policy, V14, P355, DOI 10.2307/3343044; HOGDEN HC, 1987, CDC SMALLPOX CRUSADE; *HUM RIGHTS WAT PH, 1993, LANDM DEADL LEG; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; KAKAR F, 1996, PREHOSPITAL DISASTER, V11, P41; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; MURRAY CJL, 1996, GLOBAL BURDEN DIS, P361; *OFF INT SEC PEAC, 1994, HIDD KILL GLOB LANDM; QUALLS M, 1996, MIL MED, V161, P760; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; *WORLD HLTH ASS, 1998, PUBL WHA, V518	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					465	466		10.1001/jama.280.5.465	http://dx.doi.org/10.1001/jama.280.5.465			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701084				2022-12-24	WOS:000075050200036
J	Schimmel, P; Alexander, R				Schimmel, P; Alexander, R			Protein synthesis - All you need is RNA	SCIENCE			English	Editorial Material							LARGE RIBOSOMAL-SUBUNIT; ESCHERICHIA-COLI; PEPTIDYL TRANSFERASE; TERTIARY STRUCTURE; CROSS-LINKS; SECONDARY; MODEL		Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.							FRANCESCHI FJ, 1990, J BIOL CHEM, V265, P16676; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRUGIER M, 1994, EMBO J, V13, P2219; GRIFFITH L, UNPUB; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MITCHELL P, 1990, NUCLEIC ACIDS RES, V18, P4325, DOI 10.1093/nar/18.15.4325; Nierhaus K., 1990, RIBOSOMES PROTEIN SY, P161; Nitta I, 1998, RNA, V4, P257; Nitta I, 1998, SCIENCE, V281, P666, DOI 10.1126/science.281.5377.666; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Rich A., 1962, HORIZONS BIOCH, P103; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	17	9	9	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					658	659		10.1126/science.281.5377.658	http://dx.doi.org/10.1126/science.281.5377.658			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9714675				2022-12-24	WOS:000075107900029
J	Kiser, PF; Wilson, G; Needham, D				Kiser, PF; Wilson, G; Needham, D			A synthetic mimic of the secretory granule for drug delivery	NATURE			English	Article							MAST-CELL; VESICLES; ACCUMULATION; PRODUCTS	Secretory cells contain submicroscopic granules composed of a polyanionic polymer network that is collapsed owing to the presence of hydronium ions and weak base cations(1-3). The network is encapsulated within a lipid membrane, and functions as a vehicle for the osmotically inert storage of a variety of granule-bound endogenous mediator species, such as histamine, serotonin and proteases. These species are excreted from the granule and thence from the cell in response to external biochemical signals(1-4) Hydrogels that swell and shrink in response to external stimuli might serve as synthetic analogues of secretory granules(5,6). Here we describe the systematic engineering of multi-component, environmentally responsive hydrogel microspheres, coated with a lipid bilayer to mimic more closely the natural secretory granule. These microspheres exhibit pH- and ion-dependent volume phase transitions and ion-sensitive exchange of bound cations when the encapsulating lipid membrane is porated. We stimulated poration electrically in individual microgel particles immobilized and manipulated with a micropipette. This system could find use for the triggered release of encapsulated drugs in the body.	Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; Access Pharmaceut, Dallas, TX 75207 USA; Glynn Wilson Grp, Issaquah, WA 98027 USA	Duke University	Needham, D (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA.	david.needham@duke.edu	Kiser, Patrick F/C-2843-2014	Kiser, Patrick F/0000-0002-3868-7122; Needham, David/0000-0002-0082-9148				CHEN Y, 1994, MICROSPHERES REGIONA, P2; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EICHENBAUM G, IN PRESS MACROMOLECU; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1997, Patent No. 5654006; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; KASHIWABARA M, 1995, COLLOID POLYM SCI, V273, P339, DOI 10.1007/BF00652347; KISER P, 1997, P AM CHEM SOC DIV PO, V76, P226; MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; NEEDHAM D, 1989, BIOPHYS J, V55, P1001, DOI 10.1016/S0006-3495(89)82898-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; RICKA J, 1984, MACROMOLECULES, V17, P2916, DOI 10.1021/ma00142a081; VERDUGO P, 1995, P INT S CONTR REL BI, P114; WU NZ, 1993, CANCER RES, V53, P3765	20	239	244	4	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					459	462		10.1038/28822	http://dx.doi.org/10.1038/28822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697768				2022-12-24	WOS:000075080400046
J	Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G				Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G			PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization	CELL			English	Article							CASEIN KINASE-II; MANNOSE 6-PHOSPHATE RECEPTOR; CYTOPLASMIC DOMAIN; INTRACELLULAR TRAFFICKING; PHOSPHORYLATION SITE; PROPROTEIN CONVERTASE; MESSENGER-RNAS; CELL-SURFACE; FURIN; IDENTIFICATION	We report the role of one member of a novel gene family, PACS-1, in the localization of trans-Golgi network (TGN) membrane proteins. PACS-1 directs the TGN localization of furin by binding to the protease's phosphorylated cytosolic domain. Antisense studies show TGN localization of furin and mannose-6-phosphate receptor, but not TGN46, is strictly dependent on PACS-1.Analyses in vitro and in vivo show PACS-1 has properties of a coat protein and connects furin to components of the clathrin-sorting machinery. Cell-free assays indicate TGN localization of furin is directed by a PACS-1-mediated retrieval step. Together, these findings explain a mechanism by which membrane proteins in mammalian cells are localized to the TGN.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Thomas, G (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.				NIDDK NIH HHS [DK09394, DK44629, DK37274, R01 DK037274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629, F32DK009394, R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hartmann C, 1997, DEV GENES EVOL, V207, P186, DOI 10.1007/s004270050106; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Ikonen E, 1997, J CELL SCI, V110, P2155; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KORNER C, 1994, J BIOL CHEM, V269, P16529; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mallet WG, 1996, J CELL SCI, V109, P3059; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; Norais N, 1996, J VIROL, V70, P5716, DOI 10.1128/JVI.70.8.5716-5719.1996; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Sambrook J., 1989, MOL CLONING, V1; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAO ZB, 1993, J VIROL, V67, P4464, DOI 10.1128/JVI.67.8.4464-4473.1993	47	306	316	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					205	216		10.1016/S0092-8674(00)81420-8	http://dx.doi.org/10.1016/S0092-8674(00)81420-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695949	Bronze			2022-12-24	WOS:000075020100009
J	Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU				Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU			A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock	NATURE			English	Article							CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; CAFFEINE; PROTEIN; SHIFTS; THAPSIGARGIN; RAPAMYCIN; RETICULUM; MUSCLE; RIBOSE	Circadian clocks are complex biochemical systems that cycle with a period of approximately 24 hours. They integrate temporal information regarding phasing of the solar cycle, and adjust their phase so as to synchronize an organism's internal state to the local environmental day and night(1,2). Nocturnal light is the dominant regulator of this entrainment. In mammals, information about nocturnal light is transmitted by glutamate released om retinal projections to the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Clock resetting requires the activation of ionotropic glutamate receptors, which mediate Ca2+ influx(3). The response induced by such activation depends on the clock's temporal state: during early night it delays the clock phase, whereas in late night the clock phase is advanced. To investigate this differential response, we sought signalling elements that contribute solely to phase delay. We analysed intracellular calcium-channel ryanodine receptors, which mediate coupled Ca2+ signalling, Depletion of intracellular Ca2+ stores during early night blocked the effects of glutamate. Activators of ryanodine receptors induced phase resetting only in early night; inhibitors selectively blocked delays induced by light and glutamate. These findings implicate the release of intracellular Ca2+ through ryanodine receptors in the light-induced phase delay of the circadian clock restricted to the early night.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Neurosci Program, Urbana, IL 61801 USA; Univ Illinois, Comp & Commun Serv Off, Urbana, IL 61801 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; McGill University; Howard Hughes Medical Institute; University of Iowa; University of Iowa	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Buchanan, Gordon/0000-0003-2371-4455; Campbell, Kevin/0000-0003-2066-5889				BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DENT M, 1996, NEUR ABSTR, V22; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Liu C, 1997, J NEUROSCI, V17, P659; Mathur A, 1996, AM J PHYSIOL-REG I, V270, pR1031, DOI 10.1152/ajpregu.1996.270.5.R1031; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pawlikowska L, 1996, J NEUROSCI, V16, P5372; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; PROSSER RA, 1989, J NEUROSCI, V9, P1073; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER ET, 1995, BRAIN RES, V692, P137; WEBER ET, 1995, NEUROSCI LETT, V197, P227, DOI 10.1016/0304-3940(95)11961-U; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; ZATZ M, 1995, J NEUROCHEM, V65, P1332	27	182	184	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					381	384		10.1038/28639	http://dx.doi.org/10.1038/28639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690474				2022-12-24	WOS:000074968800054
J	Zhang, NA; Gridley, T				Zhang, NA; Gridley, T			Defects in somite formation in lunatic fringe deficient mice	NATURE			English	Article							EXPRESSION; DORSAL; BOUNDARY; DELTA; NOTCH	Segmentation in vertebrates first arises when the unsegmented paraxial mesoderm subdivides to form paired epithelial spheres called somites(1,2). The Notch signalling pathway is important in regulating the formation and anterior-posterior patterning of the vertebrate somite(3-7). One component of the Notch signalling pathway in Drosophila is the fringe gene, which encodes a secreted signalling molecule required for activation of Notch during specification of the wing margins-(8-11). Here we show that mice homozygous for a targeted mutation of the lunatic fringe (Lfng) gene, one of the mouse homologues(12,13) of fringe, have defects in somite formation and anterior-posterior patterning of the somites. Somites in the mutant embryos are irregular in size and shape, and their anterior-posterior patterning is disturbed. Marker analysis revealed that in the presomitic mesoderm of the mutant embryos, sharply demarcated domains of expression of several components of the Notch signalling pathway are replaced by even gradients of gene expression. These results indicate that Lfng encodes an essential component of the Notch signalling pathway during somitogenesis in mice.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Gridley, T (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	gridley@jax.org						BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BLAIR SS, 1997, CURR BIOL, V7, pR636; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; deCelis JF, 1996, DEVELOPMENT, V122, P359; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; GOSSLER A, 1997, CURR TOP DEV BIOL, V33, P225; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; MONTARRAS D, 1991, NEW BIOL, V3, P592; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SWIATEK P, 1993, GENE DEV, P2071; Tannahill D, 1997, CELL TISSUE RES, V290, P275, DOI 10.1007/s004410050932; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG C, 1997, NATURE, V387, P288	27	344	352	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					374	377		10.1038/28625	http://dx.doi.org/10.1038/28625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690472				2022-12-24	WOS:000074968800052
J	Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y				Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y		Osaka Hepatocellular Carcinoma Prevention Stud	Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER-DISEASE; B VIRAL-HEPATITIS; CHRONIC NON-A; ALPHA-INTERFERON; CONTROLLED TRIAL; RISK-FACTORS; RANDOMIZED TRIAL; ALFA THERAPY; VIRUS	Background: The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined. Objective: To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Design: Retrospective cohort study. Setting: One university hospital and seven university-affiliated hospitals. Patients: 419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls). Intervention: Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-alpha 2a, or recombinant interferon-alpha 2b for 6 months. Measurements: The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography. Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up. Relapse was defined as a normal serum ALT revel at the end of treatment with an increase to an abnormal level after cessation of treatment. Nonresponse included all other ALT patterns. Results: Median follow-up in the interferon and control groups was 47.6 and 46.8 months, respectively. During follow-up, hepatocellular carcinoma was found in 28 interferon-treated patients and 19 controls. Cox proportional hazards regression analysis that included all patients revealed that interferon therapy (P = 0.041), older age (P = 0.003), greater histologic activity (P = 0.029), and higher histologic stage (P = 0.049) were independent factors associated with the development of hepatocellular carcinoma. The risk ratios for development of hepatocellular carcinoma in patients with sustained response, relapse, and nonresponse were 0.06 (95% CI, 0.01 to 0.46), 0.51 (CI, 0.20 to 1.27), and 0.95 (CI, 0.48 to 1.84), respectively, compared with controls. Conclusions: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Kawata, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							BRUIX J, 1989, LANCET, V2, P1004; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVID E, 1992, AM J CLIN PATHOL, V98, P397, DOI 10.1093/ajcp/98.4.397; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIODATI G, 1991, J MED VIROL, V35, P151, DOI 10.1002/jmv.1890350302; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MANABE N, 1993, HEPATOLOGY, V18, P1344, DOI 10.1016/0270-9139(93)90222-9; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; MURAKAMI R, 1990, INT J CANCER, V46, P159, DOI 10.1002/ijc.2910460203; MURAKAMI R, 1990, CANCER, V65, P1255, DOI 10.1002/1097-0142(19900301)65:5<1255::AID-CNCR2820650536>3.0.CO;2-P; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OKUDA K, 1987, CANCER RES, V47, P4967; Poynard T, 1996, HEPATOLOGY, V24, P778; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502	31	296	304	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					94	99		10.7326/0003-4819-129-2-199807150-00005	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669992				2022-12-24	WOS:000074852000003
J	Pittet, D; Harbarth, S				Pittet, D; Harbarth, S			What techniques for diagnosis of ventilator-associated pneumonia?	LANCET			English	Editorial Material									Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Geneva; Harvard University; Harvard T.H. Chan School of Public Health	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland.							Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Pittet D, 1998, HOSP INFECT, P381; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					83	84		10.1016/S0140-6736(98)85005-8	http://dx.doi.org/10.1016/S0140-6736(98)85005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672269				2022-12-24	WOS:000074775100005
J	Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O				Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O			Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro	NATURE			English	Article							GABAERGIC INTERNEURONS; PYRAMIDAL CELLS; NEURONS; RAT; CORTEX; SLICE; SYNCHRONIZATION; EXCITATION; RHYTHMS; MODEL	Acetylcholine is vital for cognitive functions of the brain. Although its actions in the individual cell are known in some detail(1), its effects at the network level are poorly understood(2). The hippocampus, which receives a major cholinergic input from the medial septum/diagonal band(3), is important in memory(4,5) and exhibits network activity at 40 Hz during relevant behaviours(6). Here we show that cholinergic activation is sufficient to induce 40-Hz network oscillations(7) in the hippocampus in vitro. Oscillatory activity is generated spontaneously in the CA3 subfield and can persist for hours. During the oscillatory state, principal neurons fire action potentials that are phase-related to the extracellular oscillation, but each neuron fires in only a small proportion of the cycles. Both excitatory and inhibitory synaptic events participate during the network oscillation in a precise temporal pattern. These results indicate that subcortical cholinergic input can control hippocampal memory processing by inducing fast network oscillations.	Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	University of Oxford	Fisahn, A (corresponding author), Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.		Paulsen, Ole/ABB-4843-2020	Paulsen, Ole/0000-0002-2258-5455	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARDO LS, 1982, BRAIN RES, V249, P315, DOI 10.1016/0006-8993(82)90066-X; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAGIN A, 1995, J NEUROSCI, V15, P47; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Cobb SR, 1997, NEUROSCIENCE, V79, P629, DOI 10.1016/S0306-4522(97)00055-9; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; FELLOUS JM, IN PRESS P COMP NEUR; FREEMAN WJ, 1968, J NEUROPHYSIOL, V31, P337, DOI 10.1152/jn.1968.31.3.337; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; HASSELMO ME, 1994, J NEUROSCI, V14, P3898; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; LILJENSTROM H, 1995, J NEUROPHYSIOL, V74, P288, DOI 10.1152/jn.1995.74.1.288; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILLES R, 1990, J PHYSL, V428, P61; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; SHUTE CCD, 1963, NATURE, V199, P1160, DOI 10.1038/1991160a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Whittington MA, 1997, P NATL ACAD SCI USA, V94, P12198, DOI 10.1073/pnas.94.22.12198; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Williams JH, 1997, J NEUROPHYSIOL, V78, P2631, DOI 10.1152/jn.1997.78.5.2631; WILSON M, 1992, J NEUROPHYSIOL, V67, P981, DOI 10.1152/jn.1992.67.4.981	30	656	666	2	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					186	189		10.1038/28179	http://dx.doi.org/10.1038/28179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671302				2022-12-24	WOS:000074705900055
J	Kemp, M				Kemp, M			Lane's landscapes	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					135	135		10.1038/28072	http://dx.doi.org/10.1038/28072			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671295	Bronze			2022-12-24	WOS:000074705900035
J	Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP				Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP			Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA TRIGLYCERIDE CONCENTRATION; MYOCARDIAL-INFARCTION; LDL CHOLESTEROL; HDL-CHOLESTEROL; A-I; MEN; ASSOCIATION; HYPERINSULINEMIA; SUBFRACTION	Context.-Epidemiological studies have established a relationship between cholesterol and low-density lipoprotein cholesterol (LDL-C) concentrations and the risk of ischemic heart disease (IHD), but up to half of patients with IHD may have cholesterol levels in the normal range. Objective.-To assess the ability to predict the risk of IHD using a cluster of nontraditional metabolic risk factors that includes elevated fasting insulin and apolipoprotein B levels as well as small, dense LDL particles. Design.-Nested case-control study. Setting.-Cases and controls were identified from the population-based cohort of the Quebec Cardiovascular Study, a prospective study conducted in men free of IHD in 1985 and followed up for 5 years. Participants.-Incident IHD cases were matched with controls selected from among the sample of men who remained IHD free during follow-up. Matching variables were age, smoking habits, body mass index, and alcohol consumption. The sample included 85 complete pairs of nondiabetic IHD cases and controls, Main Outcome Measures.-Ability of fasting insulin level, apolipoprotein B level, and LDL particle diameter to predict IHD events, defined as angina, coronary insufficiency, nonfatal myocardial infarction, anti coronary death. Results.-The risk of IHD was significantly increased in men who had elevated fasting plasma insulin and apolipoprotein B levels and small, dense LDL particles, compared with men who had normal levels for 2 of these 3 risk factors (odds ratio [OR], 5.9; 95% confidence interval [CI], 2.3-15.4). Multivariate adjustment for LDL-C, triglycerides, and high-density lipoprotein cholesterol (HDL-C) did not attenuate the relationship between the cluster of nontraditional risk factors and IHD (OR, 5.2; 95% CI, 1.7-15.7). On the other hand, the risk of IHD in men having a combination of elevated LDL-C and triglyceride levels and reduced HDL-C levels was no longer significant (OR, 1.4, 95% CI, 0.5-3.5) after multivariate adjustment for fasting plasma insulin level, apolipoprotein B level, and LDL particle size. Conclusion.-Results from this prospective study suggest that the measurement of fasting plasma insulin level, apolipoprotein B level, and LDL particle size may provide further information on the risk of IHD compared with the information provided by conventional lipid variables.	Laval Univ Hosp, Res Ctr, Lipid Res Ctr, St Foy, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Despres, JP (corresponding author), CHUL, Res Ctr, Lipid Res Ctr, 2705 Laurier Blvd,TR-93, St Foy, PQ G1V 4G2, Canada.		应, 宁宁/G-9472-2011; Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378; Tchernof, Andre/0000-0002-2587-1000				ALBERS JJ, 1978, CLIN CHEM, V24, P323; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; ASSMANN G, 1994, ATHEROSCLEROSIS, V110, pS11, DOI 10.1016/0021-9150(94)05386-W; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CORESH J, 1993, J LIPID RES, V34, P1687; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; Davignon J, 1996, ATHEROSCLEROSIS, V124, pS57, DOI 10.1016/0021-9150(96)05858-3; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Despres Jean-Pierre, 1993, Nutrition Research Reviews, V6, P137, DOI 10.1079/NRR19930010; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FRIEDEWALD WT, 1972, SCAND J CLIN LAB INV, V124, P23; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GINSBURG GS, 1991, AM J CARDIOL, V68, P187, DOI 10.1016/0002-9149(91)90742-4; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KRAUSS RM, 1982, J LIPID RES, V23, P97; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lamarche B, 1997, ARTERIOSCL THROM VAS, V17, P1098, DOI 10.1161/01.ATV.17.6.1098; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MCNAMARA JR, 1992, ARTERIOSCLER THROMB, V12, P1284, DOI 10.1161/01.ATV.12.11.1284; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; NIGON F, 1991, J LIPID RES, V32, P1741; Perry IJ, 1996, AM J EPIDEMIOL, V144, P224, DOI 10.1093/oxfordjournals.aje.a008917; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1495; Sniderman AD, 1996, CLIN CHEM, V42, P489; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Superko HR, 1996, CIRCULATION, V94, P2351, DOI 10.1161/01.CIR.94.10.2351; Tchernof A, 1996, DIABETES CARE, V19, P629, DOI 10.2337/diacare.19.6.629; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; YARNELL JWG, 1994, BRIT HEART J, V71, P293; YUAN JN, 1994, ATHEROSCLEROSIS, V110, P1, DOI 10.1016/0021-9150(94)90062-0	44	303	325	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1955	1961		10.1001/jama.279.24.1955	http://dx.doi.org/10.1001/jama.279.24.1955			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643858	Bronze			2022-12-24	WOS:000074252100031
J	Piot, P				Piot, P			The science of AIDS: A tale of two worlds	SCIENCE			English	Editorial Material									UNAIDS, CH-1211 Geneva 27, Switzerland	UNAIDS	Piot, P (corresponding author), UNAIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.								0	29	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1844	1845		10.1126/science.280.5371.1844	http://dx.doi.org/10.1126/science.280.5371.1844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669936				2022-12-24	WOS:000074323800028
J	Gauss, R; Seifert, R; Kaupp, UB				Gauss, R; Seifert, R; Kaupp, UB			Molecular identification of a hyperpolarization-activated channel in sea urchin sperm	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; GATED CHANNEL; CAMP; DROSOPHILA; FAMILY; ROD; SEQUENCE; GENES	Sea urchin eggs attract sperm through chemotactic peptides, which evoke complex changes in membrane voltage and in the concentrations of cyclic AMP, cyclic GMP and Ca2+ ions (see ref. 1 for a review). The intracellular signalling pathways and their cellular targets are largely unknown. We have now cloned, from sea urchin testis, the complementary DNA encoding a channel polypeptide, SPIH, Functional expression of SPIH gives rise to weakly K+-selective hyperpolarization-activated channels, whose activity is enhanced by the direct action of cAMP. Thus, SPIH is under the dual control of voltage and cAMP. The SPIH channel, which is confined to the sperm flagellum, may be involved in the control of flagellar beating. SPM currents exhibit all the hallmarks of hyperpolarization-activated currents (I-h)(2,3), which participate in the rhythmic firing of central neurons, control pacemaking in the heart, and curtail saturation by bright light in retinal photoreceptors(2,3). Because of their sequence(4) and functional properties, I-h channels form a class of their own within the superfamily of voltage-gated and cyclic-nucleotide-gated channels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	a.eckert@fz-juelich.de						AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BABCOCK DE, 1992, P NATL ACAD SCI USA, V86, P6001; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Darszon A., 1994, Methods (Orlando), V6, P37, DOI 10.1006/meth.1994.1006; DIFRANCESCO D, 1984, J PHYSIOL-LONDON, V348, P341, DOI 10.1113/jphysiol.1984.sp015114; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FINN JT, ANN REV PHYSL, V58, P395; Hagen V, 1996, BIOCHEMISTRY-US, V35, P7762, DOI 10.1021/bi952895b; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Labarca P, 1996, DEV BIOL, V174, P271, DOI 10.1006/dbio.1996.0072; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749	30	364	374	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					583	587		10.1038/31248	http://dx.doi.org/10.1038/31248			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634235				2022-12-24	WOS:000074150100054
J	Hawkey, PM				Hawkey, PM			Action against antibiotic resistance: no time to lose	LANCET			English	Editorial Material									Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hawkey, PM (corresponding author), Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England.							Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Chiew YF, 1998, J ANTIMICROB CHEMOTH, V41, P247, DOI 10.1093/jac/41.2.247; HALL A, 1976, NATURE, V264, P803, DOI 10.1038/264803a0; *HOUS LORDS SEL CO, 1998, 7 HOUS LORDS SEL CO, P1; *JOINT COMM US ANT, 1969, REP JOINT COMM US AN; LACEY RW, 1984, LANCET, V2, P1022; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; Munro S, 1998, AM J CLIN PATHOL, V109, P144; Piddock LJV, 1997, J ANTIMICROB CHEMOTH, V39, P177, DOI 10.1093/jac/39.2.177; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; Woodford N, 1998, ANTIMICROB AGENTS CH, V42, P502, DOI 10.1128/AAC.42.3.502	11	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1298	1299		10.1016/S0140-6736(98)22018-6	http://dx.doi.org/10.1016/S0140-6736(98)22018-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643787				2022-12-24	WOS:000073439400002
J	Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K				Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K			Mass screening for lung cancer with mobile spiral computed tomography scanner	LANCET			English	Article							DETECTION PROGRAM; NEW-YORK; PREVALENCE; SURVIVAL	Background The incidence of and mortality from lung cancer have increased steadily. Most lung cancers are not localised when first detected, but early detection is mandatory to improve prognosis. Since curable early cases are hard to visualise with conventional chest radiography, a new diagnostic means must be found. We assessed whether population-based mass screening with a spiral computed tomography scanner could contribute substantially to detection of smaller cancers, and decrease mortality. Methods In 1996, we screened in a mobile unit 5483 individuals from the general population of Matsumoto, Japan, aged between 40 years and 74 years who had undergone annual chest radiography (miniature fluorophotography) and cytological assessment of sputum. All participants had a low-dose X-ray spiral computed tomography (CT) scan of the thorax; 3967 also underwent miniature fluorophotography. We compared smokers and non-smokers. Further assessments were done for probably benign but suspicious lesions; suspicion of cancer; and indeterminate small nodules by chest radiography and conventional CT, with additional transbronchial biopsy when possible. Thoracotomy was recommended when it was strongly suspected that the patients had lung cancer. Findings 19 patients were diagnosed as having lung cancer--14 with suspicion of lung cancer, three with benign but suspicious lesions, and two with indeterminate small nodules. 18 cases were surgically confirmed, and one was clinically diagnosed. The mean size of lesions was 17 mm (range 6-47). In four of 19 patients, lung abnormality was seen on CT and miniature fluorophotography, The lung-cancer detection rate with CT was 0 4846, significantly higher than the 0 03-0 05% for standard mass assessments done previously in the same area. CT missed one case that was found solely on a sputum cytology examination. Interpretation Our results show that miniature fluorophotography or conventional chest radiography, which have been the main diagnostic techniques for lung cancer, showed few small cancers. CT was more accurate in mass screening for lung cancer and led to early detection and an accurate diagnosis of lung cancer, and should be considered in future health plans.	Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 390862, Japan; Japan Matsumoto Res Ctr, Telecommun Advancement Org, Matsumoto, Nagano, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; National Institute of Information & Communications Technology (NICT) - Japan	Sone, S (corresponding author), Shinshu Univ, Sch Med, Dept Radiol, 3-1-1 Asahi, Matsumoto, Nagano 390862, Japan.							BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; EBELING K, 1987, INT J CANCER, V40, P141, DOI 10.1002/ijc.2910400202; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Hillerdal G, 1996, LUNG CANCER-J IASLC, V15, P21, DOI 10.1016/0169-5002(96)00567-3; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; MELAMED M, 1977, CANCER, V39, P369, DOI 10.1002/1097-0142(197702)39:2<369::AID-CNCR2820390202>3.0.CO;2-I; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; SOBUE T, 1992, INT J CANCER, V50, P230, DOI 10.1002/ijc.2910500212	12	689	727	0	65	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1242	1245		10.1016/S0140-6736(97)08229-9	http://dx.doi.org/10.1016/S0140-6736(97)08229-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643744				2022-12-24	WOS:000073283600010
J	Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP				Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP			Postnatal growth and health in children born after cryopreservation as embryos	LANCET			English	Article							IN-VITRO FERTILIZATION; CONGENITAL-MALFORMATIONS; ASSISTED REPRODUCTION; INVITRO FERTILIZATION; CHRONIC ILLNESS; BIRTH; PREGNANCIES; PREVALENCE; WEIGHT	Background There is uncertainty about the health of children born from in-vitro fertilisation (IVF) with cryopreserved embryos. We investigated the postnatal growth and health (up to 18 months) of these children compared with those born after standard IVF with fresh embryos and those from spontaneous pregnancies. Methods 255 children from cryopreserved embryos were matched by maternal age, parity, single or twin pregnancy, and date of delivery with 255 children born after IVF with fresh embryos, and 252 children from spontaneous pregnancies. The main endpoint was growth; secondary endpoints were the prevalence of chronic illness, major malformations, cumulative incidence of common diseases, and development during the first 18 months. Growth was assessed by comparison with standard Swedish growth charts and by standard deviation scores. Findings Growth features were similar for both singletons and twins in the three groups, There were 6 (2.4%) of 255, 9 (3.5%) of 255, and 8 (3.2%) of 252 major malformations in the cryopreserved group, standard IVF, and spontaneous groups, respectively (p=0.6 between the cryopreserved and standard IVF group). The prevalence of chronic diseases did not differ between the three groups, with 18.0%, 15.3%, and 16.7% of children with a chronic illness in the cryopreserved group, standard IVF, and spontaneous groups, respectively. Interpretation The cryopreservation process does not adversely affect the growth and health of children during infancy and early childhood. Minor handicaps, behavioural disturbances, learning difficulties, and dysfunction of attention and perception cannot be ruled out at this age.	Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Paediat, S-41345 Gothenburg, Sweden; Univ Goteborg, Carlanderska Hosp, Fertil Ctr Scandinavla, Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg	Wennerholm, UB (corresponding author), Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden.		Albertsson-Wikland, Kerstin/D-3843-2012					BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BRANDES JM, 1992, PEDIATRICS, V90, P424; BYLUND B, IN PRESS ACTA SCAND; CADMAN D, 1987, PEDIATRICS, V79, P805; Cederblad M, 1996, HUM REPROD, V11, P2052; DARIN N, IN PRESS DEV MED CHI; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; FOYLE LW, 1995, ARCH DIS CHILD, V73, pF143; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; Golombok S, 1996, HUM REPROD, V11, P2324; Hagberg B, 1996, ACTA PAEDIATR, V85, P954, DOI 10.1111/j.1651-2227.1996.tb14193.x; HAGELIN E, 1991, J ADV NURS, V16, P15, DOI 10.1111/j.1365-2648.1991.tb01492.x; KARLBERG J, 1987, ACTA PAEDIATR SCAND, V76, P478, DOI 10.1111/j.1651-2227.1987.tb10503.x; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KARLBERG P, 1976, ACTA PAEDIATR SC   S, V258, P1; Kohler L, 1991, CHILDRENS HLTH SWEDE; KOHLER L, 1987, CLIN DEV MED, V98, P36; LASSALLE B, 1985, FERTIL STERIL, V44, P645; MORIN NC, 1989, J PEDIATR-US, V115, P222, DOI 10.1016/S0022-3476(89)80069-1; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Olivennes F, 1996, HUM REPROD, V11, P1565; RAOULDUVAL A, 1994, HUM REPROD, V9, P1097, DOI 10.1093/oxfordjournals.humrep.a138639; Saunders K, 1996, PEDIATRICS, V97, P688; SCHEFFZEK A, 1989, MONATSSCHR KINDERH, V137, P42; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; SUTCLIFFE AG, 1995, ARCH DIS CHILD, V72, P290, DOI 10.1136/adc.72.4.290; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; Wennerholm UB, 1997, HUM REPROD, V12, P1819, DOI 10.1093/humrep/12.8.1819; WESTBOM L, 1987, SCAND J SOC MED, V15, P87, DOI 10.1177/140349488701500206; WIDLUND G, 1986, SCAND J SOC MED, V14, P97, DOI 10.1177/140349488601400210; WIKLAND M, 1994, HUM REPROD, V9, P1430, DOI 10.1093/oxfordjournals.humrep.a138724	33	88	95	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1085	1090		10.1016/S0140-6736(97)08247-0	http://dx.doi.org/10.1016/S0140-6736(97)08247-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660577				2022-12-24	WOS:000073090200009
J	Jensen, TK; Hjollund, NHI; Henriksen, TB; Scheike, T; Kolstad, H; Giwercman, A; Ernst, E; Bonde, JP; Skakkebaek, NF; Olsen, J				Jensen, TK; Hjollund, NHI; Henriksen, TB; Scheike, T; Kolstad, H; Giwercman, A; Ernst, E; Bonde, JP; Skakkebaek, NF; Olsen, J			Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; CAFFEINE CONSUMPTION; DELAYED CONCEPTION; COFFEE-DRINKING; RISK-FACTORS; WOMEN; INFERTILITY; ETHANOL; FECUNDABILITY; SUBFECUNDITY	Objective: To examine the effect of alcohol consumption on the probability of conception. Design: A follow up study over six menstrual cycles or until a clinically recognised pregnancy occurred after discontinuation of contraception. Subjects: 430 Danish couples aged 20-35 years trying to conceive for the first time. Main outcome measures: Clinically recognised pregnancy. Fecundability odds ratio: odds of conception among exposed couples divided by odds among those not exposed. Results: In the six cycles of follow up 64% (179) of women with a weekly alcohol intake of less than five drinks and 55% (75) of women with a higher intake conceived. After adjustment for cycle number, smoking in either partner or smoking exposure in utero, centre of enrolment, diseases in female reproductive organs, woman's body mass index, sperm concentration, and duration of menstrual cycle, the odds ratio decreased with increasing alcohol intake from 0.61 (95% confidence interval 0.40 to 0.93) among women consuming 1-5 drinks a week to 0.34 (0.22 to 0.52) among women consuming more than 10 drinks a week (P = 0.03 for trend) compared with women with no alcohol intake. Among men no dose-response association was found after control for confounders including women's alcohol intake. Conclusion: A woman's alcohol intake is associated with decreased fecundability even among women with a weekly alcohol intake corresponding to five or fewer drinks. This finding needs further corroboration, but it seems reasonable to encourage women to avoid intake of alcohol when they are trying to become pregnant.	Natl Univ Hosp, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Occupat Med, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Perinatal Epidemiol Res Unit, Dept Obstet & Gynaecol, Aarhus, Denmark; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen N, Denmark; Aarhus Univ, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Rigshospitalet; University of Copenhagen; Aarhus University; Aarhus University; University of Copenhagen; Aarhus University	Jensen, TK (corresponding author), Natl Univ Hosp, Rigshosp, Dept Growth & Reprod, Sect GR 5064,9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	tkjensen@winsloew.ou.dk		Jensen, Tina Kold/0000-0003-2311-5778; Hjollund, Niels Henrik I/0000-0002-6697-6597				Ahlborg G, 1996, INT J EPIDEMIOL, V25, P783, DOI 10.1093/ije/25.4.783; ALDERETE E, 1995, EPIDEMIOLOGY, V6, P403, DOI 10.1097/00001648-199507000-00013; BAHAMONDES L, 1994, FERTIL STERIL, V61, P478; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BECKER U, 1989, DRUG ALCOHOL DEPEN, V24, P75, DOI 10.1016/0376-8716(89)90012-4; BECKER U, 1993, DAN MED BULL, V40, P447; Bonde JPE, 1998, REPROD TOXICOL, V12, P19, DOI 10.1016/S0890-6238(97)00096-8; BUNKER ML, 1979, J AM DIET ASSOC, V74, P28; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; Curtis KM, 1997, AM J EPIDEMIOL, V146, P32, DOI 10.1093/oxfordjournals.aje.a009189; DEMOUZON J, 1988, INT J EPIDEMIOL, V17, P378, DOI 10.1093/ije/17.2.378; DUNPHY BC, 1991, ANDROLOGIA, V23, P219; FLORACK EIM, 1994, PREV MED, V23, P175, DOI 10.1006/pmed.1994.1024; GAVALER JS, 1980, ALCOHOL CLIN EXP RES, V4, P271, DOI 10.1111/j.1530-0277.1980.tb04813.x; GRODSTEIN F, 1994, AM J PUBLIC HEALTH, V84, P1429, DOI 10.2105/AJPH.84.9.1429; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hadi H A, 1987, Obstet Gynecol Surv, V42, P69; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; Joesoef M R, 1993, Ann Epidemiol, V3, P592, DOI 10.1016/1047-2797(93)90080-N; JOFFE M, 1994, AM J EPIDEMIOL, V140, P921, DOI 10.1093/oxfordjournals.aje.a117180; LEACH RE, 1993, TERATOLOGY, V47, P57, DOI 10.1002/tera.1420470110; MELLO NK, 1983, SCIENCE, V221, P677, DOI 10.1126/science.6867739; OLDEREID NB, 1992, INT J FERTIL, V37, P343; OLSEN J, 1991, AM J EPIDEMIOL, V133, P734, DOI 10.1093/oxfordjournals.aje.a115948; Olsen J, 1996, FERTIL STERIL, V66, P95, DOI 10.1016/S0015-0282(16)58393-9; Olsen J, 1997, ALCOHOL CLIN EXP RES, V21, P206, DOI 10.1111/j.1530-0277.1997.tb03751.x; OLSEN J, 1983, INT J EPIDEMIOL, V12, P179, DOI 10.1093/ije/12.2.179; PARAZZINI F, 1993, ARCH ANDROLOGY, V31, P105; SALLMEN M, 1995, AM J IND MED, V27, P699, DOI 10.1002/ajim.4700270506; Schmidt L, 1995, BRIT J OBSTET GYNAEC, V102, P978, DOI 10.1111/j.1471-0528.1995.tb10905.x; SHARMA SC, 1970, INDIAN J MED RES, V58, P501; Stanton CK, 1995, AM J EPIDEMIOL, V142, P1322, DOI 10.1093/oxfordjournals.aje.a117600; VALIMAKI MJ, 1995, ACTA OBSTET GYN SCAN, V74, P462, DOI 10.3109/00016349509024410; WILCOX A, 1988, LANCET, V2, P1453; WILLIAMSON DF, 1987, AM J PUBLIC HEALTH, V77, P1324, DOI 10.2105/AJPH.77.10.1324; WILSNACK SC, 1984, ALCOHOL CLIN EXP RES, V8, P451, DOI 10.1111/j.1530-0277.1984.tb05700.x; ZAADSTRA BM, 1994, FERTIL STERIL, V62, P948	39	128	130	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					505	510						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712595	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075641400018
J	Price, SR; Evens, PR; Nagai, K				Price, SR; Evens, PR; Nagai, K			Crystal structure of the spliceosomal U2B ''-U2A ' protein complex bound to a fragment of U2 small nuclear RNA	NATURE			English	Article							LEUCINE-RICH REPEATS; BINDING DOMAIN; U1A PROTEIN; PREMESSENGER RNA; A-PROTEIN; RIBONUCLEOPROTEIN; RECOGNITION; SEQUENCE; IDENTIFICATION; MOTIF	We have determined the crystal structure at 2.4 Angstrom resolution of a ternary complex between the spliceosomal U2B "/U2A' protein complex and hairpin-loop IV of U2 small nuclear RNA. Unlike its close homologue the U1A protein, U2B " binds to its cognate RNA only in the presence of U2A', which contains leucine-rich repeats in its sequence. The concave surface of a parallel p-sheet within the leucine-rich-repeat region of U2A' Interacts with the ribonucleoprotein domain of U2B " on the surface opposite its RNA-binding surface. The basic carboxy-terminal region of U2A' interacts with the RNA stem. the crystal structure reveals how protein-protein interaction regulates RNA-binding specificity, and how replacing only a few key residues allows the U2B " and U1B proteins to discriminate between their cognate RNA hairpins by forming alternative networks of interactions.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Nagai, K (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	kn@mrc-lmb.cam.ac		Price, Stephen/0000-0001-7804-9849				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Biswas R, 1997, J MOL BIOL, V267, P1149, DOI 10.1006/jmbi.1997.0936; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; HARPER DS, 1992, NUCLEIC ACIDS RES, V20, P3645, DOI 10.1093/nar/20.14.3645; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1994, MANUAL; Jovine L, 1996, STRUCTURE, V4, P621, DOI 10.1016/S0969-2126(96)00066-4; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1995, J MOL BIOL, V249, P409, DOI 10.1006/jmbi.1995.0306; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PolycarpouSchwarz M, 1996, RNA, V2, P11; Price Sr, 1998, PRACT APPROACH SER, V192, P37; Saenger W., 1984, PRINCIPLES NUCL ACID; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SILLEKENS PTG, 1989, NUCLEIC ACIDS RES, V17, P1893, DOI 10.1093/nar/17.5.1893; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; Uhlenbeck OC, 1997, CELL, V90, P833, DOI 10.1016/S0092-8674(00)80348-7; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Williams DJ, 1996, J MOL BIOL, V257, P265; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	308	315	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 13	1998	394	6694					645	650		10.1038/29234	http://dx.doi.org/10.1038/29234			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716128				2022-12-24	WOS:000075384200033
J	Topham, MK; Bunting, M; Zimmerman, GA; McIntyre, TM; Blackshear, PJ; Prescott, SM				Topham, MK; Bunting, M; Zimmerman, GA; McIntyre, TM; Blackshear, PJ; Prescott, SM			Protein kinase C regulates the nuclear localization of diacylglycerol kinase-zeta	NATURE			English	Article							MOLECULAR-CLONING; SUBSTRATE MARCKS; CELL-CYCLE; MEMBRANE; FAMILY; PHOSPHORYLATION; EXPRESSION; LOCATION; ISOZYME; DOMAIN	Diacylglycerol kinases (DGKs) terminate signalling from diacylglycerol by converting it to phosphatidic acid(1-8) Diacylglycerol regulates cell growth and differentiation, and its transient accumulation in the nucleus may be particularly important in this regulation(9,10) Here we show that a fraction of DGK-zeta is found in the nucleus, where it regulates the amount of nuclear diacylglycerol. Reducing nuclear diacylglycerol levels by conditional expression of DGK-zeta attenuates cell growth. The nuclear-localization signal of DGK-zeta is located in a region that is homologous to the phosphorylation-site domain of the MARCKS protein. This is, to our knowledge, the first evidence that this domain, which is a major target for protein kinase C, can localize a protein to the nucleus. Two isoforms of protein kinase C, but not others, regulate the localization of DGK-zeta. Our results define a cycle in which diacylglycerol activates protein kinase C, which then regulates the metabolism of diacylglycerol by alternating the intracellular location of DGK-zeta. This maybe a general mechanism to control mitogenic signals that depend on nuclear diacylglycerol.	Univ Utah, Huntman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Natl Inst Environm Hlth, Res Triangle Pk, NC 27709 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Prescott, SM (corresponding author), Univ Utah, Huntman Canc Inst, Salt Lake City, UT 84112 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Houssa B, 1997, J BIOL CHEM, V272, P10422; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; KAI M, 1994, J BIOL CHEM, V269, P18492; KLAUCK TM, 1996, J BIOL CHEM, V271, P19871; LEACH KL, 1992, J BIOL CHEM, V267, P21816; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; YORK JD, 1994, J BIOL CHEM, V269, P7847	29	245	250	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					697	700		10.1038/29337	http://dx.doi.org/10.1038/29337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716136				2022-12-24	WOS:000075384200049
J	Garbe, E; Suissa, S; LeLorier, J				Garbe, E; Suissa, S; LeLorier, J			Association of inhaled corticosteroid use with cataract extraction in elderly patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; ASPIRIN-LIKE ANALGESICS; AGE-RELATED CATARACTS; RISK-FACTORS; STEROID AEROSOLS; ASTHMA; THERAPY; BECLOMETHASONE; GLUCOCORTICOIDS; EPIDEMIOLOGY	Context.-The use of systemic corticosteroids is a known risk factor for the development of cataracts. Objective.-To determine whether treatment with inhaled corticosteroids is associated with cataract extraction in the elderly. Design.-Case-control study. Setting.-Quebec universal health insurance program for all elderly (provincial health insurance plan database [RAMQ database]). Patients.-RAMQ enrollees 70 years and older. The 3677 cases were patients with a cataract extraction between 1992 and 1994. The 21 868 controls were randomly selected from patients who did not have a diagnosis of cataract and matched to cases on the index date of the case. Main Outcome Measures.-Odds ratio of cataract extraction in patients with prolonged cumulative exposure to inhaled corticosteroids compared with nonusers. Results.-Excluding patients with systemic steroid treatment and after adjusting for age, sex, diabetes, systemic hypertension, glaucoma, ophthalmic steroids, and the number of physician claims for services, use of inhaled corticosteroids for more than 3 years was associated with undergoing cataract extraction (odds ratio [OR], 3.06; 95% confidence interval [CI], 1.53-6.13). For high average daily doses of beclomethasone or budesonide (>1 mg), the OR was elevated after more than 2 years of treatment (OR, 3.40; 95% CI, 1.49-7.76), whereas for low to medium doses (less than or equal to 1 mg) of these drugs, the OR was 1.63 (95% CI, 0.85-3.13) after 2 years. Conclusion.-Prolonged administration of high doses of inhaled corticosteroids increases the likelihood of undergoing cataract extraction in elderly patients. Further studies are needed to investigate the risk of developing cataracts for low to medium doses over longer periods.	Potsdam Inst Pharmacoepidemiol & Technol Assessme, D-14482 Potsdam, Germany; Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University; Laval University; Universite de Montreal	Garbe, E (corresponding author), Potsdam Inst Pharmacoepidemiol & Technol Assessme, Otto Erich Str 7, D-14482 Potsdam, Germany.	106700.3205@compuserve.com						ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; [Anonymous], 1990, BRIT MED J, V301, P651; [Anonymous], 1993, BRIT MED J, V306, P776; BARNES NC, 1993, RESP MED, V87, P27, DOI 10.1016/S0954-6111(05)80254-9; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; Bonomi L, 1989, Dev Ophthalmol, V17, P196; Cumming RG, 1997, NEW ENGL J MED, V337, P1555; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DOLEZAL JM, 1989, AM J EPIDEMIOL, V129, P559, DOI 10.1093/oxfordjournals.aje.a115168; FORERO R, 1992, J ADOLESCENT HEALTH, V13, P707, DOI 10.1016/1054-139X(92)90068-M; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; Garbe E, 1997, NEW ENGL J MED, V337, P1555; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; HARDING JJ, 1993, BRIT J OPHTHALMOL, V77, P2, DOI 10.1136/bjo.77.1.2; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; ISAAC NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P256, DOI 10.1001/archopht.1991.01080020102053; JICK H, 1984, AM J OPHTHALMOL, V98, P355, DOI 10.1016/0002-9394(84)90328-3; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P640, DOI 10.1016/S0002-9394(14)70223-5; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; MUNOZ B, 1993, ARCH OPHTHALMOL-CHIC, V111, P110, DOI 10.1001/archopht.1993.01090010114036; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; RENFRO L, 1992, DERMATOL CLIN, V10, P505; *SAS I INC, 1992, P229 SAS I INC, P435; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; VANHEYNINGEN R, 1986, LANCET, V1, P1111; WALKER A M, 1988, Journal of Clinical Research and Drug Development, V2, P227; WEST SK, 1995, SURV OPHTHALMOL, V39, P323; World Health Organization, 1977, INT CLASS DIS 9 REVI	43	144	148	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					539	543		10.1001/jama.280.6.539	http://dx.doi.org/10.1001/jama.280.6.539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707144				2022-12-24	WOS:000075244900030
J	McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD				McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD			Decoupled temporal patterns of evolution and ecology in two post-Paleozoic clades	SCIENCE			English	Article							DIVERSITY; DIVERSIFICATION; HISTORY; DOMINANCE; CRINOIDS; BIOMASS; TIME	Counts of taxonomic diversity are the prevailing standards for documenting Large-scall patterns of evolution in the fossil record, However, the secular pattern of relative ecological importance between the bryozoan clades Cyclostomata and Cheilostomata is not reflected fully in compilations of generic diversity or within-fauna species richness, and the delayed ecological recovery of the Cheilostomata after the mass extinction at the Cretaceous-Tertiary boundary is missed entirely. These observations demonstrate that evolutionary success and ecological dominance can be decoupled and profoundly different, even over tons of millions of years.	Appalachian State Univ, Dept Geol, Boone, NC 28608 USA; Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	University of North Carolina; Appalachian State University; Field Museum of Natural History (Chicago); University of Chicago; Natural History Museum London	McKinney, FK (corresponding author), Appalachian State Univ, Dept Geol, Boone, NC 28608 USA.	mckinneyfk@appstate.edu		Taylor, Paul/0000-0002-3127-080X	NIDCR NIH HHS [DEB 9306729] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1975, COMMUNITIES ECOSYSTE; AUSICH WI, 1981, OHIO J SCI, V81, P268; AUSICH WI, 1982, SCIENCE, V216, P173, DOI 10.1126/science.216.4542.173; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BERGLUND BE, 1996, PALEOECOLOGICAL EVEN; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Cheetham A. H., 1971, Smithsonian Contributions to Paleobiology, V6, P1; FOOTE M, 1991, PALAEONTOLOGY, V34, P461; FOOTE M, 1991, Contributions from the Museum of Paleontology University of Michigan, V28, P101; Foote M, 1996, SCIENCE, V274, P1492, DOI 10.1126/science.274.5292.1492; FOOTE M, 1992, P NATL ACAD SCI USA, V89, P7325, DOI 10.1073/pnas.89.16.7325; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; FOOTE M, 1995, PALEOBIOLOGY, V21, P273, DOI 10.1017/S0094837300013300; FOWELL SJ, 1993, TECTONOPHYSICS, V222, P361, DOI 10.1016/0040-1951(93)90359-R; Gaston K.J, 1996, BIODIVERSITY BIOL NU; GORDON DP, 1996, BRYOZOANS SPACE TIME, P213; HAKANSSON E, 1962, DANMARKS GEOL UNDERS, V83, P1; Jackson J.B.C., 1988, PALEOBIOLOGY, V14, P307; Krause D. W., 1986, CONTRIBUTIONS GEOLOG, V3, P95; LIDGARD S, 1989, PALEOBIOLOGY, V15, P255, DOI 10.1017/S0094837300009441; LIDGARD S, 1993, PALEOBIOLOGY, V19, P352, DOI 10.1017/S0094837300000324; LUPIA R, IN PRESS BIOTIC RESP; McKinney F.K., 1989, BRYOZOAN EVOLUTION; MCNAUGHTON SJ, 1970, SCIENCE, V167, P131, DOI 10.1126/science.167.3915.131; PHILLIPS TL, 1984, INT J COAL GEOL, V3, P205, DOI 10.1016/0166-5162(84)90019-3; Sepkoski J.J. Jr, 1985, P11; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; SEPKOSKI JJ, 1988, PALEOBIOLOGY, V14, P221, DOI 10.1017/S0094837300011969; SEPKOSKI JJ, 1995, GLOBAL EVENTS EVENT, P35; SIGNOR PW, 1990, ANNU REV ECOL SYST, V21, P509, DOI 10.1146/annurev.es.21.110190.002453; SMITH AM, 1992, PALAEOGEOGR PALAEOCL, V93, P213, DOI 10.1016/0031-0182(92)90098-P; SMITH AM, 1994, OLSEN INT S, P177; Speijer RP, 1996, GEOL SOC SP, P343, DOI 10.1144/GSL.SP.1996.001.01.26; STAFF G, 1985, LETHAIA, V18, P209, DOI 10.1111/j.1502-3931.1985.tb00700.x; TAYLOR PD, 1988, EXTINCTION SURVIVAL, P99; THAYER CW, 1983, BIOTIC INTERACTIONS, P480; Upchurch G.R. Jr, 1989, P195; Vermeij G.J., 1987, EVOLUTION ESCALATION; Wilkinson L., 1990, SYSTAT SYSTEM STAT; WILSON E O, 1992	42	65	67	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					807	809		10.1126/science.281.5378.807	http://dx.doi.org/10.1126/science.281.5378.807			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694648				2022-12-24	WOS:000075295600044
J	Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P				Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P			Role of phosphorylation in regulation of the assembly of endocytic coat complexes	SCIENCE			English	Article							PROTEIN-KINASE-C; FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; NERVE-TERMINALS; TRANSMITTER RELEASE; CLATHRIN; DYNAMIN; AMPHIPHYSIN; INHIBITOR; POTENT	Clathrin-mediated endocytosis involves cycles of assembly and disassembly of clathrin coat components and their accessory proteins. Dephosphorylation of rat brain extract was shown to promote the assembly of dynamin 1, synaptojanin 1, and amphiphysin into complexes that also included clathrin and AP-2, Phosphorylation of dynamin 1 and synaptojanin 1 inhibited their binding to amphiphysin, whereas phosphorylation of amphiphysin inhibited its binding to AP-2 and clathrin. Thus, phosphorylation regulates the association and dissociation cycle of the clathrin-based endocytic machinery, and calcium-dependent dephosphorylation of endocytic proteins could prepare nerve terminals for a burst of endocytosis.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu			NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Merisko E M, 1986, Pancreas, V1, P110, DOI 10.1097/00006676-198603000-00002; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHOOK WJ, 1985, P NATL ACAD SCI USA, V82, P8039, DOI 10.1073/pnas.82.23.8039; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	39	269	273	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					821	824		10.1126/science.281.5378.821	http://dx.doi.org/10.1126/science.281.5378.821			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694653				2022-12-24	WOS:000075295600049
J	Whybrew, K; Murray, M; Morley, C				Whybrew, K; Murray, M; Morley, C			Diagnosing fever by touch: observational study	BRITISH MEDICAL JOURNAL			English	Article							AXILLARY		Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Cambridge CB2 2QQ, England	University of Cambridge	Morley, C (corresponding author), Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Box 226, Cambridge CB2 2QQ, England.			Morley, Colin/0000-0001-5388-0214				CLARKE S, 1992, BRIT MED J, V304, P961, DOI 10.1136/bmj.304.6832.961; Einterz EM, 1997, LANCET, V350, P781, DOI 10.1016/S0140-6736(97)24037-7; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; Shann F, 1996, ARCH PEDIAT ADOL MED, V150, P74, DOI 10.1001/archpedi.1996.02170260078013	5	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					321	321		10.1136/bmj.317.7154.321	http://dx.doi.org/10.1136/bmj.317.7154.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685279	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000075409500023
J	Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M				Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M			Regulation of a transcription factor network required for differentiation and metabolism	SCIENCE			English	Article							PYRUVATE-KINASE GENE; DEFINITIVE ENDODERM; EXPRESSION; MOUSE; INSULIN; HNF-3-BETA; NOTOCHORD; PROMOTER	Hepatocyte nuclear factors (HNFs) are a heterogeneous class of evolutionarily conserved transcription factors that are required for cellular differentiation and metabolism. Mutations in HNF-1 alpha and HNF-4 alpha genes impair insulin secretion and cause type 2 diabetes. Regulation of HNF-4/HNF-1 expression by HNF-3 alpha and HNF-3 beta was studied in embryoid bodies in which one or both HNF-3 alpha or HNF-3 beta alleles were inactivated. HNF-3 beta positively regulated the expression of HNF-4 alpha/HNF-1 alpha and their downstream targets, implicating a role in diabetes. HNF-3 beta was also necessary for expression of HNF-3 alpha. In contrast, HNF-3 alpha acts as a negative regulator of HNF-4 alpha/HNF-1 alpha demonstrating that HNF-3 alpha. and HNF-3 beta have antagonistic transcriptional regulatory functions in vivo. HNF-3 alpha does not appear to act as a classic biochemical repressor but rather exerts its negative effect by competing for HNF-3 binding sites with the more efficient activator HNF-3 beta. In addition, the HNF-3 alpha/HNF-3 beta ratio is modulated by the presence of insulin, providing evidence that the HNF network may have important roles in mediating the action of insulin.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Rockefeller University; Rockefeller University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stoffel, M (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.	stoffel@rockvax.rockefeller.edu		Dufort, Daniel/0000-0002-6477-596X; Duncan, Stephen/0000-0002-2507-7827; Navas, Maria Angeles/0000-0001-6858-2172; Stoffel, Markus/0000-0003-1304-5817				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DUNCAN S, UNPUB; Duncan SA, 1997, DEVELOPMENT, V124, P279; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Nagy A., 1993, Gene targeting: a practical approach., P147; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; SASAKI H, 1993, DEVELOPMENT, V118, P47; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Tronche F., 1994, LIVER GENE EXPRESSIO; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Vaisse C, 1997, DIABETES, V46, P1364, DOI 10.2337/diabetes.46.8.1364; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	280	294	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					692	695		10.1126/science.281.5377.692	http://dx.doi.org/10.1126/science.281.5377.692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685261				2022-12-24	WOS:000075107900040
J	Huber, C; Wachtershauser, G				Huber, C; Wachtershauser, G			Peptides by activation of amino acids with CO on (Ni,Fe)S surfaces: Implications for the origin of life	SCIENCE			English	Article								In experiments modeling volcanic or hydrothermal settings amino acids were converted into their peptides by use of coprecipitated (Ni,Fe)S and CO in conjunction with H2S (or CH3SH) as a catalyst and condensation agent at 100 degrees C and pH 7 to 10 under anaerobic, aqueous conditions. These results demonstrate that amino acids can be activated under geochemically relevant conditions. They support a thermophilic origin of Life and an early appearance of peptides in the evolution of a primordial metabolism.	Tech Univ Munich, Dept Organ Chem & Biochem, D-85747 Munich, Germany	Technical University of Munich	Wachtershauser, G (corresponding author), Tal 29, D-80331 Munich, Germany.							BRACK A, 1984, ORIGINS LIFE EVOL B, V14, P229, DOI 10.1007/BF00933662; Bujdak J, 1996, J INORG BIOCHEM, V63, P119, DOI 10.1016/0162-0134(95)00186-7; Bujdak J, 1997, J MOL EVOL, V45, P457, DOI 10.1007/PL00006250; Fox S. W., 1977, MOL EVOLUTION ORIGIN; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; LAHAV N, 1978, SCIENCE, V201, P67, DOI 10.1126/science.663639; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; RABINOWI.J, 1969, NATURE, V224, P795, DOI 10.1038/224795a0; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHWENDINGER MG, 1995, INORG CHIM ACTA, V228, P207, DOI 10.1016/0020-1693(94)04186-Y; SHOCK EL, 1992, GEOCHIM COSMOCHIM AC, V56, P3481, DOI 10.1016/0016-7037(92)90392-V; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams RJP, 1997, CELL MOL LIFE SCI, V53, P816, DOI 10.1007/s000180050102	16	443	456	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					670	672		10.1126/science.281.5377.670	http://dx.doi.org/10.1126/science.281.5377.670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685253				2022-12-24	WOS:000075107900032
J	Stern, EA; Jaeger, D; Wilson, CJ				Stern, EA; Jaeger, D; Wilson, CJ			Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo	NATURE			English	Article							MICROEXCITABLE ZONES; PRIMATE NEOSTRIATUM; PROJECTION NEURONS; RAT NEOSTRIATUM; FIRING PATTERNS; IN-VIVO; RESPONSES; MICROSTIMULATION; ORGANIZATION; OSCILLATION	The basal ganglia are an interconnected set of subcortical regions whose established role in cognition and motor control remains poorly understood An important nucleus within the basal ganglia, the striatum, receives cortical afferents that convey sensorimotor, limbic and Cognitive information(1). The activity of medium-sized spiny neurons in the striatum seems to depend on convergent input within these information channels(2). To determine the degree of correlated input, both below and at threshold for the generation of action potentials, we recorded intracellularly from pairs of spiny neurons in vivo. Here we report that the transitions between depolarized and hyperpolarized states were highly Correlated among neurons. Within individual depolarized states, some significant synchronous fluctuations in membrane potential occurred, but action potentials were not synchronized. Therefore, although the mean afferent signal across fibres is highly correlated among striatal neurons, the moment-to-moment variations around the mean, which determine the timing of action potentials, are not. We propose that the precisely timed, synchronous component of the membrane potential signals activation of cell assemblies and enables firing to occur. The asynchronous component, with low redundancy, determines the fine temporal pattern of spikes.	Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Tennessee System; University of Tennessee Health Science Center; Emory University	Stern, EA (corresponding author), Univ Tennessee, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	edstern@marlin.utmem.edu	Wilson, Charles/D-2529-2011	Wilson, Charles/0000-0002-9004-2145; Jaeger, Dieter/0000-0002-5122-1319				ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; ALEXANDER GE, 1985, J NEUROPHYSIOL, V53, P1417, DOI 10.1152/jn.1985.53.6.1417; ALEXANDER GE, 1985, J NEUROPHYSIOL, V53, P1401, DOI 10.1152/jn.1985.53.6.1401; AMZICA F, 1995, J NEUROPHYSIOL, V73, P20, DOI 10.1152/jn.1995.73.1.20; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Choi SK, 1997, J NEUROSCI, V17, P8613; Contreras D, 1997, NEUROSCIENCE, V76, P25; DIGGLE PJ, 1990, TIME SERIES; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FLAHERTY AW, 1993, J NEUROSCI, V13, P1120; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HULL CD, 1970, BRAIN RES, V22, P163, DOI 10.1016/0006-8993(70)90002-8; JAEGER D, 1995, BRAIN RES, V694, P111, DOI 10.1016/0006-8993(95)00780-T; JAEGER D, 1994, J NEUROPHYSIOL, V72, P2555, DOI 10.1152/jn.1994.72.5.2555; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; ONN SP, 1994, J NEUROPHYSIOL, V71, P1917, DOI 10.1152/jn.1994.71.5.1917; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; Plenz D, 1998, J NEUROSCI, V18, P266; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Stern EA, 1997, J NEUROPHYSIOL, V77, P1697, DOI 10.1152/jn.1997.77.4.1697; STERN EA, 1993, ADV NEURAL INF PROCE, V5, P377; Wickens JR, 1998, J NEUROPHYSIOL, V79, P2358, DOI 10.1152/jn.1998.79.5.2358; Wilson C. J., 1992, SINGLE NEURON COMPUT, P141, DOI [10.1016/B978-0-12-484815-3.50012-8, DOI 10.1016/B978-0-12-484815-3.50012-8]; WILSON CJ, 1981, BRAIN RES, V220, P67, DOI 10.1016/0006-8993(81)90211-0; WILSON CJ, 1993, PROG BRAIN RES, V99, P277; WILSON CJ, 1986, BRAIN RES, V367, P201, DOI 10.1016/0006-8993(86)91593-3; Wilson CJ, 1996, J NEUROSCI, V16, P2397; WILSON CJ, 1997, SYNAPTIC ORG BRAIN, P329	30	265	269	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					475	478		10.1038/28848	http://dx.doi.org/10.1038/28848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697769				2022-12-24	WOS:000075080400051
J	Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ				Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ			Factors associated with the transition to nonprone sleep positions of infants in the United States - The National Infant Sleep Position Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; RISK-FACTORS; NEW-ZEALAND; SIDS; EPIDEMIOLOGY; MORTALITY; TASMANIA; COHORT	Context.-Studies have demonstrated strong associations between the prone sleep position (on the stomach) and sudden infant death syndrome (SIDS), In 1992, the American Academy of Pediatrics recommended that infants be placed to sleep laterally (on their side) or supine (on their back) to reduce SIDS risk, and in 1994, the national public education campaign "Back to Sleep" was launched. Objective.-To determine the typical sleep position of infants younger than 8 months in the United States, the changes that occurred after these recommendations, and the factors associated with the placement of infants prone or supine. Design.-Annual nationally representative telephone surveys. Setting.-The 48 contiguous states of the United States. Participants.-Nighttime caregivers of infants born within the last 7 months between 1992 and 1996, Approximately 1000 interviews were conducted per year. Main Outcome Measures.-The position the infant was usually placed in for sleep, and the position the infant was most commonly found in when checked during the night's sleep. Results.-Ninety-seven percent of respondents in each wave of the survey usually placed their infant to sleep in a specific position. Infants were placed in the prone position by 70% of caregivers in 1992, prior to the campaign, but only 24% in 1996, Supine and lateral placements increased during this time period, from 13% in 1992 to 35% in 1996 and from 15% in 1992 to 39% in 1996, respectively. Significant predictors of prone placement included maternal race reported as black (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.68-3.26), mother's age 20 to 29 years (OR, 1.28; 95% CI, 1.09-1.50), region reported as the mid-Atlantic (OR, 1.41; 95% CI, 1.12-1.78) or southern states (OR, 1.47; 95% CI, 1.22-1.70), mothers with a previous child (OR, 1.68; 95% CI, 1.43-1.97), and infants younger than 8 weeks (OR, 0.63; 95% CI, 0.46-0.85), Infants aged 8 to 15 weeks were significantly more likely to be placed nonprone over time compared with the other age groups. Most of the risk factors for prone were significantly related in the opposite direction to supine placement. Conclusions.-The prevalence of infants placed in the prone sleep position declined by 66% between 1992 and 1996, Although causality cannot be proved, SIDS rates declined approximately 38% during this period. To achieve further reduction in prone sleeping, efforts to promote the supine sleep position should be aimed at groups at high risk for prone placement.	NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Epidemiol Stat & Data Syst Branch, NIH, Bethesda, MD USA; Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Neonatol & Pediat Pulmonol, Los Angeles, CA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Boston Univ, Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Children's Hospital Los Angeles; University of Southern California; Harvard University; Harvard Medical School; Boston University	Willinger, M (corresponding author), NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Execut Bldg,Room 4B03,6100 Execut Blvd,MSC 7510, Bethesda, MD 20892 USA.	mw75q@nih.gov		Corwin, Michael/0000-0002-6591-209X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022996, U10HD029067] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-2-9067, HD-2-2996] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P66; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P859; CHESSARE JB, 1995, PEDIATRICS, V96, P893; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DAVIES DP, 1989, BMJ-BRIT MED J, V298, P1518; DEJONGE GA, 1993, ARCH DIS CHILD, V69, P660, DOI 10.1136/adc.69.6.660; DOLLFUS C, 1990, PEDIATRICS, V86, P176; DWYER T, 1991, J PAEDIATR CHILD H, V27, P340, DOI 10.1111/j.1440-1754.1991.tb00415.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GIBSON E, 1995, PEDIATRICS, V96, P69; GILBERT R, 1994, ARCH DIS CHILD, V70, P445, DOI 10.1136/adc.70.5.445; Guyer B, 1996, PEDIATRICS, V98, P1007; Hiley CMH, 1996, BRIT MED J, V312, P1397, DOI 10.1136/bmj.312.7043.1397a; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOFFMAN HJ, 1996, 4 SIDS INT C JUN 23; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HUNT CE, 1992, PEDIATRICS, V90, P115; IRGENS LM, 1995, ARCH DIS CHILD, V72, P478, DOI 10.1136/adc.72.6.478; KATTWINKEL J, 1994, PEDIATRICS, V93, P820; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KOCHANEK KD, 1995, MON VITAL STAT REP S, V43, P62; LEVIN ML, 1978, AM J EPIDEMIOL, V108, P78; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; ORENSTEIN SR, 1993, PEDIATRICS, V91, P497; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Platt MJ, 1996, ARCH DIS CHILD, V75, P527, DOI 10.1136/adc.75.6.527; PONSONBY AL, 1995, PAEDIATR PERINAT EP, V9, P256, DOI 10.1111/j.1365-3016.1995.tb00141.x; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; Ventura S. J., 1994, MONTHLY VITAL STAT R, V43, P1; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P38; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46, P28; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P49; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1991, Pediatric Pathology, V11, P677	43	183	186	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					329	335		10.1001/jama.280.4.329	http://dx.doi.org/10.1001/jama.280.4.329			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686549	Bronze			2022-12-24	WOS:000074804200032
J	Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R				Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R			Presence of a newly described human DNA virus (TTV) in patients with liver disease	LANCET			English	Article							HEPATITIS-G VIRUS; PARVOVIRUS B19; INFECTION; CLONING; AGENT	Background A newly described DNA virus, named transfusion-transmitted virus (TTV), was recently detected with high prevalence in Japanese patients with fulminant hepatitis end chronic liver disease of unknown aetiology. We investigated the presence of this virus in patients with liver disease in the UK to find out whether TTV infection is associated with liver damage. Methods We used semi-nested PCR to amplify TTV DNA from serum samples from 126 adults, of whom 72 were patients with a range of chronic liver diseases, 24 had spontaneous resolution of infection with hepatitis C virus (HCV), and 30 were normal controls. Direct DNA sequencing and phylogenetic analysis were used to characterise the TTV isolates. Findings We detected TTV DNA in 18 (25%) of the 72 patients with chronic liver disease, which was not different from the 10% prevalence in normal controls (p=0.15). The rate of TTV DNA was similar among patients with various liver diseases. The majority of TTV-positive cases had no biochemical or histological evidence of significant liver damage. TTV DNA sequencing of nine isolates showed the same genotypic groups as in Japan: three patients were infected with genotype 1, which showed 4% nucleotide divergence, and six patients were infected with genotype 2 with 15-27% divergence. Interpretation The high prevalence of active TTV infection in the general population, both in the UK and in Japan, and the lack of significant liver damage, suggest that TTV, similar to hepatitis G virus (HGV), may be an example of a human virus with no clear disease association.	UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England; UCL, Sch Med, Dept Biol, London WC1E 6HX, England; UCL, Sch Med, Dept Anthropol, London WC1E 6HX, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naoumov, NV (corresponding author), UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England.	n.naoumov@ucl.ac.uk	Thomas, Mark G/A-2219-2012	Thomas, Mark G/0000-0002-2452-981X				ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; ANDERSON MJ, 1987, J VIROL METHODS, V17, P175, DOI 10.1016/0166-0934(87)90080-2; ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; Yoto Y, 1996, LANCET, V347, P1563	14	262	273	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					195	197		10.1016/S0140-6736(98)04069-0	http://dx.doi.org/10.1016/S0140-6736(98)04069-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683209				2022-12-24	WOS:000074859800013
J	Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA				Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA			Requirement for the leukocyte-specific adapter protein SLP-76 for normal T-cell development	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; ALPHA-BETA; GENE; KINASE; INHIBITION; ACTIVATION; P56(LCK); MICE	The Leukocyte-specific adapter molecule SLP-76 (Src homology 2 domain-containing Leukocyte protein of 76 kilodaltons) is rapidly phosphorylated on tyrosine residues after receptor Ligation in several hematopoietically derived cell types. Mice made deficient for SLP-76 expression contained no peripheral T cells as a result of an early block in thymopoiesis. Macrophage and natural killer cell compartments were intact in SLP-76-deficient mice, despite SLP-76 expression in these lineages in wild-type mice. Thus, the SLP-76 adapter protein is required for normal-thymocyte development and plays a crucial role in translating signals mediated by pre-T cell receptors into distal biochemical events.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.		Koretzky, Gary/AAU-5381-2021		NIGMS NIH HHS [GM53256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053256, R01GM053256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1995, ONCOGENE, V10, P1141; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHU KT, 1994, J BIOL CHEM, V269, P24095; CLEMENTS JA, UNPUB; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	25	357	363	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					416	419		10.1126/science.281.5375.416	http://dx.doi.org/10.1126/science.281.5375.416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665885				2022-12-24	WOS:000074918800048
J	Ronaghi, M; Uhlen, M; Nyren, P				Ronaghi, M; Uhlen, M; Nyren, P			A sequencing method based on real-time pyrophosphate	SCIENCE			English	Article							DNA		Royal Inst Technol, Dept Biochem & Biotechnol, SE-10044 Stockholm, Sweden	Royal Institute of Technology	Nyren, P (corresponding author), Royal Inst Technol, Dept Biochem & Biotechnol, SE-10044 Stockholm, Sweden.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DOREMUS HD, 1988, PLANT PHYSIOL, V87, P36, DOI 10.1104/pp.87.1.36; DRMANAC R, 1989, GENOMICS, V4, P114; EKSTROM B, UNPUB; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HOLMBERG A, UNPUB; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HYMAN ED, 1988, ANAL BIOCHEM, V174, P423, DOI 10.1016/0003-2697(88)90041-3; Jones DH, 1997, BIOTECHNIQUES, V22, P938, DOI 10.2144/97225rr01; Koster H, 1996, NAT BIOTECHNOL, V14, P1123, DOI 10.1038/nbt0996-1123; METZKER ML, 1994, NUCLEIC ACIDS RES, V22, P4259, DOI 10.1093/nar/22.20.4259; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; Ronaghi M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/abio.1996.0432; ROSENTHAL A, 1989, Patent No. 761107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	19	1101	1636	10	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					363	+		10.1126/science.281.5375.363	http://dx.doi.org/10.1126/science.281.5375.363			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705713				2022-12-24	WOS:000074918800035
J	St Louis, ME; Wasserheit, JN				St Louis, ME; Wasserheit, JN			Epidemiology - Elimination of syphilis in the United States	SCIENCE			English	Editorial Material									Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	St Louis, ME (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-02, Atlanta, GA 30333 USA.	mes2@cdc.gov; jzw6@cdc.gov						Berkelman RL, 1996, JAMA-J AM MED ASSOC, V275, P315, DOI 10.1001/jama.275.4.315; DOWDLE WR, 1988, ERADICATION INFECT D; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; Hook EW, 1996, SEX TRANSM DIS, V23, P5, DOI 10.1097/00007435-199601000-00004; Institute of Medicine, 1997, HIDD EP CONFR SEX TR; Jones JH, 1981, BAD BLOOD TUSKEGEE S; PARRA T, 1937, SHADOW LAND; PILLAY A, IN PRESS SCIENCE; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911	11	71	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					353	354		10.1126/science.281.5375.353	http://dx.doi.org/10.1126/science.281.5375.353			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705711				2022-12-24	WOS:000074918800028
J	Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH				Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH			Persistent parasitemia after acute babesiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI DNA; LYME-DISEASE; ANTIBIOTIC-TREATMENT; RAPID DIAGNOSIS; TRANSFUSION; MICROTI; INFECTIONS; STATE; FLUID	Background Babesiosis, a zoonosis caused by the protozoan Babesia microti, is usually nor treated when the symptoms are mild, because the parasitemia appears to be transient. However, the microscopical methods used to diagnose this infection are insensitive, and few infected people have been followed longitudinally. We compared the duration of parasitemia in people who had received specific antibabesial therapy with that in silently infected people who had not received specific therapy. Methods Forty-six babesia-infected subjects were identified from 1991 through 1996 in a prospective, community-based study designed to detect episodes of illness and of seroconversion among the residents of southeastern Connecticut and Block Island, Rhode island. Subjects with acute babesial illness were monitored every 3 months for up to 27 months by means of thin blood smears, Bab. microti polymerase-chain-reaction assays, serologic tests, and questionnaires. Results Babesial DNA persisted in the blood for a mean of 82 days in 24 infected subjects without specific symptoms who received no specific therapy. Babesial DNA persisted for 16 days in 22 acutely ill subjects who received clindamycin and quinine therapy (P = 0.03), of whom 9 had side effects from the treatment. Among the subjects who did not receive specific therapy, symptoms of babesiosis persisted for a mean of 114 days in five subjects with babesial DNA present for 3 or more months and for only 15 days in seven others in whom the DNA was detectable for less than 3 months (P<0.05); one subject had recrudescent disease after two years. Conclusions When left untreated, silent babesial infection may persist For months or even years. Although treatment with clindamycin and quinine reduces the duration of parasitemia, infection may still persist and recrudesce and side effects are common. Improved treatments are needed. (N Engl J Med 1998;339:160-5.) (C)1998, Massachusetts Medical Society.	Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA; Univ Connecticut, Sch Med, Hartford, CT 06106 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA USA; Brown Univ, Sch Med, Dept Med, Providence, RI USA; Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Clin Microbiol, Mol Microbiol Lab, Rochester, MN 55905 USA	Connecticut Children's Medical Center; University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University; Brown University; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, R01AI042402] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41157, AI 32403, AI 42402] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BISHOP R, 1992, PARASITOLOGY, V104, P215, DOI 10.1017/S0031182000061655; CONRAD P, 1991, J AM VET MED ASSOC, V199, P601; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Falagas ME, 1996, CLIN INFECT DIS, V22, P809, DOI 10.1093/clinids/22.5.809; FIGUEROA JV, 1992, J CLIN MICROBIOL, V30, P2576, DOI 10.1128/JCM.30.10.2576-2582.1992; GELFAND JA, 1995, MANDELL DOUGLAS BENN, V2, P2497; GERBER MA, 1994, J INFECT DIS, V170, P231, DOI 10.1093/infdis/170.1.231; Herwaldt BL, 1997, J INFECT DIS, V175, P1259, DOI 10.1086/593812; KAIN KC, 1993, AM J TROP MED HYG, V49, P478, DOI 10.4269/ajtmh.1993.49.478; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2014, DOI 10.1128/JCM.34.8.2014-2016.1996; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2791, DOI 10.1128/JCM.34.11.2791-2794.1996; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1997, 46 ANN M AM SOC TROP, P247; KROGSTAD DJ, 1995, MANDELL DOUGLAS BENN, V2, P2415; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; MINTZ ED, 1991, TRANSFUSION, V31, P365, DOI 10.1046/j.1537-2995.1991.31491213305.x; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; ONG KR, 1990, LANCET, V336, P112, DOI 10.1016/0140-6736(90)91624-J; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; SMITH RP, 1986, JAMA-J AM MED ASSOC, V256, P2726, DOI 10.1001/jama.256.19.2726; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; TEUTSCH SM, 1980, AM J TROP MED HYG, V29, P738, DOI 10.4269/ajtmh.1980.29.738; Wittner M, 1996, AM J TROP MED HYG, V55, P219, DOI 10.4269/ajtmh.1996.55.219; WITTNER M, 1982, ANN INTERN MED, V96, P601, DOI 10.7326/0003-4819-96-5-601; 1990, MMWR MORB MORTAL WKL, V39, P19	32	208	210	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					160	165		10.1056/NEJM199807163390304	http://dx.doi.org/10.1056/NEJM199807163390304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664092	Bronze			2022-12-24	WOS:000074782900004
J	Nagel, RL				Nagel, RL			A knockout of a transgenic mouse - Animal models of sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Nagel, RL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; Kaul DK, 1995, J CLIN INVEST, V96, P2845, DOI 10.1172/JCI118355; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; TRUDEL M, 1994, BLOOD, V84, P3189	5	24	36	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					194	195		10.1056/NEJM199807163390310	http://dx.doi.org/10.1056/NEJM199807163390310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664098				2022-12-24	WOS:000074782900010
J	Olson, MF; Paterson, HF; Marshall, CJ				Olson, MF; Paterson, HF; Marshall, CJ			Signals from Ras and Rho GTPases interact to regulate expression of p21(Waf1/Cip1)	NATURE			English	Article							CELL-TRANSFORMATION; KINASE; ACTIVATION; GROWTH; NIH-3T3-CELLS; REQUIREMENT; ONCOGENES	Small GTPases act as molecular switches in intracellular signal-transduction pathways(1). In the case of the Ras family of GTPases, one of their most important roles is as regulators of cell proliferation, and the mitogenic response to a variety of growth factors and oncogenes can be blocked by inhibiting Ras function(23). But in certain situations, activation of Ras signalling pathways arrests the cell cycle rather than causing cell proliferation(4-6). Extracellular signals may trigger different cellular responses by activating Ras-dependent signalling pathways to varying degrees(7-9). Other signalling pathways could also influence the consequences of Ras signalling. Here we show that when signalling through the Ras-related GTPase Rho is inhibited, constitutively active Ras induces the cyclin-dependent-kinase inhibitor p2I(Waf1/Cip1) and entry into the DNA-synthesis phase of the cell cycle is blocked. When Rho is active, induction of p21(Waf1/Cip1) by Ras is suppressed and Ras induces DNA synthesis. Cells that lack p21(Watl/Cip1) do not require Rho signalling for the induction of DNA synthesis by activated Ras, indicating that, once Ras has become activated, the primary requirement for Rho signalling is the suppression of p21(Waf1/Cip1) induction.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1987, ONCOGENE, V2, P41; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zeng YX, 1996, ONCOGENE, V12, P1557	29	390	402	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					295	299		10.1038/28425	http://dx.doi.org/10.1038/28425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685162				2022-12-24	WOS:000074851900053
J	Clarke, PBS				Clarke, PBS			Tobacco smoking, genes, and dopamine	LANCET			English	Editorial Material							NICOTINE; SYSTEM; REWARD		McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada	McGill University	Clarke, PBS (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada.							CLARKE PBS, 1985, BRAIN RES, V348, P355, DOI 10.1016/0006-8993(85)90456-1; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAWFORD BR, 1995, NAT MED, V1, P337, DOI 10.1038/nm0495-337; Noble EP, 1998, JNCI-J NATL CANCER I, V90, P343, DOI 10.1093/jnci/90.5.343; Rose JE, 1997, PSYCHOPHARMACOLOGY, V130, P28, DOI 10.1007/s002130050209; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203	12	18	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					84	85		10.1016/S0140-6736(98)85006-X	http://dx.doi.org/10.1016/S0140-6736(98)85006-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672270				2022-12-24	WOS:000074775100006
J	Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS				Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS			MR imaging contrast enhancement based on intermolecular zero quantum coherences	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MULTIPLE SPIN ECHOES; SOLUTION NMR; DIPOLAR-FIELD; LIQUIDS	A new method for magnetic resonance imaging (MRI) based on the detection of relatively strong signal from intermolecular zero-quantum coherences (iZQCs) is reported. Such a signal would not be observable in the conventional framework of magnetic resonance; it originates in Long-range dipolar couplings (10 micrometers to 1 millimeter) that are traditionally ignored. Unlike conventional MRI, where image contrast is based on variations in spin density and relaxation times (often with injected contrast agents), contrast with iZQC images comes from variations in the susceptibility over a distance dictated by gradient strength. phantom and in vivo (rat brain) data confirm that iZQC images give contrast enhancement. This contrast might be useful in the detection of small tumors, in that susceptibility correlates with oxygen concentration and in functional MRI.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA; Natl Res Council Canada, Inst Biodiagnost, Winnipeg, MB R3B 1Y6, Canada; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA	Princeton University; University of Minnesota System; University of Minnesota Twin Cities; National Research Council Canada; University of Pennsylvania	Warren, WS (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	wwarren@princeton.edu	Ahn, Sangdoo/A-4615-2009; Ugurbil, Kamil/AAD-6058-2022	Garwood, Michael/0000-0003-1578-9166	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08079, RR02305] Funding Source: Medline; NIGMS NIH HHS [GM35253] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BHUJWALLA ZM, 1994, NMR PHYSL BIOMEDICIN, P311; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; Broekaert P, 1996, J MAGN RESON SER A, V120, P97, DOI 10.1006/jmra.1996.0103; Cremillieux Y, 1998, MAGN RESON MED, V39, P285, DOI 10.1002/mrm.1910390216; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; DURNEY CH, 1989, J MAGN RESON, V85, P554, DOI 10.1016/0022-2364(89)90245-X; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; Lee S, 1996, J CHEM PHYS, V105, P874, DOI 10.1063/1.471968; Levitt MH, 1996, CONCEPT MAGNETIC RES, V8, P77, DOI 10.1002/(SICI)1099-0534(1996)8:2<77::AID-CMR1>3.0.CO;2-L; McKinstry RC, 1998, SCIENCE, V279, P1965, DOI 10.1126/science.279.5358.1965; Mori S, 1997, MAGNET RESON MED, V37, P336, DOI 10.1002/mrm.1910370305; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Robyr P, 1996, J MAGN RESON SER A, V121, P206, DOI 10.1006/jmra.1996.0162; SCHUPP DG, 1993, MAGNET RESON MED, V30, P18, DOI 10.1002/mrm.1910300105; Springer CS, 1994, NMR PHYSL BIOMEDICIN, P75; Vathyam S, 1996, SCIENCE, V272, P92, DOI 10.1126/science.272.5258.92; Warren WS, 1995, CHEM PHYS LETT, V247, P207, DOI 10.1016/0009-2614(95)01184-5; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; ZHOU X, 1991, P SOC MAGN RESON MED, P345	25	167	178	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					247	251		10.1126/science.281.5374.247	http://dx.doi.org/10.1126/science.281.5374.247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657717				2022-12-24	WOS:000074714200046
J	Miesenbock, G; De Angelis, DA; Rothman, JE				Miesenbock, G; De Angelis, DA; Rothman, JE			Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins	NATURE			English	Article							SIMPLEX VIRUS VECTORS; FUSION EVENTS; MAST-CELLS; MUTATIONS; SIGNAL	In neural systems, information is often carried by ensembles of cells rather than by individual units. Optical indicators(1) provide a powerful means to reveal such distributed activity, particularly when protein-based and encodable in DNA(2-4): encodable probes can be introduced into cells, tissues, or transgenic organisms by genetic manipulation, selectively expressed in anatomically or functionally defined groups of cells, and, ideally, recorded in situ, without a requirement for exogenous cofactors, Here we describe sensors for secretion and neurotransmission that fulfill these criteria We have developed pH-sensitive mutants of green fluorescent protein ('pHluorins') by structure-directed combinatorial mutagenesis, with the aim of exploiting the acidic pH inside secretory vesicles(5,6) to monitor vesicle exocytosis and recycling. When linked to a vesicle membrane protein, pHluorins were sorted to secretory and synaptic vesicles and reported transmission at individual synaptic boutons, as well as secretion and fusion pore 'flicker' of single secretory granules.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Oka, Yoshitaka/C-9670-2010; Wood, David W/B-2992-2012	Oka, Yoshitaka/0000-0002-3482-3051; Miesenboeck, Gero/0000-0003-2940-3228				ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; LAWRENCE MS, 1995, P NATL ACAD SCI USA, V92, P7247, DOI 10.1073/pnas.92.16.7247; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marconi P, 1996, P NATL ACAD SCI USA, V93, P11319, DOI 10.1073/pnas.93.21.11319; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; RAO M, 1997, J IMMUNOL, V159, P2815; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.ne.12.030189.001303; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YU SS, 1993, J BIOL CHEM, V268, P337	27	1838	1890	10	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					192	195		10.1038/28190	http://dx.doi.org/10.1038/28190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671304				2022-12-24	WOS:000074705900057
J	Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME				Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME			C-1 transfer enzymes and coenzymes linking methylotrophic bacteria and methanogenic Archaea	SCIENCE			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; TETRAHYDROMETHANOPTERIN FORMYLTRANSFERASE; FORMYLMETHANOFURAN; METHANOBACTERIUM; CYCLOHYDROLASE; DEHYDROGENASE; MECHANISM; SEQUENCE; GENE	Methanogenic and sulfate-reducing Archaea are considered to have an energy metabolism involving C-1 transfer coenzymes and enzymes unique for this group of strictly anaerobic microorganisms. An aerobic methylotrophic bacterium, Methylobacterium extorquens AM1, was found to contain a cluster of genes that are predicted to encode some of these enzymes and was shown to contain two of the enzyme activities and one of the methanogenic coenzymes. Insertion mutants were all unable to grow on C-1 compounds, suggesting that the archaeal enzymes function in aerobic C-1 metabolism. Thus, methylotrophy and methanogenesis involve common genes that cross the bacterial/archaeal boundaries.	Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA; Max Planck Inst Terr Microbiol, Dept Biochem, D-35043 Marburg, Germany	University of Washington; University of Washington Seattle; Max Planck Society	Lidstrom, ME (corresponding author), Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA.		Chistoserdova, Ludmila/K-2364-2017; Vorholt, Julia/K-3514-2016	Chistoserdova, Ludmila/0000-0002-5777-0263; Vorholt, Julia/0000-0002-6011-4910	NIGMS NIH HHS [GM36296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITUNG J, 1992, EUR J BIOCHEM, V210, P971, DOI 10.1111/j.1432-1033.1992.tb17502.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; Chistoserdova L, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P16; CHISTOSERDOVA L, UNPUB; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P1957, DOI 10.1128/jb.176.7.1957-1968.1994; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DONNELLY MI, 1985, ARCH BIOCHEM BIOPHYS, V242, P430, DOI 10.1016/0003-9861(85)90227-9; GORRIS LGM, 1994, BIOFACTORS, V4, P139; KLENK HP, 1997, ATURE, V390, P364; Lidstrom ME, 1991, PROKARYOTES, P431; MARISON IW, 1982, J GEN MICROBIOL, V128, P1441; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; POMPER B, UNPUB; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHWORER B, 1993, ARCH MICROBIOL, V159, P225, DOI 10.1007/BF00248476; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; Vaupel M, 1996, EUR J BIOCHEM, V236, P294, DOI 10.1111/j.1432-1033.1996.00294.x; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; Vorholt JA, 1997, MOL MICROBIOL, V23, P1033, DOI 10.1046/j.1365-2958.1997.2931653.x; Vorholt JA, 1997, ARCH MICROBIOL, V167, P19, DOI 10.1007/s002030050411; White RH, 1998, BBA-GEN SUBJECTS, V1380, P257, DOI 10.1016/S0304-4165(97)00148-7; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	24	218	231	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					99	102		10.1126/science.281.5373.99	http://dx.doi.org/10.1126/science.281.5373.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651254				2022-12-24	WOS:000074685800046
J	Burman, WJ; Reves, RR; Cohn, DL				Burman, WJ; Reves, RR; Cohn, DL			The case for conservative management of early HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Denver Publ Hlth, Infect Dis AIDS Clin, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Burman, WJ (corresponding author), Denver Publ Hlth, Infect Dis AIDS Clin, 605 Bannock St, Denver, CO 80204 USA.	bburman@dhha.org						Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CARR A, 1998, 5 C RETR OPP INF FEB; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1996, 11 INT C AIDS JUL 7; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; GEISELER PJ, 1987, AM REV RESPIR DIS, V135, P3; GOUJARD C, 1998, 5 C RETR OPP INF FEB; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Lennox J. L., 1997, Clinical Infectious Diseases, V25, P397; MIEDEMA F, 1998, 5 C RETR OPP INF FEB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN CLIN PRACT TR, 1997, GUID US ANT AG HIV I; PULLAR T, 1988, CLIN PHARMACOL THER, V44, P540, DOI 10.1038/clpt.1988.191; ROTH HP, 1978, CLIN PHARMACOL THER, V23, P361; RUBIO A, 1996, 3 INT C DRUG THER HI; Steger K. A., 1997, Clinical Infectious Diseases, V25, P444; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; WANG SA, 1998, CLIN INFECT DIS, V25, P444	26	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					93	95		10.1001/jama.280.1.93	http://dx.doi.org/10.1001/jama.280.1.93			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660372				2022-12-24	WOS:000074379400032
J	Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP				Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP			New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; HOMOSEXUAL BISEXUAL MEN; EARLY DIAGNOSTIC-TESTS; AIDS EPIDEMIC; TYPE-1 SEROCONVERSION; ANTIBODY-RESPONSE; INCIDENCE RATES; UNITED-STATES; PLASMA	Context.-Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention. Objective.-To develop and validate a serologic testing algorithm in which HIV-1-positive persons with reactive test results on a sensitive HIV-1 enzyme immunoassay (EIA) but nonreactive results on a less sensitive (LS) EIA are identified as having early infection. Design.-Diagnostic test and testing strategy development, validation, and application. Specimens were tested with both a sensitive HIV-1 EIA (3A11 assay) and a less sensitive modification of the same EIA (3A11-LS assay). Settings and Participants.-For assay development: 104 persons seroconverting to HIV-1 comprising 38 plasma donors, 18 patients of a sexually transmitted disease clinic in Trinidad, and 48 participants in the San Francisco Men's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS who had been infected for at least 2.5 years; and 207 persons with clinical AIDS; for testing strategy validation: 488 men in the SFMHS from 1985 through 1990 and 1 275 449 repeat blood donors at 3 American Red Cross blood centers from 1993 through 1995; and for HIV-1 incidence estimates: 2 717 910 first-time blood donors. We retrospectively identified persons eligible for a study of early infection. Main Outcome Measure.-Ability to identify early HIV infection. Results.-Estimated mean time to being 3A11 reactive/3A11-LS nonreactive was 129 days (95% confidence interval [CI], 109-149 days). Our testing strategy accurately diagnosed 95% of persons with early infection; however, 0.4% (1/268) of men with established infection and 2% (5/207) of persons with late-stage AIDS were misdiagnosed as having early HIV-1 infection. Average yearly incidence estimates in SFMHS subjects were 1.5% per year vs observed average incidence of 1.4 per 100 person-years. Incidence in repeat blood donors using the sensitive/less sensitive assay testing strategy was 2.95 per 100 000 per year (95% CI, 1.14-6.53/ 100 000) vs observed incidence of 2.60 per 100 000 person-years (95% CI, 1.49-4.21/100 000). Overall incidence in first-time blood donors was 7.18 per 100 000 per year (95% CI, 4.51-11.20/100 000) and did not change statistically significantly between 1993 and 1996. Use of the sensitive/less sensitive testing strategy alone would have identified all 17 persons with antibodies to HIV-1 eligible for a study of early HIV-1 infection and would have increased enrollment. Conclusions.-The sensitive/less sensitive testing strategy provides accurate diagnosis of early HIV-1 infection, provides accurate estimates of HIV-1 incidence, can facilitate clinical studies of early HIV-1 infection, and provides information on HIV-1 infection duration for care planning.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Atlanta, GA 30333 USA; Amer Red Cross, Natl Reference Lab Infect Dis, Rockville, MD USA; Blood Ctr Pacific, Irwin Ctr, San Francisco, CA USA; NCI, Viral Epidemiol Branch, Rockville, MD USA; Boston Biomed Inc, W Bridgewater, MA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA 94143 USA; Med Res Ctr, Port Spain, Trinidad Tobago; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	Centers for Disease Control & Prevention - USA; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Janssen, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Mailstop E-06,1600 Clifton Rd, Atlanta, GA 30333 USA.	RXJ1@cdc.gov		Satten, Glen/0000-0001-7275-5371; Hecht, Frederick/0000-0002-5782-1171				*ABB LAB, 1994, ENZ IMM DET ANT HUM; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; Beyrer C, 1996, J ACQ IMMUN DEF SYND, V12, P495, DOI 10.1097/00042560-199608150-00009; BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1994, NAT HIV SER SUMM RES, V3, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chambers J. M., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleghorn Farley R., 1996, P147; CLEGHORN FR, 1995, 2 NAT C HUM RETR REL, P57; CONWAY B, 1998, 5 C RETR OPP INF CHI, P189; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; *DCDP, 1997, HIV AIDS SURV REP, V9, P5; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Efron Bradley., 1994, INTRO BOOTSTRAP; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KAHN JO, IN PRESS N ENGL J ME; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; Lilienfeld AM, 1976, FDN EPIDEMIOLOGY; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705; Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Rothenberg ML, 1996, SEMIN ONCOL, V23, P21; SAGET B, 1998, 5 C RETR OPP INF CHI, P189; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SILVERMAN BW, 1990, J ROY STAT SOC B MET, V52, P271; Snedecor G.W., 1967, STAT METHODS; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TORIAN LV, 1997, 4 C RETR OPP INF WAS, P97; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; *UN AIDS WHO WORK, 1997, REP GLOB HIV AIDS EP, P1; Weinstock Hillard S., 1996, P336; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; [No title captured]	56	552	572	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					42	48		10.1001/jama.280.1.42	http://dx.doi.org/10.1001/jama.280.1.42			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660362				2022-12-24	WOS:000074379400022
J	Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L				Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L			Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETERODUPLEX MOBILITY ASSAY; VIRAL EXPRESSION; PERIPHERAL-BLOOD; TYPE-1; TRANSMISSION; INFECTIONS; SEROCONVERSION; REPLICATION; ACTIVATION	Context.-Genital ulcer disease has been epidemiologically linked as a risk factor in the transmission of the human immunodeficiency virus 1 (HIV-1). While herpes simplex virus 2 (HSV-2) is the most common cause of genital ulcers, no study has systematically evaluated the frequency or titer of HIV-1 virus in HSV-2 lesions. Objective.-To compare lesional HIV-1 RNA levels during and after genital HSV-2 reactivation and to evaluate the frequency, titer, and duration of HIV-1 RNA shedding in lesions due to HSV-2. Design.-Convenience sample. Setting.-Sexually transmitted disease research clinic at the University of Washington, Seattle. Patients.-Twelve HIV-infected men with a history of symptomatic HSV-2 infection who underwent daily sampling of genital lesions for HIV-1 RNA by polymerase chain reaction assay and HSV-2 by culture. Main Outcome Measure.-Detection of lesional HIV RNA and HSV-2. Results.-HIV-1 RNA was detected from lesional swabs in 25 of 26 consecutively studied HSV-2 episodes and on 67% of days in which genital lesions were noted. The HIV-1 RNA titers in lesional swabs exceeded 10 000 copies/mL of swab sample in 75% of samples (range, 2.2-3.2 x 10(5) copies/mL of swab sample). HIV-1 RNA in genital lesion swabs was seen in persons with high and low titers of plasma HIV-1 RNA and was not associated with plasma HIV-1 RNA levels. Conclusions.-HIV-1 virions can consistently be detected in genital ulcers caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency of the sexual transmission of HIV-1.	Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis M115, POB 19024,1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01228, U01 AI-35498, AI-30371] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT MA, 1989, J VIROL, V63, P1861, DOI 10.1128/JVI.63.5.1861-1868.1989; AUGENBRAUN M, 1995, ANN INTERN MED, V123, P845, DOI 10.7326/0003-4819-123-11-199512010-00006; AUGENBRAUN MH, 1994, INFECT DIS CLIN N AM, V8, P439; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; CAMERON DW, 1989, LANCET, V2, P403; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; CUNNINGHAM AL, 1985, J CLIN INVEST, V75, P226, DOI 10.1172/JCI111678; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, AIDS RES HUM RETROV, V11, P1081, DOI 10.1089/aid.1995.11.1081; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOLDEN MP, 1992, J INFECT DIS, V166, P494, DOI 10.1093/infdis/166.3.494; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; KOELLE DM, 1994, J INFECT DIS, V169, P956, DOI 10.1093/infdis/169.5.956; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; OBRIEN WA, 1995, BLOOD, V86, P1082; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OFARRELL N, 1994, INT J STD AIDS, V5, P415, DOI 10.1177/095646249400500607; OSTROVE JM, 1987, J VIROL, V61, P3726, DOI 10.1128/JVI.61.12.3726-3732.1987; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; Piot P, 1989, SEXUALLY TRANSMITTED, P711; RIOS Z, 1995, CELL MOL BIOL, V41, pS93; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WALD A, 1994, ANTIMICROB AGENTS CH, V38, P174, DOI 10.1128/AAC.38.2.174	42	240	244	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					61	66		10.1001/jama.280.1.61	http://dx.doi.org/10.1001/jama.280.1.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660365	Bronze			2022-12-24	WOS:000074379400025
J	Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N				Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N			Thrombospondin-1 is a major activator of TGF-beta 1 in vivo	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; HAMSTER OVARY CELLS; FACTOR-BETA; TGF-BETA; ENDOTHELIAL-CELLS; FACTOR-BETA-1-DEFICIENT MICE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; TRANSGENIC MICE; LATENT FORMS	The activity of TGF-beta 1 is regulated primarily extracellularly where the secreted latent form must be modified to expose the active molecule. Here we show that thrombospondin-1 is responsible for a significant proportion of the activation of TGF-beta 1 in vivo. Histological abnormalities in young TGF-beta 1 null and thrombospondin-1 null mice were strikingly similar in nine organ systems. Lung and pancreas pathologies similar to those observed in TGF-beta 1 null animals could be induced in wild-type pups by systemic treatment with a peptide that blocked the activation of TGF-beta 1 by thrombospondin-1. Although these organs produced little active TGF-beta 1 in thrombospondin null mice, when pups were treated with a peptide derived from thrombospondin-l that could activate TGF-beta 1, active cytokine was detected in situ, and the lung and pancreatic abnormalities reverted toward wild type.	Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Beth Israel Deaconness Med Ctr, Dept Pathol, Boston, MA 02215 USA; MIT, Dept Biol, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Cincinnati, Dept Pathol, Cincinnati, OH 45267 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Alabama System; University of Alabama Birmingham; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	Crawford, SE (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA.		Lawler, Jack/AAJ-1379-2020		NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NHLBI NIH HHS [R01 HL050061, HL28749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749, R01HL050061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; BOIVIN GP, 1995, AM J PATHOL, V146, P276; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Caver TE, 1996, J CLIN INVEST, V98, P2496, DOI 10.1172/JCI119068; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DAWSON DW, 1998, ANGIOGENIC AGENTS; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIOUBIN MN, 1991, J CELL BIOCHEM, V45, P112, DOI 10.1002/jcb.240450118; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1981, CANCER RES, V41, P2842; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAYCHAUDHURY A, 1994, J CELL SCI, V107, P39; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SANVITO F, 1994, DEVELOPMENT, V120, P3451; SAPERSTEIN LA, 1994, HEPATOLOGY, V19, P412; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHULZ E, 1994, ACROS CHIMICA ACTA, V1, P1; Serra R, 1996, NAT MED, V2, P390, DOI 10.1038/nm0496-390; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SJOHOLM A, 1991, AM J PHYSIOL, V260, pC1046, DOI 10.1152/ajpcell.1991.260.5.C1046; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; YAMANAKA Y, 1993, DIABETES, V42, P746, DOI 10.2337/diabetes.42.5.746; Yang YB, 1997, BIOCHEMISTRY-US, V36, P11923, DOI 10.1021/bi9710479; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	72	924	978	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1159	1170		10.1016/S0092-8674(00)81460-9	http://dx.doi.org/10.1016/S0092-8674(00)81460-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657149	Bronze			2022-12-24	WOS:000074491100011
J	Benigni, A; Remuzzi, G				Benigni, A; Remuzzi, G			Transplant tolerance: will genes protect the graft?	LANCET			English	Editorial Material									Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Benigni, A (corresponding author), Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy.		Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				CHAHINE AA, 1995, TRANSPLANTATION, V59, P1313, DOI 10.1097/00007890-199505150-00016; Deng S, 1997, TRANSPL P, V29, P770, DOI 10.1016/S0041-1345(96)00477-0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Knechtle SJ, 1997, J IMMUNOL, V159, P152; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LUTZ J, 1997, J AM SOC NEPHROL S, V8, pA502; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Olthoff KM, 1998, NAT MED, V4, P194, DOI 10.1038/nm0298-194; Perico N, 1997, DRUGS, V54, P533, DOI 10.2165/00003495-199754040-00003; Perico N, 1997, INT J CLIN LAB RES, V27, P165, DOI 10.1007/BF02912453; QIN LH, 1995, TRANSPLANTATION, V59, P809, DOI 10.1097/00007890-199503270-00002; SAYEGH MH, 1997, KIDNEY INT S58, V51, pS11; Swenson KM, 1998, TRANSPLANTATION, V65, P155	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1749	1751		10.1016/S0140-6736(05)78739-0	http://dx.doi.org/10.1016/S0140-6736(05)78739-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635942				2022-12-24	WOS:000074197600003
J	Balsalobre, A; Damiola, F; Schibler, U				Balsalobre, A; Damiola, F; Schibler, U			A serum shock induces circadian gene expression in mammalian tissue culture cells	CELL			English	Article							LEUCINE-ZIPPER PROTEINS; C-FOS; RHYTHMS; CLOCK; TRANSCRIPTION; ENTRAINMENT; LIGHT; TEF; DBP	The treatment of cultured rat-1 fibroblasts or H35 hepatoma cells with high concentrations of serum induces the circadian expression of various genes whose transcription also oscillates in living animals. Oscillating genes include rper1 and rper2 (rat homologs of the Drosophila clock gene period), and the genes encoding the transcription factors Rev-Erb alpha, DBP, and TEF. In rat-1 fibroblasts, up to three consecutive daily oscillations with an average period length of 22.5 hr could be recorded. The temporal sequence of the various mRNA accumulation cycles is the same in cultured cells and in vivo. The serum shock of rat-1 fibroblasts also results in a transient stimulation of c-fos and rper expression and thus mimics light-induced immediate-early gene expression in the suprachiasmatic nucleus.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Damiola, Francesca/0000-0002-0238-1252				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chrousos GP, 1998, ENDOCRINOLOGY, V139, P437, DOI 10.1210/endo.139.2.5857; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; EWER J, 1992, J NEUROSCI, V12, P3321; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Gwinner E, 1997, BRAIN RES BULL, V44, P439, DOI 10.1016/S0361-9230(97)00224-4; HASTINGS HM, 1997, CURR BIOL, V7, P670; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; MOORE RY, 1992, CIRCADIAN RHYTHMS, P26; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Okano T, 1997, J PINEAL RES, V22, P145, DOI 10.1111/j.1600-079X.1997.tb00316.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Portaluppi F, 1996, ANN NY ACAD SCI, V783, P113, DOI 10.1111/j.1749-6632.1996.tb26711.x; Rabinowitz L, 1996, KIDNEY INT, V49, P1738, DOI 10.1038/ki.1996.258; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1998, J NEUROSCI, V18, P1105; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	49	1462	1496	7	113	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					929	937		10.1016/S0092-8674(00)81199-X	http://dx.doi.org/10.1016/S0092-8674(00)81199-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635423	Bronze			2022-12-24	WOS:000074205700005
J	Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A				Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A			Angina pectoris caused by coronary microvascular spasm	LANCET			English	Article							INDUCED MYOCARDIAL-ISCHEMIA; ARTERY SPASM; SYNDROME-X; VARIANT ANGINA; NITRIC-OXIDE; ACETYLCHOLINE; ARTERIOGRAMS; VASODILATION; SITE; RESISTANCE	Background Microvascular angina can occur during exercise and at rest. Reduced vasodilator capacity of the coronary microvessels is implicated as a cause of angina during exercise, but the mechanism of angina at rest is not known. Our aim was to test the hypothesis that primary hyperconstriction (spasm) of microvessels causes myocardial ischaemia at rest. Methods Acetylcholine induces coronary artery spasm in patients with variant angina. We tested the effects of intracoronary acetylcholine at graded doses in 117 consecutive patients with chest pain (at rest, during exertion, or both) and no flow-limiting (>50%) organic stenosis in the large epicardial coronary arteries. We also assessed the metabolism of myocardial lactate during acetylcholine administration in 36 of the patients by measurement of lactate in paired blood samples from the coronary artery and coronary sinus vein. Findings Of the 117 patients, 63 (54%) had large-artery spasm, 29 (25%) had microvascular spasm, and 25 (21%) had atypical chest pain. The 29 patients with microvascular spasm developed angina-like chest pain, ischaemic electrocardiogram (ECG) changes, or both spontaneously (two patients) or after administration of acetylcholine (27 patients) without spasm of the large epicardial coronary arteries. Testing of paired samples of arterial and coronary sinus venous blood showed that lactate was produced during angina attack in nine of 11 patients with microvascular spasm. There was more women (p<0.01) and fewer coronary risk factors (p<0.01) in patients with microvascular spasm than in those with large-artery spasm. Interpretation Coronary microvascular spasm and resultant myocardial ischaemia may be the cause of chest pain in a subgroup of patients with microvascular angina.	Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Cardiovasc Clin, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Mohri, M (corresponding author), Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, 3-1-1 maidashi, Fukuoka 8128582, Japan.	mmohri@med.kyushu-u.ac.jp						BORTONE AS, 1989, CIRCULATION, V79, P516, DOI 10.1161/01.CIR.79.3.516; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1983, J AM COLL CARDIOL, V1, P359; Egashira K, 1996, J AM COLL CARDIOL, V27, P1444, DOI 10.1016/0735-1097(96)00021-6; Egashira K, 1996, CIRCULATION, V94, P130, DOI 10.1161/01.CIR.94.2.130; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EPSTEIN SE, 1986, J AM COLL CARDIOL, V8, P459, DOI 10.1016/S0735-1097(86)80067-5; EPSTEIN SE, 1991, CIRCULATION, V83, P73; ITO A, 1995, CIRCULATION, V92, P2636, DOI 10.1161/01.CIR.92.9.2636; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; Kemp H G, 1967, Trans Assoc Am Physicians, V80, P59; KEMP HG, 1991, J AM COLL CARDIOL, V17, P507, DOI 10.1016/S0735-1097(10)80123-8; KUGA T, 1995, CIRCULATION, V92, P183, DOI 10.1161/01.CIR.92.2.183; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MOSSERI M, 1986, CIRCULATION, V74, P964, DOI 10.1161/01.CIR.74.5.964; MOTZ W, 1991, AM J CARDIOL, V68, P996, DOI 10.1016/0002-9149(91)90485-4; NAGAI H, 1994, ANGIOLOGY, V45, P391, DOI 10.1177/000331979404500509; OKUMURA K, 1988, J AM COLL CARDIOL, V12, P883, DOI 10.1016/0735-1097(88)90449-4; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; QUYYUMI AA, 1992, CIRCULATION, V86, P1864, DOI 10.1161/01.CIR.86.6.1864; SEKIYA M, 1993, ANGIOLOGY, V44, P811, DOI 10.1177/000331979304401008; SEROTA H, 1991, AM HEART J, V121, P1807, DOI 10.1016/0002-8703(91)90031-C; SUGIISHI M, 1993, CIRCULATION, V87, P76, DOI 10.1161/01.CIR.87.1.76; SUZUKI H, 1994, INT J CARDIOL, V43, P139, DOI 10.1016/0167-5273(94)90003-5; VRINTS CJM, 1992, J AM COLL CARDIOL, V19, P21, DOI 10.1016/0735-1097(92)90046-P; Yamagishi H, 1997, JPN CIRC J, V61, P87, DOI 10.1253/jcj.61.87; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	28	220	225	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1165	1169		10.1016/S0140-6736(97)07329-7	http://dx.doi.org/10.1016/S0140-6736(97)07329-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643687				2022-12-24	WOS:000073220200009
J	Watson, P; Marcus, JN; Lynch, HT				Watson, P; Marcus, JN; Lynch, HT			Prognosis of BRCA1 hereditary breast cancer	LANCET			English	Editorial Material							CARCINOMA; MUTATION		Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; St Lukes Hosp, Dept Pathol, Chesterfield, MO 63017 USA	Creighton University; Saint Luke's Hospital - Missouri	Watson, P (corresponding author), Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA.							Eisinger F, 1996, CANCER RES, V56, P471; GAMEL JW, 1995, CANCER, V76, P1009; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Lakhani SR, 1997, LANCET, V349, P1505; Marcus JN, 1997, CANCER-AM CANCER SOC, V80, P543, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<543::AID-CNCR4>3.3.CO;2-R; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	11	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					304	305		10.1016/S0140-6736(98)22005-8	http://dx.doi.org/10.1016/S0140-6736(98)22005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652604				2022-12-24	WOS:000071864000002
J	Qiu, YL; Cho, YR; Cox, JC; Palmer, JD				Qiu, YL; Cho, YR; Cox, JC; Palmer, JD			The gain of three mitochondrial introns identifies liverworts as the earliest land plants	NATURE			English	Article							PHYLOGENETIC-RELATIONSHIPS; RBCL SEQUENCES; BRYOPHYTES	The first evidence for the emergence of land plants (embryophytes) consists of mid-Ordovician spore tetrads (similar to 476 Myr old)(1,2). The identity of the early plants that produced these spores is unclear; they are sometimes claimed to be liverworts(3,4), but there are no associated megafossils, and similar spores can be produced by a diversity of plants(2), Indeed, the earliest unequivocal megafossils of land plants consist of early vascular plants and various plants of uncertain affinity(1). Different phylogenetic analyses have identified liverworts, hornworts and bryophytes as each being the first lineage of land plants(1,2,5-13); the consensus of these conflicting topologies yields an unresolved polychotomy at the base of land plants. Here we survey 352 diverse land plants and find that three mitochondrial group II introns are present, with occasional losses, in mosses, hornworts and all major lineages of vascular plants, but are entirely absent from Liverworts, green algae and all other eukaryotes. These results indicate that liverworts are the earliest land plants, with the three introns having been acquired in a common ancestor of all other land plants, and have important implications concerning the early stages of plant evolution.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Palmer, JD (corresponding author), Univ Zurich, Inst Syst Bot, Zollikerstr 107, CH-8008 Zurich, Switzerland.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220				Capesius I, 1997, PLANT SYST EVOL, V207, P87, DOI 10.1007/BF00985210; Chaw SM, 1997, MOL BIOL EVOL, V14, P56, DOI 10.1093/oxfordjournals.molbev.a025702; Doyle J., 1986, PHYTOCHEMISTRY B, V19, P11, DOI DOI 10.2307/4119796; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; EDWARDS D, 1995, NATURE, V374, P635, DOI 10.1038/374635a0; GARBARY DJ, 1993, PLANT SYST EVOL, V188, P237; Graham L, 1993, ORIGIN LAND PLANTS; GRAY J, 1993, PALAEOGEOGR PALAEOCL, V104, P153, DOI 10.1016/0031-0182(93)90127-5; Hedderson TA, 1996, PLANT SYST EVOL, V200, P213, DOI 10.1007/BF00984936; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; Kenrick P, 1997, ORIGIN EARLY DIVERSI; Lewis LA, 1997, MOL PHYLOGENET EVOL, V7, P377, DOI 10.1006/mpev.1996.0395; Malek O, 1996, EMBO J, V15, P1403, DOI 10.1002/j.1460-2075.1996.tb00482.x; MANHART JR, 1994, MOL PHYLOGENET EVOL, V3, P114, DOI 10.1006/mpev.1994.1014; Nugent Jacqueline M., 1993, P163; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; PALMER JD, 1988, J MOL EVOL, V28, P87, DOI 10.1007/BF02143500; Pryer KM, 1995, AM FERN J, V85, P205, DOI 10.2307/1547810; Samigullin TH, 1998, FEBS LETT, V422, P47, DOI 10.1016/S0014-5793(97)01600-1; SLUIMAN HJ, 1985, PLANT SYST EVOL, V149, P217, DOI 10.1007/BF00983308; TAYLOR WA, 1995, NATURE, V373, P391, DOI 10.1038/373391b0; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054	22	260	272	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					671	674		10.1038/29286	http://dx.doi.org/10.1038/29286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716129				2022-12-24	WOS:000075384200041
J	Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG				Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG			Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; GENE-EXPRESSION; YEAST; TRANSCRIPTION; PROTEIN; ANALOGS	Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the adenosine triphosphate- binding site of the human cyclin-dependent kinase 2 (CDK2). By iterating chemical Library synthesis and biological screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified. The structural basis for the binding affinity and selectivity was determined by analysis of a three-dimensional crystal structure of a CDK2-inhibitor complex. The cellular effects of these compounds were characterized in mammalian cells and yeast. In the Latter case the effects were characterized on a genome-wide scale by monitoring changes in messenger RNA Levels in treated cells with high-density oligonucleotide probe arrays. Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may Lead to the development of new therapeutics.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Affymetrix, Santa Clara, CA 95051 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; CNRS, Biol Stn, F-29682 Roscoff, France	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Affymetrix; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS)	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Thunnissen, Andy-Mark/A-1777-2010; MEIJER, Laurent/ABE-7465-2021	Thunnissen, Andy-Mark/0000-0002-1915-9850; Morgan, David/0000-0001-8753-4416; , laurent/0000-0003-3511-4916				ANDREWS B, 1997, MOL CELL BIOL, V17, P1212; BACKES BJ, 1994, J AM CHEM SOC, V116, P11171, DOI 10.1021/ja00103a048; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; Gray NS, 1997, TETRAHEDRON LETT, V38, P1161, DOI 10.1016/S0040-4039(97)00014-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Norman TC, 1996, J AM CHEM SOC, V118, P7430, DOI 10.1021/ja9614934; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Timblin BK, 1997, MOL MICROBIOL, V26, P981, DOI 10.1046/j.1365-2958.1997.6352004.x; Timblin BK, 1996, GENETICS, V143, P57; TOYOTA A, 1993, HETEROCYCLES, V36, P1625, DOI 10.3987/COM-93-6371; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; 1368002	30	783	844	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					533	538		10.1126/science.281.5376.533	http://dx.doi.org/10.1126/science.281.5376.533			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677190	Green Submitted			2022-12-24	WOS:000075012300032
J	Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR				Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR			Racial and ethnic differences in serum cotinine levels of cigarette smokers - Third National Health and Nutrition Examination Survey, 1988-1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NONMENTHOL CIGARETTES; WHITE SMOKERS; YOUNG-ADULTS; SELF-REPORT; NICOTINE; EXPOSURE; MENTHOL; METABOLISM; CHILDREN	Context.-Cotinine, a metabolite of nicotine, is a marker of exposure to tobacco smoke. Previous studies suggest that non-Hispanic blacks have higher levels of serum cotinine than non-Hispanic whites who report similar levels of cigarette smoking. Objective.-To investigate differences in levels of serum cotinine in black, white, and Mexican American cigarette smokers in the US adult population. Design.-Third National Health and Nutrition Examination Survey, 1988-1991. Participants.-A nationally representative sample of persons aged 17 years or older who participated in the survey. Outcome Measures.-Serum cotinine levels by reported number of cigarettes smoked per day and by race and ethnicity. Results.-A total of 7182 subjects were involved in the study; 2136 subjects reported smoking at least 1 cigarette in the last 5 days, Black smokers had cotinine concentrations substantially higher at all levels of cigarette smoking than did white or Mexican American smokers (P<.001). Serum cotinine levels for blacks were 125 nmol/L (22 ng/mL) (95% confidence interval [CI], 79-176 nmol/L. [14-31 ng/mL]) to 539 nmol/L (95 ng/mL) (95% CI, 289-630 nmol/L [51-111 ng/mL]) higher than for whites and 136 nmol/L (24 ng/mL) (95% CI, 85-182 nmol/L [15-32 ng/mL]) to 641 nmol/L (113 ng/mL) (95% CI, 386-897 nmol/L [68-158 ng/mL]I) higher than for Mexican Americans, These differences do not appear to be attributable to differences in environmental tobacco smoke exposure or in number of cigarettes smoked. Conclusions.-To our knowledge, this study provides the first evidence from a national study that serum cotinine levels are higher among black smokers than among white or Mexican American smokers. If higher cotinine levels among blacks indicate higher nicotine intake or differential pharmacokinetics and possibly serve as a marker of higher exposure to cigarette carcinogenic components, they may help explain why blacks find it harder to quit and are more likely to experience higher rates of lung cancer than white smokers.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Battelle Mem Inst, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Bethesda, MD USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Caraballo, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.							Ahijevych K, 1996, PHARMACOL BIOCHEM BE, V53, P355, DOI 10.1016/0091-3057(95)02034-9; ARMITAGE AK, 1975, BRIT MED J, V4, P313, DOI 10.1136/bmj.4.5992.313; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; BENOWITZ NL, 1994, J PHARMACOL EXP THER, V268, P296; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; Bernert JT, 1997, CLIN CHEM, V43, P2281; CASKEY NH, 1993, PHARMACOL BIOCHEM BE, V46, P259, DOI 10.1016/0091-3057(93)90350-3; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P671; Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P504; Clark PI, 1996, ANN EPIDEMIOL, V6, P483, DOI 10.1016/S1047-2797(96)00049-X; Clark PI, 1996, CHEST, V110, P1194, DOI 10.1378/chest.110.5.1194; COULTAS DB, 1988, AM REV RESPIR DIS, V137, P810, DOI 10.1164/ajrccm/137.4.810; CRAWFORD FG, 1994, J NATL CANCER I, V86, P1398, DOI 10.1093/jnci/86.18.1398; ENGLISH PB, 1994, AM J PUBLIC HEALTH, V84, P1439, DOI 10.2105/AJPH.84.9.1439; HENNINGFIELD JE, 1990, AM J PUBLIC HEALTH, V80, P1040, DOI 10.2105/AJPH.80.9.1040; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; ISAAC PF, 1972, NATURE, V236, P308, DOI 10.1038/236308a0; JARVIK ME, 1994, PHYSIOL BEHAV, V56, P563, DOI 10.1016/0031-9384(94)90302-6; Knight JM, 1996, CHEST, V109, P446, DOI 10.1378/chest.109.2.446; LEADERER BP, 1991, ENVIRON SCI TECHNOL, V25, P770, DOI 10.1021/es00016a023; MCCARTHY WJ, 1992, AM J PUBLIC HEALTH, V82, P1171, DOI 10.2105/AJPH.82.8.1171; MCCARTHY WJ, 1995, AM J PUBLIC HEALTH, V85, P67, DOI 10.2105/AJPH.85.1.67; Miller BA, 1996, NIH PUBLICATION, V96-4104; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; PEREZSTABLE EJ, 1995, PREV MED, V24, P171, DOI 10.1006/pmed.1995.1031; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1057, DOI 10.2105/AJPH.80.9.1057; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; SHAH BV, 1995, SOFTWARE SURVEY DATA; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; Wagenknecht LE, 1992, AM J PUBLIC HEALTH, V82, P1173	37	376	377	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					135	139		10.1001/jama.280.2.135	http://dx.doi.org/10.1001/jama.280.2.135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669785				2022-12-24	WOS:000074608400027
J	Koltover, I; Salditt, T; Radler, JO; Safinya, CR				Koltover, I; Salditt, T; Radler, JO; Safinya, CR			An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery	SCIENCE			English	Article							GENE-TRANSFER; EXPRESSION; MEMBRANES; SERIES	A two-dimensional columnar phase in mixtures of DNA complexed with cationic liposomes has been found in the Lipid composition regime known to be significantly more efficient at transfecting mammalian cells in culture compared to the lamellar (L-alpha(subset of)) structure of cationic liposome-DNA complexes. The structure, derived from synchrotron x-ray diffraction, consists of DNA coated by cationic lipid monolayers and arranged on a two-dimensional hexagonal lattice (H-parallel to(subset of)). Two membrane-altering pathways induce the L-alpha(subset of) --> H-parallel to(subset of) transition: one where the spontaneous curvature of the Lipid monolayer is driven negative, and another where the membrane bending rigidity is lowered with a new class of helper-lipids. Optical microscopy revealed that the L-alpha(subset of) complexes bind stably to anionic vesicles (models of cellular membranes), whereas the more transfectant H-parallel to(subset of) complexes are unstable and rapidly fuse and release DNA upon adhering to anionic vesicles.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Biochem & Mol Biol Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Safinya, CR (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Dan N, 1998, BBA-BIOMEMBRANES, V1369, P34, DOI 10.1016/S0005-2736(97)00171-5; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102; Friedmann T, 1997, SCI AM, V276, P96; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; GUTTMAN GD, 1993, J PHYS II, V3, P1411, DOI 10.1051/jp2:1993210; HARRINGTON JJ, 1997, NAT GENET, V15, P21994; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; KOLTOVER I, UNPUB; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LIN AL, UNPUB; May S, 1997, BIOPHYS J, V73, P2427, DOI 10.1016/S0006-3495(97)78271-7; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; Roush W, 1997, SCIENCE, V276, P38, DOI 10.1126/science.276.5309.38; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Salditt T, 1997, PHYS REV LETT, V79, P2582, DOI 10.1103/PhysRevLett.79.2582; SEDDON JM, 1989, BIOCHIM BIOPHYS ACTA, V1031, P1; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	27	1118	1154	9	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					78	81		10.1126/science.281.5373.78	http://dx.doi.org/10.1126/science.281.5373.78			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651248				2022-12-24	WOS:000074685800040
J	Glasier, A; Baird, D				Glasier, A; Baird, D			The effects of self-administering emergency contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Emergency postcoital contraception prevents pregnancy, but it must be prescribed by a doctor and taken within 72 hours of intercourse. It has been proposed that emergency contraception be made available without a prescription. We undertook a study to learn how women might behave if given a supply of emergency contraceptive pills to keep at home. Methods We assigned 553 women to be given a replaceable supply of hormonal emergency contraceptive pills to take home (the treatment group) and 530 women to use emergency contraception obtained by visiting a doctor (the control group). The frequency of use of emergency contraception, the use of other contraceptives, and the incidence of unwanted pregnancy were determined in both groups of women one year later. Results The results for 549 women in the treatment group and 522 women in the control group were available for analysis. Three hundred seventy-nine of the women in the treatment group (69 percent) and 326 of the women in the control group (62 percent) contributed detailed information at followup. One hundred eighty of the women in the treatment group (47 percent) used emergency contraception at least once. Among those who returned the study questionnaire, 98 percent used emergency contraception correctly. There were no serious adverse effects. Eighty-seven women in the control group (27 percent) used emergency contraception at least once (P<0.001 for the comparison with the treatment group). The women in the treatment group were not more likely to use emergency contraception repeatedly. Their use of other methods of contraception was no different from that of the women in the control group. There were 18 unintended pregnancies in the treatment group and 25 in the control group (relative risk, 0.7; 95 percent confidence interval, 0.4 to 1.2), Conclusions Making emergency contraception more easily obtainable does no harm and may reduce the rate of unwanted pregnancies. [N Engl J Med 1998;339:1-4.) (C) 1998, Massachusetts Medical Society.	Univ Edinburgh, Dept Obstet & Gynaecol, Edinburgh EH4 1NL, Midlothian, Scotland; Edinburgh Healthcare Natl Hlth Serv Trust, Edinburgh, Midlothian, Scotland	University of Edinburgh	Glasier, A (corresponding author), Univ Edinburgh, Dept Obstet & Gynaecol, 18 Dean Terr, Edinburgh EH4 1NL, Midlothian, Scotland.							*DEP HLTH HUM SERV, 1997, FED REGISTER, V62, P8610; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; GLASIER A, 1995, PROVISION EMERGENCY, P16; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a; Wright DW, 1986, BR J FAM PLANN, V12, P88; 1992, PHARM J, V249, P530	8	237	240	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					1	4		10.1056/NEJM199807023390101	http://dx.doi.org/10.1056/NEJM199807023390101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647872				2022-12-24	WOS:000074500000001
J	Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J				Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J			Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Venn, A (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.		Britton, John R/G-9705-2011					ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; LUYT DK, 1993, BMJ-BRIT MED J, V306, P1386, DOI 10.1136/bmj.306.6889.1386; SCHACHTER J, 1976, J ALLERGY CLIN IMMUN, V57, P342, DOI 10.1016/0091-6749(76)90091-9; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368	5	78	80	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1945	1946		10.1136/bmj.316.7149.1945	http://dx.doi.org/10.1136/bmj.316.7149.1945			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641931	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000074636700026
J	Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA				Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA			Coordination of growth and cell division in the Drosophila wing	CELL			English	Article							GENETIC-CONTROL; CYCLIN-E; S-PHASE; TRANSLATION INITIATION; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EXPRESSION; PROLIFERATION; YEAST; G(1)	In most tissues, cell division is coordinated with increases in mass (i.e., growth). To understand this coordination, we altered rates of division in cell clones or compartments of the Drosophila wing and measured the effects on growth. Constitutive overproduction of the transcriptional regulator dE2F increased expression of the S- and M-phase initiators Cyclin E and String (Cdc25), thereby accelerating cell proliferation. Loss of dE2F or overproduction of its corepressor, RBF, retarded cell proliferation. These manipulations altered cell numbers over a 4- to 5-fold range but had little effect on clone or compartment sizes. Instead, changes in cell division rates were offset by changes in cell size. We infer that dE2F and RBF function specifically in cell cycle control, and that cell cycle acceleration is insufficient to stimulate growth. Variations in dE2F activity could be used to coordinate cell division with growth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	Neufeld, Thomas/0000-0001-5659-4811; JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17373, R01 GM051186, F32 GM017373, F32 GM017373-04, F32 GM017373-03, GM51186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDERSSON S, 1994, GENETICS, V137, P513; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; Bryant PJ, 1996, BIOESSAYS, V18, P781, DOI 10.1002/bies.950181003; Burke R, 1996, DEVELOPMENT, V122, P2261; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GONZALEZGAITAN M, 1994, MECH DEVELOP, V46, P183, DOI 10.1016/0925-4773(94)90070-1; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON LA, 1998, IN PRESS NATURE; Karim FD, 1998, DEVELOPMENT, V125, P1; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; MITCHISON JM, 1971, BIOL CELL CYCLE; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WATSON KL, 1994, J CELL SCI, P19; Weigmann K, 1997, DEVELOPMENT, V124, P3555; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	69	619	623	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1183	1193		10.1016/S0092-8674(00)81462-2	http://dx.doi.org/10.1016/S0092-8674(00)81462-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657151	Bronze			2022-12-24	WOS:000074491100013
J	Wang, ZY; Tobin, EM				Wang, ZY; Tobin, EM			Constitutive expression of the CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene disrupts circadian rhythms and suppresses its own expression	CELL			English	Article							ARABIDOPSIS; PLANTS; PHYTOCHROME; FREQUENCY; PROTEINS; PROMOTER; INCREASE; WHEAT	The CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene encodes a MYB-related transcription factor involved in the phytochrome induction of a light-harvesting chlorophyll alb-protein (Lhcb) gene. Expression of the CCA1 gene is transiently induced by phytochrome and oscillates with a circadian rhythm. Constitutive expression of CCA1 protein in transgenic plants abolished the circadian rhythm of several genes with dramatically different phases. These plants also had longer hypocotyls and delayed flowering, developmental processes regulated by light and the circadian clock. Furthermore, the expression of both endogenous CCA1 and the related LHY gene was suppressed. Our results suggest that CCA1 is a part of a feedback loop that is closely associated with the circadian clock in Arabidopsis.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tobin, EM (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.		Wang, Zhi-Yong/E-3810-2012; Rosa, Bruce/F-6393-2010	Wang, Zhi-Yong/0000-0003-4602-3390; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023167] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson S, 1996, TRENDS PLANT SCI, V1, P51, DOI 10.1016/S1360-1385(96)80029-X; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; ANDERSON SL, 1995, P NATL ACAD SCI USA, V92, P1500, DOI 10.1073/pnas.92.5.1500; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; B?nning E., 1936, BER DEUT BOT GES, V54, P590, DOI DOI 10.1038/424033A; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAMERVAL C, 1986, ELECTROPHORESIS, V7, P52, DOI 10.1002/elps.1150070108; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Harlow E, 1988, ANTIBODIES LAB MANUA; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KENIGSBUCH D, 1995, PLANT PHYSIOL, V108, P1023, DOI 10.1104/pp.108.3.1023; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kolar C, 1998, PLANT J, V13, P563, DOI 10.1046/j.1365-313X.1998.00048.x; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; LECHARNY A, 1984, PHYSIOL PLANTARUM, V60, P437, DOI 10.1111/j.1399-3054.1984.tb06089.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; Millar AJ, 1997, BIOESSAYS, V19, P209, DOI 10.1002/bies.950190306; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; NAGY F, 1993, P NATL ACAD SCI USA, V90, P6290, DOI 10.1073/pnas.90.13.6290; PIECHULLA B, 1993, PLANT MOL BIOL, V22, P533, DOI 10.1007/BF00015982; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Somers DE, 1998, DEVELOPMENT, V125, P485; Stirland JA, 1996, P ROY SOC B-BIOL SCI, V263, P345, DOI 10.1098/rspb.1996.0053; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x; ZENG H, 1997, NATURE, V380, P129; Zhong HH, 1997, PLANT CELL, V9, P947, DOI 10.1105/tpc.9.6.947; Zhong HH, 1996, MOL GEN GENET, V251, P196	45	739	794	4	124	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1207	1217		10.1016/S0092-8674(00)81464-6	http://dx.doi.org/10.1016/S0092-8674(00)81464-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657153	Bronze			2022-12-24	WOS:000074491100015
J	Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ				Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ		AIDS-Canc Match Study Grp	Spectrum of AIDS-associated malignant disorders	LANCET			English	Article							EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TESTICULAR CANCER; HODGKINS-DISEASE; LYMPHOMAS; INFECTION; TUMOR; RISK	Background To clarify which types of cancer result from AIDS, we compared the cancer experiences of people with AIDS with those of the general population by matching population-based cancer and AIDS registries in the USA and Puerto Rico. Methods We used a probabilistic matching algorithm to compare names, birth dates, and, where available, social-security numbers of 98 336 people with AIDS and 1 125 098 people with cancer aged less than 70 years. We defined AIDS-related cancers as those with both significantly raised incidence post-AIDS and increasing prevalence from 5 years pre-AIDS to 2 years post-AIDS. Findings Among people with AIDS, we found 7028 cases of Kaposi's sarcoma (KS), 1793 of non-Hodgkin lymphoma (NHL), and 712 other cases of histologically defined cancer. Incidence rates among people with AIDS were increased 310-fold for KS, 113-fold for NHL, and l.9-fold (95% CI 1.5-2.3) for other cancers. Of 38 malignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold), multiple myeloma (4.5-fold), brain cancer (3.5-fold), and seminoma (2.9-fold) were raised and increasing significantly (p<0.02) from the pre-AIDS to the post-AIDS period. Interpretation Interpretation is complicated by screening and shared risk factors, such as sexual behaviour and cigarette smoking. However, our data indicate that AIDS leads to a significantly increased risk of Hodgkin's disease, multiple myeloma, brain cancer, and seminoma. Immunological failure to control herpes or other viral infections may contribute to these malignant diseases.	NCI, Viral Epidemiol Branch, Rockville, MD USA; NCI, Pathol Lab, Bethesda, MD 20892 USA; Comp Sci Corp, Rockville, MD USA; Informat Management Serv Inc, Silver Spring, MD USA; NCI, Biostat Branch, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Goedert, JJ (corresponding author), 6130 Execut Blvd,Suite 434, Rockville, MD 20852 USA.		Jaffe, Elaine/G-8981-2014		NCI NIH HHS [N01-CP-40514, YO1-CP-0003-01, N01-CP-40521] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMANN AJ, 1993, J ACQ IMMUN DEF SYND, V6, P1224; [Anonymous], 1996, IARC MON EV CARC RIS; ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; Biggar RJ, 1996, INT J CANCER, V68, P754; *CDCP, 1996, HIV AIDS SURV REP, V8, P18; COTE TR, 1995, PREV MED, V24, P375, DOI 10.1006/pmed.1995.1061; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DAY NE, 1984, BIOMETRICS, V40, P1, DOI 10.2307/2530739; DICTOR M, 1988, INT J CANCER, V42, P346, DOI 10.1002/ijc.2910420307; Fizazi K, 1996, EUR J CANCER, V32A, P1812, DOI 10.1016/0959-8049(96)00167-0; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; HEINZER H, 1993, EUR UROL, V24, P271; *IARC, 1998, IARC MON EV CARC RIS, V70; *IARC, 1995, IARC MON EV CARC RIS, V64; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kingma DW, 1996, AM J SURG PATHOL, V20, P1511, DOI 10.1097/00000478-199612000-00011; KINGMA DW, 1994, AM J SURG PATHOL, V18, P48, DOI 10.1097/00000478-199401000-00005; KINLEN LJ, 1996, CANC EPIDEMIOLOGY PR, P532; LONDON WT, 1996, CANC EPIDEMIOLOGY PR, P772; LYTER DW, 1995, J CLIN ONCOL, V13, P2540, DOI 10.1200/JCO.1995.13.10.2540; LYTER DW, 1996, P AM SOC CLIN ONCOL, V15, P852; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; Melbye M, 1996, BRIT J CANCER, V73, P995, DOI 10.1038/bjc.1996.194; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MUELLER N, 1988, INT J CANCER, V41, P399, DOI 10.1002/ijc.2910410314; Mueller NE, 1996, CANC EPIDEMIOLOGY PR, P893; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Parravicini C, 1997, SCIENCE, V278, P1969, DOI 10.1126/science.278.5345.1969; Percy C., 1990, INT CLASSIFICATION D; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Ries L, 1994, NIH PUBLICATION, V94-2789; YU MC, 1996, CANC EPIDEMIOLOGY PR, P603	37	530	544	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1833	1839		10.1016/S0140-6736(97)09028-4	http://dx.doi.org/10.1016/S0140-6736(97)09028-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652666				2022-12-24	WOS:000074347100009
J	Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB				Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB			Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study	LANCET			English	Article							VASCULAR DEMENTIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; MENTAL STATE; ASSOCIATION; DIAGNOSIS	Background Previous studies suggested a protective effect of smoking on Alzheimer's disease, but most were case-control studies based on prevalent cases. The findings of prospective studies on the association between smoking and the risk of dementia are inconclusive. Methods We did a population-based follow-up study of elderly people who were initially free of dementia. 6870 people aged 55 years and older agreed to take part. Smoking history was taken at baseline and participants were classified as never smokers, former smokers, and current smokers. During follow-up, we recorded all incident cases of dementia, We used never smokers as the reference category to calculate relative risks of dementia and Alzheimer's disease by Cox proportional hazards regression, after adjustment for age, sex, education, and alcohol intake. We also examined modification of risk by age, sex, and the apolipoprotein E (APOE) genotype. Findings During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. Compared with never smokers, smokers had an increased risk of dementia (relative risk 2.2 [95% CI 1.3-3.6]) and Alzheimer's disease (2.3 [1.3-4.1]). Smoking was a strong risk factor for Alzheimer's disease in individuals without the APOE epsilon 4 allele (4.6 [1.5-14.2]), but had no effect in participants with this allele (0.6 [0.1-4.8]). Interpretation Smoking was associated with a doubling of the risk of dementia and Alzheimer's disease. Our finding that carriers of the APOE epsilon 4 had no increased risk of dementia suggests an interaction between smoking and the APOE epsilon 4 genotype in the aetiology of Alzheimer's disease.	Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Univ Antwerp VIB, Born Bunge Fdn,Dept Biochem, Neurogenet Lab, B-2020 Antwerp, Belgium	Erasmus University Rotterdam; Erasmus University Rotterdam; Flanders Institute for Biotechnology (VIB); University of Antwerp	Breteler, MMB (corresponding author), Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	breteler@epib.fgg.eur.nl	Breteler, Monique M.B./J-5058-2014; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017	Breteler, Monique M.B./0000-0002-0626-9305; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BARTECCHI CE, 1994, NEW ENGL J MED, V330, P907, DOI 10.1056/NEJM199403313301307; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; CRUICKSHANK JM, 1989, J HUM HYPERTENS, V3, P443; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geleijnse JM, 1996, J HYPERTENS, V14, P737, DOI 10.1097/00004872-199606000-00009; GORELICK PB, 1993, ARCH NEUROL-CHICAGO, V50, P714, DOI 10.1001/archneur.1993.00540070034011; HACHINSKI V, 1992, LANCET, V340, P645; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1988, J NEUROL NEUROSUR PS, V51, P1489, DOI 10.1136/jnnp.51.12.1489; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; PRINCE M, 1994, NEUROLOGY, V44, P97; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	29	365	386	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1840	1843		10.1016/S0140-6736(97)07541-7	http://dx.doi.org/10.1016/S0140-6736(97)07541-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652667				2022-12-24	WOS:000074347100010
J	Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA				Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA			Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CRYSTAL-STRUCTURE; TRANSMEMBRANE GLYCOPROTEIN; VARIABLE REGIONS; ATOMIC-STRUCTURE; BINDING; RESOLUTION; FRAGMENT; AIDS; HEMAGGLUTININ	The entry of human Immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the Immune system. We have solved the X-ray crystal structure at 2.5 Angstrom resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human con and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4-gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to Intervene.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; GlaxoSmithKline	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NIGMS NIH HHS [R01 GM034102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Binley JM, 1998, AIDS RES HUM RETROV, V14, P191, DOI 10.1089/aid.1998.14.191; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KWONG PD, UNPUB J BIOL CHEM; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLSHEVSKY U, 1990, J VIROL, V64; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROFY AT, 1990, J IMMUNOL, V144, P4641; RIZZUTO C, IN PRESS SCIENCE; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	50	2391	2568	2	321	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					648	659		10.1038/31405	http://dx.doi.org/10.1038/31405			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641677	Green Accepted			2022-12-24	WOS:000074289600043
J	Dowsett, M				Dowsett, M			Improved prognosis for biomarkers in breast cancer	LANCET			English	Editorial Material							EXPRESSION		Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Dowsett, M (corresponding author), Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ABE O, 1992, LANCET, V339, P71; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARTLETT K, 1993, LANCET, V341, P1293; Bast RC, 1998, J CLIN ONCOL, V16, P793; DRESSLER LG, 1992, J NATL CANCER I MONO, V11, P167; *EARL BREAST CANC, 1992, LANCET, V339, P1; ELLEDGE RM, 1993, ANNU REV MED, V44, P201, DOI 10.1146/annurev.me.44.020193.001221; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis PA, 1997, LANCET, V349, P849, DOI 10.1016/S0140-6736(05)61752-7; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Makris A, 1998, BREAST CANCER RES TR, V48, P11, DOI 10.1023/A:1005973529921; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; TIETILAINEN T, 1996, J CANC RES ONCOL, V122, P687	16	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1753	1754		10.1016/S0140-6736(05)78743-2	http://dx.doi.org/10.1016/S0140-6736(05)78743-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635946				2022-12-24	WOS:000074197600007
J	Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF				Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF			Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases	LANCET			English	Article							EXTRACELLULAR-MATRIX; PREMENOPAUSAL WOMEN; CATHEPSIN-L; CYCLE; SURGERY; CELLS; DEGRADATION; SURVIVAL; ACID	Background Retrospective studies show significant improvements in survival among women who had breast cancer resected during the luteal phase of their menstrual cycle compared with the follicular phase. We hypothesised that tumour tissue would show cyclical changes in expression of genes whose products might contribute to metastatic potential. Methods We studied 32 premenopausal women with operable breast cancer. We assayed hormones to define more accurately the menstrual phase during which surgery was done. We used northern blot analysis of RNA from fresh-frozen tumour specimens to study the patterns of expression of genes for proteolytic enzymes (cysteine proteinase cathepsin L and aspartyl proteinase cathepsin D; matrix metalloproteinases MMP-9 and MMP-2), tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and TP53. Results There was a significantly higher level of expression of RNA for cathepsin L, MMP-9, and TP53 (p=0.005, 0.03, 0.03, respectively) in tumours that were resected during the follicular and periovulatory phases of the menstrual cycle than at other times in the cycle. A similar but nonsignificant trend was seen for MMP-2 and cathepsin D. A non-significant trend in the opposite direction was seen for TIMP-1 and TIMP-2. Interpretation We found that tumour expression of genes that may contribute to proliferative capacity and metastatic potential can change in breast cancer during the course of the menstrual cycle. The finding could provide a molecular explanation for the reports of improved survival in some breast-cancer patients whose tumours were removed during the luteal phase of the menstrual cycle. Larger studies are required to extend our study, assess mechanisms of gene regulation, and verify any relevant influence in long-term survival.	London Reg Canc Ctr, London, ON N6A 4L6, Canada; London Hlth Sci Ctr, London, ON, Canada; Univ Manchester, Sch Nursing, Manchester, Lancs, England	Western University (University of Western Ontario); London Health Sciences Centre; University of Manchester	Saad, Z (corresponding author), Hope Hosp, Stott Lane, Salford M6 8HD, Lancs, England.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Winstanley, Julie/0000-0002-9353-6757				AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BRIOZZO P, 1988, CANCER RES, V48, P3688; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; FERGUSON JE, 1992, CELL TISSUE RES, V268, P167, DOI 10.1007/BF00338066; Hrushesky W., 1996, Breast Cancer Research and Treatment, V41, P272; HRUSHESKY WJM, 1989, LANCET, V2, P949; JARVIS PM, 1980, ANN NY ACAD SCI, V464, P152; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LEIS HP, 1991, BREAST, P331; LEVINE M, 1996, P AN M AM SOC CLIN, V15, P99; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; POWLES TJ, 1991, LANCET, V337, P1604; PRICE JE, 1990, CANCER RES, V50, P717; RADVIN PM, 1993, BREAST CANC RES TREA, V24, P219; RAGETH JC, 1991, ANN ONCOL, V2, P269, DOI 10.1093/oxfordjournals.annonc.a057935; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SAAD Z, 1994, BRIT J SURG, V81, P217, DOI 10.1002/bjs.1800810219; SAINSBURY R, 1991, LANCET, V338, P391; SENIE RT, 1991, ANN INTERN MED, V115, P337, DOI 10.7326/0003-4819-115-5-337; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; Thomssen C, 1995, CLIN CANCER RES, V1, P741; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VERONESI U, 1994, LANCET, V343, P1544	27	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1170	1173		10.1016/S0140-6736(97)07498-9	http://dx.doi.org/10.1016/S0140-6736(97)07498-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643688				2022-12-24	WOS:000073220200010
J	Munn, DH; Zhou, M; Attwood, JT; Bondarev, I; Conway, SJ; Marshall, B; Brown, C; Mellor, AL				Munn, DH; Zhou, M; Attwood, JT; Bondarev, I; Conway, SJ; Marshall, B; Brown, C; Mellor, AL			Prevention of allogeneic fetal rejection by tryptophan catabolism	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; INDOLEAMINE 2,3-DIOXYGENASE; DIFFERENTIATION; PREGNANCY	In 1953 Medawar pointed out that survival of the genetically disparate (allogeneic) mammalian conceptus contradicts the Laws of tissue transplantation. Rapid T cell-induced rejection of all allogeneic concepti occurred when pregnant mice were treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme expressed by trophoblasts and macrophages. Thus, by catabolizing tryptophan, the mammalian conceptus suppresses T cell activity and defends itself against rejection.	Med Coll Georgia, Inst Mol Med & Genet, Program Mol Immunol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Program Dev Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Univ Georgia, Dept Pathol, Athens, GA 30602 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; University of Georgia	Mellor, AL (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Program Mol Immunol, 1120 15th St, Augusta, GA 30912 USA.	mellor@immag.mcg.edu		Munn, David/0000-0002-7711-2858				Bonney EA, 1997, J IMMUNOL, V158, P40; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; HABARAOHKUBO A, 1991, GENE, V105, P221, DOI 10.1016/0378-1119(91)90154-4; KAMIMURA S, 1991, ACTA MED OKAYAMA, V45, P135; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; MUNN DH, 1993, CANCER RES, V53, P2603; Munn DH, 1996, J IMMUNOL, V156, P523; MUNN DH, UNPUB; MUNN DH, UNPUB HUMAN MACROPHA; POLLARD WJ, 1997, MOL REPROD DEV, V46, P54; Schrocksnadel H, 1996, OBSTET GYNECOL, V88, P47, DOI 10.1016/0029-7844(96)00084-1; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; Tarazona R, 1996, INT IMMUNOL, V8, P351, DOI 10.1093/intimm/8.3.351; ZHOU M, IN PRESS J REPROD IM; ZHOU M, UNPUB	16	1988	2128	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1191	1193		10.1126/science.281.5380.1191	http://dx.doi.org/10.1126/science.281.5380.1191			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712583				2022-12-24	WOS:000075531200053
J	Breman, JG; Henderson, DA				Breman, JG; Henderson, DA			Poxvirus dilemmas - Monkeypox, smallpox, and biologic terrorism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VIRUS STOCKS; GENOME; SEQUENCE; STRAIN; DNA		NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University	Breman, JG (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P1; Betts RK, 1998, FOREIGN AFF, V77, P26, DOI 10.2307/20048360; BREMAN JG, 1980, B WORLD HEALTH ORGAN, V58, P165; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; COHEN J, 1996, 6 PLEN M A49 VR 6 GE; FENNER F, 1988, HIST INT PUBLIC HLTH, V6; FINE PEM, 1988, INT J EPIDEMIOL, V17, P643, DOI 10.1093/ije/17.3.643; FOSTER SO, 1970, J NIGERIAN MED ASSOC, V7, P41; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; GARRETT L, 1997, NEWSDAY         0810, P1; HENDERSON DA, IN PRESS EMERG INFEC; Heymann DL, 1998, BRIT MED BULL, V54, P693, DOI 10.1093/oxfordjournals.bmb.a011720; JEZEK Z, 1987, AM J EPIDEMIOL, V126, P1082, DOI 10.1093/oxfordjournals.aje.a114747; JEZEK Z, 1988, B WORLD HEALTH ORGAN, V66, P465; Jezek Z, 1988, HUMAN MONKEYPOX, V17; JOKLIK WK, 1993, SCIENCE, V262, P1225, DOI 10.1126/science.8235652; Joklik WK, 1996, SCIENTIST, V10, P11; Kadlec RP, 1997, JAMA-J AM MED ASSOC, V278, P351, DOI 10.1001/jama.278.5.351; KUPPERMAN RH, 1993, BIOL WEAPONS WEAPONS, P35; LADNYJ ID, 1972, B WORLD HEALTH ORGAN, V46, P593; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; MAHY BWJ, 1993, SCIENCE, V262, P1223, DOI 10.1126/science.8235651; MAHY BWJ, 1993, REV MED VIROL, V3, P131, DOI 10.1002/rmv.1980030302; MAHY BWJ, 1991, ASM NEWS, V57, P577; Massung RF, 1996, VIROLOGY, V221, P291, DOI 10.1006/viro.1996.0378; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341; Mukinda VBK, 1997, LANCET, V349, P1449, DOI 10.1016/S0140-6736(05)63725-7; Preston R., 1998, NEW YORKER, P52; RAO AR, 1968, INDIAN J MED RES, V56, P1826; ROIZMAN B, 1994, INFECT AGENT DIS, V3, P215; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; Simon JD, 1997, JAMA-J AM MED ASSOC, V278, P428, DOI 10.1001/jama.278.5.428; Simon JD., 1989, TERRORISTS POTENTIAL; SUTTER G, 1995, DEV BIOL STAND, V84, P195; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P369; *WHO, 1980, HLTH INT PUBL HLTH, V4; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418; 1997, MMWR MORB MORTAL WKL, V46, P304	41	127	132	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					556	559		10.1056/NEJM199808203390811	http://dx.doi.org/10.1056/NEJM199808203390811			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709051				2022-12-24	WOS:000075447000011
J	Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR				Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR			The practice of euthanasia and physician-assisted suicide in the United States - Adherence to proposed safeguards and effects on physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACTIVE EUTHANASIA; WASHINGTON-STATE; CANCER-PATIENTS; ATTITUDES; NETHERLANDS; LIFE; END; EXPERIENCES; PREVALENCE; DECISIONS	Context.-Despite intense debates about legalization, there are few data examining the details of actual euthanasia and physician-assisted suicide (PAS) cases in the United States. Objective.-To determine whether the practices of euthanasia and PAS are consistent with proposed safeguards and the effect on physicians of having performed euthanasia or PAS. Design.-Structured in-depth telephone interviews. Setting and Participants.-Randomly selected oncologists;in the United States. Outcome Measures.-Adherence to primary and secondary safeguards for the practice of euthanasia and PAS; regret, comfort, and fear of prosecution from performing euthanasia or PAS. Results.-A total of 355 oncologists (72.6% response rate) were interviewed on euthanasia and PAS. On 2 screening questions, 56 oncologists (15.8%) reported participating in euthanasia or PAS; 53 oncologists (94.6% response rate) participated in in-depth interviews. Thirty-eight of 53 oncologists described clearly defined cases of euthanasia or PAS. Twenty-three patients (60.5%) both initiated and repeated their request for euthanasia or PAS, but 6 patients (15.8%) did not participate in the decision for euthanasia or PAS. Thirty-seven patients (97.4%) were experiencing unremitting pain or such poor physical functioning they could not perform self-care. Physicians sought consultation in 15 cases (39.5%), Overall, oncologists adhered to all 3 main safeguards in 13 cases (34.2%), (1) having the patient initiate and repeat the request for euthanasia or PAS, (2) ensuring the patient was experiencing extreme physical pain or suffering, and (3) consulting with a colleague. Those who adhered to the safeguards had known their patients longer and tended to be more religious. In 28 cases (73.7%), the family supported the decision. In all cases of pain, patients were receiving narcotic analgesia. Fifteen patients (39.5%) were enrolled in a hospice, While 19 oncologists (52.6%) received comfort from having helped a patient with euthanasia or PAS, 9 (23.7%) regretted having performed euthanasia or PAS, and 15(39.5%) feared prosecution. Conclusions.-Intractable pain or poor physical functioning seem to be nearly absolute requirements for physicians to perform euthanasia or PAS. Only one third of cases are performed consistently with proposed safeguards. For some patients, end-of-life care that includes opioid analgesia and hospice care does not obviate their desire for euthanasia or PAS. While the majority of physicians seem comforted by their actions, some experience adverse consequences from having performed euthanasia or PAS.	Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Amer Med Ctr, Ctr Canc Res, Ctr Res Methodol & Biometr, Denver, CO USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, 44 Biney St, Boston, MA 02115 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1993, J FAM PRACTICE, V37, P123; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DEROGATIS LR, 1983, JAMA-J AM MED ASSOC, V249, P751, DOI 10.1001/jama.249.6.751; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 1996, ARCH INTERN MED, V156, P825, DOI 10.1001/archinte.156.8.825; Emanuel Ezekiel, 1997, Atl Mon, V279, P73; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GEVERS JKM, 1992, J MED ETHICS, V18, P138, DOI 10.1136/jme.18.3.138; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MANDERMAAS PJ, 1991, LANCET, V388, P669; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1998, DEATH DIGNITY MAKING; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	33	100	101	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					507	513		10.1001/jama.280.6.507	http://dx.doi.org/10.1001/jama.280.6.507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	108AY	9707132				2022-12-24	WOS:000075244900013
J	Majeed, A; Lehmann, P; Kirby, L; Coleman, MP				Majeed, A; Lehmann, P; Kirby, L; Coleman, MP			Mortality from dementias and neurodegenerative disorders in people aged 15-64 in England and Wales in 1979-96	BRITISH MEDICAL JOURNAL			English	Article									Off Natl Stat, London SW1V 2QQ, England		Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.		Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807; Majeed, Azeem/0000-0002-2357-9858				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HOMER AC, 1988, BMJ-BRIT MED J, V297, P894, DOI 10.1136/bmj.297.6653.894; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					320	321		10.1136/bmj.317.7154.320	http://dx.doi.org/10.1136/bmj.317.7154.320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685278	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000075409500022
J	Pollock, AM; Vickers, N				Pollock, AM; Vickers, N			Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RATES; CONSULTATION; SURVIVAL; SURGERY; IMPACT	Objectives: To examine the relation between deprivation and acute emergency admissions for cancers of the colon, rectum, lung, and breast in south east England. Design: Ecological analysis with data from hospital episode statistics and 1991 census. Setting: North and South Thames Regional Health Authorities (population about 14 million), divided into 10 aggregations of 31 470 census enumeration districts (median population 462). Subjects: 146 639 admissions relating to 76 552 patients aged < 100 years on admission, resident in the Thames regions, admitted between 1 April 1992 and 31 March 1995. Results: Residents living in deprived areas were more likely to be admitted as emergencies and has ordinary inpatient admissions and less likely to be admitted as day cases. Adjusted odds of ordinary admissions from the most deprived tenth occurring as emergencies (relative to admissions from the most affluent tenth) were 2.29 (95% confidence interval 2.09 to 2.52) for colorectal cancer, 2.20 (1.99 to 2.43) for lung cancer, and 2.41 (2.17 to 2.67) for female breast cancer; adjusted odds of admissions as day cases were 0.70 (0.64 to 0.76), 0.50 (0.44 to 0.56), and 0.56 (0.50 to 0.62), respectively. Patients from deprived areas with lung or breast cancers were less likely to be recorded as having surgical interventions. Adjusted odds of patients fi-om the most deprived tenth receiving surgery were 0.88 (0.78 to 1.00), 0.58 (0.48 to 0.70), and 0.63 (0.56 to 0.71), respectively. Admissions for colorectal cancer from the most deprived areas were less likely to be to hospitals admitting 100 or more new patients a year; the opposite held true for breast cancer admissions. No association was found for lung cancer admissions. Conclusions: Earlier diagnostic and referral procedures in primary care in deprived areas are required if there are to be significant reductions in mortality from these cancers. A national information strategy is required to ensure the continued availability of population based data on NHS patients and to mandate standardised datasets from the private sector. Rationalisation of acute services, hospital mergers, and plans for bed closures must take into account the increased healthcare needs and inequities in access to treatment and care of residents in areas with high levels of deprivation Health authorities and primary care groups should re-examine their purchasing intentions, service reviews, and monitoring arrangements in the light of these findings.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London	Pollock, AM (corresponding author), UCL, Sch Publ Hlth, London WC1E 7HN, England.			pollock, allyson/0000-0002-7388-3110				BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; *EXP ADV GROUP CAN, 1994, POL FRAM COMM CANC S; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GILL L, 1993, J EPIDEMIOL COMMUN H, V47, P316, DOI 10.1136/jech.47.4.316; *GOV STAT SERV, 1993, HOSP EP STAT 1989 19; LAMDEN KH, 1995, J PUBLIC HEALTH MED, V17, P63; *LIANG BUISS, 1996, LIANGS REV PRIV HLTH; MAJEED F, 1995, BRIT MED J, V310, P1674, DOI 10.1136/bmj.310.6995.1674a; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MCCORMICK A, 1994, MORBIDITY STAT GEN P; SCHRIJVERS CTM, 1995, CANCER-AM CANCER SOC, V75, P2946, DOI 10.1002/1097-0142(19950615)75:12<2946::AID-CNCR2820751223>3.0.CO;2-6; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SCHRIJVERS CTM, 1995, EUR J CANCER, V31A, P1660, DOI 10.1016/0959-8049(95)00272-K; SCHRIJVERS CTM, 1995, INT J CANCER, V63, P324, DOI 10.1002/ijc.2910630303; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; Townsend P, 1988, HLTH DEPRIVATION INQ	24	67	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					245	252		10.1136/bmj.317.7153.245	http://dx.doi.org/10.1136/bmj.317.7153.245			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677214	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075081900021
J	Sakai, DH				Sakai, DH			A visit from my daughter	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					321	321		10.1001/jama.280.4.321	http://dx.doi.org/10.1001/jama.280.4.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686541				2022-12-24	WOS:000074804200018
J	Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA				Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA			Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis	NATURE			English	Article							PENTAFUNCTIONAL AROM PROTEIN; ASPERGILLUS-NIDULANS; 3-DEHYDROQUINATE; SHIKIMATE	Dehydroquinate synthase (DHQS) has long been regarded as a catalytic marvel because of its ability to perform several consecutive chemical reactions in one active site(1-7). There has been considerable debate as to whether DHQS is actively involved in all these steps(1,2), or whether several steps occur spontaneously, making DHQS a spectator in its own mechanism(3-5). DHQS performs the second step in the shikimate pathway, which is required for the synthesis of aromatic compounds in bacteria, microbial eukaryotes and plants(8). This enzyme is a potential target for new antifungal and antibacterial drugs(9,10) as the shikimate pathway is absent from mammals and DHQS is required for pathogen virulence(11). Here we report the crystal structure of DHQS, which has several unexpected features, including a previously unobserved mode for NAD(+)-binding and an active-site organization that is surprisingly similar to that of alcohol dehydrogenase, in a new protein fold, The structure reveals interactions between the active site and a substrate-analogue inhibitor, which indicate how DHQS can perform multistep catalysis without the formation of unwanted by-products.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Med Sch Newcastle Upon Tyne, New Med Sch, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Imperial College London; MRC National Institute for Medical Research; Newcastle University - UK; Michigan State University	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Exhibit Rd, London SW7 2AY, England.	k.brown@ic.ac.uk		Carpenter, Liz/0000-0001-9138-2937				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTLETT PA, 1988, J AM CHEM SOC, V110, P1628, DOI 10.1021/ja00213a049; BARTLETT PA, 1994, J ORG CHEM, V59, P2082, DOI 10.1021/jo00087a024; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASE ME, 1971, P NATL ACAD SCI USA, V68, P58, DOI 10.1073/pnas.68.1.58; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gunel- Ozcan A., 1997, MICROBIAL PATHOGEN, V17, P169; HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891, DOI 10.1099/00221287-139-12-2891; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P27; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; LAMBERT JM, 1985, BIOCHEM J, V226, P817, DOI 10.1042/bj2260817; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Montchamp JL, 1997, J AM CHEM SOC, V119, P7645, DOI 10.1021/ja961771z; MOORE JD, 1994, BIOCHEM J, V301, P297, DOI 10.1042/bj3010297; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SRINIVASAN PR, 1963, J BIOL CHEM, V238, P3176; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TRONRUD DE, 1993, TNT REFINEMENT PACKA, P1; VANDENHOMBERGH JPTW, 1992, BIOCHEM J, V284, P861, DOI 10.1042/bj2840861; WIDLANSKI T, 1989, J AM CHEM SOC, V111, P2299, DOI 10.1021/ja00188a052; [No title captured]	29	113	138	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					299	302		10.1038/28431	http://dx.doi.org/10.1038/28431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685163				2022-12-24	WOS:000074851900054
J	Glover, JR; Lindquist, S				Glover, JR; Lindquist, S			Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins	CELL			English	Article							HEAT-SHOCK PROTEINS; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; RNA-POLYMERASE; YEAST; DNAJ; THERMOTOLERANCE; HOMOLOG	Hsp104 is a stress tolerance factor that promotes the reactivation of heat-damaged proteins in yeast by an unknown mechanism. Herein, we demonstrate that Hsp104 functions in this process directly. Unlike other chaperones, Hsp104 does not prevent the aggregation of denatured proteins. However, in concert with Hsp40 and Hsp70, Hsp104 can reactivate proteins that have been denatured and allowed to aggregate, substrates refractory to the action of other chaperones. Hsp104 cooperates with the chaperones present in reticulocyte lysates but not with DnaK of E. coli. We conclude that Hsp104 has a protein remodeling activity that acts on trapped, aggregated proteins and requires specific interactions with conventional chaperones to promote refolding of the intermediates it produces.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025874, R01GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker J, 1996, MOL CELL BIOL, V16, P4378; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Bush GL, 1996, J CELL BIOL, V135, P1229, DOI 10.1083/jcb.135.5.1229; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; LEE YRJ, 1994, PLANT CELL, V6, P1889, DOI 10.1105/tpc.6.12.1889; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609; Xie YS, 1996, PROTEIN SCI, V5, P517; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	49	1068	1106	3	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					73	82		10.1016/S0092-8674(00)81223-4	http://dx.doi.org/10.1016/S0092-8674(00)81223-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674429	Bronze			2022-12-24	WOS:000074790800011
J	Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P				Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P			Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes	CELL			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; HIGH-AFFINITY BINDING; NERVE-TERMINALS; ALPHA-ADAPTIN; GOLGI STACK; IN-VITRO; DYNAMIN; MEMBRANE; DOMAIN; TRANSPORT	Clathrin-coated buds and dynamin-coated tubules morphologically similar to corresponding structures observed in synaptic membranes can be generated on protein-free liposomes by incubation with cytosol, or with clathrin coat proteins and purified dynamin, respectively. Dynamin- and clathrin-coated intermediates may form independently of each other, despite the coupling between the two processes typically observed in synaptic membranes. Formation of both structures on liposomes can occur in the absence of nucleotides. These findings indicate that interfaces between lipids and cytosolic proteins are fully sufficient to deform lipids bilayers into buds and tubules. They suggest that a main function of membrane proteins is to act as positive and negative regulators of coat assembly, therefore controlling these processes in time and space.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993; Takei, Kohji/0000-0002-6555-9425	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHEN H, 1998, IN PRESS NATURE; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HAMA K, 1977, J NEUROCYTOL, V6, P361, DOI 10.1007/BF01178223; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER J, 1971, PROC R SOC SER B-BIO, V179, P247, DOI 10.1098/rspb.1971.0096; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LOVAS B, 1971, Z ZELLFORSCH MIK ANA, V121, P341, DOI 10.1007/BF00337638; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORRIS MB, 1992, J CELL BIOCHEM, V48, P356, DOI 10.1002/jcb.240480404; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RAPAPORT I, 1997, EMBO J, V16, P2240; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; YE W, 1991, J BIOL CHEM, V266, P4442; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	279	283	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					131	141		10.1016/S0092-8674(00)81228-3	http://dx.doi.org/10.1016/S0092-8674(00)81228-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674434	hybrid			2022-12-24	WOS:000074790800016
J	Becker, S; Groner, B; Muller, CW				Becker, S; Groner, B; Muller, CW			Three-dimensional structure of the Stat3 beta homodimer bound to DNA	NATURE			English	Article							B P50 HOMODIMER; ELECTRON-DENSITY MAPS; TRANSCRIPTIONAL ACTIVITY; SIGNAL TRANSDUCERS; TROPONIN-C; BINDING; STAT; DOMAIN; RECOGNITION; ACTIVATION	STAT proteins are a family of eukaryotic transcription factors that mediate the response to a large number of cytokines and growth factors. Upon activation by cell-surface receptors or their associated kinases, STAT proteins dimerize, translocate to the nucleus and bind to specific promoter sequences on their target genes. Here we report the first crystal structure of a STAT protein bound to its DNA recognition site at 2.25 Angstrom resolution. The structure provides insight into the various steps by which STAT proteins deliver a response signal directly from the cell membrane to their target genes in the nucleus.	European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany	European Molecular Biology Laboratory (EMBL)	Muller, CW (corresponding author), European Mol Biol Lab, Grenoble Outstn, ILL BP 156, F-38042 Grenoble 9, France.	mueller@embl-grenoble.fr	Müller, Christoph W/I-7420-2012	Müller, Christoph W/0000-0003-2176-8337				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FOTELLE EDL, 1997, METHOD ENZYMOL, V276, P472; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HELM MH, 1995, SCIENCE, V267, P1347; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Muller CW, 1996, NAT STRUCT BIOL, V3, P224, DOI 10.1038/nsb0396-224; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P189; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	46	650	690	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					145	151		10.1038/28101	http://dx.doi.org/10.1038/28101			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671298				2022-12-24	WOS:000074705900043
J	Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH				Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH			Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America	ANNALS OF INTERNAL MEDICINE			English	Article						low back pain; spine; chiropractic; manipulation, orthopedic; quality of health care	RANDOMIZED CLINICAL-TRIAL; NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CORONARY-ANGIOGRAPHY; NECK COMPLAINTS; MANUAL THERAPY; CAROTID ENDARTERECTOMY; OUTCOME MEASURES; PERSISTENT BACK; FOLLOW-UP	Background: Recent U.S. practice guidelines recommend spinal manipulation for some patients with low back pain. If followed, these guidelines are likely to increase the number of persons referred for chiropractic care. Concerns have been raised about the appropriate use of chiropractic care, but systematic data are lacking. Objective: To determine the appropriateness of chiropractors' decisions to use spinal manipulation for patients with low back pain. Design: Retrospective review of chiropractic office records against preset criteria for appropriateness that were developed from a systematic review of the literature and a nine-member panel of chiropractic and medical specialists. Appropriateness criteria reflect the expected balance between risk and benefit. Setting: 131 of 185 (71%) chiropractic offices randomly sampled from sites in the United States and Canada. Patients: 10 randomly selected records of patients presenting with low back pain from each office (1310 patients total). Measurements: Sociodemographic data on patients and chiropractors; use of health care services by patients; assessment of the decision to initiate spinal manipulation as appropriate, uncertain, or inappropriate. Results: Of the 1310 patients who sought chiropractic care for low back pain, 1088 (83%) had spinal manipulation. For 859 of these patients (79%), records contained data sufficient to determine whether care was congruent with appropriateness criteria. Care was classified as appropriate in 46% of cases, uncertain in 25% of cases, and inappropriate in 29% of cases. Patients who did not undergo spinal manipulation were less likely to have a presentation judged appropriate and were more likely to have a presentation judged inappropriate than were patients who did undergo spinal manipulation (P = 0.01). Conclusions: The proportion of chiropractic spinal manipulation judged to be congruent with appropriateness criteria is similar to proportions previously described for medical procedures; thus, the findings provide some reassurance about the appropriate application of chiropractic care. However, more than one quarter of patients were treated for indications that were judged inappropriate. The number of inappropriate decisions to use chiropractic spinal manipulation should be decreased.	Rand Corp, Santa Monica, CA 90401 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Los Angeles Coll Chiropract, Whittier, CA 90609 USA; Canadian Mem Chiropract Coll, Toronto, ON M4G 3E6, Canada	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shekelle, PG (corresponding author), Rand Corp, 1700 Main St,POB 2138, Santa Monica, CA 90401 USA.		Mior, Silvano A/L-4786-2015	Mior, Silvano A/0000-0001-6575-2797				BALLANTINE HT, 1972, NEW ENGL J MED, V286, P237, DOI 10.1056/NEJM197202032860504; BENGTSON A, 1994, JAMA-J AM MED ASSOC, V271, P1260, DOI 10.1001/jama.271.16.1260; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BIGOS SJ, 1992, AHCPR PUBLICATION; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BROOK RH, 1993, SCHWEIZ MED WSCHR, V123, P249; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1989, APPROPRIATENESS USE; CURTIS P, 1992, J FAM PRACTICE, V35, P551; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; FELLEGI IP, 1980, J AM STAT ASSOC, V75, P261, DOI 10.2307/2287444; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; Kahn KL., 1992, EFFECTS DRG BASED PR, pxxiv 343; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Leape LL, 1996, ANN INTERN MED, V125, P8, DOI 10.7326/0003-4819-125-1-199607010-00003; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHEKELLE PG, 1995, J MANIP PHYSIOL THER, V18, P265; SHEKELLE PG, 1991, APPROPRIATE USE SPIN; SHEKELLE PG, 1994, USE COSTS CHIROPRACT; SHEKELLE PG, IN PRESS INT J TECH; THOMAS DR, 1987, J AM STAT ASSOC, V82, P630, DOI 10.2307/2289475; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080	50	37	37	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					9	+		10.7326/0003-4819-129-1-199807010-00003	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653012				2022-12-24	WOS:000074513300002
J	Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M				Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M			Death from heroin overdose: findings from hair analysis	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MORPHINE; BLOOD; COCAINE	Background Morphine analysis of hair is used in forensic toxicology to study the addiction history of heroin addicts. To clarify the features underlying fatal heroin intake, we measured hair morphine content in a group of deceased heroin addicts, to verify a possible correlation between fatal heroin overdoses and the addiction behaviour of these individuals before death. Methods 91 deaths were attributed to heroin overdose in Verona, Italy, in 1993-96. We analysed the hair of 37 of these individuals, and of 37 active heroin addicts, 37 former heroin users abstinent from the drug for several months, and 20 individuals with no evidence of exposure to opioids. From each individual, a hair sample of about 150 mg was analysed by RIA and high-performance liquid chromatography, to measure the morphine content. Findings The mean morphine content in the hair of the addicts who had died was 1.15 ng/mg (SD 2.35 ng/mg; range 0-12.25 ng/mg) compared with 6.07 ng/mg (4.29; 1.15-17.0) in the active heroin addicts, 0.74 ng/mg (0.93; 0.10-3.32) in the abstinent former addicts, and values below the detection limit in the non-exposed group. Hair morphine content among those who had died was significantly lower than that in active heroin consumers (p<0.0001), but not significantly different from that in the former addicts (p=0.978). Interpretation Although our findings may be subject to selection bias, since suitable hair samples were available for only 37 of the 91 addicts who had died, these findings support the theory of high susceptibility to opioid overdose after periods of intentional or unintentional abstinence, due to loss of tolerance. Medical staff running detoxification programmes should be aware of the risk inherent in relapse to heroin after a period of abstinence. Moreover, occasional heroin use without a build-up of tolerance could also give a high risk of overdose.	Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy; Univ Alabama, Dept Justice Sci, Birmingham, AL USA	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Alabama System; University of Alabama Birmingham	Tagliaro, F (corresponding author), Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy.		Tagliaro, Franco/AAB-8631-2022	Tagliaro, Franco/0000-0002-2187-9128				ADDINGTON WW, 1972, CHEST, V62, P199, DOI 10.1378/chest.62.2.199; Baselt R., 1995, DISPOSITION TOXIC DR; BRASHEAR RE, 1974, J LAB CLIN MED, V83, P451; CONE EJ, 1991, J ANAL TOXICOL, V15, P250, DOI 10.1093/jat/15.5.250; HARDINGPINK D, 1988, BRIT MED J, V297, P596, DOI 10.1136/bmj.297.6648.596; HENDERSON GL, 1993, FORENSIC SCI INT, V63, P19, DOI 10.1016/0379-0738(93)90256-A; *IT MIN INT AFF, 1996, DIR CENTR SERV ANT; KINTZ P, 1992, EUR J CLIN PHARMACOL, V42, P351; LEVINE B, 1995, J FORENSIC SCI, V40, P808; LORATAMAYO C, 1987, J CHROMATOGR-BIOMED, V422, P267, DOI 10.1016/0378-4347(87)80462-0; MARIGO M, 1986, J ANAL TOXICOL, V10, P158, DOI 10.1093/jat/10.4.158; MIYAZAWA N, 1991, FORENSIC SCI INT, V51, P65, DOI 10.1016/0379-0738(91)90206-X; PUSCHEL K, 1983, FORENSIC SCI INT, V21, P181, DOI 10.1016/0379-0738(83)90108-1; PUSCHEL K, 1993, FORENSIC SCI INT, V62, P129, DOI 10.1016/0379-0738(93)90057-H; QUESTEL F, 1996, ANN INTERN MED, V15, P616; Richards R G, 1976, J Forensic Sci, V21, P467; SACHS H, 1995, FORENSIC SCI INT, V70, P53, DOI 10.1016/0379-0738(94)01611-8; Skopp G, 1997, FORENSIC SCI INT, V84, P43, DOI 10.1016/S0379-0738(96)02047-6; Smith FP, 1996, FORENSIC SCI INT, V83, P179, DOI 10.1016/S0379-0738(96)02035-X; SPIEHLER V, 1987, J FORENSIC SCI, V32, P906; STAUB C, 1990, INT J LEGAL MED, V104, P39, DOI 10.1007/BF01816482; TAGLIARO D, 1997, FORENSIC SCI INT, V84, P129; TAGLIARO F, 1994, J CHROMATOGR A, V674, P207, DOI 10.1016/0021-9673(94)85225-1; TAGLIARO F, 1988, CHROMATOGRAPHIA, V26, P163, DOI 10.1007/BF02268144; UEMATSU T, 1989, EUR J CLIN PHARMACOL, V37, P239, DOI 10.1007/BF00679777; UGES DRA, 1996, TIAFT B, V26, P5; *US GEN ASS OFF, 1993, DRUG US MEAS STRENGT	27	89	91	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1923	1925		10.1016/S0140-6736(97)10101-5	http://dx.doi.org/10.1016/S0140-6736(97)10101-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654260				2022-12-24	WOS:000074464700010
J	Fleming, A; Copp, AJ				Fleming, A; Copp, AJ			Embryonic folate metabolism and mouse neural tube defects	SCIENCE			English	Article							MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE; FOLIC-ACID; SPINA-BIFIDA; RAT EMBRYOS; MUTANT; PAX-3; PREVENTION; GENE; VITAMIN-B12; METHIONINE	Folic acid prevents 70 percent of human neural tube defects (NTDs) but its mode of action is unclear. The deoxyuridine suppression test detects disturbance of folate metabolism in homozygous splotch (Pax3) mouse embryos that are developing NTDs in vitro. Excessive incorporation of [(3)H]thymidine in splotch embryos indicates a metabolic deficiency in the supply of folate for the biosynthesis of pyrimidine. Exogenous folic acid and thymidine both correct the biosynthetic defect and prevent some NTDs in splotch homozygotes, whereas methionine has an exacerbating effect. These data support a direct normalization of neurulation by folic acid in humans and suggest a metabolic basis for folate action.	UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England	University of London; University College London	Copp, AJ (corresponding author), UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England.	a.copp@ich.ucl.ac.uk	Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Fleming, Angeleen/0000-0003-3721-7126	NICHD NIH HHS [HD 28882] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028882] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BADEN JM, 1991, BRIT J ANAESTH, V66, P500, DOI 10.1093/bja/66.4.500; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; CHATKUPT S, 1995, J MED GENET, V32, P200, DOI 10.1136/jmg.32.3.200; COCKROFT DL, 1991, HUM REPROD, V6, P148, DOI 10.1093/oxfordjournals.humrep.a137250; COPP AJ, 1985, J EMBRYOL EXP MORPH, V88, P39; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; Daston G, 1996, DEVELOPMENT, V122, P1017; deFranchis R, 1995, LANCET, V346, P1703, DOI 10.1016/S0140-6736(95)92865-0; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Greene NDE, 1997, NAT MED, V3, P60, DOI 10.1038/nm0197-60; HELD MK, 1992, J NUTR, V122, P888; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; KIRKE PN, 1993, Q J MED, V86, P703; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Morrison K, 1997, J MED GENET, V34, P958, DOI 10.1136/jmg.34.11.958; Papapetrou C, 1996, LANCET, V348, P58, DOI 10.1016/S0140-6736(05)64382-6; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; SCOTT JM, 1994, CIBA F SYMP, V181, P180; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; VANAERTS LAGJM, 1994, TERATOLOGY, V50, P348, DOI 10.1002/tera.1420500506; VANALLEN MI, 1993, AM J MED GENET, V47, P723, DOI 10.1002/ajmg.1320470528; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; WHITEHEAD AS, 1995, J MED, V88, P763; Wilcken DEL, 1996, LANCET, V347, P340, DOI 10.1016/S0140-6736(96)90526-7; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	34	196	206	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2107	2109		10.1126/science.280.5372.2107	http://dx.doi.org/10.1126/science.280.5372.2107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641914				2022-12-24	WOS:000074435900042
J	Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK				Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK			Role of human-milk lactadherin in protection against symptomatic rotavirus infection	LANCET			English	Article							FAT-GLOBULE-MEMBRANE; ESCHERICHIA-COLI; MEXICAN CHILDREN; OLIGOSACCHARIDES; DIARRHEA; RECEPTOR; GASTROENTERITIS; INHIBITION; COHORT; MUCIN	Background Human milk contains a 46 kDa mucin-associated glycoprotein, lactadherin, which binds specifically to rotavirus and inhibits its replication. This study tested the hypothesis that lactadherin protects against symptoms of rotavirus infection. Methods 200 infants in Mexico City were recruited at birth and monitored by regular stool EIA for rotavirus, serology, and recording of feeding and stool patterns. Milk samples were obtained from the mothers weekly until 4 weeks post partum then monthly. The sample taken immediately before an infant's episode of rotavirus infection was assayed for lactadherin, butyrophilin, mucin, and secretory IgA. An infection was defined as symptomatic if diarrhoea occurred in the 5 days before or after detection of the virus. Findings 31 infants developed rotavirus infection; 15 were symptomatic and 16 had no symptoms. The median concentration of lactadherin in the milk samples (obtained 4-41 days [median 13] before the infection) was 484 (range 5.6-180) mu g/mL in the asymptomatic group and 29.2 (6.2-103.4) mu g/mL in the symptomatic group. Although these medians did not differ significantly, in logistic regression analysis adjusted for age at infection and secretory IgA concentration there was a significant difference between the groups (p=0.01). No association between symptom status and concentrations of butyrophilin, mucin, or secretory IgA was found. Interpretation Protection against rotavirus by human milk is associated with the glycoprotein lactadherin. This association is independent of products of the secretory immune system.	Shriver Ctr Mental Retardat, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Boston, MA USA; Canc Res Inst Contra Costa, Walnut Creek, CA USA; Inst Nacl Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Childrens Hosp Kings Daughters, Ctr Pediat Res, Norfolk, VA USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Harvard University; Harvard Medical School; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Eastern Virginia Medical School	Newburg, DS (corresponding author), Shriver Ctr Mental Retardat, 200 Trapelo Rd, Waltham, MA 02254 USA.		Morrow, Ardythe/GQO-8482-2022; Newburg, david/ABE-8139-2020; Ruiz-Palacios, Guillermo/GYQ-5462-2022; Taylor, Michael/K-1379-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030444] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039932] Funding Source: NIH RePORTER; NCI NIH HHS [CA39932] Funding Source: Medline; NICHD NIH HHS [HD30444, HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; Ashkenazi S, 1991, Adv Exp Med Biol, V310, P173; Buchheim W., 1988, Nestle Nutrition Workshop Series, V15, P27; CALVA JJ, 1988, LANCET, V1, P503; CERIANI RL, 1992, ANAL BIOCHEM, V201, P178, DOI 10.1016/0003-2697(92)90192-A; CERIANI RL, 1992, MONOCLONAL ANTIBODIE, P398; DUWE AK, 1989, BIOCHEM BIOPH RES CO, V165, P1305, DOI 10.1016/0006-291X(89)92745-9; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Newburg DS, 1996, J MAMMARY GLAND BIOL, V1, P271, DOI 10.1007/BF02018080; NEWBURG DS, 1992, J INFECT DIS, V166, P832, DOI 10.1093/infdis/166.4.832; NEWBURG DS, 1992, PEDIATR RES, V31, P22, DOI 10.1203/00006450-199201000-00004; NEWBURG DS, 1990, J INFECT DIS, V162, P1075, DOI 10.1093/infdis/162.5.1075; NEWBURG DS, 1996, PEDIATR RES, V39, P229; NEWBURG DS, 1996, PEDIATR RES, V39, pA229; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; OTNAESS AB, 1980, ACTA PATH MICRO IM C, V88, P247; Peterson J. A., 1996, Pediatric Research, V39, p126A; PICKERING LK, 1988, J PEDIATR-US, V112, P361, DOI 10.1016/S0022-3476(88)80313-5; RUIZPALACIOS GM, 1992, CAMPLYLOBACTER JEJUNI, P176; SCHROTEN H, 1992, INFECT IMMUN, V60, P2893, DOI 10.1128/IAI.60.7.2893-2899.1992; SHIMIZU M, 1986, BIOCHEM J, V233, P725, DOI 10.1042/bj2330725; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VELAZQUEZ FR, 1993, PEDIATR INFECT DIS J, V12, P54, DOI 10.1097/00006454-199301000-00013; VIVERGE D, 1985, ANN NUTR METAB, V29, P1, DOI 10.1159/000176947; WARREN C, 1997, GLYCOBIOLOGY, V6, P730; WEINBERG RJ, 1984, PEDIATRICS, V74, P250; YOLKEN RH, 1992, J CLIN INVEST, V90, P1984, DOI 10.1172/JCI116078; [No title captured]	30	226	253	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1160	1164		10.1016/S0140-6736(97)10322-1	http://dx.doi.org/10.1016/S0140-6736(97)10322-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643686				2022-12-24	WOS:000073220200008
J	Werther, G				Werther, G			Measuring height: to stretch or not to stretch?	LANCET			English	Editorial Material							GROWTH		Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Werther, G (corresponding author), Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia.		Werther, George/B-3784-2012					AHMED ML, 1990, ARCH DIS CHILD, V65, P1345, DOI 10.1136/adc.65.12.1345; BUCKLER JMH, 1978, ARCH DIS CHILD, V53, P762, DOI 10.1136/adc.53.9.762; STRICKLAND AL, 1972, J PEDIATR-US, V80, P1023, DOI 10.1016/S0022-3476(72)80018-0; Voss LD, 1997, ARCH DIS CHILD, V77, P319, DOI 10.1136/adc.77.4.319; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; WASSE J, 1726, PHILOS T ROY SOC LON, V33, P87; Werther GA, 1996, J PEDIATR-US, V128, pS47, DOI 10.1016/S0022-3476(96)70011-2; WHITEHOUSE RH, 1974, ANN HUM BIOL, V1, P103, DOI 10.1080/03014467400000101	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					309	310		10.1016/S0140-6736(05)78342-2	http://dx.doi.org/10.1016/S0140-6736(05)78342-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652608				2022-12-24	WOS:000071864000006
J	Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM				Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM			Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis	LANCET			English	Article							BALLOON ANGIOPLASTY; ARTERY DISEASE; PLACEMENT	Background Coronary stents are an effective treatment for selected coronary stenoses. However, thrombosis of the stented segment is a major adverse complication. Platelet aggregation has a key role in stent thrombosis. We investigated whether a polymorphism of platelet glycoprotein IIIa gene (PIA2) Is associated with an increased risk of coronary stent thrombosis. Methods 318 consecutive patients were followed up for 30 days after coronary stent insertion. The primary endpoints were death, myocardial infarction, stent-vessel occlusion, and coronary artery bypass surgery. Gel electrophoresis of PCR products was used to identify the PIA1 and PIA2 alleles. The relative risk of stent occlusion was calculated from the odds ratio on logistic regression analysis. Findings 63 (19.8%) of patients had the P1(A2) allele and 255 (80.2%) were homozygous for PIA1. Baseline clinical, angiographic, and procedural features did not differ between the groups with and without the PIA2 allele. Occlusion of the stent vessel occurred in five (1.9%) patients homozygous for PIA1 and six (9.5%) patients with PIA2 allele (odds ratio 5.26 [95% CI 1.55-17.85]). On multivariate regression analysis PIA1/A2 genotype was the only significant independent predictor of stent thrombosis. Interpretation Patients with the PIA2 allele have an increased risk of coronary stent thrombosis, which may warrant antiplatelet therapy with glycoprotein-IIb/IIIa inhibitors, although bleeding complications may also increase.	UNIV FRANKFURT, DEPT INTERNAL MED 4, DIV CARDIOL, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt				Dimmeler, Stefanie/0000-0002-1045-2436				Albiero R, 1997, CIRCULATION, V95, P1145; Baim DS, 1997, CIRCULATION, V95, P1098; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Carter AM, 1996, LANCET, V348, P485, DOI 10.1016/S0140-6736(05)64592-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Neumann FJ, 1996, J AM COLL CARDIOL, V27, P15, DOI 10.1016/0735-1097(95)00433-5; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REIBER JHC, 1994, PROGR QUANTITATIVE C; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; Samani NJ, 1997, CARDIOVASC RES, V33, P693, DOI 10.1016/S0008-6363(96)00222-2; SCHACHINGER V, 1994, CIRCULATION, V90, P2258, DOI 10.1161/01.CIR.90.5.2258; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 1997, CIRCULATION, V95, P2015, DOI 10.1161/01.CIR.95.8.2015; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	23	159	164	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	1997	350	9086					1217	1219		10.1016/S0140-6736(97)05399-3	http://dx.doi.org/10.1016/S0140-6736(97)05399-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652563				2022-12-24	WOS:A1997YD23800012
J	Meno, C; Shimono, A; Saijoh, Y; Yashiro, K; Mochida, K; Ohishi, S; Noji, S; Kondoh, H; Hamada, H				Meno, C; Shimono, A; Saijoh, Y; Yashiro, K; Mochida, K; Ohishi, S; Noji, S; Kondoh, H; Hamada, H			lefty-1 is required for left-right determination as a regulator of lefty-2 and nodal	CELL			English	Article							LEFT-RIGHT ASYMMETRY; SITUS-INVERSUS; BODY ASYMMETRY; EXPRESSION; LATERALITY; NOTOCHORD; XENOPUS; MOUSE; GENE; AXIS	lefty-1, leffy-2 and nodal are expressed on the left side of developing mouse embryos and are implicated in left-right (L-R) determination. The role of lefty-1 was examined by analyzing mutant mice lacking this gene. The lefty-1-deficient mice showed a variety of L-R positional defects in visceral organs. Unexpectedly, however, the most common feature of lefty-1(-/-) mice was thoracic left isomerism (rather than right isomerism). The lack of lefty-1 resulted in bilateral expression of nodal, lefty-2, and Pitx2 (a homeobox gene normally expressed on the left side). These observations suggest that the role of lefty-1 is to restrict the expression of lefty-2 and nodal to the left side, and that lefty-2 or nodal encodes a signal for "leftness."	Osaka Univ, Inst Mol & Cellular Biol, Div Mol Biol, Suita, Osaka 565, Japan; Osaka Univ, Inst Mol & Cellular Biol, Div Dev Biol, Suita, Osaka 565, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 770, Japan	Osaka University; Osaka University; Tokushima University	Hamada, H (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, Div Mol Biol, 1-3 Yamada Oka, Suita, Osaka 565, Japan.		Hamada, Hiroshi/N-6374-2015; Noji, Sumihare/E-3047-2010	Hamada, Hiroshi/0000-0002-7196-5948; da shi, xiang zi/0000-0002-2256-905X; Saijoh, Yukio/0000-0002-7548-4789				Anderson RH, 1996, TRENDS CARDIOVAS MED, V6, P10, DOI 10.1016/1050-1738(95)00123-9; BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1990, DEVELOPMENT, V109, P1; Chen JN, 1997, DEVELOPMENT, V124, P4373; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; ICARDO JM, 1991, CIRCULATION, V84, P2547, DOI 10.1161/01.CIR.84.6.2547; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KING T, 1997, CURR BIOL, V7, P212; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; SAWAI S, 1991, NEW BIOL, V3, P861; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YOST HJ, 1991, CIBA F SYMP, V162, P165; YOST HJ, 1992, NATURE, V357, P496	42	420	430	2	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					287	297		10.1016/S0092-8674(00)81472-5	http://dx.doi.org/10.1016/S0092-8674(00)81472-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708731	Bronze			2022-12-24	WOS:000075308400005
J	Delledonne, M; Xia, YJ; Dixon, RA; Lamb, C				Delledonne, M; Xia, YJ; Dixon, RA; Lamb, C			Nitric oxide functions as a signal in plant disease resistance	NATURE			English	Article							OXIDATIVE BURST; ARABIDOPSIS-THALIANA; ACCUMULATION; SYNTHASES; ELICITOR; PROTEIN	Recognition of an avirulent pathogen triggers the rapid production of the reactive oxygen intermediates superoxide (O-2(-)) and hydrogen peroxide (H2O2)(1). This oxidative burst drives crosslinking of the cell wall(2), induces several plant genes involved in cellular protection and defence(3,4), and is necessary for the initiation of host cell death in the hypersensitive disease-resistance response(1,3). However, this burst is not enough to support a strong disease-resistance response(4,5). Here we show that nitric oxide, which acts as a signal in the immune, nervous and vascular systems(6), potentiates the induction of hypersensitive cell death in soybean cells by reactive oxygen intermediates and functions independently of such intermediates to induce genes for the synthesis of protective natural products. Moreover, inhibitors of nitric oxide synthesis compromise the hypersensitive disease-resistance response of Arabidopsis leaves to Pseudomonas syringae, promoting disease and bacterial growth. We conclude that nitric oxide plays a key role in disease resistance in plants.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Univ Cattolica Sacro Cuore, Ist Genet, I-29100 Piacenza, Italy	Salk Institute; Noble Research Institute; Catholic University of the Sacred Heart	Lamb, C (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.		Xia, Yiji/GRR-5126-2022; Delledonne, Massimo/O-8685-2017	Delledonne, Massimo/0000-0002-7100-4581; Xia, Yiji/0000-0002-9543-8341				BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; CAMERON RK, 1994, PLANT J, V5, P715, DOI 10.1111/j.1365-313X.1994.00715.x; Chandra S, 1996, P NATL ACAD SCI USA, V93, P13393, DOI 10.1073/pnas.93.23.13393; Cueto M, 1996, FEBS LETT, V398, P159, DOI 10.1016/S0014-5793(96)01232-X; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DURNER J, IN PRESS P NATL ACAD; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; GUO ZJ, 1994, J PLANT PHYSIOL, V144, P700, DOI 10.1016/S0176-1617(11)80664-4; HEVEL JM, 1994, METHOD ENZYMOL, V23, P251; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Murphy ME, 1994, METHOD ENZYMOL, V233, P241; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259	29	1356	1664	4	224	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					585	588		10.1038/29087	http://dx.doi.org/10.1038/29087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707120				2022-12-24	WOS:000075238700050
J	Cox, CL; Zhou, Q; Sherman, SM				Cox, CL; Zhou, Q; Sherman, SM			Glutamate locally activates dendritic outputs of thalamic interneurons	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; PATCH-CLAMP RECORDINGS; CAT; NEURONS; CELLS; GABA	The relay of information through thalamus to cortex is dynamically gated, as illustrated by the retinogeniculocortical pathway(1). Important to this is the inhibitory interneuron in the lateral geniculate nucleus (LGN). For the typical neuron, synaptic information arrives through postsynaptic dendrites and is transmitted by axon terminals. However, the typical thalamic interneuron, in addition to conventional axonal outputs, has distal dendrites that serve both pre- and postsynaptic roles(2-6). These dendritic terminals participate in curious and enigmatic triadic arrangements, in which each contacts a relay cell dendrite and is contacted by a glutamatergic retinal terminal that innervates the same relay cell dendrite. Here we show that agonists of the metabotropic glutamate receptor (mGluR) activate dendritic terminals of interneurons in the absence of action potentials, thereby inhibiting the postsynaptic relay neuron. Somatic recordings from LGN interneurons reveal that there is no response to mGluR agonists, suggesting that their dendritic terminals are electrically isolated from their somata and axons, consistent with anatomical modelling of these cells', Our results offer insight into the functioning of triadic circuitry and indicate that thalamic interneurons can perform independent computations expressed through axonal as opposed to dendritic outputs.	SUNY Stony Brook, Dept Neurobiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sherman, SM (corresponding author), SUNY Stony Brook, Dept Neurobiol, Stony Brook, NY 11794 USA.	ssherman@neurobio.sunysb.edu		Cox, Charles/0000-0002-1179-7014				Arcelli P, 1997, BRAIN RES BULL, V42, P27, DOI 10.1016/S0361-9230(96)00107-4; BLOOMFIELD SA, 1989, P NATL ACAD SCI USA, V86, P3911, DOI 10.1073/pnas.86.10.3911; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FAMIGLIETTI EV, 1972, J COMP NEUROL, V144, P285, DOI 10.1002/cne.901440304; FRIEDLANDER MJ, 1981, J NEUROPHYSIOL, V46, P80, DOI 10.1152/jn.1981.46.1.80; Godwin DW, 1996, J NEUROSCI, V16, P8181; GUILLERY RW, 1966, J COMP NEUROL, V128, P21, DOI 10.1002/cne.901280104; GUILLERY RW, 1969, Z ZELLFORSCH MIK ANA, V96, P1, DOI 10.1007/BF00321474; HAMOS JE, 1985, NATURE, V317, P618, DOI 10.1038/317618a0; Lee KH, 1997, NEUROSCIENCE, V77, P335, DOI 10.1016/S0306-4522(96)00481-2; LEVAY S, 1977, J COMP NEUROL, V172, P563, DOI 10.1002/cne.901720402; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; MONTERO VM, 1986, J COMP NEUROL, V254, P228, DOI 10.1002/cne.902540207; OTTERSEN OP, 1984, ANAT EMBRYOL, V170, P197, DOI 10.1007/BF00319005; PAPE HC, 1995, NEUROSCIENCE, V68, P1105, DOI 10.1016/0306-4522(95)00205-W; RALSTON HJ, 1971, NATURE, V230, P585, DOI 10.1038/230585a0; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SHERMAN SM, 1997, SOC NEUR ABSTR, V23; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	21	70	71	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					478	482		10.1038/28855	http://dx.doi.org/10.1038/28855			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697770				2022-12-24	WOS:000075080400052
J	Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M				Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M			Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling	CELL			English	Article							TISSUE POLARITY; DROSOPHILA EYE; BETA-CATENIN; IN-VIVO; PROTEIN; GENE; WNT; XENOPUS; EMBRYOGENESIS; CONSERVATION	Frizzled family proteins have been described as receptors of Wnt signaling molecules. In Drosophila, the two known Frizzled proteins are associated with distinct developmental processes. Genesis of epithelial planar polarity requires Frizzled, whereas Dfz2 affects morphogenesis by wingless-mediated signaling. Dishevelled is required in both signaling pathways. Here, we use genetic and overexpression assays to show that Dishevelled activates JNK cascades. Rescue analysis reveals different protein domain requirements in Dishevelled far the two pathways; the C-terminal DEP domain is essential to rescue planar polarity defects and induce JNK signaling. Furthermore, the planar polarity-specific dsh(1) allele is mutated in the DEP domain. Our results indicate that different Wnt/Fz signals activate distinct intracellular pathways, and Dishevelled discriminates among them by distinct domain interactions.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mlodzik, M (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Strutt, David/E-6196-2010; Paricio, Nuria/K-2184-2014; Boutros, Michael/C-3566-2008	Strutt, David/0000-0001-8185-4515; Paricio, Nuria/0000-0001-7193-2532; Boutros, Michael/0000-0002-9458-817X				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1994, GENETICS, V137, P1; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; AXELROD JD, 1998, IN PRESS GENES DEV; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Fahmy O. G., 1959, DIS, V33, P83; Fehon RG, 1997, GENETICS, V146, P245; GUBB D, 1993, DEVELOPMENT, P269; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MOON RT, 1993, DEVELOPMENT, V119, P97; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; XU T, 1993, DEVELOPMENT, V117, P1223; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHENG L, 1995, DEVELOPMENT, V121, P3045; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	61	653	660	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					109	118		10.1016/S0092-8674(00)81226-X	http://dx.doi.org/10.1016/S0092-8674(00)81226-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674432	Bronze			2022-12-24	WOS:000074790800014
J	Kortemme, T; Ramirez-Alvarado, M; Serrano, L				Kortemme, T; Ramirez-Alvarado, M; Serrano, L			Design of a 20-amino acid, three-stranded beta-sheet protein	SCIENCE			English	Article							SIDE-CHAIN INTERACTIONS; NMR-SPECTROSCOPY; HELICAL PROTEIN; AMINO-ACIDS; QUANTUM NMR; CONFORMATION; POLYPEPTIDE; SEQUENCE; PEPTIDE; VALUES	20-residue protein (named Betanova) forming a monomeric, three-stranded, antiparallel beta sheet was designed using a structural backbone template and an iterative hierarchical approach. Structural and physicochemical characterization show that the beta-sheet conformation is stabilized by specific tertiary interactions and that the protein exhibits a cooperative two-state folding-unfolding transition, which is a hallmark of natural proteins. The Betanova molecule constitutes a tractable model system to aid in the understanding of beta-sheet formation, including beta-sheet aggregation and amyloid fibril formation.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kortemme, T (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Kortemme@EMBL-Heidelberg.DE; Ramirez@EMBL-Heidelberg.DE	Serrano, Luis/B-3355-2013	Serrano, Luis/0000-0002-5276-1392; Ramirez-Alvarado, Marina/0000-0003-2325-6773; Kortemme, Tanja/0000-0002-8494-680X				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; Ilyina E, 1997, BIOCHEMISTRY-US, V36, P5245, DOI 10.1021/bi963064o; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones DT, 1996, PROTEINS, V24, P502, DOI 10.1002/(SICI)1097-0134(199604)24:4<502::AID-PROT9>3.0.CO;2-F; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; KORTEMMA T, UNPUB; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MACIAS MJ, COMMUNICATION; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prieto J, 1997, J MOL BIOL, V268, P760, DOI 10.1006/jmbi.1997.0984; RamirezAlvarado M, 1997, J MOL BIOL, V273, P898, DOI 10.1006/jmbi.1997.1347; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; RAMIREZALVARADO M, UNPUB; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Schenck HL, 1998, J AM CHEM SOC, V120, P4869, DOI 10.1021/ja973984+; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STONEHOUSE J, 1995, J MAGN RESON SER A, V112, P43, DOI 10.1006/jmra.1995.1008; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; Wuthrich K., 1986, NMR PROTEINS NUCL AC	46	296	306	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					253	256		10.1126/science.281.5374.253	http://dx.doi.org/10.1126/science.281.5374.253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657719				2022-12-24	WOS:000074714200048
J	Sun, ZX; Hsiao, J; Fay, DS; Stern, DF				Sun, ZX; Hsiao, J; Fay, DS; Stern, DF			Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint	SCIENCE			English	Article							CELL-CYCLE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; REPLICATION; MITOSIS; GENE; TRANSCRIPTION; THREONINE	The Rad53 protein kinase of Saccharomyces cerevisiae is required for checkpoints that prevent cell division in cells with damaged or incompletely replicated DNA, The Rad9 protein was phosphorylated in response to DNA damage, and phosphorylated Rad9 interacted with the COOH-terminal forkhead homology-associated (FHA) domain of Rad53, Inactivation of this domain abolished DNA damage-dependent Rad53 phosphorylation, G(2)/M cell cycle phase arrest, and increase of RNR3 transcription but did not affect replication inhibition-dependent Rad53 phosphorylation, Thus, Rad53 integrates DNA damage signals by coupling with phosphorylated Rad9, The hitherto uncharacterized FHA domain appears to be a modular protein-binding domain.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Dept Biol, New Haven, CT 06511 USA	Yale University; Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342, New Haven, CT 06520 USA.	Stern@biomed.med.yale.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; EMILI A, IN PRESS MOL CELL; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; GARDNER R, UNPUB; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; REYNOLDS A, 1991, CURRENT PROTOCOLS MO, V2; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sun Z., UNPUB; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	30	323	331	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					272	274		10.1126/science.281.5374.272	http://dx.doi.org/10.1126/science.281.5374.272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657725				2022-12-24	WOS:000074714200054
J	Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E				Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E			Regulation of armadillo by a Drosophila APC inhibits neuronal apoptosis during retinal development	CELL			English	Article							SEGMENT POLARITY GENE; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; CELL-DEATH; PIGMENT EPITHELIUM; CONGENITAL HYPERTROPHY; MOLECULAR ANALYSIS; GARDNERS-SYNDROME; 4TH CHROMOSOME	We find that inactivation of a Drosophila homolog of the tumor suppressor APC (D-APC) causes retinal neuronal degeneration and pigment cell hypertrophy, a phenotype remarkably similar to that found in humans with germline APC mutations. Retinal degeneration in the D-APC mutant results from apoptotic cell death, which accompanies a defect in neuronal differentiation. Reduction in the Drosophila beta-catenin, Armadillo (Arm), rescues the differentiation defect and prevents apoptosis in the D-APC mutant, while Arm overexpression mimics D-APC inactivation. A mutation in dTCF, the DNA-binding protein required in Arm-mediated signal transduction, can eliminate the cell death without rescuing the differentiation defect in D-APC mutants. Uncoupling of these two Arm-induced processes suggests a novel role for the Arm/dTCF complex in the activation of apoptosis.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA	Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, E (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUETTNER H, 1975, AM J OPHTHALMOL, V79, P177, DOI 10.1016/0002-9394(75)90069-0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLIFFORD RJ, 1989, GENETICS, V123, P771; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reddy GV, 1997, DEVELOPMENT, V124, P703; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; STEITZ MC, 1998, IN PRESS DEV BIOL, V197; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; SUGIYAMA H, 1994, J FOOD HYG SOC JPN, V35, P13, DOI 10.3358/shokueishi.35.13; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1990, AM J OPHTHALMOL, V110, P550, DOI 10.1016/S0002-9394(14)77880-8; TZEPACZ C, 1997, J BIOL CHEM, V272, P21681; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WOLFF T, 1991, DEVELOPMENT, V113, P825; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	193	196	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1171	1182		10.1016/S0092-8674(00)81461-0	http://dx.doi.org/10.1016/S0092-8674(00)81461-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657150	Bronze			2022-12-24	WOS:000074491100012
J	Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K				Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K			An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast	CELL			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DNA-REPLICATION; FISSION YEAST; POLYACRYLAMIDE GELS; NUCLEAR DIVISION; S-PHASE; MITOSIS; CYCLIN	Cohesion between sister chromatids during G2 and M phases depends on the "cohesin" protein Scc1p (Mcd1p). Loss of cohesion at the metaphase to anaphase transition is accompanied by Scc1p's dissociation from chromatids, which depends on proteolysis of Pds1p mediated by a ubiquitin protein ligase called the anaphase promoting complex (APC). We show that destruction of Pds1p is the APC's sole role in triggering Scc1p's dissociation from chromatids and that Pds1p forms a stable complex with a 180 kDa protein called Esp1p, which is essential for the dissociation of Scc1p from sister chromatids and for their separation. We propose that the APC promotes sister separation not by destroying cohesins but instead by liberating the "sister-separating" Esp1 protein from its inhibitor Pds1p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); European Molecular Biology Laboratory (EMBL)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Mann, Matthias/A-3454-2013; Ciosk, Rafal/L-7327-2013	Mann, Matthias/0000-0003-1292-4799; Nasmyth, Kim/0000-0001-7030-4403; Ciosk, Rafal/0000-0003-2234-6216				BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LIANG H, 1993, EXP CELL RES, V204, P110, DOI 10.1006/excr.1993.1015; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MICHAELIS C, 1997, CELL, V91, P32; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM M, 1996, ANAL CHEM, V66, P1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	42	505	520	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1067	1076		10.1016/S0092-8674(00)81211-8	http://dx.doi.org/10.1016/S0092-8674(00)81211-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635435	Bronze			2022-12-24	WOS:000074205700017
J	Brown, P				Brown, P			BSE: the final resting place	LANCET			English	Editorial Material							SURVIVAL; VARIANT		NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA.							BROWN P, 1990, J INFECT DIS, V161, P467, DOI 10.1093/infdis/161.3.467; BROWN P, 1991, LANCET, V337, P269, DOI 10.1016/0140-6736(91)90873-N; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; Scrimgeour EM, 1996, VET REC, V139, P219; Taylor David M., 1996, P105; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	10	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1146	1147		10.1016/S0140-6736(05)79115-7	http://dx.doi.org/10.1016/S0140-6736(05)79115-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643681				2022-12-24	WOS:000073220200003
J	Xiang, ZX; Huguenard, JR; Prince, DA				Xiang, ZX; Huguenard, JR; Prince, DA			Cholinergic switching within neocortical inhibitory networks	SCIENCE			English	Article							RAT CEREBRAL-CORTEX; GABAERGIC NEURONS; MORPHOLOGICAL-CHARACTERISTICS; MONOCLONAL-ANTIBODY; ALZHEIMERS-DISEASE; PYRAMIDAL CELLS; VISUAL-CORTEX; GABA NEURONS; GUINEA-PIG; ACETYLTRANSFERASE	Differential actions of acetylcholine on the excitability of two subtypes of interneurons in layer V of the rat visual cortex were examined. Acetylcholine excited low-threshold spike (LTS) cells through nicotinic receptors, whereas it elicited hyperpolarization in fast spiking (FS) cells through muscarinic receptors. Axons of LTS cells were mainly distributed vertically to upper Layers, and those of FS cells were primarily confined to layer V. Thus, cortical cholinergic activation may reduce some forms of intralaminar inhibition, promote intracolumnar inhibition, and change the direction of information flow within cortical circuits.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University	Prince, DA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	daprince@leland.Stanford.edu	Huguenard, John/I-5016-2012; Huguenard, John/K-6429-2019	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191; Xiang, Zixiu/0000-0002-1678-209X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS012151, P01NS012151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 12151, NS 06477, NS 07280] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER TG, 1986, BEHAV NEURAL BIOL, V45, P81, DOI 10.1016/S0163-1047(86)80008-5; Alkondon M, 1997, J PHARMACOL EXP THER, V283, P1396; BARKER JL, 1988, J PHYSIOL-LONDON, V403, P41, DOI 10.1113/jphysiol.1988.sp017237; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEAULIEU C, 1991, J COMP NEUROL, V304, P666, DOI 10.1002/cne.903040412; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAVIES P, 1976, LANCET, V2, P1403; ECKENSTEIN F, 1983, NEUROSCI LETT, V36, P211, DOI 10.1016/0304-3940(83)90002-2; FOEHRING RC, 1991, J NEUROPHYSIOL, V66, P1825, DOI 10.1152/jn.1991.66.6.1825; Frazier CJ, 1998, J NEUROSCI, V18, P1187; HASSELMO ME, 1995, BEHAV BRAIN RES, V67, P1, DOI 10.1016/0166-4328(94)00113-T; HENDRY SHC, 1989, EXP BRAIN RES, V76, P467; HOUSER CR, 1983, J NEUROCYTOL, V12, P617, DOI 10.1007/BF01181527; HOUSER CR, 1983, BRAIN RES, V266, P97, DOI 10.1016/0006-8993(83)91312-4; HOUSER CR, 1985, J COMP NEUROL, V234, P17, DOI 10.1002/cne.902340103; JONES BE, 1984, CEREB CORTEX, P309; KAWAGUCHI Y, 1995, TRENDS NEUROSCI, V18, P527, DOI 10.1016/0166-2236(95)98374-8; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; KAWAGUCHI Y, 1993, J NEUROPHYSIOL, V69, P416, DOI 10.1152/jn.1993.69.2.416; KRNJEVIC K, 1974, PHYSIOL REV, V54, P418, DOI 10.1152/physrev.1974.54.2.418; LARKMAN AU, 1992, J COMP NEUROL, V323, P137, DOI 10.1002/cne.903230202; LEE KH, 1995, J NEUROPHYSIOL, V73, P2123, DOI 10.1152/jn.1995.73.5.2123; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MCCORMICK DA, 1986, NATURE, V319, P402, DOI 10.1038/319402a0; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCCORMICK DA, 1986, J PHYSIOL-LONDON, V375, P169, DOI 10.1113/jphysiol.1986.sp016112; MCCORMICK DA, 1987, J NEUROSCI, V7, P742; McQuiston A. R., 1996, Society for Neuroscience Abstracts, V22, P786; McQuiston A. R., 1997, Society for Neuroscience Abstracts, V23, P2009; Mesulam Marek-Marsel, 1995, P135; PHILLIS J W, 1968, Brain Research, V10, P297, DOI 10.1016/0006-8993(68)90201-1; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007; REECE LJ, 1991, BRAIN RES, V540, P287, DOI 10.1016/0006-8993(91)90520-6; REECE LJ, 1991, BRAIN RES, V566, P115, DOI 10.1016/0006-8993(91)91688-W; RUBERG M, 1982, BRAIN RES, V232, P129, DOI 10.1016/0006-8993(82)90615-1; Sannita WG, 1995, EEG CL N SU, P156; SAPER CB, 1984, J COMP NEUROL, V222, P313, DOI 10.1002/cne.902220302; SHUTE CCD, 1967, BRAIN, V90, P497, DOI 10.1093/brain/90.3.497; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; STEWART DJ, 1985, BRAIN RES, V358, P404, DOI 10.1016/0006-8993(85)90994-1; SZERB JC, 1967, J PHYSIOL-LONDON, V192, P329, DOI 10.1113/jphysiol.1967.sp008303; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; WAINER BH, 1984, BRAIN RES, V308, P69, DOI 10.1016/0006-8993(84)90918-1; Xiang Z., 1997, Society for Neuroscience Abstracts, V23, P359; Xiang ZX, 1998, J PHYSIOL-LONDON, V506, P715, DOI 10.1111/j.1469-7793.1998.715bv.x	47	352	357	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					985	988		10.1126/science.281.5379.985	http://dx.doi.org/10.1126/science.281.5379.985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703513				2022-12-24	WOS:000075412700046
J	Kahn, ML; Zheng, YW; Huang, W; Bigornia, V; Zeng, DW; Moff, S; Farese, RV; Tam, C; Coughlin, SR				Kahn, ML; Zheng, YW; Huang, W; Bigornia, V; Zeng, DW; Moff, S; Farese, RV; Tam, C; Coughlin, SR			A dual thrombin receptor system for platelet activation	NATURE			English	Article							MOLECULAR-CLONING; PEPTIDES; MECHANISM	Plalelet-dependent arterial thrombosis triggers most heart attacks and strokes. Because the coagulation protease thrombin is the most potent activator of platelets', identification of the platelet receptors for thrombin is critical for understanding thrombosis and haemostasis. Protease-activated receptor-1 (PAR1) is important for activation of human platelets by thrombin(2-6), but plays no apparent role in mouse platelet activation(7-9) PAR3 is a thrombin receptor that is expressed in mouse megakaryocytes(10). Here we report that thrombin responses in platelets from PAR3-deficient mice were markedly delayed and diminished but not absent. We have also identified PAR4, a new thrombin-activated receptor. PAR4 messenger RNA was detected in mouse megakaryocytes and a PAR4-activating peptide caused secretion and aggregation of PARS-deficient mouse platelets. Thus PAR3 is necessary for normal thrombin responses in mouse platelets, but a second PAR4-mediated mechanism for thrombin signalling exists. Studies with PAR-activating peptides suggest that PAR4 also functions in human platelets, which implies that an analogous dual-receptor system also operates isl humans. The identification of a two-receptor system for platelet activation by thrombin has important implications for the development of antithrombotic therapies.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.	shaun.coughlin@quickmail.ucsf.edu		Tam-Amersdorfer, Carmen/0000-0003-3123-6342				BRASS LF, 1992, J BIOL CHEM, V267, P13795; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN J, 1994, J BIOL CHEM, V269, P16041; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; Henriksen RA, 1997, ARTERIOSCL THROM VAS, V17, P3519, DOI 10.1161/01.ATV.17.12.3519; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MORTENSEN R, 1993, CURRENT PROTOCOLS MO; NOVAK EK, 1988, BRIT J HAEMATOL, V69, P371, DOI 10.1111/j.1365-2141.1988.tb02376.x; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	28	817	847	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					690	694		10.1038/29325	http://dx.doi.org/10.1038/29325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716134				2022-12-24	WOS:000075384200047
J	Burstein, GR; Gaydos, CA; Diener-West, M; Howell, MR; Zenilman, JM; Quinn, TC				Burstein, GR; Gaydos, CA; Diener-West, M; Howell, MR; Zenilman, JM; Quinn, TC			Incident Chlamydia trachomatis infections among inner-city adolescent females	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Adolescent-Medicine	MAR 04-08, 1998	ATLANTA, GEORGIA	Soc Adolescent Med			TUBAL INFERTILITY; WOMEN; CLINICS; DISEASE; PREVALENCE; CERVICITIS; DIAGNOSIS; RISK; CARE	Context.-Adolescents are at highest risk for infection with Chlamydia trachomatis, an important preventable cause of pelvic inflammatory disease and subsequent tubal factor infertility in US women. Current guidelines for delivery of adolescent primary care services recommend yearly chlamydia screening for those adolescent females considered to be at risk. Objectives.-To describe the epidemiology of prevalent and incident chlamydia infection among adolescent females to assess the appropriate interval for chlamydia screening and to define risk factors that would identify adolescent females to target for screening. Design.-Prospective longitudinal study. Patients.-A consecutive sample of 3202 sexually active females 12 through 19 years old making 5360 patient visits over a 33-month period, January 1994 through September 1996. Setting.-Baltimore, Md, family planning, sexually transmitted disease, and school-based clinics. Intervention.-Testing for C trachomatis by polymerase chain reaction. Main Outcome Measures.-Prevalence and incidence of C trachomatis infections; predictors of positive test result for C trachomatis, Results.-Chlamydia infection was found in 771 first visits (24.1%) and 299 repeat visits (13.9%); 933 adolescent females (29.1%) had at least 1 positive test result. Females who were 14 years old had the highest age-specific chlamydia prevalence rate (63 [27.5%] of 229 cases; P=.01). The chlamydia incidence rate was 28.0 cases per 1000 person-months (95% confidence interval, 24.9-31.5 cases). The median time was 7.2 months to a first positive chlamydia test result and 6.3 months to a repeat positive test result among those with repeat visits. Independent predictors of chlamydia infection-reason for clinic visit, clinic type, prior sexually transmitted diseases, multiple or new partners, or inconsistent condom use-failed to identify a subset of adolescent females with the majority of infections. Conclusions.-A high prevalence and incidence of C trachomatis infection were found among adolescent females. We, therefore, recommend screening all sexually active adolescent females for chlamydia infection every 6 months, regardless of symptoms, prior infections, condom use, or multiple partner risks.	Johns Hopkins Univ, Div Infect Dis, Baltimore, MD 21205 USA	Johns Hopkins University	Burstein, GR (corresponding author), Johns Hopkins Univ, Div Infect Dis, 720 Rutland Ave,Room 1159, Baltimore, MD 21205 USA.	gburstei@welchlink.welch.jhu.edu	Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010		NIAID NIH HHS [NIAID-P01-AI94016] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEACK RK, 1992, COMPREHENSIVE ADOLES, P956; BLYTHE MJ, 1988, J PEDIATR-US, V112, P1000, DOI 10.1016/S0022-3476(88)80236-1; Borenstein PE, 1996, J ADOLESCENT HEALTH, V18, P203, DOI 10.1016/1054-139X(95)00013-I; BRUNHAM RC, 1985, J INFECT DIS, V152, P1275, DOI 10.1093/infdis/152.6.1275; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P819; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P6; Centers for Disease Control and Prevention Chlamydia trachomatis genital infections-United States, 1995, JAMA-J AM MED ASSOC, V277, P952; CHUTIVONGSE S, 1995, SEX TRANSM DIS, V22, P71; Cohen DA, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.1.e1; COURTNEY J, 1997, 12 M INT SOC SEX TRA; *DCDP, 1997, MMWR-MORBID MORTAL W, V46, P193; *DIV SEX TRANSM DI, 1997, SEX TRANSM DIS SURV; ELSTER AB, 1994, AMA GUIDELINES ADOLE; Eng TR, 1997, HIDDEN EPIDEMIC CONF, P28; FISHER M, 1987, J PEDIATR-US, V111, P617, DOI 10.1016/S0022-3476(87)80134-8; GANS GE, 1991, AMA PROFILES ADOLESC; Gaydos CA, 1998, J INFECT DIS, V177, P417, DOI 10.1086/514207; Genc M, 1996, ANN INTERN MED, V124, P1, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00001; Gunn RA, 1997, SEX TRANSM DIS, V24, P90, DOI 10.1097/00007435-199702000-00006; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; Hillis SD, 1998, SEX TRANSM DIS, V25, P5, DOI 10.1097/00007435-199801000-00002; HILLIS SD, 1994, AM J OBSTET GYNECOL, V170, P801, DOI 10.1016/S0002-9378(94)70286-1; Hook EW, 1997, J CLIN MICROBIOL, V35, P2133, DOI 10.1128/JCM.35.8.2133-2135.1997; HOOK EW, 1990, SEXUALLY TRANSMITTED, P149; Howell MR, 1998, SEX TRANSM DIS, V25, P108, DOI 10.1097/00007435-199802000-00008; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; KELVER ME, 1989, INT J FERTIL, V34, P42; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIEU TA, 1993, AM J PUBLIC HEALTH, V83, P960, DOI 10.2105/AJPH.83.7.960; MAGDER LS, 1988, AM J EPIDEMIOL, V128, P298, DOI 10.1093/oxfordjournals.aje.a114970; MARLOTTE CK, 1990, AM J PUBLIC HEALTH, V80, P469; Marrazzo JM, 1997, ANN INTERN MED, V127, P796, DOI 10.7326/0003-4819-127-9-199711010-00004; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; Mosure DJ, 1996, AM J EPIDEMIOL, V144, P997, DOI 10.1093/oxfordjournals.aje.a008870; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; Muller, 1990, SEXUALLY TRANSMITTED, P481; NATHANSON PG, 1997, 12 M INT SOC SEX TRA; NIENSTEIN LS, 1996, ADOLESCENT HLTH CARE, P46; Oh MK, 1996, J ADOLESCENT HEALTH, V18, P270, DOI 10.1016/1054-139X(95)00232-H; Oh MK, 1997, J ADOLESCENT HEALTH, V21, P80, DOI 10.1016/S1054-139X(96)00311-4; Orr DP, 1997, J ADOLESCENT HEALTH, V20, P3, DOI 10.1016/S1054-139X(96)00220-0; PAISARNTANTIWON.R, 1995, SEX TRANSM DIS, V23, P344; Quinn TC, 1996, J CLIN MICROBIOL, V34, P1401, DOI 10.1128/JCM.34.6.1401-1406.1996; RAPPO PD, 1995, PEDIATRICS, V96, P373; Schachter J, 1996, NEW ENGL J MED, V335, P1847, DOI 10.1056/NEJM199612123352417; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SELLORS JW, 1988, FERTIL STERIL, V49, P451; SELVIN S, 1991, MONOGRAPHS EPIDEMIOL, V17, P285; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; Thorpe EM, 1996, GENITOURIN MED, V72, P93; Thrall JS, 1998, J ADOLESCENT HEALTH, V22, P184, DOI 10.1016/S1054-139X(97)00205-X; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WESTROM L, 1990, SEXUALLY TRANSMITTED, P593; WINTER L, 1990, SEX TRANSM DIS, V17, P30, DOI 10.1097/00007435-199017010-00007; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003	56	185	193	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					521	526		10.1001/jama.280.6.521	http://dx.doi.org/10.1001/jama.280.6.521			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707141	Bronze			2022-12-24	WOS:000075244900027
J	Kjos, SL; Peters, RK; Xiang, A; Thomas, D; Schaefer, U; Buchanan, TA				Kjos, SL; Peters, RK; Xiang, A; Thomas, D; Schaefer, U; Buchanan, TA			Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; CARBOHYDRATE-METABOLISM; ORAL-CONTRACEPTIVES; LIPID-METABOLISM; SERUM PROLACTIN; LACTATION; SECRETION; DYSFUNCTION; ESTRADIOL	Context.-Effective contraception is essential in women with prior gestational diabetes mellitus (GDM) but should not increase their already substantial risk of developing type 2 diabetes. Objective.-To determine whether exposure to low-dose oral contraceptives increases the risk of developing type 2 diabetes mellitus in women with recent GDM. Design.-Retrospective cohort study of 904 Latinas with GDM who gave birth between January 1987 and March 1994, in whom postpartum diabetes was excluded at 4 to 16 weeks post partum. Interventions.-At their initial postpartum visit, 443 women selected a nonhormonal form of contraception, 383 received a low-dose, estrogen-progestin combination oral contraceptive (OC), and 78 breast-feeding women received the progestin-only OC. When breast-feeding ended, patients initially taking progestin-only OCs were switched to combination OCs, Patients were followed up periodically with oral glucose tolerance tests for up to 7 1/2 years. Main Outcome Measures.-Person time was used to compute unadjusted average annual incidence rates of developing diabetes mellitus, as defined by the National Diabetes Data Group Criteria. Survival analysis was used to compute the unadjusted cumulative incidence rates and adjusted relative risks of diabetes mellitus. Results.-The unadjusted average annual incidence rates of type 2 diabetes mellitus were 8.7%, 10.4%, and 26.5%, respectively, for patients using nonhormonal forms of contraception, combination OCs, and progestin-only OCs. Cumulative incidence rates were virtually identical for patients with uninterrupted use of combination OCs and nonhormonal forms of contraception, but patients using progestin-only OCs developed diabetes mellitus more rapidly during the first 2 years of use. After adjustment for potential confounding factors, the use of progestin-only OCs almost tripled the risk of type 2 diabetes mellitus compared with equivalent use of low-dose combination OCs (adjusted relative risk, 2.87; 95% confidence interval, 1.57-5.27). The magnitude of this risk increased with duration of uninterrupted use. Conclusion.-Progestin-only OCs were associated with an increased risk of diabetes in breast-feeding Latinas with recent GDM and probably should be prescribed with caution, if at all, in these women. Long-term use of low-dose combination OCs did not increase the risk of type 2 diabetes compared with use of nonhormonal contraception. Thus, combination OCs do not appear to increase the risk of diabetes in non-breast-feeding women with recent GDM.	Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Kjos, SL (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Womens Hosp, 1240 N Mission Rd,Room L1017, Los Angeles, CA 90033 USA.	skjos@hsc.usc.edu			NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTIN DA, 1985, OBSTET GYNECOL, V65, P785; COX DR, 1972, J R STAT SOC B, V34, P187; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DELVOYE P, 1978, AM J OBSTET GYNECOL, V130, P635, DOI 10.1016/0002-9378(78)90319-8; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; HAFFNER SM, 1995, DIABETES, V44, P1386, DOI 10.2337/diabetes.44.12.1386; HOUSSAY BA, 1954, ACTA ENDOCRINOL-COP, V17, P146; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P323, DOI 10.1111/j.1365-2265.1982.tb01597.x; KALKHOFF RK, 1982, AM J OBSTET GYNECOL, V142, P735; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P1822, DOI 10.1016/0002-9378(90)90757-X; KJOS SL, 1993, OBSTET GYNECOL, V82, P451; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KUNG AWC, 1987, CONTRACEPTION, V35, P257, DOI 10.1016/0010-7824(87)90027-8; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUYCKX AS, 1986, FERTIL STERIL, V45, P635; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; MOLSTEDPEDERSEN L, 1991, DIABETES, V40, P147, DOI 10.2337/diab.40.2.S147; *NAT DIAB DAT GROU, 1979, DIABETES, V29, P1039; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; Pettitt DJ, 1996, DIABETOLOGIA, V39, P1334, DOI 10.1007/s001250050579; RADBERG T, 1982, GYNECOL OBSTET INVES, V13, P17, DOI 10.1159/000299480; RIMM EB, 1992, DIABETOLOGIA, V35, P967, DOI 10.1007/BF00401427; RYAN EA, 1988, J CLIN ENDOCR METAB, V67, P341, DOI 10.1210/jcem-67-2-341; Schaefer UM, 1997, AM J OBSTET GYNECOL, V177, P1165, DOI 10.1016/S0002-9378(97)70035-8; SKOUBY SO, 1982, OBSTET GYNECOL, V59, P325; SKOUBY SO, 1985, AM J OBSTET GYNECOL, V153, P495, DOI 10.1016/0002-9378(85)90460-0; SKOUBY SO, 1987, J CLIN ENDOCR METAB, V64, P519, DOI 10.1210/jcem-64-3-519; SPELLACY WN, 1981, J REPROD MED, V26, P295; SPELLACY WN, 1971, AM J OBSTET GYNECOL, V114, P388; SPELLACY WN, 1981, J REPROD MED, V24, P415; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; VANDERVANGE N, 1987, AM J OBSTET GYNECOL, V156, P918, DOI 10.1016/0002-9378(87)90355-3; VERMEULEN A, 1982, CONTRACEPTION, V26, P505, DOI 10.1016/0010-7824(82)90149-4; Wilcox JG, 1997, FERTIL STERIL, V67, P57, DOI 10.1016/S0015-0282(97)81856-0	38	107	114	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					533	538		10.1001/jama.280.6.533	http://dx.doi.org/10.1001/jama.280.6.533			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707143	Bronze			2022-12-24	WOS:000075244900029
J	Mofenson, LM				Mofenson, LM			Perinatal transmission of HIV in women receiving zidovudine - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; REDUCTION; INFANT; TYPE-1		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD 20892 USA.	LM65D@nih.gov	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MOFENSON LM, 1995, PEDIATR INFECT DIS J, V14, P169, DOI 10.1097/00006454-199503000-00001; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201	10	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					569	570		10.1001/jama.280.6.569	http://dx.doi.org/10.1001/jama.280.6.569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707153				2022-12-24	WOS:000075244900039
J	Logan, M; Pagan-Westphal, SM; Smith, DM; Paganessi, L; Tabin, CJ				Logan, M; Pagan-Westphal, SM; Smith, DM; Paganessi, L; Tabin, CJ			The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals	CELL			English	Article							SONIC HEDGEHOG; NODAL EXPRESSION; GENE	The mechanism by which asymmetric signals induce left-right-specific morphogenesis has been elusive. Pitx2 encodes a transcription factor expressed throughout the left lateral plate mesoderm and subsequently on the left side of asymmetric organs such as the heart and gut during organogenesis in the chick embryo. Pitx2 is induced by the asymmetric signals encoded by Nodal and Sonic hedgehog, and its expression is blocked by prior treatment with an antibody against Sonic hedgehog. Misexpression of Pitx2 on the right side of the embryo is sufficient to produce reversed heart looping and heart isomerisms, reversed body rotation, and reversed gut situs.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							Ang SL, 1996, DEVELOPMENT, V122, P243; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FURUKAWA T, 1997, CELL, V91, P1; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; ISHIZUYAOKA A, 1983, ROUX ARCH DEV BIOL, V192, P171, DOI 10.1007/BF00848687; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LOGAN M, 1998, IN PRESS DEVELOPMENT; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; RYAN AK, 1998, IN PRESS NATURE; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706	38	369	377	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					307	317		10.1016/S0092-8674(00)81474-9	http://dx.doi.org/10.1016/S0092-8674(00)81474-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708733	Bronze			2022-12-24	WOS:000075308400007
J	Piedra, ME; Icardo, JM; Albajar, M; Rodriguez-Rey, JC; Ros, MA				Piedra, ME; Icardo, JM; Albajar, M; Rodriguez-Rey, JC; Ros, MA			Pitx2 participates in the late phase of the pathway controlling left-right asymmetry	CELL			English	Article							SITUS-INVERSUS; EXPRESSION; MICE; GENE	Pitx2, a member of the bicoid-related family of homeobox-containing genes, is asymmetrically expressed in the left lateral plate mesoderm and derived tissues during chick and mouse development. Modifications of Pitx2 pattern of expression in the iv mouse mutation correlate with the situs alterations characteristic of the mutation. Misexpression experiments demonstrate that Shh and nodal positively regulate Pitx2 expression. Our results are compatible with a Pitx2 function in the late phase of the gene cascade controlling laterality.	Univ Cantabria, Fac Med, Dept Anat & Biol Celular, Santander 39011, Spain; Univ Cantabria, Fac Med, Hosp Univ Marques de Valdecilla, Santander 39011, Spain; Univ Cantabria, Fac Med, Dept Biol Mol, Santander 39011, Spain	Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; Universidad de Cantabria	Ros, MA (corresponding author), Univ Cantabria, Fac Med, Dept Anat & Biol Celular, Santander 39011, Spain.		Ros, Maria A./K-8160-2014; Icardo, Jose Manuel/ABH-5431-2020	Ros, Maria A./0000-0002-1224-7671; Icardo, Jose Manuel/0000-0001-9543-2444; Rodriguez-Rey, Jose/0000-0002-8369-3118				BROWN NA, 1990, DEVELOPMENT, V109, P1; COLLIGNON J, 1996, NATURE, V381, P1919; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; ICARDO JM, 1991, CIRCULATION, V84, P2547, DOI 10.1161/01.CIR.84.6.2547; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; LAYTON WM, 1993, TERATOLOGY, V47, P595, DOI 10.1002/tera.1420470611; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NIETO MA, 1996, METHOD CELL BIOL, V51, P220; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YUAN SP, 1995, DEV GENET, V17, P38, DOI 10.1002/dvg.1020170106	31	271	275	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					319	324		10.1016/S0092-8674(00)81475-0	http://dx.doi.org/10.1016/S0092-8674(00)81475-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708734	Bronze			2022-12-24	WOS:000075308400008
J	Dematte, JE; O'Mara, K; Buescher, J; Whitney, CG; Forsythe, S; McNamee, T; Adiga, RB; Ndukwu, IM				Dematte, JE; O'Mara, K; Buescher, J; Whitney, CG; Forsythe, S; McNamee, T; Adiga, RB; Ndukwu, IM			Near-fatal heat stroke during the 1995 heat wave in Chicago	ANNALS OF INTERNAL MEDICINE			English	Article						heat stroke; intensive care units; outcome assessment (health care); health status; activities of daily living	RHEUMATOID-ARTHRITIS; ST-LOUIS; HEATSTROKE; COAGULATION; MORBIDITY; MORTALITY; DEATHS; LIVER	Background: In July 1995, Chicago sustained a heat wave that resulted in more than 600 excess deaths, 3300 excess emergency department visits, and a substantial number of intensive care unit admissions for near-fatal heat stroke. Objective: To describe the clinical features of patients admitted to an intensive care unit with near-fatal classic heat stroke. Patients were followed for 1 year to assess delayed functional outcome and mortality. Design: Observational study. Setting: Intensive care units in the Chicago area. Patients: 58 patients admitted to the hospital from 12 July to 20 July 1995 who met the case definition of classic heat stroke. Measurements: The data collection tool was designed to compile demographic and survival data and to permit analysis of organ system function by abstracting data on physical examination findings, electrocardiography and echocardiography results, fluid resuscitation, radiography results, and laboratory findings. Data on functional status at discharge and at 1 year were collected by using a modified Stanford Health Assessment Questionnaire. Results: Patients experienced multiorgan dysfunction with neurologic impairment (100%), moderate to severe renal insufficiency (53%), disseminated intravascular coagulation (45%), and the acute respiratory distress syndrome (10%); Fifty-seven percent of patients had evidence of infection on admission. In-hospital mortality was 21%. Most survivors recovered near-normal renal, hematologic, and respiratory status, but disability persisted, resulting in moderate to severe functional-impairment in 33% of patients at hospital discharge. At 1 year, no patient had improved functional status, and an additional 28% of patients had died. Conclusions: Near-fatal classic heat stroke is associated with multiorgan dysfunction. A high percentage of patients had infection at presentation. A high mortality rate was observed during acute hospitalization and at 1 year, in addition, substantial functional impairment at discharge persisted 1 year. The degree of functional disability correlated highly with survival at 1 year.	Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Michael Reese Hosp & Med Ctr, Chicago, IL 60521 USA; Resurrect Med Ctr, Crit Care Unit, Chicago, IL 60631 USA; Univ Chicago, Pritzker Sch Med, Dean Students Off, Chicago, IL 60637 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Illinois, Chicago, IL USA	University of Chicago; Michael Reese Hospital & Medical Center; University of Chicago; Centers for Disease Control & Prevention - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ndukwu, IM (corresponding author), Univ Chicago, Pulm & Crit Care Med Sect, 5481 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00055] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN MG, 1956, JAMA-J AM MED ASSOC, V161, P1525, DOI 10.1001/jama.1956.02970160005002; BEDRAK E, 1964, J APPL PHYSIOL, V19, P469, DOI 10.1152/jappl.1964.19.3.469; BOUCHAMA A, 1993, CHEST, V104, P1498, DOI 10.1378/chest.104.5.1498; Bouchama A, 1996, CRIT CARE MED, V24, P1173, DOI 10.1097/00003246-199607000-00018; BOUCHAMA A, 1992, J APPL PHYSIOL, V73, P405, DOI 10.1152/jappl.1992.73.2.405; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P577; CHAO TC, 1981, PATHOLOGY, V13, P145, DOI 10.3109/00313028109086837; CLOWES GHA, 1974, NEW ENGL J MED, V291, P564, DOI 10.1056/NEJM197409122911106; ELKASSIMI FA, 1986, CHEST, V90, P571, DOI 10.1378/chest.90.4.571; ELLIS FP, 1980, Q J MED, V49, P1; Ferris EB, 1938, J CLIN INVEST, V17, P249, DOI 10.1172/JCI100949; FOGOROS RN, 1980, JAMA-J AM MED ASSOC, V243, P1743, DOI 10.1001/jama.243.17.1743; GRABER CD, 1971, J AMER MED ASSOC, V216, P1195, DOI 10.1001/jama.216.7.1195; Hammami MM, 1997, CRIT CARE MED, V25, P1314, DOI 10.1097/00003246-199708000-00017; HART GR, 1982, MEDICINE, V61, P189, DOI 10.1097/00005792-198205000-00005; HASSANEIN T, 1992, AM J GASTROENTEROL, V87, P1382; HUBBARD RW, 1995, WILDERNESS MED MANAG, P167; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; Kaarisalo MM, 1997, STROKE, V28, P311, DOI 10.1161/01.STR.28.2.311; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; KEW MC, 1967, Q J MED, V36, P277; KILBOURNE EM, 1982, JAMA-J AM MED ASSOC, V247, P3332, DOI 10.1001/jama.247.24.3332; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNOCHEL JP, 1974, ARCH INTERN MED, V133, P841, DOI 10.1001/archinte.133.5.841; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KNOCHEL JP, 1989, DM-DIS MON, V35, P306; Ladell WSS, 1944, LANCET, V2, P527; Ladell WSS, 1944, LANCET, V2, P491; LEVINE JA, 1969, AM J MED, V47, P251, DOI 10.1016/0002-9343(69)90151-X; MALAMUD N, 1946, Mil Surg, V99, P397; *METR CHIC HEALTHC, 1995, MCHC UPD AR HOSP RES, V6, P3; ODONNELL TF, 1975, JAMA-J AM MED ASSOC, V234, P824, DOI 10.1001/jama.234.8.824; ODONNELL TF, 1972, NEW ENGL J MED, V287, P734, DOI 10.1056/NEJM197210122871502; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAJU SF, 1973, SOUTH MED J, V66, P330, DOI 10.1097/00007611-197303000-00012; REEBACK J, 1984, J ROY SOC MED, V77, P1002, DOI 10.1177/014107688407701203; ROWELL LB, 1970, J APPL PHYSIOL, V28, P415, DOI 10.1152/jappl.1970.28.4.415; ROWELL LB, 1971, J APPL PHYSIOL, V31, P864, DOI 10.1152/jappl.1971.31.6.864; SCHUMAN SH, 1972, ENVIRON RES, V5, P59, DOI 10.1016/0013-9351(72)90020-5; SHAPIRO Y, 1990, MED SCI SPORT EXER, V22, P6; SHAPIRO Y, 1979, ANN INTERN MED, V90, P913, DOI 10.7326/0003-4819-90-6-913; SHIBOLET S, 1967, Q J MED, V36, P525; SHIBOLET S, 1962, NEW ENGL J MED, V266, P169, DOI 10.1056/NEJM196201252660404; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; SOHAL RS, 1968, ARCH INTERN MED, V122, P43, DOI 10.1001/archinte.122.1.43; STINE RJ, 1979, JACEP-J AM COLL EMER, V8, P154, DOI 10.1016/S0361-1124(79)80343-3; TEK D, 1992, Emergency Medicine Clinics of North America, V10, P299; THAYSEN JH, 1955, J CLIN INVEST, V34, P1719, DOI 10.1172/JCI103225; WOLFE F, 1988, J RHEUMATOL, V15, P1480; ZAHGER D, 1989, CHEST, V95, P1089, DOI 10.1378/chest.95.5.1089; 1995, MMWR MORB MORTAL WKL, V44, P465; 1995, AM J RESP CRIT CARE, V151, pA323	53	277	298	4	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					173	+		10.7326/0003-4819-129-3-199808010-00001	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696724				2022-12-24	WOS:000075032700001
J	Feldman, M; Cryer, B; Lee, E; Peterson, WL				Feldman, M; Cryer, B; Lee, E; Peterson, WL			Role of seroconversion in confirming cure of Helicobacter pylori infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTRITIS; SEROLOGY; HUMANS; ACID	Context.-The role of serologic testing to confirm cure of Helicobacter pylori infection after antimicrobial therapy is not completely defined. Objective.-To determine the utility of serologic testing in confirming cure of H pylori infection more than 1 year after therapy. Design.-A prospective, before-after interventional trial. Setting.-An outpatient clinical research laboratory in an academic, urban Veterans Affairs medical center. Participants.-Twenty-three otherwise healthy men and women with active H pylori infection demonstrated by gastric biopsy and with positive H pylori serologic findings. Intervention.-A 14-day course of bismuth, tetracycline, and metronidazole. Main Outcome Measures.-Determination of IgG serum antibodies to H pylori at baseline, 1 month, 3 months, and approximately 18 months after completion of therapy compared with serial gastric mucosal biopsy specimens with stains for H pylori and for histologic examination as the criterion standard. Results.-Fifteen (65%) of 23 subjects were cured of their H pylori infection as assessed by gastric biopsy, with elimination of gastritis; median antibody levels declined from 92.5 U/mL at baseline to undetectable levels at 18 months. The other 8 subjects (35%) were not cured and had persistent gastritis at 18 months; median antibody levels declined from 130.6 U/mL at baseline to 89.7 U/mL at 18 months. Sensitivity and specificity of seroconversion (from a positive to negative test result) in detecting cure of H pylori infection were 60% and 100%, respectively. Conclusion.-Undetectable antibody levels beyond the first year of therapy accurately confirm cure of H pylori infection in initially seropositive healthy subjects, with reasonable sensitivity.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, Dallas, TX 75235 USA; Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX USA; Dept Vet Affairs Med Ctr, Lab Serv, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Feldman, M (corresponding author), Vet Adm Med Ctr, Med Serv 111, 4500 S Lancaster Rd, Dallas, TX 75216 USA.	feldman.mark@dallas.va.gov						Cryer B, 1996, GASTROINTEST ENDOSC, V44, P317, DOI 10.1016/S0016-5107(96)70171-2; CUTLER A, 1993, DIGEST DIS SCI, V38, P2262, DOI 10.1007/BF01299906; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; FELDMAN M, 1994, JAMA-J AM MED ASSOC, V272, P70; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; Graham DY, 1997, GASTROENTEROLOGY, V113, pS113, DOI 10.1016/S0016-5085(97)80023-6; Hopkins RJ, 1997, GASTROENTEROLOGY, V113, pS126, DOI 10.1016/S0016-5085(97)80026-1; Howden CW, 1997, GASTROENTEROLOGY, V113, pS107, DOI 10.1016/S0016-5085(97)80022-4; Lee J, 1997, GASTROENTEROLOGY, V113, pS99, DOI 10.1016/S0016-5085(97)80021-2; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; Unge P, 1997, GASTROENTEROLOGY, V113, pS131, DOI 10.1016/S0016-5085(97)80027-3; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					363	365		10.1001/jama.280.4.363	http://dx.doi.org/10.1001/jama.280.4.363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686554	Bronze			2022-12-24	WOS:000074804200037
J	Neumann, CJ; Cohen, SM				Neumann, CJ; Cohen, SM			Boundary formation in Drosophila wing: Notch activity attenuated by the POU protein Nubbin	SCIENCE			English	Article							DORSAL/VENTRAL COMPARTMENT BOUNDARY; DORSAL-VENTRAL BOUNDARY; SPLIT COMPLEX GENES; VESTIGIAL GENE; EXPRESSION; SUPPRESSOR; ACTIVATION; RECEPTOR; SERRATE; SIGNAL	Cell interactions mediated by Notch-family receptors have been implicated in the specification of tissue boundaries in vertebrate and insect development, Although Notch Ligands are often widely expressed, tightly Localized activation of Notch is critical for the formation of sharp boundaries. Evidence is presented here that the POU domain protein Nubbin contributes to the formation of a sharp dorsoventral boundary in the Drosophila wing. Nubbin represses Notch-dependent target genes and sets a threshold for Notch activity that defines the spatial domain of boundary-specific gene expression.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				Averof M, 1997, NATURE, V385, P627, DOI 10.1038/385627a0; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cifuentes FJ, 1997, P NATL ACAD SCI USA, V94, P11405, DOI 10.1073/pnas.94.21.11405; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NG M, 1995, DEVELOPMENT, V121, P589; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	55	56	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					409	413		10.1126/science.281.5375.409	http://dx.doi.org/10.1126/science.281.5375.409			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665883				2022-12-24	WOS:000074918800046
J	Duda, RL				Duda, RL			Protein chainmail: Catenated protein in viral capsids	CELL			English	Article							RECOMBINANT BOVINE SOMATOTROPIN; VIRUS; HEAD; BACTERIOPHAGE-T4; RESOLUTION; SEQUENCE; SYSTEM	The capsid shells of bacteriophage HK97 and several other phages contain polypeptides that are covalently linked into complexes so large that they do not enter polyacrylamide gels after denaturation. The enormous apparent size of these protein complexes in HK97 derives from a novel protein topology. HK97 subunits cross-link via isopeptide bonds into oligomers that are closed rings of five or six members. However, polypeptides from neighboring pentamer and hexamer rings intertwine before the covalent cross-links form. As a result, adjacent protein rings catenate into a network similar to chainmail armor. In vitro linking and unlinking experiments provide strong support for the chainmail model, which explains the unusual properties of these bacteriophages and may apply to other macromolecular structures.	Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duda, RL (corresponding author), Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA.			Duda, Robert/0000-0002-9517-2731	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047795, GM47795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casjens SR, 1988, BACTERIOPHAGES, P1; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; DHILLON EKS, 1980, J GEN VIROL, V50, P217, DOI 10.1099/0022-1317-50-1-217; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; FORD ME, 1998, IN PRESS J MOL BIOL; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HERUTH DP, 1994, J BACTERIOL, V176, P3559, DOI 10.1128/JB.176.12.3559-3567.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIMBERGER RJ, 1994, J BACTERIOL, V176, P3631, DOI 10.1128/JB.176.12.3631-3637.1994; LUBBERS MW, 1995, APPL ENVIRON MICROB, V61, P4348, DOI 10.1128/AEM.61.12.4348-4356.1995; Murphy F.A., 1995, 6 REP INT COMM TAX V; OLSON AJ, 1983, J MOL BIOL, V171, P61, DOI 10.1016/S0022-2836(83)80314-3; POND FR, 1989, MICROBIOL REV, V53, P25, DOI 10.1128/MMBR.53.1.25-67.1989; POPA MP, 1991, J VIROL, V65, P3227, DOI 10.1128/JVI.65.6.3227-3237.1991; SCHAFER R, 1977, EUR J BIOCHEM, V73, P239, DOI 10.1111/j.1432-1033.1977.tb11312.x; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; TOU JS, 1993, J PROTEIN CHEM, V12, P237, DOI 10.1007/BF01026046; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; vanSinderen D, 1996, MOL MICROBIOL, V19, P1343, DOI 10.1111/j.1365-2958.1996.tb02478.x; VIOLAND BN, 1989, J PROTEIN CHEM, V8, P619, DOI 10.1007/BF01025602; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537	27	124	125	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					55	60		10.1016/S0092-8674(00)81221-0	http://dx.doi.org/10.1016/S0092-8674(00)81221-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674427	Bronze			2022-12-24	WOS:000074790800009
J	McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G				McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G			Confidential inquiry into quality of care before admission to intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIOPULMONARY ARREST; AVOIDABLE FACTORS; CARDIAC-ARREST; HEAD-INJURY; DOCTORS; CONSULTANTS; DEATHS; MANAGEMENT; PHYSICIANS; RESPONSES	Objective: To examine the prevalence, nature, causes, and consequences of suboptimal care before admission to intensive care units, and to suggest possible solutions. Design: Prospective confidential inquiry on the basis of structured interviews and questionnaires. Setting: A large district general hospital and a teaching hospital. Subjects: A cohort of 100 consecutive adult emergency admissions, 50 in each centre. Main outcome measures: Opinions of two external assessors on quality of care especially recognition, investigation, monitoring, and management of abnormalities of airway, breathing, and circulation, and oxygen therapy and monitoring. Results: Assessors agreed that 20 patients were well managed (group 1) and 54 patients received suboptimal care (group 2), Assessors disagreed on quality of management of 26 patients (group 3). The casemix and severity of illness, defined by the acute physiology and chronic health evaluation (APACHE II) score, were similar between centres and the three groups. In groups 1, 2, and 3 intensive care mortalities were 5 (25%), 26 (48%), and 6 (23%) respectively (P = 0.04) (group 1 versus group 2, P = 0.07). Hospital mortalities were 7 (35%), 30 (56%), and 8 (31%) (P = 0.07) and standardised hospital mortality ratios (95% confidence intervals) were 1.23 (0.49 to 2.54), 1.4 (0.94 to 2.0), and 1.26 (0.54 to 2.48) respectively. Admission to intensive care was considered late in 37 (69%) patients in group 2. Overall, a minimum of 4.5% and a maximum of 41% of admissions were considered potentially avoidable. Suboptimal care contributed to morbidity or mortality in most instances. The main causes of suboptimal care were failure of organisation, lack of knowledge, failure to appreciate clinical urgency, lack of supervision, and failure to seek advice. Conclusions: The management of airway breathing, and circulation, and oxygen therapy and monitoring in severely ill patients before admission to intensive care units may frequently be suboptimal. Major consequences may include increased morbidity and mortality and requirement for intensive care. Possible solutions include improved teaching, establishment of medical emergency teams, and widespread debate on the structure and process of acute care.	Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England; Southampton Gen Hosp, Intens Care Unit, Southampton SO16 6YD, Hants, England; Broomfield Hosp, Chelmsford CM1 7ET, Essex, England; Royal Cornwall Hosp, Truro TR1 3L, Cornwall, England; Univ Portsmouth, Sch Math Studies, Portsmouth PO1 2EG, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Royal Cornwall Hospital; University of Portsmouth	McQuillan, P (corresponding author), Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England.							ALLAN A, 1994, CLIN INTENSIVE CARE, V5, P152; Altman D.G., 1991, PRACTICAL STATISTIC; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; Capewell S, 1996, BRIT MED J, V312, P991; Daffurn K, 1994, Intensive Crit Care Nurs, V10, P115, DOI 10.1016/0964-3397(94)90007-8; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; *DEPT HLTH UK, 1992, HLTH NAT; DILLNER L, 1995, BRIT MED J, V310, P757, DOI 10.1136/bmj.310.6982.757; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRANKLIN C, 1994, CRIT CARE MED, V22, P244, DOI 10.1097/00003246-199402000-00014; GEORGE AL, 1989, AM J MED, V87, P28; Goldhill DR, 1996, ANAESTHESIA, V51, P719, DOI 10.1111/j.1365-2044.1996.tb07882.x; GOULD TH, 1994, ANAESTHESIA, V49, P807; Hourihan F., 1995, CLIN INTENSIVE CARE, V6, P269, DOI [10.3109/tcic.6.6.269.272, DOI 10.3109/TCIC.6.6.269.272]; JEFFREYS RV, 1981, LANCET, V2, P459; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; MATHER HM, 1995, BRIT MED J, V311, P1060, DOI 10.1136/bmj.311.7012.1060; MCGLOIN H, 1997, CLIN INTENSIVE CARE, V8, P104; MONTGOMERY H, 1994, BRIT MED J, V309, P1551, DOI 10.1136/bmj.309.6968.1551; MOSS F, 1995, BRIT MED J, V310, P925, DOI 10.1136/bmj.310.6984.925; *NAT CONF ENQ PER, 1993, NAT CONF ENQ PER DEA; PALAZZO M, 1993, LANCET, V342, P307; PAPPACHAN VJ, 1997, CLIN INTENSIVE CARE, V8, P97; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; POPE A, 1960, PENGUIN DICT QUOTATI; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; *ROYAL COLL PHYS L, 1996, FUT PATT CAR GEN SPE; *ROYAL COLL SURG E, 1985, REP WORK PART MAN PA; SAX FL, 1987, CRIT CARE MED, V15, P510, DOI 10.1097/00003246-198705000-00012; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIEGAL S, 1988, STAT BEHAV SCI; SMITH J, 1995, BRIT MED J, V310, P953, DOI 10.1136/bmj.310.6985.953; STONEHAM MD, 1994, LANCET, V344, P1339, DOI 10.1016/S0140-6736(94)90697-1; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNNELL RD, 1996, CLIN INTENSIVE CARE, V7, P55; 1994, REP CONF ENQ MAT DEA	42	602	622	3	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1853	1858						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632403				2022-12-24	WOS:000074686500015
J	Dale, DC; Liles, C				Dale, DC; Liles, C			How many neutrophils are enough?	LANCET			English	Editorial Material							FC-GAMMA-RIII; SITES		Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Dale, DC (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.							CROSBY WH, 1969, ARCH INTERN MED, V123, P722, DOI 10.1001/archinte.123.6.722; FLEIT HB, 1992, BLOOD, V79, P2721; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HOMBURG CHE, 1995, BLOOD, V85, P532; HUZINGA TWJ, 1990, J CLIN INVEST, V86, P416; HUZINGA TWJ, 1994, BRIT J HAEMATOL, V87, P459; INDIK ZK, 1995, BLOOD, V85, P532; Koene HR, 1998, BLOOD, V91, P1; KYLE RA, 1968, NEW ENGL J MED, V279, P1015, DOI 10.1056/NEJM196811072791902; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003	10	8	8	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1752	1753		10.1016/S0140-6736(05)78742-0	http://dx.doi.org/10.1016/S0140-6736(05)78742-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635945				2022-12-24	WOS:000074197600006
J	Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM				Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM			The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus	CELL			English	Article							AUTOSOMAL-DOMINANT IRIDOGONIODYSGENESIS; TGF-BETA-SUPERFAMILY; FORK HEAD; RIEGER SYNDROME; PROTEINS; MEMBER; EMBRYO; MAINTENANCE; HNF-3-BETA; MESENCHYME	Mf1 encodes a forkhead/winged helix transcription factor expressed in many embryonic tissues, including prechondrogenic mesenchyme, periocular mesenchyme, meninges, endothelial cells, and kidney. Homozygous null Mf1(lacZ) mice die at birth with hydrocephalus, eye defects, and multiple skeletal abnormalities identical to those of the classical mutant, congenital hydrocephalus. We show that congenital hydrocephalos involves a point mutation in Mf1, generating a truncated protein lacking the DNA-binding domain. Mesenchyme cells from Mf1(lacZ) embryos differentiate poorly into cartilage in micromass culture and do not respond to added BMP2 and TGF beta 1. The differentiation of arachnoid cells in the mutant meninges is also abnormal. The human Mf1 homolog FREAC3 is a candidate gene for ocular dysgenesis and glaucoma mapping to chromosome 6p25-pter, and deletions of this region are associated with multiple developmental disorders, including hydrocephaly and eye defects.	Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Univ Alberta, Dept Opthalmol & Med Genet, Edmonton, AB T6G 2S2, Canada	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; University of Alberta	Hogan, BLM (corresponding author), Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALASHARI M, 1995, PEDIATR PATHOL LAB M, V15, P941, DOI 10.3109/15513819509027030; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CHEN JM, 1952, J ANAT, V86, P373; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHITAYAT D, 1987, American Journal of Medical Genetics, V26, P145, DOI 10.1002/ajmg.1320260122; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dou CL, 1997, NEURON, V18, P539, DOI 10.1016/S0896-6273(00)80296-2; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gould DB, 1997, AM J HUM GENET, V61, P765; GREEN MC, 1970, DEV BIOL, V23, P585, DOI 10.1016/0012-1606(70)90142-9; GRUNEBER.H, 1971, J EMBRYOL EXP MORPH, V25, P247; GRUNEBERG H, 1953, J GENET, V51, P327, DOI 10.1007/BF03023301; Gruneberg H, 1943, J GENET, V45, P1, DOI 10.1007/BF02982770; GRUNEBERG H, 1974, J EMBRYOL EXP MORPH, V31, P207; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; Hogan B, 1994, MANIPULATING MOUSE E; Hong H.-K., 1995, American Journal of Human Genetics, V57, pA134; Huang RJ, 1997, ANAT EMBRYOL, V195, P435, DOI 10.1007/s004290050063; Iida K, 1997, DEVELOPMENT, V124, P4627; Jordan T, 1997, AM J HUM GENET, V61, P882, DOI 10.1086/514874; Kaestner KH, 1996, DEVELOPMENT, V122, P1751; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KELLY PC, 1989, CLIN GENET, V36, P204; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Labosky PA, 1996, GENOMICS, V34, P241, DOI 10.1006/geno.1996.0275; Labosky PA, 1997, DEVELOPMENT, V124, P1263; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mears AJ, 1996, AM J HUM GENET, V59, P1321; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NODEN DM, 1988, DEVELOPMENT, V103, P121; ODA Y, 1984, J COMP NEUROL, V225, P448, DOI 10.1002/cne.902250310; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ohe Y, 1996, J NEUROCHEM, V67, P964; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SASAKI H, 1993, DEVELOPMENT, V118, P47; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SOLLOWAY MJ, 1998, IN PRESS DEV GENET; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Storm EE, 1996, DEVELOPMENT, V122, P3969; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TEPPERBERG JH, 1994, AM J HUM GENET SA119, V55; TOLMIE JLT, 1997, EMERY FRIMOINS PRINC, P2145; Walter MA, 1996, OPHTHALMOLOGY, V103, P1907, DOI 10.1016/S0161-6420(96)30408-9; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Wu SCY, 1998, MECH DEVELOP, V70, P3, DOI 10.1016/S0925-4773(97)00157-3; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZURCHER VL, 1990, AM J MED GENET, V35, P261, DOI 10.1002/ajmg.1320350223	62	291	297	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					985	996		10.1016/S0092-8674(00)81204-0	http://dx.doi.org/10.1016/S0092-8674(00)81204-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635428	Bronze			2022-12-24	WOS:000074205700010
J	Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M				Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M			Venous thromboembolism and cancer	LANCET			English	Article							PULMONARY-EMBOLISM; ORAL-CONTRACEPTIVES; OVARIAN-CANCER; THROMBOSIS; RISK; MALIGNANCY	Background Although cancer has been clearly associated with venous thromboembolism (VTE), many aspects of this relation are poorly understood, including the cancer sites most affected and the cancer risk during long-term follow-up. To clarify these relations, we carried out a large, population-based analysis of VTE and cancer risk. Methods Using the Swedish Inpatient Register and linkage to the nationwide Cancer Registry, we assessed cancer incidence during 1989 among 61 998 patients without a previous cancer diagnosis admitted to hospital between 1965 and 1983 for VTE. To measure possible increases in cancer risk, we computed standardised incidence ratios (SIRs) using Swedish national cancer rates for the period of the study. Findings At the time of thromboembolic admission or during the first year of follow-up, 2509 cancers were diagnosed (SIR 3.2, 95% CI 3.1-3.4). The SIR for polycythaemia vera was 12.9 (8.6-18.7), and the SIRs for cancers of the liver, pancreas, ovary, and brain, and for Hodgkin lymphoma also exceeded 5.0. Patients aged less than 65 years had higher SIRs than those who were older. In subsequent years, 6081 cancers were diagnosed (1.3, 1.3-1.3). Even 10 years or more after admission to hospital with VTE, cancer incidence had increased (1.3, 1.3-1.4). Interpretation At the time of VTE or in the first year afterwards, we found a large increase in the risk for diagnosis of virtually all cancers. In subsequent years, a persistent 30% increase in risk remains. Either premalignant change promotes thrombosis, or cancer and thrombosis share common risk factors.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; NCI, Div Canc Etiol, Epidemiol & Biostat Program, Bethesda, MD 20892 USA	Dartmouth College; Dartmouth College; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Baron, JA (corresponding author), DHMC, 7927 Rubin Bldg,1 Med Ctr Dr, Lebanon, NH 03756 USA.	John.Baron@Dartmouth.edu	Weiderpass, Elisabete/M-4029-2016; Couturaud, Francis/Q-1366-2019; Weiderpass, Elisabete/AAP-2747-2021; Okutan, Oguzhan/I-8809-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Couturaud, Francis/0000-0002-1855-8032; Weiderpass, Elisabete/0000-0003-2237-0128; Okutan, Oguzhan/0000-0002-4660-1595	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP060538] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-60538] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X; Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; BRESLOW NE, IARC SCI PUBLICATION, V82, P131; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P423, DOI 10.1016/S0033-0620(94)80051-0; FEINLEIB M, 1972, MILBANK MEML FUND Q, V50, P123, DOI 10.2307/3349403; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; GORE JM, 1982, ANN INTERN MED, V96, P556, DOI 10.7326/0003-4819-96-5-556; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HANKINSON SE, 1995, CANCER, V76, P284, DOI 10.1002/1097-0142(19950715)76:2<284::AID-CNCR2820760219>3.0.CO;2-5; MARNETT LJ, 1992, CANCER RES, V52, P5575; MATTSSON B, 1985, INT J EPIDEMIOL, V14, P64, DOI 10.1093/ije/14.1.64; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAMKOFF JS, 1981, AM J EPIDEMIOL, V114, P488, DOI 10.1093/oxfordjournals.aje.a113214; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; TOMATIS L, 1990, IARC SCI PUBL, V100, P169; TROUSSEAU A, 1872, LECT CLIN MED DEL HO, P282; TULINIUS H, 1991, AUTOPSY EPIDEMIOLOGY, P253; VESSEY MP, 1995, BRIT J CANCER, V71, P1340, DOI 10.1038/bjc.1995.260; WEISS N, 1995, LANCET, V346, P1570, DOI 10.1016/S0140-6736(95)91921-X; Willett WC, 1996, CANCER CAUSE CONTROL, V7, P178, DOI 10.1007/BF00115648; ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	27	375	398	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1077	1080		10.1016/S0140-6736(97)10018-6	http://dx.doi.org/10.1016/S0140-6736(97)10018-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660575	hybrid			2022-12-24	WOS:000073090200007
J	Northover, J				Northover, J			Realism or nihilism in bowel cancer follow-up?	LANCET			English	Editorial Material							COLORECTAL-CANCER; COLON-CANCER; CEA; COST		St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Northover, J (corresponding author), St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England.							Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; COCHRANE JPS, 1980, BRIT MED J, V280, P593, DOI 10.1136/bmj.280.6214.593; FLETCHER RH, 1993, JAMA-J AM MED ASSOC, V270, P987, DOI 10.1001/jama.270.8.987; HAWARD R, 1997, IMPROVING OUTCOMES C; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; MAKELA J, 1996, ARCH SURG-CHICAGO, V130, P1062; MARTIN EW, 1979, AM J SURG, V137, P167, DOI 10.1016/0002-9610(79)90137-5; MOERTEL C, 1978, JAMA-J AM MED ASSOC, V78, P1065; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P219; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; SUGARBAKER P, 1994, TUMORI, V31, P126; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837	15	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1074	1076		10.1016/S0140-6736(05)79375-2	http://dx.doi.org/10.1016/S0140-6736(05)79375-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660572				2022-12-24	WOS:000073090200004
J	Dennis, DT; Meltzer, MI				Dennis, DT; Meltzer, MI			Antibiotic prophylaxis after tick bites	LANCET			English	Editorial Material							LYME-DISEASE; MISDIAGNOSIS; PREVENTION		CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	Dennis, DT (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FT COLLINS,CO, USA.		Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042	9	15	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1192		10.1016/S0140-6736(05)63449-6	http://dx.doi.org/10.1016/S0140-6736(05)63449-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652556				2022-12-24	WOS:A1997YD23800005
J	Reaich, D				Reaich, D			Odour perception in chronic renal disease	LANCET			English	Editorial Material											Reaich, D (corresponding author), S CLEVELAND HOSP,DEPT NEPHROL,MIDDLESBROUGH TS4 3BW,CLEVELAND,ENGLAND.							Griep MI, 1997, NEPHROL DIAL TRANSPL, V12, P2093, DOI 10.1093/ndt/12.10.2093; KOPPLE JD, 1994, J AM SOC NEPHROL, V5, P335	2	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1191		10.1016/S0140-6736(05)63448-4	http://dx.doi.org/10.1016/S0140-6736(05)63448-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652555				2022-12-24	WOS:A1997YD23800004
J	Gans, HA; Arvin, AM; Galinus, J; Logan, L; DeHovitz, R; Maldonado, Y				Gans, HA; Arvin, AM; Galinus, J; Logan, L; DeHovitz, R; Maldonado, Y			Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HERPES-SIMPLEX VIRUS; CELL-MEDIATED-IMMUNITY; T-CELLS; CD40 LIGAND; NEUTRALIZATION TEST; INTERFERON-GAMMA; EDMONSTON-ZAGREB; DENDRITIC CELLS; UNITED-STATES; ANTIBODY	Context.-Measles causes serious morbidity in infants, with the highest risk among those who are 6 to 12 months of age. In the United States, measles vac cine has been given at age 12 to 15 months to minimize interference by passive antibodies and to achieve the high seroprevalence required for herd immunity. Infants of mothers with vaccine-induced immunity may lose passively acquired antibodies before 12 months, leaving them susceptible to measles infection. Objective.-To assess the immunogenicity of measles vaccine in infants younger than 12 months. Design.-Cohort study conducted before and after measles immunization. Setting.-Pediatric clinic in Pale Alto, Calif. Participants.-Infants 6 (n = 27), 9 (n = 26), and 12 (n = 34) months of age were enrolled; 72 provided both initial and follow-up samples. Main Outcome Measures.-Evaluation of immunogenicity before and 12 weeks after measles vaccination, including measles neutralizing antibody titers, measles-specific T-cell proliferation, and cytokine profiles. Results.-Measles neutralizing antibodies were present before vaccination in 52% (12/23), 35% (7/20), and 0% (0/22) of 6-, 9-, and 12-month-old infants, respectively. in the absence of detectable passive antibodies, geometric mean titers after vaccination were significantly lower in 6-month-old infants compared with 9-month-old infants (27 vs 578, P =.01) and 12-month-old infants (27 vs 972, P=.001). The seroconversion rate, defined as a 4-fold rise in antibody titer, in these 6-month-old infants was only 67%, and only 36% of these infants achieved seroprotective neutralizing antibody titers of 120 or higher after vaccination compared with 100% of 9- and 12-month-old infants lacking detectable passive antibody prior to vaccination. T-cell proliferation and cytokine responses to measles did not differ with age. Conclusions.-Humoral immunity was deficient in 6-month-old infants given measles vaccine, even in the absence of detectable passively acquired neutralizing antibodies. Comparison of their responses with those of 9- and 12-month-old infants indicates that a developmental maturation pf the immune response to measles may occur during the first year of life, which affects the immunogenicity Of measles vaccine.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Palo Alto Med Fdn, Dept Pediat, Palo Alto, CA 94301 USA	Stanford University; Palo Alto Medical Foundation Research Institute	Gans, HA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, G-312, Stanford, CA 94305 USA.	drhayley@leland.stanford.edu			NIAID NIH HHS [AI37127] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037127] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AABY P, 1991, EXPANDED PROGRAMME I; ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; ALBRECHT P, 1981, J VIROL METHODS, V3, P251, DOI 10.1016/0166-0934(81)90062-8; Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BLACK FL, 1976, VIRAL INFECTIONS HUM, P297; BLACK FL, 1989, PROG MED VIROL, V36, P1; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; BURCHETT SK, 1992, J INFECT DIS, V165, P813, DOI 10.1093/infdis/165.5.813; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; CHERRY JD, 1972, J PEDIATR-US, V81, P217, DOI 10.1016/S0022-3476(72)80287-7; CHERRY JD, 1992, TXB PEDIATRIC INFECT, P1591; CLEMENTS CJ, 1995, CURR TOP MICROBIOL, V191, P13; CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; GRIFFIN DE, 1994, J INFECT DIS, V170, pS24, DOI 10.1093/infdis/170.Supplement_1.S24; HARDY GE, 1970, AM J EPIDEMIOL, V91, P286, DOI 10.1093/oxfordjournals.aje.a121138; HAYWARD AR, 1984, J IMMUNOL, V133, P2469; HUNT DWC, 1994, BLOOD, V84, P4333, DOI 10.1182/blood.V84.12.4333.bloodjournal84124333; Hussey GD, 1996, J INFECT DIS, V173, P1320, DOI 10.1093/infdis/173.6.1320; JOHNSON CE, 1994, PEDIATRICS, V93, P939; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; Klaus S J, 1994, Semin Immunol, V6, P279, DOI 10.1006/smim.1994.1036; KRUGMAN RD, 1977, J PEDIATR-US, V91, P766, DOI 10.1016/S0022-3476(77)81036-6; LENNON JL, 1986, J PEDIATR-US, V108, P671, DOI 10.1016/S0022-3476(86)81039-3; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MALDONADO YA, 1995, PEDIATRICS, V96, P447; Markowitz LE, 1996, PEDIATRICS, V97, P53; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; Markowitz LE, 1994, VACCINES, P229; Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726; MCGRAW TT, 1986, PEDIATRICS, V77, P45; MURPHY MD, 1984, PEDIATRICS, V74, P90; NONOYAMA S, 1995, J CLIN INVEST, V95, P66, DOI 10.1172/JCI117677; Oxenius A, 1996, J EXP MED, V183, P2209, DOI 10.1084/jem.183.5.2209; PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004; PASS RF, 1981, INFECT IMMUN, V34, P166, DOI 10.1128/IAI.34.1.166-170.1981; Peter G, 1997, 1997 RED BOOK REPORT, P344; RATNAM S, 1995, J CLIN MICROBIOL, V33, P811, DOI 10.1128/JCM.33.4.811-815.1995; SCHLUEDERBERG A, 1973, AM J EPIDEMIOL, V97, P402, DOI 10.1093/oxfordjournals.aje.a121521; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SHELTON JD, 1978, PEDIATRICS, V62, P961; Siegrist CA, 1997, VACCINE, V15, P798, DOI 10.1016/S0264-410X(96)00253-8; STETLER HC, 1986, PEDIATRICS, V77, P471; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; SULLENDER WM, 1987, J INFECT DIS, V155, P28, DOI 10.1093/infdis/155.1.28; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; WARD BJ, 1995, J INFECT DIS, V172, P1591, DOI 10.1093/infdis/172.6.1591; WEDGWOOD JF, 1994, MT SINAI J MED, V61, P406; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; YEAGER AS, 1977, JAMA-J AM MED ASSOC, V237, P347, DOI 10.1001/jama.237.4.347; 1997, MMWR MORB MORTAL WKL, V46, P766	58	208	214	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					527	532		10.1001/jama.280.6.527	http://dx.doi.org/10.1001/jama.280.6.527			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707142	Bronze			2022-12-24	WOS:000075244900028
J	Nightingale, SL				Nightingale, SL			New warnings added to cisapride labeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-24	WOS:000075050200007
J	Darling, M				Darling, M			Low-dose aspirin not for pre-eclampsia	LANCET			English	Editorial Material									Rotunda Hosp, Dublin 1, Ireland		Darling, M (corresponding author), Rotunda Hosp, Dublin 1, Ireland.							[Anonymous], 1996, Br J Obstet Gynaecol, V103, P39; BEROYZ G, 1994, LANCET, V343, P619; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Golding J, 1998, BRIT J OBSTET GYNAEC, V105, P293, DOI 10.1111/j.1471-0528.1998.tb10089.x; PARAZZINI F, 1993, LANCET, V341, P396; Rotchell YE, 1998, BRIT J OBSTET GYNAEC, V105, P286, DOI 10.1111/j.1471-0528.1998.tb10088.x; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701	7	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					342	342		10.1016/S0140-6736(05)60465-5	http://dx.doi.org/10.1016/S0140-6736(05)60465-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717919				2022-12-24	WOS:000075110500007
J	Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC				Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC			Complete genome sequence of Treponema pallidum, the syphilis spirochete	SCIENCE			English	Article							PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE; OUTER-MEMBRANE ULTRASTRUCTURE; ENDOFLAGELLAR SHEATH PROTEIN; ESCHERICHIA-COLI; SUBSP PALLIDUM; PHOSPHOTRANSFERASE SYSTEM; ENTAMOEBA-HISTOLYTICA; ENTEROCOCCUS-HIRAE; MOLECULAR-CLONING; PORIN ACTIVITY	The complete genome sequence of Treponema pallidum was determined and shown to be 1,138,006 base pairs containing 1041 predicted coding sequences (open reading frames). Systems for DNA replication, transcription, translation, and repair are intact, but catabolic and biosynthetic activities are minimized. The number of identifiable transporters is small, and no phoiphoenolpyruvate: phosphotransferase carbohydrate transporters were found. Potential virulence factors include a family of 12 potential membrane proteins and several putative hemolysins. Comparison of the T. pallidum genome sequence with that of another pathogenic spirochete, Borrelia burgdorferi, the agent of Lyme disease, identified unique and common genes and substantiates the considerable diversity observed among pathogenic spirochetes.	Inst Genom Res, Rockville, MD 20850 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77225 USA	J. Craig Venter Institute; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Fraser, CM (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	tpdb@tigr.org	Salzberg, Steven/Q-6514-2019; Norris, Steven James/K-6586-2019; Salzberg, Steven L/F-6162-2011; Weinstock, George/C-6314-2013	Salzberg, Steven/0000-0002-8859-7432; Norris, Steven James/0000-0002-2501-8034; Salzberg, Steven L/0000-0002-8859-7432; Weinstock, George/0000-0002-2997-4592; Fraser, Claire/0000-0003-1462-2428	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031068] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; BARBIERI JT, 1981, INFECT IMMUN, V31, P1071, DOI 10.1128/IAI.31.3.1071-1077.1981; BARONDES SH, 1993, MOL MENTAL ILLNESS; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Blanco DR, 1996, J BACTERIOL, V178, P6685, DOI 10.1128/jb.178.23.6685-6692.1996; BLANCO DR, 1995, J BACTERIOL, V177, P3556, DOI 10.1128/jb.177.12.3556-3562.1995; Bruchhaus I, 1996, BIOCHEM J, V316, P57, DOI 10.1042/bj3160057; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cartwright Frederick Fox, 1972, DIS HIST; Champion CI, 1997, J BACTERIOL, V179, P1230, DOI 10.1128/jb.179.4.1230-1238.1997; CHAMPION CI, 1990, INFECT IMMUN, V58, P1697, DOI 10.1128/IAI.58.6.1697-1704.1990; CHARON NW, 1992, RES MICROBIOL, V143, P597, DOI 10.1016/0923-2508(92)90117-7; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; COX CD, 1983, PATHOGENESIS IMMUNOL, P57; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; DEATH A, 1993, RES MICROBIOL, V144, P529, DOI 10.1016/0923-2508(93)90002-J; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; Fenno JC, 1996, J BACTERIOL, V178, P2489, DOI 10.1128/jb.178.9.2489-2497.1996; Fenno JC, 1997, J BACTERIOL, V179, P1082, DOI 10.1128/jb.179.4.1082-1089.1997; FIELDSTEEL AH, 1981, INFECT IMMUN, V32, P908, DOI 10.1128/IAI.32.2.908-915.1981; FITZGERALD TJ, 1982, BRIT J VENER DIS, V58, P1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Freist W, 1997, BIOL CHEM, V378, P1103; Greene SR, 1997, DNA SEQUENCE, V7, P267, DOI 10.3109/10425179709034046; Guina T, 1997, MOL MICROBIOL, V24, P1201, DOI 10.1046/j.1365-2958.1997.4291786.x; Hagman KE, 1997, INFECT IMMUN, V65, P1701, DOI 10.1128/IAI.65.5.1701-1709.1997; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; ISAACS RD, 1990, INFECT IMMUN, V58, P2025, DOI 10.1128/IAI.58.7.2025-2034.1990; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JOHNSON RC, 1981, PROCARYOTES, P582; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; KAISER GE, 1975, NATURE, V255, P656, DOI 10.1038/255656a0; KEMP RG, 1993, J BACTERIOL, V175, P5723, DOI 10.1128/JB.175.17.5723-5724.1993; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; Limberger RJ, 1996, J BACTERIOL, V178, P4628, DOI 10.1128/jb.178.15.4628-4634.1996; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; LYSKO PG, 1977, INFECT IMMUN, V16, P885, DOI 10.1128/IAI.16.3.885-890.1977; LYSKO PG, 1978, INFECT IMMUN, V21, P462, DOI 10.1128/IAI.21.2.462-473.1978; Mathers DA, 1996, INFECT IMMUN, V64, P2904, DOI 10.1128/IAI.64.8.2904-2910.1996; MATSUURA A, 1972, J VITAMINOL, V18, P29, DOI 10.5925/jnsv1954.18.29; NEILSEN H, 1997, PROTEIN ENG, V10, P1; Nichols HJ, 1913, J AMER MED ASSOC, V60, P108, DOI 10.1001/jama.1913.04340020016005; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; NORRIS SJ, 1988, J BACTERIOL, V170, P4072, DOI 10.1128/jb.170.9.4072-4082.1988; NORRIS SJ, UNPUB; OAKES SG, 1982, BRIT J VENER DIS, V58, P220; OBRIEN WE, 1975, J BIOL CHEM, V250, P8690; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; PALLESEN L, 1989, INFECT IMMUN, V57, P2166, DOI 10.1128/IAI.57.7.2166-2172.1989; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Porcella SF, 1996, GENE, V177, P115, DOI 10.1016/0378-1119(96)00286-7; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; REEVES RE, 1976, J BIOL CHEM, V251, P2958; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROBINSON EN, 1993, SYPHILIS DIS HIST ME, P334; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHILLER NL, 1977, INFECT IMMUN, V16, P60, DOI 10.1128/IAI.16.1.60-68.1977; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SELL S, 1983, INT REV EXP PATHOL, V24, P204; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; SONHAMMER EL, 1997, PROTEINS, V28, P405; Stamm LV, 1997, FEMS MICROBIOL LETT, V155, P115, DOI 10.1016/S0378-1097(97)00375-3; STAMM LV, 1991, INFECT IMMUN, V59, P1572, DOI 10.1128/IAI.59.4.1572-1575.1991; Stamm LV, 1996, DNA SEQUENCE, V6, P293, DOI 10.3109/10425179609020876; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VANHORN KG, 1983, CAN J MICROBIOL, V29, P1141, DOI 10.1139/m83-175; WALKER EM, 1991, J BACTERIOL, V173, P5585, DOI 10.1128/jb.173.17.5585-5588.1991; WALKER EM, 1995, J BACTERIOL, V177, P1797, DOI 10.1128/jb.177.7.1797-1804.1995; WONG GHW, 1983, INFECT IMMUN, V41, P636, DOI 10.1128/IAI.41.2.636-643.1983	86	785	1483	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					375	388		10.1126/science.281.5375.375	http://dx.doi.org/10.1126/science.281.5375.375			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665876				2022-12-24	WOS:000074918800039
J	ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA				ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA			Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen	LANCET			English	Article							ALANINE AMINOTRANSFERASE; HBV-DNA; CIRRHOSIS; CARRIERS	Background Hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B e antigen (anti-HBe) commonly coexist, and laboratory tests are often requested to assess histological hepatitis activity. An optimum panel of tests has not been found and the usefulness of hepatitis B virus (HBV) DNA assays in this context has not been established. We assessed various blood tests to find which best predicted hepatitis activity. Methods Routine plasma biochemical liver tests and serum HBV DNA (hybridisation and PCR assays) were assessed prospectively in 123 patients positive for HBsAg and anti-HBe. We scored histological hepatitis activity (hepatitis activity index) and determined whether chronic active hepatitis (chronic hepatitis with portal and periportal lesions) was present. We analysed the relation between laboratory data and the hepatitis activity index or risk of chronic active hepatitis by multiple regression and multiple logistic regression, respectively. Findings The analyses provided models for predicting either the hepatitis activity index or the risk of chronic active hepatitis. Aspartate aminotransferase was the most important test in the two models. The contribution of HBV DNA and other assays, especially alanine-aminotransferase activity, were of no practical importance. Interpretation Because screening by aspartate-aminotransferase activity could not be improved by the addition of other assays or HBV DNA, patients positive for HBsAg and anti-HBe could be screened for chronic active hepatitis with a single assay and counselling of patients can be improved if proper reference values are used.	Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Virol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1100 DE Amsterdam, Netherlands; Municipal Publ Hlth Serv, Dept Infect Dis Control, Amsterdam, Netherlands; Dutch Red Cross Blood Transfus Serv, Cent Lab, Dept Viral Serol, Amsterdam, Netherlands; Erasmus Univ Hosp Rotterdam, Dept Hepatogastroenterol, Rotterdam, Netherlands; Univ Hosp, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Public Health Service Amsterdam; Erasmus University Rotterdam; Erasmus MC	ter Borg, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, POB 22700, NL-1100 DE Amsterdam, Netherlands.							ALBERTI A, 1994, ANTIVIR RES, V24, P145, DOI 10.1016/0166-3542(94)90063-9; BERGMEYER HU, 1986, J CLIN CHEM CLIN BIO, V24, P481; CARLONI G, 1987, J MED VIROL, V21, P15, DOI 10.1002/jmv.1890210104; Colloredo G, 1996, J HEPATOL, V25, P644, DOI 10.1016/S0168-8278(96)80233-9; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Mangia A, 1996, DIGEST DIS SCI, V41, P2447, DOI 10.1007/BF02100141; MCCULLOUGH AJ, 1987, HEPATOLOGY, V7, P49, DOI 10.1002/hep.1840070112; NIITSUMA H, 1997, GASTROENTEROLOGY, V92, P119; PAZ MOA, 1986, J HEPATOL, V3, P371, DOI 10.1016/S0168-8278(86)80491-3; RAPICETTA M, 1990, EPIDEMIOL INFECT, V104, P511, DOI 10.1017/S0950268800047518; SCHEUER PJ, 1994, LIVER BIOPSY INTERPR, P117; VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000, DOI 10.1016/0016-5085(94)90760-9; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; *WHO, 1993, GLOB HLTH SIT PROJ E; WILLIAMS ALB, 1988, GASTROENTEROLOGY, V95, P734, DOI 10.1016/S0016-5085(88)80022-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; YANG PM, 1987, HEPATO-GASTROENTEROL, V34, P251; ZAAIJER HL, 1994, J CLIN MICROBIOL, V32, P2088, DOI 10.1128/JCM.32.9.2088-2091.1994; Zavaglia C, 1997, LIVER, V17, P83	24	51	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1914	1918		10.1016/S0140-6736(97)09391-4	http://dx.doi.org/10.1016/S0140-6736(97)09391-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654258				2022-12-24	WOS:000074464700008
J	Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV				Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV			Abolition of long-term stability of new hippocampal place cell maps by NMDA receptor blockade	SCIENCE			English	Article							COMPLEX-SPIKE CELLS; SPATIAL MEMORY; ANTAGONIST MK-801; UNIT-ACTIVITY; POTENTIATION; ENVIRONMENT; RAT; CPP; ASPARTATE; PERFORMANCE	Hippocampal pyramidal cells are called place cells because Each cell tends to fire only when the animal is in a particular part of the environment-the cell's firing field. Acute pharmacological blockade, of N-methyl-D-aspartate (NMDA) glutamate receptors was used to investigate how NMDA-based synaptic plasticity participates in the formation and maintenance of the firing fields. The results suggest that the formation and short-term stability of firing fields in a new environment involve plasticity that is independent of NMDA receptor activation. By contrast, the long-term stabilization of newly established firing fields required normal NMDA receptor function and, therefore, may be related to other NMDA-dependent processes such as long-term potentiation and spatial teaming.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Physiol, Brooklyn, NY 11203 USA	McGill University; New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Muller, RV (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Hargreaves, Eric/H-4891-2011	Kentros, Clifford/0000-0003-3850-3829; Hargreaves, Eric/0000-0001-5311-9804	NATIONAL INSTITUTE ON AGING [T32AG000189] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AGO 00189] Funding Source: Medline; PHS HHS [R01 45923, R01 20686] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; AUSTIN K B, 1990, Society for Neuroscience Abstracts, V16, P263; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; Bures J, 1997, P NATL ACAD SCI USA, V94, P343, DOI 10.1073/pnas.94.1.343; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; COLE BJ, 1993, PSYCHOPHARMACOLOGY, V111, P465, DOI 10.1007/BF02253537; CURRAN HV, 1986, BIOL PSYCHOL, V23, P179, DOI 10.1016/0301-0511(86)90081-5; Davis S, 1997, J NEUROSCI METH, V75, P75, DOI 10.1016/S0165-0270(97)00053-8; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; HERNANDEZ RV, 1994, BRAIN RES, V656, P215, DOI 10.1016/0006-8993(94)91388-9; HETHERINGTON PA, 1993, BEHAV NEUROSCI, V107, P434, DOI 10.1037/0735-7044.107.3.434; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; Isaac JTR, 1996, J PHYSIOLOGY-PARIS, V90, P299, DOI 10.1016/S0928-4257(97)87901-6; JARBE TU, 1986, ACTA NEUROL SCAND  S, V109, P37; KENTROS C, UNPUB; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRIS RG, 1997, T R SOC LONDON B, V352, P1489; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1987, J NEUROSCI, V7, P1935; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; PELLICANO MP, 1993, PHYSIOL BEHAV, V54, P563, DOI 10.1016/0031-9384(93)90250-J; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; Rotenberg A., 1997, Society for Neuroscience Abstracts, V23, P501; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; THOMPSON LT, 1990, BRAIN RES, V509, P189; UNGERER A, 1991, BRAIN RES, V549, P59, DOI 10.1016/0006-8993(91)90599-Q; WARD L, 1990, PHARMACOL BIOCHEM BE, V35, P785, DOI 10.1016/0091-3057(90)90359-P; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	42	371	376	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2121	2126		10.1126/science.280.5372.2121	http://dx.doi.org/10.1126/science.280.5372.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641919				2022-12-24	WOS:000074435900047
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Homing viruses	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA USA.							Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; ITZHAKI JE, 1991, NUCLEIC ACIDS RES, V19, P3835, DOI 10.1093/nar/19.14.3835; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1956	1957						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669951				2022-12-24	WOS:000074323800071
J	Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M				Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M			A family of hyperpolarization-activated mammalian cation channels	NATURE			English	Article							THALAMIC RELAY NEURONS; VOLTAGE-CLAMP ANALYSIS; CYCLIC-AMP; SINOATRIAL NODE; PROTEIN-KINASE; MODULATION; I(F); SEQUENCE; SUBUNIT; HEART	Pacemaker activity of spontaneously active neurons(1-3) and heart cells(4-6) is controlled by a depolarizing, mixed Na+/K+ current, named I-h (or I-f in the sinoatrial node of the heart)(1,4). This current is activated on hyperpolarization of the plasma membrane. In addition to depolarizing pacemaker cells, I-h is involved in determining the resting membrane potential of neurons(1,2) and provides a mechanism to limit hyperpolarizing currents in these cells(7-9). Hormones and neurotransmitters that induce a rise in cyclic AMP levels increase I-h by a mechanism that is independent of protein phosphorylation, and which involves direct binding of the cyclic nucleotide to the channel that mediates I-h(10-13). Here we report the molecular cloning and functional expression of the gene encoding a hyperpolarization-activated cation channel (HAC1) that is present in brain and heart. This channel exhibits the general properties of I-h channels. We have also identified full-length sequences of two related channels, HAC2 and HAC3, that are specifically expressed in the brain, indicating the existence of a family of hyperpolarization-activated cation channels.	Tech Univ Munchen, Inst Pharmakol & Toxikol, D-80802 Munchen, Germany	Technical University of Munich	Biel, M (corresponding author), Tech Univ Munchen, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munchen, Germany.		Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; BAYLISS DA, 1994, J NEUROPHYSIOL, V71, P119, DOI 10.1152/jn.1994.71.1.119; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; HO WK, 1994, PFLUG ARCH EUR J PHY, V426, P68, DOI 10.1007/BF00374672; Ludwig A, 1997, J NEUROSCI, V17, P1339; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P319, DOI 10.1113/jphysiol.1990.sp018332; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; SOLOMON JS, 1993, J PHYSIOL-LONDON, V462, P393, DOI 10.1113/jphysiol.1993.sp019561; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; YU HG, 1995, J PHYSIOL-LONDON, V485, P469, DOI 10.1113/jphysiol.1995.sp020743; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	28	750	792	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					587	591		10.1038/31255	http://dx.doi.org/10.1038/31255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634236				2022-12-24	WOS:000074150100055
J	Everett, SM; Axon, ATR				Everett, SM; Axon, ATR			Early gastric cancer: disease or pseudo-disease?	LANCET			English	Editorial Material									Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Everett, SM (corresponding author), Gen Infirm, Ctr Digest Dis, Great George St, Leeds LS1 3EX, W Yorkshire, England.							ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; COLEMAN MP, 1993, IARC SCI PUBL, V121, P193; CORREA P, 1994, CANCER SURV, V20, P55; *DEP HLTH SOC SEC, 1986, BREAST CANC SCREEN R; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; FONSECA L, 1994, ONCOLOGY, V51, P485; FUJII T, 1994, JPN J CLIN ONCOL, V24, P128; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HAMPSON LG, 1990, CAN J SURG, V33, P349; HISAMICHI S, 1989, WORLD J SURG, V13, P31, DOI 10.1007/BF01671151; IKEDA Y, 1994, SEMIN SURG ONCOL, V10, P150, DOI 10.1002/ssu.2980100218; KOHLI Y, 1981, J CLIN GASTROENTEROL, V3, P129, DOI 10.1097/00004836-198106000-00005; KURIHARA M, CANC MORTALITY STAT, P63; ROKKAS T, 1991, GUT, V32, P1110, DOI 10.1136/gut.32.10.1110; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; VONHOLSTEIN CS, 1991, SCAND J GASTROENTERO, V26, P1020, DOI 10.3109/00365529109003951; YAMAZAKI H, 1989, CANCER-AM CANCER SOC, V63, P613, DOI 10.1002/1097-0142(19890215)63:4<613::AID-CNCR2820630402>3.0.CO;2-0; YOSHIDA S, 1993, GASTRIC CANCER, P246	20	44	46	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1350	1352		10.1016/S0140-6736(98)04365-7	http://dx.doi.org/10.1016/S0140-6736(98)04365-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643813				2022-12-24	WOS:000073439400042
J	Clark, S				Clark, S			Training in orthopaedic spinal surgery	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Clark, S (corresponding author), Lancet, London WC1B 3SL, England.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1224	1224		10.1016/S0140-6736(05)79314-4	http://dx.doi.org/10.1016/S0140-6736(05)79314-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643740				2022-12-24	WOS:000073283600006
J	Nutt, JG				Nutt, JG			Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease	LANCET			English	Editorial Material							LEVODOPA		Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Pharmacol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Nutt, JG (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.							Agid Y, 1997, LANCET, V350, P712, DOI 10.1016/S0140-6736(05)63511-8; Baas H, 1997, J NEUROL NEUROSUR PS, V63, P421, DOI 10.1136/jnnp.63.4.421; HAUSER RA, IN PRESS MOV DISORD; Jorga KM, 1997, CLIN PHARMACOL THER, V62, P300, DOI 10.1016/S0009-9236(97)90033-3; Kieburtz K, 1997, ANN NEUROL, V42, P747; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; Mannisto P T, 1992, Prog Drug Res, V39, P291; NUTT JG, 1987, ANN NEUROL, V21, P584, DOI 10.1002/ana.410210610; NUTT JG, 1994, NEUROLOGY, V44, P913, DOI 10.1212/WNL.44.5.913; Rajput AH, 1997, NEUROLOGY, V49, P1066, DOI 10.1212/WNL.49.4.1066; ROBERTS JW, 1993, NEUROLOGY, V43, P2685, DOI 10.1212/WNL.43.12.2685; Ruottinen HM, 1996, J NEUROL NEUROSUR PS, V60, P36, DOI 10.1136/jnnp.60.1.36; Waters CH, 1997, NEUROLOGY, V49, P665, DOI 10.1212/WNL.49.3.665	13	32	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1221	1222		10.1016/S0140-6736(05)79311-9	http://dx.doi.org/10.1016/S0140-6736(05)79311-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643737				2022-12-24	WOS:000073283600003
J	Leu, JY; Chua, PR; Roeder, GS				Leu, JY; Chua, PR; Roeder, GS			The meiosis-specific hop2 protein of S-cerevisiae ensures synapsis between homologous chromosomes	CELL			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; SYNAPTIC ADJUSTMENT; ESCHERICHIA-COLI; GENE CONVERSION; RECA HOMOLOGS; YEAST; SEGREGATION; DNA	The hop2 mutant of S. cerevisiae displays a novel phenotype: meiotic chromosomes form nearly wild-type amounts of synaptonemal complex, but most chromosomes are engaged in synapsis with nonhomologous partners. The meiosis-specific Hop2 protein localizes to chromosomes prior to and during synapsis and in the absence of the double-strand breaks that initiate recombination. hop2 strains sustain a wild-type level of meiotic double-strand breaks, but these breaks remain unrepaired. The hop2 mutant arrests at the pachytene stage of meiotic prophase with the RecA-like protein Dmc1 located at numerous sites along synapsed chromosomes. We propose that the Hop2 protein functions to prevent synapsis between nonhomologous chromosomes.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.		Leu, Jun-Yi/A-7364-2009	Leu, Jun-Yi/0000-0001-5445-2799	NIGMS NIH HHS [GM-28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOJKO M, 1990, GENETICS, V124, P593; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; DERNBURG AF, 1995, TELOMERES, P295; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; Goldman ASH, 1996, GENETICS, V144, P43; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HOEKSTRA MF, 1991, METHOD ENZYMOL, V194, P329; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENKINS G, 1992, J CELL SCI, V103, P415; JinksRobertson S, 1997, GENETICS, V146, P69; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MOSES MJ, 1982, CHROMOSOMA, V84, P457, DOI 10.1007/BF00292848; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; PARKER DR, 1969, MUTAT RES, V7, P393, DOI 10.1016/0027-5107(69)90110-9; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Prinz S, 1997, GENETICS, V146, P781; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1998, IN PRESS GENES DEV; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SEARS ER, 1976, ANNU REV GENET, V10, P31, DOI 10.1146/annurev.ge.10.120176.000335; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; Tung KS, 1998, GENETICS, V149, P817; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	48	154	159	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					375	386		10.1016/S0092-8674(00)81480-4	http://dx.doi.org/10.1016/S0092-8674(00)81480-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708739	hybrid			2022-12-24	WOS:000075308400013
J	Sit, TL; Vaewhongs, AA; Lommel, SA				Sit, TL; Vaewhongs, AA; Lommel, SA			RNA-mediated trans-activation of transcription from a viral RNA	SCIENCE			English	Article							NECROTIC MOSAIC-VIRUS; INFECTIOUS TRANSCRIPTS; SUBGENOMIC RNA; PLANTS; INVITRO; REGION	The red clover necrotic mosaic virus genome is composed of two single-stranded RNA components, RNA-1 and RNA-2. The viral capsid protein is translated from a subgenomic RNA (sgRNA) that is transcribed from genomic RNA-1, Here, a 34-nucleotide sequence in RNA-2 is shown to be required for transcription of sgRNA. Mutations that prevent base-pairing between the RNA-1 subgenomic promoter and the 34-nucleotide trans-activator prevent expression of a reporter gene. A model is proposed in which direct binding of RNA-2 to RNA-1 trans-activates sgRNA synthesis. This RNA-mediated regulation of transcription is unusual among RNA viruses, which typically rely on protein regulators.	N Carolina State Univ, Dept Plant Pathol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Lommel, SA (corresponding author), N Carolina State Univ, Dept Plant Pathol, Box 7616, Raleigh, NC 27695 USA.	steve_lommel@ncsu.edu		Sit, Tim/0000-0001-7302-823X				Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Gallie DR, 1996, PLANT MOL BIOL, V32, P145, DOI 10.1007/BF00039381; GE ZM, 1993, P JPN ACAD B-PHYS, V69, P113, DOI 10.2183/pjab.69.113; GE ZM, 1992, J GEN VIROL, V73, P2483, DOI 10.1099/0022-1317-73-9-2483; Giesman-Cookmeyer D., 1995, PATHOGENESIS HOST SP, V3, P157; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; KENDALL TL, 1992, J GEN VIROL, V73, P2479, DOI 10.1099/0022-1317-73-9-2479; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; Liebhaber S A, 1997, Nucleic Acids Symp Ser, P29; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; MILLER WS, COMMUNICATION; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; SIT TL, UNPUB; VAEWHONGS AA, 1995, VIROLOGY, V212, P607, DOI 10.1006/viro.1995.1518; XIONG ZG, 1991, VIROLOGY, V182, P388, DOI 10.1016/0042-6822(91)90687-7; Zavriev SK, 1996, VIROLOGY, V216, P407, DOI 10.1006/viro.1996.0076; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	24	174	177	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					829	832		10.1126/science.281.5378.829	http://dx.doi.org/10.1126/science.281.5378.829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694655				2022-12-24	WOS:000075295600051
J	Klingauf, J; Kavalali, ET; Tsien, RW				Klingauf, J; Kavalali, ET; Tsien, RW			Kinetics and regulation of fast endocytosis at hippocampal synapses	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; CAPACITANCE MEASUREMENTS; TRANSMITTER RELEASE; EXOCYTOSIS; CELLS; CALCIUM; FUSION	Presynaptic nerve terminals often contain as few as a hundred vesicles(1,2) and so must recycle them soon after exocytosis to preserve synaptic transmission and presynaptic morphology(3,4) during repetitive firing. The kinetics(3,4) and mechanisms(5) of vesicular endocytosis and repriming have therefore been studied. Vesicles in hippocampal nerve terminals can become available to release their contents within similar to 40 s of the previous round of exocytosis(6,7). Studies using the styryl dye FM1-43 (ref. 3) have estimated the time constant for endocytosis as similar to 20-30 s (refs 4, 8), at least half of the total recycling time, which is much slower than endocytosis in other secretory systems(9-11). It seems paradoxical that the neurosecretory terminals that could benefit the most from rapid endocytosis do not use such a mechanism. Here we demonstrate the existence of fast endocytosis in hippocampal nerve terminals and derive its kinetics from fluorescence measurements using dyes with varying rates of membrane departitioning. The rapid mode of vesicular retrieval was much faster after exposure to staurosporine or elevated extracellular calcium. Thus hippocampal synapses take advantage of efficient mechanisms for endocytosis, and their vesicular retrieval is subject to modulatory control.	Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University	Tsien, RW (corresponding author), Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.							Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; Henkel AW, 1995, J NEUROSCI, V15, P8246; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Kraszewski K, 1996, J NEUROSCI, V16, P5905; Lagnado L, 1996, NEURON, V17, P957, DOI 10.1016/S0896-6273(00)80226-3; LIU G, 1995, NATURE, V268, P1624; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; Plattner H, 1997, J MEMBRANE BIOL, V158, P197, DOI 10.1007/s002329900257; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Schikorski T, 1997, J NEUROSCI, V17, P5858; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885	30	326	332	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					581	585		10.1038/29079	http://dx.doi.org/10.1038/29079			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707119				2022-12-24	WOS:000075238700049
J	Sato, K; Wickner, W				Sato, K; Wickner, W			Functional reconstitution of Ypt7p GTPase and a purified vacuole SNARE complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ALKALINE-PHOSPHATASE; ALPHA-SNAP; PROTEIN; FUSION; TRANSPORT; DOCKING; INHERITANCE; SYNTAXIN-1	Membrane trafficking has heretofore been studied with intact organelles. Here, fusion-competent proteoliposomes were reconstituted from a yeast vacuole detergent extract. Homotypic vacuole fusion requires many membrane proteins, including the Ypt7p guanosine triphosphatase and a "SNARE complex" with Vam3p and Nyv1p. Proteoliposomes from extracts immunodepleted of either Vam3p or Ypt7p could not fuse, but vesicles reconstituted from a mixture of these depleted extracts had restored fusion activity. Purified preassembled vacuolar SNARE complex, when reconstituted with a SNARE-depleted extract, was fully functional for fusion. Thus, solubilized integral membrane components can be reconstituted for priming, docking, and fusion steps of organelle trafficking.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.							CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; KANEKO Y, 1987, GENE, V58, P137; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SATO K, UNPUB; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; YAMADA H, 1989, J BIOL CHEM, V264, P1723; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	23	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					700	702		10.1126/science.281.5377.700	http://dx.doi.org/10.1126/science.281.5377.700			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685264				2022-12-24	WOS:000075107900043
J	Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM				Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM			Crystal structure of the signal sequence binding subunit of the signal recognition particle	CELL			English	Article							METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; DNA RECOGNITION; PEPTIDE COMPLEX; GTP HYDROLYSIS; 4.5S RNA; SRP; CALMODULIN	The crystal structure of the signal sequence binding subunit of the signal recognition particle (SRP) from Thermus aquaticus reveals a deep groove bounded by a flexible loop and lined with side chains of conserved hydrophobic residues. The groove defines a flexible, hydrophobic environment that is likely to contribute to the structural plasticity necessary for SRP to bind signal sequences of different lengths and amino acid sequence. The structure also reveals a helix-turn-helix motif containing an arginine-rich alpha helix that is required for binding to SRP RNA and is implicated in forming the core of an extended RNA binding surface.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Keenan, RJ (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841; Keenan, Robert/0000-0003-1466-0889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032384, R01GM032384, R01GM024485] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09270] Funding Source: Medline; NIGMS NIH HHS [GM-32384, GM-24485] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRUNGER AT, 1996, XPLOR VERSION 3843; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurita K, 1996, J BIOL CHEM, V271, P13140, DOI 10.1074/jbc.271.22.13140; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lentzen G, 1996, RNA, V2, P244; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER MS, 1994, INT J ONCOL, V4, P5; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Schmitz U, 1996, RNA, V2, P1213; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; Takamatsu H, 1997, EUR J BIOCHEM, V248, P575, DOI 10.1111/j.1432-1033.1997.00575.x; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	63	227	229	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					181	191		10.1016/S0092-8674(00)81418-X	http://dx.doi.org/10.1016/S0092-8674(00)81418-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695947	Bronze, Green Published			2022-12-24	WOS:000075020100007
J	Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS				Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS			Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76	CELL			English	Article							T-CELL DEVELOPMENT; TYROSINE KINASE; MUTANT MICE; ALPHA-BETA; LYMPHOCYTE DEVELOPMENT; THYMIC SELECTION; TCR-BETA; B-CELLS; GENE; DIFFERENTIATION	The adaptor protein SLP-76 is expressed in T lymphocytes and myeloid cells and is a substrate for ZAP-70 and Syk. We generated a SLP-76 null mutation in mice by homologous recombination in embryonic stem cells to evaluate the role of SLP-76 in T cell development and activation. SLP-76-deficient mice exhibited subcutaneous and intraperitoneal hemorrhaging and impaired viability. Analysis of lymphoid cells revealed a profound block in thymic development with absence of double-positive CD4(+)8(+) thymocytes and of peripheral T cells. This block could not be overcome by in vivo treatment with anti-CD3. V-D-J rearrangement of the TCR beta locus was not obviously affected. B cell development was normal. These results indicate that SLP-76 collects all pre-TCR signals that drive the development and expansion of double-positive thymocytes.	Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute	Geha, RS (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aifantis I, 1997, IMMUNITY, V7, P601, DOI 10.1016/S1074-7613(00)80381-7; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ardouin L, 1998, J EXP MED, V187, P105, DOI 10.1084/jem.187.1.105; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; daSilva AJ, 1997, BIOCHEM SOC T, V25, P361, DOI 10.1042/bst0250361; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fehling HJ, 1997, IMMUNITY, V6, P703, DOI 10.1016/S1074-7613(00)80446-X; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hollander GA, 1996, P NATL ACAD SCI USA, V93, P4994, DOI 10.1073/pnas.93.10.4994; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; LEVELT CN, 1995, IMMUNITY, V3, P215, DOI 10.1016/1074-7613(95)90091-8; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WALLACE VA, 1995, EUR J IMMUNOL, V25, P1312, DOI 10.1002/eji.1830250527; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	53	317	323	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					229	238		10.1016/S0092-8674(00)81422-1	http://dx.doi.org/10.1016/S0092-8674(00)81422-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695951	Bronze			2022-12-24	WOS:000075020100011
J	Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM				Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM			Micrometastases and survival in stage II colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; LYMPH-NODE MICROMETASTASES; PROGNOSTIC-SIGNIFICANCE; REVERSE-TRANSCRIPTASE; GENETIC DIAGNOSIS; ALLELIC LOSS; TUMOR-CELLS; CARCINOMA; IDENTIFICATION; THERAPY	Background Standard treatment of colorectal cancer includes adjuvant chemotherapy for patients with stage III disease (defined by the presence of lymphnode metastases), but not for patients with stage II tumors (who have no lymph-node metastases). However, 20 percent of patients with stage II tumors die of recurrent disease. We investigated whether the detection of micrometastases can be used to identify patients with stage II disease who are at high risk for recurrence. Methods We analyzed 192 lymph nodes from 26 consecutive patients with stage II colorectal cancer, using a carcinoembryonic antigen-specific nested reverse-transcriptase polymerase chain reaction. Five-year follow-up information was obtained on all patients. Observed and adjusted survival rates were assessed in the patients with and the patients without micrometastases. Results Micrometastases were detected in one or more lymph nodes from 14 of 26 patients (54 percent). The adjusted five-year survival rate (for which only cancer-related deaths were considered) was 50 percent in this group, whereas in the 12 patients without micrometastases, the survival rate was 91 percent (P=0.02 by the log-rank test). The observed five-year survival rates were 36 percent and 75 percent, respectively (P=0.03). The groups were similar with respect to age, sex, tumor side (location in relation to the flexura lienalis), degree of tumor differentiation (grade), and diameter of the primary tumor. Conclusions Molecular detection of micrometastases is a prognostic tool in stage II colorectal cancer. (N Engl J Med 1998;339:223-8.) (C)1998, Massachusetts Medical Society.	Leiden Univ, Med Ctr, Dept Surg K6R, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Tollenaar, RAEM (corresponding author), Leiden Univ, Med Ctr, Dept Surg K6R, POB 9600, NL-2300 RC Leiden, Netherlands.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				Adell G, 1996, EUR J SURG, V162, P637; [Anonymous], 1997, J CLIN PATHOL; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1972, J R STAT SOC B, V34, P187; CUTAIT R, 1991, DIS COLON RECTUM, V34, P917, DOI 10.1007/BF02049708; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; GOLDHIRSCH A, 1990, LANCET, V335, P1565; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; Gunn J, 1996, LAB INVEST, V75, P611; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; JEFFERS MD, 1994, J PATHOL, V172, P183, DOI 10.1002/path.1711720205; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MORI M, 1995, CANCER RES, V55, P3417; Nakamori S, 1997, DIS COLON RECTUM, V40, pS29, DOI 10.1007/BF02062017; NEUMAIER M, 1995, GENE, V159, P43, DOI 10.1016/0378-1119(94)00522-T; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; SCHOENFELD A, 1994, CANCER RES, V54, P2986; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G	31	528	556	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					223	228		10.1056/NEJM199807233390403	http://dx.doi.org/10.1056/NEJM199807233390403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673300				2022-12-24	WOS:000074918700003
J	Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN				Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN			Ethnic and socioeconomic differences in cardiovascular disease risk factors - Findings for women from the third national health and nutrition examination survey, 1988-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; STANFORD 5-CITY PROJECT; NON-HISPANIC WHITES; MEXICAN-AMERICANS; UNITED-STATES; COMMUNITY INTERVENTION; SOCIAL INEQUALITIES; PREVALENCE; MORTALITY	Context.-Cardiovascular disease (CVD) risk factors are higher among ethnic minority women than among white women in the United States. However, because ethnic minority women are disproportionately poor, socioeconomic status (SES) may substantially explain these risk factor differences. Objective.-To determine whether differences in CVD risk factors by ethnicity could be attributed to differences in SES. Design.-Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Setting.-Eighty-nine mobile examination centers. Participants.-A total of 1762 black, 1481 Mexican American, and 2023 white women, aged 25 to 64 years, who completed both the home questionnaire and medical examination. Main Outcome Measures.-Ethnicity and years of education (SES) in relation to systolic blood pressure, cigarette smoking, body mass index (BMI, a measure of weight in kilograms divided by the square of height in meters), physical inactivity, non-high-density lipoprotein cholesterol (non-HDL-C [the difference between total cholesterol and HDL-C]), and non-insulin-dependent diabetes mellitus. Results.-As expected, most CVD risk factors were higher among ethnic minority women than among white women. After adjusting for years of education, highly significant differences in blood pressure, BMI, physical inactivity, and diabetes remained for both black and Mexican American women compared with white women (P<.001). In addition, women of lower SES from each of the 3 ethnic groups had significantly higher prevalences of smoking and physical inactivity and higher levels of BMI and non-HDL-C than women of higher SES (P<.001). Conclusions.-These findings provide the greatest evidence to date of higher CVD risk factors among black and Mexican American women than among white women of comparable SES. The striking differences by both ethnicity and SES underscore the critical need to improve screening, early detection, and treatment of CVD-related conditions for black and Mexican American women, as well as for women of lower SES in all ethnic groups.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Winkleby, MA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 1000 Welch Rd, Palo Alto, CA 94304 USA.	marilyn_winkleby@scrdp.stanford.edu			NHLBI NIH HHS [1-RO3-HL-57100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL057100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Anderson NB, 1995, HEALTH PSYCHOL, V14, P589, DOI 10.1037/0278-6133.14.7.589; ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; BOYKO EJ, 1991, DIABETES, V40, P509, DOI 10.2337/diabetes.40.4.509; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; COWIE CC, 1993, AM J EPIDEMIOL, V137, P719, DOI 10.1093/oxfordjournals.aje.a116732; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAY JC, 1996, P251130 US BUR CENS; DIEHL AK, 1989, ADV INTERNAL MED, V34, P79; DIEZROUX AV, 1995, AM J EPIDEMIOL, V141, P960, DOI 10.1093/oxfordjournals.aje.a117363; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FINUCANE TE, 1990, J GEN INTERN MED, V5, P120, DOI 10.1007/BF02600511; FORTMANN SP, 1995, AM J EPIDEMIOL, V142, P576, DOI 10.1093/oxfordjournals.aje.a117678; FRANCO LJ, 1985, AM J EPIDEMIOL, V121, P684, DOI 10.1093/aje/121.5.684; FRANK E, 1992, JAMA-J AM MED ASSOC, V268, P1566, DOI 10.1001/jama.268.12.1566; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gidding SS, 1996, AM J CARDIOL, V78, P304, DOI 10.1016/S0002-9149(96)00282-2; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; Goff DC, 1997, CIRCULATION, V95, P1433; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAFFNER SM, 1993, HYPERTENSION, V21, P83, DOI 10.1161/01.HYP.21.1.83; HAMMAN RF, 1989, AM J EPIDEMIOL, V129, P295, DOI 10.1093/oxfordjournals.aje.a115134; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; HENDEE WR, 1991, JAMA-J AM MED ASSOC, V265, P248; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KAUTZ JA, 1981, CIRCULATION, V64, P730, DOI 10.1161/01.CIR.64.4.730; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KELSEY JL, 1986, METHODS OBSERVATIONA; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMANYIKA SK, 1993, ANN INTERN MED, V119, P650, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00005; LIAO Y, 1995, PUBLIC HEALTH REP, V110, P572; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LUEPKER RV, 1993, CIRCULATION, V88, P2172, DOI 10.1161/01.CIR.88.5.2172; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MARIN G, 1993, PUBLIC HEALTH REP, V108, P546; MARMOT MG, 1986, LANCET, V2, P274; MARTIN DC, 1993, STAT MED, V12, P329, DOI 10.1002/sim.4780120315; MCDOWELL A, 1981, VITAL HLTH STAT, V1; MILLER HW, 1977, VITAL HLTH STAT, V1; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; Molina C, 1994, LATINO HLTH US GROWI, P23; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; *NAT HEART LUNG BL, 1995, C SOC STAT CARD HLTH; NAUMBURG EH, 1993, J FAM PRACTICE, V36, P425; *PHS, 1990, DHHS PUBL; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PUGH JA, 1988, J GEN INTERN MED, V3, P331, DOI 10.1007/BF02595790; Ramirez AG, 1996, PUBLIC HEALTH REP, V111, P25; REESE JW, 1977, HEW CDC PUBLICATION; REYNES JF, 1993, AM J PREV MED, V9, P365, DOI 10.1016/S0749-3797(18)30689-5; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SORLIE PD, 1993, JAMA-J AM MED ASSOC, V270, P2464, DOI 10.1001/jama.270.20.2464; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; Stafford RS, 1997, J AM COLL CARDIOL, V29, P139, DOI 10.1016/S0735-1097(96)00441-X; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Syme SL, 1996, ANN EPIDEMIOL, V6, P463, DOI 10.1016/S1047-2797(96)00097-X; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEPT HHS, 1989, DHHS PUBL, pCH6; VEGA WA, 1994, ANNU REV PUBL HEALTH, V15, P39, DOI 10.1146/annurev.pu.15.050194.000351; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENNEKER MB, 1987, JAMA-J AM MED ASSOC, V261, P253; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; Winkleby MA, 1997, ANN EPIDEMIOL, V7, pS96, DOI 10.1016/S1047-2797(97)80012-9; Winkleby MA, 1997, J CLIN EPIDEMIOL, V50, P645, DOI 10.1016/S0895-4356(97)00020-6; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winkleby MA, 1996, PREV MED, V25, P203, DOI 10.1006/pmed.1996.0047	87	438	441	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					356	362		10.1001/jama.280.4.356	http://dx.doi.org/10.1001/jama.280.4.356			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	100FC	9686553	Bronze			2022-12-24	WOS:000074804200036
J	Nightingale, SL				Nightingale, SL			Proposal published on dissemination of information on unapproved uses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-24	WOS:000074379400005
J	Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC				Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC			p115 RhoGEF, a GTPase activating protein for G alpha(12) and G alpha(13)	SCIENCE			English	Article							ALPHA-SUBUNITS; DBL FAMILY; PURIFICATION; INHIBITION; CLONING; CELLS; RGS4	Members of the regulators of G protein signaling (RGS) family stimulate the intrinsic guanosine triphosphatase (GTPase) activity of the alpha subunits of certain heterotrimeric guanine nucleotide-binding proteins (G proteins). The guanine nucleotide exchange factor (GEF) for Rho, p115 RhoGEF, has an amino-terminal region with similarity to RGS proteins. Recombinant p115 RhoGEF and a fusion protein containing the amino terminus of p115 had specific activity as GTPase activating proteins toward the alpha subunits of the G proteins G(12) and G(13), but not toward members of the G(s), G(i), or G(q) subfamilies of G alpha proteins. This GEF may act as an intermediary in the regulation of Rho proteins by G(13) and G(12).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kozasa, T (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	tohru.kozasa@email.swmed.edu; bollag@onyx-pharm.com; slernwei@utsw.swmed.edu		Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; INGI T, IN PRESS J NEUROSCI; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KOZASA T, UNPUB; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	35	709	717	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2109	2111		10.1126/science.280.5372.2109	http://dx.doi.org/10.1126/science.280.5372.2109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641915				2022-12-24	WOS:000074435900043
J	Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A				Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A			Complementation cloning of NEMO, a component of the I kappa B kinase complex essential for NF-kappa B activation	CELL			English	Article							VIRUS TYPE-I; RAT FIBROBLASTS; TAX PROTEIN; EXPRESSION; PATHWAY	We have characterized a flat cellular variant of HTLV-1 Tax-transformed rat fibroblasts, 5R, which is unresponsive to all tested NF-kappa B activating stimuli, and we report here its genetic complementation. The recovered full-length cDNA encodes a 48 kDa protein, NEMO (NF-kappa B Essential MOdulator), which contains a putative leucine zipper motif. This protein is absent from 5R cells, is part of the high molecular weight I kappa B kinase complex, and is required for its formation. In vitro, NEMO can homodimerize and directly interacts with IKK-2. The NEMO cDNA was also able to complement another NF-kappa B-unresponsive cell line, 1.3E2, in which the protein is also absent, allowing us to demonstrate that this factor is required not only for Tax but also for LPS, PMA, and IL-1 stimulation of NF-kappa B activity.	Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, F-75724 Paris 15, France; Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS, URA 1773, F-75724 Paris, France; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; British Columbia Cancer Agency; Kyoto University	Yamaoka, S (corresponding author), Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.		, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595; Weil, Robert/0000-0001-5235-0932				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	917	965	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1231	1240		10.1016/S0092-8674(00)81466-X	http://dx.doi.org/10.1016/S0092-8674(00)81466-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657155	Bronze			2022-12-24	WOS:000074491100017
J	Wainberg, MA; Friedland, G				Wainberg, MA; Friedland, G			Public health implications of antiretroviral therapy and HIV drug resistance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ZIDOVUDINE-RESISTANCE; HETEROSEXUAL TRANSMISSION; TYPE-1 RNA; IN-VIVO; SEROPOSITIVE INDIVIDUALS; GENITAL SECRETIONS; SEMINAL PLASMA; INFECTION	Widespread use of antiretroviral agents and increasing occurrence of human immunodeficiency virus (HIV) strains resistant to these drugs have given rise to a number of important issues. Some of these concerns are distinct from the obvious question of the relationship between drug resistance and treatment failure and have potentially widespread public health implications. The relevant issues include but are not limited to the following. (1) frequency with which drug-resistant virus may be transmitted via sexual, intravenous, or mother-to-child routes; (2) ability of drug-resistant variants to be transmitted, a question that relates, in part, to the relative fitness of such strains; (3) effectiveness of antiviral therapy in diminishing viral burden in both blood and genital secretions, and whether this may be compromised in persons harboring resistant virus; and (4) importance of patient adherence to antiviral therapy and its relationship to sustained reduction in viral load to minimize the appearance in and transmission of drug-resistant virus from both blood and genital secretions. Thus, prevention of both development of HIV drug resistance as well as transmission of drug-resistant variants is a central issue of public: health importance. Unless this topic is appropriately addressed, the likelihood is that drug-resistant variants of HIV, if able to successfully replicate, will sustain the epidemic and limit the effectiveness of antiviral therapy.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; Yale Univ, Sch Med, AIDS Program, New Haven, CT USA	McGill University; Yale University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdwa@musica.mcgill.ca						Albrecht H, 1998, AIDS, V12, P333; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bayer R, 1997, IMPLICATIONS OF ANTIRETROVIRAL TREATMENTS, P95; BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121; Byrn RA, 1997, LANCET, V350, P1141, DOI 10.1016/S0140-6736(97)24042-0; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P468; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; COLGROVE R, 1998, 5 C RETR OPP INF CHI; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONWAY B, 1997, INT WORKSH HIV DRUG; CONWAY B, 1996, 3 INT C DRUG THER HI; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; CORELLI RL, 1991, DICP ANN PHARMAC, V25, P1374; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEEKS S, 1998, 5 C RETR OPP INF CHI; Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998; DEOLIVEIRA CF, 1998, 5 C RETR OPP INF CHI; deRonde A, 1996, AIDS, V10, P231, DOI 10.1097/00002030-199602000-00017; Doyon L, 1996, J VIROL, V70, P3763, DOI 10.1128/JVI.70.6.3763-3769.1996; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERON J, 1998, 5 C RETR OPP INF CHI; EVANS JS, 1998, 5 C RETR OPP INF CHI; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; GRIFFITH S, 1990, BRIT J GEN PRACT, V40, P114; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HART C, 1998, 5 C RETR OPP INF CHI; Haynes R. B., 1979, COMPLIANCE HLTH CARE; Haynes RB, 1996, LANCET, V348, P383; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOESLEY C, 1998, 5 C RETR OPP INF CHI; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KATZENSTEIN DA, 1992, J ACQ IMMUN DEF SYND, V5, P107; Kotler DP, 1998, AIDS, V12, P597, DOI 10.1097/00002030-199806000-00008; KRAVCIK S, 1998, 5 C RETR OPP INF CHI; KROODSMA KL, 1994, J INFECT DIS, V170, P1292, DOI 10.1093/infdis/170.5.1292; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LENNOX J, 1997, 4 C RETR OPP INF WAS; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MAYERS D, 1997, INT WORKSH HIV DRUG; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER JSG, 1995, ANN INTERN MED, V123, P561, DOI 10.7326/0003-4819-123-8-199510150-00001; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MOORE RD, 1997, 37 INT C ANT AG CHEM; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUMA RD, 1995, AIDS CARE, V7, P439, DOI 10.1080/09540129550126399; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; NIJHUIS M, 1997, INT WORKSH HIV DRUG; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; POMERANTZ R, 1998, 5 C RETR OPP INF CHI; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; Quigg M, 1997, AIDS, V11, P835; Ragni MV, 1998, J ACQ IMMUN DEF SYND, V17, P42, DOI 10.1097/00042560-199801010-00006; RASHEED S, 1995, J REPROD MED, V40, P747; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; Sackett DL, 1979, COMPLIANCE HLTH CARE; SALOMON H, 1995, ANTIVIR CHEM CHEMOTH, V6, P222, DOI 10.1177/095632029500600404; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; UVIN CU, 1998, 5 C RETR OPP INF CHI; VERNAZZA L, 1998, 5 C RETR OPP INF CHI; Vernazza PL, 1996, J VIROL METHODS, V56, P33, DOI 10.1016/0166-0934(95)01899-9; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; VUTHIPONGSE P, 1998, MMWR-MORBID MORTAL W, V47, P151; WAHLBERG J, 1994, J INFECT DIS, V169, P611, DOI 10.1093/infdis/169.3.611; WAINBERG M, 1996, 3 INT C DRUG THER HI; WALL TL, 1995, DRUG ALCOHOL DEPEN, V37, P261, DOI 10.1016/0376-8716(94)01080-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Williams A, 1997, AIDS Clin Care, V9, P51; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu C, 1997, J INFECT DIS, V176, P941, DOI 10.1086/516539; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	110	375	388	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1977	1983		10.1001/jama.279.24.1977	http://dx.doi.org/10.1001/jama.279.24.1977			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643862				2022-12-24	WOS:000074252100035
J	Geiger, H; Sick, S; Bonifer, C; Muller, AM				Geiger, H; Sick, S; Bonifer, C; Muller, AM			Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts	CELL			English	Article							YOLK-SAC; DEVELOPMENTAL REGULATION; EMBRYO; MICE; FETUSES; REGION; LOCUS; SPLANCHNOPLEURA; DIFFERENTIATION; CULTURE	To elucidate whether the differentiation capacity of hematopoietic stem cells (HSCs) is influenced by specific microenvironments, adult mouse bone marrow-derived HSCs were injected into mouse blastocysts. Embryos developing from injected blastocysts contained donor-derived cells at various developmental stages, and progeny of the stem cells were detected in hematopoietic tissues. Thus, HSCs derived from an adult animal survive after injection into blastocysts and are able to participate in hematopoietic development. We further find that the erythroid progeny of transplanted adult HSCs express embryonic/fetal-type globin genes and, conversely, that embryonic and fetal progenitor cells transplanted into adult recipients transcribe the adult-type globin gene. Thus, the developmental potential of adult HSCs is evidently more plastic than previously thought, and the developmental stage of the hematopoietic microenvironment controls the developmental fate of transplanted progenitor cells.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Max Planck Society; University of Freiburg	Muller, AM (corresponding author), Max Planck Inst Immunobiol, D-79108 Freiburg, Germany.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BLANCHET JP, 1982, DEV GENET, V3, P197, DOI 10.1002/dvg.1020030303; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Faust N, 1997, EXP HEMATOL, V25, P432; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; FLEISCHMAN RA, 1984, J EXP MED, V159, P731, DOI 10.1084/jem.159.3.731; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Herzenberg L. A., 1992, ANN N Y ACAD SCI, V651, P1, DOI 10.1111/j.1749-6632.1992.tb24588.x; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LANSDORP PM, 1994, BLOOD CELLS, V20, P376; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1971, HAEMOPOIETIC CELLS, P172; MORRIS L, 1991, DEVELOPMENT, V112, P517; MOUCHIROUD G, 1981, BLOOD, V57, P586; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OKADA S, 1992, BLOOD, V80, P3044; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; Tanosaki R, 1997, BRIT J HAEMATOL, V98, P1017, DOI 10.1046/j.1365-2141.1997.2983115.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; VanZant G, 1997, EXP HEMATOL, V25, P187; WEISSMAN IL, 1976, COLD SPRING HARB SYM, V41, P9, DOI 10.1101/SQB.1977.041.01.005; Yoder MC, 1997, P NATL ACAD SCI USA, V94, P6776, DOI 10.1073/pnas.94.13.6776; ZANJANI ED, 1982, NATURE, V295, P244, DOI 10.1038/295244a0	45	105	112	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1055	1065		10.1016/S0092-8674(00)81210-6	http://dx.doi.org/10.1016/S0092-8674(00)81210-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635434	Bronze			2022-12-24	WOS:000074205700016
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Evolution of indirect reciprocity by image scoring	NATURE			English	Article							TIT-FOR-TAT; PRISONERS-DILEMMA; COOPERATION	Darwinian evolution has to provide an explanation for cooperative behaviour. Theories of cooperation are based on kin selection (dependent on genetic relatedness)(1,2), group selection(3-5) and reciprocal altruism(6-9). The idea of reciprocal altruism usually involves direct reciprocity: repeated encounters between the same individuals allow for the return of an altruistic act by the recipient(10-16). Here we present a new theoretical framework, which is based on indirect reciprocity(17) and does not require the same two individuals ever to meet again, individual selection can nevertheless favour cooperative strategies directed towards recipients that have helped others in the past. Cooperation pays because it confers the image of a valuable community member to the cooperating individual. We present computer simulations and analytic models that specify the conditions required for evolutionary stability(18) of indirect reciprocity. We show that the probability of knowing the 'image' of the recipient must exceed the cost-to-benefit ratio of the altruistic act. We propose that the emergence of indirect reciprocity was a decisive step for the evolution of human societies.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Vienna, Inst Math, A-1090 Vienna, Austria	University of Oxford; University of Vienna	Nowak, MA (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	martin.nowak@zoo.ox.ac.uk	Nowak, Martin A/A-6977-2008					Alexander R., 2008, ESSAYS PEDAGOGY; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Binmore K., 1992, FUN GAMES TEXT GAME; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI 10.1515/9781400858712; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; ESHEL I, 1972, THEOR POPUL BIOL, V3, P258, DOI 10.1016/0040-5809(72)90003-2; FRANK SA, 1995, J THEOR BIOL, V176, P403, DOI 10.1006/jtbi.1995.0208; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hofbauer J., 1998, EVOLUTIONARY GAMES P; Krebs J.R., 1987, BEHAV ECOL, Vsecond; Marler P, 1996, IBIS, V138, P26; MAY RM, 1987, NATURE, V327, P15, DOI 10.1038/327015a0; Maynard Smith J., 1982, pi; Michod R.E., 1985, P95; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; NOWAK MA, UNPUB J THEOR BIOL; PECK JR, 1986, AM NAT, V127, P209, DOI 10.1086/284479; POLLOCK G, 1992, J THEOR BIOL, V159, P25, DOI 10.1016/S0022-5193(05)80765-9; Sudgen R, 1986, EC RIGHTS COOPERATIO; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Williams G.C., 1971, GROUP SELECTION; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; Wilson E.O., 1975, P1; Zahavi Amotz, 1997, HANDICAP PRINCIPLE M	30	1517	1557	8	289	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					573	577		10.1038/31225	http://dx.doi.org/10.1038/31225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634232				2022-12-24	WOS:000074150100051
J	Selwyn, PA				Selwyn, PA			Prospects for improvement in physicians' communication skills and in prevention of HIV infection	LANCET			English	Editorial Material									Yale Univ, Sch Med, AIDS Program, New Haven, CT 06510 USA	Yale University	Selwyn, PA (corresponding author), Yale Univ, Sch Med, AIDS Program, 333 Cedar St, New Haven, CT 06510 USA.							[Anonymous], AIDS BEHAV; Epstein RM, 1998, ANN INTERN MED, V128, P435, DOI 10.7326/0003-4819-128-6-199803150-00003; Fallowfield L, 1998, J CLIN ONCOL, V16, P1961, DOI 10.1200/JCO.1998.16.5.1961; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MCKUSKER J, 1994, DRUG ALCOHOL DEPEN, V34, P129; Stein MD, 1998, ARCH INTERN MED, V158, P253, DOI 10.1001/archinte.158.3.253	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					506	506		10.1016/S0140-6736(05)79247-3	http://dx.doi.org/10.1016/S0140-6736(05)79247-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716053				2022-12-24	WOS:000075435300007
J	Geiger, H; Naraghi, R; Schobel, HP; Frank, H; Sterzel, RB; Fahlbusch, R				Geiger, H; Naraghi, R; Schobel, HP; Frank, H; Sterzel, RB; Fahlbusch, R			Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension	LANCET			English	Article							NITRIC-OXIDE; NEUROVASCULAR COMPRESSION; BRAIN-STEM; OBLONGATA; RATS	Background About 20% of adults worldwide will develop hypertension. Studies and clinical observations suggest an association between hypertension and pulsatile compression of the ventrolateral medulla oblongata by a looping artery. We investigated whether neurosurgical microvascular decompression substantially decreases blood pressure long-term in patients with severe essential hypertension. Methods We included eight patients who had received three or more antihypertensive drugs without adequate control of blood pressure, intolerable side-effects, or both. All patients underwent microvascular decompression at the root-entry zone of cranial nerves IX and X after neurovascular compression of the ventrolateral medulla oblongata was seen on magnetic-resonance angiography. Findings 3 months after surgery, blood pressure and antihypertensive regimens had decreased substantially in three patients. Four patients who were followed up for more than 1 year became normotensive, but their antihypertensive regimens remained the same as those at 3 months. One patient did not improve. No complications associated with decompression occurred. One patient experienced a transient vocal-cord paresis after the laryngeal part of the vagus nerve was manoeuvered during surgery. Interpretation We showed a direct causal relation between raised blood pressure and irritation of cranial nerves IX and X. A subgroup of patients with essential hypertension may exist who have secondary forms of hypertension related to neurovascular compression at the ventrolateral medulla and who may be successfully treated with decompression.	Univ Frankfurt, Dept Internal Med 4, Div Nephrol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Clin Neurosurg, D-8520 Erlangen, Germany; Univ Erlangen Nurnberg, Med Clin 4, D-8520 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Geiger, H (corresponding author), Univ Frankfurt, Dept Internal Med 4, Div Nephrol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Naraghi, Ramin/0000-0003-3643-791X				AKIMURA T, 1995, AM J NEURORADIOL, V16, P401; CHALMERS J, 1991, J HYPERTENS, V9, P675, DOI 10.1097/00004872-199108000-00001; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GRANATA A, 1985, AM J PHYSIOL, V17, pH547; HANSEN J, 1994, HYPERTENSION, V24, P439, DOI 10.1161/01.HYP.24.4.439; Hirooka Y, 1996, J HYPERTENS, V14, P1317, DOI 10.1097/00004872-199611000-00010; JANNETTA PJ, 1985, ANN SURG, V202, P253, DOI 10.1097/00000658-198508000-00018; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; Morimoto S, 1997, HYPERTENSION, V29, P514, DOI 10.1161/01.HYP.29.1.514; Morimoto S, 1997, HYPERTENSION, V30, P77, DOI 10.1161/01.HYP.30.1.77; NARAGHI R, 1994, LANCET, V344, P1466, DOI 10.1016/S0140-6736(94)90289-5; NARAGHI R, 1992, J NEUROSURG, V77, P103, DOI 10.3171/jns.1992.77.1.0103; PALKOVITS M, 1995, CLIN EXP HYPERTENS, V17, P101, DOI 10.3109/10641969509087058; Tseng CJ, 1996, HYPERTENSION, V27, P36, DOI 10.1161/01.HYP.27.1.36; TSUCHIHASHI T, 1994, HYPERTENSION, V24, P648, DOI 10.1161/01.HYP.24.6.648; Yamamoto I, 1991, Neurol Med Chir (Tokyo), V31, P1, DOI 10.2176/nmc.31.1	16	88	92	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					446	449		10.1016/S0140-6736(97)11343-5	http://dx.doi.org/10.1016/S0140-6736(97)11343-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708753				2022-12-24	WOS:000075252000012
J	Stern, S; Altkorn, D; Levinson, W				Stern, S; Altkorn, D; Levinson, W			Detection of prostate and colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN; SERUM		Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Dept Med, Gen Internal Med Sect, 5841 S Maryland,MC 6098, Chicago, IL 60637 USA.	wendy@medicine.bsd.uchicago.edu						Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; Coley CM, 1997, ANN INTERN MED, V126, P480; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Helfand M, 1997, JAMA-J AM MED ASSOC, V277, P44, DOI 10.1001/jama.277.1.44; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; Smart CR, 1997, CANCER, V80, P1835, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1835::AID-CNCR23>3.0.CO;2-5; US Preventive Services Task Force, 1998, GUID CLIN PREV SERV; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46; vonEschenbach A, 1997, CANCER, V80, P1805, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1805::AID-CNCR17>3.3.CO;2-8; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					117	118		10.1001/jama.280.2.117	http://dx.doi.org/10.1001/jama.280.2.117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669770				2022-12-24	WOS:000074608400001
J	Kahn, J				Kahn, J			Success and sadness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					89	89		10.1001/jama.280.1.89	http://dx.doi.org/10.1001/jama.280.1.89			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660370				2022-12-24	WOS:000074379400030
J	Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD				Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD		Bangkok Collaborative Perinatal HIV Transmissi	HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	10th International Conference on AIDS	AUG 07-12, 1994	YOKOHAMA, JAPAN				HUMAN-IMMUNODEFICIENCY-VIRUS; TO-MALE TRANSMISSION; YOUNG MEN; NORTHERN THAILAND; INFECTION; FEMALE	Context.-Most prior studies of the human immunodeficiency virus (H[V) epidemic in Thailand have focused on commercial sex encounters; however, because the epidemic increasingly concerns stable heterosexual relationships, determining risk factors for this form of transmission is warranted. Objectives.-To determine temporal trends in HIV prevalence, risk factors for H[V seropositivity, and rates of partner serodiscordance for pregnant women in Bangkok, Thailand. Design.-Retrospective review of hospital antenatal clinic HIV test results from 1991 through 1996. Baseline demographic and behavioral risk factors for HIV were assessed for subjects enrolled from November 1992 through March 1994. Setting.-Two Bangkok hospitals with routine antenatal clinic HIV counseling and testing. Participants.-The HIV-positive pregnant women enrolled in a perinatal HIV transmission study and their partners and HIV-negative pregnant controls. Results.-From 1991 through 1996, antenatal clinic HIV seroprevalence increased from 1.0% to 2.3%. On multivariate analysis of data from 342 HIV-positive and 344 HIV-negative pregnant women, more than 1 lifetime sex partner, history of a sexually transmitted disease, and a high-risk sex partner were the most important factors for seropositivity tall P<.001). Twenty-six percent of partners of HIV-positive women were HIV negative. Women reporting more than 1 lifetime sex partner were more likely to have an HIV-negative partner than women reporting only 1 (45% vs 8%; relative risk, 5.5; 95% confidence interval, 3.2-9.5; P<.001); women reporting no high-risk behaviors were less likely to have an H[V-negative partner (10% vs 44%; relative risk, 0.2; 95% confidence interval, 0.1-0.4; P<.001). Conclusions.-Prevalence of HIV in pregnant women has increased steadily in Bangkok from 1991 through 1996, Sex with current partners was the only identified risk exposure for about half (52%) of the HIV-positive women. Although few HIV-positive pregnant women reported high-risk behaviors, more than 1 lifetime partner and a partner with high-risk behavior were strong risk factors for seropositivity. Together with the unexpected finding that one fourth of partners of seropositive pregnant women were seronegative, these data emphasize that women in the general population are at risk for HIV because of the risk behavior of both current and previous partners.	Minist Publ Hlth, HIV AIDS Collaborat, Nonthaburi 11000, Thailand; Minist Publ Hlth, Rajavithi Hosp, Bangkok, Thailand; Ctr Dis Control & Prevent, Atlanta, GA USA; Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand; Minist Publ Hlth, Childrens Hosp, Dept Med Serv, Bangkok, Thailand	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Rajavithi Hospital; Centers for Disease Control & Prevention - USA; Mahidol University; Ministry of Public Health - Thailand	Shaffer, N (corresponding author), Minist Publ Hlth, HIV AIDS Collaborat, DMS 6 Bldg,Tivanon Rd, Nonthaburi 11000, Thailand.	nas4@cdc.gov		Weniger, Bruce/0000-0002-5450-5464				ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; DEVINCENZI I, 1992, BRIT MED J, V304, P809; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Manopaiboon C, 1998, J ACQ IMMUN DEF SYND, V18, P54, DOI 10.1097/00042560-199805010-00009; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MASTRO TD, 1995, AIDS, V9, P523; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; SHAFFER N, 1996, 11 INT C AIDS JUL 7; Sirisopana N, 1996, J ACQ IMMUN DEF SYND, V11, P492, DOI 10.1097/00042560-199604150-00010; SITTITRAI W, 1994, AIDS, V8, pS143; SITTITRAI W, 1992, REPORT 1990 SURVEY P, P33; *THAIL MIN PUBL HL, 1996, RESULTS 14 ROUND HIV; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P225; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P237; UNGEHUSAK K, 1995, THAI AIDS J, V7, P177; UNGEHUSAK K, 1996, J ACQ IMMUN DEF SYND, V12, P500; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	29	58	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					49	54		10.1001/jama.280.1.49	http://dx.doi.org/10.1001/jama.280.1.49			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZW145	9660363	Bronze			2022-12-24	WOS:000074379400023
J	Walker, BD; Basgoz, N				Walker, BD; Basgoz, N			Treat HIV-1 infection like other infections - Treat it	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-LYMPHOCYTES; IN-VIVO		Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	bwalker@helix.mgh.harvard.edu						Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CURRIER JS, 1998, 5 C RETR OPP INF FEB; DEEKS S, 1998, JAMA-J AM MED ASSOC, V27, P1343; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; MILLER K, IN PRESS CLIN INFECT; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Spruance SL, 1997, ANN INTERN MED, V126, P355, DOI 10.7326/0003-4819-126-5-199703010-00003; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	21	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					91	93		10.1001/jama.280.1.91	http://dx.doi.org/10.1001/jama.280.1.91			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660371				2022-12-24	WOS:000074379400031
J	Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA				Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA			A 9 angstrom resolution x-ray crystallographic map of the large ribosomal subunit	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; PROTEIN; CRYSTALLIZATION; REFINEMENT; EXTENSION; PARTICLES; SYMMETRY	The 50S subunit of the ribosome catalyzes the peptidyl-transferase reaction of protein synthesis. We have generated X-ray crystallographic electron density maps of the large ribosomal subunit from Haloarcula marismortui at various resolutions up to 9 Angstrom using data from crystals that diffract to 3 Angstrom. Positioning a 20 Angstrom resolution EM image of these particles in the crystal lattice produced phases accurate enough to locate the bound heavy atoms in three derivatives using difference Fourier maps, thus demonstrating the correctness of the EM model and its placement in the unit cell. At 20 Angstrom resolution, the X-ray map is similar to the EM map; however, at 9 Angstrom it reveals long, continuous, but branched features whose shape, diameter, and right-handed twist are consistent with segments of double-helical RNA that crisscross the subunit.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009; Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628	NIGMS NIH HHS [GM-22778, GM-29169, GM-54216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BECKMANN R, 1997, BOTT, V278, P2123; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1997, METHOD ENZYMOL, V276, P558, DOI 10.1016/S0076-6879(97)76078-6; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V13, P458; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Dube P, 1998, STRUCTURE, V6, P389, DOI 10.1016/S0969-2126(98)00040-9; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENSTEIN M, 1994, BIOPHYSICAL METHODS, P213; FRANCESCHI F, 1993, TRANSLATIONAL APPARATUS, P397; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HUBER R, 1985, MOL REPLACEMENT, P58; JACK A, 1975, J MOL BIOL, V97, P163, DOI 10.1016/S0022-2836(75)80032-5; KNALEIN J, 1997, J MOL BIOL, V270, P1; LADENSTEIN R, 1987, J MOL BIOL, V195, P751, DOI 10.1016/0022-2836(87)90196-3; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LEONARD KR, 1979, J MOL BIOL, V128, P155; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MALHOTRA A, 1998, IN PRESS J MOL BIOL; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Neuefeind T, 1997, BIOL CHEM, V378, P219; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Podjarny AD, 1997, METHOD ENZYMOL, V276, P641, DOI 10.1016/S0076-6879(97)76084-1; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; ROSSMANN MG, 1995, CURR OPIN STRUC BIOL, V5, P650, DOI 10.1016/0959-440X(95)80058-1; Schlunzen F, 1995, BIOCHEM CELL BIOL, V73, P739, DOI 10.1139/o95-082; SHEVACK A, 1985, FEBS LETT, V184, P68, DOI 10.1016/0014-5793(85)80655-4; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; Thygesen J, 1996, STRUCTURE, V4, P513, DOI 10.1016/S0969-2126(96)00057-3; VANBOHLEN K, 1991, J MOL BIOL, V222, P11; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1996, RIBOSOMAL RNA STRUCT, P23; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH AE, 1980, BIOCHEM INT, V1, P428; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845	56	211	222	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1105	1115		10.1016/S0092-8674(00)81455-5	http://dx.doi.org/10.1016/S0092-8674(00)81455-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657144	hybrid			2022-12-24	WOS:000074491100006
J	Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM				Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM			Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila	CELL			English	Article							MACHADO-JOSEPH DISEASE; PROGRAMMED CELL-DEATH; SPINOCEREBELLAR ATAXIA; CAG EXPANSIONS; GENE; EXPRESSION; RETINA; EYE; DIFFERENTIATION; MELANOGASTER	Spinocerebellar ataxia type 3 (SCA3/MJD) is one of at least eight human neurodegenerative diseases caused by glutamine-repeat expansion. We have recreated glutamine-repeat disease in Drosophila using a segment of the SCA3/MJD protein. Targeted expression of the protein with an expanded polyglutamine repeat led to nuclear inclusion (NI) formation and late-onset cell degeneration. Differential sensitivity to the mutant transgene was observed among different cell types, with neurons being particularly susceptible; NI formation alone was not sufficient for degeneration. The viral antiapoptotic gene P35 mitigated polyglutamine-induced degeneration in vivo. Our results demonstrate that cellular mechanisms of human glutamine-repeat disease are conserved in invertebrates. This fly model will aid in identifying additional factors that modulate neurodegeneration.	Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Iowa	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA.			Bonini, Nancy/0000-0003-0226-5291				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RANUM LPW, 1995, AM J HUM GENET, V57, P603; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wolff Tanya, 1993, P1277; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	40	506	523	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					939	949		10.1016/S0092-8674(00)81200-3	http://dx.doi.org/10.1016/S0092-8674(00)81200-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635424	hybrid			2022-12-24	WOS:000074205700006
J	Yoshioka, H; Meno, C; Koshiba, K; Sugihara, M; Itoh, H; Ishimaru, Y; Inoue, T; Ohuchi, H; Semina, EV; Murray, JC; Hamada, H; Noji, S				Yoshioka, H; Meno, C; Koshiba, K; Sugihara, M; Itoh, H; Ishimaru, Y; Inoue, T; Ohuchi, H; Semina, EV; Murray, JC; Hamada, H; Noji, S			Pitx2, a bicoid-type homeobox gene, is involved in a lefty-signaling pathway in determination of left-right asymmetry	CELL			English	Article							RETROVIRAL VECTORS; EXPRESSION; MOUSE	Signaling molecules such as Activin, Sonic hedgehog, Nodal, Lefty, and Vg1 have been found to be involved in determination of left-right (L-R) asymmetry in the chick, mouse, or frog. However, a common signaling pathway has not yet been identified in vertebrates. We report that Pitx2, a bicoid-type homeobox gene expressed asymmetrically in the left lateral plate mesoderm, may be involved in determination of L-R asymmetry in both mouse and chick. Since Pitx2 appears to be downstream of lefty-1 in the mouse pathway, we examined whether mouse Lefty proteins could affect the expression of Pitx2 in the chick. Our results indicate that a common pathway from lefty-1 to Pitx2 likely exists for determination of L-R asymmetry in vertebrates.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Osaka Univ, Inst Mol & Cellular Biol, Osaka 5650871, Japan; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA; Kyoto Univ, Grad Sch, Fac Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Tokushima University; Osaka University; University of Iowa; University of Iowa; Kyoto University	Noji, S (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, 2-1 Minami Jyosanjima Cho, Tokushima 7708506, Japan.		Noji, Sumihare/E-3047-2010; Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948				Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hummel K. P., 1959, Journal of Heredity, V50, P9; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Kuwana T, 1996, INT J DEV BIOL, V40, P1061; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; NOHNO T, 1995, BIOCHEM BIOPH RES CO, V206, P33, DOI 10.1006/bbrc.1995.1005; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	25	308	311	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					299	305		10.1016/S0092-8674(00)81473-7	http://dx.doi.org/10.1016/S0092-8674(00)81473-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708732	Bronze			2022-12-24	WOS:000075308400006
J	Lenton, TM				Lenton, TM			Gaia and natural selection	NATURE			English	Review							ATMOSPHERIC SULFUR; BIOTIC ENHANCEMENT; EARTHS ATMOSPHERE; MASS EXTINCTIONS; DIMETHYL SULFIDE; NUMERICAL-MODEL; FOSSIL RECORD; CLOUD ALBEDO; CLIMATE; HYPOTHESIS	Evidence indicates that the Earth self-regulates at a state that Is tolerated by rife, but why should the organisms that leave the most descendants be the ones that contribute to regulating their planetary environment? The evolving Gaia theory focuses on the feedback mechanisms, stemming from naturally selected traits of organisms, that could generate such self-regulation.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Lenton, TM (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.		Lenton, Tim M/X-1893-2018	Lenton, Tim M/0000-0002-6725-7498				ALVAREZ W, 1984, SCIENCE, V223, P1135, DOI 10.1126/science.223.4641.1135; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; ANDREAE MO, 1986, ROLE AIR SEA EXCHANG, P331, DOI DOI 10.1007/978-94-009-4738-2_14; [Anonymous], GEOPHYS AMAZONIA VEG; AYERS GP, 1991, NATURE, V353, P834, DOI 10.1038/353834a0; Betts RA, 1997, NATURE, V387, P796, DOI 10.1038/42924; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; Brasseur G. P., 1991, TRACE GAS EMISSION P, P1; BUDYKO MI, 1969, TELLUS, V21, P611, DOI 10.3402/tellusa.v21i5.10109; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; CALDEIRA K, 1989, NATURE, V337, P732, DOI 10.1038/337732a0; Chapin FS, 1997, SCIENCE, V277, P500, DOI 10.1126/science.277.5325.500; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Darwin C., 1959, WHATS NEW, V67, P2; DAWKINS R, 1983, EXTENDED PHENOTYPE; DEDUVE C, 1995, VITAL DUST; Doolittle WF, 1981, COEVOLUTION Q, V29, P58; EHRLICH P, 1991, P19; Eisele FL, 1997, PHILOS T ROY SOC B, V352, P191, DOI 10.1098/rstb.1997.0014; Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0; FALKOWSKI PG, 1992, SCIENCE, V256, P1311, DOI 10.1126/science.256.5061.1311; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; Gage DA, 1997, NATURE, V387, P891, DOI 10.1038/43160; Gallimore RG, 1996, NATURE, V381, P503, DOI 10.1038/381503a0; Hamilton WD, 1998, ETHOL ECOL EVOL, V10, P1, DOI 10.1080/08927014.1998.9522867; Hamilton WD, 1996, NEW SCI, V151, P62; HAMILTON WD, 1995, J APPL ECOL, V32, P451, DOI 10.2307/2404643; Hansen J, 1996, GEOPHYS RES LETT, V23, P1665, DOI 10.1029/96GL01040; Harding SP, 1996, J THEOR BIOL, V182, P109, DOI 10.1006/jtbi.1996.0146; HARDING SP, UNPUB TELLUS; Hayes JM, 1994, NOBEL S, P220; HITCHCOCK DR, 1967, ICARUS, V7, P149, DOI 10.1016/0019-1035(67)90059-0; Holland H. D., 1978, CHEM ATMOSPHERE OCEA; Holland H.D., 1984, CHEM EVOLUTION ATMOS; Jackson T.A., 1970, AM J SCI, V269, P446, DOI [10.2475/ajs.269.5.446, DOI 10.2475/AJS.269.5.446]; KASTING JF, 1993, ICARUS, V101, P108, DOI 10.1006/icar.1993.1010; KEELING R, 1991, P118; KERR RA, 1988, SCIENCE, V240, P393, DOI 10.1126/science.240.4851.393; KIRCHNER JW, 1989, REV GEOPHYS, V27, P223, DOI 10.1029/RG027i002p00223; KLINGER L F, 1991, P247; KUMP IR, 1995, FUTURE CLIMATES WORL, P537; Laland KN, 1996, J EVOLUTION BIOL, V9, P293, DOI 10.1046/j.1420-9101.1996.9030293.x; LEGRAND M, 1991, NATURE, V350, P144, DOI 10.1038/350144a0; Legrand M, 1997, PHILOS T ROY SOC B, V352, P241, DOI 10.1098/rstb.1997.0019; Liss P.S., 1993, INTERACTIONS C N P S, P259, DOI [10.1007/978-3-642-76064-8_11, DOI 10.1007/978-3-642-76064-8_11]; Liss PS, 1997, PHILOS T R SOC B, V352, P159, DOI 10.1098/rstb.1997.0011; Lotka A. J., 1956, ELEMENTS MATH BIOL, DOI DOI 10.2307/1909476; Lovelock J, 1997, PHILOS T ROY SOC B, V352, P143, DOI 10.1098/rstb.1997.0009; Lovelock James., 1979, GAIA NEW LOOK LIFE E; Lovelock James, 1995, AGES GAIA; LOVELOCK JE, 1994, NATURE, V369, P732, DOI 10.1038/369732a0; LOVELOCK JE, 1973, NATURE, V241, P194, DOI 10.1038/241194a0; LOVELOCK JE, 1972, NATURE, V237, P452, DOI 10.1038/237452a0; LOVELOCK JE, 1974, TELLUS, V26, P2, DOI 10.1111/j.2153-3490.1974.tb01946.x; LOVELOCK JE, 1992, PHILOS T R SOC B, V338, P383, DOI 10.1098/rstb.1992.0156; LOVELOCK JE, 1982, PLANET SPACE SCI, V30, P795, DOI 10.1016/0032-0633(82)90112-X; LOVELOCK JE, 1974, ORIGINS LIFE EVOL B, V5, P93, DOI 10.1007/BF00927016; LOVELOCK JE, 1982, NATURE, V296, P561, DOI 10.1038/296561a0; LOVELOCK JE, 1986, B AM METEOROL SOC, V67, P392; LOVELOCK JE, 1990, NATURE, V344, P100, DOI 10.1038/344100a0; LOVELOCK JE, 1972, ATMOS ENVIRON, V6, P579, DOI 10.1016/0004-6981(72)90076-5; LOVELOCK JE, 1989, T RSE EARTH, V80, P169; LOVELOCK JE, 1989, REV GEOPHYS, V27, P215, DOI 10.1029/RG027i002p00215; LOVELOCK JE, 1975, PROC R SOC SER B-BIO, V189, P167, DOI 10.1098/rspb.1975.0051; LOVELOCK JE, 1965, NATURE, V207, P568, DOI 10.1038/207568a0; Lovelock JE, 1983, BIOMINERALIZATION BI, P15; Mackenzie F. T., 1993, INTERACTIONS C N P S, P1; MADDOCK L, 1991, TELLUS B, V43, P331, DOI 10.1034/j.1600-0889.1991.t01-2-00006.x; MARGULIS L, 1974, ICARUS, V21, P471, DOI 10.1016/0019-1035(74)90150-X; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; NEWMAN MJ, 1977, SCIENCE, V198, P1035, DOI 10.1126/science.198.4321.1035; OFFICER CB, 1987, NATURE, V326, P143, DOI 10.1038/326143a0; ORESKES N, 1994, SCIENCE, V263, P641, DOI 10.1126/science.263.5147.641; OttoBliesner BL, 1997, NATURE, V385, P804, DOI 10.1038/385804a0; PATTEN BC, 1981, AM NAT, V118, P886, DOI 10.1086/283881; RAMPINO MR, 1988, NATURE, V332, P63, DOI 10.1038/332063a0; RAMPINO MR, 1987, NATURE, V327, P468, DOI 10.1038/327468a0; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Ravishankara AR, 1997, PHILOS T ROY SOC B, V352, P171, DOI 10.1098/rstb.1997.0012; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; SAUNDERS PT, 1994, J THEOR BIOL, V166, P365, DOI 10.1006/jtbi.1994.1033; Schneider Stephen, 1984, COEVOLUTION CLIMATE; Schrodinger E, 1944, WHAT IS LIFE; SCHWARTZMAN DW, 1989, NATURE, V340, P457, DOI 10.1038/340457a0; SCHWARTZMAN DW, 1991, GLOBAL PLANET CHANGE, V90, P357; SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322; Smith J. M., 1995, MAJOR TRANSITIONS EV; STOCKER S, 1995, J THEOR BIOL, V175, P495, DOI 10.1006/jtbi.1995.0156; TURNER SM, 1988, LIMNOL OCEANOGR, V33, P364, DOI 10.4319/lo.1988.33.3.0364; vonBloh W, 1997, TELLUS B, V49, P249, DOI 10.1034/j.1600-0889.49.issue3.2.x; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6; WATSON AJ, 1983, TELLUS B, V35, P284, DOI 10.1111/j.1600-0889.1983.tb00031.x; WATSON AJ, 1996, GAIA ACTION SCI LIVI, P65; WATSON AJ, 1991, NEW SCI INSIDE SCI, V48, P1; Wayne, 1991, CHEM ATMOSPHERES INT; WHITFIELD M, 1981, INTERDISCIPL SCI REV, V6, P12; Wolfe GV, 1997, NATURE, V387, P894, DOI 10.1038/43168	99	184	193	3	141	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					439	447		10.1038/28792	http://dx.doi.org/10.1038/28792			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697767				2022-12-24	WOS:000075080400041
J	Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M				Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M			Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; MEN; POPULATIONS; IMPACT	Background Type 2 (non-insulin-dependent) diabetes is associated with a marked increase in the risk of coronary heart disease. It has been debated whether patients with diabetes who have not had myocardial infarctions should be treated as aggressively for cardiovascular risk factors as patients who have had myocardial infarctions. Methods To address this issue, we compared the seven-year incidence of myocardial infarction (fatal and nonfatal) among 1373 nondiabetic subjects with the incidence among 1059 diabetic subjects, all from a Finnish population-based study. Results The seven-year incidence rates of myocardial infarction in nondiabetic subjects with and without prior myocardial infarction at base line were 18.8 percent and 3.5 percent, respectively (P<0.001). The seven-year incidence rates of myocardial infarction in diabetic subjects with and without prior myocardial infarction at base line were 45.0 percent and 20.2 percent, respectively (P<0.001). The hazard ratio for death from coronary heart disease for diabetic subjects without prior myocardial infarction as compared with nondiabetic subjects with prior myocardial infarction was not significantly different from 1.0 (hazard ratio, 1.4; 95 percent confidence interval, 0.7 to 2.6) after adjustment for age and sex, suggesting similar risks of infarction in the two groups. After further adjustment for total cholesterol, hypertension, and smoking, this hazard ratio remained close to 1.0 (hazard ratio, 1.2; 95 percent confidence interval, 0.6 to 2.4). Conclusions Our data suggest that diabetic patients without previous myocardial infarction have as high a risk of myocardial infarction as nondiabetic patients with previous myocardial infarction. These data provide a rationale for treating cardiovascular risk factors in diabetic patients as aggressively as in nondiabetic patients with prior myocardial infarction. (N Engl J Med 1998;339:229-34.) (C) 1998, Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Turku Univ, Dept Med, Turku, Finland	University of Texas System; University of Texas Health San Antonio; University of Eastern Finland; University of Turku	Haffner, SM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Greiver, Michelle/N-8764-2015; Northe, Hilda/I-1916-2012	Greiver, Michelle/0000-0001-8957-0285; Northe, Hilda/0000-0002-8873-5014; Lehto, Seppo/0000-0003-0414-5285				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179; [Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1998, AM HEART ASS 38 ANN; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V209, P3015; Haffner SM, 1997, DIABETES CARE, V20, P469, DOI 10.2337/diacare.20.4.469; HERLITZ J, 1992, CARDIOLOGY, V80, P237, DOI 10.1159/000175008; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; LAAKSO M, 1995, DIABETOLOGIA, V38, P487, DOI 10.1007/s001250050310; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Pyorala K, 1997, DIABETES CARE, V20, P1048; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; Rosengren A, 1997, EUR HEART J, V18, P754; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Weinfeld, 1981, STROKE S1, V12, pI13; *WHO, 1983, PUBL WHO; Wingard DL., 1995, DIABETES AM, P429	26	4895	5116	0	193	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					229	234		10.1056/NEJM199807233390404	http://dx.doi.org/10.1056/NEJM199807233390404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673301	Bronze			2022-12-24	WOS:000074918700004
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			The heat is on!	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					368	369		10.1126/science.281.5375.368	http://dx.doi.org/10.1126/science.281.5375.368			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705715				2022-12-24	WOS:000074918800038
J	Greenberg, DS				Greenberg, DS			Of human poundage	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					158	158		10.1016/S0140-6736(98)85078-2	http://dx.doi.org/10.1016/S0140-6736(98)85078-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672320				2022-12-24	WOS:000074775100071
J	Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD				Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD			Activated RSC-nucleosome complex and persistently altered form of the nucleosome	CELL			English	Article							YEAST SWI/SNF COMPLEX; DNA; TRANSCRIPTION; BINDING; DISPLACEMENT; DISRUPTION; INITIATION; HISTONES; PROTEIN	RSC, an abundant, essential chromatin-remodeling complex, related to SWI/SNF complex, binds nucleosomes and naked DNA with comparable affinities, as shown by gel shift analysis. The RSC-nucleosome complex is converted in the presence of ATP to a slower migrating form. This activated complex exhibits greatly increased susceptibility to endo- and exonucleases but retains a full complement of histones. Activation persists in the absence of ATP, and on removal of RSC, the nucleosome is released in an altered form, with a diminished electrophoretic mobility, greater sedimentation rate, and marked instability at elevated ionic strength. The reaction is reversible in the presence of RSC and ATP, with conversion of the altered form back to the nucleosome.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LORCH Y, 1994, P NATL ACAD SCI USA, V91, P11032, DOI 10.1073/pnas.91.23.11032; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PRUNELL A, 1977, COLD SPRING HARB SYM, V42, P103, DOI 10.1101/SQB.1978.042.01.011; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	22	174	174	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					29	34		10.1016/S0092-8674(00)81218-0	http://dx.doi.org/10.1016/S0092-8674(00)81218-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674424	Bronze			2022-12-24	WOS:000074790800006
J	Ezekowitz, M				Ezekowitz, M			Antithrombotics for left-ventricular impairment?	LANCET			English	Editorial Material									Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA	Yale University	Ezekowitz, M (corresponding author), Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA.		Ezekowitz, Michael/AAJ-2543-2021					Al-Khadra AS, 1998, J AM COLL CARDIOL, V31, P749, DOI 10.1016/S0735-1097(98)00006-0; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; Loh E, 1997, NEW ENGL J MED, V336, P251, DOI 10.1056/NEJM199701233360403	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1904	1904		10.1016/S0140-6736(05)78610-4	http://dx.doi.org/10.1016/S0140-6736(05)78610-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654255	hybrid			2022-12-24	WOS:000074464700005
J	Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N				Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N			Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria	CELL			English	Article							ANTEROGRADE AXONAL-TRANSPORT; INTRACELLULAR-DISTRIBUTION; MICROTUBULE ORGANIZATION; ENDOPLASMIC-RETICULUM; ORGANELLE TRANSPORT; SUPERFAMILY PROTEIN; GOLGI-APPARATUS; NERVOUS-SYSTEM; RAT-BRAIN; IN-VIVO	Mouse kif5B gene was disrupted by homologous recombination. kif5B(-/-) mice were embryonic lethal with a severe growth retardation at 9.5-11.5 days postcoitum. To analyze the significance of this conventional kinesin heavy chain in organelle transport, we studied the distribution of major organelles in the extraembryonic cells. The null mutant cells impaired lysosomal dispersion, while brefeldin A could normally induce the breakdown of their Golgi apparatus. More prominently, their mitochondria abnormally clustered in the perinuclear region. This mitochondrial phenotype was reversed by an exogeneous expression of KIF5B, and a subcellular fractionation revealed that KIF5B is associated with mitochondria. These data collectively indicate that kinesin is essential for mitochondrial and lysosomal dispersion rather than for the Golgi-to-ER traffic in these cells.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan.		Kanai, Yoshimitsu/W-3486-2019; Takeda, Sen/I-8462-2012; Okada, Yasushi/N-5067-2015; Nonaka, Shigenori/I-2132-2013	Takeda, Sen/0000-0001-7090-2139; Okada, Yasushi/0000-0003-2601-3689; Nonaka, Shigenori/0000-0002-8093-0325; Kanai, Yoshimitsu/0000-0002-0375-6853; Tanaka, Yosuke/0000-0001-5376-5726				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; BostUsinger L, 1997, EXP EYE RES, V64, P781, DOI 10.1006/exer.1996.0271; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brown NA, 1990, POSTIMPLANTATION MAM, P93; BURKHARDT JK, 1993, J CELL SCI, V104, P151; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Funakoshi T, 1996, J CELL BIOL, V133, P1347, DOI 10.1083/jcb.133.6.1347; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAESSMANN M, 1994, CELL BIOL LAB HDB, V3, P3; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HammAlvarez SF, 1997, EXP EYE RES, V64, P141, DOI 10.1006/exer.1996.0198; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HENSON JH, 1992, J CELL SCI, V103, P309; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; Hogan B, 1994, MANIPULATING MOUSE E; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hurd DD, 1996, GENETICS, V142, P195; Hurd DD, 1996, GENETICS, V144, P1075; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JELLALI A, 1994, CELL MOTIL CYTOSKEL, V28, P79, DOI 10.1002/cm.970280108; Johnson KJ, 1996, EUR J CELL BIOL, V69, P276; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; Lin SXH, 1996, CELL MOTIL CYTOSKEL, V34, P299; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MALEKZADEHHEMMAT K, 1993, CELL MOL BIOL, V39, P279; MARKS DL, 1994, J CELL SCI, V107, P2417; Meng YX, 1997, ENDOCRINOLOGY, V138, P1979, DOI 10.1210/en.138.5.1979; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKABE S, 1991, J NEUROSCI, V11, P1918; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHMITZ F, 1994, EUR J CELL BIOL, V63, P77; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Spector D. L., 1998, CELLS LAB MANUAL; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; Sturmer K, 1996, CELL TISSUE RES, V286, P547, DOI 10.1007/s004410050725; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TANAHASHI S, 1992, FUSION ENG DES, V19, P269, DOI 10.1016/0920-3796(92)90035-3; TANAKA Y, 1995, J CELL SCI, V108, P1883; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; WATANABE A, 1993, GENE DEV, V7, P403; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; Yang ZH, 1997, GENOMICS, V45, P123, DOI 10.1006/geno.1997.4901; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112	81	482	491	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1147	1158		10.1016/S0092-8674(00)81459-2	http://dx.doi.org/10.1016/S0092-8674(00)81459-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657148	Bronze			2022-12-24	WOS:000074491100010
J	Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD				Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD			Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service	LANCET			English	Article							AIR-FLOW LIMITATION; CONTROLLED TRIAL; HEALTH WORKER; DISABILITY; IMPAIRMENT; DEPRESSION; COPD	Background Exacerbations of chronic obstructive pulmonary disease are a major cause of hospital admissions, but do not require intensive investigation or complex therapy. We investigated the suitability of home care for severe uncomplicated exacerbations. Methods Over 3.5 years we assessed 962 patients with exacerbations of chronic obstructive pulmonary disease after referral to a hospital respiratory department by their family physicians. All patients had chest radiographs, oxygen-saturation or arterial-gas analysis, spirometry, and physical assessment. Unless admission was thought to be essential, patients were allowed home with a customised treatment package. Each patient was visited daily by a respiratory nurse who monitored progress and treatment compliance and provided education and reassurance. Findings 145 (15%) of 962 required admission at initial referral and 115 (12%) were admitted later. 653 (68%) patients were managed entirely at home and 49 (5%) were referred inappropriately. One patient died at home. All patients had severe disease with a mean forced expiratory volume in 1 s of 1.02 L and 395 (41%) had required hospital admission in the previous year. Interpretation After formal assessment in a hospital respiratory unit, many patients with exacerbations of chronic obstructive pulmonary disease can be treated at home by respiratory nurses.	Royal Infirm, Dept Resp Med, Glasgow G31 2ER, Lanark, Scotland; Royal Alexandra Hosp, Palsley, England; Sultan Qaboos Univ, Coll Med, Muscat, Oman	Royal Infirmary of Edinburgh; Sultan Qaboos University	Stevenson, RD (corresponding author), Royal Infirm, Dept Resp Med, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; GIFT AG, 1993, HEART LUNG, V22, P289; HAGGERTY MC, 1991, CHEST, V100, P607, DOI 10.1378/chest.100.3.607; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; KELLNER R, 1992, GEN HOSP PSYCHIAT, V14, P20, DOI 10.1016/0163-8343(92)90022-3; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; *LUNG ASTHM INF AG, 1992, SICK ABS RESP DIS; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SMALL SP, 1992, HEART LUNG, V21, P568	9	90	91	3	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1853	1855		10.1016/S0140-6736(97)11048-0	http://dx.doi.org/10.1016/S0140-6736(97)11048-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652670				2022-12-24	WOS:000074347100013
J	Jessop, DS				Jessop, DS			beta-endorphin in the immune system - mediator of pain and stress?	LANCET			English	Editorial Material									Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England	University of Bristol	Jessop, DS (corresponding author), Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England.							BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Carr DJJ, 1996, P SOC EXP BIOL MED, V213, P248; JESSOP DS, 1995, J NEUROIMMUNOL, V60, P29, DOI 10.1016/0165-5728(95)00049-8; JESSOP DS, 1998, CURR OPIN ENDOCRINOL, V5, P52; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5	9	23	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1828	1829		10.1016/S0140-6736(05)78799-7	http://dx.doi.org/10.1016/S0140-6736(05)78799-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652661				2022-12-24	WOS:000074347100004
J	Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T				Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T			Male-to-female sex reversal in M33 mutant mice	NATURE			English	Article							SRY-RELATED GENE; Y-CHROMOSOME; CAMPOMELIC DYSPLASIA; POLYCOMB PROTEIN; DROSOPHILA; MOUSE; EXPRESSION; DIFFERENTIATION; MUTATIONS; EMBRYOS	Polycomb genes in Drosophila maintain the repressed state of homeotic and other developmentally regulated genes(1-4) by mediating changes in higher-order chromatin structure(5-7). M33, a mouse homologue of Polycomb, was isolated by means of the structural similarity of its chromodomain(8). The fifth exon of M33 contains a region of homology shared by Drosophila and Xenopus(8,9). In Drosophila, its deletion results in the loss of Polycomb function(10). Here we have disrupted M33 in mice by inserting a poly(A) capture-type neo(r) targeting vector into its fifth exon. More than half of the resultant M33(cterm)/M33(cterm) mutant mice died before weaning, and survivors showed male-to-female sex reversal. Formation of genital ridges was retarded in both XX and XY M33(cterm)/M33(cterm) embryos. Gonadal growth defects appeared near the time of expression of the Y-chromosome-specific Sry gene(11), suggesting that M33 deficiency may cause sex reversal by interfering with steps upstream of Sry. M33(cterm)\M33(cterm) mice may be a valuable model in which to test opposing views regarding sex determination.	Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Natl Inst Genet, Mammalian Genet Lab, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Katoh-Fukui, Y (corresponding author), Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan.	kan@libra.ls.m-kagaku.co.jp	Katoh-Fukui, Yuko/Y-5383-2019	Katoh-Fukui, Yuko/0000-0001-6858-3693				Akasaka T, 1996, DEVELOPMENT, V122, P1513; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Burgoyne P.S., 1991, Seminars in Developmental Biology, V2, P277; CATTANACH BM, 1987, ANN NY ACAD SCI, V513, P27, DOI 10.1111/j.1749-6632.1987.tb24996.x; Core N, 1997, DEVELOPMENT, V124, P721; EICHER EM, 1983, J EXP ZOOL, V228, P297, DOI 10.1002/jez.1402280213; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MITTWOCH U, 1989, J THEOR BIOL, V137, P445, DOI 10.1016/S0022-5193(89)80039-6; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; NAGAMINE CM, 1992, MAMM GENOME, V3, P84, DOI 10.1007/BF00431251; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Uchida K, 1996, MAMM GENOME, V7, P481, DOI 10.1007/s003359900147; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	30	233	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					688	692		10.1038/31482	http://dx.doi.org/10.1038/31482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641679				2022-12-24	WOS:000074289600054
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			The C-elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VITRONECTIN RECEPTOR; ATP-BINDING; MACROPHAGE RECOGNITION; MULTIDRUG RESISTANCE; ADENYLATE KINASE; APOPTOTIC CELLS; P-GLYCOPROTEIN; BODY REGION; DEATH	The C. elegans gene ced-7 functions in the engulfment of cell corpses during programmed cell death. We report that the CED-7 protein has sequence similarity to ABC transporters, is broadly expressed during embryogenesis, and is localized to the plasma membrane. Mosaic analysis revealed that ced-7 functions in both dying cells and engulfing cells during the engulfment process. We propose that CED-7 functions to translocate molecules that mediate homotypic adhesion between the cell surfaces of the dying and engulfing cells. Like CED-7, the mammalian ABC transporter ABC1 has been implicated in the engulfment of cell corpses, suggesting that CED-7 and ABC1 may be functionally similar and that the molecular mechanism underlying cell corpse engulfment during programmed cell death may be conserved from nematodes to mammals.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRENNER S, 1974, GENETICS, V77, P71; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; CULOTTI JG, 1978, GENETICS, V90, P243; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; Guenther C, 1996, DEVELOPMENT, V122, P3509; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; Harlow E, 1988, ANTIBODIES LAB MANUA; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUVKUN G, 1989, GENETICS, V121, P501; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1991, CHEST, V99, pS6, DOI 10.1378/chest.99.3_Supplement.6S-a; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; [No title captured]	64	232	245	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					951	960		10.1016/S0092-8674(00)81201-5	http://dx.doi.org/10.1016/S0092-8674(00)81201-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635425	Green Submitted, Bronze			2022-12-24	WOS:000074205700007
J	Nayak, A; Zastrow, DJ; Lickteig, R; Zahniser, NR; Browning, MD				Nayak, A; Zastrow, DJ; Lickteig, R; Zahniser, NR; Browning, MD			Maintenance of late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor synthesis	NATURE			English	Article							LONG-TERM POTENTIATION; SILENT SYNAPSES; CA1 REGION; INDUCTION; PHOSPHORYLATION; NEURONS; BRAIN; CREB	Long-term potentiation (LTP) is a form of synaptic plasticity that has been extensively studied as a putative mechanism underlying learning and memory. A late phase of LTP occurring 3-5 hours after stimulation and depending on transcription, protein synthesis and cyclic-AMP-dependent protein kinase (protein kinase A, or PKA) has been described(1-3), but it is not known whether transcription of presynaptic and/or postsynaptic genes is required to support late-phase LTP. Here we show that late-phase LTP can be obtained in rat hippocampal CA1 mini-slices in which the cell bodies of presynaptic Schaffer collateral/ commissural fibres are rr moved. Thus, transcription of presynaptic genes is not necessary to support maintenance of late-phase LTP. The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor is the predominant mediator of the ionotropic response to synaptically released glutamate in the hippocampus and it has been implicated in LTP maintenance. We find that synthesis of AMPA receptor subunits is increased three hours after LTP induction: this effect on the synthesis of the AMPA receptor is blocked by inhibitors of PKA and of transcription. Our results support the idea of a postsynaptic mechanism maintaining late-phase LTP, in which AMPA receptor synthesis is increased as a result of PKA-dependent gene transcription.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nayak, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.							Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HAYCOCK JW, 1988, P NATL ACAD SCI USA, V85, P1677, DOI 10.1073/pnas.85.5.1677; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PARFITT KD, 1992, HIPPOCAMPUS, V2, P59, DOI 10.1002/hipo.450020108; Snell LD, 1996, MOL BRAIN RES, V40, P71; STONE LM, 1994, J NEUROSCI, V14, P301; Voronin LL, 1996, NEUROSCIENCE, V74, P323, DOI 10.1016/0306-4522(96)00207-2; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501	18	175	176	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					680	683		10.1038/29305	http://dx.doi.org/10.1038/29305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716131				2022-12-24	WOS:000075384200044
J	Lee, SE; Moore, JK; Holmes, A; Umezu, K; Kolodner, RD; Haber, JE				Lee, SE; Moore, JK; Holmes, A; Umezu, K; Kolodner, RD; Haber, JE			Saccharomyces Ku70, Mre11/Rad50, and RPA proteins regulate adaptation to G2/M arrest after DNA damage	CELL			English	Article							STRAND-BREAK REPAIR; END-JOINING REPAIR; HOMOLOGOUS RECOMBINATION; BINDING PROTEIN; CELL-CYCLE; ILLEGITIMATE RECOMBINATION; MEIOTIC RECOMBINATION; A PHOSPHORYLATION; CEREVISIAE; YEAST	Saccharomyces cells suffering a single unrepairable double-strand break (DSB) exhibit a long, but transient arrest at G2/M. hdf1 cells, lacking Ku70p, fail to escape from this RAD9/RAD17-dependent checkpoint. The effect of hdf1 results from its accelerated 5' to 3' degradation of the broken chromosome. Permanent arrest in hdf1 cells is suppressed by rad50 or mre11 deletions that retard this degradation. Wild-type HDF1 cells also become permanently arrested when they experience two unrepairable DSBs. Both DSB-induced arrest conditions are suppressed by a mutation in the single-strand binding protein, RPA. We suggest that escape from the DNA damage-induced G2/M checkpoint depends on the extent of ssDNA created at broken chromosome ends. RPA appears to play a key intermediate step in this adaptation.	Brandeis Univ, Dept Biol, Rosenstiel Ctr MS029, Waltham, MA 02454 USA; Brandeis Univ, Keck Inst Cellular Visualizat, Rosenstiel Ctr MS029, Waltham, MA 02454 USA; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA	Brandeis University; Brandeis University; Harvard University; Dana-Farber Cancer Institute	Haber, JE (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Ctr MS029, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM70122, GM20056, GM50006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006, R37GM020056, F31GM070122, R01GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; IVANOV EL, 1992, GENETICS, V132, P651; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; JOHZUKA K, 1995, GENETICS, V139, P1521; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Morrow DM, 1997, GENETICS, V147, P371; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; OGAWA H, 1995, ADV BIOPHYS, V31, P67, DOI 10.1016/0065-227X(95)99383-Z; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Siede W, 1996, GENETICS, V142, P91; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; Umezu K, 1998, GENETICS, V148, P989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEINERT TA, 1993, GENETICS, V134, P63; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	58	617	622	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					399	409		10.1016/S0092-8674(00)81482-8	http://dx.doi.org/10.1016/S0092-8674(00)81482-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708741	Bronze			2022-12-24	WOS:000075308400015
J	Ryan, AK; Blumberg, B; Rodriguez-Esteban, C; Yonei-Tamura, S; Tamura, K; Tsukui, T; de la Pena, J; Sabbagh, W; Greenwald, J; Choe, S; Norris, DP; Robertson, EJ; Evans, RM; Rosenfeld, MG; Belmonte, JCI				Ryan, AK; Blumberg, B; Rodriguez-Esteban, C; Yonei-Tamura, S; Tamura, K; Tsukui, T; de la Pena, J; Sabbagh, W; Greenwald, J; Choe, S; Norris, DP; Robertson, EJ; Evans, RM; Rosenfeld, MG; Belmonte, JCI			Pitx2 determines left-right asymmetry of internal organs in vertebrates	NATURE			English	Article							NODAL EXPRESSION; MICE DEFICIENT; LIMB BUD; GENE; DEFECTS; TRANSCRIPTION; INITIATION; ACTIVINS; INDUCE; AXIS	The handedness of visceral organs is conserved among vertebrates anal is regulated by asymmetric signals relayed by molecules such as Shh, Nodal and activin. The gene Pitx2 is expressed in the left lateral plate mesoderm and, subsequently, In the left heart and gut of mouse, chick and Xenopus embryos. Misexpression of Shh and Nodal induces Pitx2 expression, whereas inhibition of activin signalling blocks it. Misexpression of Pitx2 alters the relative position of organs and the direction of body rotation In chick and Xenopus embryos. Changes in Pitx2 expression are evident in mouse mutants with laterality defects. Thus, Pitx2 seems to serve as a critical downstream transcription target that mediates left-right asymmetry in vertebrates.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Salk Institute; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Evans, Ronald/0000-0002-9986-5965				Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Blumberg B, 1997, DEVELOPMENT, V124, P373; Blumberg B, 1998, GENE DEV, V12, P1269, DOI 10.1101/gad.12.9.1269; BURN J, 1991, CIBA F SYMP, V162, P282; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DONALSON CJ, UNPUB BIOCHEMISTRY; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HIROFUMI A, 1998, P NATL ACAD SCI USA, V95, P4573; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Kosaki K, 1998, SEMIN CELL DEV BIOL, V9, P89, DOI 10.1006/scdb.1997.0187; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lander A, 1998, SEMIN CELL DEV BIOL, V9, P35, DOI 10.1006/scdb.1997.0185; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LOGAN M, IN PRESS CELL; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; MENO C, IN PRESS CELL; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Splitt MP, 1996, J MED GENET, V33, P498, DOI 10.1136/jmg.33.6.498; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; Supp DM, 1998, SEMIN CELL DEV BIOL, V9, P77, DOI 10.1006/scdb.1997.0186; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Vogel A, 1996, DEVELOPMENT, V122, P1737; WILKINSON DG, 1993, IN SITU HYBRIDISATIO; Wood WB, 1997, ANNU REV CELL DEV BI, V13, P53; YONEI S, 1995, DEV BIOL, V170, P542, DOI 10.1006/dbio.1995.1235	51	425	434	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					545	551		10.1038/29004	http://dx.doi.org/10.1038/29004			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707115				2022-12-24	WOS:000075238700037
J	Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K				Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K			Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL-CANCER; CHEMICAL-TESTS; NEGATIVE COLONOSCOPY; RECTAL EXAMINATION; UPPER ENDOSCOPY; CR-51 METHOD; SENSITIVITY; MORTALITY; DISEASE; POLYPS	Background Although bleeding lesions anywhere in the gastrointestinal tract can cause a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gastrointestinal and colonic lesions is unknown. Methods During a period of 30 months, we prospectively studied all patients with at least one stool specimen containing fecal occult blood who were referred for further evaluation. Fecal occult blood was detected by standard guaiac-based tests of stool specimens obtained as part of routine screening or of stool obtained by digital rectal examination. Patients with documented iron-deficiency anemia or active gastrointestinal bleeding were excluded from the study. All participants had a detailed history taken and underwent colonoscopy, followed by esophagogastroduodenoscopy. Results Of the 409 patients with fecal occult blood who were referred, 310 were potentially eligible to participate, and 248 (mean age, 61 years; range, 40 to 89) were studied; 40 percent were women. We identified lesions consistent with occult bleeding in 119 patients (48 percent); in 71 bleeding lesions were found in the upper gastrointestinal tract, and in 54 they were identified in the colon. Six patients had abnormalities in both areas. The most common upper gastrointestinal lesions were esophagitis (23 patients), gastric ulcer (14), gastritis (12), and duodenal ulcer (10). Thirty patients with lesions in the upper gastrointestinal tract were long-term users of aspirin, ethanol, nonsteroidal antiinflammatory drugs, or a combination of these substances. The most com mon colonic lesions were adenomas more than 1.0 cm in diameter (29 patients), carcinoma (13), colitis (5), and vascular ectasia (5). Although the overall sensitivity of symptoms for the detection of gastrointestinal lesions was low, logistic-regression analysis demonstrated that the presence of symptoms in the upper gastrointestinal tract was associated with the detection of lesions in the upper gastrointestinal tract (odds ratio, 2.6; 95 percent confidence interval, 1.4 to 4.7). In both patients with symptoms and those without symptoms, the prevalence of lesions in the upper gastrointestinal tract was greater than or equal to that of colonic lesions. Conclusions In a group of patients with positive fecal occult-blood tests who were referred for further evaluation, from which those with iron-deficiency anemia and active bleeding had been excluded, up per gastrointestinal lesions were identified more frequently than colonic lesions. (N Engl J Med 1998; 339:153-9.) (C)1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Liver Res Lab, Sands Bldg,Rm 334,Res Dr,Box 3038, Durham, NC 27710 USA.							AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; BRINT SL, 1993, SOUTHERN MED J, V86, P601, DOI 10.1097/00007611-199306000-00001; CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P245, DOI 10.1080/00365521.1984.12005716; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P235, DOI 10.1080/00365521.1984.12005715; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Ferguson A, 1996, GUT, V38, P120, DOI 10.1136/gut.38.1.120; GELLER AJ, 1993, AM J GASTROENTEROL, V88, P1184; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; Kleinbaum D, 1988, APPL REGRESSION ANAL; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANCE P, 1993, GASTROENTEROLOGY, V104, P1852, DOI 10.1016/0016-5085(93)90669-4; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Lieberman D, 1996, LANCET, V348, P1463, DOI 10.1016/S0140-6736(05)65886-2; LIEBERMAN DA, 1990, ARCH INTERN MED, V150, P740; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; Marks RD, 1997, GASTROENTEROLOGY, V112, pA29; MORRIS DW, 1976, AM J DIG DIS, V21, P845, DOI 10.1007/BF01072075; OSTROW JD, 1973, AM J DIG DIS, V18, P930, DOI 10.1007/BF01072436; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Rockey D, 1997, GASTROENTEROLOGY, V112, pA40; SAS Institute, 1990, SAS STAT US GUID, V2; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; STROEHLEIN JR, 1976, AM J DIG DIS, V21, P841, DOI 10.1007/BF01072074; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; YOUNG GP, 1993, JAMA-J AM MED ASSOC, V270, P451, DOI 10.1001/jama.1993.03510040055022; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	37	138	141	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					153	159		10.1056/NEJM199807163390303	http://dx.doi.org/10.1056/NEJM199807163390303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664091				2022-12-24	WOS:000074782900003
J	Arias, IM				Arias, IM			New genetics of inheritable jaundice and cholestatic liver disease	LANCET			English	Editorial Material									Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Arias, IM (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.							BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Jansen P L, 1995, Prog Liver Dis, V13, P125; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; ZHANG X, 1997, HEPATOLOGY, V26, pA69	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					82	83		10.1016/S0140-6736(98)85004-6	http://dx.doi.org/10.1016/S0140-6736(98)85004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672268				2022-12-24	WOS:000074775100004
J	Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD				Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD			Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study	BRITISH MEDICAL JOURNAL			English	Article									Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; Univ Southampton, Fac Med Hlth & Biol Sci, Sch Med, Southampton SO16 7PX, Hants, England	University of Southampton	Martin, RM (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; BEM JL, 1988, BRIT MED J, V296, P1319, DOI 10.1136/bmj.296.6632.1319; *JOINT FORM COMM, 1997, BRIT NATL FORMULARY, P10; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; RAWLINS MD, 1993, BR J CLIN PHARM, V35, P590	5	129	136	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					119	120		10.1136/bmj.317.7151.119	http://dx.doi.org/10.1136/bmj.317.7151.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657787	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000075081700022
J	Husband, DJ				Husband, DJ			Malignant spinal cord compression: prospective study of delays in referral and treatment	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS	Objectives: To examine the delay in presentation diagnosis, and treatment of malignant spinal cord compression and to define the effect of this delay on motor and bladder function at the time of treatment Design: Prospective study of all new patients presenting to a regional cancer centre with this condition. Setting: Regional cancer centre. Subjects: 301 consecutive patients. Main outcome measures: Interval from onset of symptoms to presentation and treatment, delay at each stage of referral, and functional deterioration. Results: The median (range) delay from onset of symptoms of spinal cord compression to treatment was 14 (0-840) days. Of the total delay 3 (0-300) days were accounted for by patients, 3 (0-330) days by general practitioners, 4 (0-794) days by the district general hospital, and 0 (0-114) days by the treatment unit Initial presentation to the regional cancer centre with symptoms of malignant spinal cord compression led to a significant reduction in delay to treatment and improved functional status at the time of treatment Deterioration of motor or bladder function greater than or equal to 1 grade occurred at the general practice stage in 28% (57) and 18% (36) of patients, the general hospital stage in 36% (83) and 29% (66), and the treatment unit stage in 6% (19) and 5% (15), respectively. Conclusions: Unacceptable delay in diagnosis, investigation, and referral occurs in most patients with malignant spinal cord compression and results in preventable loss of function before treatment Improvement in the outcome of such patients requires earlier diagnosis and treatment.	Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England	Clatterbridge Cancer Centre	Husband, DJ (corresponding author), Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England.							BACH F, 1990, ACTA NEUROCHIR, V107, P37, DOI 10.1007/BF01402610; BOOGERD W, 1993, CANCER TREAT REV, V19, P129, DOI 10.1016/0305-7372(93)90031-L; BYRNE TN, 1995, NEUROLOGICAL COMPLIC, P23; CAMPBELL MJ, 1989, STAT CONFIDENCE; Delaney TF, 1993, CANC PRINCIPLES PRAC, P2118; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; JOHNSTON RA, 1993, J NEUROL NEUROSUR PS, V56, P1046, DOI 10.1136/jnnp.56.10.1046; Posner J.B., 1995, NEUROLOGICAL COMPLIC; SIEGEL S, 1988, NONPARAMETRIC STAT	10	112	116	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					18	21		10.1136/bmj.317.7150.18	http://dx.doi.org/10.1136/bmj.317.7150.18			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651261	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000075081600017
J	Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG				Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG			Congenital heart disease caused by mutations in the transcription factor NKX2-5	SCIENCE			English	Article							MOLECULAR-CLONING; TINMAN; GENES	Mutations in the gene encoding the homeobox transcription factor NKX2-5 were found to cause nonsyndromic, human congenital heart disease. A dominant disease locus associated with cardiac malformations and atrioventricular conduction abnormalities was mapped to chromosome 5q35, where NKX2-5, a Drosophila tinman homolog, is located. Three different NKX2-5 mutations were identified. Two are predicted to impair binding of NKX2-5 to target DNA, resulting in haploinsufficiency, and a third potentially augments target-DNA binding. These data indicate that NKX2-5 is important for regulation of septation during cardiac morphogenesis and for maturation and maintenance of atrioventricular node function throughout life.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harrisburg Hosp, Harrisburg, PA 17104 USA; Oregon Hlth Sci Univ, Div Pediat Cardiol, Portland, OR 97201 USA; Childrens Natl Med Ctr, Div Pediat Cardiol, Washington, DC 20010 USA; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Oregon Health & Science University; Children's National Health System; Minneapolis Heart Institute Foundation	Seidman, JG (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.		Schott, jean-Jacques/F-8842-2013	Schott, jean-Jacques/0000-0002-9578-9475				Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BASSON CT, 1995, CIRCULATION, V91, P1326, DOI 10.1161/01.CIR.91.5.1326; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1993, DEVELOPMENT, V118, P719; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOFFMAN JIE, 1990, PEDIATR CLIN N AM, V37, P25; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kostrzewa M, 1996, HUM GENET, V97, P399, DOI 10.1007/BF02185781; Li QY, 1997, NAT GENET, V15, P21; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MOORE KL, 1998, DEV HUMAN CLIN ORIEN, P349; MOORMAN AFM, 1994, TRENDS CARDIOVAS MED, V4, P257, DOI 10.1016/1050-1738(94)90029-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PEASE WE, 1976, CIRCULATION, V53, P759, DOI 10.1161/01.CIR.53.5.759; Schott JJ, UNPUB; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Turbay D, 1996, MOL MED, V2, P86, DOI 10.1007/BF03402205	19	958	997	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					108	111		10.1126/science.281.5373.108	http://dx.doi.org/10.1126/science.281.5373.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651244				2022-12-24	WOS:000074685800049
J	Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P				Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P			Association of missense and 5 '-splice-site mutations in tau with the inherited dementia FTDP-17	NATURE			English	Article							PROTEIN-TAU; ALZHEIMERS-DISEASE; LOCALIZATION; PARKINSONISM; COMPLEX; GENE; RNA	Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)(1-9), historically termed Pick's disease(10). Most FTDP-17 cases show neuronal and/or glial inclusions that stain positively with antibodies raised against the microtubule-associated protein Tau, although the Tau pathology varies considerably in both its quantity (or severity) and characteristics(1-8,12). Previous studies have mapped the FTDP-17 locus to a 2-centimorgan region on chromosome 17q21.11; the tau gene also lies within this region. We have now sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon in. The splice-site mutations all destabilize a potential stem-loop structure which is probably involved in regulating the alternative splicing of exon10 (ref. 13). This causes more frequent usage of the 5' splice site and an increased proportion of tan transcripts that include exon 10. The increase in exon 10(+) messenger RNA will increase the proportion of Tau containing four microtubule-binding repeats, which is consistent with the neuropathology described in several families with FTDP-17 (refs 12, 14).	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands; Erasmus Univ, Dept Neurol, Rotterdam, Netherlands; Karolinska Inst, Inst Clin Neurophysiol & Family Med, Geriatr Med Sect, S-14186 Huddinge, Sweden; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mayo Clin, Rochester, MN 56007 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Princess Alexandra Hosp, Dept Psychiat, Woolloongabba, Qld 4102, Australia; Mater Misericordiae Hosp, Dept Anat Pathol, Brisbane, Qld 4101, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Queensland Inst Med Res, Human Genet Lab, Herston, Qld 4029, Australia; Garvan Inst Med Res, Sydney, NSW 2010, Australia; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dept Biomed Sci, Waltham, MA 02154 USA; Manchester Royal Infirm, Dept Neurol, Manchester M13 9WL, Lancs, England; St Marys Hosp, Dept Clin Genet, Manchester M13 0GH, Lancs, England; Univ Manchester, Dept Pathol Sci, Manchester M13 9PT, Lancs, England	Mayo Clinic; Washington University (WUSTL); Erasmus University Rotterdam; Erasmus University Rotterdam; Karolinska Institutet; University of Manchester; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic; Washington University (WUSTL); University of Pennsylvania; Columbia University; University of Queensland; QIMR Berghofer Medical Research Institute; Garvan Institute of Medical Research; University of Manchester; University of Manchester; University of Manchester	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	hutton.michael@mayo.edu; heutink@kgen.fgg.eut.nl	Lynch, Timothy/M-1316-2019; Houlden, Henry J/C-1532-2008; Pickering-Brown, Stuart/D-4008-2009; Craufurd, David/G-5277-2013; hayward, nicholas k/C-1367-2015; Morris, John C/A-1686-2012; hayward, nick/AAV-8802-2020; Hardy, John/C-2451-2009; Dodd, Peter Ronald/A-4865-2010; de Graaff, Esther/D-3287-2011; Schofield, Peter/C-9669-2011	Houlden, Henry J/0000-0002-2866-7777; Pickering-Brown, Stuart/0000-0003-1561-6054; hayward, nicholas k/0000-0003-4760-1033; Hardy, John/0000-0002-3122-0423; Dodd, Peter Ronald/0000-0001-5970-0181; Dickson, Dennis W/0000-0001-7189-7917; Snowden, Julie/0000-0002-3976-4310; Heutink, Peter/0000-0001-5218-1737; Schofield, Peter/0000-0003-2967-9662; Kwok, John/0000-0001-9574-6195; Goate, Alison/0000-0002-0576-2472; van Swieten, John/0000-0001-6278-6844				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Baker M, 1997, ANN NEUROL, V42, P794, DOI 10.1002/ana.410420516; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; CONSTANT.J, 1974, EUR NEUROL, V11, P208, DOI 10.1159/000114320; Dark F, 1997, AUST NZ J PSYCHIAT, V31, P139, DOI 10.3109/00048679709073812; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Froelich S, 1997, AM J MED GENET, V74, P380, DOI 10.1002/(SICI)1096-8628(19970725)74:4<380::AID-AJMG8>3.0.CO;2-T; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Heutink P, 1997, ANN NEUROL, V41, P150, DOI 10.1002/ana.410410205; Higgins JJ, 1998, NEUROLOGY, V50, P270, DOI 10.1212/WNL.50.1.270; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; Yamaoka LH, 1996, AM J HUM GENET, V59, P1306	28	2719	2812	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					702	705		10.1038/31508	http://dx.doi.org/10.1038/31508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641683				2022-12-24	WOS:000074289600058
J	Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L				Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L			A nutrient-sensing pathway regulates leptin gene expression in muscle and fat	NATURE			English	Article							INSULIN-RESISTANCE; OBESE GENE; IN-VIVO; HEXOSAMINE BIOSYNTHESIS; GLUCOSE-TRANSPORT; HUMANS; ADIPOSITY; PRODUCT; PROTEIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is synthesized and released in response to increased energy storage in adipose tissue(1-4). However, it is still not known how incoming energy is sensed and transduced into increased expression of the ob gene. The hexosamine biosynthetic pathway is a cellular 'sensor' of energy availability(5-8) and mediates the effects of glucose on the expression of several gene products(9-12). Here we provide evidence for rapid activation of ob gene expression in skeletal muscle by glucosamine. Increased tissue concentrations of the end product of the hexosamine biosynthetic pathway, UDP-N-acetylglucosamine (UDP-GlcNAc), result in rapid and marked increases in leptin messenger RNA and protein levels (although these levels were much lower than those in fat). Plasma leptin levels and leptin mRNA and protein levels in adipose tissue also increase. Most important, stimulation of leptin synthesis is reproduced by either hyperglycaemia or hyperlipidaemia, which also increase tissue levels of UDP-N-acetylglucosamine in conscious rodents(7). Finally, incubation of 3T3-L1 pre-adipocytes and L6 myocytes with glucosamine rapidly induces ob gene expression. Our findings are the first evidence of inducible leptin expression in skeletal muscle and unveil an important biochemical Link between increased availability of nutrients and leptin expression.	Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Liu, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu						Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; Wang JL, 1997, DIABETES, V46, P325; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	637	663	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					684	688		10.1038/31474	http://dx.doi.org/10.1038/31474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641678				2022-12-24	WOS:000074289600053
J	Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG				Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG			The antigenic structure of the HIV gp120 envelope glycoprotein	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZING ANTIBODIES; CD4 BINDING; RECEPTOR; EPITOPE; CELLS; RETROVIRUS; EXPOSURE; REGION	The human immunodeficiency virus HIV-1 establishes persistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS). The HIV-1 envelope glycoproteins, gp120 and gp41, are assembled into a trimeric complex that mediates virus entry into target cells(1). HIV-1 entry depends on the sequential interaction of the gp120 exterior envelope glycoprotein with the receptors on the cell, CD4 and members of the chemokine receptor family(2-4). The gp120 glycoprotein, which can be shed from the envelope complex, elicits both virus-neutralizing and non-neutralizing antibodies during natural infection. Antibodies that lack neutralizing activity are often directed against the gp120 regions that are occluded on the assembled trimer and which are exposed only upon shedding(5,6). Neutralizing antibodies, by contrast, must access the functional envelope glycoprotein complex(7) and typically recognize conserved or variable epitopes near the receptor-binding regions(8-11). Here we describe the spatial organization of conserved neutralization epitopes on gp120, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody(12). A large fraction of the predicted accessible surface of gp120 in the trimer is composed of variable, heavily glycosylated core and loop structures that surround the receptor-binding regions. Understanding the structural basis for the ability of HIV-1 to evade the humoral immune response should assist in the design of a vaccine.	Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; Howard Hughes Medical Institute; GlaxoSmithKline; Tulane University	Sodroski, JG (corresponding author), Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.							ALLEN J, 1983, SCIENCE, V228, P1091; BINLEY J, 1997, AIDS RES HUM RETROV, V14, P191; Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; Karlsson GB, 1997, J VIROL, V71, P4218, DOI 10.1128/JVI.71.6.4218-4225.1997; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MOORE JP, 1994, J VIROL, V68, P8350, DOI 10.1128/JVI.68.12.8350-8364.1994; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; WATKINS BA, 1993, J VIROL, V67, P7493, DOI 10.1128/JVI.67.12.7493-7500.1993; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	30	1042	1116	2	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					705	711		10.1038/31514	http://dx.doi.org/10.1038/31514			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641684	Bronze			2022-12-24	WOS:000074289600059
J	Brewster, R; Lee, J; Altaba, ARI				Brewster, R; Lee, J; Altaba, ARI			Gli/Zic factors pattern the neural plate by defining domains of cell differentiation	NATURE			English	Article							NEUROGENESIS; XENOPUS; INDUCTION; ECTODERM; EMBRYOS; PROTEIN; CREST; TUBE	Three cell types differentiate in the early frog neural plate: neural crest at the lateral edges, floorplate at the midline and primary neurons in three bilateral stripes. Floorplate cells and ventral neurons are induced by Sonic hedgehog(1,2) (Shh) and neural crest and dorsal. neurons are induced by epidermal factors such as bone morphogenetic proteins (BMPs)(3). Neurogenesis in a subset of cells within the stripes involves lateral inhibition(4). However, the process by which pools of precursors are defined in stereotypic domains in response to inductive signals is unknown. Here we show that frog Zic2 encodes a zinc-finger transcription factor of the Gli superfamily which is expressed in stripes that alternate with those in which primary neurons differentiate and overlap the domains of floorplate and neural crest progenitors. Zic2 inhibits neurogenesis and induces neural crest differentiation. Conversely, Gli proteins are widely expressed, induce neurogenesis and inhibit neural crest differentiation. Zic2 is therefore a vertebrate pre-pattern gene, encoding anti-neurogenic and crest-inducing functions that counteract the neurogenic but not the floorplate-inducing activity of Gli proteins. We propose that the combined function of Gli/Zic genes responds to inductive signals and induces patterned neural cell differentiation.	NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, New York, NY 10016 USA	New York University	Altaba, ARI (corresponding author), NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	ria@saturn.med.nyu.edu		Ruiz i Altaba, Ariel/0000-0003-2292-3933				Altaba AR, 1996, MECH DEVELOP, V60, P207, DOI 10.1016/S0925-4773(96)00618-1; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Baker NE, 1997, CURR BIOL, V7, P122, DOI 10.1016/S0960-9822(06)00056-X; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee J, 1997, DEVELOPMENT, V124, P2537; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2	23	196	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					579	583		10.1038/31242	http://dx.doi.org/10.1038/31242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634234				2022-12-24	WOS:000074150100053
J	Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M				Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M			Shotgun sequencing of the human genome	SCIENCE			English	Article							MAP; PROJECT; TAGS; DNA		TIGR, Rockville, MD 20850 USA; Perkin Elmer Appl Biosyst, Foster City, CA 94404 USA	J. Craig Venter Institute; Thermo Fisher Scientific; Applied Biosystems	Venter, JC (corresponding author), TIGR, Rockville, MD 20850 USA.			Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, 1995, NATURE S, V37, P3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FRASER CM, IN PRESS SCIENCE; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; GREEN E, 1997, GENOME RES, V7, P410; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	22	222	244	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1540	1542		10.1126/science.280.5369.1540	http://dx.doi.org/10.1126/science.280.5369.1540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644018				2022-12-24	WOS:000074061200021
J	Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH				Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH			Predictors of systemic embolism in patients with mitral stenosis - A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						embolism; mitral valve stenosis; anticoagulants; atrial fibrillation; balloon dilation	PRESSURE HALF-TIME; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; SPONTANEOUS ECHO CONTRAST; ATRIAL-FIBRILLATION; VALVE DISEASE; COMMISSUROTOMY; COMPLICATIONS; PREVENTION; ACCURACY; CATHETER	Background: Most studies of the predictors of systemic embolism in patients with mitral stenosis have been retrospective. Objective: To prospectively study factors associated with systemic embolism in mitral stenosis. Design: Prospective cohort study. Setting: University-affiliated medical institution with 3000 beds. Patients: 534 consecutive patients with a mitral valve area of 2.0 cm(2) or less; 132 patients were in sinus rhythm, and 402 were in atrial fibrillation. Measurements: Nine clinical and 10 echocardiographic variables were assessed for prediction of systemic embolism over a mean (+/- SD) follow-up of 36.9 +/- 22.5 months. Diagnosis of systemic embolism was based on symptoms and signs (sudden onset of peripheral arterial ischemic or neurologic manifestations without prodromes) and on findings on computed tomography, angiography, and surgery. Results: For patients in sinus rhythm, age (relative risk [RR], 1.12 [95% CI, 1.04 to 1.21]), the presence of a left atrial thrombus (RR, 37.1 [CI, 2.82 to 487.8]), mitral valve area (RR, 16.9 [CI, 1.53 to 187.0]), and the presence of significant aortic regurgitation (RR, 22.4 [CI, 2.72 to 184.8]) were positively associated with embolism. For patients in atrial fibrillation, previous embolism (RR, 3.11 [CI, 1.66 to 5.85]) was positively associated with embolism; percutaneous balloon mitral commissurotomy (RR, 0.37 [CI, 0.18 to 0.79]) was a negative predictor. Conclusions: It may be prudent to give anticoagulants not only to patients in atrial fibrillation and patients with previous systemic embolism but also to those showing a left atrial thrombus or significant aortic regurgitation on echocardiography. Early percutaneous balloon mitral commissurotomy may also help prevent systemic embolism in patients with mitral stenosis.	Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, Taipei 105, Taiwan; Deaking Univ, Burwood, Vic, Australia	Chang Gung Memorial Hospital; Chang Gung University; Deakin University	Chiang, CW (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, 199 Tung Hwa N Rd, Taipei 105, Taiwan.			LO, Sing Kai/0000-0001-8401-1759				[Anonymous], 1986, Arch Neurol, V43, P71; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CASELLA L, 1964, ARCH INTERN MED, V114, P773, DOI 10.1001/archinte.1964.03860120085008; Chiang C W, 1992, Changgeng Yi Xue Za Zhi, V15, P72; CHIANG CW, 1994, CHEST, V106, P396, DOI 10.1378/chest.106.2.396; CHIANG CW, 1988, AM HEART J, V115, P908, DOI 10.1016/0002-8703(88)90899-X; CHIANG CW, 1987, J ULTRAS MED, V6, P525; Chiang CW, 1998, AM J CARDIOL, V81, P515, DOI 10.1016/S0002-9149(97)00943-0; Cooper J W, 1989, J Am Soc Echocardiogr, V2, P56; COULSHED N, 1970, BRIT HEART J, V32, P26; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; Dixon WJ, 1990, BMDP STAT SOFTWARE M; EASTON JD, 1980, STROKE, V11, P433, DOI 10.1161/01.STR.11.5.433; HATLE L, 1979, CIRCULATION, V60, P1096, DOI 10.1161/01.CIR.60.5.1096; HORSTKOTTE D, 1991, EUR HEART J, V12, P55, DOI 10.1093/eurheartj/12.suppl_B.55; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; HWANG JJ, 1992, AM J CARDIOL, V70, P769, DOI 10.1016/0002-9149(92)90557-F; ILICETO S, 1985, AM J CARDIOL, V55, P603, DOI 10.1016/0002-9149(85)90267-X; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; Loyd D, 1988, J Am Soc Echocardiogr, V1, P313; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PEVERILL RE, 1995, CIRCULATION, V92, P96; RICHARDS KL, 1986, CIRCULATION, V73, P964, DOI 10.1161/01.CIR.73.5.964; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; RUIZ CE, 1990, AM J CARDIOL, V65, P473, DOI 10.1016/0002-9149(90)90813-G; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SELVIN S, 1995, PRACTICAL BIOSTATIST, P124; SIGEL B, 1981, INVEST RADIOL, V16, P71, DOI 10.1097/00004424-198101000-00013; SMITH MD, 1986, CIRCULATION, V73, P100, DOI 10.1161/01.CIR.73.1.100; THOMAS JD, 1987, J AM COLL CARDIOL, V10, P923, DOI 10.1016/S0735-1097(87)80290-5; VAHANIAN A, 1989, AM J CARDIOL, V63, P847, DOI 10.1016/0002-9149(89)90055-6	33	101	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					885	+		10.7326/0003-4819-128-11-199806010-00001	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634425				2022-12-24	WOS:000073808600001
J	Arner, P				Arner, P			Not all fat is alike	LANCET			English	Editorial Material							REGIONAL ADIPOSITY		Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden	Karolinska Institutet	Arner, P (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden.			Arner, Peter/0000-0002-6208-6220				ABATE N, 1995, PROG LIPID RES, V34, P53, DOI 10.1016/0163-7827(94)00006-8; ARNER P, 1996, DIABETES REV, V4, P450; Bjorntorp P, 1998, HDB OBESITY, P573; BLUM WF, 1997, LEPTIN VOICE ADIPOSE, P1; Frayn KN, 1996, CLIN SCI, V90, P243, DOI 10.1042/cs0900243; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Lefebvre AM, 1998, DIABETES, V47, P98, DOI 10.2337/diabetes.47.1.98; Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; VANHARMELEN V, IN PRESS DIABETES	10	132	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1301	1302		10.1016/S0140-6736(05)79052-8	http://dx.doi.org/10.1016/S0140-6736(05)79052-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643790				2022-12-24	WOS:000073439400005
J	McClure, SJ; Caruana, L; Davie, AP; Goldthorp, S; McMurray, JJV				McClure, SJ; Caruana, L; Davie, AP; Goldthorp, S; McMurray, JJV			Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care	BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; DIASTOLIC DYSFUNCTION; ATRIAL; BRAIN; ECHOCARDIOGRAPHY; DIAGNOSIS; MANAGEMENT; COMMUNITY; MORTALITY	Objectives: To determine whether blood natriuretic peptide concentrations are helpful in identifying or excluding left ventricular systolic dysfunction in stable survivors of acute myocardial infarction. Design: Comparison of blood natriuretic peptide concentrations with echocardiographic assessment of left ventricular systolic function in a general practice population. Setting: Practices in Western District of Glasgow audit group. Subjects: 134 long term survivors of myocardial infarction recalled for echocardiography as part of a primary care secondary prevention audit. Main outcome measures: Area under the receiver operating curve for brain natriuretic peptide and N-terminal atrial natriuretic peptide. Results: Brain natriuretic peptide was of some diagnostic utility in identifying the minority of subjects with severe left ventricular dysfunction (area under curve = 0.73) but was unable to discriminate between patients with moderately severe dysfunction and those with preserved left ventricular function (area under curve for moderate or severe dysfunction = 0.54). The corresponding values for N-terminal atrial natriuretic peptide for severe and moderate or severe dysfunction were 0.55 and 0.56 respectively. Conclusions: Blood natriuretic peptide concentrations are not useful in identifying important left ventricular systolic dysfunction in stable survivors of myocardial infarction.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Stn Rd Surg, Glasgow, Lanark, Scotland	University of Glasgow	McMurray, JJV (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				BUCKLEY MG, 1993, J HUM HYPERTENS, V7, P245; CHOY AMJ, 1994, BRIT HEART J, V72, P16; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; Davie AP, 1996, BRIT MED J, V313, P300, DOI 10.1136/bmj.313.7052.300c; Davis KM, 1996, J GERONTOL A-BIOL, V51, pM95, DOI 10.1093/gerona/51A.3.M95; FRANCIS CM, 1995, BRIT MED J, V310, P634, DOI 10.1136/bmj.310.6980.634; Friedl W, 1996, HEART, V76, P129, DOI 10.1136/hrt.76.2.129; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Jensen-Urstad K, 1998, AM J CARDIOL, V81, P538, DOI 10.1016/S0002-9149(97)00964-8; LANG CC, 1994, AM HEART J, V127, P1635, DOI 10.1016/0002-8703(94)90401-4; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MURDOCH DR, 1997, HEART, V78, P549; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; NORTHRIDGE DB, 1989, BRIT MED J, V299, P603, DOI 10.1136/bmj.299.6699.603; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; ROBB SD, 1997, J AM COLL CARDIOL, V29, P965; SANDERSON JE, 1995, BRIT HEART J, V74, P502; STRUTHERS AD, 1995, Q J MED, V273, P1450; Tsutamoto T, 1997, AM HEART J, V134, P910, DOI 10.1016/S0002-8703(97)80014-2; WHEELDON NM, 1993, Q J MED, V86, P17; Willenheimer RB, 1997, SCAND CARDIOVASC J, V31, P9, DOI 10.3109/14017439709058063; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988	28	72	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					516	519						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712601				2022-12-24	WOS:000075641400024
J	Bashford, JNR; Norwood, J; Chapman, SR				Bashford, JNR; Norwood, J; Chapman, SR			Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To establish the relation between new prescriptions for proton pump inhibitors and recorded upper gastrointestinal morbidity within a large computerised general practitioner database. Design: Retrospective survey of morbidity and prescribing data linked to new prescriptions for proton pump inhibitors and comparison with licensed indications between 1991 and 1995. Setting: General Practice Research Database and prescribing analysis and cost (PACT) data for the former West Midlands region. Subjects: Information for 612 700 patients in the General Practice Research Database. Anonymous PACT data for all general practitioners in West Midlands region. Main outcome measures: Diagnostic codes linked to the first prescriptions issued for proton pump inhibitors; relation between new prescriptions and licensed indications; yearly change in ratio of new to repeat prescriptions and prescribing volumes measured as defined daily doses. Results: Oesophagitis was the commonest recorded indication in 1991, accounting for 31% of new prescriptions, but was third in 1995 (14%). During the study new prescriptions increased substantially, especially for duodenal disease (780%) and non-ulcer dyspepsia (690%). In 1995 non-specific morbidity accounted for 46% of new prescriptions. The total volume of prescribing rose 10-fold between 1991 and 1995, when repeat prescribing accounted for 77% of the total. Conclusions: Changes in recorded morbidity associated with new prescriptions of proton pump inhibitors did not necessarily reflect changes in licensed indications. Although general practitioners seemed to respond to changes in licensing, particularly for duodenal and gastric disease, prescribing for unlicensed indications non-ulcer dyspepsia and non-specific abdominal pain increased.	Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England	Keele University	Chapman, SR (corresponding author), Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England.							Agreus L, 1997, BRIT MED J, V315, P1284, DOI 10.1136/bmj.315.7118.1284; Bateman DN, 1997, LANCET, V349, P1637, DOI 10.1016/S0140-6736(05)62629-3; Boath EH, 1997, SOC SCI MED, V45, P1571, DOI 10.1016/S0277-9536(97)00094-4; BRADLEY C, 1992, BR J GEN PRACT, V42, P458; *BRIT SOC GASTR, 1996, GUID GASTR, V1; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; Fleming D. M., 1994, Pharmaceutical Medicine (London), V8, P161; HALL G, 1992, PHARMACOEPIDEM DR S, V1, P33; Harris CM, 1996, BRIT J GEN PRACT, V46, P649; HEMINKI E, 1975, SOC SCI MED, V9, P111; HEPBURN A, 1991, PRESCRIBERS J, V31, P49; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; MARINKER M, 1994, CONTROVERSIES HLTH C; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; *OFF NAT STAT, 1996, GEN PRACT RES DAT IN; Pryce AJ, 1996, BRIT MED J, V313, P1621, DOI 10.1136/bmj.313.7072.1621; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; STRICKLANDHODGE B, 1988, J ROY SOC MED, V81, P207, DOI 10.1177/014107688808100407; *WHO COLL CTR DRUG, 1991, GUID DDD	22	104	105	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					452	456						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703528				2022-12-24	WOS:000075490200021
J	Bastian, H; Keirse, MJNC; Lancaster, PAL				Bastian, H; Keirse, MJNC; Lancaster, PAL			Perinatal death associated with planned home birth in Australia: population based study	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY	Objective: To assess the risk of perinatal death in planned home births in Australia. Design: Comparison of data an planned home births during 1985-90, notified to Homebirth Australia, with national data on perinatal deaths and outcomes of home births internationally. Results: 50 perinatal deaths occurred in 7002 planned home births in Australia during 1985-90: 7.1 per 1000 (95% confidence interval 5.2 to 9.1) according to Australian definitions and 6.4 per 1000 (4.6 to 8.3) according to World Health Organisation definitions. The perinatal death rate in infants weighing more than 2500 g was higher than the national average (5.7 versus 3.6 per 1000: relative risk 1.6; 1.1 to 2.4) as were intrapartum deaths not due to malformations or immaturity (2.7 versus 0.9 per 1000: 3.0; 1.9 to 4.8). More than half (52%) of the deaths were associated with intrapartum asphyxia. Conclusions: Australian home births carried a high death rate compared with both all Australian births ana home births elsewhere. The two largest contributors to the excess mortality were underestimation of the risks associated with post-term birth, twin pregnancy and breech presentation, and a lack of response to fetal distress.	Flinders Univ S Australia, Flinders Med Ctr, Dept Obstet & Gynaecol, Adelaide, SA 5100, Australia; Univ New S Wales, Australian Inst Hlth & Welf, Natl Perinatal Stat Unit, Sydney, NSW 2052, Australia	Flinders Medical Centre; Flinders University South Australia; University of New South Wales Sydney	Bastian, H (corresponding author), POB 569, Blackwood, SA 5051, Australia.	hilda.bastian@flinders.edu.au		Bastian, Hilda/0000-0001-8544-7386				Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; Barron SL, 1996, BRIT MED J, V313, P1306; BASTIAN H, 1992, HOME BIRTHS AUSTR 19; BASTIAN H, 1990, HOME BIRTHS AUSTR 19; CHAMBERLAIN G, 1996, HOME BIRTHS REPORT 1; Gardner M. J., 1989, STAT CONFIDENCE; Gulbransen G, 1997, NEW ZEAL MED J, V110, P87; LECKYTHOMPSON M, 1989, CELEBRATING REVOLUTI, P43; Lumley J, 1985, Aust Fam Physician, V14, P1104; Macfarlane A, 1996, BRIT MED J, V312, P754; MEHLMADRONA L, 1997, NURSE MIDWIFERY, V42, P91; *MIDIRS NHS CTR RE, 1997, INF CHOIC WOM; *MIDIRS NHS CTR RE, 1997, INF CHOIC PROF; ODENT M, 1991, MOTHERING, V58, P80; TEW M, 1995, SAFER CHILDBIRTH CRI, P311; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; WIEGERS TA, 1996, BRIT MED J, V313, P1276; WOODCOCK HC, EPIDEMIOLOGICAL STUD; *ZIEK, 1987, VERL IND 1987 FIN RE	19	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					384	388						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694754				2022-12-24	WOS:000075409600025
J	Blusztajn, JK				Blusztajn, JK			Developmental neuroscience - Choline, a vital amine	SCIENCE			English	Editorial Material							MEMORY		Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.	jbluszta@bu.edu		/0000-0001-8438-3122				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Food and Nutrition Board IOM, 1998, DIETARY REFERENCE IN; GARNER SC, 1995, J NUTR, V125, P2851; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572, DOI 10.1093/ajcn/64.4.572; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Tsai AY, 1998, FASEB J, V12, pA235; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1998, FASEB J, V12, P3049	18	306	316	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					794	795		10.1126/science.281.5378.794	http://dx.doi.org/10.1126/science.281.5378.794			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9714685				2022-12-24	WOS:000075295600039
J	Kim, KK; Kim, R; Kim, SH				Kim, KK; Kim, R; Kim, SH			Crystal structure of a small heat-shock protein	NATURE			English	Article							ELECTRON-DENSITY MAPS; ALPHA-CRYSTALLIN; MOLECULAR CHAPERONE; IN-VITRO; 2.8-ANGSTROM; FAMILY; DOMAIN	The principal heat-shock proteins that have chaperone activity (that is, they protect newly made proteins from misfolding) belong to five conserved classes: HSP100, HSP90, HSP70, HSP60 and the small heat-shock proteins (sHSPs). The sHSPs can form large multimeric structures and have a wide range of cellular functions, including endowing cells with thermotolerance in vivo(1,2) and being able to act as molecular chaperones in vitro(3-8); sHSPs do this by forming stable complexes with folding intermediates of their protein substrates(9,10). However, there is little information available about these structures or the mechanism by which substrates are protected from thermal denaturation by sHSPs. Here we report the crystal structure of a small heat-shock protein from Methanococcus jannaschii, a hyperthermophilic archaeon. The monomeric folding unit is a composite beta-sandwich in which one of the beta-strands comes from a neighbouring molecule. Twenty-four monomers form a hollow spherical complex of octahedral symmetry, with eight trigonal and six square 'windows'. The sphere has an outer diameter of 120 Angstrom and an inner diameter of 65 Angstrom.	Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, 220 Melvin Calvin Lab, Berkeley, CA 94720 USA.							BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER A, 1993, XPLOR VERSION 3 1; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; *GCG, 1991, GEN COMP GROUP PROGR; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACOB U, 1993, J BIOL CHEM, V268, P1517; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KK, 1998, J STRUCT BIOL, V121, P76, DOI 10.1006/jsbi.1998.3969; KIM R, IN PRESS P NATL ACAD; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; TSENG TS, 1992, PLANT MOL BIOL, V18, P963, DOI 10.1007/BF00019209; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Yeh CH, 1997, P NATL ACAD SCI USA, V94, P10967, DOI 10.1073/pnas.94.20.10967	27	772	819	2	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					595	599		10.1038/29106	http://dx.doi.org/10.1038/29106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707123				2022-12-24	WOS:000075238700053
J	Smith, MA; Doliszny, KM; Shahar, E; McGovern, PG; Arnett, DK; Luepker, RV				Smith, MA; Doliszny, KM; Shahar, E; McGovern, PG; Arnett, DK; Luepker, RV			Delayed hospital arrival for acute stroke: The Minnesota stroke survey	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; time factors; patient education; Asian Americans; activities of daily living	ACUTE MYOCARDIAL-INFARCTION; ACUTE ISCHEMIC STROKE; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; SPECIAL-WRITING-GROUP; PREHOSPITAL DELAY; TIME; INTERVENTION; THROMBOLYSIS; GUIDELINES	Background: Although recent advances have been made in the treatment of acute stroke, patients often arrive at the hospital too late to receive the maximum benefit from these new therapies. Objective: To investigate characteristics that influence the time from symptom onset to hospital arrival (delay time) for patients with acute stroke. Design: Retrospective medical record review. Setting: Minneapolis-St. Paul metropolitan hospitals. Patients: A 50% random sample of all patients 30 to 79 years of age who were hospitalized with acute stroke from 1991 to 1993. Measurements: Patients were identified through discharge diagnosis lists by using the International Classification of Diseases, 9th Revision. Trained nurses abstracted the medical records. Stroke events were validated by using neuroimaging reports and additional clinical criteria (1895 patients). An accelerated failure time model was used to identify patient characteristics that independently predicted delay time. For 70% of patients (n = 1334), delay time was calculated from the medical record by subtracting the recorded time of symptom onset from the admission time. For the remaining 30% of patients (n = 561), the time of symptom onset was not recorded, and an approximate delay time was estimated from all available information. Results: Among patients with a calculated delay time, half arrived within 3 hours of symptom onset and 90% arrived within 24 hours. Patients with approximated delay times tended to have longer delays, and less than 40% of these patients arrived within 24 hours of symptom onset. Some characteristics associated (P < 0.05) with longer delay included Asian/Pacific Islander ethnicity, dependence in any activities of daily living before stroke, and several symptoms at stroke onset. Characteristics associated (P < 0.05) with shorter delay included admission through the emergency department, presence of syncope or seizures at stroke onset, previous myocardial infarction, abnormal mental status, and greater disability at presentation (measured by the Rankin scale). Conclusions: Most patients arrive at the hospital too late to receive the maximum benefit from emerging stroke therapies. Efforts to reduce delays in hospital arrival after acute stroke can maximize the effectiveness of these thera pies by specifically targeting persons at risk for longer delay.	Univ Minnesota, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities	Luepker, RV (corresponding author), Univ Minnesota, Div Epidemiol, Sch Publ Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams HP, 1996, STROKE, V27, P1711; ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; ALONZO AA, 1986, SOC SCI MED, V22, P1297, DOI 10.1016/0277-9536(86)90093-6; Barinaga M, 1996, SCIENCE, V272, P664; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; DAVALOS A, 1995, STROKE, V26, P2233, DOI 10.1161/01.STR.26.12.2233; Dorman P, 1996, LANCET, V348, P1600, DOI 10.1016/S0140-6736(05)65688-7; Dracup K, 1997, ANN INTERN MED, V126, P645, DOI 10.7326/0003-4819-126-8-199704150-00010; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; Fogelholm R, 1996, STROKE, V27, P398, DOI 10.1161/01.STR.27.3.398; GALLERANI M, 1993, ACTA NEUROL SCAND, V87, P482; Gurwitz JH, 1997, ANN INTERN MED, V126, P593, DOI 10.7326/0003-4819-126-8-199704150-00001; Hachinski V, 1996, JAMA-J AM MED ASSOC, V276, P995, DOI 10.1001/jama.276.12.995; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835; HARRISON I, 1971, HLTH FAMILY MED SOCI; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KENYON LW, 1991, CIRCULATION, V84, P1969, DOI 10.1161/01.CIR.84.5.1969; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; LEIBSON CL, 1994, STROKE, V25, P2348, DOI 10.1161/01.STR.25.12.2348; Mechanic D., 1978, MED SOCIOLOGY; MOSS AJ, 1969, AM J CARDIOL, V24, P659, DOI 10.1016/0002-9149(69)90453-6; MOSS AJ, 1970, CIRCULATION, V41, P737, DOI 10.1161/01.CIR.41.5.737; NORRIS JW, 1982, LANCET, V1, P328; Pincus MM, 1997, JAMA-J AM MED ASSOC, V277, P19, DOI 10.1001/jama.277.1.19; RANKIN J, 1957, Scott Med J, V2, P200; Rosamond WD, 1998, ACAD EMERG MED, V5, P45, DOI 10.1111/j.1553-2712.1998.tb02574.x; SAS Institute Inc, 1989, SAS STAT US GUID VER; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; Shahar E, 1997, STROKE, V28, P275, DOI 10.1161/01.STR.28.2.275; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325	35	128	131	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					190	+		10.7326/0003-4819-129-3-199808010-00005	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696726				2022-12-24	WOS:000075032700003
J	Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA				Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA			An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients	LANCET			English	Article							SOLID-ORGAN TRANSPLANTATION; ANTI-HLA ANTIBODIES; HEART-TRANSPLANTATION; ALLOGRAFT-REJECTION; LUNG-TRANSPLANTATION; SURVIVAL; MICROCHIMERISM; CELLS	Background Transplant-related coronary-artery disease (TCAD) develops frequently in cardiac-allograft recipients, and limits long-term survival. We examined the relation between this disorder and cumulative frequency of high-grade rejection, and investigated whether concomitant use of three immunological factors at the time of a low-grade endomyocardial biopsy can predict progression to high-grade rejection. Methods We investigated the relation between the cumulative annual frequency of high-grade rejection and TCAD in 198 recipients of cardiac transplantation between 1992 and 1996 by means of Kaplan-Meier actuarial life-tables. Endomyocardial biopsy, lymphocyte-growth assays, and anti-HLA antibody measurements were compiled over 12 months in 102 patients during their first post-transplant year. We calculated predictive values for high-grade rejection within 90 days by chi(2), Kaplan Meier survival curves, and by multivariable logistic regression analyses. Findings We found a direct correlation between cumulative annual frequency of rejection and TCAD onset with highest risk in those with more than 0.75 rejections per year (p=0.0002). After a low-grade endomyocardial biopsy (0 or 1A), one or more donor-recipient HLA-DR matches protected against high-grade rejections (p<0.001). Among individuals with one or two DR matches, the negative predictive value for progression from a low-grade biopsy to a high-grade rejection was 87% in the presence of a negative lymphocyte-growth assay. Among individuals with no DR matches, the presence of either lymphocyte-growth assay or IgG anti-major-histocompatibility complex (MHC) class II antibodies was independently associated With high probability of progression to rejection (64% and 68%, respectively, p<0.0005). When both assays were positive, concomitantly with a low-grade endomyocardial biopsy, the positive predictive value for progression to a high-grade rejection was 86% (p<0.0001). For endomyocardial-biopsy grades 1B or 2, a positive lymphocyte-growth assay alone was associated with high-grade rejection in 100% of cases. Interpretation Use of an algorithm combining three immunological factors at the time of a low-grade endomyocardial biopsy enables prospective stratification of cardiac transplant recipients into risk categories for progression to high-grade rejection. Low-risk individuals require fewer biopsies, moderate-risk individuals require an ongoing schedule of surveillance biopsies, and high-risk individuals require rational organisation of interventional strategies aimed at preventing rejection. Additional predictive factors are needed to identify moderate-risk individuals who will progress to rejection. Ultimately, successful intervention may have an impact on the subsequent complication of TCAD.	Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA	Columbia University	Itescu, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, 622 W 168th St,PH 14 W, New York, NY 10032 USA.	si5@columbia.edu						BILLINGHAM ME, 1990, J HEART TRANSPLANT, V9, P272; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; CONSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, pS90; Creemers P, 1997, NEPHRON, V75, P166, DOI 10.1159/000189526; DEMATTOS AM, 1994, TRANSPLANTATION, V57, P626; FISCHER PE, 1995, J HEART LUNG TRANSPL, V14, P1156; GEORGE JF, 1995, J HEART LUNG TRANSPL, V14, P856; HALL T S, 1986, Journal of Heart Transplantation, V5, P419; HESS ML, 1983, CIRCULATION, V68, P94; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; ITESCU S, 1998, IN PRESS CIRCULATION; JARCHO J, 1994, J HEART LUNG TRANSPL, V13, P583; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMKES BM, 1992, J HEART LUNG TRANSPL, V11, pS221; KEOGH A, 1995, J HEART LUNG TRANSPL, V14, P444; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KORMOS R, 1992, J HEART LUNG TRANSPL, V11, pS104; Krieger NR, 1996, J EXP MED, V184, P2013, DOI 10.1084/jem.184.5.2013; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIU Z, 1993, J EXP MED, V177, P1643, DOI 10.1084/jem.177.6.1643; Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MARKUS PM, 1993, CELL TRANSPLANT, V2, P345, DOI 10.1177/096368979300200418; REED EF, 1996, TRANSPLANTATION, V61, P556; RIZEQ MN, 1994, J HEART LUNG TRANSPL, V13, P862; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SMITH JD, 1992, TRANSPLANTATION, V53, P1358, DOI 10.1097/00007890-199206000-00034; SMITH JD, 1995, LANCET, V346, P1318, DOI 10.1016/S0140-6736(95)92341-1; Starzl T E, 1994, Prog Liver Dis, V12, P191; SUCIUFOCA N, 1991, TRANSPLANTATION, V51, P716, DOI 10.1097/00007890-199103000-00033; Tugulea S, 1997, TRANSPLANTATION, V64, P842, DOI 10.1097/00007890-199709270-00009; VALENTINE H, 1991, J HEART LUNG TRANSPL, V10, P757; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; White JA, 1995, J HEART LUNG TRANSPL, V14, P1052; WINTERS GL, 1995, CIRCULATION, V91, P1975, DOI 10.1161/01.CIR.91.7.1975; WISENBERG G, 1987, AM J CARDIOL, V60, P130, DOI 10.1016/0002-9149(87)90999-4; ZAVAZAVA N, 1993, TISSUE ANTIGENS, V42, P20, DOI 10.1111/j.1399-0039.1993.tb02161.x; ZEEVI A, 1995, TRANSPLANTATION, V59, P616	40	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					263	270		10.1016/S0140-6736(98)09475-6	http://dx.doi.org/10.1016/S0140-6736(98)09475-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690405	hybrid			2022-12-24	WOS:000074974500008
J	Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW				Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW			Provision of syringes: the cutting edge of harm reduction in prison?	BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS-DRUG-USERS; HEPATITIS-C VIRUS; HIV-INFECTION; AUSTRALIAN PRISON; RISK BEHAVIOR; NEEDLE; AIDS; PREVALENCE; EXCHANGE; PENITENTIARY		Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland; Univ Geneva, Inst Med Legale, CH-1211 Geneva, Switzerland	University of Bern; University of Geneva	Nelles, J (corresponding author), Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland.							ANON C, 1995, REV ESP ENFERM DIG, V87, P505; BREWER TF, 1992, AIDS, V6, P623, DOI 10.1097/00002030-199207000-00002; Council of Europe, 1993, R936 COUNC EUR; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1995, AIDS, V9, P825, DOI 10.1097/00002030-199508000-00001; DOLAN K, 1994, MED J AUSTRALIA, V160, P734, DOI 10.5694/j.1326-5377.1994.tb125930.x; DOLAN K, 1997, STRATEGIES DRUGS AID, P213; DUBOISARBER F, 1991, EVALUATION AIDS PRAV; FORD PM, 1995, CAN MED ASSOC J, V153, P1605; Frischer M, 1996, LANCET, V347, P768, DOI 10.1016/S0140-6736(96)90121-X; Gaiter J, 1996, AM J PUBLIC HEALTH, V86, P1201, DOI 10.2105/AJPH.86.9.1201; Gaube J, 1993, Gesundheitswesen, V55, P246; HARDING TW, 1997, HARM REDUCTION PRISO, P161; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; Mahon N, 1996, AM J PUBLIC HEALTH, V86, P1211, DOI 10.2105/AJPH.86.9.1211; MARTIN G S, 1990, AIDS Care, V2, P275, DOI 10.1080/09540129008257740; MEYENBERG R, 1996, INFEKTIONSPROPHYLAXE; MYERS T, 1995, ADDICTION, V90, P217, DOI 10.1111/j.1360-0443.1995.tb01039.x; Nelles J., 1997, HARM REDUCTION PRISO, P239; NELLES J, 1997, KURZEVALUATION PILOT; NELLES J, 1997, HARM REDUCTION PRISO; Nelles J., 1995, DRUG HIV PREVENTION; NELLES J, 1997, INT J DRUG POLICY, V1, P2; PAPE U, 1996, 54 KRIM FORSCH NIED; Polych C, 1995, MENS HLTH ILLNESS GE, P139; STARK K, 1995, SCAND J INFECT DIS, V27, P331, DOI 10.3109/00365549509032726; STARK K, 1995, ADDICTION, V90, P1367, DOI 10.1111/j.1360-0443.1995.tb03554.x; STEPHENS RC, 1991, AM J PUBLIC HEALTH, V81, P568, DOI 10.2105/AJPH.81.5.568; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; THOMAS PA, 1994, AIDS PRISON; VLAHOV D, 1993, EUR J EPIDEMIOL, V9, P566, DOI 10.1007/BF00209538; *WHO, 1993, GLOB PROGR AIDS WHO; 1995, LANCET, V346, P1397	35	31	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					270	273		10.1136/bmj.317.7153.270	http://dx.doi.org/10.1136/bmj.317.7153.270			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677225	Green Published			2022-12-24	WOS:000075081900031
J	Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD				Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD			Prevalence and predictors of the prone sleep position among inner-city infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; PROGRAM; COHORT; HEALTH; RISK; SIDS; BACK; CARE	Context.-The prone sleep position is associated with an increased risk of sudden infant death syndrome (SIDS), but few studies have assessed factors associated with the choice of infant sleep position. Objectives.-To describe infant sleep position in a cohort of infants born to predominantly low-income, inner-city mothers and to identify predictors of the prone sleep position in this population. Design.-Prospective birth cohort study. Patients and Setting.-Three hundred ninety-four mother-infant dyads, systematically selected from 3 District of Columbia hospitals between August 1995 and September 1996, Mothers were interviewed shortly after delivery and again at 3 to 7 months postpartum. Main Outcome Measures.-Position in which infants were placed for sleep on the night prior to the 3- to 7-month interview. Results.-At 3 to 7 months of age, 157 infants (40%) were placed for sleep in the prone position. Independent predictors of prone sleep position included poverty (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.10-2.99), black race (OR, 2.06; 95% CI, 1.05-4.04), presence of infant's grandmother in the home (OR, 1.83; 95% CI, 1.11-3.00), and intent, as measured shortly after delivery, to place the infant in the prone position (OR, 2.28; 95% CI, 1.44-3.60), Importantly, of the 43 mothers who observed their infants in the prone sleep position while in the hospital, 40 (93%) intended to place their infants prone at home. Conclusions.-A substantial proportion of infants in this predominantly low-income population were placed in the prone sleep position. Educational efforts should address both initial intentions and reinforcement of the correct sleep position, once initiated. Hospitals should ensure that healthy newborn infants are placed in the supine sleep position during the postpartum hospital stay.	NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA; Res Triangle Inst, Rockville, MD USA; Georgetown Univ Hosp, Div Neonatol, Washington, DC 20007 USA; Univ Dist Columbia, Dept Biol & Environm Sci, Washington, DC USA; Childrens Natl Med Ctr, Dept Neonatol, Washington, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Research Triangle Institute; Georgetown University; University of the District of Columbia; Children's National Health System	Brenner, RA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, 6100 Execut Blvd,Room 7B03, Bethesda, MD 20892 USA.	BrennerR@nih.gov		Simons-Morton, Bruce/0000-0003-1099-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U18HD030447, U18HD030450, U18HD030458] Funding Source: NIH RePORTER; NICHD NIH HHS [U18-HD30458, U18-HD30450, U18-HD30447] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1996, FED REGISTER, V61, P8286; Bandura A., 1986, SOCIAL FDN THOUGHT A; BATES AS, 1995, JAMA-J AM MED ASSOC, V272, P1105; BURD L, 1994, PUBLIC HEALTH REP, V109, P446; CHESSARE JB, 1995, PEDIATRICS, V96, P893; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; ELLEN JM, 1995, PEDIATR EMERG CARE, V11, P223, DOI 10.1097/00006565-199508000-00008; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Hiley CMH, 1995, ARCH DIS CHILD, V73, P496, DOI 10.1136/adc.73.6.496; Johnson CM, 1996, PEDIATRICS, V98, P163; KAHN A, 1993, PEDIATRICS, V91, P1112; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; Kemp JS, 1996, SLEEP, V19, pS263, DOI 10.1093/sleep/19.suppl_10.S263; MARKESTAD T, 1995, ACTA PAEDIATR, V84, P375, DOI 10.1111/j.1651-2227.1995.tb13653.x; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; PONSONBY AL, 1995, ARCH DIS CHILD, V72, P204, DOI 10.1136/adc.72.3.204; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; Rogers EM, 1983, DIFFUSION INNOVATION; Sawczenko A, 1996, SLEEP, V19, pS267; Taylor JA, 1996, ARCH PEDIAT ADOL MED, V150, P834, DOI 10.1001/archpedi.1996.02170330060010; Taylor JA, 1996, J PEDIATR-US, V128, P626, DOI 10.1016/S0022-3476(96)80126-0; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664; WILLINGER M, 1995, PEDIATR ANN, V24, P358, DOI 10.3928/0090-4481-19950701-07; Willinger M, 1998, JAMA-J AM MED ASSOC, V280, P329, DOI 10.1001/jama.280.4.329; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1995, JAMA-J AM MED ASSOC, V273, P818, DOI 10.1001/jama.273.10.818	34	85	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					341	346		10.1001/jama.280.4.341	http://dx.doi.org/10.1001/jama.280.4.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686551	Bronze			2022-12-24	WOS:000074804200034
J	Ghosh, S; Drummond, HE; Ferguson, A				Ghosh, S; Drummond, HE; Ferguson, A			Neglect of growth and development in the clinical monitoring of children and teenagers with inflammatory bowel disease: review of case records	BRITISH MEDICAL JOURNAL			English	Article									Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Ferguson, A (corresponding author), Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							BARTON JR, 1989, BRIT MED J, V298, P865, DOI 10.1136/bmj.298.6677.865; KURTZ Z, 1996, SERVICES YOUNG PEOPL, P141	2	14	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					120	121		10.1136/bmj.317.7151.120	http://dx.doi.org/10.1136/bmj.317.7151.120			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657788	Green Published, Green Submitted			2022-12-24	WOS:000075081700023
J	Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G				Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G			Antagonism between extradenticle function and Hedgehog signalling in the developing limb	NATURE			English	Article							HUMAN PROTOONCOGENE PBX1; LONG-RANGE ACTION; DISTAL-LESS; MORPHOGEN GRADIENT; DROSOPHILA EMBRYO; LEG DEVELOPMENT; GENE ACTIVITY; WINGLESS; PROTEIN; PATTERN	The Drosophila homeobox gene extradenticle (exd) encodes a highly conserved cofactor of Hox proteins(1-3). exd activity is regulated post-translationally by a mechanism involving nuclear translocation(4,5); only nuclear Exd protein is functional. The exd gene is required for patterning of the proximal region of the leg(6,7), whereas patterning of the distal region requires signalling by the Wingless (Wg) and Decapentaplegic (Dpp)(8,9) proteins, which are in turn activated by Hedgehog (Hh)(10). Here we show that exd function and Dpp/Wg signalling are antagonistic and divide the leg into two mutually exclusive domains. In the proximal domain, exd activity prevents cells from responding to Dpp and Wg, Conversely, in the distal domain, exd function is suppressed by the Dpp/Wg response gene Distal-less (Dll), which prevents the nuclear transport of Exd, We also found that the product of a murine homologue of exd (Pbx1) is regulated at the subcellular level, and that its pattern of nuclear localization in the mouse limb resembles that of Exd in the Drosophila leg. These findings suggest that the division of the limb into two antagonistic domains, as defined by exd (Pbx1) function and Hh signalling, may be a general feature of limb development.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrat Program Cellular Mol & Biophys Stud, New York, NY 10032 USA; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Columbia University; Columbia University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Morata, G (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain.		Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767; Morata, Gines/0000-0003-3274-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575, R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058575, R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIAZBENJUMES FJ, 1994, NATURE, V32, P175; Fuse N, 1996, DEVELOPMENT, V122, P1059; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1997, DEVELOPMENT, V124, P125; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MARDON G, 1994, DEVELOPMENT, V120, P3473; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Torres M, 1995, DEVELOPMENT, V121, P4057; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	29	129	130	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					196	200		10.1038/28197	http://dx.doi.org/10.1038/28197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671305				2022-12-24	WOS:000074705900058
J	Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK				Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK			Complete structure of the 11-subunit bovine mitochondrial cytochrome bc(1) complex	SCIENCE			English	Article							IRON-SULFUR PROTEIN; C REDUCTASE; PROCESSING PEPTIDASE; BC1 COMPLEX; BEEF-HEART; UBIQUINOL; OXIDOREDUCTASE; OXIDATION; BINDING; SITE	Mitochondrial cytochrome bc(1) complex performs two functions: It is a respiratory multienzyme complex and it recognizes a mitochondrial targeting presequence. Refined crystal structures of the 11-subunit bc(1) complex from bovine heart reveal full views of this bifunctional enzyme. The "Rieske" iron-sulfur protein subunit shows significant conformational changes in different crystal forms, suggesting a new electron transport mechanism of the enzyme. The mitochondrial targeting presequence of the "Rieske" protein (subunit 9) is lodged between the two "core" subunits at the matrix side of the complex. These "core" subunits are related to the matrix processing peptidase, and the structure unveils how mitochondrial targeting presequences are recognized.	Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ Frankfurt Klinikum, ZBC, D-60590 Frankfurt, Germany; Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France	Uppsala University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Swedish University of Agricultural Sciences; Goethe University Frankfurt; Goethe University Frankfurt Hospital; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	Iwata, S (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	iwata@xray.bmc.uu.se; BKJap@lbl.gov	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1997, IN PRESS P 9 INT S P; DENG K, 1996, BIOPHYS J, V72, pA319; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, 1997, BIOINORG CHEM, P312; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Robinson, 1982, CYCLOTRONS CYTOCHROM, P263, DOI 10.1016/B978-0-12-397580-5.50026-0; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1998, BIOCHIM BIOPHYS ACTA, V1365, P261; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1991, J BIOL CHEM, V266, P6416; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	1032	1068	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					64	71		10.1126/science.281.5373.64	http://dx.doi.org/10.1126/science.281.5373.64			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651245				2022-12-24	WOS:000074685800037
J	Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF				Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF			Metabolic abnormalities in developmental dyslexia detected by H-1 magnetic resonance spectroscopy	LANCET			English	Article							DEFICITS; CHILDREN	Background Neurological and physiological deficits have been reported in the brain in developmental dyslexia. The temporoparietal cortex has been directly implicated in dyslexic dysfunction, and substantial indirect evidence suggests that the cerebellum is also implicated. We wanted to find out whether the neurological and physiological deficits manifested as biochemical changes in the brain. Methods We obtained localised proton magnetic resonance spectra bilaterally from the temporo-parietal cortex and cerebellum of 14 well-defined dyslexic men and 15 control men of similar age. Findings We found biochemical differences between dyslexic men and controls in the left temporo-parietal lobe (ratio of choline-containing compounds [Cho] to N-acetylaspartate [NA] p less than or equal to 0.01) and right cerebellum (Cho/NA, p less than or equal to 0.01; creatine [Cre] to NA p less than or equal to 0.05; (not significant). We found lateral biochemical differences in dyslexic men in both these brain regions (Cho/NA in temporo-parietal lobe, left vs right, p less than or equal to 0.01; Cre/NA in cerebellum, left vs right, p less than or equal to 0.001). We found no such lateral differences in controls. There was no significant relation between the degree of contralateral chemical difference and handedness in dyslexic or control men. Interpretation We suggest that the observed differences reflect changes in cell density in the temporo-parietal lobe in developmental dyslexia and that the altered cerebral structural symmetry in dyslexia is associated with abnormal development of cells or intracellular connections or both. The cerebellum is biochemically asymmetric in dyslexic men, indicating altered development of this organ. These differences provide direct evidence of the involvement of the cerebellum in dyslexic dysfunction.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; John Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Sydney; University of Oxford; Radcliffe Infirmary; University of Oxford	Rae, C (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.	crae@biochem.usyd.edu.au	Rae, Caroline/B-7537-2008; Blamire, Andrew/AAU-6100-2021; Thompson, Campbell/E-2885-2010	Rae, Caroline/0000-0003-0673-8084; Thompson, Campbell/0000-0002-5164-3327; Blamire, Andrew/0000-0002-8749-1257; Richardson, Alex/0000-0001-5650-4409				ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; CASTLES A, 1993, COGNITION, V47, P149, DOI 10.1016/0010-0277(93)90003-E; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; FAWCETT AJ, 1992, PERCEPT MOTOR SKILL, V75, P507, DOI 10.2466/pms.1992.75.2.507; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; HIER DB, 1978, ARCH NEUROL-CHICAGO, V35, P90, DOI 10.1001/archneur.1978.00500260028005; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE WJ, 1980, NEUROPSYCHOLOGIA, V18, P111, DOI 10.1016/0028-3932(80)90093-7; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; NICOLSON RI, 1995, P ROY SOC B-BIOL SCI, V259, P43, DOI 10.1098/rspb.1995.0007; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; Rae C, 1996, P ROY SOC B-BIOL SCI, V263, P1061, DOI 10.1098/rspb.1996.0156; RAMSEY JM, 1992, ARCH NEUROL-CHICAGO, V49, P527; SNOWLING MJ, 1987, DYXLEXIA COGNITIVE D; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; STEIN JF, 1992, PHYSIOL REV, V72, P967, DOI 10.1152/physrev.1992.72.4.967; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; TEDESCHI G, 1995, NEUROLOGY, V45, P1384, DOI 10.1212/WNL.45.7.1384; TRACEY I, 1995, LANCET, V345, P1260, DOI 10.1016/S0140-6736(95)90923-0; VAN IJZENDOORN MH, 1994, READ RES QUART, V29, P267; WILSHER CR, 1987, J CLIN PSYCHOPHARM, V7, P230	25	138	138	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1849	1852		10.1016/S0140-6736(97)99001-2	http://dx.doi.org/10.1016/S0140-6736(97)99001-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652669				2022-12-24	WOS:000074347100012
J	Stell, IM; Gransden, WR				Stell, IM; Gransden, WR			Simple tests for septic bursitis: comparative study	BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust	Stell, IM (corresponding author), Univ London Kings Coll Hosp, Kings Healthcare NHS Trust, Dept Accid & Emergency, London SE5 9RS, England.							FREEMONT AJ, 1991, ANN RHEUM DIS, V50, P101, DOI 10.1136/ard.50.2.101; HO G, 1979, ARCH INTERN MED, V139, P1269, DOI 10.1001/archinte.139.11.1269; RADDATZ DA, 1987, J RHEUMATOL, V14, P1160; VONESSEN R, 1986, ANN RHEUM DIS, V45, P454, DOI 10.1136/ard.45.6.454; ZIMMERMANN B, 1995, SEMIN ARTHRITIS RHEU, V24, P391, DOI 10.1016/S0049-0172(95)80008-5	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1877	1877						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632407	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000074686500024
J	Cavert, W; Hase, AT				Cavert, W; Hase, AT			A National Tissue Bank to track HIV eradication and immune reconstitution	SCIENCE			English	Editorial Material									Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Cavert, W (corresponding author), Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; McArthur JC, 1997, ANN NEUROL, V42, P689, DOI 10.1002/ana.410420504; *OFF AIDS RES ADV, 1996, REP NIH AIDS RES PRO; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKER NG, 1998, NAT MED, V4, P208; Price RW, 1997, ANN NEUROL, V42, P675, DOI 10.1002/ana.410420502; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	16	10	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1865	1866		10.1126/science.280.5371.1865	http://dx.doi.org/10.1126/science.280.5371.1865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669943				2022-12-24	WOS:000074323800039
J	Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD				Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD			Family history of colorectal adenomatous polyps and increased risk for colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; adenomatous polyposis coli; age factors; colonoscopy; risk factors	NONPOLYPOSIS COLON-CANCER; FIRST-DEGREE RELATIVES; LARGE BOWEL; TUMORS; SUSCEPTIBILITY; INHERITANCE; DISEASE; HABITS; AGE	Background: The risk for colorectal cancer among family members of patients with colorectal cancer is well established, but the risk among family members of patients with colorectal adenomas is less well established. Objective: To examine the risk for colorectal cancer among first-degree relatives of patients with adenoma compared with that among first-degree relatives of controls without adenoma. Design: Reconstructed cohort study. Setting: Three university-based colonoscopy practices in New York City. Patients: 1554 first-degree relatives of 244 patients with newly diagnosed adenomas and 2173 first-degree relatives of 362 endoscopically normal controls. Measurements: Structured interviews were used to obtain family history. Adjusted relative risks (RR) were estimated from Cox proportional hazards regression models. Results: The risk for colorectal cancer was elevated (RR, 1.74 [95% CI, 1.24 to 2.45]) among first-degree relatives of patients with newly diagnosed adenomas compared with the risk among first-degree relatives of controls. This increased risk was the same for parents (RR, 1.58 [CI, 1.07 to 2.34]) and siblings (RR, 1.58 [CI, 0.81 to 3.08]). First-degree relatives of patients with adenomas did not have elevated risk for other cancers. The risk for colorectal cancer among family members increased with decreasing age at diagnosis of adenoma in probands. Among first-degree relatives of patients who were 50 years of age or younger when the adenoma was diagnosed, the risk was more than four times greater (RR, 4.36 [CI, 2.24 to 8.51]) than that among first-degree relatives of patients who were older than 60 years of age when the adenoma was diagnosed. Conclusions: First-degree relatives of patients with newly diagnosed adenomas, particularly of patients who are 50 years of age or younger at diagnosis, are at increased risk for colorectal cancer and should undergo screening similar to that recommended for relatives of patients with colorectal cancer.	Columbia Presbyterian Med Ctr, Div Oncol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Dept Surg, New York, NY 10032 USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10027 USA; Mt Sinai Sch Med, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai	Neugut, AI (corresponding author), Columbia Presbyterian Med Ctr, Div Oncol, 630 W 168th St, New York, NY 10032 USA.	ain1@columbia.edu			NATIONAL CANCER INSTITUTE [T32CA009529, R01CA037196] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA37196, 5T32-CA09529-11A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; BAZZOLI F, 1995, GASTROENTEROLOGY, V109, P783, DOI 10.1016/0016-5085(95)90385-2; BONELLI L, 1988, INT J CANCER, V41, P513; BOUTRON MC, 1995, GUT, V37, P830, DOI 10.1136/gut.37.6.830; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; GUILLEM JG, 1992, DIS COLON RECTUM, V35, P523, DOI 10.1007/BF02050530; HALL NR, 1994, BRIT J SURG, V81, P1485, DOI 10.1002/bjs.1800811029; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; KATO I, 1990, JPN J CANCER RES, V81, P115, DOI 10.1111/j.1349-7006.1990.tb02536.x; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KHOURY MJ, 1995, EPIDEMIOLOGY, V6, P511, DOI 10.1097/00001648-199509000-00009; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUNE GA, 1991, NUTR CANCER, V16, P25, DOI 10.1080/01635589109514137; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LeMarchand L, 1996, AM J EPIDEMIOL, V144, P1122, DOI 10.1093/oxfordjournals.aje.a008890; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; NEUGUT AI, 1993, AM J GASTROENTEROL, V88, P1179; NEUGUT AI, 1993, CANCER EPIDEM BIOMAR, V2, P159; NEUGUT AI, 1993, ANN INTERN MED, V118, P91, DOI 10.7326/0003-4819-118-2-199301150-00002; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Winawer SJ, 1996, NEW ENGL J MED, V334, P82, DOI 10.1056/NEJM199601113340204	34	108	109	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					900	+		10.7326/0003-4819-128-11-199806010-00006	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634428				2022-12-24	WOS:000073808600004
J	Boysen, G; Truelsen, T				Boysen, G; Truelsen, T			Looking beyond first-ever stroke incidence	LANCET			English	Editorial Material							RISK-FACTORS; RACE		Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark; Kommune Hosp, Inst Prevent Med, DK-1399 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Boysen, G (corresponding author), Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark.		Truelsen, Thomas/AAY-1549-2020					*AM HEART ASS, 1997, HEART STROK STAT UPD; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brown RD, 1996, STROKE, V27, P373; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HORNER RD, 1991, STROKE, V22, P1497, DOI 10.1161/01.STR.22.12.1497; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; RESCH JA, 1970, ATHEROSCLEROSIS, V12, P401, DOI 10.1016/0021-9150(70)90044-4; SACCO RL, 1995, NEUROLOGY, V45, P659, DOI 10.1212/WNL.45.4.659; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4	11	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1073	1074		10.1016/S0140-6736(05)79374-0	http://dx.doi.org/10.1016/S0140-6736(05)79374-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660571				2022-12-24	WOS:000073090200003
J	Carballo, E; Lai, WS; Blackshear, PJ				Carballo, E; Lai, WS; Blackshear, PJ			Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin	SCIENCE			English	Article							FINGER TRANSCRIPTION FACTOR; MESSENGER-RNA DEGRADATION; TNF-ALPHA; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; PROTEIN; GENE; EXPRESSION; ARTHRITIS; DISEASE	Tumor necrosis factor-alpha (TNF-alpha) is a major mediator of both acute and chronic inflammatory responses in many diseases. Tristetraprolin (TTP), the prototype of a class of Cys-Cys-Cys-His (CCCH) zinc finger proteins, inhibited TNF-alpha production from macrophages by destabilizing its messenger RNA. This effect appeared to result from direct TTP binding to the AU-rich element of the TNF-alpha messenger RNA. TTP is a cytosolic protein in these cells, and its biosynthesis was induced by the same agents that stimulate TNF-alpha production. including TNF-alpha itself. These findings identify TTP as a component of a negative feedback Loop that interferes with TNF-alpha production by destabilizing its messenger RNA. This pathway represents a potential target for anti-TNF-alpha therapies.	NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; CARBALLO E, UNPUB; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; JACOB CO, 1992, J AUTOIMMUN, V5, P133, DOI 10.1016/0896-8411(92)90028-O; Jorres A, 1997, CYTOKINE, V9, P119, DOI 10.1006/cyto.1996.0145; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lai W.-Y., UNPUB; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; LAI WS, 1990, J BIOL CHEM, V265, P16556; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; Lorenz HM, 1996, J IMMUNOL, V156, P1646; ODEH M, 1990, J INTERN MED, V228, P549, DOI 10.1111/j.1365-2796.1990.tb00278.x; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; SHALABY MR, 1989, TRANSPLANTATION, V47, P1057, DOI 10.1097/00007890-198906000-00028; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi Y, 1997, J BIOL CHEM, V272, P29290, DOI 10.1074/jbc.272.46.29290; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	36	968	996	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					1001	1005		10.1126/science.281.5379.1001	http://dx.doi.org/10.1126/science.281.5379.1001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703499	Green Submitted			2022-12-24	WOS:000075412700051
J	Schmid, DS				Schmid, DS			Role of HHV-8 in Kaposi sarcoma - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DNA-SEQUENCES; HERPESVIRUS; ANTIBODIES; INFECTION; ANTIGENS		Ctr Dis Control & Prevent, Viral Immunol Sect, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Schmid, DS (corresponding author), Ctr Dis Control & Prevent, Viral Immunol Sect, Atlanta, GA 30333 USA.							BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Blauvelt A, 1997, J INFECT DIS, V176, P771, DOI 10.1086/517298; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	15	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					570	571		10.1001/jama.280.6.570	http://dx.doi.org/10.1001/jama.280.6.570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707154				2022-12-24	WOS:000075244900040
J	Strathdee, SA; Palepu, A; Cornelisse, PGA; Yip, B; O'Shaughnessy, MV; Montaner, JSG; Schechter, MT; Hogg, RS				Strathdee, SA; Palepu, A; Cornelisse, PGA; Yip, B; O'Shaughnessy, MV; Montaner, JSG; Schechter, MT; Hogg, RS			Barriers to use of free antiretroviral therapy in injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV; ZIDOVUDINE; INFECTION; ACCESS	Context.-In British Columbia, human immunodeficiency virus (HIV)-infected persons eligible for antiretroviral therapy may receive it free but the extent to which HIV-infected injection drug users access it is unknown. Objective.-To identify patient and physician characteristics associated with antiretroviral therapy utilization in HIV-infected injection drug users. Design.-Prospective cohort study with record linkage between survey data and data from a provincial HIV/AIDS (acquired immunodeficiency syndrome) drug treatment program. Setting.-British Columbia, where antiretroviral therapies are offered free to all persons with HIV infection with CD4 cell counts less than 0.50x10(9)/L (500/mu L) and/or HIV-1 RNA levels higher than 5000 copies/mL. Subjects.-A total of 177 HIV-infected injection drug users eligible for antiretroviral therapy, recruited through the prospective cohort study since May 1996. Main Outcome Measures.-Patient use of antiretroviral drugs through the provincial drug treatment program and physician experience treating HIV infection. Results.-After a median of 11 months after first eligibility, only 71 (40%) of 177 patients had received any antiretroviral drugs, primarily double combinations (47/ 71 [66%]). Both patient and physician characteristics were associated with use of antiretroviral drugs. After adjusting for CD4 cell count and HIV-1 RNA level at eligibility, odds of not receiving antiretrovirals were increased more than 2-fold for females (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.08-5.93) and 3-fold for those not currently enrolled in drug or alcohol treatment programs (OR, 3.49; 95% CI, 1.45-8.40), Younger drug users were less likely to receive therapy (OR, 0.47/ 10-y increase; 95% CI, 0.28-0.80). Those with physicians having the least experience treating persons with HIV infection were more than 5 times less likely to receive therapy (OR, 5.55; 95% CI, 2.49-12.37). Conclusions.-Despite free antiretroviral therapy, many HIV-infected injection drug users are not receiving it. Public health efforts should target younger and female drug users, and physicians with less experience treating HIV infection.	St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of British Columbia	Hogg, RS (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Hogg, Robert S/B-2783-2012; Strathdee, Steffanie A/B-9042-2009; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155; Palepu, Anita/0000-0002-7881-4800				Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Celentano DD, 1998, JAMA-J AM MED ASSOC, V280, P544, DOI 10.1001/jama.280.6.544; GRAHAM NMH, 1994, J CLIN EPIDEMIOL, V47, P1003, DOI 10.1016/0895-4356(94)90115-5; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Heath KV, 1997, CLIN INVEST MED, V20, P381; HELLINGER FJ, 1993, HEALTH SERV RES, V28, P543; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MONTANER JSG, 1996, THERAPEUTIC GUIDELIN; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOR V, 1992, MED CARE, V30, P17, DOI 10.1097/00005650-199201000-00002; OCONNOR PG, 1992, AM J MED, V93, P382, DOI 10.1016/0002-9343(92)90166-9; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALEPU A, 1997, CAN J INFECT DIS, V8, pA27; Patrick DM, 1997, INT J STD AIDS, V8, P437, DOI 10.1258/0956462971920497; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; Strathdee SA, 1997, AIDS, V11, pF59, DOI 10.1097/00002030-199708000-00001; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008	21	444	450	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					547	549		10.1001/jama.280.6.547	http://dx.doi.org/10.1001/jama.280.6.547			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707146	Bronze			2022-12-24	WOS:000075244900032
J	Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C				Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C			Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to true years and extending the age of invitation to a final screen from 64 to 69. Design: Computer simulation model which first simulates life histories for women in the absence of a screening programme for breast cancer and then assesses haw these life histories would be changed by introducing different screening policies. The model was informed by screening and cost data from the NHS breast screening programme. Setting: North West region of England. Main outcome measures: Numbers of deaths prevented, life years gained, and costs. Results: Compared with the current breast screening programme both modifications would increase the number of deaths prevented and the number of life years saved. The current screening policy costs pound 2522 per life year gained; extending the age range of the programme would cost pound 2612 and shortening the interval pound 2709 per life year gained: The marginal cost per life year gained of extending the age range of the screening programme is pound 2990 and of shortening the screening interval is pound 3545. Conclusions: If the budget for the NHS breast screening-programme were to allow for two more invitations per woman, substantial mortality reductions would follow from extending the age range screened or reducing the screening interval. The difference between the two policies is so small that either could be chosen.	Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, NL-3000 DR Rotterdam, Netherlands; Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England; Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England; W Pennine Hlth Author, Dept Publ Hlth Med, Oldham OL1 2PN, England	Erasmus University Rotterdam; University of Manchester; University of York - UK	Boer, R (corresponding author), Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, POB 1738, NL-3000 DR Rotterdam, Netherlands.	boer@mgz.fgg.eur.nl	de+Koning, Harry/AAF-9062-2019; Boer, Robert/AAH-2901-2022; Boer, Robert/AFM-0525-2022; Boer, Rob/E-6473-2015	de+Koning, Harry/0000-0003-4682-3646; Boer, Robert/0000-0003-0680-001X; Boer, Robert/0000-0003-0680-001X; Boer, Rob/0000-0003-0680-001X				BEEMSTERBOER PMM, 1994, INT J CANCER, V58, P623, DOI 10.1002/ijc.2910580502; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHAMBERLAIN J, 1993, BRIT MED J, V307, P543; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; FORREST APM, 1987, REPORT HLTH MINISTER; PACI E, 1995, J CANC, V3, P348; *SCOTT CANC THER N, 1996, SCOTT BREAST CANC AU; Street AD, 1996, P2003 U YORK YORK HL; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VANOORTMARSSEN GJ, 1990, CANCER-AM CANCER SOC, V66, P1601, DOI 10.1002/1097-0142(19901001)66:7<1601::AID-CNCR2820660727>3.0.CO;2-O	12	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					376	379						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694752				2022-12-24	WOS:000075409600023
J	Flore, O; Rafii, S; Ely, S; O'Leary, JJ; Hyjek, EM; Cesarman, E				Flore, O; Rafii, S; Ely, S; O'Leary, JJ; Hyjek, EM; Cesarman, E			Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus	NATURE			English	Article							DNA-SEQUENCES; INFECTION; LYMPHOMA	Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, is invariably present in Kaposi's sarcoma lesions(1,2) KSHV contains several viral oncogenes and serological evidence suggests that KSHV infection is necessary for the development of Kaposi's sarcoma, but cellular transformation by this virus has not so far been demonstrated. KSHV is found in the microvascular endothelial cells in Kaposi's sarcoma lesions and in the spindle 'tumour' cells(3,4), which are also thought to be of endothelial origin. Here we investigate the biological consequences of infecting human primary endothelial cells with purified KSHV particles. We find that infection causes long-term proliferation and survival of these cells, which are associated with the acquisition of telomerase activity and anchorage-independent growth. KSHV was present in only a subset of cells, and paracrine mechanisms were found to be responsible for the survival of uninfected cells. Their survival may have been mediated by upregulation of a receptor for vascular endothelial growth factor. Our results indicate that transformation of endothelial cells by KSHV, as well as paracrine mechanisms that are induced by this virus, may be critical in the pathogenesis of Kaposi's sarcoma.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Univ Cagliari, Dipartimento Med Interna, I-09100 Cagliari, Italy; Coombe Womens Hosp, Dept Pathol, Dublin, Ireland; St James Hosp, Dublin 8, Ireland; Trinity Coll Dublin, Dublin, Ireland	Cornell University; Cornell University; University of Cagliari; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin	Cesarman, E (corresponding author), Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA.	ecesarm@mail.med.cornell.edu						Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Chan SR, 1998, VIROLOGY, V240, P118, DOI 10.1006/viro.1997.8911; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kennedy MM, 1997, J CLIN PATHOL-MOL PA, V50, P96, DOI 10.1136/mp.50.2.96; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; MIECZYSLAW AP, 1995, METH CELL SCI, V17, P1; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; OLEARY J, 1997, PCR IN SITU HYBRIDIC; RAFII S, 1995, BLOOD, V86, P3353, DOI 10.1182/blood.V86.9.3353.bloodjournal8693353; REED JA, IN PRESS BLOOD; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RIENKE U, 1975, FED PROC, V34, P71; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583	20	325	334	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					588	592		10.1038/29093	http://dx.doi.org/10.1038/29093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707121				2022-12-24	WOS:000075238700051
J	Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J				Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J			Relation between obesity from childhood to adulthood and the metabolic syndrome: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Pieksamaki Dist Hlth Ctr, Pieksamaki 76101, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	University of Eastern Finland	Vanhala, M (corresponding author), Community Hlth Ctr City Imatra, Virastokatu 2, Imatra 55100, Finland.	Mauno.Vanhala@pp.inet.fi						BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; LAAKSO M, 1993, CARDIOVASC RISK FACT, V1, P55; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010	5	161	170	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					319	319		10.1136/bmj.317.7154.319	http://dx.doi.org/10.1136/bmj.317.7154.319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685277	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000075409500021
J	Swanson, WJ; Vacquier, VD				Swanson, WJ; Vacquier, VD			Concerted evolution in an egg receptor for a rapidly evolving abalone sperm protein	SCIENCE			English	Article							SPECIES-SPECIFICITY; POSITIVE SELECTION; TRANSCRIPTION; FERTILIZATION; DIVERGENCE; MODULES; BINDING; LYSIN	Gamete interactions during fertilization exhibit species specificity. In abalone, the sperm protein Lysin species-specifically creates a hole in the egg envelope. Lysin evolves rapidly by positive Darwinian selection. Evolution of the egg receptor for Lysin provides the selective pressure for Lysin's divergence. The egg receptor for lysin is a tandemly repeated sequence that evolves by concerted evolution. Concerted evolution in the egg receptor could explain the rapid, adaptive evolution in sperm Lysin and may provide an underlying molecular mechanism that gives rise to species-specific fertilization.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Swanson, WJ (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.			Swanson, Willie/0000-0002-6553-0921	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Giudice G, 1973, DEV BIOL SEA URCHIN, P162; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LEE YH, 1995, MOL BIOL EVOL, V12, P231; METZ EC, 1994, BIOL BULL-US, V187, P23, DOI 10.2307/1542162; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Muse SV, 1996, MOL BIOL EVOL, V13, P105, DOI 10.1093/oxfordjournals.molbev.a025549; NEI M, 1986, MOL BIOL EVOL, V3, P418; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; OHTA T, 1984, GENETICS, V108, P501; OSANAI K, 1982, GAMETE RES, V5, P49, DOI 10.1002/mrd.1120050106; Owen B, 1971, Bull Los Ang City Mus Sci, VNo. 9, P1; PALUMBI SR, 1994, ANNU REV ECOL SYST, V25, P547, DOI 10.1146/annurev.ecolsys.25.1.547; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; ROLDAN ERS, 1989, J EXP ZOOL, V250, P321, DOI 10.1002/jez.1402500312; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SHAW A, 1993, SCIENCE, V262, P1864, DOI 10.1126/science.8266073; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SUMMERS RG, 1975, EXP CELL RES, V96, P63, DOI 10.1016/S0014-4827(75)80037-1; Swanson WJ, 1997, P NATL ACAD SCI USA, V94, P6724, DOI 10.1073/pnas.94.13.6724; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Vacquier VD, 1997, J MOL EVOL, V44, pS15, DOI 10.1007/PL00000049; Vacquier VD, 1993, ZYGOTE, V1, P181, DOI 10.1017/S0967199400001465; Yanagimachi R., 1988, P135	31	173	183	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					710	712		10.1126/science.281.5377.710	http://dx.doi.org/10.1126/science.281.5377.710			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685267				2022-12-24	WOS:000075107900046
J	England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM				England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM			Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; FUNCTIONAL EXPRESSION; FAMILY; DIVERSITY; DISTINCT; PEPTIDE	The venom of predatory marine snails is a rich source of natural products that act on specific receptors and ion channels within the mammalian nervous system. A 41-amino acid peptide, sigma-conotoxin GVIIIA, was purified on the basis of its ability to inactivate the 5-HT3 receptor, an excitatory serotonin-gated ion channel. sigma-Conotoxin contains a brominated tryptophan residue, which may be important for peptide activity because the endogenous Ligand for the 5-HT3 receptor is a hydroxylated derivative of tryptophan. sigma-Conotoxin inactivates the 5-HT3 receptor through competitive antagonism and is a highly selective inhibitor of this receptor. Serotonin receptors can now be included among the molecular targets of natural polypeptide neurotoxins.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Salk Institute	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@socrates.ucsf.edu			NIGMS NIH HHS [GM44298, GM48677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677, R01GM044298] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Green T, 1998, NEURON, V20, P427, DOI 10.1016/S0896-6273(00)80986-1; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LUCAS JJ, 1995, TRENDS PHARMACOL SCI, V16, P246, DOI 10.1016/S0165-6147(00)89034-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; PATRICK J, 1987, ANN NY ACAD SCI, V505, P194; SAXENA PR, 1995, PHARMACOL THERAPEUT, V66, P339, DOI 10.1016/0163-7258(94)00005-N; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; ZIFA E, 1992, PHARMACOL REV, V44, P401	26	112	118	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					575	578		10.1126/science.281.5376.575	http://dx.doi.org/10.1126/science.281.5376.575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677203				2022-12-24	WOS:000075012300045
J	Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A				Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A			Spatial organization of transcription elongation complex in Escherichia coli	SCIENCE			English	Article							RNA-POLYMERASE; TERMINATION	During RNA synthesis in the ternary elongation complex, RNA polymerase enzyme holds nucleic acids in three contiguous sites: the double-stranded DNA-binding site (DBS) ahead of the transcription bubble, the RNA-DNA heteroduplex-binding site (HBS), and the RNA-binding site (RBS) upstream of HBS. Photochemical cross-linking allowed mapping of the DNA and RNA contacts to specific positions on the amino acid sequence. Unexpectedly, the same protein regions were found to participate in both DBS and RES. Thus, DNA entry and RNA exit occur close together in the RNA polymerase molecule, suggesting that the three sites constitute I single unit. The results explain how RNA in the integrated unit RBS-HBS-DBS may stabilize the ternary complex, whereas a hairpin in RNA result in its dissociation.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.		Kozlov, Maxim/GLN-3047-2022; Gusarov, Ivan/AAJ-6282-2020	Kozlov, Maxim/0000-0002-5994-9099; Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; KURIYAN J, 1994, J MOL BIOL, V234, P915; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; NUDLER E, UNPUB; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793	16	71	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					424	428		10.1126/science.281.5375.424	http://dx.doi.org/10.1126/science.281.5375.424			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665887				2022-12-24	WOS:000074918800050
J	Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J				Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J			Combinatorial chemistry in insects: A library of defensive macrocyclic polyamines	SCIENCE			English	Article							EPILACHNA-BOREALIS; SQUASH-BEETLE; SECRETION	The pupal defensive secretion of the coccinellid beetle Epilachna borealis is composed principally of a combinatorial Library of macrocyclic polyamines. These compounds constitute a previously unrecognized family of natural products, characterized by extremely Large-ring lactonic structures derived from a small set of (2-hydroxyethylamino)alkanoic acids. The combinatorial assembly of these simple building blocks generates a high degree of structural diversity, which is further increased by slow. spontaneous intramolecular rearrangement of the macrocycles.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA; Trinity Coll, Dept Biol, Hartford, CT 06106 USA; Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University; Trinity College; Cornell University	Schroder, FC (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Schroeder, Frank/H-5026-2012	Attygalle, Athula/0000-0002-5847-2794; Schroeder, Frank/0000-0002-4420-0237	NIAID NIH HHS [AI2908] Funding Source: Medline; NIGMS NIH HHS [GM53830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI002908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attygalle AB, 1996, EXPERIENTIA, V52, P616, DOI 10.1007/BF01969741; Attygalle AB, 1996, NATURWISSENSCHAFTEN, V83, P277; ATTYGALLE AB, 1993, P NATL ACAD SCI USA, V90, P5204, DOI 10.1073/pnas.90.11.5204; Daloze Desire, 1995, Chemoecology, V5-6, P173, DOI 10.1007/BF01240602; Eisner Thomas, 1992, Psyche (Cambridge), V99, P265, DOI 10.1155/1992/54859; GIANNIS A, 1989, ANGEW CHEM INT EDIT, V28, P218, DOI 10.1002/anie.198902181; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HINTON H. E., 1955, TRANS SOC BRIT ENT, V12, P49; King AG, 1996, CHEM REV, V96, P1105; MUKAIYAMA T, 1977, CHEM LETT, P441, DOI 10.1246/cl.1977.441; OLIYAI R, 1995, BIOORG MED CHEM LETT, V5, P2735, DOI 10.1016/0960-894X(95)00454-2; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; SCHRODER FR, UNPUB	13	57	61	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					428	431		10.1126/science.281.5375.428	http://dx.doi.org/10.1126/science.281.5375.428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665888				2022-12-24	WOS:000074918800051
J	Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D				Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D			Control of pain initiation by endogenous cannabinoids	NATURE			English	Article							MOLECULAR CHARACTERIZATION; FORMALIN TEST; RECEPTOR; BRAIN; RATS; ANANDAMIDE; NEURONS; TISSUE	The potent analgesic effects of cannabis-like drugs(1-4) and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord(5,6) indicate that endogenous cannabinoids such as anandamide(7) may contribute to the control of pain transmission within the central nervous system (CNS)(8). Here we show that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor(9), exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR141716A and the CB2 antagonist SR144528 prolong and enhance the pain behaviour produced by tissue damage. These results indicate that peripheral CB1-like and CBZ-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.	Univ Naples, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Inst Neurosci, San Diego, CA 92121 USA	University of Naples Federico II	Piomelli, D (corresponding author), Univ Naples, Dipartimento Farmacol Sperimentale, 49 Via D Montesano, I-80131 Naples, Italy.	piomelli@nsi.edu	Giuffrida, Andrea/H-3770-2013	Giuffrida, Andrea/0000-0002-3773-0694; CALIGNANO, Antonio/0000-0002-1742-3179				ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Cadas H, 1997, J NEUROSCI, V17, P1226; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fields H. L., 1987, PAIN; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; JAGGAR SI, IN PRESS PAIN; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; MARTIN BR, 1981, LIFE SCI, V29, P565, DOI 10.1016/0024-3205(81)90434-3; MARTIN WJ, 1993, BRAIN RES, V629, P300, DOI 10.1016/0006-8993(93)91334-O; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Richardson JD, 1998, J NEUROSCI, V18, P451; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6	29	871	907	1	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					277	281		10.1038/28393	http://dx.doi.org/10.1038/28393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685157	Green Submitted			2022-12-24	WOS:000074851900048
J	Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G				Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G			Increased risk for venous thrombosis in carriers of the prothrombin G -> A(20210) gene variant	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; COAGULATION-FACTOR-V; ANTIPHOSPHOLIPID ANTIBODIES; DEFICIENT FAMILIES; RESISTANCE; THROMBOEMBOLISM; THROMBOPHILIA; MUTATION	Background: A mutation in the prothrombin gene (G-->A(20210)) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis. Objective: To determine whether the prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis. Design: Case-control study. Setting: Two thrombosis centers in southern Italy. Patients: 281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls. Measurements: Medical history was collected on standardized questionnaires. The presence of prothrombin G-->A(20210) and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function. Results: In 150 controls, increased prothrombin activity (P < 0.001) was associated with the prothrombin A(20210) allele. This allele was more frequent in patients than in controls (8.01% compared with 2.29%; P < 0.001) and was associated with an increased risk for thrombosis (odds ratio, 3.88 [95% CI, 2.23 to 6.74]). The increased prevalence of this allele was independent of the presence of the factor V Leiden mutation. After adjustment for sex, age, arterial thrombosis, and factor V Leiden mutation, the risk was still significantly elevated (odds ratio, 3.13 [CI, 1.89 to 5.21]). Moreover, the overall prevalence of inherited coagulation abnormalities was significantly higher in patients with thrombosis of the lower extremities than in patients with thrombosis of the upper extremities (odds ratio, 3.77 [CI, 1.10 to 12.93]). Fourteen patients carried both the prothrombin G-->A(20210) and factor V Leiden mutations. Conclusions: The prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis, particularly in patients with a history of thrombosis of the lower extremities.	IRCCS, Unita Aterosclerosi & Trombosi, I-71013 San Giovanni Rotondo, Italy; Osped Antonio Cardarelli, Naples, Italy; Univ Palermo, Palermo, Italy	IRCCS Casa Sollievo Della Sofferenza; Antonio Cardarelli Hospital; University of Palermo	Margaglione, M (corresponding author), IRCCS, Unita Aterosclerosi & Trombosi, Casa Sollievo Sofferenza,Viale Cappuccini, I-71013 San Giovanni Rotondo, Italy.		Grandone, Elvira/M-1127-2019	Grandone, Elvira/0000-0002-8980-9783; Di Minno, Giovanni/0000-0003-4235-7166; MARGAGLIONE, MAURIZIO/0000-0001-5627-9221				AMES PRJ, 1995, THROMB HAEMOSTASIS, V73, P768; Ames PRJ, 1996, THROMB HAEMOSTASIS, V76, P190; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Margaglione M, 1996, THROMB HAEMOSTASIS, V76, P814; MARGAGLIONE M, 1995, THROMB HAEMOSTASIS, V73, P579; Martinelli I, 1997, ANN INTERN MED, V126, P707, DOI 10.7326/0003-4819-126-9-199705010-00006; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417	19	198	204	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					89	93		10.7326/0003-4819-129-2-199807150-00003	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669991				2022-12-24	WOS:000074852000002
J	Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J				Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J			A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor	SCIENCE			English	Article							FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION; CELL-LINE; STAT3; ERYTHROPOIETIN; INTERLEUKIN-6; DIMERIZATION; BINDING; CSF	A nonpeptidyl small molecule SB 247464, capable of activating granulocyte-colony-stimulating factor (G-CSF) signal transduction pathways, was identified in a high-throughput assay in cultured cells. Like G-CSF, SE 247464 induced tyrosine phosphorylation of multiple signaling proteins and stimulated primary murine bone marrow cells to form granulocytic colonies in vitro. It also elevated peripheral blood neutrophil counts in mice. The extracellular domain of the murine G-CSF receptor was required for the activity of SE 247464, suggesting that the compound acts by oligomerizing receptor chains. The results indicate that a small molecule can activate a receptor that normally binds a relatively Large protein Ligand.	Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Mol Virol & Host Def US, Collegeville, PA 19426 USA; Ligand Pharmaceut Inc, Dept New Leads Discovery, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Med Chem US, Collegeville, PA 19426 USA; SmithKline Beecham Pharmaceut, Dept Oncol, King Of Prussia, PA 19406 USA	Ligand Pharmaceuticals; GlaxoSmithKline; Ligand Pharmaceuticals; GlaxoSmithKline; GlaxoSmithKline	Lamb, P (corresponding author), Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; DEMETRI GD, 1991, BLOOD, V78, P2791; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KOMATSU N, 1993, BLOOD, V82, P456; METCALF D, 1983, J CELL PHYSIOL, V116, P198, DOI 10.1002/jcp.1041160211; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	19	149	165	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					257	259		10.1126/science.281.5374.257	http://dx.doi.org/10.1126/science.281.5374.257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657720				2022-12-24	WOS:000074714200049
J	Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG				Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG			Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma	LANCET			English	Article							OBLIGATE HETEROZYGOTES; BRONCHIAL-ASTHMA; REACTIVITY; AIRWAY	Background Cystic fibrosis is a recessive disorder mainly characterised by lung disease. We tested the hypothesis that individuals heterozygous for the common cystic fibrosis Delta F508 mutation are at risk of obstructive pulmonary disease. Methods We studied a cross-sectional sample from the general population of Copenhagen, Denmark, aged 20 years and older, We did spirometry to measure forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), and did genotyping on blood samples of 9141 individuals. We asked all participants whether they had asthma, and asked for information on smoking and other factors that could have contributed to obstructive pulmonary disease. Findings We identified 250 carriers of the Delta F508 mutation (2.7% [95% CI 2.5-3.1]). 9% of carriers reported having asthma compared with 6% of non-carriers (p=0.04). The odds ratio for asthma in participants heterozygous for Delta F508 mutation was 2.0 (1.2-3.5, p=0.02). Furthermore, among individuals with airway obstruction, the percentage predicted FEV1 and FVC were significantly lower in participants heterozygous for Delta F508 than in non-carriers (49 vs 58%, p=0.004; and 70 vs 82%, p<0.001, respectively), mainly due to an effect in those with self-reported asthma. Interpretation Cystic fibrosis Delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.	Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Univ Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital	Nordestgaard, BG (corresponding author), Glostrup Univ Hosp, Dept Clin Biochem, Nordre Ringvej, DK-2600 Glostrup, Denmark.		Dahl, Morten/F-4219-2014; Nordestgaard, Borge Gronne/ABF-1310-2020	Dahl, Morten/0000-0002-6686-312X; 				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BATTEN J, 1963, LANCET, V1, P1348; BYARD PJ, 1988, AM REV RESPIR DIS, V138, P312, DOI 10.1164/ajrccm/138.2.312; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1989, J APPL PHYSIOL, V66, P2124, DOI 10.1152/jappl.1989.66.5.2124; DAVIS PB, 1984, AM REV RESPIR DIS, V129, P911; DAVIS PB, 1987, THORAX, V42, P120, DOI 10.1136/thx.42.2.120; GOLD WM, 1994, TXB RESP MED, P870; HALLETT WY, 1965, AM REV RESPIR DIS, V90, P714; KHOURY MJ, 1993, FUNDAMENTALS GENETIC, P77; LANGE P, 1991, EUR RESPIR J, V4, P1080; Leupold W, 1979, Monogr Paediatr, V10, P119; MENNIE M, 1995, NAT MED, V1, P978, DOI 10.1038/nm1095-978b; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; ORZALESI MM, 1963, ACTA PAEDIATR, V52, P267, DOI 10.1111/j.1651-2227.1963.tb03779.x; Sandford AJ, 1997, EUR RESPIR J, V10, P1380, DOI 10.1183/09031936.97.10061380; SCHROEDER SA, 1995, NAT MED, V1, P703, DOI 10.1038/nm0795-703; SCHWARTZ M, 1992, ACTA PAEDIATR, V81, P522, DOI 10.1111/j.1651-2227.1992.tb12287.x; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; WOOD JA, 1959, NEW ENGL J MED, V260, P951, DOI 10.1056/NEJM195905072601901; WOOLCOCK AJ, 1994, TXB RESP MED, P1288	25	89	90	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1911	1913		10.1016/S0140-6736(97)11419-2	http://dx.doi.org/10.1016/S0140-6736(97)11419-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654257				2022-12-24	WOS:000074464700007
J	Tsien, RY; Miyawaki, A				Tsien, RY; Miyawaki, A			Seeing the machinery of live cells	SCIENCE			English	Article							EXCITATION; MICROSCOPY; PROTEINS		Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	rtsien@ucsd.edu	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235	NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Farinas J, 1998, BIOPHYS J, V74, pA184; GRIFFIN BA, IN PRESS SCIENCE; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, UNPUB; Murphy JT, 1997, CURR BIOL, V7, P870, DOI 10.1016/S0960-9822(06)00375-7; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	28	141	146	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1954	1955		10.1126/science.280.5371.1954	http://dx.doi.org/10.1126/science.280.5371.1954			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669950				2022-12-24	WOS:000074323800069
J	Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T				Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T			Dynein arms are oscillating force generators	NATURE			English	Article							SEA-URCHIN SPERM; IONTOPHORETIC APPLICATION; MICROTUBULES INVITRO; FLAGELLAR AXONEMES; TETRAHYMENA CILIA; SUBUNIT; ACTOMYOSIN; DIRECTION; ATP	Eukaryotic flagella beat rhythmically(1). Dynein is a protein that powers flagellar motion, and oscillation may be inherent to this protein(2-5). Here we determine whether oscillation is a property of dynein arms themselves or whether oscillation requires an intact axoneme(6), which is the central core of the flagellum and consists of a regular array of microtubules. Using optical trapping nanometry(7,8), we measured the force generated by a few dynein arms on an isolated doublet microtubule, When the dynein arms on the doublet microtubule contact a singlet microtubule and are activated by photolysis of caged ATP(8), they generate a peak force of similar to 6 pN and move the singlet microtubule over the doublet microtubule in a processive manner. The force and displacement oscillate with a peak-to-peak force and amplitude of similar to 2 pN and similar to 30 nm, respectively. The geometry of the interaction indicates that very few (possibly one) dynein arms are needed to generate the oscillation. The maximum frequency of the oscillation at 0.75 mM ATP is similar to 70 Hz; this frequency decreases as the ATP concentration decreases. A similar oscillatory force is also generated by inner dynein arms alone on doublet microtubules that are depleted of outer dynein arms. The oscillation of the dynein arm may be a basic mechanism underlying flagellar beating.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan; JRDC, ERATO, Yanagida Biotron Project, Osaka 5620035, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1080071, Japan; Osaka Univ, Sch Med, Dept Physiol, Osaka 5650871, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Osaka University	Shingyoji, C (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan.	chikako@biol.s.u-tokyo.ac.jp	Yanagida, Toshio/D-1919-2009					Brokaw C.J., 1989, CELL MOVEMENT, V1, P267; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS BH, 1973, J CELL SCI, V13, P337; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; MOSS AG, 1992, J CELL BIOL, V118, P1177, DOI 10.1083/jcb.118.5.1177; OMOTO CK, 1989, J THEOR BIOL, V137, P163, DOI 10.1016/S0022-5193(89)80203-6; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHINGYOJI C, 1995, J CELL SCI, V108, P1359; SHINGYOJI C, 1977, NATURE, V265, P269, DOI 10.1038/265269a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1982, SYM SOC EXP BIOL, P159; Thomas N, 1998, J PHYS D APPL PHYS, V31, P253, DOI 10.1088/0022-3727/31/3/002; Thomas N, 1996, J PHYSIOL-LONDON, V491P, pP124; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; YOKOTA E, 1994, J CELL SCI, V107, P353	30	197	202	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					711	714		10.1038/31520	http://dx.doi.org/10.1038/31520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641685				2022-12-24	WOS:000074289600060
J	Smith, L				Smith, L			Death in springtime	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Smith, L (corresponding author), Mt Sinai Hosp, 1 Gustave L Levy Pl,Box 118, New York, NY 10029 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					955	955		10.7326/0003-4819-128-11-199806010-00019	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634438				2022-12-24	WOS:000073808600014
J	Starr, JM; Inch, S; Cross, S; MacLennan, WJ; Deary, IJ				Starr, JM; Inch, S; Cross, S; MacLennan, WJ; Deary, IJ			Blood pressure and ageing: longitudinal cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Geriatr Med Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Starr, JM (corresponding author), Royal Victoria Hosp, Edinburgh EH4 2DN, Midlothian, Scotland.		Starr, John/C-8951-2011; Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				Bush T L, 1989, Aging (Milano), V1, P39; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; Starr J.M., 1996, EPIDEMIOLOGY OLD AGE; Starr JM, 1997, AGE AGEING, V26, P295, DOI 10.1093/ageing/26.4.295	5	15	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712598				2022-12-24	WOS:000075641400021
J	Fahlke, C; Rhodes, TH; Desai, RR; George, AL				Fahlke, C; Rhodes, TH; Desai, RR; George, AL			Pore stoichiometry of a voltage-gated chloride channel	NATURE			English	Article							TORPEDO ELECTROPLAX; POTASSIUM CHANNELS; ION-CHANNEL; ARCHITECTURE; SITE	Ion channels allow ions to pass through cell membranes by forming aqueous permeation pathways (pores). In contrast to most known ion channels, which have single pores, a chloride channel belonging to the CIC family(1) (Torpeno ClC-0) has functional features that suggest that it has a unique 'double-barrelled' architecture in which each of two subunits forms an independent pore. This model is based on single-channel recordings of ClC-0 that has two equally spaced and independently gated conductance states(2-4), Other ClC isoforms do not behave in this way(5,6), raising doubts about the applicability of the model to all CIC channels. Here we determine the pore stoichiometry of another CIC isoform, human ClC-1, by chemically modifying cysteines that have been substituted for other amino acids located within the CIC ion-selectivity filter(7). The ClC-1 channel can be rendered completely susceptible to block by methanethiosulphonate reagents when only one of the two subunits contains substituted cysteines. Thiol side chains placed at corresponding positions in both subunits can form intersubunit disulphide bridges and coordinate Cd2+, indicating that the pore-forming regions from each subunit line the same conduction pathway. We conclude that human ClC-1 has a single functional pore.	Vanderbilt Univ, Sch Med, Dept Med Nephrol & Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Fahlke, C (corresponding author), Vanderbilt Univ, Sch Med, Dept Med Nephrol & Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952				Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fersht A., 1985, ENZYME STRUCTURE MEC; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JENTSCH TJ, 1994, CURR TOP MEMBR, V42, P35, DOI 10.1016/S0070-2161(08)60817-5; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x	24	56	57	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					687	690		10.1038/29319	http://dx.doi.org/10.1038/29319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716133				2022-12-24	WOS:000075384200046
J	Andrulis, ED; Neiman, AM; Zappulla, DC; Sternglanz, R				Andrulis, ED; Neiman, AM; Zappulla, DC; Sternglanz, R			Perinuclear localization of chromatin facilitates transcriptional silencing	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SIR4 PROTEINS; YEAST; TELOMERES; RAP1; HETEROCHROMATIN; RETENTION; NUCLEUS; DOMAIN; MOTIFS	Transcriptional silencing in Saccharomyces cerevisiae at the HM mating-type loci and telomeres occurs through the formation of a heterochromatin-like structure. HM silencing is regulated by cis-acting elements, termed silencers, and by trans-acting factors that bind to the silencers. These factors attract the four SIR (silent information regulator) proteins, three of which (SIR2-4) spread from the silencers to alter chromatin, hence silencing nearby genes(1-4). We show here that an HMR locus with a defective silencer can be silenced by anchoring the locus to the nuclear periphery. This was accomplished by fusing integral membrane proteins to the GAL4 DNA-binding domain and overproducing the hybrid proteins, causing them to accumulate in the endoplasmic reticulum and the nuclear membrane. We expressed the hybrid proteins in a strain carrying an HMR silencer with GALA-binding sites (UAS(G)) replacing silencer elements, causing the silencer to become anchored to the nuclear periphery and leading to silencing of a nearby reporter gene. This silencing required the hybrids of the GAL4 DNA-binding domain with membrane proteins, the UASG sites and the SIR proteins. Our results indicate that perinuclear localization helps to establish transcriptionally silent chromatin.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	rolf@life.bio.sunysb.edu	Zappulla, David/C-7818-2009	Zappulla, David/0000-0001-8242-3493				BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Harlow E, 1988, ANTIBODIES LAB MANUA; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	26	378	387	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					592	595		10.1038/29100	http://dx.doi.org/10.1038/29100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707122				2022-12-24	WOS:000075238700052
J	Toka, HR; Bahring, S; Chitayat, D; Melby, JC; Whitehead, R; Jeschke, E; Wienker, TF; Toka, O; Schuster, H; Luft, FC				Toka, HR; Bahring, S; Chitayat, D; Melby, JC; Whitehead, R; Jeschke, E; Wienker, TF; Toka, O; Schuster, H; Luft, FC			Families with autosomal dominant brachydactyly type E, short stature, and severe hypertension	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Rare, monogenic forms of hypertension may give insight into novel mechanisms relevant to essential hypertension. Autosomal dominant hypertension with brachydactyly has been documented in a single Turkish kindred; the gene was mapped to chromosome 12p. Objective: To describe the molecular genetics of additional families with autosomal dominant hypertension and brachydactyly. Design: Case series. Setting: Tertiary care medical centers. Patients: An Ii-member Canadian family and a 7-member U.S. family, neither of Turkish background, with autosomal dominant hypertension and type E brachydactyly. Measurements: Clinical evaluation, genotyping, and haplotype analyses. Results: The mode of inheritance, the type E brachydactyly, and the propensity for stroke were consistent with autosomal dominant hypertension with brachydactyly. The same markers on chromosome 12p cosegregated with the phenotype in the families. A haplotype analysis strongly supported the conclusion that these families have a molecular defect in the same gene. Conclusions: The syndrome of autosomal dominant hypertension and brachydactyly is not confined to patients of Turkish origin. All persons with brachydactyly should have their blood pressure measured, and the syndrome should be considered if hypertension is found.	Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Boston Univ, Med Ctr, Endocrine Sect, Boston, MA 02118 USA; Humboldt Univ, Berlin, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Boston University; Humboldt University of Berlin	Luft, FC (corresponding author), Franz Volhard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.		Toka, Hakan/AAQ-2162-2021	Luft, Friedrich/0000-0002-8635-1199				BRICKMAN AS, 1988, AM J MED, V85, P785; Chitayat D, 1997, AM J MED GENET, V73, P279, DOI 10.1002/(SICI)1096-8628(19971219)73:3<279::AID-AJMG10>3.0.CO;2-G; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Morimoto S, 1997, HYPERTENSION, V30, P77, DOI 10.1161/01.HYP.30.1.77; Naraghi R, 1997, STROKE, V28, P1749, DOI 10.1161/01.STR.28.9.1749; NARAGHI R, 1994, LANCET, V344, P1466, DOI 10.1016/S0140-6736(94)90289-5; RICCARDI VM, 1974, J PEDIATR-US, V84, P251, DOI 10.1016/S0022-3476(74)80614-1; Schuster H, 1996, NAT GENET, V13, P98, DOI 10.1038/ng0596-98; Schuster H, 1996, HYPERTENSION, V28, P1085, DOI 10.1161/01.HYP.28.6.1085; Schuster H, 1998, KIDNEY INT, V53, P167, DOI 10.1046/j.1523-1755.1998.00732.x; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85	11	28	28	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					204	208		10.7326/0003-4819-129-3-199808010-00008	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696728				2022-12-24	WOS:000075032700005
J	Klenerman, P; Zinkernagel, RM				Klenerman, P; Zinkernagel, RM			Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL RECEPTOR ANTAGONISTS; CHORIOMENINGITIS VIRUS; ESCAPE MUTANTS; SELECTION; RESISTANT	Some viruses, including human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in humans, and lymphocytic choriomeningitis virus (LCMV) in mice, are initially controlled by cytotoxic T lymphocytes (CTLs), but may subsequently escape through mutation of the relevant T-cell epitope(1-3), Some of these mutations preserve the normal binding to major histocompatibility complex class I molecules, but present an altered surface to the T-cell antigen receptor(4,5). The exact role of these so-called altered peptide ligands in vivo is not clear. Here we report that mice primed with LCMV-WE strain respond to a subsequent infection by WE-derived CTL epitope variants with a CTL response directed against the initial epitope rather than against the new variant epitope, This phenomenon of 'original antigenic sin' was initially described in influenza(6-8) and is an asymmetric pattern of protective antibody crossreactivity determined by exposure to previously existing strains, which may therefore extend to some CTL responses. Original antigenic sin by CTL leads to impaired clearance of variant viruses infecting the same individual and so may enhance the immune escape of mutant viruses evolving in an individual host.	Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland	University of Zurich	Zinkernagel, RM (corresponding author), Univ Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.			klenerman, paul/0000-0003-4307-9161				AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; Bachmann MF, 1997, J VIROL, V71, P5764, DOI 10.1128/JVI.71.8.5764-5768.1997; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; DESTGROTH SF, 1966, J EXP MED, V124, P347, DOI 10.1084/jem.124.3.347; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FRANCIS T, 1953, ANN INTERN MED, V39, P203, DOI 10.7326/0003-4819-39-2-203; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GOOD MF, 1993, PARASITE IMMUNOL, V15, P187, DOI 10.1111/j.1365-3024.1993.tb00599.x; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P470; JACOBSON S, 1980, NATURE, V283, P311, DOI 10.1038/283311a0; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; Kent SJ, 1997, J IMMUNOL, V158, P807; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; MCADAM S, 1995, J IMMUNOL, V155, P2729; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; WEINER D, 1995, P NATL ACAD SCI USA, V82, P2755; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	30	282	297	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					482	485		10.1038/28860	http://dx.doi.org/10.1038/28860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697771				2022-12-24	WOS:000075080400053
J	Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R				Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R			Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei	NATURE			English	Article							MOUSE OOCYTES; TRANSPLANTATION; FERTILIZATION; EMBRYOS; MICROINJECTION; INVITRO; GENE	Until recently, fertilization was the only way to produce viable mammalian offspring, a process implicitly involving male and female gametes, However, techniques involving fusion of embryonic or fetal somatic cells with enucleated oocytes have become steadily more successful in generating cloned young(1-3). Dolly the sheep(4) was produced by electrofusion of sheep mammary-derived cells with enucleated sheep oocytes. Here we investigate the factors governing embryonic development by introducing nuclei from somatic cells (Sertoli, neuronal and cumulus cells) taken from adult mice into enucleated mouse oocytes. We found that some enucleated oocytes receiving Sertoli or neuronal nuclei developed in vitro and implanted following transfer, but none developed beyond 8.5 days post coitum; however, a high percentage of enucleated oocytes receiving cumulus nuclei developed in vitro. Once transferred, many of these embryos implanted and, although most were subsequently resorbed, a significant proportion (2 to 2.8%) developed to term. These experiments show that for mammals, nuclei from terminally differentiated, adult somatic cells of known phenotype introduced into enucleated oocytes are capable of supporting full development.	Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA; Univ Tokyo, Fac Agr, Dept Vet Anat, Bunkyo Ku, Tokyo 113, Japan; Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England; Univ Pavia, Dipartimento Biol Anim, Lab Biol Sviluppo, I-27100 Pavia, Italy; Jackson Lab, Bar Harbor, ME 04609 USA	University of Hawaii System; University of Tokyo; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Pavia; Jackson Laboratory	Yanagimachi, R (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA.			Perry, Tony/0000-0003-3136-5355				BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; CZOLOWSKA R, 1984, J CELL SCI, V69, P19; DIETRICH W, 1992, GENETICS, V131, P423; Eppig JJ, 1997, BIOL REPROD, V56, P976, DOI 10.1095/biolreprod56.4.976; Epstein C.J, 1986, CONSEQUENCES CHROMOS; ERICKSON RP, 1993, MOL REPROD DEV, V35, P114, DOI 10.1002/mrd.1080350203; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kono T, 1997, Rev Reprod, V2, P74; Kono Tomohiro, 1993, Journal of Reproduction and Development, V39, P301, DOI 10.1262/jrd.39.301; Kuretake S, 1996, BIOL REPROD, V55, P789, DOI 10.1095/biolreprod55.4.789; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Schuetz AW, 1996, REPROD FERT DEVELOP, V8, P935, DOI 10.1071/RD9960935; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; TSUNODA Y, 1993, J REPROD FERTIL, V98, P537, DOI 10.1530/jrf.0.0980537; TSUNODA Y, 1989, DEVELOPMENT, V107, P407; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YANAGIDA K, 1991, BIOL REPROD, V44, P440, DOI 10.1095/biolreprod44.3.440	26	1733	2047	4	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					369	374		10.1038/28615	http://dx.doi.org/10.1038/28615			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690471				2022-12-24	WOS:000074968800051
J	Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK				Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK			Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?	LANCET			English	Article							GENE-EXPRESSION; BLOOD-PRESSURE; HYPERTENSION; PROLIFERATION; ANGIOGENESIS; INDUCTION; MORTALITY; MYOCYTES; GROWTH; TUMORS	Background Previous studies have reported an increased risk of cancer with calcium-channel blockers in man. Other work in animals suggests that inhibitors of angiotensin-1-converting enzyme (ACE) protect against cancer. We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other antihypertensive drugs. Methods Our retrospective cohort study was based on the records of 5207 patients who attended the Glasgow Blood Pressure Clinic between Jan 1, 1980, and Dec 31, 1995. The patients' records are linked with the Registrar General Scotland and the West of Scotland Cancer Registry. Findings Compared with the West of Scotland controls, the relative risks of incident and fatal cancer among the 1559 patients receiving ACE inhibitors were 0.72 (95% CI 0.55-0.92) and 0.65 (0.44-0.93). Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calcium-channel blockers 1416, diuretics 2099, beta-blockers 2681), the corresponding relative risks were 1.10 (0.97-1.22) and 1.03 (0.87-1.20). The relative risk of cancer was lowest in women on ACE inhibitors: 0.63 (0.41-0.93) for incident cancer; 0.48 (0.23-0.88) for fatal cancer; and 0.37 (0.12-0.87) for female-specific cancers. The reduced relative risk of cancer in patients on ACE inhibitors was greatest with follow-up of longer than 3 years. Calcium-channel blockers, diuretics, and beta-blockers had no apparent effect on risk of cancer. Interpretation Long-term use of ACE inhibitors may protect against cancer. The status of this finding is more that of hypothesis generation than of hypothesis testing; randomised controlled trials are needed.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Ruchill Hosp, W Scotland Canc Surveillance Unit, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Lever, AF (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.							Alderman M, 1997, J HYPERTENS, V15, P105; BOEHM T, 1997, NATURE, V390, P335; BROWN JJ, 1979, HYPERTENSION, V1, P159, DOI 10.1161/01.HYP.1.3.159; CHEN L, 1991, P SOC EXP BIOL MED, V196, P280; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; Elliott WJ, 1996, AM J HYPERTENS, V9, P409; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GILLIS CR, 1987, CANC INCIDENCE 5 CON, V5, P704; Hamet P, 1996, HYPERTENSION, V28, P321, DOI 10.1161/01.HYP.28.3.321; HANSSON L, 1994, AM J HYPERTENS, V7, pS82; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P287; Hii SI, 1998, BRIT J CANCER, V77, P880, DOI 10.1038/bjc.1998.145; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; HOLE DJ, 1993, BRIT MED J, V306, P609, DOI 10.1136/bmj.306.6878.609; INWANG ER, 1997, BRIT J CANCER, V75, P79; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; leNoble FAC, 1996, J VASC RES, V33, P480, DOI 10.1159/000159187; LEON DA, 1993, LANCET, V342, P479, DOI 10.1016/0140-6736(93)91599-H; Lindop GBM, 1993, RENIN ANGIOTENSIN SY, P54; LYALL F, 1992, J HYPERTENS, V10, P1463, DOI 10.1097/00004872-199210120-00005; Marsigliante S, 1996, CANCER LETT, V110, P19, DOI 10.1016/S0304-3835(96)04449-7; MCINNES GT, 1995, J HUM HYPERTENS, V9, P429; *MEMB CLIN GLASG B, 1972, J R COLL PHYSICIANS, V7, P87; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; Reddy MK, 1995, P SOC EXP BIOL MED, V210, P221; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TAYLOR GM, 1988, AM J PATHOL, V130, P543; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; *WHO INT AG RES CA, 1991, IARC SCI PUBL, V95; Wing LMH, 1997, CLIN EXP PHARMACOL P, V24, P188; YEO WW, 1991, Q J MED, V293, P763	41	477	496	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					179	184		10.1016/S0140-6736(98)03228-0	http://dx.doi.org/10.1016/S0140-6736(98)03228-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683206				2022-12-24	WOS:000074859800010
J	Gutman, S; Richter, K; Alpert, S				Gutman, S; Richter, K; Alpert, S			Update on FDA regulation of in vitro diagnostic devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, Rockville, MD 20850 USA	US Food & Drug Administration (FDA)	Gutman, S (corresponding author), US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, 2098 Gaither Rd, Rockville, MD 20850 USA.							*FDA, 1988, ASS SAF EFF HOM US I; *INT STAND O, 1994, QUAL SYST MOD QUAL A; 1995, FED REG, V60, P237; 1996, FED REG, V61, P195	4	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					190	192		10.1001/jama.280.2.190	http://dx.doi.org/10.1001/jama.280.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669798				2022-12-24	WOS:000074608400039
J	Bellaiche, Y; The, I; Perrimon, N				Bellaiche, Y; The, I; Perrimon, N			Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion	NATURE			English	Article							HEREDITARY MULTIPLE EXOSTOSES; INDIAN HEDGEHOG; PROTEIN; GENE; FAMILY	Hedgehog (Hh) proteins act through both short-range and long-range signalling to pattern tissues during invertebrate and vertebrate development(1). The mechanisms allowing Hedgehog to diffuse over a long distance and to exert its long-range effects are not understood. Here we identify a new Drosophila gene, named tout-velu, that is required for diffusion of Hedgehog. Characterization of tout-velu shows that it encodes an integral membrane protein that belongs to the EXT gene family. Members of this family are involved in the human multiple exostoses syndrome, which affects bone morphogenesis(2-4). Our results, together with the previous characterization of the role of Indian Hedgehog in bone morphogenesis(5-7), lead us to propose that the multiple exostoses syndrome is associated with abnormal diffusion of Hedgehog proteins. These results show the existence of a new conserved mechanism required for diffusion of Hedgehog.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	perrimon@rascal.med.harvard.edu	The, Inge/B-8884-2011	Perrimon, Norbert/0000-0001-7542-472X				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Chen CH, 1996, LAB ROBOTICS AUTOMAT, V8, P87; Clines GA, 1997, GENOME RES, V7, P359, DOI 10.1101/gr.7.4.359; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Mullor JL, 1997, DEVELOPMENT, V124, P1227; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Perrimon N, 1996, GENETICS, V144, P1681; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIEMER D, 1995, J CELL SCI, V108, P3189; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; STICKENS D, BIOCH MOL MED, V16, P97; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; XU T, 1993, DEVELOPMENT, V117, P1223	28	417	427	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					85	88		10.1038/27932	http://dx.doi.org/10.1038/27932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665133				2022-12-24	WOS:000074579600054
J	Johnston, LA; Edgar, BA				Johnston, LA; Edgar, BA			Wingless and Notch regulate cell-cycle arrest in the developing Drosophila wing	NATURE			English	Article							GENE-EXPRESSION; LINEAGE RESTRICTION; S-PHASE; ACHAETE; EMBRYOGENESIS; MELANOGASTER; RECEPTION; BOUNDARY; TISSUES; SIGNAL	In developing organs, the regulation of cell proliferation and patterning of cell fates is coordinated. How this coordination is achieved, however, is unknown. In the developing Drosophila wing, both cell proliferation and patterning require the secreted morphogen Wingless (Wg) at the dorsoventral compartment boundary (reviewed in ref. 1). Late in wing development, Wg also induces a zone of non-proliferating cells at the dorsoventral boundary. This zone gives rise to sensory bristles of the adult wing margin(2,3). Here we investigate how Wg coordinates the cell cycle with patterning by studying the regulation of this growth arrest. We show that Wg, in conjunction with Notch, induces arrest in both the G1 and G2 phases of the cell cycle in separate subdomains of the zone of non-proliferating cells. Wg induces G2 arrest in two subdomains by inducing the proneural genes achaete and scute, which downregulate the mitosis-inducing phosphatase String (Cdc25)(4), Notch activity creates a third domain by preventing arrest at G2 in wg-expressing cells, resulting in their arrest in G1.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Johnston, LA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373, R01GM051186] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051186, F32 GM017373, F32 GM017373-03, F32 GM017373-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; deCelis JF, 1996, DEVELOPMENT, V122, P359; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Johnston LA, 1996, DEVELOPMENT, V122, P3519; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SERRANO N, 1997, CURR BIOL, V7, P186; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; USUI K, 1992, DEVELOPMENT, V116, P601; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; XU T, 1993, DEVELOPMENT, V117, P1223; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	30	222	227	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					82	84		10.1038/27925	http://dx.doi.org/10.1038/27925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665132				2022-12-24	WOS:000074579600053
J	Nightingale, SL				Nightingale, SL			Video program on guidelines for the use of antiretroviral agents in pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-24	WOS:000074379400007
J	Pierre, P; Mellman, I				Pierre, P; Mellman, I			Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells	CELL			English	Article							HUMAN CYSTATIN-C; CYSTEINE PROTEINASE-INHIBITORS; COLONY-STIMULATING FACTOR; CATHEPSIN-S; LANGERHANS CELLS; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; CYTOPLASMIC TAIL; DOWN-REGULATION; HLA-DM	Dendritic cells (DCs) developmentally regulate their capacity for antigen presentation by controlling the transport and surface expression of MHC class II molecules. These events reflect a developmental regulation of invariant (li) chain cleavage, most likely by the cysteine protease cathepsin S. In immature DCs, inefficient Il chain cleavage due to low cathepsin S activity leads to the transport of class II-ii chain complexes to lysosomes, while in mature DCs, elevated cathepsin S activity results in efficient delivery of class II alpha beta dimers to.the plasma membrane. Cathepsin S is not controlled transcriptionally but by a novel mechanism involving alterations in the expression and localization of an endogenous cathepsin S inhibitor cystatin C. Thus, the ratio of cystatin C to cathepsin S in developing DCs helps to determine the fate of newly synthesized MHC class II molecules.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020	pierre, philippe/0000-0003-0863-8255	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034098, R01AI034098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033904] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34098] Funding Source: Medline; NIGMS NIH HHS [GM-33904] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1991, BIOMED BIOCHIM ACTA, V50, P587; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Cresswell P, 1998, SCIENCE, V280, P394, DOI 10.1126/science.280.5362.394; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Drake JR, 1997, J EXP MED, V186, P1299, DOI 10.1084/jem.186.8.1299; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KNOCH H, 1994, INT J ONCOL, V5, P77; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LENARCIC B, 1991, FEBS LETT, V280, P211, DOI 10.1016/0014-5793(91)80295-E; Leonardi A, 1996, BIOL CHEM H-S, V377, P319; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Miyake T, 1996, MOL BRAIN RES, V37, P273; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; Pierre P, 1998, CURR OPIN IMMUNOL, V10, P145, DOI 10.1016/S0952-7915(98)80242-2; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; PIETERS J, 1993, J CELL SCI, V106, P831; Rider BJ, 1996, MOL IMMUNOL, V33, P625, DOI 10.1016/0161-5890(96)00022-3; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SHI GP, 1994, J BIOL CHEM, V269, P11530; SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	62	318	326	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1135	1145		10.1016/S0092-8674(00)81458-0	http://dx.doi.org/10.1016/S0092-8674(00)81458-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657147	hybrid			2022-12-24	WOS:000074491100009
J	DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA				DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA			Structure of a heparin-linked biologically active dimer of fibroblast growth factor	NATURE			English	Article							SIGNAL TRANSDUCTION; BINDING DOMAIN; RECEPTOR; OLIGOMERIZATION; IDENTIFICATION; MITOGENESIS; ACTIVATION	The fibroblast growth factors (FGFs) form a large family of structurally related, multifunctional proteins that regulate various biological responses(1.) They mediate cellular functions by binding to transmembrane FGF receptors(2), which are protein tyrosine kinases. FGF receptors are activated by oligomerization(3), and both this activation and FGF-stimulated biological responses require heparin-like molecules as well as FGF(4), Heparins are linear anionic polysaccharide chains; they are typically heterogeneously sulphated on alternating L-iduronic and D-glucosamino sugars, and are nearly ubiquitous in animal tissues as heparan sulphate proteoglycans on cell surfaces and in the extracellular matrix. Although several crystal structures have been described for FGF molecules in complexes with heparin-like sugars(5-7), the nature of a biologically active complex has been unknown until now. Here we describe the X-ray crystal structure, at 2.9 Angstrom resolution, of a biologically active dimer of human acidic FGF in a complex with a fully sulphated, homogeneous heparin decassacharide. The dimerization of heparin-linked acidic FGF observed here is an elegant mechanism for the modulation of signalling through combinatorial homodimerization and heterodimerization of the 12 known members of the FGF family.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Pharmacia & Upjohn Inc, S-11287 Stockholm, Sweden; Rhone Poulenc Rorer, Collegeville, PA 19426 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; New York University; Pfizer; Pharmacia Corporation	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	hendw@convex.hhmi.columbia.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; HENDERSON IC, 1990, ANN ONCOL, V1, P9, DOI 10.1093/oxfordjournals.annonc.a057685; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OTWINOWSKI Z, 1993, 15662 DENZO SERC DAR; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	29	318	332	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					812	817		10.1038/31741	http://dx.doi.org/10.1038/31741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655399				2022-12-24	WOS:000074433100056
J	King, M				King, M			Misled by moonshine	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1218	1218		10.1016/S0140-6736(05)79179-0	http://dx.doi.org/10.1016/S0140-6736(05)79179-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643734				2022-12-24	WOS:000073220200076
J	Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT				Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT			Impact of anti-vaccine movements on pertussis control: the untold story	LANCET			English	Review							UNITED-STATES; CHILDREN; IMMUNIZATION; EPIDEMIOLOGY; EXPERIENCE; EFFICACY; SAFETY	To assess the impact of anti-vaccine movements that targeted pertussis whole-cell vaccines, we compared pertussis incidence in countries where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the former East Germany, Poland, and the USA) with countries where immunisation was disrupted by anti-vaccine movements (Sweden, Japan, Uh, The Russian Federation, Ireland, Italy, the former West Germany, and Australia). Pertussis incidence was 10 to 100 times lower in countries where high vaccine coverage was maintained than in countries where immunisation programs were compromised by anti-vaccine movements. Comparisons of neighbouring countries with high and low vaccine coverage further underscore the efficacy of these vaccines. Given the safety and cost-effectiveness of whole-cell pertussis vaccines, our study shows that, far from being obsolete, these vaccines continue to have an important role in global immunisation.	Emory Univ, Gangarosa Int Hlth Fdn, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; WHO, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Georgia, GA 30333 USA; Publ Hlth Lab Serv, London, England	Emory University; Emory University; Rollins School Public Health; World Health Organization; Centers for Disease Control & Prevention - USA; Public Health England	Gangarosa, EJ (corresponding author), 5305 Greencastle Way, Stone Mt, GA 30087 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1982, BRIT MED J, V285, P357; BINKIN NJ, 1992, PEDIATR INFECT DIS J, V11, P653; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P22; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; COULTER HL, 1991, DTP SHOT DARK WHY P; Evans G, 1996, PEDIATR INFECT DIS J, V15, P477, DOI 10.1097/00006454-199606000-00002; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; FINGER H, 1991, DEV BIOLOGICALS, V73, P343; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; Halsey NA, 1996, PEDIATRICS, V97, P279; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Howell F, 1992, Commun Dis Rep CDR Rev, V2, pR31; JOO I, 1991, DEV BIOLOGICALS, V73, P357; KANAI K, 1980, JPN J MED SCI BIOL, V33, P107, DOI 10.7883/yoken1952.33.107; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; KIMURA M, 1988, Acta Paediatrica Japonica, V30, P109; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LESTER R, 1993, MED J AUSTRALIA, V159, P631, DOI 10.5694/j.1326-5377.1993.tb138057.x; Lindgren C, 1997, EUR J PEDIATR, V156, P405, DOI 10.1007/s004310050626; MACINTYRE CR, 1994, MED J AUSTRALIA, V161, P295; MALLESON PN, 1977, LANCET, V1, P237; MENDELSOHN R, 1988, IMMUNICATIONS TERRIB; MILLER E, 1996, DEV BIOL STAND, V89, P301; NICOLL A, 1988, ARCH DIS CHILD, V63, P41, DOI 10.1136/adc.63.1.41; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Plotkin SA, 1997, PEDIATR INFECT DIS J, V16, P508, DOI 10.1097/00006454-199705000-00011; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; SALISBURY D, 1992, 25 NAT IMM C P 1991, P49; SCHEIBNER V, 1996, VACCINATION 100 YEAR; STEWART GT, 1977, LANCET, V1, P234; STROFFOLINI T, 1989, INFECTION, V17, P280, DOI 10.1007/BF01650708; STROM J, 1960, BRIT MED J, V2, P1184, DOI 10.1136/bmj.2.5207.1184; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; Taylor CE, 1997, AM J PUBLIC HEALTH, V87, P922, DOI 10.2105/AJPH.87.6.922; VELIMIROVIC B, 1991, WHO M NAT PROGR MAN	42	427	447	4	85	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					356	361		10.1016/S0140-6736(97)04334-1	http://dx.doi.org/10.1016/S0140-6736(97)04334-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652634				2022-12-24	WOS:000071864000044
J	Winzeler, EA; Richards, DR; Conway, AR; Goldstein, AL; Kalman, S; McCullough, MJ; McCusker, JH; Stevens, DA; Wodicka, L; Lockhart, DJ; Davis, RW				Winzeler, EA; Richards, DR; Conway, AR; Goldstein, AL; Kalman, S; McCullough, MJ; McCusker, JH; Stevens, DA; Wodicka, L; Lockhart, DJ; Davis, RW			Direct allelic variation scanning of the yeast genome	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OLIGONUCLEOTIDE ARRAYS; GENETIC-LINKAGE; HUMAN DNA; SEQUENCE; HYBRIDIZATION; POLYMORPHISMS; SELECTION; STRAINS	As more genomes are sequenced. the identification and characterization of the causes of heritable variation within a species will be increasingly important. It is demonstrated that allelic variation in any two isolates of a species can be scanned, mapped, and scored directly and efficiently without allele-specific polymerase chain reaction. without creating new strains or constructs, and without knowing the specific nature of the variation. A total of 3714 biallelic markers, spaced about every 3.5 kilobases, were identified by analyzing the patterns obtained when total genomic DNA from two different strains of yeast was hybridized to high-density oligonucleotide arrays. The markers were then used to simultaneously map a multidrug-resistance locus and four other Loci with high resolution (11 to 64 kilobases).	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Affymetrix, Santa Clara, CA 95051 USA	Stanford University; Duke University; Stanford University; Affymetrix	Winzeler, EA (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.		Winzeler, Elizabeth/AAP-6752-2020; McCullough, Michael/C-3295-2014	Winzeler, Elizabeth/0000-0002-4049-2113; McCullough, Michael/0000-0001-7829-4684	NHGRI NIH HHS [HG00185-01, 1R01 HG01633] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001633] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALZI E, 1994, J BIOL CHEM, V269, P2206; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; CHATTOO BB, 1979, GENETICS, V93, P51; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; Dietrich FS, 1997, NATURE, V387, P78, DOI 10.1038/387s078; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MCCUSKER JH, 1994, GENETICS, V136, P1261; MORTIMER RK, 1986, GENETICS, V113, P35; NELSON SF, 1993, NAT GENET, V4, P11, DOI 10.1038/ng0593-11; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Sherman F., 1974, METHODS YEAST GENETI; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WINZELER EA, UNPUB; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	23	306	334	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1194	1197		10.1126/science.281.5380.1194	http://dx.doi.org/10.1126/science.281.5380.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712584				2022-12-24	WOS:000075531200054
J	Woo, RA; McLure, KG; Lees-Miller, SP; Rancourt, DE; Lee, PWK				Woo, RA; McLure, KG; Lees-Miller, SP; Rancourt, DE; Lee, PWK			DNA-dependent protein kinase acts upstream of p53 in response to DNA damage	NATURE			English	Article							V(D)J RECOMBINATION; GENE-EXPRESSION; SCID MUTATION; CELL-LINES; REPAIR	The tumour suppressor p53 becomes activated as a transcription factor in response to DNA damage(1-3), but the mechanism for this activation is unclear. A good candidate for an upstream activator of p53 is the DNA-dependent protein kinase (DNA-PK) that depends on the presence of DNA breaks for its activity(4-6). Here we investigate the link between DNA damage and the activation of DNA-PK and of p53. To determine whether DNA-PK is an upstream mediator of the p53 DNA-damage response, we analysed a severe combined-immunodeficiency (SCID) mouse cen Line, SCGR11 (reb 7, 8), and the human glioma cell line M059J (ref. 9), Both cell lines lack any detectable DNA-PK activity. We find that p53 is incapable of binding to DNA in the absence of DNA-PK, that DNA-PK is necessary but not sufficient for activation of p53 sequence-specific DNA binding, and that this activation occurs in response to DNA damage. Our results establish DNA-PK as a link between DNA damage and p53 activation, and reveal the existence of a mammalian DNA-damage-response pathway.	Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Lee, PWK (corresponding author), Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada.			Lees-Miller, Susan/0000-0001-5809-2516				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELDIERY WS, 1993, CELL, V75, P817; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HARPER JW, 1993, CELL, V75, P805; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang LC, 1996, CANCER RES, V56, P2940; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SKUP D, 1980, P NATL ACAD SCI-BIOL, V77, P152, DOI 10.1073/pnas.77.1.152; TISHLER RB, 1993, CANCER RES, V53, P2212; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	28	284	302	21	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					700	704		10.1038/29343	http://dx.doi.org/10.1038/29343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716137				2022-12-24	WOS:000075384200050
J	Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P				Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P			DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission	SCIENCE			English	Article							NEOSTRIATAL NEURONS; BASAL GANGLIA; NUCLEUS-ACCUMBENS; CAUDATE-PUTAMEN; RAT STRIATUM; MUTANT MICE; RECEPTORS; COCAINE; D1; PHOSPHOPROTEIN	Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor. Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication. The results show that DARPP-32 plays a central role in regulating the efficacy of dopaminergic neurotransmission.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06519 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Univ Tennessee, Dept Anat & Neurobiol, Coll Med, Memphis, TN 38163 USA; Coll France, INSERM, U114, F-75005 Paris, France; Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Hoechst Marion Roussel Inc, Somerville, NJ 08807 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA	Rockefeller University; Yale University; University of Tennessee System; University of Tennessee Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Chicago Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; Florida State University	Fienberg, AA (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	fienba@rockvax.rockefeller.edu	Hiroi, Noboru/E-2215-2013; O'Callaghan, James/O-2958-2013; Girault, Jean-Antoine/F-7518-2013; Miller, Diane/O-2927-2013; anand, amit/A-7222-2009	Hiroi, Noboru/0000-0002-6846-5969; Girault, Jean-Antoine/0000-0002-7900-1705; Song, Wen-Jie/0000-0003-2909-3098; Haile, Colin/0000-0001-8293-7291	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005794, P01DA010044, P01DA008227] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10044, F31 DA005794, DA 08227] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE A, 1987, BRAIN RES, V418, P262, DOI 10.1016/0006-8993(87)90094-1; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; COLE DC, UNPUB; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; CORBETT R, UNPUB; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLORAN B, 1990, NEUROSCI LETT, V116, P136, DOI 10.1016/0304-3940(90)90399-T; GALLI T, 1992, NEUROSCIENCE, V50, P769, DOI 10.1016/0306-4522(92)90203-E; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIRAULT JA, 1986, NEUROSCIENCE, V19, P1109, DOI 10.1016/0306-4522(86)90127-2; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KONRADI C, 1994, J NEUROSCI, V14, P5623; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Langley KC, 1997, NEUROSCIENCE, V78, P977, DOI 10.1016/S0306-4522(96)00583-0; Levine MS, 1996, J NEUROSCI, V16, P5870; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nishi A, 1997, J NEUROSCI, V17, P8147; NISHI A, UNPUB; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; ONN SP, UNPUB; OUIMET CC, 1990, J NEUROCYTOL, V19, P39, DOI 10.1007/BF01188438; OUIMET CC, 1984, J NEUROSCI, V4, P114; OUIMET CC, UNPUB; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SHCIFFMAN SN, 1994, J PHYSIOL-LONDON, V483, P95; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Snyder G., 1996, Society for Neuroscience Abstracts, V22, P380; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SVENNINGSSON P, UNPUB; UCHIMURA N, 1986, BRAIN RES, V375, P368, DOI 10.1016/0006-8993(86)90760-2; WALAAS SI, 1983, NATURE, V301, P69; WHITE SR, 1995, BRAIN RES, V681, P167, DOI 10.1016/0006-8993(95)00309-E; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	47	372	410	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					838	+		10.1126/science.281.5378.838	http://dx.doi.org/10.1126/science.281.5378.838			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694658				2022-12-24	WOS:000075295600054
J	Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC				Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC			How temperature changes reset a circadian oscillator	SCIENCE			English	Article							CLOCK MUTANTS; NEUROSPORA; LIGHT; PHASE; TIMELESS; ENTRAINMENT; FREQUENCY; PROTEIN; PERIOD	Circadian rhythms control many physiological activities. The environmental entrainment of rhythms involves the immediate responses of clock components. Levels of the clock protein FRQ were measured in Neurospora at various temperatures; at higher temperatures, the amount of FRQ oscillated around higher Levels. Absolute FRQ amounts thus identified different times at different temperatures, so temperature shifts corresponded to shifts in clock time without immediate synthesis or turnover of components. Moderate temperature changes could dominate Light-to-dark shifts in the influence of circadian timing. Temperature regulation of clock components could explain temperature resetting of rhythms and how single transitions can initiate rhythmicity from characteristic circadian phases.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, JC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	jay.c.dunlap@dartmouth.edu	Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457	NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS, P311; BARRETT RK, 1995, J NEUROSCI, V15, P5681; BellPedersen D, 1996, J GENET, V75, P387, DOI 10.1007/BF02966317; BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005; Bunning E, 1973, PHYSL CLOCK; BUNNING E, 1935, JB WISS BOT, V81, P411; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Czeisler C. A., 1978, THESIS STANFORD U; DHARMANANDA S, 1980, THESIS U CALIFORNIA; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; GOOCH VD, 1985, TEMPORAL ORDER, P232; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Johnson C.H., 1990, ATLAS PHASE RESPONSE; KING PY, 1997, CELL, V89, P641; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; MENAKER M, 1971, BIOCHRONOMETRY, P81; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NAKASHIMA H, 1987, J INTERDISCIPL CYCLE, V18, P1; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; PETERSON EL, 1980, J THEOR BIOL, V84, P281, DOI 10.1016/S0022-5193(80)80008-7; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; Pittendrigh CS, 1959, PHOTOPERIODISM RELAT, P475, DOI DOI 10.1177/0748730413516309; RENSING L, 1989, CHRONOBIOL INT, V6, P297, DOI 10.3109/07420528909056933; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; SWEENEY B, 1968, INSECT PHYSL, V14, P669; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; UNDERWOOD H, 1987, Journal of Biological Rhythms, V2, P179, DOI 10.1177/074873048700200302; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Winfree A.T., 1980, GEOMETRY BIOL TIME, V8; Young MW, 1996, COLD SPRING HARB SYM, V61, P279	51	176	183	6	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					825	829		10.1126/science.281.5378.825	http://dx.doi.org/10.1126/science.281.5378.825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694654	Green Submitted			2022-12-24	WOS:000075295600050
J	Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L				Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L			Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							CANCER		Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17111 Stockholm, Sweden; Karolinska Inst, Dept Med, S-17111 Stockholm, Sweden	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska Institutet	Baecklund, E (corresponding author), Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden.			Sparen, Par/0000-0002-5184-8971; Klareskog, Lars/0000-0001-9601-6186				GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; MYLLYKANGASLUOSUJARVI R, 1995, SCAND J RHEUMATOL, V24, P76, DOI 10.3109/03009749509099288; PRIOR P, 1984, ANN RHEUM DIS, V43, P128, DOI 10.1136/ard.43.2.128; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; SYMMONS DPM, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90241-4	5	303	308	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					180	181		10.1136/bmj.317.7152.180	http://dx.doi.org/10.1136/bmj.317.7152.180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665898	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000075047800025
J	Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM				Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM			Detection of a novel DNA virus (TTV) in blood donors and blood products	LANCET			English	Article							HEPATITIS-C VIRUS; NON-A; HEMOPHILIA; DETERGENT; OUTBREAK; GLOBULIN; SOLVENT	Background A newly discovered DNA virus, transfusion-transmitted virus (TTV), has been implicated as a cause of post-transfusion hepatitis. We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting factors. We also investigated the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF). Methods We extracted DNA from plasma of blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor concentrates, immunoglobulin preparations). We detected TTV by PCR using primers from a conserved region in the TTV genome. Findings TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerated regular blood donors. Infection occurred more frequently in older donors (mean age 53 years), compared with the age prolife of donors infected with hepatitis C virus and other parenterally-transmitted viruses. TTV contamination was found in ten (56%) of 18 batches of factor VIII and IX concentrate manufactured from such nonremunerated donors, and in seven (44%) of 16 batches of commercially available products. Whereas solvent or detergent treatment had little effect on the detection of TTV in factor VIII and IX by PCR, this virucidal step seemed to inactivate TTV infectivity. TTV infection was detected in four (19%) of 21 patients with FHF; in three cases, infection was detected at the onset of disease and could thus not be excluded from its aetiology. Interpretation TTV viraemia is frequent in the blood-donor population, and transmission of TTV through transfusion of blood components may have occurred extensively. Clinical assessment of infected donors and recipients of blood and blood products, and assessment of TTV's aetiological role in hepatic and extra-hepatic disease, are urgently needed.	Univ Edinburgh, Dept Med Microbiol, Edinburgh EH3 9HB, Midlothian, Scotland; Edinburgh & SE Scotland Blood Transfus Serv, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Haematol, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Simmonds, P (corresponding author), Univ Edinburgh, Dept Med Microbiol, Teviot Pl, Edinburgh EH3 9HB, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GARSON JA, 1990, LANCET, V335, P1473, DOI 10.1016/0140-6736(90)91510-H; Hanley JP, 1998, THROMB HAEMOSTASIS, V79, P291; Haydon GH, 1997, J VIRAL HEPATITIS, V4, P45, DOI 10.1046/j.1365-2893.1997.00122.x; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1002/hep.1840220504; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; LAWLOR E, 1994, VOX SANG, V67, P18, DOI 10.1111/j.1423-0410.1994.tb00968.x; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Yap PL, 1996, CLIN EXP IMMUNOL, V104, P35, DOI 10.1111/cei.1996.104.s1.35	21	349	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					191	195		10.1016/S0140-6736(98)03056-6	http://dx.doi.org/10.1016/S0140-6736(98)03056-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683208				2022-12-24	WOS:000074859800012
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Chemical weddings	SCIENCE			English	Article													Wood, David W/B-2992-2012					EVANS TC, IN PRESS PROTEIN SCI; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205	3	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					367	368		10.1126/science.281.5375.367	http://dx.doi.org/10.1126/science.281.5375.367			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705714				2022-12-24	WOS:000074918800037
J	Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH				Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH			Insecticidal toxins from the bacterium Photorhabdus luminescens	SCIENCE			English	Article							BACILLUS-THURINGIENSIS; XENORHABDUS; LARVAE; LEPIDOPTERA; HETERORHABDITIDAE; RESISTANCE; NEMATODES; MOTH	Transgenic plants expressing Bacillus thuringiensis (Bt) toxins are currently being deployed for insect control. In response to concerns about Bt resistance, we investigated a toxin secreted by a different bacterium Photorhabdus luminescens, which lives in the gut of entomophagous nematodes. In insects infected by the nematode, the bacteria are released into the insect hemocoel; the insect dies and the nematodes and bacteria replicate in the cadaver. The toxin consists of a series of four native complexes encoded by toxin complex loci tca, tcb, tcc, and tcd. Both tca and tcd encode complexes with high oral toxicity to Manduca sexta and therefore they represent potential alternatives to Bt for transgenic deployment.	Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	ffrench-Constant, RH (corresponding author), Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA.			ffrench-Constant, Richard/0000-0001-5385-9888; Blackburn, Michael/0000-0001-5541-4831; Bhartia, Rohit/0000-0002-1434-7481				AKHURST RJ, 1982, J GEN MICROBIOL, V128, P3061; BANNO Y, 1984, REV INFECT DIS S1, V6, P11; BOWEN D, 1995, THESIS U WISCONSIN M; BOWEN D, IN PRESS APPL ENV MI; CLARKE DJ, 1995, J INVERTEBR PATHOL, V66, P149, DOI 10.1006/jipa.1995.1078; DUNPHY GB, 1988, J GEN MICROBIOL, V134, P1017; DUNPHY GB, 1988, INT J PARASITOL, V18, P729, DOI 10.1016/0020-7519(88)90112-9; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; ENSIGN JC, 1997, Patent No. 17432; GOTZ P, 1981, P R SOC LONDON B, V211, P330; GUINEY D, COMMUNICATION; HOFTE H, 1989, MICROBIOL REV, V53, P242; JOHNSON JL, 1990, CURR MICROBIOL, V20, P397, DOI 10.1007/BF02095867; KHAN A, 1977, J INVERTEBR PATHOL, V29, P253, DOI 10.1016/S0022-2011(77)80030-X; KINSINGER RA, 1979, ANN ENTOMOL SOC AM, V72, P787, DOI 10.1093/aesa/72.6.787; Libby SJ, 1997, INFECT IMMUN, V65, P1786, DOI 10.1128/IAI.65.5.1786-1792.1997; MCGAUGHEY WH, 1985, SCIENCE, V229, P193, DOI 10.1126/science.229.4709.193; McGaughey WH, 1998, NAT BIOTECHNOL, V16, P144, DOI 10.1038/nbt0298-144; PAUL VJ, 1981, J CHEM ECOL, V7, P589, DOI 10.1007/BF00987707; POINAR GO, 1977, NEMATOLOGICA, V23, P97, DOI 10.1163/187529277X00273; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; SCHMIDT TM, 1988, APPL ENVIRON MICROB, V54, P2793, DOI 10.1128/AEM.54.11.2793-2797.1988; SUTTER GR, 1967, J INVERTEBR PATHOL, V9, P90, DOI 10.1016/0022-2011(67)90048-1; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; YAMANAKA S, 1992, ARCH MICROBIOL, V158, P387; Yu CG, 1997, APPL ENVIRON MICROB, V63, P532, DOI 10.1128/AEM.63.2.532-536.1997	26	335	397	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2129	2132		10.1126/science.280.5372.2129	http://dx.doi.org/10.1126/science.280.5372.2129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641921				2022-12-24	WOS:000074435900049
J	Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G				Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G			Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by G alpha(13)	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE C-BETA-1; RAS; STATE; IDENTIFICATION; DEACTIVATION; SITE	Signaling pathways that link extracellular factors to activation of the monomeric guanosine triphosphatase (GTPase) Rho control cytoskeletal rearrangements and cell growth. Heterotrimeric guanine nucleotide-binding proteins (G proteins) participate in several of these pathways, although their mechanisms are unclear. The GTPase activities of two G protein alpha subunits, G alpha(12 )and G alpha(13), are stimulated by the Rho guanine nucleotide exchange factor p115 RhoGEF. Activated G alpha(13) bound tightly to p115 RhoGEF and stimulated its capacity to catalyze nucleotide exchange on Rho, In contrast, activated G alpha(12) inhibited stimulation by G alpha(13). Thus, p115 RhoGEF can directly link heterotrimeric G protein a subunits to regulation of Rho.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	sternwei@utsw.swmed.edu; bollag@onyx-pharm.com		Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM 31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM031954, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, UNPUB; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Singer WD, 1996, J BIOL CHEM, V271, P4504; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	30	648	658	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2112	2114		10.1126/science.280.5372.2112	http://dx.doi.org/10.1126/science.280.5372.2112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641916				2022-12-24	WOS:000074435900044
J	Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL				Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL			Perennial Antarctic lake ice: An oasis for life in a polar desert	SCIENCE			English	Article								The permanent ice covers of Antarctic lakes in the McMurdo Dry Valleys develop liquid water inclusions in response to solar heating of internal aeolian-derived sediments. The ice sediment particles serve as nutrient (inorganic and organic)-enriched microzones for the establishment of a physiologically and ecologically complex microbial consortium capable of contemporaneous photosynthesis,.nitrogen fixation, and decomposition. The consortium is capable of physically and chemically establishing and modifying a relatively nutrient- and organic matter-enriched microbial "oasis" embedded in the lake ice cover.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA; Univ Illinois, Chicago, IL 60607 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Oregon State University; University of North Carolina; University of North Carolina Chapel Hill; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Pinckney, James/0000-0002-6056-6511; Lanoil, Brian/0000-0001-8603-8330				Adams EE, 1998, ANTARCT RES SER, V72, P281; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Clow GD, 1988, J CLIMATE, V1, P715, DOI 10.1175/1520-0442(1988)001<0715:COAPSR>2.0.CO;2; FELIP M, 1995, APPL ENVIRON MICROB, V61, P2394, DOI 10.1128/AEM.61.6.2394-2401.1995; FELSENSTEIN J, 1991, PHYLIP; FLETT RJ, 1976, CAN J MICROBIOL, V22, P43, DOI 10.1139/m76-006; FRITSEN CH, 1994, SCIENCE, V266, P782, DOI 10.1126/science.266.5186.782; Fritsen CH, 1998, J PHYCOL, V34, P587, DOI 10.1046/j.1529-8817.1998.340587.x; Fritsen CH, 1998, ANTARCT RES SER, V72, P269; Lane D.J., 1991, 16S 23S RRNA SEQUENC, P115, DOI DOI 10.1007/S00227-012-2133-0; MCKAY CP, 1989, REV GEOPHYS, V27, P189, DOI 10.1029/RG027i002p00189; MCKAY CP, 1992, ADV SPACE RES-SERIES, V12, P231, DOI 10.1016/0273-1177(92)90177-Y; MCKAY CP, 1985, NATURE, V313, P561, DOI 10.1038/313561a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; PAERL HW, 1979, LIMNOL OCEANOGR, V24, P1166, DOI 10.4319/lo.1979.24.6.1166; Parsons T.R., 1984, MANUAL BIOL CHEM MET; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; Priscu JC, 1997, GLOBAL CHANGE BIOL, V3, P301, DOI 10.1046/j.1365-2486.1997.00147.x; PRISCU JC, UNPUB; REDFIELD AC, 1958, AM SCI, V46, P205; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALKI RK, 1988, SCIENCE, V239, P487; Wing K., 1993, ANTARCT J US, V28, P246	24	282	304	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2095	2098		10.1126/science.280.5372.2095	http://dx.doi.org/10.1126/science.280.5372.2095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641910				2022-12-24	WOS:000074435900038
J	Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA				Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA		Am Med Assoc	Sleepiness, driving, and motor vehicle crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AUTOMOBILE ACCIDENTS; OPERATIONAL SETTINGS; DRIVER SLEEPINESS; MANAGING FATIGUE; SHIFT WORK; APNEA; NARCOLEPSY; DISORDERS; VIGILANCE; INSOMNIA	Objective.-To assess the contribution of driver sleepiness to highway crashes and review recent recommendations to change federal hours-of-service regulations for commercial motor vehicle drivers. Data Sources.-Information was derived from a search of the MEDLINE, Transportation Research information Service (TRIS), and Bibliographic Electronic Databases of Sleep (BEDS) databases from 1975 through 1997 and from manual review of the reference lists in relevant journal articles, government publications, conference proceedings, and textbooks. Data Synthesis.-Driver sleepiness is a causative factor in 1% to 3% of all US motor vehicle crashes. Surveys of the prevalence of sleepy behavior in drivers suggest that sleepiness may be a more common cause of highway crashes than is reflected in these estimates. About 96% of sleep-related crashes involve passenger vehicle drivers and 3% involve drivers of large trucks. Risk factors include youth, shift work, alcohol and other drug use, over-the-counter and prescription medications, and sleep disorders. Conclusions.-Increased awareness of the relationship between sleepiness and motor vehicle crashes will promote the health and safely of drivers and highway users. Physicians can contribute by encouraging good sleep habits, recognizing and treating sleep-related problems, and counseling patients about the risks of driving while sleepy. To protect public health and safety, the American Medical Association recommends continued research on devices and technologies to detect the signs of sleepiness and prevent the deterioration of driver alertness and performance. Educational programs about the risks of falling asleep while driving are needed for physicians, the public, and commercial truck drivers.	Amer Med Assoc, Council Sci Affairs, Chicago, IL 60610 USA	American Medical Association	Lyznicki, JM (corresponding author), Amer Med Assoc, Council Sci Affairs, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014				*AA FDN TRAFF SAF, 1985, REP DET EV ROL FAT H; AKERSTEDT T, 1994, J SLEEP RES, V3, P152, DOI 10.1111/j.1365-2869.1994.tb00122.x; Akerstedt T, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00221.x; AKERSTEDT T, 1988, SLEEP, V11, P17, DOI 10.1093/sleep/11.1.17; ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; ALDRICH MS, 1990, NEW ENGL J MED, V323, P389; *AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS; American Psychiatric Association, 1994, DIAGN CRIT DSM 4; [Anonymous], 1995, FACT AFF FAT HEAV TR, V1-2; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BEILOCK R, 1995, ACCIDENT ANAL PREV, V27, P33, DOI 10.1016/0001-4575(94)00042-K; Braver Elisa R., 1992, Journal of Public Health Policy, V13, P341, DOI 10.2307/3342733; BROWN ID, 1994, HUM FACTORS, V36, P298, DOI 10.1177/001872089403600210; Brown ID, 1997, ACCIDENT ANAL PREV, V29, P525, DOI 10.1016/S0001-4575(97)00032-8; BROWN ID, 1993, ALCOHOL DRUGS DRIVIN, V9, P239; *CAN MED ASS, 1991, PHYS GUID DRIV EX; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P869; Chaska B, 1996, AM FAM PHYSICIAN, V53, P247; CORFITSEN MT, 1994, ACCIDENT ANAL PREV, V26, P617, DOI 10.1016/0001-4575(94)90023-X; Culebras A, 1996, CLIN HDB SLEEP DISOR; DEMENT WC, 1993, JAMA-J AM MED ASSOC, V269, P1548, DOI 10.1001/jama.269.12.1548; Dement WC, 1997, NEW ENGL J MED, V337, P783, DOI 10.1056/NEJM199709113371111; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; Dinges DF, 1997, SLEEP, V20, P267; DOEGE TC, 1986, MED CONDITIONS AFFEC; Evans L., 1991, TRAFFIC SAFETY DRIVE; *EXP PAN DRIV FAT, 1997, DROWS DRIV AUT CRASH; *FED HIGHW ADM, 1995, 1995 TRUCK BUS SAF S; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V86, P1034, DOI 10.1016/S0091-6749(05)80250-7; George CFP, 1996, SLEEP, V19, P711, DOI 10.1093/sleep/19.9.711; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; HARTENBAUM NP, 1997, DOT MED EXAMINATION; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; HERTZ RP, 1988, ACCIDENT ANAL PREV, V20, P431, DOI 10.1016/0001-4575(88)90041-3; Horne JA, 1996, PSYCHOPHYSIOLOGY, V33, P306, DOI 10.1111/j.1469-8986.1996.tb00428.x; Horne JA, 1995, J SLEEP RES, V4, P23, DOI 10.1111/j.1365-2869.1995.tb00222.x; HUBLIN C, 1994, SLEEP, V17, pS7, DOI 10.1093/sleep/17.suppl_8.S7; Itoi A, 1993, CAN DRIVERS AVOID FA; KANEKO T, 1992, ACCIDENT ANAL PREV, V24, P437, DOI 10.1016/0001-4575(92)90055-N; KNIPLING RR, 1996, 15 INT TECHN C ENH S; KNIPLING RR, 1994, INT VEH HIGHW SOC AM; Knipling RR., 1994, CRASHES FATALITIES R; KNIPLING RR, 1995, ANN M ASS ADV AUT ME; KOELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233, DOI 10.1007/BF02245951; Kryger M, 1994, PRINCIPLES PRACTICE; Kupfer DJ, 1997, NEW ENGL J MED, V336, P341, DOI 10.1056/NEJM199701303360506; LAUBER JK, 1988, SLEEP, V11, P503; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; Maycock G, 1997, ACCIDENT ANAL PREV, V29, P453, DOI 10.1016/S0001-4575(97)00024-9; McCartt AT, 1996, ACCIDENT ANAL PREV, V28, P511, DOI 10.1016/0001-4575(96)00021-8; McCartt AT, 1997, ASS ADV AUT MED 41 A; Mitler MM, 1997, NEW ENGL J MED, V337, P755, DOI 10.1056/NEJM199709113371106; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; *NAT COM SLEEP DIS, 1993, WAK AM NAT SLEEP AL; *NAT SAF COUNC, 1909, ACC FACTS; *NAT SAF COUNC TRA, 1991, NCHRP SYNTH, V191; *NAT SLEEP FDN, 1997, US CONT SHOULD RUMBL; *NAT TRANSP SAF BO, 1990, NTSBSS9001 NAT TRANS, V1; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; OGILVIE RD, 1989, SLEEP, V12, P458, DOI 10.1093/sleep/12.5.458; OHANLON JF, 1986, DRUGS DRIVING; OHANLON JF, 1995, 75 ANN M TRANSP RES; Pack AI, 1995, ACCIDENT ANAL PREV, V27, P769, DOI 10.1016/0001-4575(95)00034-8; Pack AM, 1995, J SLEEP RES, V24, P452; PAKOLA SJ, 1995, SLEEP, V18, P787, DOI 10.1093/sleep/18.9.787; PARTINEN M, 1994, PRINCIPLES PRACTICE; Pary R, 1996, POSTGRAD MED, V100, P195, DOI 10.3810/pgm.1996.11.117; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; Reyner LA, 1998, SLEEP, V21, P46; ROEHRS T, 1994, ALCOHOL CLIN EXP RES, V18, P154, DOI 10.1111/j.1530-0277.1994.tb00896.x; Rosa RR, 1997, PLAIN LANGUAGE SHIFT, P97; Rosekind MR, 1996, BEHAV MED, V21, P157, DOI 10.1080/08964289.1996.9933753; Rosekind MR, 1996, BEHAV MED, V21, P166, DOI 10.1080/08964289.1996.9933754; ROSEN RC, 1993, SLEEP, V16, P249, DOI 10.1093/sleep/16.3.249; STOOHS RA, 1995, CHEST, V107, P1275, DOI 10.1378/chest.107.5.1275; STOOHS RA, 1994, SLEEP, V17, P619; STROHL KP, 1994, AM J RESP CRIT CARE, V150, P1463; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; *US C, 1991, PUBL US C; WANG JS, 1993, ASS ADV AUT MED 40 A; WANG JS, 1994, DOT PUBLICATION; WEBB WB, 1995, SLEEP, V18, P276, DOI 10.1093/sleep/18.4.276; Williamson AM, 1996, ACCIDENT ANAL PREV, V28, P709, DOI 10.1016/S0001-4575(96)00044-9; WYLIE CD, 1996, FHWA PUBLICATION; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1996, FED REG, V61, P57251	91	289	313	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1908	1913		10.1001/jama.279.23.1908	http://dx.doi.org/10.1001/jama.279.23.1908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634264				2022-12-24	WOS:000074109700040
J	Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W				Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W			The preprotein translocation channel of the outer membrane of mitochondria	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN IMPORT RECEPTOR; GENERAL INSERTION PORE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; SECRETORY PROTEINS; CATIONIC CHANNEL; CELL VIABILITY; COMPLEX	The preprotein translocase of the outer membrane of mitochondria (TOM complex) facilitates the recognition, insertion, and translocation of nuclear-encoded mitochondrial preproteins. We have purified the TOM complex from Neurospora crassa and analyzed its composition and functional properties. The TOM complex contains a cation-selective high-conductance channel. Upon reconstitution into liposomes, it mediates integration of proteins into and translocation across the lipid bilayer. TOM complex particles have a diameter of about 138 Angstrom, as revealed by electron microscopy and image analysis; they contain two or three centers of stain-filled openings, which we interpret as pores with an apparent diameter of about 20 Angstrom. We conclude that the structure reported here represents the protein-conducting channel of the mitochondrial outer membrane.	Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, D-80336 Munich, Germany; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; CNRS, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; Univ Wurzburg, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany; Philipps Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany	University of Munich; University of Alberta; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wurzburg; Max Planck Society; Philipps University Marburg	Kunkele, KP (corresponding author), Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, Goethestr 33, D-80336 Munich, Germany.		Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720; Nussberger, Stephan/0000-0003-3619-4452; Benz, Roland/0000-0002-9510-9265; Lill, Roland/0000-0002-8345-6518				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; COURT DA, 1995, CAN J BOT, V73, pS193; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Dekker PJT, 1996, BIOL CHEM, V377, P535; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; FEVRE F, 1994, BIOPHYS J, V66, P1887, DOI 10.1016/S0006-3495(94)80982-8; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1982, J MOL BIOL, V161, P134, DOI 10.1016/0022-2836(82)90282-0; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOPING IS, 1995, FEBS LETT, V373, P45; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HALLERMAYER G, 1974, H-S Z PHYSIOL CHEM, V355, P279, DOI 10.1515/bchm2.1974.355.1.279; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Haucke V, 1997, TRENDS CELL BIOL, V7, P103, DOI 10.1016/S0962-8924(96)10052-0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hille B, 1992, IONIC CHANNELS EXCIT, P291; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; NAKAI M, 1995, FEBS LETT, V357, P202; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; Sebald W, 1979, Methods Enzymol, V55, P144; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	75	311	315	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1009	1019		10.1016/S0092-8674(00)81206-4	http://dx.doi.org/10.1016/S0092-8674(00)81206-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635430	Bronze			2022-12-24	WOS:000074205700012
J	Liu, QA; Hengartner, MO				Liu, QA; Hengartner, MO			Candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHOSPHOTYROSINE INTERACTION DOMAIN; RECEPTOR-MEDIATED PHAGOCYTOSIS; VITRONECTIN RECEPTOR; MACROPHAGE RECOGNITION; SIGNAL-TRANSDUCTION; GENETIC MOSAICS; SH3 DOMAINS; PTB DOMAIN; DEATH	The rapid engulfment (phagocytosis) of cells undergoing programmed cell death (apoptosis) is a fundamental biological process that is not well understood. Here we report the cloning and functional characterization of ced-6, a gene specifically required for the engulfment of apoptotic cells in the nematode C. elegans. The CED-6 protein contains a phosphotyrosine binding domain at its N terminus and a proline/serine-rich region in its C-terminal half. Genetic mosaic analysis demonstrates that ced-6 acts within engulfing cells. We also show that ced-6 can promote the engulfment of cells at both early and late stages of apoptosis. Our data suggest that CED-6 is an adaptor molecule acting in a signal transduction pathway that specifically mediates the recognition and engulfment of apoptotic cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hengartner, MO (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Liu, Alison/0000-0002-4636-0920; Hengartner, Michael/0000-0002-7584-596X; Liu (liu qiong), Alison/0000-0003-0171-6441	NIGMS NIH HHS [GM-52540] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BIANCO C, 1975, J EXP MED, V141, P1278, DOI 10.1084/jem.141.6.1278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRENNER S, 1974, GENETICS, V77, P71; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS RE, 1991, GENETICS, V129, P79; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMAN RK, 1984, GENETICS, V108, P165; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Hodgkin J, 1997, C ELEGANS, P881; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mello C, 1995, METHOD CELL BIOL, P452; Metchnikoff E, 1983, LECT COMP PATHOLOGY; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1985, GENETICS, V109, P493; Sambrook JFE, 1989, MOL CLONING LAB MANU; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Sun AY, 1997, GENETICS, V147, P1077; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; [No title captured]	64	164	176	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					961	972		10.1016/S0092-8674(00)81202-7	http://dx.doi.org/10.1016/S0092-8674(00)81202-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635426	Bronze, Green Accepted			2022-12-24	WOS:000074205700008
J	Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U				Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U			Ethanol intoxication in Drosophila: Genetic and pharmacological evidence for regulation by the cAMP signaling pathway	CELL			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; MUTANT MICE LACKING; MUSHROOM BODIES; PREFERENTIAL EXPRESSION; A RECEPTORS; ALCOHOL; MEMORY; DUNCE; MELANOGASTER	Upon exposure to ethanol, Drosophila display behaviors that are similar to ethanol intoxication in rodents and humans. Using an inebriometer to measure ethanol-induced loss of postural control, we identified cheapdate, a mutant with enhanced sensitivity to ethanol. Genetic and molecular analyses revealed that cheapdate is an allele of the memory mutant amnesiac. amnesiac has been postulated to encode a neuropeptide that activates the cAMP pathway. Consistent with this, we find that enhanced ethanol sensitivity of cheapdate can be reversed by treatment with agents that increase cAMP levels or PKA activity. Conversely, genetic or pharmacological reduction in PKA activity results in increased sensitivity to ethanol. Taken together, our results provide functional evidence for the involvement of the cAMP signal transduction pathway in the behavioral response to intoxicating levels of ethanol.	Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94110 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Moore, MS (corresponding author), Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F32AA005482, R01AA010035] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10035, F32 AA05482] Funding Source: Medline; NINDS NIH HHS [T32 NS07067] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Buck KJ, 1996, BEHAV GENET, V26, P313, DOI 10.1007/BF02359387; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COHAN FM, 1986, GENETICS, V114, P145; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; GORDON AS, 1992, G PROTEINS, V8, P191; GRANT KA, 1995, CLIN NEUROSCI, V3, P155; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Iourgenko V, 1997, FEBS LETT, V413, P104, DOI 10.1016/S0014-5793(97)00891-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER JD, 1977, GENETICS, V85, P259; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; QUI Y, 1991, J MOL BIOL, V222, P553; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHUCKIT MA, 1988, ARCH GEN PSYCHIAT, V45, P211; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WEBER KE, 1988, INEBRIOMETER, V67, P91; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301	39	365	371	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					997	1007		10.1016/S0092-8674(00)81205-2	http://dx.doi.org/10.1016/S0092-8674(00)81205-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635429	Bronze, Green Submitted			2022-12-24	WOS:000074205700011
J	Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ				Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ			Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; electrocardiography, ambulatory; time factors; arrhythmia; palpitations		Background: Continuous-loop event recorders are widely used for the evaluation of palpitations, but the optimal duration of monitoring is unknown. Objective: To determine the yield, timing, and incremental cost-effectiveness of each week of event monitoring for palpitations. Design: Prospective cohort study. Patients: 105 consecutive outpatients referred for the placement of a continuous-loop event recorder for the evaluation of palpitations. Measurements: Diagnostic yield, incremental cost, and cost-effectiveness for each week of monitoring. Results: The diagnostic yield of continuous-loop event recorders was 1.04 diagnoses per patient in week 1, 0.15 diagnoses per patient in week 2, and 0.01 diagnoses per patient in week 3 and beyond. Over time, the cost effectiveness ratio increased from $98 per new diagnosis in week 1 to $576 per new diagnosis in week 2 and $5832 per new diagnosis in week 3. Conclusions: In patients referred for evaluation of palpitations, the diagnostic yield of continuous-loop event recording decreases rapidly after 2 weeks of monitoring. A 2-week monitoring period is reasonably cost-effective for most patients and should be the standard period for continuous-loop event recording for the evaluation of palpitations.	Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cohen, DJ (corresponding author), Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, 330 Brookline Ave, Boston, MA 02115 USA.							DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Fogel RI, 1997, AM J CARDIOL, V79, P207, DOI 10.1016/S0002-9149(96)00717-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kinlay S, 1996, ANN INTERN MED, V124, P16, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00003; KRAHN AD, 1995, CIRCULATION, V92, P1819, DOI 10.1161/01.CIR.92.7.1819; REIFFEL JA, 1991, J ELECTROCARDIOL, V24, P165, DOI 10.1016/0022-0736(91)90007-9	7	87	91	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					890	+		10.7326/0003-4819-128-11-199806010-00002	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634426				2022-12-24	WOS:000073808600002
J	Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN				Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN			Is current eye-care-policy focus almost exclusively on cataract adequate to deal with blindness in India?	LANCET			English	Article							VISUAL-ACUITY; BALTIMORE	Background India's National Programme for Control of Blindness focuses almost exclusively on cataract, based on a national survey done in the 1980s which reported that cataract caused 80% of the blindness in India, No current population-based data on the causes of blindness in India are available, We assessed the rate and causes of blindness in an urban population in southern India. Methods We selected 2954 participants by stratified, random, cluster, systematic sampling from Hyderabad city. Eligible participants were interviewed and given a detailed ocular assessment, including visual acuity, refraction, slitlamp biomicroscopy, applanation intraocular pressure, gonioscopy, dilatation, grading of cataract, stereoscopic fundus assessment, and automated-threshold visual fields. Findings 2522 participants, including 1399 aged 30 years or more, were assessed. 49 participants tall aged greater than or equal to 30 years) were blind (presenting distance visual acuity <6/60 or central visual field <20 degrees in the better eye). The rate of blindness among those aged 30 years or more, adjusted for age and sex, was 3.08% ([95% CI 1.95-4.21]), Causes included cataract (29.7%), retinal disease (17.1%), corneal disease (15.4%), refractive error (12.5%), glaucoma (12.1%), and optic atrophy (11.0%). 15.7% of the blindness caused by visual-field constriction would have been missed without visual-field examination. Also without visual-field and detailed dilated-fundus assessments, blindness attributed to cataract would have been overestimated by up to 75.8%. If the use of cataract surgery in this urban population was half that found in this study, which simulates the situation in rural India, cataract would have caused 51.8% (39.4-64.2) of blindness, significantly less than the 80% accepted by current policy. Interpretation Much of the blindness in this Indian population was due to non-cataract causes. The previous national survey did not include detailed dilated-fundus assessment and visual-field examination which could have led to overestimation of cataract as a cause of blindness in India. Policy-makers in India should encourage well-designed population-based epidemiological studies from which to develop a comprehensive long-term policy on blindness in addition to dealing with cataract.	LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Hyderabad 500034, Andhra Pradesh, India; Univ Melbourne, Dept Ophthalmol, Epidemiol Res Unit, Melbourne, Vic, Australia	L. V. Prasad Eye Institute; University of Melbourne	Dandona, L (corresponding author), LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Rd 2 Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.			Dandona, Rakhi/0000-0003-0926-788X; McCarty, Catherine/0000-0003-1089-0142; Naduvilath, Thomas/0000-0001-8813-2048				Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035; *DAN ASS NAT PROGR, 1997, RAP ASS CAT BLINDN P, P10; Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514; Dandona Lalit, 1998, Indian Journal of Ophthalmology, V46, P93; Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; *GOV IND DIR GEN H, 1993, PRES STAT NAT PROGR; *HUMPHR INSTR INC, 1974, HUMPHR FIELD AN 2 US; *INT ARM EP STUD G, 1995, OLK, V39, P367; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; MOHAN M, 1992, PRESENT STATUS NATL, P79; OLK RJ, 1993, DIABETIC RETINOPATHY, P3; PRADESH A, 1995, CENSUS INDIA 1991; *REG GEN CENS COMM, 1992, CENS IND 1991 FIN PO; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SCHEIE HG, 1957, ARCH OPHTHALMOL-CHIC, V58, P510, DOI 10.1001/archopht.1957.00940010526005; SHAFFER R N, 1960, Trans Am Acad Ophthalmol Otolaryngol, V64, P112; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Taylor H, 1988, LENS RES, V5, P175; Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0; *WHO, 1973, INT STAT CLASS DIS R, V518, P10; 1994, HDB STAT HYDERABAD D	27	115	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1312	1316		10.1016/S0140-6736(97)09509-3	http://dx.doi.org/10.1016/S0140-6736(97)09509-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643793				2022-12-24	WOS:000073439400008
J	Grant, RM; Abrams, DI				Grant, RM; Abrams, DI			Not all is dead in HIV-1 graveyard	LANCET			English	Editorial Material							LYMPHOCYTES		Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Grant, RM (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.			Grant, Robert/0000-0002-0851-7085				Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					308	309		10.1016/S0140-6736(05)78343-4	http://dx.doi.org/10.1016/S0140-6736(05)78343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652607				2022-12-24	WOS:000071864000005
J	Kaiser, BN; Finnegan, PM; Tyerman, SD; Whitehead, LF; Bergersen, FJ; Day, DA; Udvardi, MK				Kaiser, BN; Finnegan, PM; Tyerman, SD; Whitehead, LF; Bergersen, FJ; Day, DA; Udvardi, MK			Characterization of an ammonium transport protein from the peribacteroid membrane of soybean nodules	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ION-CHANNEL; IDENTIFICATION; ATPASE; FAMILY; PLANTS; CELLS; NH4+	Nitrogen-fixing bacteroids in Legume root nodules are surrounded by the plant-derived peribacteroid membrane, which controls nutrient transfer between the symbionts, A nodule complementary DNA (GmSAT1) encoding an ammonium transporter has been isolated from soybean. GmSAT1 is preferentially transcribed in nodules and immunoblotting indicates that GmSAT1 is Located on the peribacteroid membrane. [C-14]methylammonium uptake and patch-clamp analysis of yeast expressing GmSAT1 demonstrated that it shares properties with a soybean peribacteroid membrane NH4+ channel described elsewhere. GmSAT1 is likely to be involved in the transfer of fixed nitrogen from the bacteroid to the host.	Australian Natl Univ, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia; Flinders Univ S Australia, Dept Biol, Adelaide, SA 5001, Australia	Australian National University; Flinders University South Australia	Day, DA (corresponding author), Australian Natl Univ, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Day, David/F-6325-2011; Tyerman, Steve D/F-9056-2010; Kaiser, Brent N/O-7458-2015; Kaiser, Brent/L-6092-2019; Udvardi, Michael/GPX-4653-2022; Finnegan, Patrick M/B-3469-2011	Day, David/0000-0001-7967-2173; Tyerman, Steve D/0000-0003-2455-1643; Kaiser, Brent N/0000-0001-6167-2423; Kaiser, Brent/0000-0001-6167-2423; Udvardi, Michael/0000-0001-9850-0828; Finnegan, Patrick M/0000-0001-5021-1138				BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; DELVES AC, 1986, PLANT PHYSIOL, V82, P588, DOI 10.1104/pp.82.2.588; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; Harlow E., 1988, ANITBODIES LAB MANUA; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; KAISER B, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; ROST B, 1995, PROTEIN SCI, V4, P521; Roth E, 1988, MOL GENETICS PLANT M, P220; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; TYERMAN SD, 1995, NATURE, V378, P629, DOI 10.1038/378629a0; Udvardi MK, 1997, ANNU REV PLANT PHYS, V48, P493, DOI 10.1146/annurev.arplant.48.1.493; YANG LJO, 1990, PLANTA, V182, P437, DOI 10.1007/BF02411397	26	67	71	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1998	281	5380					1202	1206		10.1126/science.281.5380.1202	http://dx.doi.org/10.1126/science.281.5380.1202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712587				2022-12-24	WOS:000075531200057
J	Amiel, SA				Amiel, SA			Hypoglycaemia avoidance - technology and knowledge	LANCET			English	Editorial Material							NOCTURNAL HYPOGLYCEMIA; DIABETIC-PATIENTS; ACTING INSULIN		Univ London Kings Coll, Sch Med, Dept Med, London SE5 9PJ, England	University of London; King's College London	Amiel, SA (corresponding author), Univ London Kings Coll, Sch Med, Dept Med, London SE5 9PJ, England.							BINDER C, 1984, DIABETES CARE, V7, P188, DOI 10.2337/diacare.7.2.188; BOYLE PJ, 1994, P NATL ACAD SCI USA, V91, P9352, DOI 10.1073/pnas.91.20.9352; CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6; Fanelli C, 1998, DIABETES, V47, pA109; FRANCIS AJ, 1983, BRIT MED J, V286, P1173, DOI 10.1136/bmj.286.6372.1173; GALE EAM, 1979, LANCET, V1, P1049; GEORGE E, 1995, DIABETOLOGIA, V38, P1183, DOI 10.1007/s001250050410; Heinemann L, 1996, DIABETIC MED, V13, P625, DOI 10.1002/(SICI)1096-9136(199607)13:7<625::AID-DIA134>3.3.CO;2-U; HELLER SR, 1997, DIABETES S1, V46, pA151; HOME PD, 1984, DIABET MED, V1; JACOBS AJM, 1997, DIABETES CARE, V20, P1279; KANE K, 1998, DIABETOLOGIA, V41, P322; MATYKA K, 1996, DIABET MED S3, V13, pA39; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WHINCUP G, 1987, ARCH DIS CHILD, V62, P333, DOI 10.1136/adc.62.4.333	16	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					502	503		10.1016/S0140-6736(05)79244-8	http://dx.doi.org/10.1016/S0140-6736(05)79244-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716050				2022-12-24	WOS:000075435300004
J	DeAngelis, GC; Cumming, BG; Newsome, WT				DeAngelis, GC; Cumming, BG; Newsome, WT			Cortical area MT and the perception of stereoscopic depth	NATURE			English	Article							VISUAL AREA; MACAQUE MONKEY; RHESUS-MONKEY; CORTEX; PERFORMANCE; SENSITIVITY; DISPARITY; NEURONS; MICROSTIMULATION; MECHANISMS	Stereopsis is the perception of depth based on small positional differences between images formed on the two retinae (known as binocular disparity). Neurons that respond selectively to binocular disparity were first described three decades ago(1,2), and have since been observed in many visual areas of the primate brain, including V1, V2, V3, MT and MST3-8. Although disparity-selective neurons are thought to form the neural substrate for stereopsis, the mere existence of disparity-selective neurons does not guarantee that they contribute to stereoscopic depth perception. Some disparity-selective neurons may play other roles, such as guiding vergence eye movementsg(9,10). Thus, the roles of different visual areas in stereopsis remain poorly defined. Here we show that visual area MT is important in stereoscopic vision: electrical stimulation of clusters of disparity-selective MT neurons can bias perceptual judgements of depth, and the bias is predictable from the disparity preference of neurons at the stimulation site. These results show that behaviourally relevant signals concerning stereoscopic depth are present in MT.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Oxford	Newsome, WT (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019	DeAngelis, Gregory/0000-0002-1635-1273				Albright T D, 1993, Rev Oculomot Res, V5, P177; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Bradley DC, 1998, NATURE, V392, P714, DOI 10.1038/33688; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; Cox DR., 1989, ANAL BINARY DATA; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; Deangelis G. C., 1996, Society for Neuroscience Abstracts, V22, P717; Dodd J. V., 1997, Society for Neuroscience Abstracts, V23, P1125; FELLEMAN DJ, 1987, J NEUROPHYSIOL, V57, P889, DOI 10.1152/jn.1987.57.4.889; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; PETTIGREW JD, 1968, EXP BRAIN RES, V6, P391; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROY JP, 1992, J NEUROSCI, V12, P2478; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423	23	300	303	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					677	680		10.1038/29299	http://dx.doi.org/10.1038/29299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716130				2022-12-24	WOS:000075384200043
J	Van Peenen, HJ				Van Peenen, HJ			Hafiz Ali goes home	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Van Peenen, HJ (corresponding author), 1414 E Hartford,Unit 9, Ponca City, OK 74604 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					249	251		10.7326/0003-4819-129-3-199808010-00016	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696736				2022-12-24	WOS:000075032700012
J	Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG				Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG			Pioneer axon guidance by UNC-129, a C-elegans TGF-beta	SCIENCE			English	Article							GROWTH-FACTOR-BETA; DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; TRANSFORMING GROWTH-FACTOR-BETA-2; 3-DIMENSIONAL STRUCTURE; COLORECTAL-CANCER; NETRIN CUES; GENE; RECEPTOR; ENCODES	The unc-129 gene, Like the unc-6 netrin gene, is required.to guide pioneer motoraxons along the dorsoventral axis of Caenorhabditis elegans. unc-129 encodes a member of the transforming growth factor-beta (TGF-beta) superfamily of secreted signaling molecules and is expressed in dorsal, but not ventral, rows of body wall muscles. Ectopic expression of UNC-129 from ventral body wall muscle disrupts growth cone and cell migrations that normally occur along the dorsoventral axis. Thus, UNC-129 mediates expression of dorsoventral polarity information required for axon guidance and guided cell migrations in C. elegans.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Rutgers State Univ, Waksman Inst, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Culotti, JG (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	culotti@mshri.on.ca	Culotti, Joseph/G-6467-2013	Colavita, Antonio/0000-0001-9391-5282; Culotti, Joseph/0000-0001-6325-4612				[Anonymous], [No title captured]; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; COLAVITA A, UNPUB; DURBIN RM, 1987, THESIS KINGS COLL CA; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NASH B, UNPUB; OKKEMA PG, 1993, GENETICS, V135, P385; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Su M.-D., UNPUB; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	27	185	199	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					706	709		10.1126/science.281.5377.706	http://dx.doi.org/10.1126/science.281.5377.706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685266				2022-12-24	WOS:000075107900045
J	Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM				Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM			Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; ADULT LIFE; INFANCY	Objective: To establish whether fetal growth rate (as distinct from size at birth) is associated with mortality from ischaemic heart disease. Design: Cohort study based on uniquely detailed obstetric records with 97% follow up over the entire life course and linkage to census data in adult life. Subjects: All 14 611 babies delivered at the Uppsala Academic Hospital, Sweden, during 1915-29 followed up to end of 1995. Main outcome measures: Mortality from ischaemic heart disease and other causes. Results: Cardiovascular disease showed an inverse association with birth weight for both men and women, although this was significant only for men. In men a 1000 g increase in birth weight was associated with a proportional reduction in the rate of ischaemic heart disease of 0.77 (95% confidence interval 0.67 to 0.90). Adjustment for socioeconomic circumstances at birth and in adult life led to slight attenuation of this effect Relative to the lowest fourth of birth weight for gestational age, mortality from ischaemic heart disease in men in the second, third, and fourth fourths was 0.81 (0.66 to 0.98), 0.63 (0.50 to 0.78), and 0.67 (0.54 to 0.82), respectively The inclusion of birth weight per se and birth weight for gestational age in the same model strengthened the association with birth weight for gestational age but removed the association with birth weight Conclusion: This study provides by far the most persuasive evidence of a real association between size at birth and mortality from ischaemic heart disease in men, which cannot be explained by methodological artefact or socioeconomic confounding. It strongly suggests that it is variation in fetal growth rate rather than size at birth that is aetiologically important.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Uppsala Univ, Inst Geriatr, S-75125 Uppsala, Sweden; Univ Stockholm, Dept Sociol, S-10691 Stockholm, Sweden	University of London; London School of Hygiene & Tropical Medicine; Uppsala University; Stockholm University	Leon, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.	dleon@lshtm.ac.uk	Berglund, Lars/AAA-3188-2019; Koupil, Ilona/AAC-9067-2020; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010	Koupil, Ilona/0000-0002-7034-1922; Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Erikson R., 1992, CONSTANT FLUX STUDY; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; KOUPILOVA I, 1997, J HYPERTENS       S4, V15, P46; KOUPILOVA I, 1997, ACTA U UPSAL, V698, P7; KRAMER MS, 1990, PEDIATRICS, V86, P707; KRAMER MS, 1987, PEDIATRICS, V80, P502; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LEON DA, 1997, LIFE COURSE INFLUENC; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; *STAT CORP, 1997, STAT REF MAN REL 5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Vik T, 1997, EARLY HUM DEV, V48, P167, DOI 10.1016/S0378-3782(96)01852-X	24	574	584	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					241	245		10.1136/bmj.317.7153.241	http://dx.doi.org/10.1136/bmj.317.7153.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677213	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000075081900020
J	Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD				Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD		Cooperative Thyrotoxicosis Therapy Follow Stud	Cancer mortality following treatment for adult hyperthyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID-CANCER; I-131 THERAPY; GRAVES-DISEASE; THYROTOXICOSIS; CARCINOMA; WOMEN; RISK	Context.-High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic I-131 to the development of cancer, its extensive medical use indicates the need for additional evaluation. Objective.-To evaluate cancer mortality among hyperthyroid patients, particularly after I-131 treatment. Design.-A retrospective cohort study. Setting.-Twenty-five clinics in the United States and 1 clinic in England. Patients.-A total of 35 593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with I-131. Main Outcome Measure.-Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism. Results.-Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86). Conclusions.-Neither hyperthyroidism nor I-131 treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following I-131 treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, I-131 appears to be a safe therapy for hyperthyroidism.	NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA; Vanderbilt Univ, Nashville, TN USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; George Washington Univ, Washington, DC 20052 USA; Mayo Clin, Rochester, MN USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ So Calif, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital; Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health; Research Triangle Institute; George Washington University; Mayo Clinic; University System of Ohio; University of Cincinnati; University of Southern California	Ron, E (corresponding author), NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA.		Brill, Aaron/H-3732-2014	Brill, Aaron/0000-0001-7538-086X	NCI NIH HHS [N01-CP-41060] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP041060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Becker David V., 1996, P943; BECKER DV, 1989, RAD THYROID, P57; BECKER DV, 1971, FURTHER ADV THYROID, P603; Cox D. R., 1974, THEORETICAL STAT; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; DOBYNS BM, 1977, RAD ASS THYROID CARC, P459; FRANCESCHI S, 1989, INT J EPIDEMIOL, V18, P578, DOI 10.1093/ije/18.3.578; FURSZYFE.J, 1972, METABOLISM, V21, P197, DOI 10.1016/0026-0495(72)90041-8; GLOBEL B, 1989, RAD RISK PROTECTOIN, P565; GOLDMAN MB, 1990, CANCER RES, V50, P2283; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; GRAHAM GD, 1986, ANN INTERN MED, V105, P900, DOI 10.7326/0003-4819-105-6-900; GREEN M, 1961, BRIT MED J, V1, P210; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; Hall P, 1996, RADIAT RES, V145, P86, DOI 10.2307/3579200; HALNAN KE, 1983, BMJ-BRIT MED J, V287, P8121; HANCOCK BW, 1977, CANCER, V39, P298, DOI 10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO;2-C; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1988, JNCI-J NATL CANCER I, V80, P1132, DOI 10.1093/jnci/80.14.1132; *INT COMM RAD PROT, 1988, ANN ICRP, V18, P275; KLEIN I, 1994, ANN INTERN MED, V121, P281, DOI 10.7326/0003-4819-121-4-199408150-00010; LOEVINGER R, 1956, RAD DOSIMETRY, P870; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; PRESTON D. L., 1993, EPICURE USERS GUIDE; RON E, 1987, JNCI-J NATL CANCER I, V79, P1; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Tompkins E, 1970, MED RADIONUCLIDES RA, P431; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; *US DHEW, 1967, PHS PUBL, V1693; Volpe R, 1989, THYROID FUNCTION DIS, P214; WILLIAMS ED, 1986, LANCET, V2, P456; World Health Organization, 1957, MAN INT STAT CLASS D; ZANZONICO P B, 1989, Journal of Nuclear Medicine, V30, P833	39	247	268	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					347	355		10.1001/jama.280.4.347	http://dx.doi.org/10.1001/jama.280.4.347			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686552	Bronze			2022-12-24	WOS:000074804200035
J	Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB				Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB			Impaired fetal growth and atherosclerosis of carotid and peripheral arteries	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; IN-UTERO; DEATH; MEN; BIRTH; WEIGHT; SIZE	Background Although epidemiological studies suggest that people with low birthweight are at higher risk of coronary heart disease and stroke in adult life than those of higher birthweight, the mechanisms underlying this relation are unclear. We investigated whether impaired fetal growth leads to an increased risk of atherosclerosis by assessment of the carotid and lower-limb arteries in a group of people aged around 70 years for whom birthweight data were available. Methods 2232 singleton babies were born to married mothers at a maternity hospital in Sheffield, UK, between 1922 and 1926, and had complete birth records. We traced 829 survivors and invited 395 who still lived in Sheffield to take part in this study. 322 agreed; they were interviewed at home and 181 underwent duplex ultrasonographic examination of the extracranial parts of the carotid arteries. Atherosclerosis in the arteries of the lower limb was assessed in 186 people by the ankle brachial-pressure index (ABPI). Findings The prevalence and severity of carotid atherosclerosis was greatest in those with the lowest recorded birthweight. The risk of carotid stenosis was greater for people who had weighed 6.5 lb or less at birth than for those who weighed over 7.5 lb (odds ratio 5.3 [95% CI 2.0-14.0]), after adjustment for cardiovascular risk factors and gestational age at birth. The odds ratio for atherosclerotic disease in the lower limbs (low ABPI) was highest in people with the lowest recorded birthweight, but this relation was not significant (odds ratio 2.3 [1.0-5.6]). Interpretation Increased atherogenesis may be one mechanism mediating the observed epidemiological link between impaired fetal growth and cardiovascular disease. Adaptations made by the fetus in response to influences that retard its growth may have long-term consequences for the structure and metabolism of the vascular system.	Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; No Gen Hosp, Dept Med Phys, Sheffield S5 7AU, S Yorkshire, England	University of Southampton; Northern General Hospital	Martyn, CN (corresponding author), Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	c.martyn@mrc.soton.ac.uk	Gale, Catharine R/B-1653-2012					ALLAN PLP, 1991, EPIDEMIOLOGY PERIPHE, P41; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; GIRAL P, 1991, ARCH INTERN MED, V151, P950, DOI 10.1001/archinte.151.5.950; JOENSUU T, 1994, J INTERN MED, V236, P79; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; Martyn CN, 1996, BRIT MED J, V312, P1393; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pasterkamp G, 1998, ATHEROSCLEROSIS, V137, P205, DOI 10.1016/S0021-9150(97)00255-4; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; RIZZO G, 1991, AM J OBSTET GYNECOL, V165, P876, DOI 10.1016/0002-9378(91)90431-P; SALONEN JT, 1993, CIRCULATION, V87, P56; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817	23	125	128	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					173	178		10.1016/S0140-6736(97)10404-4	http://dx.doi.org/10.1016/S0140-6736(97)10404-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683205				2022-12-24	WOS:000074859800009
J	Buchel, C; Price, C; Friston, K				Buchel, C; Price, C; Friston, K			A multimodal language region in the ventral visual pathway	NATURE			English	Article							TEMPORAL-LOBE; CORTEX; EXTRASTRIATE; WORDS; ACTIVATION; IMPAIRMENT; ALEXIA; OBJECT; FACES; AREA	Reading words and naming pictures involves the association of visual stimuli with phonological and semantic knowledge. Damage to a region of the brain in the left basal posterior temporal lobe (BA37), which is strategically situated between the visual cortex and the more anterior temporal cortex, leads to reading and naming deficits(1,2). Additional evidence implicating this region in linguistic processing comes from functional neuroimaging studies of reading in normal subjects(3-7) and subjects with developmental dyslexia(8,9). Here we test whether the visual component of reading is essential for activation of BA37 by comparing cortical activations elicited by word processing in congenitally blind, late-blind and sighted subjects using functional neuroimaging. Despite the different modalities used (visual and tactile), all groups of subjects showed a common activation of BA37 by words relative to non-word letter-strings. These findings agree with the proposal that BA37 is an association area that integrates converging inputs from many regions(10). Our study confirms a prediction of theories of brain function that depend on convergence zones; the absence of one input (that is, visual) does not alter the response properties of such a convergence region.	Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Buchel, C (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		Friston, Karl/D-9230-2011	Friston, Karl/0000-0001-7984-8909; Price, Catherine/0000-0001-7448-4835	Wellcome Trust [051067] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; Bookheimer SY, 1995, HUM BRAIN MAPP, V3, P93, DOI 10.1002/hbm.460030206; BRUNSWICK N, UNPUB BRAIN; Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; BURNSTINE TH, 1990, NEUROLOGY, V40, P966, DOI 10.1212/WNL.40.6.966; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEsposito M, 1997, NEUROPSYCHOLOGIA, V35, P725, DOI 10.1016/S0028-3932(96)00121-2; FARAH MJ, 1990, VISUAL AGNOSIA; FIEZ JA, 1995, J COGNITIVE NEUROSCI, V7, P357, DOI 10.1162/jocn.1995.7.3.357; Foundas AL, 1998, NEUROCASE, V4, P35, DOI 10.1093/neucas/4.1.35; Friedman RF, 1993, CLIN NEUROPSYCHOLOGY, P37; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LUDERS H, 1986, NEUROLOGY, V36, P505, DOI 10.1212/WNL.36.4.505; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1997, NEUROIMAGE, V5, P261, DOI 10.1006/nimg.1997.0269; Puce A, 1996, J NEUROSCI, V16, P5205; RAPCSAK SZ, 1987, BRAIN LANG, V31, P109, DOI 10.1016/0093-934X(87)90063-0; Rumsey JM, 1997, ARCH NEUROL-CHICAGO, V54, P562, DOI 10.1001/archneur.1997.00550170042013; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SUZUKI WA, 1993, J NEUROSCI, V13, P2430, DOI 10.1523/JNEUROSCI.13-06-02430.1993; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3	28	299	305	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					274	277		10.1038/28389	http://dx.doi.org/10.1038/28389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685156				2022-12-24	WOS:000074851900047
J	Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL				Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL			A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation	CELL			English	Article							TATA-BINDING PROTEIN; YEAST SWI/SNF COMPLEX; HISTONE ACETYLATION; X-CHROMOSOME; ACTIVATION; CHROMATIN; H4; ENHANCEMENT; REPRESSION; CELLS	A number of transcriptional coactivator proteins have been identified as histone acetyltransferase (HAT) proteins, providing a direct molecular basis for the coupling of histone acetylation and transcriptional activation. The yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex requires the coactivator protein Gcn5 for HAT activity. Identification of protein subunits by mass spectrometry and immunoblotting revealed that the TATA binding protein-associated factors (TAF(II)s) TAF(II)90, -68/61, -60, -25/23, and -20/17 are integral components of this complex. in addition, TAF(II)68 was required for both SAGA-dependent nucleosomal HAT activity and transcriptional activation from chromatin templates in vitro. These results illustrate a role for certain TAF(II) proteins in the regulation of gene expression at the level of chromatin modification that is distinct from the TFIID complex and TAF(II)145.	Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Washington, Hlth Sci Ctr, Dept Mol Biotechnol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Washington; University of Washington Seattle	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA.				PHS HHS [11823-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GAITLIN CL, 1998, IN PRESS J ANAL BIOC; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; UTLEY RT, 1998, IN PRESS NATURE; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YATES JR, 1994, CELL BIOL LABORATORY, P380	59	376	395	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					45	53		10.1016/S0092-8674(00)81220-9	http://dx.doi.org/10.1016/S0092-8674(00)81220-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674426	Bronze			2022-12-24	WOS:000074790800008
J	Schnitzler, G; Sif, S; Kingston, RE				Schnitzler, G; Sif, S; Kingston, RE			Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state	CELL			English	Article							TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA PROTEIN; CHROMATIN STRUCTURE; COMPLEX; DNA; BINDING; DISRUPTION; SEQUENCES; RECEPTOR; FAMILY	The human SWI/SNF complex remodels nucleosome structure in an ATP-dependent manner, although the nature of this change has not been determined. Here we show that hSWI/SNF and ATP generate an altered nucleosomal structure that is stable in the absence of SWI/SNF. This product has an altered sensitivity to digestion by DNAse, restriction enzymes, and micrococcal nuclease, and an increased affinity for GAL4. It has the same protein composition but is approximately twice the size of a normal nucleosome. Incubation of the altered nucleosome with hSWI/SNF converts this structure back to a standard nucleosome in an ATP-dependent process. These results suggest that hSWI/SNF acts by facilitating an exchange between normal and altered, more accessible, nucleosome conformations.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA.		Sif, Said/AAE-5554-2019	Sif, Said/0000-0001-6268-1145				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Harlow E, 1988, ANTIBODIES LAB MANUA; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; NOLL H, 1989, METHOD ENZYMOL, V170, P55; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Strober BE, 1996, MOL CELL BIOL, V16, P1576; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU HM, 1979, BIOCHEMISTRY-US, V18, P3960, DOI 10.1021/bi00585a018	36	246	249	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					17	27		10.1016/S0092-8674(00)81217-9	http://dx.doi.org/10.1016/S0092-8674(00)81217-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674423	Bronze			2022-12-24	WOS:000074790800005
J	Nightingale, SL				Nightingale, SL			Advisory on need for caution with use of vacuum-assisted delivery devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-24	WOS:000074379400006
J	Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR				Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR			Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development	NATURE			English	Article							NERVOUS-SYSTEM; BONE-MARROW; LYMPHOCYTE CHEMOATTRACTANT; HIV-1 ENTRY; CELL-LINE; SDF-1; LESTR/FUSIN; EXPRESSION; MIGRATION; LIGAND	Chemokines and their receptors are important in cell migration during inflammation(1), in the establishment of functional lymphoid microenvironments(2), and in organogenesis(3). The chemokine receptor CXCR4 is broadly expressed in cells of both the immune and the central nervous systems(4,5) and can mediate migration of resting leukocytes and haematopoietic progenitors in response to its ligand, SDF-1 (refs 6-9). CXCR4 is also a major receptor for strains of human immunodeficiency virus-1 (HIV-1) that arise during progression to immunodeficiency and AIDS dementia(10). Here we show that mice lacking CXCR4 exhibit haematopoietic and cardiac defects identical to those of SDF-1-deficient mice(3), indicating that CXCR4 may be the only receptor for SDF-1. Furthermore, fetal cerebellar development in mutant animals is markedly different from that in wild-type animals, with many proliferating granule cells invading the cerebellar anlage. This is, to our knowledge, the first demonstration df the involvement of a G-protein-coupled chemokine receptor in neuronal cell migration and patterning in the central nervous system. These results may be important for designing strategies to block HIV entry into cells and for understanding mechanisms of pathogenesis in AIDS dementia.	NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	New York University; Howard Hughes Medical Institute; New York University; Columbia University	Zou, YR (corresponding author), NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA.	zou@saturn.med.nyu.edu	Kottmann, Andreas/Y-1180-2019; Taniuchi, Ichiro/N-6399-2015	Kottmann, Andreas/0000-0002-5435-7502; Taniuchi, Ichiro/0000-0002-9853-9068				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3; LANDRETH KS, 1988, J IMMUNOL, V140, P845; Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0	29	2010	2116	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					595	599		10.1038/31269	http://dx.doi.org/10.1038/31269			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634238				2022-12-24	WOS:000074150100057
J	Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC				Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC			Increased risk for cancer in patients with the Peutz-Jeghers syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						Peutz-Jeghers syndrome; genital neoplasms, female; breast neoplasms; gastrointestinal neoplasms; risk	SEX CORD TUMOR; ANNULAR TUBULES; POLYPOSIS SYNDROMES; ADENOMA-MALIGNUM	Background: Some reports describe an increased risk for cancer in patients with the Peutz-Jeghers syndrome. Objective: To characterize occurrences of cancer in a large cohort of patients with the Peutz-Jeghers syndrome. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 34 patients with the Peutz-Jeghers syndrome identified from Mayo Clinic records from 1945 to 1996. Measurements: Cases of cancer documented by chart review and telephone follow-up. Results: 26 cases of noncutaneous cancer developed in 18 of the 34 patients: 10 cases of gastrointestinal cancer and 16 cases of extraintestinal cancer. With the use of SEER (Surveillance, Epidemiology, and End Results) data for comparison, the relative risk for cancer was 18.5 (95% CI, 8.5 to 35.2) in women with the Peutz-Jeghers syndrome and 6.2 (CI, 2.5 to 12.8) in men with the syndrome (P = 0.001). In women, the relative risk for breast and gynecologic cancer was 20.3 (CI, 7.4 to 44.2). Conclusions: The Peutz-Jeghers syndrome is associated with an increased risk for cancer. The relative risk for breast and gynecologic cancers is particularly high.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Hartmann, LC (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.			McDonnell, Shannon/0000-0001-6201-369X				Amos CI, 1997, CANCER RES, V57, P3653; CANTU JM, 1980, CANCER, V46, P223, DOI 10.1002/1097-0142(19800701)46:1<223::AID-CNCR2820460137>3.0.CO;2-8; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; COHEN PR, 1991, AM J MED, V90, P606; DOZOIS RR, 1969, ARCH SURG-CHICAGO, V98, P509; DUBOIS RS, 1982, J PEDIATR-US, V101, P568, DOI 10.1016/S0022-3476(82)80705-1; FINAN MC, 1989, DERMATOL CLIN, V7, P419, DOI 10.1016/S0733-8635(18)30575-8; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gilchrist DM, 1997, CAN J GASTROENTEROL, V11, P421, DOI 10.1155/1997/859106; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LINOS DA, 1981, ARCH SURG-CHICAGO, V116, P1182; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; NUSS DD, 1978, ARCH DERMATOL, V114, P743, DOI 10.1001/archderm.114.5.743; *SEER PROGR, 1993, NIH PUB; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; SRIVATSA PJ, 1994, GYNECOL ONCOL, V53, P256, DOI 10.1006/gyno.1994.1127; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	20	285	303	3	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					896	+		10.7326/0003-4819-128-11-199806010-00004	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634427				2022-12-24	WOS:000073808600003
J	Mindel, A				Mindel, A			Genital herpes - how much of a public-health problem?	LANCET			English	Article							SIMPLEX VIRUS TYPE-2; RISK-FACTORS; INFECTION; PREVALENCE; TRANSMISSION; VALACICLOVIR; EPIDEMIOLOGY; FAMCICLOVIR; FREQUENCY; ANTIBODY		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, GPO Box 1614, Sydney, NSW 2001, Australia.	amindel@mail.usyd.edu.au		Mindel, Adrian/0000-0002-8780-9982				Ashley RL, 1997, GENITOURIN MED, V73, P235; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CAMERON DW, 1989, LANCET, V2, P403; CARNEY O, 1993, GENITOURIN MED, V69, P457; *CDCP, 1982, MMWR-MORBID MORTAL W, V31, P137; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1997, 37 INT C ANT AG CHEM; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; Fairley I, 1997, GENITOURIN MED, V73, P259; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; *GOV STAT SERV, 1996, SEX TRANSM DIS ENGL, P1; Huerta K, 1996, J ADOLESCENT HEALTH, V18, P384, DOI 10.1016/1054-139X(96)00019-5; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; Langeland N, 1998, INT J STD AIDS, V9, P104, DOI 10.1258/0956462981921765; MEHEUS A, 1983, SEX TRANSM DIS, V10, P33, DOI 10.1097/00007435-198301000-00007; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1995, ANTIVIRAL CHEMOTHERA; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PERSSON K, 1995, SCAND J INFECT DIS, V27, P195, DOI 10.3109/00365549509019008; Rosenthal SL, 1997, CLIN INFECT DIS, V24, P135, DOI 10.1093/clinids/24.2.135; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SMITH J, 1997, HERPES, V4, P55; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; TAYAL SC, 1994, INT J STD AIDS, V5, P359, DOI 10.1177/095646249400500514; Thackray AM, 1996, ANTIMICROB AGENTS CH, V40, P846, DOI 10.1128/AAC.40.4.846; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY RJ, 1993, J MED VIROL, P13	34	39	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			16	18						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652715				2022-12-24	WOS:000074347300006
J	Anderson, GB; Seidel, GE				Anderson, GB; Seidel, GE			Developmental biology - Cloning for profit	SCIENCE			English	Article							SHEEP EMBRYOS; NUCLEAR TRANSPLANTATION; INVIVO		Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA; Colorado State Univ, Anim Reprod & Biotechnol Lab, Ft Collins, CO 80523 USA	University of California System; University of California Davis; Colorado State University	Anderson, GB (corresponding author), Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA.		Seidel, George/AAE-2371-2019					Butler D, 1998, NATURE, V392, P113, DOI 10.1038/32238; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Seidel G. E. Jr., 1997, Theriogenology, V47, P236, DOI 10.1016/S0093-691X(97)82363-1; SMITH LC, 1989, BIOL REPROD, V40, P1027, DOI 10.1095/biolreprod40.5.1027; SZELL A, 1991, THERIOGENOLOGY, V36, P379, DOI 10.1016/0093-691X(91)90466-Q; Vignon X, 1998, THERIOGENOLOGY, V49, P392, DOI 10.1016/S0093-691X(98)90745-2; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	11	13	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1400	1401		10.1126/science.280.5368.1400	http://dx.doi.org/10.1126/science.280.5368.1400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9634416				2022-12-24	WOS:000073883400044
J	Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS				Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS			Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure	LANCET			English	Article							NITRIC-OXIDE; NITROSOGLUTATHIONE	Background Nitric oxide (NO) gas concentrations are high in the expired air of individuals with asthma, but not consistently so in the expired air of people with pneumonia. S-nitrosothiols are naturally occurring bronchodilators, the concentrations of which are raised in the airways of patients with pneumonia. Airway S-nitrosothiols have not been studied in asthma. Methods Tracheal S-nitrosothiol concentrations from eight asthmatic children in respiratory failure were compared with those of 21 children undergoing elective surgery. Results Mean S-nitrosothiol concentrations in asthmatic children were lower than in normal children (65 [SD 45] nmol/L vs 502 [SD 429] nmol/L) and did not vary with inspired oxygen concentration or airway thiol concentration. Interpretation Severe asthma is associated with low concentrations of airway S-nitrosothiols. This is the first reported deficiency of an endogenous bronchodilator in the human asthmatic airway lining fluid, We suggest that S-nitrosothiol metabolism may be a target for the development of new asthma therapies.	Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA; USN, Med Ctr, Dept Pediat, Div Pulm, San Diego, CA 92152 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA	University of Virginia; United States Department of Defense; United States Navy; Duke University; Howard Hughes Medical Institute; Duke University	Gaston, B (corresponding author), Univ Virginia Hlth Syst, Box 386, Charlottesville, VA 22908 USA.	bmg3g@virginia.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL52529, HLO2582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, K08HL002582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; BANNENBERG G, 1995, J PHARMACOL EXP THER, V272, P1238; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; FANG K, 1998, IN PRESS AM J RESP C; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; JIA L, 1996, NATURE, V380, P21; Lewis SJ, 1996, EUR J PHARMACOL, V312, pR3, DOI 10.1016/0014-2999(96)00607-3; LEWIS SJ, 1993, AM REV RESPIR DIS, V147, P1461; MASSARO AF, 1995, AM J RESP CRIT CARE, V151, P832; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEHTA S, 1997, AM J PHYSIOL, V272, P124; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Raghavender B, 1997, J PEDIATR-US, V130, P944, DOI 10.1016/S0022-3476(97)70281-6; RICCIARDOLO F, 1998, IN PRESS LANCET; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RUTGERS S, 1992, AM J RESP CRIT CARE, V155; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VANIN AF, 1997, BIOL CHEM, V1, P191; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	27	181	187	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1317	1319		10.1016/S0140-6736(97)07485-0	http://dx.doi.org/10.1016/S0140-6736(97)07485-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643794				2022-12-24	WOS:000073439400009
J	Parkin, DE				Parkin, DE			Prognostic factors for success of endometrial ablation and resection	LANCET			English	Editorial Material							HYSTERECTOMY; MENORRHAGIA; TRIAL; WOMEN		Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Parkin, DE (corresponding author), Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland.							ABRAMOVICH DR, 1995, BRIT J OBSTET GYNAEC, V102, P249; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Chullapram T, 1996, OBSTET GYNECOL, V88, P71, DOI 10.1016/0029-7844(96)00085-3; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1360, DOI 10.1111/j.1471-0528.1997.tb11004.x; Davis JR, 1998, AM J CLIN PATHOL, V109, P96; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Gannon MJ, 1996, BRIT J OBSTET GYNAEC, V103, P1029, DOI 10.1111/j.1471-0528.1996.tb09556.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979	8	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1147	1148		10.1016/S0140-6736(05)79116-9	http://dx.doi.org/10.1016/S0140-6736(05)79116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643682				2022-12-24	WOS:000073220200004
J	Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y				Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y			Lung as reservoir for antidepressants in pharmacokinetic drug interactions	LANCET			English	Article							BINDING-SITES; TRICYCLIC ANTIDEPRESSANTS; SEROTONIN TRANSPORTER; H-3 IMIPRAMINE; AMINES; BRAIN; ACCUMULATION; FLUOXETINE; INHIBITION; COCAINE	Background Although high-affinity imipramine binding sites have been reported in both rat and human lung, the role of the lungs in the pharmacokinetics of antidepressants has not received much attention. Substantial accumulation of selective serotonin-reuptake inhibitors (SSRIs) in the lungs has been reported. We have investigated the role of the lungs in pharmacokinetic drug interactions between tricyclic antidepressants and SSRIs. Methods We used a carbon-11-labelled form of the imipramine derivative cyanoimipramine to measure uptake in the lungs and brain of healthy volunteers by positron emission tomography. Clomipramine (50 mg) was administered to measure the effect of antidepressants with high affinity for the serotonin transporter on lung and brain uptake. Findings A large proportion of the injected C-11-cyanoimipramine (68-86% in the four volunteers) was extracted by the lungs. Clomipramine decreased the lung uptake from 68% to 35% and from 81% to 54% in the two volunteers studied. By contrast, whole-brain uptake was low in control studies (1.7-2.0% in three volunteers) and increased after clomipramine administration (to 4.5-4.9%). Plasma radioactivity was also higher after clomipramine than in control studies. Interpretation The lungs may function as a reservoir for antidepressants with high affinity to the serotonin transporter. The accumulated antidepressants may be displaced by other antidepressants, and this displacement would substantially increase plasma concentrations and thus cause toxic effects.	Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, Chiba 263, Japan; Japan Sci & Technol Corp, CREST, Chiba, Japan	National Institutes for Quantum Science & Technology; Japan Science & Technology Agency (JST)	Suhara, T (corresponding author), Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, 9-1 Anagawa 4 Chome, Chiba 263, Japan.	suhara@nirs.go.jp	Obata, Takayuki/AAR-9820-2020	Obata, Takayuki/0000-0001-7678-5033				ANDERSON MW, 1974, J PHARMACOL EXP THER, V189, P456; CATRAVAS JD, 1980, J PHARMACOL EXP THER, V213, P120; DOWNS JM, 1989, AM J PSYCHIAT, V146, P814; HASHIMOTO K, 1987, NUCL MED BIOL, V14, P587; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IWASAWA Y, 1973, J PHARMACOL EXP THER, V186, P498; JUNOD AF, 1972, J PHARMACOL EXP THER, V183, P182; JUNOD AF, 1975, LUNG METABOLISM, P219; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; MORIN D, 1984, BIOCHEM BIOPH RES CO, V120, P926, DOI 10.1016/S0006-291X(84)80195-3; PAUL SM, 1980, LIFE SCI, V26, P953, DOI 10.1016/0024-3205(80)90116-2; PISTOLESI M, 1988, AM REV RESPIR DIS, V138, P1429, DOI 10.1164/ajrccm/138.6.1429; RAISMAN R, 1983, EUR J PHARMACOL, V94, P345, DOI 10.1016/0014-2999(83)90426-0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SCHLYER DJ, 1992, SYNAPSE, V11, P10, DOI 10.1002/syn.890110103; SHIUE CY, 1995, NUCL MED BIOL, V22, P613, DOI 10.1016/0969-8051(94)00146-B; Suhara T, 1996, Ann Nucl Med, V10, P85; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; VESTAL RE, 1980, J PHARMACOL EXP THER, V214, P106; WILSON AGE, 1982, DRUG METAB DISPOS, V10, P281; WOLFE J, 1987, J PHARMACOL EXP THER, V241, P196	21	74	76	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					332	335		10.1016/S0140-6736(97)07336-4	http://dx.doi.org/10.1016/S0140-6736(97)07336-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652614				2022-12-24	WOS:000071864000014
J	Sieger, MT; Simpson, WC; Orlando, TM				Sieger, MT; Simpson, WC; Orlando, TM			Production of O-2 on icy satellites by electronic excitation of low-temperature water ice	NATURE			English	Article							D2O ICE; GANYMEDE; OXYGEN; IONS	The signature of condensed molecular oxygen has been reported in recent optical-reflectance measurements of the jovian moon Ganymede(1), and a tenuous oxygen atmosphere has been observed on Europa(2). The surfaces of these moons contain large amounts of water ice, and it is thought that O-2 is formed by the sputtering of ice by energetic particles from the jovian magnetosphere(3-8). Understanding how O-2 might be formed from low-temperature ice is crucial for theoretical and experimental simulations of the surfaces and atmospheres of icy bodies in the Solar System. Here we report laboratory measurements of the threshold energy, cross-section and temperature dependence of O-2 production by electronic excitation of ice in vacuum, following electron-beam irradiation. Molecular oxygen is formed by direct excitation and dissociation of a stable precursor molecule, rather than (as has been previously thought) by diffusion and chemical recombination of precursor fragments. The large cross-section for O-2 production suggests that electronic excitation plays an important part in the formation of O-2 on Ganymede and Europa.	Pacific NW Lab, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Orlando, TM (corresponding author), Pacific NW Lab, WR Wiley Environm Mol Sci Lab, MS K8-88,POB 999, Richland, WA 99352 USA.	tm_orlando@pnl.gov	Sieger, Matthew/B-4261-2011	Sieger, Matthew/0000-0001-7387-3660				Bednarek J, 1996, J AM CHEM SOC, V118, P9387, DOI 10.1021/ja960518w; BROWN WL, 1982, NUCL INSTRUM METHODS, V198, P1, DOI 10.1016/0167-5087(82)90043-6; BROWN WL, 1978, PHYS REV LETT, V40, P1027, DOI 10.1103/PhysRevLett.40.1027; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Calvin WM, 1997, ICARUS, V130, P505, DOI 10.1006/icar.1997.5842; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Ip WH, 1997, GEOPHYS RES LETT, V24, P2631, DOI 10.1029/97GL02814; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; JOHNSON RE, 1981, SCIENCE, V212, P1027, DOI 10.1126/science.212.4498.1027; Johnson RE, 1996, REV MOD PHYS, V68, P305, DOI 10.1103/RevModPhys.68.305; KIMMEL GA, 1995, PHYS REV LETT, V75, P2606, DOI 10.1103/PhysRevLett.75.2606; Lacombe S, 1997, PHYS REV LETT, V79, P1146, DOI 10.1103/PhysRevLett.79.1146; LANZEROTTI LJ, 1978, GEOPHYS RES LETT, V5, P155, DOI 10.1029/GL005i002p00155; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; REIMANN CT, 1984, SURF SCI, V147, P227, DOI 10.1016/0039-6028(84)90177-8; Sieger MT, 1997, PHYS REV B, V56, P4925, DOI 10.1103/PhysRevB.56.4925; Simpson WC, 1997, J CHEM PHYS, V107, P8668, DOI 10.1063/1.475019; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUB IA, 1968, J CHEM PHYS, V49, P2499, DOI 10.1063/1.1670446; Vidal RA, 1997, SCIENCE, V276, P1839, DOI 10.1126/science.276.5320.1839; WESTLEY MS, 1995, NATURE, V373, P405, DOI 10.1038/373405a0	23	134	135	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					554	556		10.1038/29015	http://dx.doi.org/10.1038/29015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707116				2022-12-24	WOS:000075238700039
J	Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL				Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL			lunatic fringe is an essential mediator of somite segmentation and patterning	NATURE			English	Article							SIGNALING MOLECULE; GENE FAMILY; EXPRESSION; NOTCH1; REGION; CELLS	The gene lunatic fringe encodes a secreted factor with significant sequence similarity to the Drosophila gene fringe(1-5). fringe has been proposed to function as a boundary-specific signalling molecule in the wing imaginal disc, where it is required to localize signalling activity by the protein Notch to the presumptive wing margin(3,6). By targeted disruption in mouse embryos, we show here that lunatic fringe is likewise required for boundary formation. lunatic fringe mutants fail to form boundaries between individual GRAPHICS somites, the initial segmental unit of the vertebrate trunk. Hn addition, the normal alternating rostral-caudal pattern of the semitic mesoderm is disrupted, suggesting that intersomitic boundary formation and rostral-caudal patterning of somites are mechanistically Linked by a process that requires lunatic fringe activity. As a result, the derivatives of the somitic mesoderm, especially the axial skeleton, are severely disorganized in lunatic fringe mutants. Taken together our results demonstrate an essential function for a vertebrate fringe homologue and suggest a model in which lunatic fringe modulates Notch signalling in the segmental plate to regulate somitogenesis and rostral-caudal patterning of somites simultaneously.	Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Johnson, RL (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.			Aulehla, Alexander/0000-0003-3487-9239				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Christ B, 1998, ANAT EMBRYOL, V197, P1; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; Hogan B, 1994, MANIPULATING MOUSE E; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; STERN CD, 1987, DEVELOPMENT, V99, P261; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; WILLIAMS R, 1995, MECH DEVELOP, V53, P357, DOI 10.1016/0925-4773(95)00451-3; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	28	340	350	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					377	381		10.1038/28632	http://dx.doi.org/10.1038/28632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690473				2022-12-24	WOS:000074968800053
J	Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D				Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D			V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling	NATURE			English	Article							POSITIVE SELECTION; GERMINAL-CENTERS; CELLS; DEATH; THYMOCYTES; TOLERANCE; APOPTOSIS	In lymphocytes, DNA recombinations that generate the antigen-receptor genes can sometimes be reinduced in receptor-bearing cells in a process called receptor editing, which modifies the specificity of the receptor for antigen. In immature B lymphocytes, B-cell antigen receptor (BCR) signalling stimulates immune tolerance by receptor editing(1-5). More mature splenic B cells can also be induced to undergo V(D)J recombination, which generates diversity in the immune system, either by immunization with foreign proteins(6-9) or by stimulation in vitro with interleukin-4 and lipopolysaccharides(8-10). Here we show that immune tolerance is unlikely to induce V(D)J recombination in mature B cells, because BCR ligation actively inhibits V(D)J recombination induced by interleukin-ii and lipopolysaccharide. Furthermore, immunization of immunoglobulin transgenic mice with ligands of varying avidities for the BCR showed that low-avidity antigen could induce strong V(D)J recombination, whereas non-binding or high-avidity ligands could not. These data suggest that V(D)J recombination induced during the immune response modifies the antigen receptors of B cells with weak, but not strong, reactivity to antigen, potentially rescuing cells with improved receptor affinity and promoting their contribution to the immune response. Thus BCR signalling regulates V(D)J recombination in both tolerance and immunity, but in strikingly different ways.	Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Tokyo, Inst Med Sci, Dept Infect Dis & Appl Immunol, Minato Ku, Tokyo 108, Japan	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tokyo	Nemazee, D (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA.				NIAID NIH HHS [R01 AI033608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1998, J EXP MED, V187, P795, DOI 10.1084/jem.187.5.795; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KOUSKOFF V, UNPUB J EXP MED; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MARRACK P, 1993, IMMUNOL REV, V133, P119, DOI 10.1111/j.1600-065X.1993.tb01513.x; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; PAPAVASILIOU E, 1997, SCIENCE, V278, P298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	106	110	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					292	295		10.1038/28419	http://dx.doi.org/10.1038/28419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685161	Green Accepted			2022-12-24	WOS:000074851900052
J	Senn, S				Senn, S			In the blood: proposed new requirements for registering generic drugs	LANCET			English	Editorial Material							BIOEQUIVALENCE		UCL, Dept Stat Sci, London WC1E 6BT, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Senn, S (corresponding author), UCL, Dept Stat Sci, Mortimer St, London WC1E 6BT, England.		Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				ANDERSON S, 1990, J PHARMACOKINET BIOP, V18, P259, DOI 10.1007/BF01062202; *FDA, 1997, IN IV BIOEQ STUD BAS; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Senn S., 2021, THE BLIND DAT; Senn S, 1993, CROSS OVER TRIALS CL, V2nd; SHEINER LB, 1992, STAT MED, V11, P1777, DOI 10.1002/sim.4780111311; Steinijans V. W., 1993, Clinical Research and Regulatory Affairs, V10, P203, DOI 10.3109/10601339309079568; Steinijans V. W., 1995, DRUG INF J, V29, P1055	9	29	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					85	86						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672271				2022-12-24	WOS:000074775100007
J	Henry, GL; Melton, DA				Henry, GL; Melton, DA			Mixer, a homeobox gene required for endoderm development	SCIENCE			English	Article							MESSENGER-RNA; XENOPUS EMBRYOS; TGF-BETA; SPEMANNS-ORGANIZER; EXPRESSION; INDUCTION; LAEVIS; MESODERM; SEQUENCE; PROTEINS	An expression cloning strategy in Xenopus laevis was used to isolate a homeobox-containing gene, Mixer, that can cause embryonic cells to form endoderm. Mixer transcripts are found specifically in the prospective endoderm of gastrula, which coincides with the time and place that endodermal cells become histologically distinct and irreversibly determined. Loss-of-function studies with a dominant inhibitory mutant demonstrate that Mixer activity is required for endoderm development. In particular, the expression of Sox17 alpha and Sox17 beta, two previously identified endodermal determinants, require Mixer function. Together, these data suggest that Mixer is an embryonic transcription factor involved in specifying the endodermal germ layer.	Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BAUER DV, 1994, DEVELOPMENT, V120, P1179; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GORDON JI, 1983, J BIOL CHEM, V258, P3356; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HENRY G, UNPUB; Henry GL, 1996, DEVELOPMENT, V122, P1007; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KESSLER DA, UNPUB; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V20B, P157; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V21B, P1; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH JC, 1991, CELL, V71, P731; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; TAKATA CHINAKI, 1960, EMBRYOLOGIA, V5, P38, DOI 10.1111/j.1440-169X.1960.tb00265.x; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WRIGHT CVE, 1988, DEVELOPMENT, V105, P787	35	167	179	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					91	96		10.1126/science.281.5373.91	http://dx.doi.org/10.1126/science.281.5373.91			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651252				2022-12-24	WOS:000074685800044
J	Seidemann, E; Zohary, E; Newsome, WT				Seidemann, E; Zohary, E; Newsome, WT			Temporal gating of neural signals during performance of a visual discrimination task	NATURE			English	Article							AREA MT; FUNCTIONAL-PROPERTIES; RESPONSE PROPERTIES; ATTENTION; MACAQUE; DIRECTION; NEURONS; MONKEY; MICROSTIMULATION; ORGANIZATION	The flow of neural signals within the cerebral cortex must be subject to multiple controls as behaviour unfolds in time. In a visual discrimination task that includes a delay period, the transmission of sensory signals to circuitry that mediates memory, decision-making and motor-planning must be governed closely by 'filtering' or 'gating' mechanisms so that extraneous events occurring before, during or after presentation of the critical visual stimulus have little or no effect on the subject's behavioural responses. Here we study one such mechanism physiologically by applying electrical microstimulation(1-3) to columns of directionally selective neurons in the middle temporal visual area(4-9) at varying times during single trials of a direction-discrimination task. The behavioural effects of microstimulation varied strikingly according to the timing of delivery within the trial, indicating that signals produced by microstimulation may be subject to active 'gating'. Our results show several important features of this gating process: first, signal flow is modulated upwards on onset of the visual stimulus and downwards, typically with a slower time course, after stimulus offset; second, gating efficacy can be modified by behavioural training; and third, gating is implemented primarily downstream of the middle temporal visual area.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel	Howard Hughes Medical Institute; Stanford University; Stanford University; Hebrew University of Jerusalem	Seidemann, E (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019	Seidemann, Eyal/0000-0003-2841-5948				ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Cox DR., 1970, ANAL BINARY DATA; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; MOUNTCASTLE VB, 1984, DYNAMIC ASPECTS NEOC, P159; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302	19	60	60	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					72	75		10.1038/27906	http://dx.doi.org/10.1038/27906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665129				2022-12-24	WOS:000074579600050
J	Phoolcharoen, W				Phoolcharoen, W			HIV/AIDS prevention in Thailand: Success and challenges	SCIENCE			English	Editorial Material							YOUNG MEN; NORTHERN THAILAND; INFECTION		Minist Publ Hlth, Dept Communicable Dis Control, Amphur Muang Nonthaburi 11000, Thailand	Ministry of Public Health - Thailand	Phoolcharoen, W (corresponding author), Minist Publ Hlth, Dept Communicable Dis Control, Tivanont Rd, Amphur Muang Nonthaburi 11000, Thailand.							*ARM MED SC RES I, 1998, REP HIV PREV RAT NEW; CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; CELENTANO DD, 1993, AIDS, V7, P1647, DOI 10.1097/00002030-199312000-00016; Epidemiology Division, 1998, REP HIV SER SENT SUR; FORD NJ, 1994, AIDS CARE, V6, P517, DOI 10.1080/09540129408258667; FRERICHS R, 1995, J PUBLIC HLTH, V8, P20; HAVANON N, 1993, STUD FAMILY PLANN, V24, P1, DOI 10.2307/2939210; KHAMBOONRUANG C, 1996, 10 INT C AIDS VANC C; Lyttleton C, 1996, Med Anthropol, V16, P363; Mills S, 1997, AIDS, V11, pS43; *NAT EC SOC DEV BO, 1998, EST UN RES 1997 EC C; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; PORAPAKKHAM Y, 1996, AIDSCAP POLICY WORKI; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Sawanpanyalert P, 1996, J INFECT DIS, V174, P870, DOI 10.1093/infdis/174.4.870; SITTITRAL W, 1992, THAI SEXUAL BEHAV; Sugisaki Shigemitsu, 1998, 1998 HARV AS BUS C H; [No title captured]	19	50	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1873	1874		10.1126/science.280.5371.1873	http://dx.doi.org/10.1126/science.280.5371.1873			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669947				2022-12-24	WOS:000074323800043
J	Zhou, W; King, WM				Zhou, W; King, WM			Premotor commands encode monocular eye movements	NATURE			English	Article							PONTINE RETICULAR-FORMATION; ALERT MONKEYS; NEURONS; ABDUCENS	Binocular coordination of eye movements is essential for stereopsis (depth perception) and to prevent double vision. More than a century ago, Hering and Helmholtz debated the neural basis of binocular coordination. Helmholtz(1) believed that each eye is controlled independently and that binocular coordination is learned, Hering(2) believed that both eyes are innervated by common command signals that yoke the eye movements (Hering's law of equal innervation). Here we provide evidence that Hering's law is unlikely to be correct. We show that premotor neurons in the paramedian pontine reticular formation that were thought to encode conjugate(3-6) velocity commands for saccades (rapid eye movements) actually encode monocular commands for either right or left eye saccades, However, 66% of the abducens motor neurons, which innervate the ipsilateral lateral rectus muscle, fire as a result of movements of either eye. The distribution of sensitivity to ipsilateral and contralateral eye movements across the abducens motor neuron pool may provide a basis for learning binocular coordination in infancy and adapting it throughout life.	Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Zhou, W (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol, 2500 N State St, Jackson, MS 39216 USA.			King, Michael/0000-0002-7848-6595				FUCHS AF, 1970, J NEUROPHYSIOL, V33, P382, DOI 10.1152/jn.1970.33.3.382; FUCHS AF, 1985, ANNU REV NEUROSCI, V8, P307, DOI 10.1146/annurev.ne.08.030185.001515; Helmholtz J. A., 1910, TREATISE PHYSL OPTIC; HENN V, 1976, BRAIN RES, V108, P307, DOI 10.1016/0006-8993(76)90188-8; Henn V, 1982, Hum Neurobiol, V1, P87; HENN V, 1973, J NEUROPHYSIOL, V36, P115, DOI 10.1152/jn.1973.36.1.115; Hering E., 1977, THEORY BINOCULAR VIS; KELLER EL, 1974, J NEUROPHYSIOL, V37, P316, DOI 10.1152/jn.1974.37.2.316; King W. M., 1997, Society for Neuroscience Abstracts, V23, P1559; LUSCHEI ES, 1972, J NEUROPHYSIOL, V35, P445, DOI 10.1152/jn.1972.35.4.445; MAYS LE, 1984, J NEUROPHYSIOL, V52, P743, DOI 10.1152/jn.1984.52.4.743	11	159	161	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					692	695		10.1038/31489	http://dx.doi.org/10.1038/31489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641680				2022-12-24	WOS:000074289600055
J	Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A				Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A			Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; CELL-ADHESION; GENE; FAMILY; LOCUS; LINKAGE; COMPLEX; MEMBER; YEAST	Hereditary spastic paraplegia (HSP) is characterized by progressive weakness and spasticity of the lower limbs due to degeneration of corticospinal axons. We found that patients from a chromosome 16q24.3-linked HSP family are homozygous for a 9.5 kb deletion involving a gene encoding a novel protein, named Paraplegin. Two additional Paraplegin mutations, both resulting in a frameshift, were found in a complicated and in a pure form of HSP. Paraplegin is highly homologous to the yeast mitochondrial ATPases, AFG3, RCA1, and YME1, which have both proteolytic and chaperon-like activities at the inner mitochondrial membrane. Immunofluorescence analysis and import experiments showed that Paraplegin localizes to mitochondria. Analysis of muscle biopsies from two patients carrying Paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Natl Neurol Inst C Besta, I-20132 Milan, Italy; Univ Naples Federico II, CNR, Dept Neurol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, Dept Mol & Cellular Biol Pathol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, CEOS, I-80136 Naples, Italy; Misericordia Hosp, Dept Neurol, I-58100 Grosseto, Italy; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, F-75013 Paris, France; Univ Vita Salute, I-20132 Milan, Italy; Childrens Hosp Bambino Gesu, I-00165 Rome, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); IRCCS Istituto Neurologico Besta; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Vita-Salute San Raffaele University; IRCCS Bambino Gesu	Ballabio, A (corresponding author), Telethon Inst Genet & Med, I-20132 Milan, Italy.		Casari, Giorgio/J-3070-2018; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021; Silva, Patricio Fernandez/U-2256-2017; De Fusco, Maurizio/AAN-7358-2020; BALLABIO, Andrea/AAL-2672-2020; Cocozza, Sergio/F-6488-2010; Mora, Marina/J-2883-2018	Casari, Giorgio/0000-0002-0115-8980; Zeviani, Massimo/0000-0002-9067-5508; Silva, Patricio Fernandez/0000-0001-8971-7355; BALLABIO, Andrea/0000-0003-1381-4604; Mora, Marina/0000-0002-5765-2320	Telethon [TGM97000, 767, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1984, LAB INVEST, V50, P147; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BONNEAU D, 1993, J MED GENET, V30, P381, DOI 10.1136/jmg.30.5.381; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMICHELE G, 1998, IN PRESS AM J HUM GE; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Durbin H, 1997, P NATL ACAD SCI USA, V94, P14578, DOI 10.1073/pnas.94.26.14578; DURBIN H, 1994, GENOMICS, V19, P181, DOI 10.1006/geno.1994.1038; DURR A, 1994, NEUROLOGY, V44, P1274, DOI 10.1212/WNL.44.7.1274; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FILLA A, 1992, J NEUROL, V239, P351, DOI 10.1007/BF00867594; Fink JK, 1997, CURR OPIN NEUROL, V10, P313, DOI 10.1097/00019052-199708000-00006; FINK JK, 1995, AM J HUM GENET, V56, P188; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIGLI GL, 1993, AM J MED GENET, V45, P711, DOI 10.1002/ajmg.1320450610; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARDING AE, 1981, J MED GENET, V18, P436, DOI 10.1136/jmg.18.6.436; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HENTATI A, 1994, HUM MOL GENET, V3, P1263, DOI 10.1093/hmg/3.8.1263; IOANNOU PA, 1996, CURRENT PROTOCOLS HU, P1; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KELMAN Z, 1993, ONCOGENE, V8, P37; KOYAMA K, 1993, GENOMICS, V16, P264, DOI 10.1006/geno.1993.1173; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LizcanoGil LA, 1997, AM J MED GENET, V68, P1, DOI 10.1002/(SICI)1096-8628(19970110)68:1<1::AID-AJMG1>3.0.CO;2-V; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PELOSI L, 1991, J NEUROL NEUROSUR PS, V54, P1099, DOI 10.1136/jnnp.54.12.1099; POLO JM, 1993, J NEUROL NEUROSUR PS, V56, P175, DOI 10.1136/jnnp.56.2.175; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; Reid E, 1997, J MED GENET, V34, P499, DOI 10.1136/jmg.34.6.499; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; RHEIN J, 1914, J NERV MENT DIS, V44, P115; ROBERTS L, 1991, SCIENCE, V254, P805, DOI 10.1126/science.1948063; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHADY W, 1991, J NEUROL NEUROSUR PS, V54, P1099; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SUTHERLAND JM, 1975, HDB CLIN NEUROLOGY, V22, P420; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TEDESCHI G, 1991, J NEUROL SCI, V103, P55, DOI 10.1016/0022-510X(91)90284-E; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Webb S, 1997, EPILEPSIA, V38, P495, DOI 10.1111/j.1528-1157.1997.tb01741.x; Zeviani M, 1997, CURR OPIN NEUROL, V10, P160, DOI 10.1097/00019052-199704000-00015	57	609	628	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					973	983		10.1016/S0092-8674(00)81203-9	http://dx.doi.org/10.1016/S0092-8674(00)81203-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635427	Bronze			2022-12-24	WOS:000074205700009
J	Turka, LA				Turka, LA			What's new in transplant immunology: Problems and prospects	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTRATHYMIC ISLET TRANSPLANTATION; LONG-TERM ACCEPTANCE; ALLOGRAFT-REJECTION; CARDIAC ALLOGRAFTS; CYCLOSPORINE; PREVENTION; CHIMERISM	In the past 40 years, transplantation has moved from an experimental form of therapy used almost exclusively for renal failure to an accepted treatment for end-stage kidney disease, heart disease, liver disease, lung disease, and diabetes mellitus. Tissue transplantation for conditions from thermal injury to Parkinson disease is being investigated. The primary barrier in transplantation medicine is the immunologic reaction of the recipient to donor organs and tissues. Currently available drugs permit excellent short-term graft survival but have not led to reliable longterm survival. Recent advances in the understanding of this immune response have suggested new approaches to induction of immunologic tolerance and reduction of late graft losses. Because of the excellent short-term success of current agents, integration of these new approaches into clinical trials is challenging and raises important questions about the design of such trials.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Turka, LA (corresponding author), Univ Penn, Dept Med, 901 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.							BIERER BE, 1993, CURR OPIN HEMATOL, P149; Elwood ET, 1997, LANCET, V349, P1358, DOI 10.1016/S0140-6736(96)09105-2; GarciaMorales R, 1997, J CLIN INVEST, V99, P1118, DOI 10.1172/JCI119240; Gjertson DW, 1995, TRANSPLANTATION, V60, P1384, DOI 10.1097/00007890-199560120-00002; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Lui S L, 1996, Curr Opin Nephrol Hypertens, V5, P508, DOI 10.1097/00041552-199611000-00009; MORRIS PJ, 1994, KIDNEY TRANSPLANTATI, P524; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Paul Leendert C., 1996, P567; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; Sykes M, 1990, Semin Immunol, V2, P401; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001	22	6	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					946	948		10.7326/0003-4819-128-11-199806010-00015	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634435				2022-12-24	WOS:000073808600011
J	Wellems, TE; Wootton, JC; Fujioka, H; Su, XZ; Cooper, R; Baruch, D; Fidock, DA				Wellems, TE; Wootton, JC; Fujioka, H; Su, XZ; Cooper, R; Baruch, D; Fidock, DA			P-falciparum CG2, linked to chloroquine resistance, does not resemble Na+/H+ exchangers	CELL			English	Article									NIAID, NIH, Bethesda, MD 20892 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Case Western Reserve University	Wellems, TE (corresponding author), NIAID, NIH, Bethesda, MD 20892 USA.			Su, Xinzhuan/0000-0003-3246-3248; Fidock, David/0000-0001-6753-8938				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Ridley RG, 1998, CURR BIOL, V8, pR346, DOI 10.1016/S0960-9822(98)70218-0; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; Sanchez CP, 1998, CELL, V92, P601, DOI 10.1016/S0092-8674(00)81127-7; SONNHAMMER ELL, 1998, IN PRESS ISMB; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X	10	21	21	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					285	286		10.1016/S0092-8674(00)81471-3	http://dx.doi.org/10.1016/S0092-8674(00)81471-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708730	Bronze			2022-12-24	WOS:000075308400004
J	Carmeliet, P; Dor, Y; Herbert, JM; Fukumura, D; Brusselmans, K; Dewerchin, M; Neeman, M; Bono, F; Abramovitch, R; Maxwell, P; Koch, CJ; Ratcliffe, P; Moons, L; Jain, RK; Collen, D; Keshet, E				Carmeliet, P; Dor, Y; Herbert, JM; Fukumura, D; Brusselmans, K; Dewerchin, M; Neeman, M; Bono, F; Abramovitch, R; Maxwell, P; Koch, CJ; Ratcliffe, P; Moons, L; Jain, RK; Collen, D; Keshet, E			Role of HIF-1 alpha or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis	NATURE			English	Article							GLUCOSE-REGULATED PROTEINS; INDUCIBLE FACTOR-1; ARREST; P21	As a result of deprivation of oxygen (hypoxia) and nutrients, the growth and viability of cells is reduced(1). Hypoxia-inducible factor (KIF)-1 alpha helps to restore oxygen homeostasis by inducing glycolysis, erythropoiesis and angiogenesis(2-4). Here we show that hypoxia and hypoglycaemia reduce proliferation and increase apoptosis in wild-type (HIF-1 alpha(+/+)) embryonic stem (ES) cells, but not in ES cells with inactivated HIF-1 alpha. genes (HIF-1 alpha(-/-)); however, a deficiency of HIF-1 alpha does not affect apoptosis induced by cytokines. We find that hypoxia/hypoglycaemia-regulated genes involved in controlling the cell cycle are either HIF-1 alpha-dependent (those encoding the proteins p53, p21, Bcl-2) or HLF-1 alpha-independent (p27, GADD153), suggesting that there are at least two different adaptive responses to being deprived of oxygen and nutrients, Loss of HIF-1 alpha. reduces hypoxia-induced expression of vascular endothelial growth factor, prevents formation of large vessels in ES-derived tumours, and impairs vascular function, resulting in hypoxic microenvironments within the tumour mass, However, growth of HIF-1 alpha. tumours was not retarded but was accelerated, owing to decreased hypoxia-induced apoptosis and increased stress-induced proliferation. As hypoxic stress contributes to many (patho)biological disorders(1,5), this new role for HIF-1 alpha in hypoxic control of cell growth and death may be of general pathophysiological importance.	Catholic Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Sanofi Rech, Haemobiol Res Dept, F-31036 Toulouse, France; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; John Radcliffe Hosp, Welcome Trust Ctr Human Genet, Inst Mol Med, Oxford OX3 7BN, England; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Flanders Institute for Biotechnology (VIB); Hebrew University of Jerusalem; Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Weizmann Institute of Science; University of Oxford; Wellcome Centre for Human Genetics; University of Pennsylvania	Carmeliet, P (corresponding author), Catholic Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	Peter.Carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; Dor, Yuval/C-2405-2011; Keshet, Eli/GQR-0445-2022; Jain, Rakesh K/I-1384-2017; Neeman, Michal/AAH-9602-2019; Neeman, Michal/A-8264-2008; Maxwell, Patrick H/C-5557-2008	Carmeliet, Peter/0000-0001-7961-1821; Jain, Rakesh K/0000-0001-7571-3548; Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X; Maxwell, Patrick H/0000-0002-0338-2679; Ratcliffe, Peter/0000-0002-2853-806X; Moons, Lieve (Godelieve)/0000-0003-0186-1411	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramovitch R, 1998, MAGN RESON MED, V39, P813, DOI 10.1002/mrm.1910390519; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbert JM, 1997, FEBS LETT, V413, P401, DOI 10.1016/S0014-5793(97)00915-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KOBAYASHI N, 1994, AM J PHYSIOL, V266, pH1910, DOI 10.1152/ajpheart.1994.266.5.H1910; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; PRICE BD, 1992, CANCER RES, V52, P3814; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	30	2081	2202	5	303	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					485	490		10.1038/28867	http://dx.doi.org/10.1038/28867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697772				2022-12-24	WOS:000075080400054
J	Fulop, V; Bocskei, Z; Polgar, L				Fulop, V; Bocskei, Z; Polgar, L			Prolyl oligopeptidase: An unusual beta-propeller domain regulates proteolysis	CELL			English	Article							PROLINE-SPECIFIC ENDOPEPTIDASE; ALPHA/BETA-HYDROLASE FOLD; FLAVOBACTERIUM-MENINGOSEPTICUM; CRYSTAL-STRUCTURE; G-PROTEIN; SECONDARY-STRUCTURE; ENZYME; SEQUENCE; CLONING; PURIFICATION	Prolyl oligopeptidase is a large cytosolic enzyme that belongs to a new class of serine peptidases. The enzyme is involved in the maturation and degradation of peptide hormones and neuropeptides, which relate to the induction of amnesia. The 1.4 Angstrom resolution crystal structure is presented here. The enzyme contains a peptidase domain with an alpha/beta hydrolase fold, and its catalytic triad (Ser554, His680, Asp641) is covered by. the central tunnel of an unusual beta propeller. This domain makes prolyl oligopeptidase an oligopeptidase by excluding large structured peptides from the active. site. In this way, the propeller protects larger peptides and proteins from proteolysis in the cytosol. The structure is also obtained with a transition state inhibitor, which may facilitate drug design to treat memory disorders.	Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Eotvos Lorand Univ, Dept Theoret Chem, H-117 Budapest, Hungary; Chinoin Chem & Pharmaceut Works Ltd, H-1325 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	University of Oxford; University of Warwick; Eotvos Lorand University; Sanofi-Aventis; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Fulop, V (corresponding author), Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.		Fulop, Vilmos/AAZ-7720-2021		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOCSKEI Z, 1998, IN PRESS ACTA CRYS D; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAMARGO ACM, 1979, J BIOL CHEM, V254, P5304; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; CYGLER M, 1993, PROTEIN SCI, V2, P366; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEFENTHAL T, 1993, APPL MICROBIOL BIOT, V40, P90, DOI 10.1007/BF00170434; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FUKUNARI A, 1994, NEUROSCI LETT, V176, P201, DOI 10.1016/0304-3940(94)90082-5; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; ISHIURA S, 1990, FEBS LETT, V260, P131, DOI 10.1016/0014-5793(90)80084-V; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SCALONI A, 1994, J BIOL CHEM, V269, P15076; Shinoda M, 1997, BIOCHEM BIOPH RES CO, V235, P641, DOI 10.1006/bbrc.1997.6730; Smith L. C., 1992, CURR OPIN STRUC BIOL, V2, P490, DOI DOI 10.1016/0959-440X(92)90076-J; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	60	443	454	2	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					161	170		10.1016/S0092-8674(00)81416-6	http://dx.doi.org/10.1016/S0092-8674(00)81416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695945	Bronze			2022-12-24	WOS:000075020100005
J	Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR				Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR			Electrical coupling underlies high-frequency oscillations in the hippocampus in vitro	NATURE			English	Article							FIELD BURST ACTIVITY; RAT HIPPOCAMPAL; PYRAMIDAL NEURONS; SLICES; CELLS; MECHANISMS; POTENTIALS; NETWORKS; MODEL; PH	Coherent oscillations, in which ensembles of neurons fire in a repeated and synchronous manner, are thought to be important in higher brain functions. In the hippocampus, these discharges are categorized according to their frequency as theta (4-10 Hz)(1), gamma (20-80 Hz)(2) and high-frequency (similar to 200 Hz)(3-5) discharges, and they occur in relation to different behavioural states. The synaptic bases of theta and gamma rhythms have been extensively studied(6,7) but the cellular bases for high-frequency oscillations are not understood. Here we report that high-frequency network oscillations are present in rat brain slices in vitro, occurring as a brief series of repetitive population spikes at 150-200 Hz in all hippocampal principal cell layers. Moreover, this synchronous activity is not mediated through the more commonly studied modes of chemical synaptic transmission, but is in fact a result of direct electrotonic coupling of neurons, most Likely through gap-junctional connections. Thus high-frequency oscillations synchronize the activity of electrically coupled subsets of principal neurons within the well-documented synaptic network of the hippocampus.	Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England; Humboldt Univ, Inst Physiol Charite, D-10117 Berlin, Germany	University of Birmingham; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Draguhn, A (corresponding author), Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England.		Jefferys, John G R/AAF-1164-2021; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Jefferys, John/0000-0003-0106-4412; Schmitz, Dietmar/0000-0003-2741-5241	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; CHURCH J, 1991, J NEUROSCI, V11, P3289; COBB SR, 1995, NATURE, V378, P612; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; JEFFERYS JGR, 1981, J PHYSIOL-LONDON, V319, P143, DOI 10.1113/jphysiol.1981.sp013897; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; LESLIE J, 1998, J PHYSIOL-LONDON, V146, pP506; LLINAS R, 1974, J NEUROPHYSIOL, V37, P560, DOI 10.1152/jn.1974.37.3.560; Logan SD, 1996, J PHYSIOL-LONDON, V495, P491, DOI 10.1113/jphysiol.1996.sp021609; MACVICAR BA, 1985, BRAIN RES, V330, P141, DOI 10.1016/0006-8993(85)90015-0; MACVICAR BA, 1981, SCIENCE, V213, P782, DOI 10.1126/science.6266013; Patrylo PR, 1996, NEUROSCIENCE, V74, P107, DOI 10.1016/0306-4522(96)00111-X; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; PINAULT D, 1995, BRAIN RES REV, V21, P42, DOI 10.1016/0165-0173(95)00004-M; Rash JE, 1997, J COMP NEUROL, V388, P265, DOI 10.1002/(SICI)1096-9861(19971117)388:2<265::AID-CNE6>3.0.CO;2-#; Simburger E, 1997, HISTOCHEM CELL BIOL, V107, P127, DOI 10.1007/s004180050097; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Strata F, 1997, J NEUROSCI, V17, P1435; STUMPF C, 1965, ELECTROEN CLIN NEURO, V18, P477, DOI 10.1016/0013-4694(65)90128-8; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, P3; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Traub RD, 1995, J COMPUT NEUROSCI, V2, P283, DOI 10.1007/BF00961440; VALIANTE TA, 1995, J NEUROSCI, V15, P6946; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; VANEY DI, 1993, P ROY SOC B-BIOL SCI, V252, P93, DOI 10.1098/rspb.1993.0051; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; YLINEN A, 1995, J NEUROSCI, V15, P30	30	526	535	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					189	192		10.1038/28184	http://dx.doi.org/10.1038/28184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671303				2022-12-24	WOS:000074705900056
J	Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ				Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ		French Perinatal Cohort	Perinatal HIV-1 transmission - Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOTHER-TO-CHILD; CESAREAN-SECTION; INFECTED WOMEN; INFANT; COMPLICATIONS; PREGNANCY; RISK	Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.	Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France; INSERM, U149, Paris, France; INSERM, U292, Le Kremlin Bicetre, France; Hop La Grave, Serv Gynecol Obstet, Toulouse, France; Hop Archet 2, Serv Gynecol Obstet, Nice, France; Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France; Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Necker Enfants Malad, Serv Pediat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mandelbrot, L (corresponding author), Hop Cochin Port Royal, Serv Gynecol Obstet 1, 123 Blvd Port Royal, F-75014 Paris, France.	laurent.mandelbrot@cch.ap-hop-paris.fr	Mandelbrot, Laurent/AAD-3554-2019	Mandelbrot, Laurent/0000-0002-5883-7597				[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Bulterys M, 1996, AIDS, V10, P923, DOI 10.1097/00002030-199607000-00019; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; HOGBERG U, 1994, OBSTET GYNECOL, V84, P240; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kuhn L, 1997, AIDS, V11, P429, DOI 10.1097/00002030-199704000-00005; KUHN L, 1994, AM J PUBLIC HEALTH, V84, P1110, DOI 10.2105/AJPH.84.7.1110; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Lin HH, 1996, OBSTET GYNECOL, V87, P244, DOI 10.1016/0029-7844(95)00385-1; LoussertAjaka I, 1997, AIDS, V11, P1575, DOI 10.1097/00002030-199713000-00005; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1997, AIDS PATIENT CARE ST, V11, P139, DOI 10.1089/apc.1997.11.139; MANDELBROT L, 1997, 1 SEM ANN RECH CLIN, pA42; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; NEWELL ML, 1994, LANCET, V343, P1464; Newell ML, 1996, AIDS, V10, P1675; Newell ML, 1998, BRIT J OBSTET GYNAEC, V105, P281, DOI 10.1111/j.1471-0528.1998.tb10087.x; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SCARAVELLI G, 1995, EUR J OBSTET GYN R B, V62, P7, DOI 10.1016/0301-2115(95)02143-U; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; VANDEPERRE P, 1995, AM J OBSTET GYNECOL, V173, P483, DOI 10.1016/0002-9378(95)90270-8	40	202	208	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					55	60		10.1001/jama.280.1.55	http://dx.doi.org/10.1001/jama.280.1.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660364	Bronze			2022-12-24	WOS:000074379400024
J	Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ				Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ			Rating the appropriateness of coronary angiography - Do practicing physicians agree with an expert panel and with each other?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NEW-YORK-STATE; PRACTICE GUIDELINES; PRIMARY ANGIOPLASTY; CARDIAC PROCEDURES; CLINICAL-PRACTICE; UNITED-STATES; MEDICAL-CARE; SPECIALTY; CARDIOLOGISTS	Background Evaluations of the appropriateness of medical care are important to monitor the quality of care and to contain costs and enhance safety by reducing inappropriate care. Experts' views are usually incorporated into evaluations of appropriateness. However, practicing physicians may not concur with these views, and physicians' clinical backgrounds may influence their beliefs. Methods We asked 1058 internists, family practitioners, and cardiologists in California, Florida, New York, Pennsylvania, and Texas to rate the appropriateness of coronary angiography after acute myocardial infarction for 20 common indications. Nine clinical experts also rated these indications using an established consensus method. Results For 17 of the 20 indications, median ratings of surveyed physicians and the expert panel agreed within 1 unit on a 9-unit scale. Patients' older age had a negative effect on ratings by the expert panel but not on ratings by surveyed physicians. In multivariable analyses of surveyed physicians, cardiologists rated angiography as significantly more appropriate than did primary care physicians for complicated indications, and for uncomplicated indications cardiologists who performed invasive procedures gave higher appropriateness ratings for angiography than did cardiologists who did not perform such procedures and primary care physicians. For uncomplicated indications, physicians from hospitals providing coronary angioplasty and bypass surgery rated angiography as more appropriate than physicians from other hospitals. Physicians from New York and those employed by health maintenance organizations rated angiography as less appropriate than other physicians. Conclusions Surveyed physicians agreed with clinical experts about the appropriateness of coronary angiography after myocardial infarction for most indications, indicating that well-designed expert panels can closely reflect the views of practicing physicians. Variations in beliefs among practicing physicians suggest that evaluations of medical practice should incorporate the views of a range of relevant types of physicians. (N Engl J Med 1998;338:1896-904.) (C) 1998, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.			Normand, Sharon-Lise/0000-0001-7027-4769	AHRQ HHS [HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; [Anonymous], CORONARY ANGIOGRAPHY; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; BATTISTA RN, 1995, J CLIN EPIDEMIOL, V48, P875, DOI 10.1016/0895-4356(94)00199-Z; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; BOROWSKY SJ, 1995, J AM COLL CARDIOL, V26, P1484, DOI 10.1016/0735-1097(95)00337-1; BROOK RH, 1988, LANCET, V1, P750; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; DiSalvo TG, 1996, J AM COLL CARDIOL, V27, P262, DOI 10.1016/0735-1097(95)00488-2; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LANDRUM MB, IN PRESS STAT MED; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; Peterson ED, 1997, ANN INTERN MED, V126, P556, DOI 10.7326/0003-4819-126-7-199704010-00012; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; PILOTE L, 1995, MED CARE, V33, P598, DOI 10.1097/00005650-199506000-00003; Poses RM, 1997, MED CARE, V35, P603, DOI 10.1097/00005650-199706000-00006; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Wennberg DE, 1997, J GEN INTERN MED, V12, P172	41	134	134	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1896	1904		10.1056/NEJM199806253382608	http://dx.doi.org/10.1056/NEJM199806253382608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637811				2022-12-24	WOS:000074352800008
J	Rainer, G; Asaad, WF; Miller, EK				Rainer, G; Asaad, WF; Miller, EK			Selective representation of relevant information by neurons in the primate prefrontal cortex	NATURE			English	Article							NEURAL MECHANISMS; VISUAL-ATTENTION; MEMORY	The severe limitation of the capacity of working memory, the ability to store temporarily and manipulate information(1), necessitates mechanisms that restrict access to it. Here we report tests to discover whether the activity of neurons in the prefrontal (PF) cortex, the putative neural correlate of working memory(2-8), might reflect these mechanisms and preferentially represent behaviourally relevant information. Monkeys performed a 'delayed-matching-to-sample' task with an array of three objects. Only one of the objects in the array was relevant for task performance and the monkeys needed to find that object (the target) and remember its location. For many PF neurons, activity to physically identical arrays varied with the target location; the location of the non-target objects had little or no influence on activity. Information about the target location was present in activity as early as 140 ms after array onset. Also, information about which object was the target was reflected in the sustained activity of many PF neurons. These results suggest that the prefrontal cortex is involved in selecting and maintaining behaviourally relevant information.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Miller, EK (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	ekm@ai.mit.edu	Asaad, Wael/I-8485-2012; Rainer, Gregor/B-5876-2012; Miller, Earl K./AAE-8187-2019	Asaad, Wael/0000-0003-4406-9096; Miller, Earl K./0000-0002-0582-6958; Rainer, Gregor/0000-0002-5805-2220				Baddeley A, 1986, WORKING MEMORY; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; Hasegawa R, 1998, J NEUROPHYSIOL, V79, P322, DOI 10.1152/jn.1998.79.1.322; HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794; Kahneman D., 1973, ATTENTION EFFORT; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Miller EK, 1996, J NEUROSCI, V16, P5154; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Moody SL, 1998, J NEUROSCI, V18, P399; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; SHEPARD M, 1997, Q J EXP PSYCHOL-A, V38, P475	19	428	436	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					577	579		10.1038/31235	http://dx.doi.org/10.1038/31235			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634233				2022-12-24	WOS:000074150100052
J	Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D				Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D			Complications of use of intrauterine devices among HIV-1-infected women	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; INFECTION; TRANSMISSION; KENYA; RISK; CRITERIA; NAIROBI	Background A WHO expert group and the International Planned Parenthood Federation recommend against use of intrauterine devices (IUDs) in HIV-1-infected women based on theoretical concerns about pelvic infection and increased blood loss, We investigated whether the risk of complications after IUD insertion is higher in HIV-1-infected women than in non-infected women. Methods 649 (156 HIV-1 infected 493 non-infected) women in Nairobi, Kenya, who requested and met local eligibility criteria for insertion of an IUD were enrolled, We gathered information on IUD-related complications, including pelvic inflammatory disease, removals due to infection, pain, or bleeding, expulsions, and pregnancies at 1 and 4 months after insertion. Patients' HIV-1 status was masked from physicians. Findings Complications were identified in 48 of 615 women (11 [7.6%] HIV-1-infected women, 37 [7.9%] non-infected), Incident pelvic inflammatory disease (two [1.4%] HIV-1 infected, one [0.2%] non-infected) and infection-related complications (any tenderness, removal of IUD for infection or pain; ten [6.9%] HIV-1 infected, 27 [5.7%] non-infected) were also rare and similar in the two groups. Complication rates were similar by CD4 (immune) status. Multivariate analyses suggested no association between HIV-1 infection and increased risks for overall complications (odds ratio 0.8 [95% CI 0.4-1.7]) or infection-related complications (1.0 [0.5-2.3]), adjusted for marital status, study site, previous IUD use, ethnic origin, and frequency of sexual intercourse, but a slight increase cannot be ruled out. Interpretation Our data suggest that IUDs may be a safe contraceptive method for appropriately selected HIV-1-infected women with continuing access to medical services.	Family Hlth Int, Res Triangle Pk, NC 27709 USA; Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya	University of Nairobi	Morrison, CS (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	cmorrison@fhi.org	Kokonya, Donald/GLR-2492-2022	Kokonya, Donald/0000-0002-4206-9933				BRBOSA C, 1997, OBSTET GYNECOL, V89, P65; BUKUSI E, 1996, 11 INT C AIDS JUL; CARAEL M, 1988, AIDS, V2, P201; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; COHEN C, 1996, 11 INT C AIDS JUL; DEVINCENZI I, 1992, BRIT MED J, V304, P809; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; *IPPF INT MED ADV, 1991, IPPF MED B, V25, P1; Kapiga SH, 1998, AIDS, V12, P75, DOI 10.1097/00002030-199801000-00009; KELSEY JL, 1986, METHODS OBSERVATIONA; KORN AP, 1993, OBSTET GYNECOL, V82, P765; LADIPO O A, 1991, Advances in Contraception, V7, P43, DOI 10.1007/BF01850718; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; MATI JKG, 1995, INT J GYNECOL OBSTET, V48, P61; MAULDIN WP, 1994, P 4 INT C IUDS, P1; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUSICCO M, 1994, P 4 INT C IUDS, P179; PLOURDE PJ, 1992, J INFECT DIS, V166, P86, DOI 10.1093/infdis/166.1.86; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Sweet RL, 1997, LANCET, V349, P1265, DOI 10.1016/S0140-6736(05)62501-9; *UNAIDS WHO, 1997, REP GLOB HIV AIDS EP; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO SCI WORK GROU, 1996, MED EL CRIT IN CONT	29	73	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1238	1241		10.1016/S0140-6736(97)10319-1	http://dx.doi.org/10.1016/S0140-6736(97)10319-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643743				2022-12-24	WOS:000073283600009
J	Godward, S; Dezateux, C				Godward, S; Dezateux, C		MRC Working Paryt Congenital Dislocation Hip	Surgery for congenital dislocation of the hip in the UK as a measure of outcome of screening	LANCET			English	Article							LATE DIAGNOSIS; MANAGEMENT; INFANTS	Background Universal clinical screening for congenital dislocation of the hip to detect hip instability in neonates was introduced in the UK as a national policy in 1969, but its effectiveness is not known. We aimed to assess the extent to which surgery for congenital dislocation of the hip is the result of a failure of detection through screening or follows non-surgical treatment after detection by screening. Methods We established a national orthopaedic surveillance scheme and used routine hospital data for inpatients for 20% of births in the UK (Scotland and the Northern and Wessex regions) to ascertain the number of children aged under 5 years per 1000 livebirths who had received at lease one operative procedure for congenital dislocation of the hip from April, 1993, to April, 1994. Estimates of the incidence of operative procedures were adjusted for under-ascertainment by capture-recapture techniques. Findings The ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip in the UK was 0.78 per 1000 livebirths (95% CI 0.72-0.84). Congenital dislocation of the hip had not been detected by routine screening in 222 (70%) of 318 children reported to the national orthopaedic surveillance scheme. In 112 (35%) children the diagnosis was made primarily as a result of parental concern. 67 (21%) children had previously received non-surgical treatment. In Scotland and the Northern and Wessex regions, 81 cases were notified to the national orthopaedic surveillance scheme, 62 cases were identified only through routine hospital data on inpatients, and an estimated 20 cases were not identified by either source, making a total of 163 cases. Thus, 81 (50%) of these 163 cases were identified by surveillance, 125 (77%) by routine data, and 143 (88%) by both sources. Interpretation The incidence of a first operative procedure for congenital dislocation of the hip in the UK was similar to that reported before screening was introduced. In most children who received surgery, congenital dislocation of the hip was not detected by screening, Formal evaluation of current and alternative screening policies, including universal primary ultrasound imaging, is needed.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Dezateux, C (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.	c.dezateux@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276				BENNET GC, 1992, J BONE JOINT SURG BR, V74, P643, DOI 10.1302/0301-620X.74B5.1527106; CATFORD JC, 1982, BMJ-BRIT MED J, V285, P1527, DOI 10.1136/bmj.285.6354.1527; CATTERALL A, 1994, J BONE JOINT SURG BR, V76B, P515, DOI 10.1302/0301-620X.76B4.8027129; DAVID TJ, 1983, LANCET, V2, P147; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dezateux C, 1995, J Med Screen, V2, P200; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; GODWARD S, 1996, ARCH DIS CHILD, V75, P1; Hall S M, 1988, Arch Dis Child, V63, P344; HEY K, 1994, ARCH DIS CHILD-FETAL, V71, pF198, DOI 10.1136/fn.71.3.F198; Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; KNOX EG, 1987, J EPIDEMIOL COMMUN H, V41, P283, DOI 10.1136/jech.41.4.283; LECK I, 1986, J ROY COLL PHYS LOND, V20, P56; LECK I, 1968, TERATOLOGY, V1, P263, DOI 10.1002/tera.1420010305; LENNOX IAC, 1993, J BONE JOINT SURG BR, V75, P72, DOI 10.1302/0301-620X.75B1.8421040; MacFarlane A, 1980, J MATERN CHILD HLTH, V5, P13; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; *OFF NAT STAT, 1996, POP TRENDS, P84; *OFF POP CENS SURV, 1993, CLASS SURG OP PROC; PATTERSON CC, 1995, PAEDIATR PERINAT EP, V9, P90, DOI 10.1111/j.1365-3016.1995.tb00121.x; PLACE MJ, 1978, LANCET, V2, P249; RAO S, 1986, NEW ZEAL MED J, V99, P752; RECORD R G, 1958, Br J Prev Soc Med, V12, P8; RICHARDS ID, 1971, BRIT J PREV SOC MED, V25, P59; SANFRIDSON J, 1991, ACTA ORTHOP SCAND, V62, P87, DOI 10.3109/17453679108999228; SMITHELLS RW, 1968, BRIT J PREV SOC MED, V22, P36; *STAND MED ADV COM, 1969, SCREEN DET CONG DISL; Standing Medical Advisory Committee and the Standing Nursing and Midwifery Advisory Committee, 1986, SCREEN DET CONG DISL; STONE DH, 1992, AM J EPIDEMIOL, V136, P498, DOI 10.1093/oxfordjournals.aje.a116523; TREDWELL SJ, 1992, CLIN ORTHOP RELAT R, P63; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047; YNGVE D, 1990, J PEDIATR ORTHOPED, V10, P777, DOI 10.1097/01241398-199011000-00013; 1991, LANCET, V337, P947	35	92	93	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1149	1152		10.1016/S0140-6736(97)10466-4	http://dx.doi.org/10.1016/S0140-6736(97)10466-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643684				2022-12-24	WOS:000073220200006
J	Elsman, J				Elsman, J			Relevance of pregnancy and lactation to osteoporosis?	LANCET			English	Editorial Material							BONE-MINERAL DENSITY; CALCIUM; TURNOVER; WOMEN; METABOLISM; RECOVERY; MARKERS; MASS		Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research	Elsman, J (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia.		Eisman, John A/C-2886-2014					Abrams SA, 1998, J CLIN ENDOCR METAB, V83, P1056, DOI 10.1210/jc.83.4.1056; Affinito P, 1996, J CLIN ENDOCR METAB, V81, P2314, DOI 10.1210/jc.81.6.2314; CROSS NA, 1995, J BONE MINER RES, V10, P1312; CROSS NA, 1995, AM J CLIN NUTR, V61, P514, DOI 10.1093/ajcn/61.3.514; Gulson BL, 1997, J LAB CLIN MED, V130, P51, DOI 10.1016/S0022-2143(97)90058-5; KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4; KALKWARF KJ, 1997, NEW ENGL J MED, V337, P523; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384; Krebs NF, 1997, AM J CLIN NUTR, V65, P1738, DOI 10.1093/ajcn/65.6.1738; Laskey MA, 1998, AM J CLIN NUTR, V67, P685, DOI 10.1093/ajcn/67.4.685; LEPRE F, 1993, NEW ENGL J MED, V328, P666, DOI 10.1056/NEJM199303043280917; Liel Y, 1998, SOUTH MED J, V91, P33, DOI 10.1097/00007611-199801000-00006; Lopez JM, 1996, OSTEOPOROSIS INT, V6, P153, DOI 10.1007/BF01623940; PRENTICE A, 1995, AM J CLIN NUTR, V62, P58, DOI 10.1093/ajcn/62.1.58; Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059; Ritchie LD, 1998, AM J CLIN NUTR, V67, P693, DOI 10.1093/ajcn/67.4.693; SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D; Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549; TUPPURAINEN M, 1995, ACTA OBSTET GYN SCAN, V74, P624, DOI 10.3109/00016349509013475; Yamaga A, 1996, J CLIN ENDOCR METAB, V81, P752, DOI 10.1210/jc.81.2.752	21	36	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					504	505		10.1016/S0140-6736(05)79245-X	http://dx.doi.org/10.1016/S0140-6736(05)79245-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716051				2022-12-24	WOS:000075435300005
J	van Beek, I; Dwyer, R; Dore, GJ; Luo, KH; Kaldor, JM				van Beek, I; Dwyer, R; Dore, GJ; Luo, KH; Kaldor, JM			Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; PREVALENCE; HCV; TRANSMISSION; BEHAVIORS; AMSTERDAM; ANTIBODY; MARYLAND; HBV	Objectives: To estimate the incidence of HIV and hepatitis C virus and risk factors for seroconversion among a cohort of injecting drug users. Design: Retrospective cohort study. Setting: Primary healthcare facility in central Sydney. Subjects: Injecting drug users tested for HIV-1 antibody (n = 1179) and antibodies to hepatitis C virus (n = 1078) from February 1992 to October 1995. Main outcome measures: Incidence of HIV-1 and hepatitis C virus among seronegative subjects who injected drugs and underwent repeat testing. Demographic and behavioural risk factors for hepatitis seroconversion. Results: Incidence of HIV-1 among 426 initially seronegative injecting drug users was 0.17/100 person years (two seroconversions) compared with an incidence of hepatitis C virus of 20.9/100 person years (31 seroconversions) among 152 injecting drug users initially negative for hepatitis C virus. Incidence of hepatitis C virus among injecting drug users aged less than 20 years was 75.6/100 person years. Independent risk factors for hepatitis C virus seroconversion were age less than 20 years and a history of imprisonment. Conclusions: In a setting where prevention measures have contributed to the maintenance of low prevalence and incidence of HIV-1, transmission of hepatitis C virus continues at extremely high levels, particularly among young injecting drug users.	Kirketon Rd Ctr, Kings Cross, NSW 1340, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	University of New South Wales Sydney; Kirby Institute	van Beek, I (corresponding author), Kirketon Rd Ctr, POB 22, Kings Cross, NSW 1340, Australia.	ivanbeek@oxemail.com.au	Dore, Gregory John/ABD-5665-2021; Dwyer, Robyn/K-9826-2019; Kaldor, John M/D-4545-2011; Dwyer, Robyn/K-3652-2013	Dore, Gregory John/0000-0002-4741-2622; Dwyer, Robyn/0000-0002-1886-0733; Dwyer, Robyn/0000-0002-1886-0733				BELL J, 1990, MED J AUSTRALIA, V153, P274, DOI 10.5694/j.1326-5377.1990.tb136900.x; BODSWORTH NJ, 1994, GENITOURIN MED, V70, P206; Breslow NE., 1987, STAT METHODS CANC RE, P81; CHAMOT E, 1992, AIDS, V6, P430, DOI 10.1097/00002030-199204000-00013; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; CROFTS N, 1994, EUR J EPIDEMIOL, V10, P687, DOI 10.1007/BF01719282; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; Crofts N, 1997, MED J AUSTRALIA, V167, P17, DOI 10.5694/j.1326-5377.1997.tb138757.x; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; FRANCISCI D, 1995, EUR J EPIDEMIOL, V11, P123, DOI 10.1007/BF01719475; GALEAZZI B, 1995, LIVER, V15, P209; Gaube J, 1993, Gesundheitswesen, V55, P246; GIRARDI E, 1990, SCAND J INFECT DIS, V22, P751, DOI 10.3109/00365549009027133; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; LOVE A, 1994, EPIDEMIOL INFECT, V113, P529, DOI 10.1017/S0950268800068540; MAJID A, 1995, J MED VIROL, V46, P48, DOI 10.1002/jmv.1890460111; NAKATA S, 1994, J GASTROEN HEPATOL, V9, P416, DOI 10.1111/j.1440-1746.1994.tb01265.x; PATTI AM, 1993, INT J EPIDEMIOL, V22, P135, DOI 10.1093/ije/22.1.135; QUARANTA JF, 1994, J MED VIROL, V42, P29, DOI 10.1002/jmv.1890420106; ROBINSON GM, 1995, NEW ZEAL MED J, V108, P103; THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005; VANAMEIJDEN EJC, 1993, EUR J EPIDEMIOL, V9, P255, DOI 10.1007/BF00146260; VANBEEK I, 1994, GENITOURIN MED, V70, P321; VANBEEK I, 1994, SEX WORK SEX WORKERS; VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823, DOI 10.1093/infdis/162.4.823; VLAHOV D, 1993, EUR J EPIDEMIOL, V9, P566, DOI 10.1007/BF00209538; WADDELL RG, 1994, MED J AUSTRALIA, V161, P286; YE S, 1993, CHIN J EPIDEMIOL, V14, P45; ZELDIS JB, 1992, WESTERN J MED, V156, P30	29	162	164	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					433	437						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703523	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000075490200016
J	Aladjem, MI; Rodewald, LW; Kolman, JL; Wahl, GM				Aladjem, MI; Rodewald, LW; Kolman, JL; Wahl, GM			Genetic dissection of a mammalian replicator in the human beta-globin locus	SCIENCE			English	Article							BIDIRECTIONAL DNA-REPLICATION; CELL-CYCLE; FUNCTIONAL ELEMENTS; ANIMAL-CELLS; ORIGIN; INITIATION; XENOPUS; DOMAIN; IDENTIFICATION; CHROMOSOMES	The timing and localization of DNA replication initiation in mammalian cells are heritable traits, but it is not known whether initiation requires specific DNA sequences. A site-specific recombination strategy was used to show that DNA sequences previously identified as replication initiation sites could initiate replication when transferred to new chromosomal Locations. An 8-kilobase DNA sequence encompassing the origin of DNA replication in the human P-globin Locus initiated replication in the simian genome. Specific deletions within the globin origin did not initiate replication in these chromosomal sites. These data suggest that initiation of DNA replication in mammalian cells requires specific sequence information and extend the replicon hypothesis to higher eukaryotes.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [R01CA048405, U01CA048405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051104] Funding Source: NIH RePORTER; NCI NIH HHS [CA48405] Funding Source: Medline; NIGMS NIH HHS [GM51104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1997, MOL CELL BIOL, V17, P857, DOI 10.1128/MCB.17.2.857; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; BELL SP, 1993, COLD SPRING HARB SYM, V58, P435, DOI 10.1101/SQB.1993.058.01.050; BIELINSKY AK, 1998, MOL CELL BIOL, V279, P95; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BURHANS WC, 1994, SCIENCE, V263, P639, DOI 10.1126/science.8303270; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Clyne RK, 1997, METHODS, V13, P221, DOI 10.1006/meth.1997.0522; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DePamphilis ML, 1993, CURR OPIN CELL BIOL, V5, P434, DOI 10.1016/0955-0674(93)90008-E; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; Diffley JFX, 1995, J CELL SCI, P67; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; EPNER E, 1991, P NATL ACAD SCI USA, V88, P153; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HAMLIN JL, COMMUNICATION; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SAUER B, 1990, New Biologist, V2, P441; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; Shimizu N, 1996, NAT GENET, V12, P65, DOI 10.1038/ng0196-65; SNAPKA RM, 1983, P NATL ACAD SCI-BIOL, V80, P7533, DOI 10.1073/pnas.80.24.7533; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Strehl S, 1997, MOL CELL BIOL, V17, P6157, DOI 10.1128/MCB.17.10.6157; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YOON Y, 1995, MOL CELL BIOL, V15, P2482	57	172	181	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					1005	1009		10.1126/science.281.5379.1005	http://dx.doi.org/10.1126/science.281.5379.1005			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703500				2022-12-24	WOS:000075412700052
J	Winfree, E; Liu, FR; Wenzler, LA; Seeman, NC				Winfree, E; Liu, FR; Wenzler, LA; Seeman, NC			Design and self-assembly of two-dimensional DNA crystals	NATURE			English	Article							DOUBLE-CROSSOVER MOLECULES; ATOMIC FORCE MICROSCOPE; NUCLEIC-ACID JUNCTIONS; GOLD SPHERES; CONSTRUCTION; NANOCONSTRUCTION; COMPONENTS; SEQUENCES; BIOCHIP; DEVICE	Molecular self-assembly presents a 'bottom-up' approach to the fabrication of objects specified with nanometre precision. DNA molecular structures and intermolecular interactions are particularly amenable to the design and synthesis of complex molecular objects. We report the design and observation of two-dimensional crystalline forms of DNA that self-assemble from synthetic DNA double-crossover molecules. Intermolecular interactions between the structural units are programmed by the design of 'sticky ends' that associate according to Watson-Crick complementarity, enabling us to create specific periodic patterns on the nanometre scale. The patterned crystals have been visualized by atomic force microscopy.	CALTECH, Pasadena, CA 91125 USA; NYU, Dept Chem, New York, NY 10003 USA	California Institute of Technology; New York University	Winfree, E (corresponding author), CALTECH, Pasadena, CA 91125 USA.	winfree@hope.caltech.edu; ned.seeman@nyu.edu	Winfree, Erik/L-4002-2013	Winfree, Erik/0000-0002-5899-7523				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Carter ES, 1996, COMPUT APPL BIOSCI, V12, P25; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; Grunbaum B., 1986, TILINGS PATTERNS; HADDON RC, 1985, P NATL ACAD SCI USA, V82, P1874, DOI 10.1073/pnas.82.7.1874; HANSMA HG, 1992, SCIENCE, V256, P1180, DOI 10.1126/science.256.5060.1180; JOANNOPOLOUS JD, 1995, PHOTONIC CRYSTALS MO; Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o; LIU B, 1994, NANOBIOLOGY, V3, P177; MA RI, 1986, NUCLEIC ACIDS RES, V14, P9745, DOI 10.1093/nar/14.24.9745; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; NIEMEYER CM, 1994, NUCLEIC ACIDS RES, V22, P5530, DOI 10.1093/nar/22.25.5530; OUPOROV IV, 1995, BIOPHYS J, V68, P266, DOI 10.1016/S0006-3495(95)80183-9; PETRILLO ML, 1988, BIOPOLYMERS, V27, P1337, DOI 10.1002/bip.360270902; Qiu HX, 1997, J MOL BIOL, V267, P881, DOI 10.1006/jmbi.1997.0918; REIF J, 1997, IN PRESS P 3 DIMACS; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RIBEIRO FR, 1995, J MOL CATAL A-CHEM, V96, P245; ROBINSON BH, 1987, PROTEIN ENG, V1, P295, DOI 10.1093/protein/1.4.295; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; SHAIU WL, 1993, J VAC SCI TECHNOL A, V11, P820, DOI 10.1116/1.578311; SHAIU WL, 1993, NUCLEIC ACIDS RES, V21, P99, DOI 10.1093/nar/21.1.99; SUN S, 1996, PROT ENG, V9, P1205; Vainshtein B. K., 1994, MODERN CRYSTALLOGRAP, V1; Wang H., 1963, P S MATH THEOR AUT, P23; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Winfree E., 1996, DNA BASED COMPUTERS, P199; WINFREE E, 1996, P 2 DIMACS M DNA BAS; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163; ZHANG YW, 1994, J AM CHEM SOC, V116, P1661, DOI 10.1021/ja00084a006	40	2141	2264	27	775	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					539	544		10.1038/28998	http://dx.doi.org/10.1038/28998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707114				2022-12-24	WOS:000075238700036
J	Ewart, WR; Winikoff, B				Ewart, WR; Winikoff, B			Toward safe and effective medical abortion	SCIENCE			English	Article									Wellcome Trust, London NW1 2BE, England; Populat Council, New York, NY 10017 USA	University of London; University College London; Population Council	Ewart, WR (corresponding author), Wellcome Trust, 183 Euston Rd, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Cameron ST, 1996, BRIT J OBSTET GYNAEC, V103, P1222, DOI 10.1111/j.1471-0528.1996.tb09633.x; GIRAKU L, 1997, ADDRESSING COMPLICAT; *POP INF PROGR J H, 1997, ISSUES WORLD HLTH 1, V25; WHO, 1993, AB TAB AV DAT FREQ M; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8	5	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					520	521		10.1126/science.281.5376.520	http://dx.doi.org/10.1126/science.281.5376.520			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9705721				2022-12-24	WOS:000075012300024
J	Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J				Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J			The structural basis of the activation of Ras by Sos	NATURE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; GDP-GTP EXCHANGERS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; MOLECULAR MECHANISM; EF-TU; PROTEIN; RESIDUES; COMPLEX	The crystal structure of human H-Ras complexed with the pas guanine-nucleotide-exchange-factor region of the Son of sevenless (Sos) protein has been determined at 2.8 Angstrom resolution. The normally tight interaction of nucleotides with pas is disrupted by Sos in two ways. First, the insertion into gas of an alpha-helix from Sos results in the displacement of the Switch 1 region of Ras, opening up the nucleotide-binding site. Second, side chains presented by this helix and by a distorted conformation of the Switch 2 region of pas alter title chemical environment of the binding site for the phosphate groups of the nucleotide and the associated magnesium ion, so that their binding is no longer favoured. Sos does not impede the binding sites for the base and the ribose of GTP or sop, so the Ras-Sos complex adopts a structure that allows nucleotide release and rebinding.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BERNSTEIN FC, 1978, ARCH BIOCHEM BIOPHYS, V185, P584, DOI 10.1016/0003-9861(78)90204-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; BRUNGER AT, IN PRESS ACTA CRYS D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LAI SHY, 1993, COMPUT IND ENG, V25, P13, DOI 10.1016/0360-8352(93)90209-G; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	46	587	596	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					337	343		10.1038/28548	http://dx.doi.org/10.1038/28548			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690470				2022-12-24	WOS:000074968800041
J	Yasuda, R; Noji, H; Kinosita, K; Yoshida, M				Yasuda, R; Noji, H; Kinosita, K; Yoshida, M			F-1-ATPase is a highly efficient molecular motor that rotates with discrete 120 degrees steps	CELL			English	Article							ESCHERICHIA-COLI F1-ATPASE; CATALYTIC SITE; MITOCHONDRIAL ATPASE; COOPERATIVITY; HYDROLYSIS	A single molecule of F-1-ATPase, a portion of ATP synthase, is by itself a rotary motor in which a central gamma subunit rotates against a surrounding cylinder made of alpha(3)beta(3) subunits. Driven by three catalytic beta s, each fueled with ATP, gamma makes discrete 120 degrees steps, occasionally stepping backward. The work done in each step is constant over a broad range of imposed load and is close to the free energy of hydrolysis of one ATP molecule.	Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Keio University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Teikyo University	Kinosita, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER B, 1997, J BIOL CHEM, V272, P19621; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kagawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P247, DOI 10.1006/bbrc.1997.7574; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1997, FEBS LETT, V413, P55, DOI 10.1016/S0014-5793(97)00878-8; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SOUID AK, 1995, J BIOL CHEM, V270, P9074, DOI 10.1074/jbc.270.16.9074; STRYER L, 1995, BIOCHEMISTRY-US, P443; XIAO R, 1994, J BIOL CHEM, V269, P19232; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	37	669	681	4	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1117	1124		10.1016/S0092-8674(00)81456-7	http://dx.doi.org/10.1016/S0092-8674(00)81456-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657145	Bronze			2022-12-24	WOS:000074491100007
J	Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P				Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P			Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase	NATURE			English	Article							DEPOLYMERIZING FACTOR; ZINC-FINGER; IDENTIFICATION; PROTEIN; MOTIFS	Cell division, cell motility and the formation and maintenance of specialized structures in differentiated cells depend directly on the regulated dynamics of the actin cytoskeleton(1,2). To understand the mechanisms of these basic cellular processes, the signalling pathways that link external signals to the regulation of the actin cytoskeleton need to be characterized(2,3). Here we identify a pathway for the regulation of cofilin, a ubiquitous actin-binding protein that is essential for effective depolymerization of actin filaments(4-8). LIM-kinase 1, also known as KIZ, is a protein kinase with two amino-terminal LIM motifs(9-11) that induces stabilization of F-actin structures in transfected cells. Dominant-negative LIM-kinase1 inhibits the accumulation of the F-actin. Phosphorylation experiments in vivo and in vitro provide evidence that cofilin is a physiological substrate of LIM-kinase 1. Phosphorylation by LIM-kinase 1 inactivates cofilin, leading to accumulation of actin filaments. Constitutively active Rac augmented cofilin phosphorylation and LIM-kinase 1 autophosphorylation whereas phorbol ester inhibited these processes. Our results define a mechanism for the regulation of cofilin and hence of actin dynamics in vivo. By modulating the stability of actin cytoskeletal structures, this pathway should play a central role in regulating cell motility and morphogenesis.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Friedrich Miescher Institute for Biomedical Research; Walter & Eliza Hall Institute	Caroni, P (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stanyon, Clem/AAM-5040-2020	Arber, Silvia/0000-0002-6261-250X; Stanyon, Clement/0000-0001-5030-6823				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; CALIER MF, 1997, J CELL BIOL, V136, P1307; DAVID IB, 1995, CR HEBD ACAD SCI, V318, P295; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; MICHISON TJ, 1996, CELL, V84, P371; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; NAGOAKA R, 1995, J CELL SCI, V108, P581; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; vonArx P, 1995, J CELL BIOL, V131, P1759, DOI 10.1083/jcb.131.6.1759; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	22	1125	1144	2	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					805	809		10.1038/31729	http://dx.doi.org/10.1038/31729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655397				2022-12-24	WOS:000074433100054
J	Blennerhassett, M				Blennerhassett, M			Deadly charades	BRITISH MEDICAL JOURNAL			English	Article											Blennerhassett, M (corresponding author), Wyville Lodge, York YO62 4AQ, N Yorkshire, England.							Arnott SJ, 1996, LANCET, V348, P1049; KESEY K, 1973, ONE FLEW CUCKOOS NES	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1890	1891						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632414				2022-12-24	WOS:000074686500032
J	Korber, B; Theiler, J; Wolinsky, S				Korber, B; Theiler, J; Wolinsky, S			Limitations of a molecular clock applied to considerations of the origin of HIV-1	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; ENVELOPE GENES; GAG GENES; SEQUENCE; ISOLATE; RECOMBINATION; TRANSMISSION; INFECTIONS; EVOLUTION		Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Calif Los Alamos Natl Lab, Space & Remote Sensing Sci Grp NIS2, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Theoret Div T10, Los Alamos, NM 87545 USA	Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Wolinsky, S (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Korber, Bette/0000-0002-2026-5757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070001] Funding Source: NIH RePORTER; NIAID NIH HHS [3-Y01-AI-70001-13] Funding Source: Medline; NICHD NIH HHS [R01-HD-31756] Funding Source: Medline; PHS HHS [Y1-A1-4058-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BECKETT S, 1981, ILL SEEN ILL SAID, P76; Beddows S, 1998, J GEN VIROL, V79, P77, DOI 10.1099/0022-1317-79-1-77; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997; Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR R, 1998, AIDS RES HUM RETROV, V72, P1552; Cornelissen M, 1996, J VIROL, V70, P8209, DOI 10.1128/JVI.70.11.8209-8212.1996; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; DIGHE PK, 1997, HUMAN RETROVIRUSES A, P74; DOMS RW, 1997, HIV MOL IMMUNOLOGY D, P1; DSOUZA MP, 1997, INFECT DIS, V175, P1056; ELGEN M, 1996, TRENDS MICROBIOL, V4, P216; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GINSPARG P, 1905, COMMUNICATION; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; Gunthard HF, 1998, J VIROL, V72, P2422; HAMMOND J, 1997, HUMAN RETROVIRUSES 3, P206; Hillis David M., 1996, P515; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; Kanki P J, 1997, AIDS, V11 Suppl B, pS33; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; Korber B T, 1995, AIDS, V9 Suppl A, pS5; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KUIKEN CL, MOL EVOLUTION HIV; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; LEITNER T, 1997, HUMAN RETROVIRUSES 3, P25; LI WH, 1988, MOL BIOL EVOL, V5, P313; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; *LOS AL NAT LAB, 1997, THEOR BIOL BIOPH; LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640, DOI 10.1128/JVI.69.9.5640-5649.1995; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; McCutchan FE, 1996, AIDS, V10, pS13; McCutchan FE, 1998, AIDS RES HUM RETROV, V14, P329, DOI 10.1089/aid.1998.14.329; MCCUTCHAN FE, 1998, P 5 ANN HIV DYN EV M, V5, P23; Moore J P, 1995, AIDS, V9 Suppl A, pS117; NEWTON I, 1947, PRINCIPIA, P6; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PEETERS M, 1998, P 5 ANN HIV DYN EV M, V5, P73; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Press W.H, 1992, NUMERICAL RECIPES C, P666; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230; ROBERTSON DL, 1997, HUMAN RETROVIRUSES A, P25; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; Salminen MO, 1997, J VIROL, V71, P2647, DOI 10.1128/JVI.71.4.2647-2655.1997; SHARMA KD, 1994, HYDROL PROCESS, V8, P27, DOI 10.1002/hyp.3360080103; SHARP P, 1988, NATURE, V333, P315; Swofford David L., 1996, P407; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	64	68	72	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1868	1871		10.1126/science.280.5371.1868	http://dx.doi.org/10.1126/science.280.5371.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669945				2022-12-24	WOS:000074323800041
J	Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V				Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V		SAGE Study Grp	Management of pain in elderly patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME; GERIATRIC PAIN; PREVALENCE; RELIEF; ETHNICITY; RESIDENTS; PROGRAM; HOSPICE; SAMPLE; CARE	Context.-Cancer pain can be relieved with pharmacological agents as indicated by the World Health Organization (WHO). All too frequently pain management is reported to be poor. Objective.-To evaluate the adequacy of pain management in elderly and minority cancer patients admitted to nursing homes. Design.-Retrospective, cross-sectional study. Setting.-A total of 1492 Medicare-certified and/or Medicaid-certified nursing homes in 5 states participating in the Health Care Financing Administration's demonstration project, which evaluated the implementation of the Resident Assessment Instrument and its Minimum Data Set. Study Population.-A group of 13 625 cancer patients aged 65 years and older discharged from the hospital to any of the facilities from 1992 to 1995, Data were from the multilinked Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Main Outcome Measure.-Prevalence and predictors of daily pain and of analgesic treatment. Pain assessment was based on patients' report and was completed by a multidisciplinary team of nursing home personnel that observed, over a 7-day period, whether each resident complained or showed evidence of pain daily. Results.-A total of 4003 patients (24%, 29%, and 38% of those aged greater than or equal to 85 years, 75 to 84 years, and 65 to 74 years, respectively) reported daily pain. Age, gender, race, marital status, physical function, depression, and cognitive status were all independently associated with the presence of pain. Of patients with daily pain, 16% received a WHO level 1 drug, 32% a WHO level 2 drug, and only 26% received morphine. Patients aged 85 years and older were less likely to receive either weak opiates or morphine than those aged 65 to 74 years (13% vs 38%, respectively). More than a quarter of patients (26%) in daily pain did not receive any analgesic agent. Patients older than 85 years in daily pain were also more likely to receive no analgesia (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.13-1.73), Other independent predictors of failing to receive any analgesic agent were minority race (OR, 1.63; 95% CI, 1.18-2.26 for African Americans), low cognitive performance (OR, 1.23; 95% CI, 1.05-1.44), and the number of other medications received (Oc, 0.65; 95% CI, 0.5-0.84 for 11 or more medications). Conclusions.-Daily pain is prevalent among nursing home residents with cancer and is often untreated, particularly among older and minority patients.	Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA; Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Rome, Italy; St Christophers Hospice, London, England; Harvard Univ, Sch Med, Hebrew Rehabil Ctr Aged, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Hackensack, NJ USA; Hackensack Univ Med Ctr, Homecare Inst, Hackensack, NJ USA	Brown University; Brown University; Brown University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center	Gambassi, G (corresponding author), Brown Univ, Ctr Gerontol & Hlth Care Res, Box G-B213, Providence, RI 02912 USA.	Giovanni_Gambassi@brown.edu	Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X	PHS HHS [17C90428] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ball JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; Bernabei R, 1998, J AM GERIATR SOC, V46, P251, DOI 10.1111/j.1532-5415.1998.tb02553.x; BERNABEI R, IN PRESS J GERONTOL; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COHENMANSFIELD J, 1993, J GERONTOL, V48, pP96, DOI 10.1093/geronj/48.2.P96; CORRAN TM, 1994, PROG PAIN RES MANAG, V2, P895; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Elliott TE, 1997, J PAIN SYMPTOM MANAG, V13, P191, DOI 10.1016/S0885-3924(96)00275-8; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Fisher-Morris M, 1997, AGE AGEING, V26, P497, DOI 10.1093/ageing/26.6.497; FOLEY KM, 1995, J CLIN ONCOL, V13, P2149, DOI 10.1200/JCO.1995.13.9.2149; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; GOLDBERG RJ, 1986, J CHRON DIS, V39, P37, DOI 10.1016/0021-9681(86)90105-0; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; HIGGINSON I, 1994, SOC SCI MED, V38, P553, DOI 10.1016/0277-9536(94)90251-8; *I MED, 1997, APPR DEATH IMPR CAR, P51; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KWENTUS JA, 1985, GERIATRICS, V40, P48; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lindesay J, 1997, INT J GERIATR PSYCH, V12, P344, DOI 10.1002/(SICI)1099-1166(199703)12:3<344::AID-GPS504>3.0.CO;2-I; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; MELDING PS, 1991, PAIN, V46, P119, DOI 10.1016/0304-3959(91)90064-5; Mogil JS, 1997, PAIN, V70, P267, DOI 10.1016/S0304-3959(97)03333-2; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; PORTENOY RK, 1992, ONCOLOGY, V2, P86; Porter FL, 1996, PAIN, V68, P413, DOI 10.1016/S0304-3959(96)03210-1; Repetto L, 1998, CANCER, V82, P760, DOI 10.1002/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V; Rischer JB, 1996, JOINT COMM J QUAL IM, V22, P683, DOI 10.1016/S1070-3241(16)30275-9; SAS, 2003, US GUID STAT; SCHECHTERN L, 1989, PEDIATR CLIN N AM, V36, P631; Scherder EJA, 1997, ALZ DIS ASSOC DIS, V11, P171, DOI 10.1097/00002093-199709000-00010; Schroll M, 1997, LANCET, V350, P604, DOI 10.1016/S0140-6736(05)63321-1; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; STEIN WM, 1993, J PAIN SYMPTOM MANAG, V8, P474, DOI 10.1016/0885-3924(93)90190-7; STJERNSWARD J, 1988, CANCER SURV, V7, P195; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Vallerand A H, 1997, Semin Oncol Nurs, V13, P16, DOI 10.1016/S0749-2081(97)80045-9; Yeager K A, 1997, Cancer Pract, V5, P39; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 1991, MINIMUM DATA SET PLU	57	759	776	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1877	1882		10.1001/jama.279.23.1877	http://dx.doi.org/10.1001/jama.279.23.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634258	Bronze			2022-12-24	WOS:000074109700034
J	Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T				Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T			The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract	NATURE			English	Article							BLOOD-VESSEL DEVELOPMENT; HIV-1 INFECTION; TYROSINE KINASE; ANGIOGENESIS; ENTRY; MICE; GENE; VASCULOGENESIS; LESTR/FUSIN; ENDOTHELIUM	Vascularization of organs generally occurs by remodelling of the preexisting vascular system during their differentiation and growth to enable them to perform their specific functions during development. The molecules required by early vascular systems, many of which are receptor tyrosine kinases and their ligands, have been defined by analysis of mutant mice(1-3). As most of these mice die during early gestation before many of their organs have developed, the molecules responsible for vascularization during organogenesis have not been identified. The cell-surface receptor CXCR4 (refs 4-6) is a seven-transmembrane-spanning, G-protein-coupled receptor for the CXC chemokine PBSF/SDF-1 (for pre-B-cell growth-stimulating factor/stromal-cell-derived factor), which is responsible for B-cell lymphopoiesis, bone-marrow myelopoiesis and cardiac ventricular septum formation(7). CXCR4 also functions as a co-receptor for T-cell-line tropic human immunodeficiency virus HIV-1 (ref. 8). Here we report that CXCR4 is expressed in developing vascular endothelial cells, and that mice lacking CXCR4 or PBSF/SDF-1 have defective formation of the large vessels supplying the gastrointestinal tract. In addition, mice lacking CXCR4 die in utero and are defective in vascular development, haematopoiesis and cardiogenesis, like mice lacking PBSF/SDF-1, indicating that CXCR4 is a primary physiological receptor for PBSF/SDF-1. We conclude that PBSF/SDF-1 and CXCR4 define a new signalling system for organ vascularization.	Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, Osaka 59002, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Div Social Med,Bunkyo Ku, Tokyo 113, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Sakyo Ku, Kyoto 606, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 565, Japan	Osaka University; University of Tokyo; Kyoto University; Osaka University	Nagasawa, T (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, 840 Murodo Cho, Osaka 59002, Japan.		Kishimoto, Tadamitsu/C-8470-2009; Iizasa, Hisashi/A-9821-2012	Nagasawa, Takashi/0000-0002-1085-0960; Yoshida, Hisahiro/0000-0001-6360-5988				Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VECCHI A, 1994, EUR J CELL BIOL, V63, P247	30	1255	1337	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					591	594		10.1038/31261	http://dx.doi.org/10.1038/31261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634237				2022-12-24	WOS:000074150100056
J	Shafer, RW; Winters, MA; Palmer, S; Merigan, TC				Shafer, RW; Winters, MA; Palmer, S; Merigan, TC			Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients	ANNALS OF INTERNAL MEDICINE			English	Article							ZIDOVUDINE; INFECTION	Background: Drug resistance of HIV-1 is an obstacle to the long-term efficacy of antiretroviral therapy. Objective: To characterize reverse transcriptase and protease genes of multidrug-resistant HIV-1 isolates. Design: Descriptive case series. Setting: Academic medical center. Patients: Four consecutive patients with HIV-1 infection were selected because they had previously received many antiretroviral drugs and had not achieved plasma HIV-1 RNA suppression despite treatment with several three-drug combinations. Measurements: Reverse transcriptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1. Results: Isolates of HIV-1 from the four patients shared seven protease mutations and eight reverse transcriptase mutations. These mutations were present in biological clones and at three time points in three of the patients. Susceptibility testing showed high-level resistance (30-fold to >100-fold) to zidovudine, lamivudine, saquinavir, indinavir, and nelfinavir and lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine. Conclusions: Simultaneous resistance to almost all available antiretroviral drugs may occur in HIV-1. The concordance and persistence of mutations in drug-resistant HIV-1 isolates suggest that some combinations of reverse transcriptase and protease mutations give the virus a selective advantage in the presence of various drug combinations.	Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA	Stanford University	Shafer, RW (corresponding author), Stanford Univ, Med Ctr, Div Infect Dis, Room S-156, Stanford, CA 94305 USA.	rshafer@cmgm.stanford.edu	Merigan, Thomas/AGQ-7464-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HERTOGS K, 1998, P 5 C RETR OPP INF C; LARDER B, 1996, 5 INT WORKSH HIV DRU, P61; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Myers GK, 1995, HUMAN RETROVIRUSES A; PALMER S, 1998, P 5 C RETR OPP INF C; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; SCHAPIRO JM, 1997, ANTIVIR THER S, P57; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; SHAFER RW, 1993, J VIROL METHODS, V41, P297, DOI 10.1016/0166-0934(93)90019-N; Shafer RW, 1997, J CLIN MICROBIOL, V35, P520, DOI 10.1128/JCM.35.2.520-522.1997; WINTERS MA, 1997, ANTIVIR THER S, P11; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	20	171	175	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					906	911		10.7326/0003-4819-128-11-199806010-00008	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634429				2022-12-24	WOS:000073808600005
J	Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ				Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ			Poliomyelitis-like illness due to Japanese encephalitis virus	LANCET			English	Article							GUILLAIN-BARRE-SYNDROME; NORTHERN CHINA; ANTIBODIES	Background Acute flaccid paralysis remains common among Vietnamese children despite a pronounced fall in the incidence of poliomyelitis. Methods During 1995, all 22 children presenting with acute flaccid paralysis to a referral centre in Ho Chi Mlnh City, Vietnam, had virological cultures and antibody measurements done on serum, cerebrospinal fluid, and faeces. A year later the children were reassessed and electrophysiological studies were done. Findings Wild poliovirus type 1 was isolated from the faeces of only one patient, and non-polio enteroviruses from three patients. 12 (55%) of the 22 children with acute flaccid paralysis had evidence of acute Japanese encephalitis virus (JEV) infection, compared with only one (1%) of 88 age-matched hospital controls (children with diphtheria; p<0.0001). Compared with JEV-negative patients, weakness in JEV-infected children was more rapid in onset, tended to be asymmetrical, but was less likely to involve the arms. All 12 children with JEV infection were febrile at the onset of weakness, seven had acute retention of urine, and ten had CSF pleiocytosis. Seven of eight JEV-negative patients met the case-definition of Guillain-Barre syndrome, compared with only one of 12 JEV-positive children. At follow-up, patients with JEV infection had greater disability and were more likely to have muscle wasting than were JEV-negative children. Nerve conduction and electromyographic studies indicated damage to the anterior horn cells. Interpretation JEV causes an acute flaccid paralysis in children that has similar clinical and pathological features to poliomyelitis. In endemic areas, children with acute flaccid paralysis should be investigated for evidence of JEV infection.	Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; John Radcliffe Hosp, Ctr Trop Med & Infect Dis, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Inst Pasteur, Ho Chi Minh City, Vietnam; USA, Dept Virol, Med Component, Armed Forces Res Inst Med Sci, Bangkok, Thailand	University of Oxford; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	White, NJ (corresponding author), Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam.		White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978; Solomon, Tom/0000-0001-7266-6547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; Breinl A., 1918, MED J AUSTRALIA, V1, P209; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P169; BURKE DS, 1982, J CLIN MICROBIOL, V16, P1034, DOI 10.1128/JCM.16.6.1034-1042.1982; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P412; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; KUMAR R, 1991, INDIAN PEDIATR, V23, P1525; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MISRA UK, 1994, J NEUROL NEUROSUR PS, V57, P1484, DOI 10.1136/jnnp.57.12.1484; PREVOT M., 1954, BULLL SOC PATHOL EXOT, V47, P490; Read SJ, 1997, J CLIN MICROBIOL, V35, P691, DOI 10.1128/JCM.35.3.691-696.1997; Solomon T, 1997, NEUROL INFECT EPIDEM, V2, P191; Tangermann RH, 1997, J INFECT DIS, V175, pS97, DOI 10.1093/infdis/175.Supplement_1.S97; *WHO, 1997, WEEKLY EPIDEMIOL REC, V5, P27; *WHO, 1993, AC ONS FLACC PAR; World Health Organization, 1992, MAN VIR INV POL; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P965; 1993, MORBID MORTAL WEEKLY, V42, P1	20	186	191	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1094	1097		10.1016/S0140-6736(97)07509-0	http://dx.doi.org/10.1016/S0140-6736(97)07509-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660579				2022-12-24	WOS:000073090200011
J	Arant, BS				Arant, BS			Screening for urinary abnormalities: worth doing and worth doing well	LANCET			English	Editorial Material									Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA	University of Tennessee System; University of Tennessee Health Science Center	Arant, BS (corresponding author), Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA.							*AM AC PED, 1993, POL REF GUID COMPR G; DODGE WF, 1976, J PEDIATR-US, V88, P327, DOI 10.1016/S0022-3476(76)81012-8; Graff L, 1983, HDB ROUTINE URINALYS; Kaplan RE, 1997, PEDIATRICS, V100, P919, DOI 10.1542/peds.100.6.919; KUNIN CM, 1970, J INFECT DIS, V122, P382, DOI 10.1093/infdis/122.5.382; Linshaw MA, 1997, PEDIATRICS, V100, P1031, DOI 10.1542/peds.100.6.1031; LIPPMAN RW, 1957, URINE URINARY SEDIME	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					307	308		10.1016/S0140-6736(05)78344-6	http://dx.doi.org/10.1016/S0140-6736(05)78344-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652606				2022-12-24	WOS:000071864000004
J	Sattar, N; Hopkinson, ZEC; Greer, IA				Sattar, N; Hopkinson, ZEC; Greer, IA			Insulin-sensitising agents in polycystic-ovary syndrome	LANCET			English	Editorial Material							RESISTANCE		Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Univ NHS Trust, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow; University of Glasgow	Sattar, N (corresponding author), Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland.			Sattar, Naveed/0000-0002-1604-2593				Acbay O, 1996, FERTIL STERIL, V65, P946, DOI 10.1016/S0015-0282(16)58266-1; CASIMIRRI F, 1997, INT J OBESITY S2, V21, pS61; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; VANDERSPUY ZM, 1996, HUM REPROD, V11, P167; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7	12	39	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					305	307		10.1016/S0140-6736(05)78345-8	http://dx.doi.org/10.1016/S0140-6736(05)78345-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652605				2022-12-24	WOS:000071864000003
J	Su, XD; Gastinel, LN; Vaughn, DE; Faye, I; Poon, P; Bjorkman, PJ				Su, XD; Gastinel, LN; Vaughn, DE; Faye, I; Poon, P; Bjorkman, PJ			Crystal structure of hemolin: A horseshoe shape with implications for homophilic adhesion	SCIENCE			English	Article							CELL-ADHESION; IMMUNOGLOBULIN SUPERFAMILY; BINDING-SITES; MOLECULE L1; PROTEINS; RESOLUTION; MEMBER; IMMUNITY; COMPLEX; DOMAINS	Hemolin, an insect immunoglobulin superfamily member, is a Lipopolysaccharide-binding immune protein induced during bacterial infection. The 3.1 angstrom crystal structure reveals a bound phosphate and patches of positive charge, which may represent the Lipopolysaccharide binding site, and a new and unexpected arrangement of four immunoglobulin-like domains forming a horseshoe. Sequence analysis and analytical ultracentrifugation suggest that the domain arrangement is a feature of the L1 family of neural cell adhesion molecules related to hemolin. These results are relevant to interpretation of human L1 mutations in neurological diseases and suggest a domain swapping model for how L1 family proteins mediate homophilic adhesion.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Stockholm, Dept Genet, S-10691 Stockholm, Sweden; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Stockholm University; University of California System; University of California Los Angeles	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abagyan RA, 1997, J MOL BIOL, V273, P355, DOI 10.1006/jmbi.1997.1287; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDERSSON K, 1987, INSECT BIOCHEM, V17, P133, DOI 10.1016/0020-1790(87)90153-3; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bettencourt R, 1997, EUR J BIOCHEM, V250, P630, DOI 10.1111/j.1432-1033.1997.00630.x; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, IN PRESS ACTA CRYS D; *CCP4, 1994, COLL COMP PROJ; Chen CL, 1997, DEV BIOL, V181, P1, DOI 10.1006/dbio.1996.8437; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COPLEY RR, 1994, J MOL BIOL, V242, P321; Daffre S, 1997, FEBS LETT, V408, P127, DOI 10.1016/S0014-5793(97)00397-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drescher B, 1996, EUR J NEUROSCI, V8, P2467, DOI 10.1111/j.1460-9568.1996.tb01541.x; ERICKSON H, UNPUB; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; FAYE I, 1997, MOL MECH IMMUNE RESP; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HUBER AH, 1994, THESIS CALTECH PASAD; Hughes AL, 1998, IMMUNOGENETICS, V47, P283, DOI 10.1007/s002510050360; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADENDORFF NE, 1991, ARCH INSECT BIOCHEM, V18, P285, DOI 10.1002/arch.940180410; LanzMendoza H, 1996, CELL IMMUNOL, V169, P47, DOI 10.1006/cimm.1996.0089; LINDSTROMDINNETZ I, 1995, EUR J BIOCHEM, V230, P920, DOI 10.1111/j.1432-1033.1995.tb20637.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTHERFORD G, UNPUB; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stowell MHB, 1996, J APPL CRYSTALLOGR, V29, P608, DOI 10.1107/S0021889896004712; SU X, UNPUB; SUMMERS MD, 1987, MANUAL METHODS BACUL, P1; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Zhao L, 1996, J INSECT PHYSIOL, V42, P73, DOI 10.1016/0022-1910(95)00084-4	55	142	149	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					991	995		10.1126/science.281.5379.991	http://dx.doi.org/10.1126/science.281.5379.991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703515				2022-12-24	WOS:000075412700048
J	Wu, MX; Ao, ZH; Prasad, KVS; Wu, RL; Schlossman, SF				Wu, MX; Ao, ZH; Prasad, KVS; Wu, RL; Schlossman, SF			IEX-1L, an apoptosis inhibitor involved in NF-kappa B-mediated cell survival	SCIENCE			English	Article							EARLY-RESPONSE GENE; MICE LACKING; DEATH; EXPRESSION; PROTEIN	Transcription factors of the nuclear factor-kappa B/rel (NF-kappa B) family may be important in cell survival by regulating unidentified, anti-apoptotic genes. One such gene that protects cells from apoptosis induced by pas or tumor necrosis factor type or (TNF), IEX-1L, is described here. Its transcription induced by TNF was decreased in cells with defective NF-kappa B activation, rendering them sensitive to TNF-induced apoptosis, which was abolished by transfection with IEX-1L. In support, overexpression of antisense IEX-1L partially blocked TNF-induced expression of IEX-1L and sensitized normal cells to killing. This study demonstrates a key role of IEX-1L in cellular resistance to TNF-induced apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Wu, MX (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012069, R01AI012069, P30AI028691] Funding Source: NIH RePORTER; NIAID NIH HHS [P30AI28691, AI12069] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALDWIN JAS, 1996, ANNU REV IMMUNOL, V4, P649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHARLES CH, 1993, ONCOGENE, V8, P797; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kondratyev AD, 1996, CANCER RES, V56, P1498; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Schafer H, 1996, CANCER RES, V56, P2641; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M.C., UNPUB	17	384	396	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					998	1001		10.1126/science.281.5379.998	http://dx.doi.org/10.1126/science.281.5379.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703517				2022-12-24	WOS:000075412700050
J	Ishii, N; Fujii, M; Hartman, PS; Tsuda, M; Yasuda, K; Senoo-Matsuda, N; Yanase, S; Ayusawa, D; Suzuki, K				Ishii, N; Fujii, M; Hartman, PS; Tsuda, M; Yasuda, K; Senoo-Matsuda, N; Yanase, S; Ayusawa, D; Suzuki, K			A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes	NATURE			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CAENORHABDITIS-ELEGANS; UBIQUINONE OXIDOREDUCTASE; SENSITIVE MUTANT; COMPLEX-II; DAMAGE; DEFICIENCY	Much attention has focused on the aetiology of oxidative damage in cellular and organismal ageing(1-4). Especially toxic are the reactive oxygen byproducts of respiration and other biological processes(5). A mev-1(kn1) mutant of Caenorhabditis elegans has been found to be hypersensitive to raised oxygen concentrations(6,7), Unlike the wild type, its lifespan decreases dramatically as oxygen concentrations are increased from 1 tee 60% (ref. 7). Strains bearing this mutation accumulate markers of ageing (such as fluorescent materials and protein carbonyls) faster than the wild type(8,9). We show here that mev-1 encodes a subunit of the enzyme succinate dehydrogenase cytochrome b, which is a component of complex II of the mitochondrial electron transport chain. We found that the ability of complex II to catalyse electron transport from succinate to ubiquinone is compromised in mev-l animals. This may cause an indirect increase in superoxide levels, which in turn leads to oxygen hypersensitivity and premature ageing. Our results indicate that mev-1 governs the rate of ageing by modulating the cellular response to oxidative stress.	Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan; Yokohama City Univ, Kihara Inst Biol Res, Dept Biochem, Kanagawa 2440813, Japan; Texas Christian Univ, Dept Biol, Ft Worth, TX 76129 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Lab, Tokyo 1948533, Japan	Tokai University; Yokohama City University; Texas Christian University; Kyowa Kirin Ltd	Ishii, N (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan.		Yasuda, Kayo/ABA-5867-2021	Yasuda, Kayo/0000-0002-6205-9249				Ackrell B A, 1978, Methods Enzymol, V53, P466; Adachi H, 1998, J GERONTOL A-BIOL, V53, pB240, DOI 10.1093/gerona/53A.4.B240; AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; HARMAN D, 1968, J GERONTOL, V23, P476, DOI 10.1093/geronj/23.4.476; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN JJ, 1988, J NEUROL SCI, V84, P189, DOI 10.1016/0022-510X(88)90124-4; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603; RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; YU L, 1987, J BIOL CHEM, V262, P1137	25	536	553	7	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					694	697		10.1038/29331	http://dx.doi.org/10.1038/29331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716135				2022-12-24	WOS:000075384200048
J	May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ				May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ			Hypothalamic activation in cluster headache attacks	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; ORBITAL PHLEBOGRAPHY; ANGINA-PECTORIS; PAIN; MIGRAINE; FIBERS; BRAIN	Background Cluster headache, one of the most severe pain syndromes in human beings, is usually described as a vascular headache. However, the striking circadian rhythmicity of this strictly half-sided pain syndrome cannot be readily explained by the vascular hypothesis. We aimed to assess changes in regional cerebral blood flow (rCBF) in patients with cluster headache. Methods We used positron emission tomography (PET) to assess the changes in rCBF, as an index of synaptic activity, during nitroglycerin-induced cluster headache attacks in nine patients who had chronic cluster headache. Eight patients who had cluster headache but were not in the bout acted as a control group. Findings In the acute pain slate, activation was seen in the ipsilateral inferior hypothalamic grey matter, the contralateral ventroposterior thalamus, the anterior cingulate cortex, and bilaterally in the insulae. Activation in the hypothalamus was seen solely in the pain state and was not seen in patients who have cluster headache but were out of the bout. Interpretation Our findings establish central nervous system dysfunction in the region of the hypothalamus as the primum movens in the pathophysiology of cluster headache. We suggest that a radical reappraisal of this type of headache is needed and that it should in general terms, be regarded as a neurovascular headache, to give equal weight to the pathological and physiological mechanisms that are at work.	UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Univ London, Dept Clin Neurol, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London	May, A (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	amay@ion.ucl.ac.uk	Frackowiak, Richard/H-4383-2011; Goadsby, Peter J/B-2267-2009; Goadsby, Peter J/Z-1970-2019; Frackowiak, Richard S/I-1809-2013	Frackowiak, Richard/0000-0002-3151-822X; Goadsby, Peter J/0000-0003-3260-5904; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOVIM G, 1992, HEADACHE, V32, P408; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHAZOT G, 1984, CEPHALALGIA, V4, P213, DOI 10.1046/j.1468-2982.1984.0404213.x; EKBOM K, 1968, ARCH NEUROL-CHICAGO, V19, P487, DOI 10.1001/archneur.1968.00480050057005; EKBOM K, 1970, ACTA NEUROL SCAND, V46, P225, DOI 10.1111/j.1600-0404.1970.tb05618.x; EKEROT CF, 1991, J PHYSIOL-LONDON, V441, P257, DOI 10.1113/jphysiol.1991.sp018750; FANCIULLACCI M, 1995, PAIN, V60, P119, DOI 10.1016/0304-3959(94)00097-X; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GOADSBY PJ, 1987, AM J PHYSIOL, V253, pR270, DOI 10.1152/ajpregu.1987.253.2.R270; GOADSBY PJ, 1994, BRAIN, V117, P427, DOI 10.1093/brain/117.3.427; GOADSBY PJ, 1991, HEADACHE, V31, P365, DOI 10.1111/j.1526-4610.1991.hed3106365.x; GOADSBY PJ, 1997, HEADACHE; GOADSBY PJ, 1988, BASIC MECHANISMS HEA, P413; HANNERZ J, 1987, CEPHALALGIA, V7, P207, DOI 10.1046/j.1468-2982.1987.0703207.x; HARDEBO JE, 1994, HEADACHE, V34, P125, DOI 10.1111/j.1526-4610.1994.hed3403125.x; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; ISLER H, 1993, CEPHALALGIA, V13, P172, DOI 10.1046/j.1468-2982.1993.1303172.x; KUDROW L, 1987, CEPHALALGIA, V7, P197, DOI 10.1046/j.1468-2982.1987.0703197.x; KUNKLE EC, 1952, T AM NEUROL ASSOC, P240; LEONE M, 1990, CEPHALALGIA, V10, P235, DOI 10.1046/j.1468-2982.1990.1005235.x; May A, 1998, PAIN, V74, P61, DOI 10.1016/S0304-3959(97)00144-9; Mesulam M. M., 1985, INSULA REIL MAN MONK; MINOSHIMA S, 1995, J CEREB BLOOD FLOW M, V15, P859; NELSON RF, 1978, HEADACHE, V18, P265, DOI 10.1111/j.1526-4610.1978.hed1805265.x; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Talairach J., 1988, COPLANAR STEREOTAXIC; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658	32	778	792	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					275	278		10.1016/S0140-6736(98)02470-2	http://dx.doi.org/10.1016/S0140-6736(98)02470-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690407				2022-12-24	WOS:000074974500010
J	Slaytor, EK; Ward, JE				Slaytor, EK; Ward, JE			How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets	BRITISH MEDICAL JOURNAL			English	Article									Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Newtown, NSW 2042, Australia		Ward, JE (corresponding author), Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Locked Bag 8, Newtown, NSW 2042, Australia.	jward@nah.rpa.cs.nsw.gov.au						BAINES C, 1992, CAN MED J ASS, V142, P2147; CURRY SJ, 1993, PREV MED, V22, P350, DOI 10.1006/pmed.1993.1029; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; McCormick J, 1996, J CLIN EPIDEMIOL, V49, P619, DOI 10.1016/0895-4356(96)00039-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153	5	110	112	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					263	264		10.1136/bmj.317.7153.263	http://dx.doi.org/10.1136/bmj.317.7153.263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677220	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000075081900027
J	Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC				Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC		Study of Osteoporotic Fractures Res Grp	Physical activity and osteoporotic fracture risk in older women	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	BONE-MINERAL DENSITY; HIP FRACTURE; POSTMENOPAUSAL WOMEN; EXERCISE; CALCIUM	Background: Physical activity has been related to enhanced bone mass and improved physical functioning and thus may reduce the risk for osteoporotic fracture. Objective: To determine whether higher levels of physical activity are related to lower incidence of hip, wrist, and vertebral fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore, Maryland; Portland, Oregon; Minneapolis, Minnesota; and the Monongahela Valley, Pennsylvania. Participants: 9704 nonblack women 65 years of age or older. Measurements: Physical activity was assessed by questionnaire at baseline. Hip and wrist fractures were followed for an average of 7.6 years. The incidence of vertebral fracture was determined morphometrically by using radiography at baseline and an average of 3.7 years later. Results: Higher levels of leisure time, sport activity, and household chores and fewer hours of sitting daily were associated with a significantly reduced relative risk for hip fracture after adjustment for age, dietary factors, falls at baseline, and functional and health status. Very active women (fourth and fifth quintiles) had a statistically significant 36% reduction in hip fractures (relative risk, 0.64 [95% CI, 0.45 to 0.89]) compared with the least active women (lowest quintile). The intensity of physical activity was also related to fracture risk: Moderately to vigorously active women had statistically significant reductions of 42% and 33% in risk for hip and vertebral fractures, respectively, compared with inactive women. Total physical activity, hours of household chores per day, and hours of sitting per day were not significantly associated with wrist or vertebral fractures. Conclusions: Among older community-dwelling women, physical activity is associated with a reduced risk for hip fracture but not wrist or vertebral fracture.	Univ Vermont, Coll Med, Burlington, VT USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Minnesota, Vet Affairs Med Ctr, Minneapolis, MN USA	University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Gregg, EW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Highway NE,Mailstop K-10, Atlanta, GA 30341 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036; Gregg, Edward/0000-0003-2381-6822	NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582, 1-R01-AR35583] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583, R01AR035582] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baudoin C, 1996, BONE, V18, pS149, DOI 10.1016/8756-3282(95)00496-3; BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1992, J BONE MINER RES, V7, P639; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; CHILIBECK PD, 1995, SPORTS MED, V19, P103, DOI 10.2165/00007256-199519020-00003; CHRISTIANSEN C, 1991, AM J MED, V90, P107; COUPLAND C, 1993, J EPIDEMIOL COMMUN H, V47, P441, DOI 10.1136/jech.47.6.441; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; Grisso JA, 1997, AM J EPIDEMIOL, V145, P786, DOI 10.1093/oxfordjournals.aje.a009171; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MELTON LJ, 1995, J BONE MINER RES, V10, P175; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NEVITT MC, 1992, FALLS BALANCE GAIT D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Paganini-Hill A, 1991, Epidemiology, V2, P16; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Snow-Harter C, 1991, Exerc Sport Sci Rev, V19, P351; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; Stevens JA, 1997, ANN EPIDEMIOL, V7, P54, DOI 10.1016/S1047-2797(96)00110-X; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889	33	246	251	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					81	88		10.7326/0003-4819-129-2-199807150-00002	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669990				2022-12-24	WOS:000074852000001
J	Berkenkamp, S; Kirpekar, F; Hillenkamp, F				Berkenkamp, S; Kirpekar, F; Hillenkamp, F			Infrared MALDI mass spectrometry of large nucleic acids	SCIENCE			English	Article							IONS; RNA; PCR	Mass spectrometry has become an increasingly important tool of high accuracy, efficiency, and speed for the routine analysis of nucleic acids. To make it useful for large-scale sequencing of genomic material as required for example in genotyping and clinical diagnosis, it is necessary to find approaches that allow the analysis of sequences much larger than the 100 nucleotides currently possible. Matrix-assisted laser desorption/ionization (MALDI) mass spectra of synthetic DNA, restriction enzyme fragments of plasmid DNA, and RNA transcripts up to a size of 2180 nucleotides are reported. The demonstrated mass accuracy of 1 percent or better and the sample requirement of a few femtomoles or Less surpass all currently available techniques for the analysis of large nucleic acids. DNA and RNA can be analyzed with only a limited investment in sample purification.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark	University of Munster; University of Southern Denmark	Hillenkamp, F (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.	hillenk@uni-muenster.de		Kirpekar, Finn/0000-0003-1901-2266				Berkenkamp S, 1997, RAPID COMMUN MASS SP, V11, P1399; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; Fuerstenau SD, 1995, RAPID COMMUN MASS SP, V9, P1528, DOI 10.1002/rcm.1290091513; HOPERT A, 1993, J IMMUNOL METHODS, V164, P91, DOI 10.1016/0022-1759(93)90279-G; KIRPEKAR F, 1994, NUCLEIC ACIDS RES, V22, P3866, DOI 10.1093/nar/22.19.3866; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LIMBACH PA, 1995, J AM SOC MASS SPECTR, V6, P27, DOI 10.1016/1044-0305(94)00086-F; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Muddiman DC, 1996, ANAL CHEM, V68, P3705, DOI 10.1021/ac960689j; Naito Y, 1997, J AM SOC MASS SPECTR, V8, P737, DOI 10.1016/S1044-0305(97)00083-4; Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; NUI S, 1998, J AM SOC MASS SPECTR, V9, P1; Ross PL, 1997, ANAL CHEM, V69, P3966, DOI 10.1021/ac970312t	15	182	206	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					260	262		10.1126/science.281.5374.260	http://dx.doi.org/10.1126/science.281.5374.260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657721				2022-12-24	WOS:000074714200050
J	Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A				Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A			Are current regulations for approval of in vitro diagnostic devices adequate?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TESTS		New England Pediat LLP, Stamford, CT 06902 USA; Carolinas Med Ctr, New Britain, CT USA		Levine, D (corresponding author), New England Pediat LLP, 166 W Broad St,Suite 103, Stamford, CT 06902 USA.	ARosen45@aol.com						ALPERT S, 1998, SUBM 510K CHANG EX D; *AM AC PED, 1997, 1997 REED BOOK REP C, V199, P329; BANKS PM, 1993, HUM PATHOL, V24, P1153, DOI 10.1016/0046-8177(93)90208-X; BONE RC, 1995, CRIT CARE MED, V23, P1756; BURLINGTON DB, 1997, FDA PUBLIC HLTH ADVI; BURLINGTON DB, 1997, FDA SAFETY ALERT RIS; DOSHI ML, 1986, AM J PUBLIC HEALTH, V76, P512, DOI 10.2105/AJPH.76.5.512; Genel M, 1997, PEDIATRICS, V99, P597, DOI 10.1542/peds.99.4.597; LEVINE D, 1994, PEDIATRICS, V94, P892; Levine D, 1997, PEDIATRICS, V100, P267, DOI 10.1542/peds.100.2.267; RHEINSTEIN PH, 1993, AM FAM PHYSICIAN, V48, P636; SAVAGE RA, 1994, HUM PATHOL, V25, P548, DOI 10.1016/0046-8177(94)90131-7; *US DEP HHS, 1992, REV CRIT IN VITR DIA, P1; WAGNER L, 1997, ARCH PATHOL LAB MED, V121, P539; Wilson M, 1997, J CLIN MICROBIOL, V35, P3112, DOI 10.1128/JCM.35.12.3112-3115.1997; 1997, NY TIEMS        0724, pA20	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					187	189		10.1001/jama.280.2.187	http://dx.doi.org/10.1001/jama.280.2.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669797				2022-12-24	WOS:000074608400038
J	Schulz, H; Hennecke, H; Thony-Meyer, L				Schulz, H; Hennecke, H; Thony-Meyer, L			Prototype of a heme chaperone essential for cytochrome c maturation	SCIENCE			English	Article							ESCHERICHIA-COLI; BRADYRHIZOBIUM-JAPONICUM; BIOGENESIS; CONSTRUCTION; PERIPLASM; CLEAVAGE; BACTERIA; PATHWAY; SYSTEM; C(550)	Heme, the iron-containing cofactor essential for the activity of many enzymes, is incorporated into its target proteins by unknown mechanisms. Here, an Escherichia coli hemoprotein, CcmE, was shown to bind heme in the bacterial periplasm by way of a single covalent bond to a histidine. The heme was then released and delivered to apocytochrome c. Thus, CcmE can be viewed as a heme chaperone guiding heme to its appropriate biological partner and preventing illegitimate complex formation.	ETH Zurich, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thony-Meyer, L (corresponding author), ETH Zurich, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	lthoeny@micro.biol.ethz.ch						BASILE G, 1980, J BIOL CHEM, V255, P7181; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldman BS, 1998, MOL MICROBIOL, V27, P871, DOI 10.1046/j.1365-2958.1998.00708.x; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GRELLET F, 1996, U72502 GENBANK; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Zufferey R, 1998, J BIOL CHEM, V273, P6452, DOI 10.1074/jbc.273.11.6452	24	161	174	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1998	281	5380					1197	1200		10.1126/science.281.5380.1197	http://dx.doi.org/10.1126/science.281.5380.1197			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712585				2022-12-24	WOS:000075531200055
J	Wijnen, JT; Vasen, HFA; Khan, PM; Zwinderman, AH; van der Klift, H; Mulder, A; Tops, C; Moller, P; Fodde, R; Menko, F; Taal, B; Nagengast, F; Brunner, H; Kleibeuker, J; Sijmons, R; Griffioen, G; Brocker-Vriends, A; Bakker, E; van Leeuwen-Cornelisse, I; Meijers-Heijboer, A; Lindhout, D; Breuning, M; Post, J; Schaap, C; Apold, J; Heimdal, K; Bertario, L; Bisgaard, ML; Goetz, P				Wijnen, JT; Vasen, HFA; Khan, PM; Zwinderman, AH; van der Klift, H; Mulder, A; Tops, C; Moller, P; Fodde, R; Menko, F; Taal, B; Nagengast, F; Brunner, H; Kleibeuker, J; Sijmons, R; Griffioen, G; Brocker-Vriends, A; Bakker, E; van Leeuwen-Cornelisse, I; Meijers-Heijboer, A; Lindhout, D; Breuning, M; Post, J; Schaap, C; Apold, J; Heimdal, K; Bertario, L; Bisgaard, ML; Goetz, P			Clinical findings with implications for genetic testing in families with clustering of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRADIENT-GEL-ELECTROPHORESIS; MICROSATELLITE INSTABILITY; COLON-CANCER; MUTATION ANALYSIS; APC GENE; HNPCC; POLYPOSIS; MAJORITY; RECEPTOR; HOMOLOG	Background Germ-line mutations in DNA mismatch-repair genes (MSH2, MLH1, PIMS1, PMS2, and MSH6) cause susceptibility to hereditary nonpolyposis colorectal cancer. We assessed the prevalence of MSH2 and MLH1 mutations in families suspected of having hereditary nonpolyposis colorectal cancer and evaluated whether clinical findings can predict the outcome of genetic testing. Methods We used denaturing gradient gel electrophoresis to identify MSH2 and MLH1 mutations in 184 kindreds with familiar clustering of colorectal cancer or other cancers associated with hereditary nonpolyposis colorectal cancer. Information on the site of cancer, the age at diagnosis, and the number of affected family members was obtained from all families. Results Mutations of MSH2 or MLH1 were found in 47 of the 184 kindreds (26 percent). Clinical factors associated with these mutations were early age at diagnosis of colorectal cancer, the occurrence in the kindred of endometrial cancer or tumors of the small intestine, a higher number of family members with colorectal or endometrial cancer, the presence of multiple colorectal cancers or both colorectal and endometrial cancers in a single family member, and fulfillment of the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colorectal cancer (at least three family members in two or more successive generations must have colorectal cancer, one of whom is a first-degree relative of the other two; cancer must be diagnosed before the age of 50 in at least one family member; and familial adenomatous polyposis must be ruled out). Multivariate analysis showed that a younger age at diagnosis of colorectal cancer, fulfillment of the Amsterdam criteria, and the presence of endometrial cancer in the kindred were independent predictors of germ-line mutations of MSH2 or MLH1. These results were used to devise a logistic model for estimating the likelihood of a mutation in MSH2 and MLH1. Conclusions Assessment of clinical findings can improve the rate of detection of mutations of DNA mismatch-repair genes in families suspected of having hereditary nonpolyposis colorectal cancer. (N Engl J Med 1998;339:511-8.) (C)1998, Massachusetts Medical Society.	Fdn Detect Hereditary Tumors, NL-2333 AA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gastroenterol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; Leiden Univ, Med Ctr, Clin Genet Ctr, Leiden, Netherlands; Norwegian Radium Hosp, Unit Med Genet, Oslo, Norway; Vrije Univ Amsterdam, Univ Hosp, Amsterdam, Netherlands; Netherlands Canc Inst, Amsterdam, Netherlands; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Groningen Hosp, Groningen, Netherlands; Erasmus Univ, Rotterdam, Netherlands; Clin Genet Ctr, NL-3501 CA Utrecht, Netherlands; Clin Genet Ctr, Maastricht, Netherlands; Haukeland Hosp, N-5021 Bergen, Norway; Norwegian Radium Hosp, Oslo, Norway; Ist Nazl Tumori, I-20133 Milan, Italy; Univ Copenhagen, Hvidovre Hosp, Danish Hereditary Nonpolyposis Colorectal Canc Re, DK-2650 Hvidovre, Denmark; Charles Univ Prague, Prague, Czech Republic	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Oslo; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Radboud University Nijmegen; University of Groningen; Erasmus University Rotterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Oslo; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Copenhagen; Charles University Prague	Vasen, HFA (corresponding author), Fdn Detect Hereditary Tumors, Rijnsburgerweg 10,Poortgebouw Zuid, NL-2333 AA Leiden, Netherlands.		Sijmons, Rolf/E-5829-2012; Lindhout, Dick/AAH-5765-2019; Bakker, Egbert/D-3525-2009; Fodde, Riccardo/AAW-9394-2021; Breuning, Martijn H/E-3429-2010; Brunner, Han/C-9928-2013	Sijmons, Rolf/0000-0001-8446-2779; Bakker, Egbert/0000-0002-2843-7357; Fodde, Riccardo/0000-0001-9839-4324; Vasen, Hans/0000-0003-2682-2603; Lindhout, Dick/0000-0001-9580-624X; Bertario, Lucio/0000-0001-5653-1431				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Akiyama Y, 1997, CANCER RES, V57, P3920; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 1996, J MOL MED-JMM, V74, P547; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, CANCER RES, V55, P242; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1994, GUT, V35, P1262, DOI 10.1136/gut.35.9.1262; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300	38	293	309	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					511	518		10.1056/NEJM199808203390804	http://dx.doi.org/10.1056/NEJM199808203390804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709044				2022-12-24	WOS:000075447000004
J	Kim, J; Yu, W; Kovalski, K; Ossowski, L				Kim, J; Yu, W; Kovalski, K; Ossowski, L			Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay	CELL			English	Article							PLASMINOGEN-ACTIVATOR; CHORIOALLANTOIC MEMBRANE; METASTATIC ABILITY; CHICK-EMBRYO; TUMOR-CELLS; CARCINOMA; INVASION; UROKINASE; EXPRESSION; MODEL	Proteases are crucial for cancer metastasis, but due to lack of assays, their role in intravasation has not yet been tested. We have developed a human Alu sequence PCR-based assay to quantitate intravasated cells in an in vivo model. We demonstrated that metalloproteinases (MMPs), and most likely MMP-9, are required for intravasation by showing that marimastat, an inhibitor of MMPs, reduced intravasation by more than 90%, and that only tumor cell lines expressing MMP-9 intravasated. Cells with low surface urokinase plasminogen activator (uPA) and uPA receptor (uPAR) were also incapable of intravasation, despite the presence of high levels of MMP-9. We concluded that breaching of the vascular wall is a rate-limiting step for intravasation, and consequently for metastasis, and that cooperation between uPA/uPAR and MMP-9 is required to complete this step.	CUNY Mt Sinai Sch Med, Div Neoplast Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ossowski, L (corresponding author), CUNY Mt Sinai Sch Med, Div Neoplast Dis, New York, NY 10029 USA.				NCI NIH HHS [CA-40758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG PB, 1982, CANCER RES, V42, P1826; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DAVIES B, 1993, CANCER RES, V53, P2087; Eccles SA, 1996, CANCER RES, V56, P2815; FOLTZ CM, 1982, INTERACTION PLATELET, P353; HEARING VJ, 1988, CANCER RES, V48, P1270; Hua J, 1996, CANCER RES, V56, P5279; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; LENGYEL E, 1995, CANCER RES, V55, P963; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIRAYLOPEZ R, 1987, CANCER RES, V47, P3558; NoguchiTakino M, 1996, INT J ONCOL, V8, P97; OSSOWSKI L, 1980, CANCER RES, V40, P2300; OSSOWSKI L, 1992, CANCER RES, V52, P6754; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; POSTE G, 1980, CANCER RES, V40, P1636; RIZZO V, 1993, MICROVASC RES, V46, P320, DOI 10.1006/mvre.1993.1056; Shioda T, 1997, AM J PATHOL, V150, P2099; Sundareshan P, 1997, CANCER LETT, V113, P17, DOI 10.1016/S0304-3835(96)04552-1; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zubair AC, 1996, CANCER LETT, V107, P91, DOI 10.1016/0304-3835(96)04347-9	31	386	406	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					353	362		10.1016/S0092-8674(00)81478-6	http://dx.doi.org/10.1016/S0092-8674(00)81478-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708737	Bronze			2022-12-24	WOS:000075308400011
J	Nightingale, SL				Nightingale, SL			New combination therapy approved for hepatitis C relapse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-24	WOS:000075050200008
J	Catalano, SM; Shatz, CJ				Catalano, SM; Shatz, CJ			Activity-dependent cortical target selection by thalamic axons	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; RETINOTECTAL PROJECTION; SUBPLATE NEURONS; CONNECTIONS; RAT; TETRODOTOXIN; MORPHOLOGY; NEOCORTEX; CIRCUITS	Connections in the developing nervous system are thought to be formed initially by an activity-independent process of axon pathfinding and target selection and subsequently refined by neural activity. Blockade of sodium action potentials by intracranial infusion of tetrodotoxin in cats during the early period when axons from the Lateral geniculate nucleus (LCN) were in the process of selecting visual cortex as their target altered the pattern and precision of this thalamocortical projection. The majority of LCN neurons, rather than projecting to visual cortex, elaborated a significant projection within the subplate of cortical areas normally bypassed. Those axons that did project to their correct target were topographically disorganized. Thus, neural activity is required for initial targeting decisions made by thalamic axone as they traverse the subplate,	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Catalano, SM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Catalano, Susan/0000-0001-7278-3233	NEI NIH HHS [EY02838, EY06491] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; BOLZ J, 1992, J NEUROSCI, V12, P3054, DOI 10.1523/JNEUROSCI.12-08-03054.1992; Campbell G, 1997, VISUAL NEUROSCI, V14, P779, DOI 10.1017/S0952523800012724; CATALANO SM, UNPUB; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DALVA MB, 1994, J NEUROSCI, V14, P3588; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GOODMAN CS, 1993, NEURON S, V10, P77; HERRMANN K, 1995, P NATL ACAD SCI USA, V92, P11244, DOI 10.1073/pnas.92.24.11244; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KRISTT DA, 1979, ANAT EMBRYOL, V157, P217, DOI 10.1007/BF00305161; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLSON MD, 1994, J NEUROSCI, V14, P208; SCHMIDT JT, 1990, J NEUROBIOL, V21, P900, DOI 10.1002/neu.480210608; SHATZ CJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P472, DOI 10.1001/archopht.1993.01090040064031; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VALVERDE F, 1989, J COMP NEUROL, V290, P118, DOI 10.1002/cne.902900108	27	194	200	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					559	562		10.1126/science.281.5376.559	http://dx.doi.org/10.1126/science.281.5376.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677198				2022-12-24	WOS:000075012300040
J	Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M				Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M			Degradation signal masking by heterodimerization of MAT alpha 12 and MATa1 blocks their mutual destruction by the ubiquitin-proteasome pathway	CELL			English	Article							HOMEO DOMAIN; HOMEODOMAIN PROTEINS; IN-VIVO; YEAST; REPRESSOR; ALPHA-2; DNA; MUTAGENESIS; SEQUENCES; CHAINS	Proteolysis by the ubiquitin-proteasome pathway is often regulated, but the mechanisms underlying such regulation remain ill-defined. In Saccharomyces cerevisiae, cell type is controlled by the MAT transcription factors. The alpha 2 repressor is a known ubiquitin pathway substrate in cu haploid cells. We show that a1 is rapidly degraded in a haploids. In a/alpha diploids, alpha 2 and a1 are stabilized by heterodimerization. Association depends on N-terminal coiled-coil interactions between al and alpha 2. Residues in alpha 2 important for these interactions overlap a critical determinant of an alpha 2 degradation signal, which we delimit by extensive mutagenesis. Our data provide a detailed description of a natural ubiquitin-dependent degradation signal and point to a molecular mechanism for regulated turnover in which proteolytic signals are differentially masked in alternative multiprotein complexes.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hochstrasser, M (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046904, T32GM007183, R01GM046904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46904, GM07183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HARASHIMA S, 1989, MOL CELL BIOL, V9, P4523, DOI 10.1128/MCB.9.10.4523; HO YC, 1994, EMBO J, V13, P1403; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kopski KM, 1997, GENETICS, V147, P409; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486	35	136	139	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					217	227		10.1016/S0092-8674(00)81421-X	http://dx.doi.org/10.1016/S0092-8674(00)81421-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695950	Bronze			2022-12-24	WOS:000075020100010
J	Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M				Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M			Developmental selection of var gene expression in Plasmodium falciparum	NATURE			English	Article							HUMAN CEREBRAL MALARIA; INFECTED ERYTHROCYTES; ANTIGENIC VARIATION; PROTEINS; CYTOADHERENCE; PHENOTYPES; ADHERENCE; DIVERSE; FAMILY	The protozoan Plasmodium falciparum causes lethal malaria(1). Adhesion of erythrocytes infected with P. falciparum to vascular endothelium and to uninfected red blood cells (rosetting) maybe involved in the pathogenesis of severe malaria(2-4). The binding is mediated by the antigenically variant erythrocyte-membrane-protein-1 (PfEMP-1)(5-8), which is encoded by members of the P. falciparum var gene famjily(9,10). The control of expression and switching of var genes seems to lack resemblance.to mechanisms operating in variant gene families of other microbial pathogens(11,12). Here we show that multiple, distinct var gene transcripts (about 24 or more) can be detected by reverse transcription and polymerase chain reaction in bulk cultures of the rosetting parasite FCR3S1.2, despite the adhesive homogeneity of the cultures. We also detected several var transcripts in single erythrocytes infected with a ring-stage parasite of FCR3S1.2, and found that different var genes are transcribed simultaneously from several chromosomes in the same cell. In contrast, we detected only one var transcript, FCR3S1.2 var-1, which encodes the rosetting PfEMP-1 protein(13), in individual rosette-adhesive trophozoite-infected cells, and we found only one PfEMP-1 type at the erythrocyte surface by labelling with (125)iodine and immunoprecipitation. We conclude that a single P. falciparum parasite simultaneously transcribes multiple var genes but, through a developmentally regulated process, selects only one PfEMP-1 to reach the surface of the host cell.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Changchun Univ Agr & Anim Sci, Changchun 130062, Peoples R China; Astra Res Ctr, Bangalore, Karnataka, India	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Jilin University	Wahlgren, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.							Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; PIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	24	259	265	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					392	395		10.1038/28660	http://dx.doi.org/10.1038/28660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690477				2022-12-24	WOS:000074968800057
J	Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A				Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A			Uncoupling of nonreceptor tyrosine kinases from PLC-gamma 1 in an SLP-76-deficient T cell	SCIENCE			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; GENE-EXPRESSION; ACTIVATION; PHOSPHORYLATION; SLP-76; PROTEIN; PHOSPHOPROTEIN; GRB2	Activation of nonreceptor protein tyrosine kinases (PTKs) is essential for T cell receptor (TCR) responsiveness; however, the function of individual PTK substrates is often uncertain. A mutant T cell Line was isolated that Lacked expression of SLP-76 (SH2 domain-containing Leukocyte protein of 76 kilodaltons), a hematopoietically expressed adaptor protein and PTK substrate. SLP-76 was not required for TCR-induced tyrosine phosphorylation of most proteins, but was required for optimal tyrosine phosphorylation and activation of phospholipase C-gamma l (PLC-gamma l), as well as Ras pathway activation. TCR-inducible gene expression was dependent on SLP-76. Thus, coupling of TCR-regulated PTKs to downstream signaling pathways requires SLP-76.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, Box 0795, San Francisco, CA 94143 USA.			Kadlecek, Theresa/0000-0002-1020-8169; Yablonski, Deborah/0000-0003-2979-0440	NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER; NCI NIH HHS [CA72531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fang N, 1996, J IMMUNOL, V157, P3769; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P471; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	32	358	364	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					413	416		10.1126/science.281.5375.413	http://dx.doi.org/10.1126/science.281.5375.413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665884				2022-12-24	WOS:000074918800047
J	Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR				Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR			Combined effects of angiostatin and ionizing radiation in antitumour therapy	NATURE			English	Article							ANGIOGENESIS; CANCER; SUPPRESSION; CARCINOMA; DISEASE; AGENTS	Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for tumour progression(1-5). Angiostatin, a proteolytic fragment of plasminogen(6) that was first isolated from the serum and urine of tumour-bearing mice(7), inhibits angiogenesis and thereby growth of primary(8) and metastatic(7,9,10) tumours. Radiotherapy is important in the treatment of many human cancers, but is often unsuccessful because of tumour cell radiation resistance(11,12). Here we combine radiation with angiostatin to target tumour vasculature that is genetically stable and therefore less likely to develop resistance(13-15). The results show an antitumour interaction between ionizing radiation and angiostatin for four distinct tumour types, at doses of radiation that are used in radiotherapy. The combination produced no increase in toxicity towards normal tissue. In vitro studies show that radiation and angiostatin have combined cytotoxic effects on endothelial cells, but not tumour cells. In vivo studies show that these agents, in combination, target the tumour vasculature. Our results provide support for combining ionizing radiation with angiostatin to improve tumour eradication without increasing deleterious effects.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Chicago; University of Chicago; University of Chicago; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weichselbaum, RR (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	rrw@rover.uchicago.edu	Sukhatme, Vikas/W-2776-2019; Gorski, David/AAE-6399-2022	Gorski, David/0000-0002-9805-6699				Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOULDS G, 1985, INT J CLIN PHARM RES, V2, P79; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HANAHAN D, 1996, J NATL CANCER I, V88, P1091; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Sim BKL, 1997, CANCER RES, V57, P1329; TEICHER BA, 1992, CANCER RES, V52, P6702; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V14, P907, DOI 10.1016/0360-3016(88)90013-2; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684	15	608	639	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					287	291		10.1038/28412	http://dx.doi.org/10.1038/28412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685160				2022-12-24	WOS:000074851900051
J	Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ				Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ			Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; POLYMORPHISM	Serum paraoxonase (PON1) is an esterase that is associated with high-density lipoproteins (HDLs) in the plasma; it is involved in the detoxification of organophosphate insecticides such as parathion and chlorpyrifos(1-3). PON1 may also confer protection against coronary artery disease by destroying pro-inflammatory oxidized lipids present in oxidized low-density lipoproteins (LDLs)(4-8). To study the role of PON1 in vivo we created PON1-knockout mice by gene targeting. Compared with their wild-type littermates, PON1-deficient mice were extremely sensitive to the toxic effects of chlorpyrifos oxon, the activated form of chlorpyrifos, and were more sensitive to chlorpyrifos itself. HDLs isolated from PON1-deficient mice were unable to prevent LDL oxidation in a co-cultured cell model of the artery wall, and both HDLs and LDLs isolated from PON1-knockout mice were more susceptible to oxidation by co-cultured cells than the lipoproteins from wild-type littermates. When fed on a high-fat, high-cholesterol diet, PON1-null mice were more susceptible to atherosclerosis than their wild-type littermates.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lusis, AJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, 47-123 CHS, Los Angeles, CA 90095 USA.							COSTA LG, 1990, TOXICOL APPL PHARM, V103, P66, DOI 10.1016/0041-008X(90)90263-T; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; Heinecke JW, 1998, AM J HUM GENET, V62, P20, DOI 10.1086/301691; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798; LI WF, 1995, TOXICOL LETT, V76, P219, DOI 10.1016/0378-4274(95)80006-Y; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MURPHY SD, 1980, TOXICOLOGY BASIC SCI, P357; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; TAFURI J, 1987, ANN EMERG MED, V16, P193, DOI 10.1016/S0196-0644(87)80015-X; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	17	913	950	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					284	287		10.1038/28406	http://dx.doi.org/10.1038/28406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685159				2022-12-24	WOS:000074851900050
J	Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ				Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ			Clinical, physiological, and radiological study of a new purpose-designed artificial bowel sphincter	LANCET			English	Article							FECAL INCONTINENCE; ANAL INCONTINENCE	Background Studies of the use of artificial urinary sphincters for faecal incontinence have led to refinement and adaptation of such sphincters to the anatomy of the anal region. We aimed to test this new device. Methods Six women, median age 53 (range 32-58) years, who were unsuitable for sphincter repair, had an artificial bowel sphincter implanted as a one-stage procedure without colostomy cover. Clinical assessment, physiological testing, and endosonography were done before and after the operation. Plain radiography, three-dimensional endosonography, and magnetic-resonance imaging were done after the operation, to define its anatomical location. Results Median follow-up was 10 (range 5-13) months and the device was functional in five patients. In one patient, the device was removed after ulceration through the skin, Of the patients with intact devices, Wexner incontinence scores improved from a median of 19 (18-20) of 20 before the operation, to 3 (0-6) of 20 after the operation, Median anal pressure at rest significantly increased from 60 (range 30-80) cm H2O to 110 (100-120) cm H2O, Functional anal-canal length varied after the operation from 3.3 cm to 3.8 cm. There was no significant change in the maximum tolerated volume of the rectum (140 [80-230] vs 100 [75-250] mt), or rectal compliance (2.9 [2.8-6.0] cm H2O/mL vs 3.5 [2.3-7.3] cm H2O/mL). All the imaging techniques accurately located the implant relative to the anal canal and pelvic floor in each patient. Interpretation The new artificial bowel sphincter provided a good functional result in five of the six patients, the surgical procedure was straightforward, and the maximum resting anal pressure rose without affecting rectal function. The ease of visualisation of such implants in situ should aid simple management of complications, should they arise.	St Marks Hosp, Dept Physiol, London EC1V 2PS, England; St Marks Hosp, Dept Radiol, London EC1V 2PS, England; St Marks Hosp, Dept Surg, London EC1V 2PS, England	Imperial College London; Imperial College London; Imperial College London	Nicholls, RJ (corresponding author), St Marks Hosp, Dept Surg, Northwick Pk,Watford Rd, Harrow HA1 3UJ, Middx, England.		Halligan, Steve/C-5875-2009	Halligan, Steve/0000-0003-0632-5108; Gold, Darren/0000-0003-4478-9747				BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; CHRISTIANSEN J, 1987, LANCET, V1, P244; Geerdes BP, 1996, DIS COLON RECTUM, V39, P912, DOI 10.1007/BF02053991; JORGE JMN, 1993, SOUTH MED J, V86, P924, DOI 10.1097/00007611-199308000-00016; KAMM MA, 1990, DIS COLON RECTUM, V33, P419, DOI 10.1007/BF02156270; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; Lehur PA, 1996, DIS COLON RECTUM, V39, P1352, DOI 10.1007/BF02054523; LEO ME, 1993, J UROLOGY, V150, P1412, DOI 10.1016/S0022-5347(17)35793-2; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; NEILL ME, 1981, BRIT J SURG, V68, P531, DOI 10.1002/bjs.1800680804; Scott F B, 1973, Urology, V1, P252; Wong WD, 1996, DIS COLON RECTUM, V39, P1345	13	82	85	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					105	109		10.1016/S0140-6736(97)11427-1	http://dx.doi.org/10.1016/S0140-6736(97)11427-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672276				2022-12-24	WOS:000074775100014
J	Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ				Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ			Interaction of human Arp2/3 complex and the Listeria monocytogenes ActA protein in actin filament nucleation	SCIENCE			English	Article							HOST-CELL ACTIN; PROLINE-RICH REGION; SACCHAROMYCES-CEREVISIAE; OWN CYTOSKELETON; FOCAL ADHESION; MOTILITY; GENE; POLYMERIZATION; MOVEMENT; PROFILIN	Actin filament assembly at the cell surface of the pathogenic bacterium Listeria monocytogenes requires the bacterial ActA surface protein and the host cell Arp2/3 complex. Purified Arp2/3 complex accelerated the nucleation of actin polymerization in vitro, but pure ActA had no effect. However, when combined, the Arp2/3 complex and ActA synergistically stimulated the nucleation of actin filaments. This mechanism of activating the host Arp2/3 complex at the L. monocytogenes surface may be similar to the strategy used by cells to control Arp2/3 complex activity and hence the spatial and temporal distribution of actin polymerization.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; University of California System; University of California Berkeley	Welch, MD (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868	NIAID NIH HHS [AI26919] Funding Source: Medline; NIGMS NIH HHS [GM48027] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1996, EMBO J, V15, P6426, DOI 10.1002/j.1460-2075.1996.tb01034.x; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huang ME, 1996, YEAST, V12, P839, DOI 10.1002/(SICI)1097-0061(199607)12:9<839::AID-YEA982>3.0.CO;2-8; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; Machesky LM, 1997, BIOCHEM J, V328, P105; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1992, J CELL BIOL, V118, P71, DOI 10.1083/jcb.118.1.71; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; WELCH MD, 1998, METHODS ENZYMOL, V298; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	41	411	439	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					105	108		10.1126/science.281.5373.105	http://dx.doi.org/10.1126/science.281.5373.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651243				2022-12-24	WOS:000074685800048
J	Rainey, PB; Travisano, M				Rainey, PB; Travisano, M			Adaptive radiation in a heterogeneous environment	NATURE			English	Article							EVOLUTION; ADAPTATION; BACTERIA; DIVERSIFICATION; POLYMORPHISM; POPULATIONS; DIVERGENCE; TESTS	Successive adaptive radiations have played a pivotal role in the evolution of biological diversity(1-3). The effects of adaptive radiation are often seen(4-6), but the underlying causes are difficult to disentangle and remain unclear(7-9). Here we examine directly the role of ecological opportunity and competition in driving genetic diversification. We use the common aerobic bacterium Pseudomonas fluorescens(10), which evolves rapidly under novel environmental conditions to generate a large repertoire of mutants(11-13). When provided with ecological opportunity (afforded by spatial structure), identical populations diversify morphologically, but when ecological opportunity is restricted there is no such divergence. In spatially structured environments, the evolution of variant morphs follows a predictable sequence and we show that competition among the newly evolved niche-specialists maintains this variation. These results demonstrate that the elementary processes of mutation and selection alone are suifficient to promote rapid proliferation of new designs and support the theory that trade-offs in competitive ability drive adaptive radiation(14,15).	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Rainey, PB (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	prainey@worf.molbiol.ox.ac.uk	Travisano, Michael/AAI-4809-2020; Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; Bell G, 1997, HEREDITY, V78, P498, DOI 10.1038/hdy.1997.78; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; CHARLESWORTH B, 1982, EVOLUTION, V46, P16; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; DOBZHANSKY T, 1972, SCIENCE, V177, P664, DOI 10.1126/science.177.4050.664; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Gould S.J, 1989, WONDERFUL LIFE BURGE; Grant PR, 1986, ECOLOGY EVOLUTION DA; Haldane J. B. S., 1932, CAUSES EVOLUTION; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HEDRICK PW, 1986, ANNU REV ECOL SYST, V17, P535; HOPF FA, 1993, EVOL ECOL, V7, P142, DOI 10.1007/BF01239385; KLEIN D, 1993, NATURE, V364, P330, DOI 10.1038/364330a0; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; MORRIS SC, 1979, SCI AM, V241, P122, DOI 10.1038/scientificamerican0779-122; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Otte D., 1989, SPECIATION ITS CONSE; Rainey PB, 1996, MOL MICROBIOL, V19, P521, DOI 10.1046/j.1365-2958.1996.391926.x; Rainey PB, 1993, ADV MICROB ECOL, P263; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; SHAPRIO JA, 1986, BACTERIA BIOL PSEUDO, P27; TAPER MT, 1994, OXFORD SURVEYS EVOLU, V8, P63; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1996, ECOLOGY, V77, P2119, DOI 10.2307/2265706	30	860	878	3	425	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					69	72		10.1038/27900	http://dx.doi.org/10.1038/27900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665128				2022-12-24	WOS:000074579600049
J	Roingeard, P; Brand, D				Roingeard, P; Brand, D			Budding of human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHU Tours, F-37044 Tours, France	CHU Tours	Roingeard, P (corresponding author), CHU Tours, F-37044 Tours, France.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					32	32		10.1056/NEJM199807023390106	http://dx.doi.org/10.1056/NEJM199807023390106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647877				2022-12-24	WOS:000074500000006
J	Tzivion, G; Luo, ZJ; Avruch, J				Tzivion, G; Luo, ZJ; Avruch, J			A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity	NATURE			English	Article							14-3-3-PROTEINS; ACTIVATION; C-RAF-1; IDENTIFICATION; PATHWAY; BINDING	cRaf-1 is a mitogen-activated protein kinase that is the main effector recruited by GTP-bound Ras in order to activate the MAP kinase pathway(1). Inactive Raf is found in the cytosol in a complex with Hsp90, Hsp50 (Cdc37)(2,3) and the 14-3-3 proteins(4). GTP-bound Ras binds Raf and is necessary but not sufficient for the stable activation of Raf that occurs in response to serum, epidermal growth factor, platelet-derived growth factor or insulin(5-8). These agents cause a two- to threefold increase in overall phosphorylation of Raf on serine/threonine residues(8,9), and treatment of cRaf-1 with protein (serine/threonine) phosphatases can deactivate it, at least partially(10). The role of 14-3-3 proteins in the regulation of Raf's kinase activity is uncertain(4,11) and is investigated here. Active Raf can be almost completely deactivated in vitro by displacement of 14-3-3 using synthetic phosphopeptides. Deactivation can be substantially reversed by addition of purified recombinant bacterial 14-3-3; however, Raf must have been previously activated in vivo to be reactivated by 14-3-3 in vitro. The ability of 14-3-3 to support Raf activity is dependent on phosphorylation of serine residues on Raf and on the integrity of the 14-3-3 dimer; mutant monomeric forms of 14-3-3, although able to bind Raf in vivo, do not enable Raf to be activated in vivo or restore Raf activity after displacement of 14-3-3 in vitro. The 14-3-3 protein is not required to induce dimerization of Raf, We propose that dimeric 14-3-3 is needed both to maintain Raf in an inactive state in the absence of GTP-bound Ras and to stabilize an active conformation of Raf produced during activation in vivo.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu	Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; 				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KNOCKEL L, 1997, GENE DEV, V11, P1140; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; STANCATO LE, 1995, J BIOL CHEM, V268, P21711; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	383	391	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					88	92		10.1038/27938	http://dx.doi.org/10.1038/27938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665134				2022-12-24	WOS:000074579600055
J	Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM				Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM			beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia	LANCET			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASHKENAZI JEWS; CHOLESTEROL; MUTATION; POPULATION; IDENTIFICATION; FREQUENCIES; GENOTYPE; DNA	Background Gaucher's disease is the most common lysosomal storage disorder, caused by deficiency of glucocerebrosidase resulting from homozygosity for any of several mutations of the glucocerebrosidase gene locus. Affected people have decreased concentrations of LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C). We assessed the association between mutations in the glucocerebrosidase locus and hypo-alpha-lipoproteinaemia. Methods We studied 258 people from 43 unrelated Spanish families. 57 participants were affected, 137 were nonaffected carriers, and 64 were non-carriers. We determined glucocerebrosidase genotypes and measured plasmid lipids, apolipoproteins A-I, B, and E, and leucocyte glucocerebrosidase activity. Findings The most common glucocerebrosidase mutations were N37OS (45%), L444P (23%), and G377S (5%). Deletions and recombinants accounted for another 5%, and point mutations in exons 5, 6, 9, and 10 were present in 12%, Affected participants had lower LDL-C and HDL-C concentrations than non-affected carriers (p<0.001) and non-carriers (p<0 001). HDL-C values were also significantly different between the non-affected carriers and non-carriers. Mutations at this locus may account for as much as 19.5% of the genetic variability in HDL-C in the population studied. Interpretation Heterozygosity for these mutations at the glucocerebrosidase locus does not result in clinical expression of Gaucher's disease but can decrease HDLC concentrations, Given the high frequency of these mutations, the glucocerebrosidase locus might lead to familial low alpha-lipoproteinaemia in up to 2% of the general population and be one of the most common known genetic causes of HDL-C.	Univ Zaragoza, Fac Sci, Dept Biochem Mol & Cellular Biol, E-50009 Zaragoza, Spain; Univ Hosp, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Haematol, Zaragoza, Spain; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA; Tufts Univ, Lipid Metab Lab JM HNRCA, Boston, MA 02111 USA	University of Zaragoza; Miguel Servet University Hospital; Miguel Servet University Hospital; Miguel Servet University Hospital; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA)	Ordovas, JM (corresponding author), Tufts Univ, JM USDA Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.	ordovas_li@hnrc.tufts.edu	Calvo, Juan Ignacio Pérez/I-4194-2019; MOZAS, PILAR/AAR-8624-2021; Ordovas, Jose/B-8727-2013	Calvo, Juan Ignacio Pérez/0000-0003-2361-9941; Ordovas, Jose/0000-0002-7581-5680; Myers, Richard/0000-0002-8365-2674	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AMARAL O, 1993, BIOCHEM MED METAB B, V49, P97, DOI 10.1006/bmmb.1993.1011; BEUTLER E, 1990, CLIN CHIM ACTA, V194, P161, DOI 10.1016/0009-8981(90)90130-K; BEUTLER E, 1994, HUM MUTAT, V4, P212, DOI 10.1002/humu.1380040307; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1994, MOL MED, V1, P82, DOI 10.1007/bf03403534; BEUTLER E, 1993, AM J HUM GENET, V52, P85; Beutler E., 1995, METABOLIC MOL BASES, P2641; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; Cormand B, 1997, HUM GENET, V100, P75, DOI 10.1007/s004390050468; DeMarchi JM, 1996, HUM MUTAT, V8, P116; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; GINSBERG H, 1984, CLIN GENET, V26, P109; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRABOWSKI GA, 1993, ADV HUM GENET, V21, P377; LACERDA L, 1994, CLIN GENET, V45, P298; LAUBSCHER KH, 1994, HUM MUTAT, V3, P411, DOI 10.1002/humu.1380030418; LE NA, 1988, METABOLISM, V37, P240, DOI 10.1016/0026-0495(88)90102-3; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MIDDLETONPRICE HR, 1988, HUM GENET, V79, P283, DOI 10.1007/BF00366253; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MISTRY PK, 1995, LANCET, V346, P982, DOI 10.1016/S0140-6736(95)91680-6; *NIH, 1995, GAUCH DIS CURR ISS D; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; UCHIYAMA A, 1994, HUM MOL GENET, V3, P1183, DOI 10.1093/hmg/3.7.1183; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	27	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1919	1923		10.1016/S0140-6736(97)09490-7	http://dx.doi.org/10.1016/S0140-6736(97)09490-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654259	hybrid			2022-12-24	WOS:000074464700009
J	Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL				Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL			Modulation of AMPA receptor unitary conductance by synaptic activity	NATURE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; EXCITATORY AMINO-ACIDS; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; SILENT SYNAPSES; BRAIN-SLICES; GLUTAMATE; CHANNELS	Activity-dependent alteration in synaptic strength is a fundamental property of the vertebrate central nervous system and is thought to underlie learning and memory. The most extensively studied model of activity-dependent synaptic plasticity is longterm potentiation (LTP) of glutamate-responsive (glutamatergic) synapses, a widespread phenomenon involving multiple mechanisms(1). The best characterized form of LTP occurs in the CA1 region of the hippocampus, in which LTP is initiated by transient activation of NMDA (N-methyl-D-aspartate) receptors and is expressed as a persistent increase in synaptic transmission through AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole pionate) receptors(2). This increase is due, at least in part, to a postsynaptic modification of AMPA-receptor function(3); this modification could be caused by an increase in the number of receptors, their open probability, their kinetics or their single-channel conductance. Here we show that the induction of LTP in the CA1 region of the hippocampus is often associated with an increase in single-channel conductance of AMPA receptors. This shows that elementary channel properties can be rapidly modified by synaptic activity and provides an insight into one molecular mechanism by which glutamatergic synapses can alter their strength.	Univ Bristol, Sch Med Sci, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Collingridge, GL (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, Univ Walk, Bristol BS8 1TD, Avon, England.		collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLAY JR, 1983, BIOPHYS J, V42, P151, DOI 10.1016/S0006-3495(83)84381-1; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HINES M, 1984, INT J BIOMED COMPUT, V15, P69, DOI 10.1016/0020-7101(84)90008-4; HOMES WR, 1990, J NEUROPHYSIOL, V63, P1148; Isaac JTR, 1996, P NATL ACAD SCI USA, V93, P8710, DOI 10.1073/pnas.93.16.8710; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; SHRIKE AM, 1997, J NEUROPHYSIOL, V78, P2682; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	30	397	411	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					793	797		10.1038/31709	http://dx.doi.org/10.1038/31709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655394				2022-12-24	WOS:000074433100051
J	Choo, V				Choo, V			Outlook for sexually transmitted diseases	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Choo, V (corresponding author), Lancet, London WC1B 3SL, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1832	1832		10.1016/S0140-6736(05)78803-6	http://dx.doi.org/10.1016/S0140-6736(05)78803-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652665				2022-12-24	WOS:000074347100008
J	Marshall, SJ				Marshall, SJ			On being a ginseng connoisseur	LANCET			English	Editorial Material																			0	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1898	1898		10.1016/S0140-6736(05)78859-0	http://dx.doi.org/10.1016/S0140-6736(05)78859-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652710				2022-12-24	WOS:000074347100072
J	Li, P; Zhuo, M				Li, P; Zhuo, M			Silent glutamatergic synapses and nociception in mammalian spinal cord	NATURE			English	Article							LONG-TERM POTENTIATION; NUCLEI RETICULARIS-GIGANTOCELLULARIS; SUBSTANTIA GELATINOSA NEURONS; SUPERFICIAL DORSAL HORN; DESCENDING FACILITATION; PARS-ALPHA; RAT; INFLAMMATION; PLASTICITY; TRANSMISSION	Neurons in the superficial dorsal horn of the spinal cord are important for conveying sensory information from the periphery to the central nervous system(1,2). Some synapses between primary afferent fibres and spinal dorsal horn neurons may be inefficient or silent(3). Ineffective sensory transmission could result from a small postsynaptic current that fails to depolarize the cell to threshold for an action potential or from a cell with a normal postsynaptic current but an increased threshold for action potentials. Here we show that some cells in the superficial dorsal horn of the lumbar spinal cord have silent synapses: they do not respond unless the holding potential is moved from -70 mV to +40 mV. Serotonin (5-hydroxytryptamine, 5-HT), an important neurotransmitter of the raphe-spinal projecting pathway, transforms silent glutamatergic synapses into functional ones. Therefore, transformation of silent glutamatergic synapses may serve as a cellular mechanism for central plasticity in the spinal cord.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zhuo, M (corresponding author), Washington Univ, Dept Anesthesiol, Campus Box 8054, St Louis, MO 63110 USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241				BEYER WH, 1968, HDB TABLES PROBABILI; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; GEBHART GF, 1990, BRAINSTEM MECH BEHAV, P315; HARRIS JA, 1996, NEUROSCIENCE, V14, P7; Hori Y, 1996, J PHYSIOL-LONDON, V492, P867, DOI 10.1113/jphysiol.1996.sp021352; HYLDEN JLK, 1989, PAIN, V37, P229, DOI 10.1016/0304-3959(89)90135-8; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; LopezGarcia JA, 1996, EUR J NEUROSCI, V8, P2188, DOI 10.1111/j.1460-9568.1996.tb00740.x; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MENETREY D, 1982, PAIN, V13, P343, DOI 10.1016/0304-3959(82)90003-3; Paxinos G., 1998, RAT BRAIN STEROTAXIC; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TODD AJ, 1994, J NEUROSCI, V14, P774; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhuo M, 1997, J NEUROPHYSIOL, V78, P746, DOI 10.1152/jn.1997.78.2.746; ZHUO M, 1991, BRAIN RES, V550, P35, DOI 10.1016/0006-8993(91)90402-H; ZHUO M, 1992, J NEUROPHYSIOL, V67, P1599, DOI 10.1152/jn.1992.67.6.1599	29	212	225	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					695	698		10.1038/31496	http://dx.doi.org/10.1038/31496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641681				2022-12-24	WOS:000074289600056
J	Mahanty, NK; Sah, P				Mahanty, NK; Sah, P			Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala	NATURE			English	Article							RAT BASOLATERAL AMYGDALA; NEOCORTICAL NEURONS; CA2+ PERMEABILITY; B SUBUNIT; CHANNELS; LOCALIZATION; TRANSMISSION; HIPPOCAMPUS; EXPRESSION; RECORDINGS	Fear conditioning is a paradigm that has been used as a model for emotional learning in animals'. The cellular correlate of fear conditioning is thought to be associative N-methyl-D-aspartate (NMDA) receptor-dependent synaptic plasticity within the amygdala(1-3). Here we show that glutamatergic synaptic transmission to inhibitory interneurons in the basolateral amygdala is mediated solely by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. In contrast to AMPA receptors at inputs to pyramidal neurons, these receptors have an inwardly rectifying current-voltage relationship, indicative of a high permeability to calcium(4 5), Tetanic stimulation of inputs to interneurons caused an immediate and sustained increase in the efficacy of these synapses. This potentiation required a rise in postsynaptic calcium, but was independent of NMDA receptor activation. The potentiation of excitatory inputs to interneurons was reflected as an increase in the amplitude of the GABAA-mediated inhibitory synaptic current in pyramidal neurons. These results demonstrate that excitatory synapses onto interneurons within a fear conditioning circuit show NMDA-receptor independent long-term potentiation. This plasticity might underlie the increased synchronization of activity between neurons in the basolateral amygdala after fear conditioning(6).	Univ Newcastle, Fac Med & Hlth Sci, Neurosci Grp, Newcastle, NSW 2308, Australia; Univ Newcastle, Fac Med & Hlth Sci, Discipline Human Physiol, Newcastle, NSW 2308, Australia	University of Newcastle; University of Newcastle	Sah, P (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Neurosci Grp, Newcastle, NSW 2308, Australia.		Sah, Pankaj/C-8175-2009	Sah, Pankaj/0000-0001-5063-1589				BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; FARB CR, 1995, J COMP NEUROL, V362, P86, DOI 10.1002/cne.903620106; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Isa T, 1996, J PHYSIOL-LONDON, V491, P719, DOI 10.1113/jphysiol.1996.sp021252; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; MAHANTY NK, 1996, SOC NEUR ABSTR, V22; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; McDonald AJ, 1996, NEUROSCI LETT, V208, P175, DOI 10.1016/0304-3940(96)12585-4; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Racca C, 1996, EUR J NEUROSCI, V8, P1580, DOI 10.1111/j.1460-9568.1996.tb01303.x; RAINNIE DG, 1991, J NEUROPHYSIOL, V66, P999, DOI 10.1152/jn.1991.66.3.999; RAINNIE DG, 1993, J NEUROPHYSIOL, V69, P1350, DOI 10.1152/jn.1993.69.4.1350; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; Smith BN, 1996, J NEUROPHYSIOL, V76, P1958, DOI 10.1152/jn.1996.76.3.1958; Washburn MS, 1997, J NEUROSCI, V17, P9393; WASHBURN MS, 1992, J NEUROSCI, V12, P4066	29	308	311	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					683	687		10.1038/29312	http://dx.doi.org/10.1038/29312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716132				2022-12-24	WOS:000075384200045
J	Dernburg, AF; McDonald, K; Moulder, G; Barstead, R; Dresser, M; Villeneuve, AM				Dernburg, AF; McDonald, K; Moulder, G; Barstead, R; Dresser, M; Villeneuve, AM			Meiotic recombination in C-elegans initiates by a conserved mechanism and is dispensable for homologous chromosome synapsis	CELL			English	Article							DOUBLE-STRAND BREAKS; NEMATODE CAENORHABDITIS-ELEGANS; PACHYTENE KARYOTYPE ANALYSIS; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; SYNAPTONEMAL COMPLEXES; YEAST MEIOSIS; 3 DIMENSIONS; HOT-SPOT; MUTANTS	Chromosome segregation at meiosis I depends on pairing and crossing-over between homologs. In most eukaryotes, pairing culminates with formation of the proteinaceous synaptonemal complex (SC). In budding yeast, recombination initiates through double-strand DNA breaks (DSBs) and is thought to be essential for SC formation. Here, we examine whether this mechanism for initiating meiotic recombination is conserved, and we test the dependence of homologous chromosome synapsis on recombination in C. elegans. We find that a homolog of the yeast DSB-generating enzyme, Spo11p, is required for meiotic exchange in this metazoan, and that radiation-induced breaks partially alleviate this dependence. Thus, initiation of recombination by DSBs is apparently conserved. However, homologous synapsis is independent of recombination in the nematode, since it occurs normally in a C. elegans spo-11 null mutant.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Univ Calif Berkeley, Electron Microscopy Lab, Berkeley, CA 94720 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Stanford University; University of California System; University of California Berkeley; Oklahoma Medical Research Foundation	Villeneuve, AM (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.			Dernburg, Abby/0000-0001-8037-1079	NIGMS NIH HHS [R01 GM053804, GM53804-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BRENNER S, 1974, GENETICS, V77, P71; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; DEMBURG AF, 1998, METHOD CELL BIOL, V53, P187; DURBIN R, 1991, A C ELEGANS DATABASE; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GOLDSTEIN P, 1982, CHROMOSOMA, V84, P585, DOI 10.1007/BF00292857; GOLDSTEIN P, 1982, CHROMOSOMA, V86, P577, DOI 10.1007/BF00330128; GRELL RF, 1970, CHROMOSOMA, V31, P434, DOI 10.1007/BF00285834; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HAWLEY RS, 1980, GENETICS, V94, P625; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HODGKIN J, 1979, GENETICS, V91, P67; HOWARD RJ, 1987, EXP MYCOL, V11, P250, DOI 10.1016/0147-5975(87)90014-4; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KIM JS, 1987, GENOME, V29, P457, DOI 10.1139/g87-079; Kiss JZ, 1995, TECHNIQUES MODERN BI, P89; KLAPHOLZ S, 1985, GENETICS, V110, P187; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MCDONALD K, 1998, MOL BIOL; MCKIM KS, 1988, GENETICS, V120, P987; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; MCKIM KS, 1993, GENETICS, V134, P749; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; NAG DK, 1995, GENETICS, V141, P75; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; NELSON DW, 1985, GENE, V38, P245, DOI 10.1016/0378-1119(85)90224-0; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Prinz S, 1997, GENETICS, V146, P781; Riddle D. L, 1997, C ELEGANS, P47; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSE AM, 1984, MOL GEN GENET, V195, P52, DOI 10.1007/BF00332723; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHEDL T, 1997, DEV GENETICS GERM LI, P241; SCHMEKEL K, 1995, TRENDS CELL BIOL, V5, P239, DOI 10.1016/S0962-8924(00)89017-0; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THORNE LW, 1993, GENETICS, V134, P29; VILLENEUVE AM, 1994, GENETICS, V136, P887; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207; WOLFE J, 1976, CHROMOSOMA, V55, P289, DOI 10.1007/BF00292827; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZETKA M, 1995, TRENDS GENET, V11, P27, DOI 10.1016/S0168-9525(00)88983-0	54	562	576	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					387	398		10.1016/S0092-8674(00)81481-6	http://dx.doi.org/10.1016/S0092-8674(00)81481-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708740	Bronze			2022-12-24	WOS:000075308400014
J	Kuida, K; Haydar, TF; Kuan, CY; Gu, Y; Taya, C; Karasuyama, H; Su, MSS; Rakic, P; Flavell, RA				Kuida, K; Haydar, TF; Kuan, CY; Gu, Y; Taya, C; Karasuyama, H; Su, MSS; Rakic, P; Flavell, RA			Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking Caspase 9	CELL			English	Article							CELL; ENZYME; DEFICIENT; ENCODES; BCL-2	Caspases are essential components of the mammalian cell death machinery. Here we test the hypothesis that Caspase 9 (Casp9) is a critical upstream activator of caspases through gene targeting in mice. The majority of Casp9 knockout mice die perinatally with a markedly enlarged and malformed cerebrum caused by reduced apoptosis during brain development. Casp9 deletion prevents activation of Casp3 in embryonic brains in vivo, and Casp9-deficient thymocytes show resistance to a subset of apoptotic stimuli, including absence of Casp3-like cleavage and delayed DNA fragmentation. Moreover, the cytochrome c-mediated cleavage of Casp3 is absent in the cytosolic extracts of Casp9-deficient cells but is restored after addition of in vitro-translated Casp9. Together, these results indicate that Casp9 is a critical upstream activator of the caspase cascade in vivo.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan	Vertex Pharmaceuticals; Yale University; Howard Hughes Medical Institute; Yale University; Tokyo Metropolitan Institute of Medical Science	Flavell, RA (corresponding author), Vertex Pharmaceut Inc, Cambridge, MA 02139 USA.		Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836; Haydar, Tarik/0000-0001-6772-3076				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KALLEN B, 1955, J ANAT, V89, P153; Kaufman M.H., 1992, ATLAS MOUSE DEV; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WANG S, 1998, CELL, V12, P806; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	1390	1416	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					325	337		10.1016/S0092-8674(00)81476-2	http://dx.doi.org/10.1016/S0092-8674(00)81476-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708735	hybrid			2022-12-24	WOS:000075308400009
J	Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D				Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D			Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family	CELL			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TFIID COMPLEX; MULTIPLE INTERACTIONS; BINDING PROTEIN; TBP; ACTIVATION; SUBUNITS	Determination of the crystal structure of the human Tap-associated factor (hTAF(II))28/hTAF(II)18 heterodimer shows that these TAF(II)s form a novel histone-like pair in the TFIID complex. The histone folds in hTAF(II)28 and hTAF(II)18 were not predicted from their primary sequence, indicating that these TAF(II)s define a novel family of atypical histone fold sequences. The TAF(II)18 and TAF(II)28 histone fold moths are also present in the N- and C-terminal regions of the SPT3 proteins, suggesting that the histone fold in SPT3 may be reconstituted by intramolecular rather than classical intermolecular interactions. The;existence of additional histone-like pairs in both the TFIID and SAGA complexes shows that the histone fold is a more commonly used motif for mediating TAF-TAF interactions than previously believed.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163,CU Strasbourg, F-67404 Illkirch, France.		ruff, marc/J-3011-2013; Lavigne, Anne-Claire/O-8805-2015	ruff, marc/0000-0001-5451-6377; Romier, Christophe/0000-0002-3680-935X; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; BRUNGER AT, 1992, XPLOR VERSION 3 1; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gribskov M, 1996, METHOD ENZYMOL, V266, P198; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Roberts SM, 1997, GENETICS, V147, P451; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SLESAREV AI, 1998, NUCLEIC ACIDS RES, V26, P247; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	53	118	130	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					239	249		10.1016/S0092-8674(00)81423-3	http://dx.doi.org/10.1016/S0092-8674(00)81423-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695952	Bronze			2022-12-24	WOS:000075020100012
J	Kersh, EN; Shaw, AS; Allen, PM				Kersh, EN; Shaw, AS; Allen, PM			Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation	SCIENCE			English	Article							PROTEIN-TYROSINE KINASES; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; TCR-ZETA; MURINE THYMOCYTES; CYTOPLASMIC TAIL; PARTIAL AGONISTS; MHC COMPLEXES; CHAIN	The T cell receptor (TCR) alpha beta heterodimer interacts with its ligands with high specificity, but surprisingly Low affinity. The role of the zeta component of the murine TCR in contributing to the Fidelity of antigen recognition was examined. With sequence-specific phosphotyrosine antibodies, it was found that zeta undergoes a series of ordered phosphorylation events upon TCR engagement. Completion of phosphorylation steps is dependent on the nature of the TCR ligand. Thus, the phosphorylation steps establish thresholds for T cell activation. This study documents the sophisticated molecular events that follow the engagement of a low-affinity receptor.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Allen, PM (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	allen@immunology.wustl.edu						Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; GRAKOUI A, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KERSH EN, UNPUB; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LaFace DM, 1997, J IMMUNOL, V158, P2057; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Lin SY, 1997, J EXP MED, V185, P707, DOI 10.1084/jem.185.4.707; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SHINKAI Y, 1995, IMMUNITY, V2, P401; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; SHORES EW, 1963, CURR OPIN IMMUNOL, V9380, P97; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Sousa CRE, 1996, J EXP MED, V184, P149, DOI 10.1084/jem.184.1.149; Stone JD, 1997, J IMMUNOL, V158, P5773; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; van Oers NSC, 1998, J IMMUNOL, V160, P163; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; Yamazaki T, 1997, J IMMUNOL, V158, P1634	59	266	275	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					572	575		10.1126/science.281.5376.572	http://dx.doi.org/10.1126/science.281.5376.572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677202				2022-12-24	WOS:000075012300044
J	Xie, T; Spradling, AC				Xie, T; Spradling, AC			decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary	CELL			English	Article							BETA SIGNALING PATHWAY; BAG-OF-MARBLES; DPP RECEPTORS; THICK VEINS; I RECEPTORS; PROTEIN; GENE; PATTERN; TRANSCRIPTION; MELANOGASTER	Stem cells are thought to occupy special local environments, or niches, established by neighboring cells that give them the capability for self-renewal. Each ovariole in the Drosophila ovary contains two germline stem cells surrounded by a group of differentiated somatic cells that express hedgehog and wingless. Here we show that the BMP2/4 homolog decapentaplegic (dpp) is specifically required to maintain female germline stem cells and promote their division. Overexpression of dpp blocks germline stem cell differentiation. Conversely, mutations in dpp or its receptor (saxophone) accelerate stem cell loss and retard stem cell division. We constructed mutant germline stem cell clones to show that the dpp signal is directly received by germline stem cells. Thus, dpp signaling helps define a niche that controls germline stem cell proliferation.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Spradling, AC (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BAKER D, 1992, GENE DEV, V6, P2312; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Burke R, 1996, DEVELOPMENT, V122, P2261; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen EH, 1997, DEVELOPMENT, V124, P205; Das P, 1998, DEVELOPMENT, V125, P1519; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; DECUEVAS M, 1998, IN PRESS DEVELOPMENT; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; Forbes A, 1998, DEVELOPMENT, V125, P679; Forbes AJ, 1996, DEVELOPMENT, V122, P3283; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hudson JB, 1998, DEVELOPMENT, V125, P1407; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIANG L, 1994, DEVELOPMENT, V120, P1201; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; Lin HF, 1997, DEVELOPMENT, V124, P2463; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.3.CO;2-O; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Matunis E, 1997, DEVELOPMENT, V124, P4383; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Penton A, 1997, SCIENCE, V275, P203, DOI 10.1126/science.275.5297.203; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Spradling AC, 1997, COLD SPRING HARB SYM, V62, P25; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Twombly V, 1996, DEVELOPMENT, V122, P1555; Wharton K, 1996, GENETICS, V142, P493; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223; Zaccai M, 1996, ZYGOTE, V4, P159, DOI 10.1017/S096719940000304X; Zhao GQ, 1996, GENE DEV, V10, P1657, DOI 10.1101/gad.10.13.1657; Zhao GQ, 1998, DEVELOPMENT, V125, P1103	61	511	524	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					251	260		10.1016/S0092-8674(00)81424-5	http://dx.doi.org/10.1016/S0092-8674(00)81424-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695953	Bronze			2022-12-24	WOS:000075020100013
J	Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW				Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW			Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor	NATURE			English	Article							ALANINE-SCANNING MUTAGENESIS; ALPHA-SUBUNIT; BINDING DOMAIN; GENE; DETERMINANTS; SPECIFICITY; SITE	The type-1 insulin-like growth-factor receptor (IGF-1R) and insulin receptor (IR) are closely related members of the tyrosine-kinase receptor superfamily. IR is essential for glucose homeostasis, whereas IGF-1R is involved in both normal growth and development and malignant transformation. Homologues of these receptors are found in animals as simple as cnidarians. The epidermal growth-factor receptor (EGFR) family is closely related to the IR family and has significant sequence identity to the extracellular portion we describe here. We now present the structure of the first three domains of IGF-1R (L1-Cys-rich-L2) determined to a 2.4 Angstrom resolution. The L domains each consist of a single-stranded right-handed beta-helix. The Cys-rich region is composed of eight disulphide-bonded modules, seven of which form a rod-shaped domain with modules associated in an unusual manner. The three domains surround a central space of sufficient size to accommodate a ligand molecule. Although the fragment (residues 1-462) does not bind ligand, many of the determinants responsible for hormone binding and ligand specificity map to this central site. This structure therefore shows how the IR subfamily might interact with their ligands.	CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Ward, CW (corresponding author), CSIRO, Div Mol Sci, 343 Royal Parade, Parkville, Vic 3052, Australia.	tom.barrett@bioresi.com.au; colin.ward@molsci.csiro.au	Lovrecz, George/H-8602-2013; Cosgrove, Leah J/A-7764-2010	Cosgrove, Leah J/0000-0002-8340-4291				BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; BAYNE ML, 1988, J BIOL CHEM, V264, P11004; BRUNGER AT, 1996, XPLOR REFERENCE MANU; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HOLM I, 1993, J MOL BIOL, V233, P125; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KUROSE T, 1994, J BIOL CHEM, V269, P29190; McKern NM, 1997, PROTEIN SCI, V6, P2663; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; STEIGEMAN W, 1974, THESIS TU MUNICH; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; TAYLOR S, 1994, ENDOCR REV, V2, P58; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7	30	221	244	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					395	399		10.1038/28668	http://dx.doi.org/10.1038/28668			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690478				2022-12-24	WOS:000074968800058
J	de Groen, PC; Barry, JA; Schaller, WJ				de Groen, PC; Barry, JA; Schaller, WJ			Applying World Wide Web technology to the study of patients with rare diseases	ANNALS OF INTERNAL MEDICINE			English	Article								Randomized, controlled trials of sporadic diseases are rarely conducted. Recent developments in communication technology, particularly the World Wide Web, allow efficient dissemination and exchange of information. However, software for the identification of patients with a ra re disease and subsequent data entry and analysis in a secure Web database are currently not available. To study cholangiocarcinoma, a rare cancer of the bile ducts, we developed a computerized disease tracing system coupled with a database accessible on the Web. The tracing system scans computerized information systems on a daily basis and forwards demographic information on patients with bile duct abnormalities to an electronic mailbox. If informed consent is given, the patient's demographic and preexisting medical information available in medical database servers are electronically forwarded to a UNIX research database. Information from further patient-physician interactions and procedures is also entered into this database. The database is equipped with a Web user interface that allows data entry from various platforms (PC-compatible, Macintosh, and UNIX workstations) anywhere inside or outside our institution. To ensure patient confidentiality and data security, the database includes all security measures required for electronic medical records. The combination of a Web-based disease tracing system and a database has broad applications, particularly for the integration of clinical research within clinical practice and for the coordination of multicenter trials.	Mayo Clin & Mayo Fdn, Div Gastroenterol, Rochester, MN 55905 USA	Mayo Clinic	de Groen, PC (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol, 200 1st St SW, Rochester, MN 55905 USA.							Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Sirica A. E., 1997, BILIARY PANCREATIC D, P229; WALL L, 1996, PROGRAMMING PERL	3	20	29	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					107	113		10.7326/0003-4819-129-2-199807150-00009	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669969				2022-12-24	WOS:000074852000006
J	Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O				Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O			Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer	NATURE			English	Article							MALIGNANT RHABDOID TUMOR; SWI/SNF COMPLEX; BINDING; STIMULATION; PROTEIN; KIDNEY; SNF5	Malignant rhabdoid tumours (MRTs) are extremely aggressive cancers of early childhood. They can occur in various locations, mainly the kidney, brain and soft tissues(1,2). Cytogenetic and molecular analyses have shown that the deletion of region 11.2 of the long arm of chromosome 22 (22q11.2) is a recurrent genetic characteristic of MRTs, indicating that this locus may encode a tumour suppressor gene(3-8). Here we map the most frequently deleted part of chromosome 22q11.2 from a panel of 13 MRT cell lines. We observed six homozygous deletions that delineate the smallest region of overlap between the cell lines. This region is found in the hSNF5/3INI1 gene, which encodes a member of the chromatin-remodelling SWI/SNF multiprotein complexes(9-12). We analysed the sequence of hSNF5/INI1 and found frameshift or nonsense mutations of this gene in six other cell lines. These truncating mutations of one allele were associated with the loss of the other allele. Identical alterations were observed in corresponding primary tumour DNAs but not in matched constitutional DNAs, indicating that they had been acquired somatically. The observation of bi-allelic alterations of hSNF5/INI1 in MRTs suggests that loss-of-function mutations of hSNF5/INI1 contribute to oncogenesis.	Inst Curie, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Tubingen, Kinderklin, D-72070 Tubingen, Germany	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; Eberhard Karls University of Tubingen	Delattre, O (corresponding author), Inst Curie, Sect Rech, Lab Pathol Mol Canc, 26 Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; delattre, olivier/0000-0002-8730-2276				Biegel JA, 1996, GENE CHROMOSOME CANC, V16, P94, DOI 10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOUGLASS EC, 1990, GENE CHROMOSOME CANC, V2, P210, DOI 10.1002/gcc.2870020308; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FORT DW, 1994, GENE CHROMOSOME CANC, V11, P146, DOI 10.1002/gcc.2870110303; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HANDGRETINGER R, 1990, CANCER RES, V50, P2177; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LYNCH HT, 1983, CANCER-AM CANCER SOC, V52, P290, DOI 10.1002/1097-0142(19830715)52:2<290::AID-CNCR2820520216>3.0.CO;2-L; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1998, EMBO J, V16, P101; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHASHI V, 1994, GENE CHROMOSOME CANC, V10, P49, DOI 10.1002/gcc.2870100108; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SOULIE J, 1986, CANCER GENET CYTOGEN, V21, P117, DOI 10.1016/0165-4608(86)90037-3; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WICK MR, 1995, SEMIN DIAGN PATHOL, V12, P233	28	1116	1160	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					203	206		10.1038/28212	http://dx.doi.org/10.1038/28212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671307				2022-12-24	WOS:000074705900060
J	Gureje, O; Von Korff, M; Simon, GE; Gater, R				Gureje, O; Von Korff, M; Simon, GE; Gater, R			Persistent pain and well-being - A World Health Organization study in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; PSYCHOLOGICAL-PROBLEMS; DEPRESSION; DISABILITY; SYMPTOMS; ILLNESS	Context.-There is little information on the extent of persistent pain across cultures. Even though pain is a common reason for seeking health care, information on the frequency and impacts of persistent pain among primary care patients is inadequate. Objective.-To assess the prevalence and impact of persistent pain among primary care patients. Design and Setting.-Survey data were collected from representative samples of primary care patients as part of the World Health Organization Collaborative Study of Psychological Problems in General Health Care, conducted in 15 centers in Asia, Africa, Europe, and the Americas. Participants.-Consecutive primary care attendees between the age of majority (typically 18 years) and 65 years were screened (n = 25 916) and stratified random samples interviewed (n = 5438). Main Outcome Measures.-Persistent pain, defined as pain present most of the time for a period of 6 months or more during the prior year, and psychological illness were assessed by the Composite International Diagnostic interview, Disability was assessed by the Groningen Social Disability Schedule and by activity-limitation days in the prior month. Results.-Across all 15 centers, 22% of primary care patients reported persistent pain, but there was wide variation in prevalence rates across centers (range, 5.5%-33.0%). Relative to patients without persistent pain, pain sufferers were more likely to have an anxiety or depressive disorder (adjusted odds ratio [OR], 4, 14, 95% confidence interval [CI], 3.52-4.86), to experience significant activity limitations (adjusted OR, 1.63; 95% CI, 1.41-1.89), and to have unfavorable health perceptions (adjusted OR, 1.26; 95% CI, 1.07-1.49), The relationship between psychological disorder and persistent pain was observed in every center, while the relationship between disability and persistent pain was inconsistent across centers. Conclusions.-Persistent pain was a commonly reported health problem among primary care patients and was consistently associated with psychological illness across centers. Large variation in frequency and the inconsistent relationship between persistent pain and disability across centers suggests caution in drawing conclusions about the role of culture in shaping responses to persistent pain when comparisons are based on patient samples drawn from a limited number of health care settings in each culture.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Coll Hosp, Dept Psychiat, Ibadan, Nigeria; Withington Hosp, Dept Psychiat, Manchester M20 8LR, Lancs, England	Group Health Cooperative; University of Ibadan; University College Hospital, Ibadan	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave, Seattle, WA 98101 USA.		Gureje, Oye/J-1183-2014	Gureje, Oye/0000-0003-0094-5947; VonKorff, Michael/0000-0001-5386-8477	NIDCR NIH HHS [DE08773-10] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; Bates M S, 1995, Med Anthropol, V16, P141; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; LERESCHE L, IN PRESS HDB PAIN SY; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; MOORE R, 1990, PSYCHOSOM MED, V52, P171, DOI 10.1097/00006842-199003000-00005; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; ROY R, 1984, COMPR PSYCHIAT, V25, P96, DOI 10.1016/0010-440X(84)90027-0; SANDERS SH, 1992, CLIN J PAIN, V8, P317, DOI 10.1097/00002508-199212000-00006; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SCHAPPERT SM, 1992, VITAL HLTH STAT, V18; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; USTN TB, 1995, MENTAL ILLNESS GEN H; Von Korff M., 1995, MENTAL ILLNESS GEN H; VONKORFF A, 1988, PAIN, V32, P173; VONKORFF M, 1993, PAIN, V55, P251, DOI 10.1016/0304-3959(93)90154-H; VonKorff M, 1996, J CLIN EPIDEMIOL, V49, P297, DOI 10.1016/0895-4356(95)00512-9; VonKorff M, 1996, BRIT J PSYCHIAT, V168, P101, DOI 10.1192/S0007125000298474; VONKORFFM, 1992, PAIN, V50, P133; *WHO, 1989, WHO PUBL; WIERSMA D, 1988, INT J REHABIL RES, V11, P213, DOI 10.1097/00004356-198809000-00001; World Health Organization, 1992, INT STAT CLASS DIS	24	967	1002	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					147	151		10.1001/jama.280.2.147	http://dx.doi.org/10.1001/jama.280.2.147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY321	9669787	Bronze			2022-12-24	WOS:000074608400029
J	Fiorillo, CD; Williams, JT				Fiorillo, CD; Williams, JT			Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons	NATURE			English	Article							CEREBELLAR GRANULE CELLS; VENTRAL TEGMENTAL AREA; EXCITATORY AMINO-ACID; SYNAPTIC POTENTIALS; RAT; RECEPTORS; CONDUCTANCE; BRAIN; CA-2+-ATPASE; ACTIVATION	Rapid information transfer within the brain depends on chemical signalling between neurons that is mediated primarily by glutamate and GABA (gamma-aminobutyric acid), acting at ionotropic receptors to cause excitatory or inhibitory postsynaptic potentials (EPSPs or IPSPs), respectively. In addition, synaptically released glutamate acts on metabotropic receptors to excite neurons on a slower timescale through second-messenger cascades, including phosphoinositide hydrolysis'. We now report a unique IPSP mediated by the activation of metabotropic glutamate receptors. Tn ventral midbrain dopamine neurons, activation of metabotropic glutamate receptors (mGluR1) mobilized calcium from caffeine/ryanodine-sensitive stores and increased an apamin-sensitive potassium conductance. The underlying potassium conductance and dependence on calcium stores set this IPSP apart from the slow IPSPs described so far(2-4). The mGluR-induced hyperpolarization was dependent on brief exposure to agonist, because prolonged application of exogenous agonist desensitized the hyperpolarization and caused the more commonly reported depolarization(1,5,6). The rapid rise and brief duration of synaptically released glutamate in the extracellular space can therefore mediate a rapid excitation through activation of ionotropic receptors, followed by inhibition through the mGluR1 receptor. Thus the idea that glutamate is solely an excitatory neurotransmitter must be replaced with a more complex view of its dual function in synaptic transmission.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Williams, JT (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Fiorillo, Christopher Dante/C-1718-2011	Fiorillo, Christopher/0000-0002-7232-9505				BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; CAMERON DL, 1993, NATURE, V366, P344, DOI 10.1038/366344a0; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; Johnson SW, 1997, NEUROSCI LETT, V231, P13, DOI 10.1016/S0304-3940(97)00508-9; JOHNSON SW, 1992, J NEUROSCI, V12, P2000; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KALIVAS PW, 1995, J NEUROSCI, V15, P5379, DOI 10.1523/jneurosci.15-07-05379.1995; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KOLINSKI CM, INPRESS NEUROSCIENCE; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MERCURI NB, 1993, NEUROSCIENCE, V56, P399, DOI 10.1016/0306-4522(93)90341-C; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; PAN ZZ, 1989, J NEUROPHYSIOL, V62, P481, DOI 10.1152/jn.1989.62.2.481; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shen KZ, 1997, EUR J NEUROSCI, V9, P48, DOI 10.1111/j.1460-9568.1997.tb01352.x; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SHIRASAKI T, 1994, J PHYSIOL-LONDON, V475, P439, DOI 10.1113/jphysiol.1994.sp020084; SURPRENANT A, 1987, J PHYSIOL-LONDON, V382, P87, DOI 10.1113/jphysiol.1987.sp016357; TESTA CM, 1994, J NEUROSCI, V14, P3005; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	30	226	232	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					78	82		10.1038/27919	http://dx.doi.org/10.1038/27919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665131				2022-12-24	WOS:000074579600052
J	Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL				Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL			DNA binding and cleavage by the nuclear intron-encoded homing endonuclease I-PpoI	NATURE			English	Article							CRYSTAL-STRUCTURE; FINGER DOMAIN; MINOR-GROOVE; ZINC-FINGER; PROTEIN; RECOGNITION; COMPLEX; FAMILY; MOTIF	Homing endonucleases are a diverse collection of proteins that are encoded by genes with mobile, self-splicing introns(1-3). They have also been identified in self-splicing inteins (protein introns)(4). These enzymes promote the movement of the DNA sequences that encode them from one chromosome location to another; they do this by making a site-specific double-strand break at a target site in an allele that lacks the corresponding mobile intron(3). The target sites recognized by these small endonucleases are generally long (14-44 base pairs). Four families of homing endonucleases have been identified, including the LAGLIDADG, the His-Cys box, the GIY-YIG and the H-N-H endonucleases(1). The first identified His-Cys box homing endonuclease was I-PpoI from the slime mould Physarum polycephalum(5,6). Its gene resides in one of only a few nuclear introns known to exhibit genetic mobility(7). Here we report the structure of the I-PpoI homing endonuclease bound to homing-site DNA determined to 1.8 Angstrom resolution. I-PpoI displays an elongated fold of dimensions 25 x 35 x 80 Angstrom, with mixed (alpha/beta topology. Each I-PpoI monomer contains three antiparallel beta-sheets flanked by two long ol-helices and a long carboxy-terminal tail, and is stabilized by two bound zinc ions 15 Angstrom apart. The enzyme possesses a new zinc-bound fold and endonuclease active site. The structure has been determined in both uncleaved substrate and cleaved product complexes.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	bstoddar@fred.fhcrc.org						BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; *DAR LAB, 1979, 4 CCP4 SERC UK COLL; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; ELLISON EL, 1993, MOL CELL BIOL, V13, P7531, DOI 10.1128/MCB.13.12.7531; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FLICK KE, 1997, PROTEIN SCI, V6, P1; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; JOHANSEN S, 1993, NUCLEIC ACIDS RES, V21, P4405, DOI 10.1093/nar/21.18.4405; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LASKOWSKI RJ, 1993, J APPL CRYSTALLOGR, V26, P383; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; 1996, QUANTA96 XRAY STRUCT	27	187	197	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					96	101		10.1038/27952	http://dx.doi.org/10.1038/27952			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665136				2022-12-24	WOS:000074579600057
J	Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H				Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H			The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3	NATURE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; TRANSFORMING ACTIVITY; MYELOID-LEUKEMIA; BLASTIC CRISIS; EXPRESSION; PROTEIN; GENE; ACTIVATION; RECEPTOR; DOMAIN	Evi-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells(1-5). Evi-1 has two zinc-finger domains, one with seven repeats of a zinc-finger motif and one with three repeats(6), and it has characteristics of a transcriptional regulator(7,8). Although Evi-1 is thought to be able to promote growth and to block differentiation in some cell types(9-11), its biological functions are poorly understood. Here we study the mechanisms that underlie oncogenesis induced by Evi-1 by investigating whether Evi-1 perturbs signalling through transforming growth factor-beta (TGF-beta), one of the most studied growth-regulatory factors, which inhibits proliferation of a wide range of cell types(12). We show that Evi-1 represses TGF-beta signalling and antagonizes the growth-inhibitory effects of TGF-beta. Two separate regions of Evi-1 are responsible for this repression; one of these regions is the first zinc-finger domain. Through this domain, Evi-1 interacts with Smad3, an intracellular mediator of TGF-beta signalling(13), thereby suppressing the transcriptional activity of Smad3, These results define a new function of Evi-1 as a repressor of signalling through TGF-beta.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1138655, Japan; Nagoya Univ, Fac Sci, Dept Biol Mol, Chikusa Ku, Nagoya, Aichi 46401, Japan	University of Tokyo; Nagoya University	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.			Takahashi, Tokiharu/0000-0002-5785-8660				Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; KUROKAWA M, 1995, ONCOGENE, V11, P833; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lopingco MC, 1996, CURR TOP MICROBIOL, V211, P211; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	29	298	312	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					92	96		10.1038/27945	http://dx.doi.org/10.1038/27945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665135				2022-12-24	WOS:000074579600056
J	Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK				Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK			Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli	SCIENCE			English	Article							OUTER-MEMBRANE PROTEINS; BUNDLE-FORMING PILUS; TISSUE-CULTURE CELLS; LOCALIZED ADHERENCE; TWITCHING MOTILITY; BINDING PROTEINS; GENETIC-LOCUS; PLASMID; SEROTYPES; PATHOGENESIS	Type IV bundle-forming pill of enteropathogenic Escherichia coli are required for the localized adherence and autoaggregation phenotypes, Whether these pill are also required for virulence was tested in volunteers by inactivating bfpA or bfpT (perA) encoding, respectively, the pilus subunit and the bfp operon transcriptional activator. Both mutants caused significantly less diarrhea. Mutation of the bfpF nucleotide-binding domain Caused increased piliation, enhanced localized adherence, and abolished the twitching motility-dispersal phase of the autoaggregation phenotype. The bfpF mutant colonized the human intestine but was about 200-fold less virulent. Thus, BfpF is required for dispersal from the bacterial aggregate and for full virulence.	Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med,Stanford Program Vaccine Res, Dept Microbiol & Immunol, Stanford, CA 94305 USA; San Jose State Univ, Dept Biol Sci, San Jose, CA 95912 USA; Univ Tokyo, Inst Med Sci, Dept Bacteriol, Tokyo, Japan	Stanford University; Stanford University; California State University System; San Jose State University; University of Tokyo	Schoolnik, GK (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA.	ml.gks@forsythe.stanford.edu			NCRR NIH HHS [MO1-RR00070] Funding Source: Medline; NIAID NIH HHS [1RO1-AI39521] Funding Source: Medline; NIDDK NIH HHS [1RO3-DK52038] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052038] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHA RP, 1998, INFECT IMMUN, V66, P122; BALDINI MM, 1983, J PEDIATR GASTR NUTR, V2, P534, DOI 10.1097/00005176-198302030-00023; BALDINI MM, 1986, INFECT IMMUN, V52, P334, DOI 10.1128/IAI.52.1.334-336.1986; BIEBER D, UNPUB; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Donnenberg Michael S., 1995, P709; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HILL SM, 1991, GUT, V32, P154, DOI 10.1136/gut.32.2.154; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; JERSE AE, 1991, INFECT IMMUN, V59, P3869, DOI 10.1128/IAI.59.11.3869-3875.1991; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; LEVINE MM, 1985, J INFECT DIS, V152, P550, DOI 10.1093/infdis/152.3.550; Manning PA, 1997, GENE, V192, P1; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NATARO JP, 1985, INFECT IMMUN, V48, P378, DOI 10.1128/IAI.48.2.378-383.1985; NATARO JP, 1987, INFECT IMMUN, V55, P2370, DOI 10.1128/IAI.55.10.2370-2377.1987; Puente JL, 1996, MOL MICROBIOL, V20, P87, DOI 10.1111/j.1365-2958.1996.tb02491.x; Ramer SW, 1996, J BACTERIOL, V178, P6555, DOI 10.1128/jb.178.22.6555-6563.1996; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; SCALETSKY ICA, 1984, INFECT IMMUN, V45, P534, DOI 10.1128/IAI.45.2.534-536.1984; SOHEL I, 1993, MOL MICROBIOL, V7, P563, DOI 10.1111/j.1365-2958.1993.tb01147.x; Sohel I, 1996, J BACTERIOL, V178, P2613, DOI 10.1128/jb.178.9.2613-2628.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; Swanson J., 1989, MOBILE DNA, P743; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; TAYLOR CJ, 1986, J PEDIATR GASTR NUTR, V5, P70, DOI 10.1097/00005176-198601000-00013; Tobe T, 1996, MOL MICROBIOL, V21, P963, DOI 10.1046/j.1365-2958.1996.531415.x; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VUOPIOVARKILA J, 1991, J EXP MED, V174, P1167, DOI 10.1084/jem.174.5.1167; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V	45	363	368	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2114	2118		10.1126/science.280.5372.2114	http://dx.doi.org/10.1126/science.280.5372.2114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641917				2022-12-24	WOS:000074435900045
J	Xu, ZY; Sato, K; Wickner, W				Xu, ZY; Sato, K; Wickner, W			LMA1 binds to vacuoles at Sec18p (NSF), transfers upon ATP hydrolysis to a t-SNARE (Vam3p) complex, and is released during fusion	CELL			English	Article							PROTEIN DISULFIDE-ISOMERASE; SACCHAROMYCES-CEREVISIAE; ALPHA-SNAP; ESCHERICHIA-COLI; IN-VITRO; YEAST; INHERITANCE; SEGREGATION; THIOREDOXIN; MEMBRANE	Vacuole fusion requires Sec18p (NSF), Sec17p (alpha-SNAP), Ypt7p (GTP binding protein), Vam3p (t-SNARE), Nyv1p (V-SNARE), and LMA1 (low M-r activity 1, a heterodimer of thioredoxin and I-2(B)). LMA1 requires Sec18p for saturable, high-affinity binding to vacuoles, and Sec18p "priming" ATPase requires both Sec17p and LMA1. Either the sec18-1 mutation and deletion of I-2(B), or deletion of both I-2(B), and p13 (an I-2(B) homolog) causes a striking synthetic vacuole fragmentation phenotype. Upon Sec18p ATP hydrolysis, LMA1 transfers to (and stabilizes) a Vam3p complex. LMA1 is released from vacuoles in a phosphatase-regulated reaction. This LMA1 cycle explains how priming by Sec18p is coupled to t-SNARE stabilization and to fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.				NIAMS NIH HHS [T32AR07576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel F, 1997, SHORT PROTOCOLS MOL; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUBER HE, 1986, J BIOL CHEM, V261, P5006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MAIER K, 1979, J BIOL CHEM, V254, P8491; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHU P, 1991, EUR J BIOCHEM, V197, P1, DOI 10.1111/j.1432-1033.1991.tb15874.x; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	44	75	80	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1125	1134		10.1016/S0092-8674(00)81457-9	http://dx.doi.org/10.1016/S0092-8674(00)81457-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657146	Bronze			2022-12-24	WOS:000074491100008
J	Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M				Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M			Chemical processing in the coma as the source of cometary HNC	NATURE			English	Article							ABUNDANCE RATIO; HCN	The discovery of hydrogen isocyanide (HNC) in comet Hyakutake with an abundance (relative to hydrogen cyanide, KCN) similar to that seen in dense interstellar clouds raised the possibility that these molecules might be surviving interstellar material(1). The preservation of material from the Sun's parent molecular cloud would provide important constraints on the processes that took place in the protostellar nebula. But another possibility is that HNC is produced by photochemical processes in the coma, which means that its abundance could not be used as a direct constraint on conditions in the early Solar System. Here we show that the HNC/HCN ratio determined for comet Hale-Bopp varied with heliocentric distance in a way that matches the predictions of models of gas-phase chemical production of HNC in the coma, but cannot be explained if the HNC molecules were coming from the comet's nucleus. We conclude that HNC forms mainly by chemical reactions in the coma, and that such reactions need to be considered when attempting to deduce the composition of the nucleus from observations of the coma.	Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Smithsonian Astrophys Observ, Cambridge, MA 02138 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Ottawa, ON K1A 0R6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA	University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Smithsonian Institution; University of Hawaii System; National Research Council Canada	Irvine, WM (corresponding author), Univ Massachusetts, Five Coll Radio Astron Observ, 619 LGRC, Amherst, MA 01003 USA.							Bergin EA, 1997, ASTROPHYS J, V486, P316, DOI 10.1086/304510; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; FESTOU MC, 1993, ASTRON ASTROPHYS REV, V5, P37, DOI 10.1007/BF00872923; Fomenkova M. N., 1997, Astronomical Society of the Pacific Conference Series, V122, P415; GOLDSMITH PF, 1986, ASTROPHYS J, V310, P383, DOI 10.1086/164692; GOLDSMITH PF, 1981, ASTROPHYS J, V249, P524, DOI 10.1086/159312; HERBST E, 1978, ASTROPHYS J, V222, P508, DOI 10.1086/156163; HIROTA T, IN PRESS ASTROPHYS J; IRVINE WH, IN PRESS FARADAY DIS, V109; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; IRVINE WM, 1997, ESA, P277; LOVAS FJ, 1992, J PHYS CHEM REF DATA, V21, P181, DOI 10.1063/1.555920; Lovell AJ, 1998, ASTROPHYS J, V497, pL117, DOI 10.1086/311288; LOVELL AJ, IN PRESS EARTH MOON; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OLOFSSON H, 1982, ASTRON ASTROPHYS, V107, P128; RODGERS SD, IN PRESS ASTROPHYS J; SCHMIDT HU, 1988, COMPUT PHYS COMMUN, V49, P17, DOI 10.1016/0010-4655(88)90214-7; Shiba Y, 1998, J CHEM PHYS, V108, P698, DOI 10.1063/1.475443; TACCONIGARMAN LE, 1990, ASTROPHYS J, V364, P672, DOI 10.1086/169450; WINK J, IN PRESS EARTH MOON; IN PRESS EARTH MOON	26	64	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					547	550		10.1038/31171	http://dx.doi.org/10.1038/31171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634231				2022-12-24	WOS:000074150100043
J	Ryan, EA				Ryan, EA			Pancreas transplants: for whom?	LANCET			English	Editorial Material							QUALITY-OF-LIFE; KIDNEY-TRANSPLANTATION; DIABETES-MELLITUS; MORTALITY		Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, EA (corresponding author), Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada.							Alejandro R, 1997, DIABETES, V46, P1983, DOI 10.2337/diabetes.46.12.1983; Bloom RD, 1997, TRANSPLANTATION, V64, P1689, DOI 10.1097/00007890-199712270-00010; Busing M, 1997, EXP CLIN ENDOCR DIAB, V105, P92; Gruessner RWG, 1997, TRANSPLANTATION, V64, P1572, DOI 10.1097/00007890-199712150-00011; Kendall DM, 1997, DIABETES, V46, P249, DOI 10.2337/diabetes.46.2.249; Kinkhabwala M, 1996, AM J SURG, V171, P516, DOI 10.1016/S0002-9610(97)89613-4; Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649; Landgraf R, 1996, DIABETOLOGIA, V39, P1415, DOI 10.1007/s001250050593; LARSEN JL, 1992, DIABETES CARE, V15, P35, DOI 10.2337/diacare.15.1.35; Manske CL, 1995, LANCET, V346, P1658, DOI 10.1016/S0140-6736(95)92838-3; Martinenghi S, 1997, DIABETES CARE, V20, P272, DOI 10.2337/diacare.20.3.272; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; Piehlmeier W, 1996, EUR J SURG, V162, P933; Stratta RJ, 1997, DIABETES CARE, V20, P362, DOI 10.2337/diacare.20.3.362; SUTHERLAND DER, 1997, CURRENT THERAPY ENDO, P496	15	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1072	1073		10.1016/S0140-6736(98)22015-0	http://dx.doi.org/10.1016/S0140-6736(98)22015-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660570				2022-12-24	WOS:000073090200002
J	Endow, SA; Waligora, KW				Endow, SA; Waligora, KW			Determinants of kinesin motor polarity	SCIENCE			English	Article							PROTEIN; NCD; DROSOPHILA; DOMAIN; MICROTUBULES; POLYMERASE; MOVEMENT	The kinesin motor protein family members move along microtubules with characteristic polarity. Chimeric motors containing the stalk and neck of the minus-end-directed motor, Ncd, fused to the motor domain of plus-end-directed kinesin were analyzed. The Ncd stalk and neck reversed kinesin motor polarity, but mutation of the Ncd neck reverted the chimeric motor to plus-end movement. Thus, residues or regions contributing to motor polarity must be present in both the Ncd neck and the kinesin motor core. The neck-motor junction was critical for Ncd minus-end movement; attachment of the neck to the stalk may also play a role.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Endow, SA (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; Endow SA, 1998, BIOESSAYS, V20, P108, DOI 10.1002/(SICI)1521-1878(199802)20:2<108::AID-BIES2>3.0.CO;2-P; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; HATSUMI M, 1992, J CELL SCI, V103, P1013; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1992, J CELL SCI, V101, P303; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	130	131	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1200	1202		10.1126/science.281.5380.1200	http://dx.doi.org/10.1126/science.281.5380.1200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712586				2022-12-24	WOS:000075531200056
J	Martinsen, BJ; Bronner-Fraser, M				Martinsen, BJ; Bronner-Fraser, M			Neural crest specification regulated by the helix-loop-helix repressor Id2	SCIENCE			English	Article							DNA-BINDING; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATOR; GENE; DIFFERENTIATION; EXPRESSION; CELLS; DROSOPHILA; GROWTH; EXTRAMACROCHAETAE	Vertebrate neural crest cells, derived from the neural folds, generate a variety of tissues, such as cartilage, ganglia, and cranial.(intramembranous) bone, The chick homolog of the helix-loop-helix transcriptional regulator Id2 is expressed in cranial but not trunk neural folds and subsequently in some migrating cranial neural crest cells. Ectopic expression of Id2 with recombinant retroviruses converted ectodermal cells to a neural crest fate, demonstrating that proper regulation of Id2 is important for sustaining epidermal traits. In addition, overexpression of Id2 resulted in overgrowth and premature neurogenesis of the dorsal neural tube. These results suggest that Id2 may allocate ectodermal precursors into neural rather than epidermal lineages.	CALTECH, Beckman Inst 139 74, Div Biol, Pasadena, CA 91125 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA	California Institute of Technology; University of California System; University of California Irvine	Bronner-Fraser, M (corresponding author), CALTECH, Beckman Inst 139 74, Div Biol, Pasadena, CA 91125 USA.			Bronner, Marianne/0000-0003-4274-1862	NINDS NIH HHS [NS36585, NS34671] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034671, R01NS036585, R37NS036585] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hara E, 1996, DEV GENET, V18, P161; Homburger SA, 1996, DEV DYNAM, V206, P112, DOI 10.1002/(SICI)1097-0177(199605)206:1<112::AID-AJA10>3.0.CO;2-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; LEBLANC GG, 1990, DEV BIOL, V137, P318, DOI 10.1016/0012-1606(90)90257-J; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; LEDOUARIN NM, 1982, DEV CELL BIOL SERIES, V12; MORGAN BA, 1996, METHOD CELL BIOL, V51, P186; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Sawai S, 1997, MECH DEVELOP, V65, P175, DOI 10.1016/S0925-4773(97)00071-3; Sechrist J, 1995, DEVELOPMENT, V121, P4103; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; ZHANG H, 1995, MECH DEVELOP, V50, P119, DOI 10.1016/0925-4773(94)00329-L	33	126	128	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					988	991		10.1126/science.281.5379.988	http://dx.doi.org/10.1126/science.281.5379.988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703514				2022-12-24	WOS:000075412700047
J	Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K				Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K			Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion	SCIENCE			English	Article							BINDING PROTEIN; ALPHA-CATENIN; BETA-CATENIN; IDENTIFICATION; FAMILY; RHO; INTERLEUKIN-3; PLAKOGLOBIN; ACTIVATION; FILOPODIA	The small guanosine triphosphatases (GTPases) Cdc42 and Rad regulate E-cadherin-mediated cell-cell adhesion. IQGAP1, a target: of Cdc42 and Rac1,was localized with E-cadherin and beta-catenin at sites of cell-cell contact in mouse L Fibroblasts expressing E-cadherin (EL cells), and interacted with E-cadherin and beta-catenin both in vivo and in vitro. IQGAP1 induced the dissociation of alpha-catenin from a cadherin-catenin complex in vitro and in vivo. Overexpression of IQGAP1 in EL cells, but not in L cells expressing an E-cadherin-alpha-catenin chimeric protein, resulted in a decrease in E-cadherin-mediated cell-cell adhesive activity. Thus, IQGAP1, acting downstream of Cdc42 and Rac1, appears to regulate cell-cell adhesion through the cadherin-catenin pathway.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Japan Sci & Technol, PRESTO, Inheritance & Variat Grp, Kyoto 6190237, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Cent Lab Key Technol, Kirin Brewery, Yokohama 2360004, Japan; Kazusa DNA Res Inst, Kazusa CDNA Res Grp, Kisarazu 2920812, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1620052, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068397, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Hiroshima University; Kirin Brewery Company Limited; Kazusa DNA Research Institute; National Institute of Infectious Diseases (NIID); Kyoto University	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		KURODA, SHINYA/G-4961-2014; Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806				Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; KURODA S, UNPUB; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143	27	410	426	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					832	835		10.1126/science.281.5378.832	http://dx.doi.org/10.1126/science.281.5378.832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694656				2022-12-24	WOS:000075295600052
J	Diamond, HS; Goldberg, E; Janosky, JE				Diamond, HS; Goldberg, E; Janosky, JE			The effect of full-time faculty hospitalists on the efficiency of care at a community teaching hospital	ANNALS OF INTERNAL MEDICINE			English	Article						hospitalists; quality of health care; cost-benefit analysis; patient readmission; length of stay	UNIT	Background: Hospitalists are increasingly being used for inpatient care. Objective: To investigate whether the use of hospitalists is beneficial. Design: Retrospective cohort study. Setting: Inpatient medical service of a 500-bed community teaching hospital. Participants: 1620 patients in the study group, seen during the hospitalist year; 1679 patients from the same outpatient practice as the study group, seen during the previous year (prehospitalist year); an unselected comparison group of 3413 patients seen during the prehospitalist year and 3223 patients seen during the hospitalist year; and a subset of the unselected comparison group, cared for by outpatient practices, who had a prehospitalist length of stay similar to that of the study group (743 patients in the prehospitalist year and 786 in the hospitalist year). Interventions: Full-time faculty hospitalists cared for the study group, were in the hospital during normal working hours, and made decisions throughout the day. In the prehospitalist year and in the comparison groups, primary care physicians managed their own hospitalized patients. Measurements: Length of stay; cost of care; costs of hematology and chemistry evaluation, pharmacy, and radiology; and readmissions were determined for the prehospitalist and hospitalist years. Results: In the study group, median length of stay decreased from 6.01 to 5.01 days (P < 0.001). Median cost of care decreased from $4139 to $3552 (P < 0.001), and the 14-day readmission rate decreased from 9.9 to 4.64 readmissions per 100 admissions (P < 0.001). In the comparison groups, length of stay decreased but both cost of care and readmission rates increased. Conclusion: Hospitalists may improve the efficiency of inpatient care. Further study in various settings is needed to verify these findings.	Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA; Univ Pittsburgh, Sch Med, Div Biostat, Dept Med & Clin Epidemiol, Pittsburgh, PA 15261 USA	West Penn Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Diamond, HS (corresponding author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA.							BRANDNER J, 1995, MANAGED CARE     JUL, P19; BROOK RH, 1987, HLTH CARE FINANCE RE, P39; CAMERON JM, 1985, NEW ENGL J MED, V312, P1233, DOI 10.1056/NEJM198505093121906; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; DIAMOND HS, 1993, J GEN INTERN MED, V8, P614, DOI 10.1007/BF02599717; GIPE B, 1996, COST QUALITY, V2, P6; HORN SD, 1983, AM J PUBLIC HEALTH, V73, P25, DOI 10.2105/AJPH.73.1.25; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Moore J D Jr, 1997, Mod Healthc, V27, P54; Moore J D Jr, 1997, Mod Healthc, V27, P58; NELSON JR, 1997, HOSPITALIST, V1, P1; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	16	135	135	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					197	+		10.7326/0003-4819-129-3-199808010-00006	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104UA	9696727				2022-12-24	WOS:000075032700004
J	Tarnow-Mordi, WO				Tarnow-Mordi, WO			Room air or oxygen for asphyxiated babies?	LANCET			English	Editorial Material							RANDOMIZATION; TRIALS		Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland	University of Dundee	Tarnow-Mordi, WO (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland.							ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; American Heart Association Emergency Cardiac Care Committee and Subcommittees, 1992, J AMER MED ASSOC, V268, P2276, DOI [10.1001/jama.268.16.2276, DOI 10.1001/JAMA.268.16.2276]; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; GRANT A, 1989, LANCET, V2, P345; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; SAUGSTAD OD, 1990, ACTA PAEDIATR SCAND, V79, P881, DOI 10.1111/j.1651-2227.1990.tb11348.x; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SAUGSTAD OD, 1996, PRENAT NEONAT MED, V1, P26; SAUGSTAD OD, 1998, PEDIATRICS, V102; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; TarnowMordi W, 1997, BRIT J OBSTET GYNAEC, V104, P763, DOI 10.1111/j.1471-0528.1997.tb12015.x	11	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					341	342		10.1016/S0140-6736(05)60464-3	http://dx.doi.org/10.1016/S0140-6736(05)60464-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717918				2022-12-24	WOS:000075110500006
J	White, A; Ding, XC; vanderSpek, JC; Murphy, JR; Ringe, D				White, A; Ding, XC; vanderSpek, JC; Murphy, JR; Ringe, D			Structure of the metal-ion-activated diphtheria toxin repressor tox operator complex	NATURE			English	Article							REGULATORY ELEMENT DTXR; CORYNEBACTERIUM-DIPHTHERIAE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; BINDING; RESOLUTION; SITE; REFINEMENT; REVEALS; ERRORS	The virulent phenotype of the pathogenic bacterium Corynebacterium diphtheriae is conferred by diphtheria toxin, whose expression is an adaptive response to low concentrations of iron. The expression of the toxin gene (tox) is regulated by the repressor DtxR (ref. 1), which is activated by transition metal ions. X-ray crystal structures of DtxR with(2-5) and without (apo-form(2)) its coordinated transition metal ion have established the general architecture of the repressor, identified the location of the metal-binding sites, and revealed a metal-ion-triggered subunit-subunit 'caliper-like' conformational change, Here we report the three-dimensional crystal structure of the complex between a biologically active Ni(II)-bound DtxR(C102D) mutant, in which a cysteine is replaced by an aspartate at residue 102, and a 33-base-pair DNA segment containing the toxin operator toxO. This structure shows that DNA interacts with two dimeric repressor proteins bound to opposite sides of the tox operator. We propose that a metal-ion-induced helix-to-coil structural transition in the amino-terminal region of the protein is partly responsible for the unique mode of repressor activation by transition metal ions.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr MS029, Waltham, MA 02454 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Dept Chem, Waltham, MA 02454 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Brandeis University; Brandeis University; Brandeis University; Boston University	Ringe, D (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr MS029, Waltham, MA 02454 USA.	ringe@binah.cc.brandeis.edu						Albright RA, 1998, P NATL ACAD SCI USA, V95, P3431, DOI 10.1073/pnas.95.7.3431; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kercher MA, 1997, CURR OPIN STRUC BIOL, V7, P76, DOI 10.1016/S0959-440X(97)80010-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; MUST LM, BACTERIAL PROTIN TOX, V6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIERING N, 1995, P NATL ACAD SCI USA, V92, P9843, DOI 10.1073/pnas.92.21.9843; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAO X, 1995, P NATL ACAD SCI USA, V92, P6803, DOI 10.1073/pnas.92.15.6803; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; WANG ZO, 1994, INFECT IMMUN, V62, P1600, DOI 10.1128/IAI.62.5.1600-1608.1994; XU T, 1992, J BIOL CHEM, V267, P21761; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317	30	135	145	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					502	506		10.1038/28893	http://dx.doi.org/10.1038/28893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697776				2022-12-24	WOS:000075080400058
J	Brown, P				Brown, P			On the origins of BSE	LANCET			English	Editorial Material									NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA.							Taylor DM, 1998, VET REC, V143, P6, DOI 10.1136/vr.143.1.6; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					252	253		10.1016/S0140-6736(05)60255-3	http://dx.doi.org/10.1016/S0140-6736(05)60255-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690401				2022-12-24	WOS:000074974500004
J	Roland, M; van Tulder, M				Roland, M; van Tulder, M			Should radiologists change the way they report plain radiography of the spine?	LANCET			English	Editorial Material									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands	University of Manchester; Vrije Universiteit Amsterdam	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 6PL, Lancs, England.		van Tulder, Maurits/AAB-9785-2022	van Tulder, Maurits/0000-0002-7589-8471				*AG HLTH CAR POL R, 1994, AC LOW BACK PROBL AD; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; HAPLIN SF, 1991, BRIT MED J, V303, P813; KELLGREN JH, 1963, ATLAS STANDARD RADIO, V2, P20; ROSEN M, 1995, BACK PAIN; *ROYAL COLL RAD, 1995, MAK BEST US DEP RAD; SuarezAlmazor ME, 1997, JAMA-J AM MED ASSOC, V277, P1782, DOI 10.1001/jama.277.22.1782; vanTulder MW, 1997, SPINE, V22, P427, DOI 10.1097/00007632-199702150-00015; WADDELL G, 1996, LOW BACK PAIN EVIDEN	13	41	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					229	230		10.1016/S0140-6736(97)11499-4	http://dx.doi.org/10.1016/S0140-6736(97)11499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683228				2022-12-24	WOS:000074859800044
J	Emanuel, EJ; Battin, MP				Emanuel, EJ; Battin, MP			What are the potential cost savings from legalizing physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINAL CANCER-PATIENTS; ACTIVE EUTHANASIA; MEDICAL DECISIONS; MANAGED DEATH; DATA SHOW; LAST YEAR; CARE; LIFE; END; ATTITUDES		Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; Univ Utah, Dept Philosophy, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Internal Med, Div Med Eth, Salt Lake City, UT USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, 44 Binney St, Boston, MA 02115 USA.							Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DORONZIO JC, 1993, NY TIMES        0608, pA25; Emanuel EJ, 1998, MINN LAW REV, V82, P983; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRYE A, 1994, WASHINGTON POST 0102, pC3; Ginzberg E, 1980, Inquiry, V17, P293; GODEC MS, 1993, WASHINGTON POST 0502, pC3; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAPUMA J, 1995, ARCH INTERN MED, V155, P1553, DOI 10.1001/archinte.1995.00430140133014; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LONG SH, 1984, INQUIRY-J HEALTH CAR, V21, P315; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; *NAT HOSP ORG, 1995, AN COST SAV MED HOSP; PETERSON PG, 1996, AM GROW UP IT GROWS, P176; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; Riley G F, 1989, Health Care Financ Rev, V11, P1; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Maas PJ, 1992, HEALTH POLICY, V22, P1	42	53	53	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					167	172		10.1056/NEJM199807163390306	http://dx.doi.org/10.1056/NEJM199807163390306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ922	9664094				2022-12-24	WOS:000074782900006
J	de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM				de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM			Effect of interleukin 8 in meconium on in-vitro neutrophil chemotaxis	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; ASPIRATION SYNDROME; INHIBITION; IL-8; INFLAMMATION; FLUID	Background Pneumonitis, characterised by large numbers of neutrophils in the lung, is an important feature of the meconium aspiration syndrome. The mechanism underlying the neutrophil influx is not known. We have investigated whether meconium has chemotactic activity and whether such activity is related to the presence of interleukin 8. Methods The chemotactic activity of meconium on neutrophils from newborn infants was assessed in a Boyden-chamber assay. Interleukin 8 and formyl-methionyl-leucyl-phenylalanine (f-MLP) served as positive controls. Inhibition of chemotaxis was assessed with monoclonal antibody to interleukin 8. The interleukin-8 concentration was measured by ELISA. Findings Sterile meconium suspension from seven unrelated newborn babies increased migration of neutrophils from neonates in comparison with random migration (79, 72, 70, 50, 58, 88 mu m vs 46 mu m; p<0,001). This effect was greatest at a meconium concentration of 5 g/L, although differences between samples from individual babies were observed. Interleukin 8 was present in all meconium suspensions (480-3980 ng/L). Anti-interleukin-8 inhibited neutrophil migration. Interpretation Interleukin 8 is present in meconium and it induces chemotaxis of neutrophils in vitro. This mechanism may have a role in the pathogenesis of pneumonitis in meconium aspiration syndrome.	Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Biochem Med, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Beaufort, AJ (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, POB 9600, NL-2300 RC Leiden, Netherlands.			de Beaufort, Arnout Jan/0000-0003-1990-2672				BERGER HM, 1994, J R COLL PHYSICIANS, V1, P24; CLARK P, 1995, AM J OBSTET GYNECOL, V173, P1301, DOI 10.1016/0002-9378(95)91375-0; DAVEY AM, 1993, PEDIATR PULM, V16, P101, DOI 10.1002/ppul.1950160205; DIRKES K, 1995, J PEDIATR SURG, V30, P979, DOI 10.1016/0022-3468(95)90325-9; Elferink JGR, 1997, BRIT J PHARMACOL, V121, P643, DOI 10.1038/sj.bjp.0701167; ELFERINK JGR, 1993, EUR J PHARM-MOLEC PH, V246, P157, DOI 10.1016/0922-4106(93)90093-O; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Jones CA, 1996, PEDIATR RES, V39, P966, DOI 10.1203/00006450-199606000-00007; KATZ VL, 1992, AM J OBSTET GYNECOL, V166, P171, DOI 10.1016/0002-9378(92)91856-6; Miller EJ, 1996, CRIT CARE MED, V24, P1448, DOI 10.1097/00003246-199609000-00004; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; Olah KS, 1996, J REPROD IMMUNOL, V32, P89, DOI 10.1016/S0165-0378(96)00990-4; Perks B., 1997, European Respiratory Journal Supplement, V10, p303S; PERLMAN EJ, 1989, HUM PATHOL, V20, P701, DOI 10.1016/0046-8177(89)90159-7; RAPPAPORT S, 1950, SCIENCE, V85, P715; Soukka H, 1997, PEDIATR PULM, V23, P205, DOI 10.1002/(SICI)1099-0496(199703)23:3<205::AID-PPUL6>3.0.CO;2-M; SUN B, 1993, ACTA PAEDIATR, V82, P182, DOI 10.1111/j.1651-2227.1993.tb12635.x; TYLER DC, 1978, PEDIATRICS, V62, P454; Yokoi K, 1997, LAB INVEST, V76, P375; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	21	65	65	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					102	105		10.1016/S0140-6736(98)85013-7	http://dx.doi.org/10.1016/S0140-6736(98)85013-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672275				2022-12-24	WOS:000074775100013
J	Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K				Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K			The initiator function of DnaA protein is negatively regulated by the sliding clamp of the E-coli chromosomal replicase	CELL			English	Article							POLYMERASE-III HOLOENZYME; IN-VITRO REPLICATION; ESCHERICHIA-COLI; BETA-SUBUNIT; ENZYMATIC REPLICATION; ORIGIN REGION; MUTANT; SEQA; GENE; PURIFICATION	The beta subunit of DNA polymerase III is essential far negative regulation of the initiator protein, DnaA. DnaA inactivation occurs through accelerated hydrolysis of ATP bound to DnaA; the resulting ADP-DnaA fails to initiate replication. The ability of beta subunit to promote DnaA inactivation depends on its assembly as a sliding clamp on DNA and must be accompanied by a partially purified factor, IdaB protein. DnaA inactivation in the presence of IdaB and DNA polymerase III is further stimulated by DNA synthesis, indicating close linkage between initiator inactivation and replication. In vivo, DnaA predominantly takes on the ADP form in a beta subunit-dependent manner. Thus, the initiator is negatively regulated by action of the replicase, a mechanism that may be key to effective control of the replication cycle.	Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Kyushu University; Georgetown University	Katayama, T (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan.			Katayama, Tsutomu/0000-0001-9994-1684	NIGMS NIH HHS [R01 GM049700, GM49700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM049700, R01GM049700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1995, CELL, V82, P877, DOI 10.1016/0092-8674(95)90020-9; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROOKE E, 1992, J BIOL CHEM, V267, P16779; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; ECHOLS H, 1961, J MOL BIOL, V3, P425, DOI 10.1016/S0022-2836(61)80055-7; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1996, EMBO J, V15, P2313, DOI 10.1002/j.1460-2075.1996.tb00585.x; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1997, MOL MICROBIOL, V25, P661, DOI 10.1046/j.1365-2958.1997.5001872.x; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MIKI T, 1978, MOL GEN GENET, V158, P217, DOI 10.1007/BF00267192; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOZAKI N, 1988, J BIOL CHEM, V263, P14176; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SAKAKIBARA Y, 1980, MOL GEN GENET, V178, P541, DOI 10.1007/BF00337859; Sambrook JFE, 1989, MOL CLONING LAB MANU; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	66	262	264	0	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					61	71		10.1016/S0092-8674(00)81222-2	http://dx.doi.org/10.1016/S0092-8674(00)81222-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674428	hybrid			2022-12-24	WOS:000074790800010
J	Iiri, T; Farfel, Z; Bourne, HR				Iiri, T; Farfel, Z; Bourne, HR			G-protein diseases furnish a model for the turn-on switch	NATURE			English	Article							HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; BETA-GAMMA; GTP HYDROLYSIS; ALPHA-SUBUNIT; TRANSDUCIN; RHODOPSIN; MECHANISM; ACTIVATION; G(I-ALPHA-1)	How does a trimeric a protein on the inside of a cell membrane respond to activation by a transmembrane receptor? G-protein mutations in patients with hypertension and inherited endocrine disorders enhance or block signals from stimulated receptors. In combination with three-dimensional crystal structures and results from biochemical experiments, the phenotypes produced by these mutations suggest a model for the molecular activation mechanism that relays hormonal and sensory signals transmitted by many transmembrane receptors.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Tel Aviv Univ, Biochem Pharmacol Lab, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Med E, IL-52621 Tel Hashomer, Israel	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	h_bourne@quickmail.ucsf.edu						Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P9998; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; IIRI T, 1998, NAT GENET, V18, P45; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; SUNAHARA RK, 1997, GSA SCI, V278, P1943; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WEST RE, 1985, J BIOL CHEM, V260, P4428	45	161	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					35	38		10.1038/27831	http://dx.doi.org/10.1038/27831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665125				2022-12-24	WOS:000074579600039
J	Luzuriaga, K; Sullivan, JL				Luzuriaga, K; Sullivan, JL			Prevention and treatment of pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFANT		Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Sullivan, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Suite 318,Biotech II,373 Plantat St, Worcester, MA 01605 USA.	John.Sullivan@banyan.ummed.edu						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1998, MMWR MORB MORTAL WKL, V47; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Luzuriaga K, 1996, JAMA-J AM MED ASSOC, V275, P1360; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MIROCHNICK M, IN PRESS J INFECT DI; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *UNAIDS WHO WORK G, 1998, GLOB HIV AIDS EP EST; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911	22	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					17	18		10.1001/jama.280.1.17	http://dx.doi.org/10.1001/jama.280.1.17			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660351				2022-12-24	WOS:000074379400010
J	Shishido, E; Takeichi, M; Nose, A				Shishido, E; Takeichi, M; Nose, A			Drosophila synapse formation: Regulation by transmembrane protein with leu-rich repeats, CAPRICIOUS	SCIENCE			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; MOTOR AXONS; MOTONEURONS; EMBRYO; SUBSET; GENES	Upon reaching the target region, neuronal growth cones transiently search through potential targets and form synaptic connections with only a subset of these. The capricious (caps) gene may regulate these processes in Drosophila. caps encodes a transmembrane protein with leucine-rich repeats (LRRs). During the formation of neuromuscular synapses, caps is expressed in a small number of synaptic partners, including muscle 12 and the motorneurons that innervate it. Loss-of-function and ectopic expression of caps alter the target specificity of muscle 12 motorneurons, indicating a role for caps in selective synapse formation.	Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University	Nose, A (corresponding author), Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138654, Japan.	nose@bio.phys.s.u-tokyo.ac.jp	Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Shishido, Emiko/0000-0002-2474-1343				BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; JIA XX, 1993, J NEUROBIOL, V24, P1025, DOI 10.1002/neu.480240804; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kose H, 1997, DEVELOPMENT, V124, P4143; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Landgraf M, 1997, J NEUROSCI, V17, P9642; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; Nose A, 1997, DEVELOPMENT, V124, P1433; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Raghavan S, 1997, NEURON, V18, P873, DOI 10.1016/S0896-6273(00)80327-X; Rose D, 1997, DEVELOPMENT, V124, P1561; SHISHIDO E, UNPUB; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	30	97	99	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2118	2121		10.1126/science.280.5372.2118	http://dx.doi.org/10.1126/science.280.5372.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641918				2022-12-24	WOS:000074435900046
J	Sweitzer, SM; Hinshaw, JE				Sweitzer, SM; Hinshaw, JE			Dynamin undergoes a GTP-dependent conformational change causing vesiculation	CELL			English	Article							PROTEIN-KINASE-C; MEDIATED ENDOCYTOSIS; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; SH3 DOMAINS; DROSOPHILA; SHIBIRE; IDENTIFICATION; MUTATIONS	The dynamin family of GTPases is essential for receptor-mediated endocytosis and synaptic vesicle recycling, and it has recently been shown to play a role in vesicle formation from the trans-Golgi network. Dynamin is believed to assemble around the necks of clathrin-coated pits and assist in pinching vesicles from the plasma membrane. This role would make dynamin unique among GTPases in its ability to act as a mechanochemical enzyme. Data presented here demonstrate that purified recombinant dynamin binds to a lipid bilayer in a regular pattern to form helical tubes that constrict and vesiculate upon GTP addition. This suggests that dynamin alone is sufficient for the formation of constricted necks of coated pits and supports the hypothesis that dynamin is the force-generating molecule responsible for membrane fission.	NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sweitzer, SM (corresponding author), NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.							Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	39	526	534	2	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1021	1029		10.1016/S0092-8674(00)81207-6	http://dx.doi.org/10.1016/S0092-8674(00)81207-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635431	Bronze			2022-12-24	WOS:000074205700013
J	Brewer, JB; Zhao, Z; Desmond, JE; Glover, GH; Gabrieli, JDE				Brewer, JB; Zhao, Z; Desmond, JE; Glover, GH; Gabrieli, JDE			Making memories: Brain activity that predicts how well visual experience will be remembered	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HIPPOCAMPAL-FORMATION; ACTIVATION; ANATOMY; LOBE	Experiences are remembered or forgotten, but the neural determinants for the mnemonic fate of experience are unknown. Event-related functional magnetic resonance imaging was used to identify specific brain activations that differentiated between visual experiences that were later remembered well, remembered less well, or forgotten. During scanning of medial temporal lobe and frontal lobe regions, subjects viewed complex, color photographs. Subjects later received a test of memory for the photographs. The magnitudes of focal activations in right prefrontal cortex and in bilateral parahippocampal cortex predicted which photographs were later remembered well, remembered less well, or forgotten.	Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Brewer, JB (corresponding author), Stanford Univ, Neurosci Program, Bldg 420,Jordan Hall, Stanford, CA 94305 USA.		Gabrieli, John/AAJ-2869-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Buckner RL, 1998, NEURON, V20, P285, DOI 10.1016/S0896-6273(00)80456-0; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Gabrieli JDE, 1996, PSYCHOL SCI, V7, P278, DOI 10.1111/j.1467-9280.1996.tb00374.x; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Glover GH, 1998, MAGN RESON MED, V39, P361, DOI 10.1002/mrm.1910390305; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; HAYES C, 1996, P 4 ANN M ISMRM NEW; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Martin A, 1997, HIPPOCAMPUS, V7, P587, DOI 10.1002/(SICI)1098-1063(1997)7:6<587::AID-HIPO1>3.0.CO;2-C; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Rombouts SARB, 1997, HIPPOCAMPUS, V7, P594, DOI 10.1002/(SICI)1098-1063(1997)7:6<594::AID-HIPO2>3.3.CO;2-I; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SANQUIST TF, 1984, PSYCHOPHYSIOLOGY, V23, P298; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	34	836	851	4	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1185	1187		10.1126/science.281.5380.1185	http://dx.doi.org/10.1126/science.281.5380.1185			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712581				2022-12-24	WOS:000075531200051
J	Ofri, D				Ofri, D			Autopsy room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Ofri, Danielle/0000-0001-9865-7104					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					402	402		10.1001/jama.280.5.402	http://dx.doi.org/10.1001/jama.280.5.402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701057				2022-12-24	WOS:000075050200001
J	Simonsen, A; Lippe, R; Christoforidis, S; Gaullier, JM; Brech, A; Callaghan, J; Toh, BH; Murphy, C; Zerial, M; Stenmark, H				Simonsen, A; Lippe, R; Christoforidis, S; Gaullier, JM; Brech, A; Callaghan, J; Toh, BH; Murphy, C; Zerial, M; Stenmark, H			EEA1 links PI(3)K function to Rab5 regulation of endosome fusion	NATURE			English	Article							ENDOCYTIC MEMBRANE-FUSION; SMALL GTPASE RAB5; PHOSPHATIDYLINOSITOL 3-KINASE; PATHWAY; LOCALIZATION; WORTMANNIN	GTPases and lipid kinases regulate membrane traffic along the endocytic pathway by mechanisms that are not completely understood(1-4). Fusion between early endosomes requires phosphatidyl-inositol-3-OH kinase (PI(3)K) activity(5-7) as well as the small GTPase Rab5 (ref. 8). Excess Rab5-GTP complex restores endosome fusion when PI(3)K is inhibited(5,9), Here we identify the early-endosomal autoantigen EEA1 (refs 10-12) which binds the PI(3)K product phosphatidylinositol-3-phosphate, as a new Rab5 effector that is required for endosome fusion. The association of EEA1 with the endosomal membrane requires Rab5-GTP and PI(3)K activity, and excess Rab5-GTP stabilizes the membrane association of EEA1 even when PI(3)K is inhibited. The identification of EEA1 as a direct Rab5 effector provides a molecular link between PI(3)K and Rab5, and its restricted distribution to early endosomes(10) indicates that EEA1 may confer directionality to Rab5-dependent endocytic transport.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; European Mol Biol Lab, D-69012 Heidelberg, Germany; Inst Biol, EM Unit, N-0316 Oslo, Norway; Monash Univ Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of Oslo; European Molecular Biology Laboratory (EMBL); Monash University; Max Planck Society	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Stenmark, Harald/B-8868-2008; Murphy, Carol/ABE-4282-2021	Murphy, Carol/0000-0003-1353-8558; Christoforidis, Savvas/0000-0002-0210-0713; Lippe, Roger/0000-0001-5066-3070; Simonsen, Anne/0000-0003-4711-7057; Brech, Andreas/0000-0002-9803-1774				BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Jones AT, 1998, MOL BIOL CELL, V9, P323, DOI 10.1091/mbc.9.2.323; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OIKKONEN VM, 1997, INT REV CYTOL, V176, P1; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	26	884	903	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					494	498		10.1038/28879	http://dx.doi.org/10.1038/28879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697774				2022-12-24	WOS:000075080400056
J	Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA				Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA			Reversible hydrogels from self-assembling artificial proteins	SCIENCE			English	Article							GCN4 LEUCINE-ZIPPER; COILED-COILS; SEQUENCES; MODEL	Recombinant DNA methods were used to create artificial proteins that undergo reversible gelation in response to changes in pH or temperature. The proteins consist of terminal Leucine zipper domains flanking a central, flexible, water-soluble polyelectrolyte segment. Formation of coiled-coil aggregates of the terminal domains in near-neutral aqueous solutions triggers formation of a three-dimensional polymer network, with the polyelectrolyte segment retaining solvent and preventing precipitation of the chain. Dissociation of the coiled-coil aggregates through elevation of pH or temperature causes dissolution of the gel and a return to the viscous behavior that is characteristic of polymer solutions. The mild conditions under which gel formation can be controlled (near-neutral pH and near-ambient temperature) suggest that these materials have potential in bioengineering applications requiring encapsulation or controlled release of molecular and cellular species.	Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; USA, Sci & Technol Directorate, Natick Res Dev & Engn Ctr, Natick, MA 01760 USA	University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	Tirrell, DA (corresponding author), Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.		Wirtz, Denis/A-3257-2010					CLARK AH, 1987, ADV POLYM SCI, V83, P57; Guenet J.-M., 1992, THERMOREVERSIBLE GEL, DOI 10.1002/adma.19930050316; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mason TG, 1996, J MOL STRUCT, V383, P81, DOI 10.1016/S0022-2860(96)09272-1; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; McGrath K., 1997, PROTEIN BASED MAT; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MORRIS ER, 1980, J MOL BIOL, V138, P349, DOI 10.1016/0022-2836(80)90291-0; Nijenhuis K.T., 1997, THERMOREVERSIBLE NET, DOI 10.1007/BFb0008699; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	27	888	943	10	387	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					389	392		10.1126/science.281.5375.389	http://dx.doi.org/10.1126/science.281.5375.389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665877				2022-12-24	WOS:000074918800040
J	Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S				Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S			Molecular coproscopy: Dung and diet of the extinct ground sloth Nothrotheriops shastensis	SCIENCE			English	Article							ANCIENT DNA; ENZYMATIC AMPLIFICATION; EXTRACTION; MECHANISM; RETRIEVAL; SEQUENCES; DAMAGE; PLANTS; FOOD; PCR	DNA from excrements can be amplified by means of the polymerase chain reaction. However, this has not been possible with ancient feces. Cross-Links between reducing sugars and amino groups were shown to exist in a Pleistocene coprolite from Gypsum Cave, Nevada. A chemical agent, N-phenacylthiazolium bromide,,that cleaves such cross-links made it possible to amplify DNA sequences. Analyses of these DNA sequences showed that the coprolite is derived from an extinct sloth, presumably the Shasta ground sloth Nothrotheriops shastensis. Plant DNA sequences from seven groups of plants were identified in the coprolite. The plant assemblage that formed part of the sloth's diet exists today at elevations about 800 meters higher than the cave.	Univ Munich, Max Planck Inst Evolutionary Anthropol, D-80333 Munich, Germany; Univ Munich, Inst Zool, D-80333 Munich, Germany; Dames & Moore, Las Vegas, NV 89119 USA; Univ Arizona, Dept Geosci, Desert Lab, Tucson, AZ 85721 USA; Univ Bristol, Dept Geol, Biogeochem Res Ctr, Bristol BS8 1RJ, Avon, England; Div Ion Phys, Angstrom Lab, S-75121 Uppsala, Sweden	Max Planck Society; University of Munich; University of Munich; University of Arizona; University of Bristol	Poinar, HN (corresponding author), Univ Munich, Max Planck Inst Evolutionary Anthropol, Luisenstr 14, D-80333 Munich, Germany.		Hofreiter, Michael/A-3996-2017	Hofreiter, Michael/0000-0003-0441-4705				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; Evershed RP, 1997, SCIENCE, V278, P432, DOI 10.1126/science.278.5337.432; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Handt O, 1996, AM J HUM GENET, V59, P368; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; HANSEN RM, 1978, PALEOBIOLOGY, V4, P302, DOI 10.1017/S0094837300006011; HARRINGTON MR, 1933, GYPSUM CAVE, V8; Hickman JC., 1993, JEPSON MANUAL; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; HOSS M, 1992, NATURE, V359, P199, DOI 10.1038/359199a0; HOSS M, 1995, THESIS LUDWIGMAXIMIL; KOHN M, 1995, MOL ECOL, V4, P95, DOI 10.1111/j.1365-294X.1995.tb00196.x; Kohn MH, 1997, TRENDS ECOL EVOL, V12, P223, DOI 10.1016/S0169-5347(97)01050-1; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; KRINGS M, 1997, CELL, V90; Laudermilk J.D., 1934, CARNEGIE I WASHINGTO, V453, P31; LEE AT, 1987, MUTAT RES, V179, P151, DOI 10.1016/0027-5107(87)90305-8; LONG A, 1974, SCIENCE, V186, P638, DOI 10.1126/science.186.4164.638; MARTIN PS, 1961, AM J SCI, V259, P102, DOI 10.2475/ajs.259.2.102; MAURON J, 1981, PROG FOOD NUTR SCI, V5, P5; MULDER MM, 1991, J ANAL APPL PYROL, V19, P175, DOI 10.1016/0165-2370(91)80042-7; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1993, SCI AM, V269, P86; Paabo S., 1990, PCR PROTOCOLS GUIDE, P159; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; POINAR HN, UNPUB; SAIZJIMENEZ C, 1984, ORG GEOCHEM, V6, P417, DOI DOI 10.1016/0146-6380(84)90064-0; SPAULDING WG, 1990, PACKRAT MIDDENS LAST, pCH9; Stankiewicz BA, 1997, NEW PHYTOL, V135, P375, DOI 10.1046/j.1469-8137.1997.00638.x; Stankiewicz BA, 1997, SCIENCE, V276, P1541, DOI 10.1126/science.276.5318.1541; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAYLOR P, 1996, MOL BIOL EVOL, V13, P2839; THORNE RF, 1992, BOT REV, V58, P225, DOI 10.1007/BF02858611; VANBERGEN PF, 1994, GEOCHIM COSMOCHIM AC, V58, P3823, DOI 10.1016/0016-7037(94)90366-2; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; WEENEN H, 1994, ACS SYM SER, V543, P142	41	352	374	2	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					402	406		10.1126/science.281.5375.402	http://dx.doi.org/10.1126/science.281.5375.402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665881				2022-12-24	WOS:000074918800044
J	Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK				Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK			A multidisciplinary approach to therapy for unresectable malignant thymoma	ANNALS OF INTERNAL MEDICINE			English	Article							INVASIVE THYMOMA; NEOADJUVANT CHEMOTHERAPY; CLINICAL STAGES; CISPLATIN; SURVIVAL; CYCLOPHOSPHAMIDE; INTERGROUP; RESECTION; PHASE	Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor. Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma. Design: Prospective cohort study. Setting: Tertiary care cancer center. Participants: All eligible patients had newly diagnosed, histologically proven, unresectable malignant thymoma. Intervention: The treatment regimen consisted of induction chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone). Tissue samples were taken at the time of surgical resection for assessment of tumor necrosis and Ki-67 expression. Measurements: Tumor response and resectability (both overall and after induction chemotherapy) and disease-free survival rate in patients who received multimodal therapy. Results: 13 patients were consecutively enrolled from February 1990 to December 1996, and 12 evaluable patients were assessed for response. Disease responded to induction chemotherapy completely in 3 patients (25%) and partially in 8 patients (67%); 1 patient had a minor response (8%). Eleven patients had surgical resection; 1 refused surgery. Tumors were removed completely in 9 (82%) and incompletely in 2 (18%) of 11 patients who had been receiving radiation therapy and consolidation chemotherapy. All 12 patients are alive (100% at 7 years), with a median follow-up of 43 months, and 10 patients are disease free (73 % disease-free survival at 7 years). A high correlation was seen between tumor necrosis after induction chemotherapy and Ki-67 expression (r = -0.88). Conclusions: Aggressive multimodal treatment is highly effective and may cure locally advanced, unresectable malignant thymoma.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Shin, DM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Ray, Dana M/C-3470-2013; Shin, Dong Moon/G-9649-2013	Shin, Dong Moon/0000-0002-8245-4174; Putnam, Joe/0000-0002-7504-2104				BERRUTI A, 1993, ANN ONCOL, V4, P429, DOI 10.1093/oxfordjournals.annonc.a058527; BLUMBERG D, 1995, ANN THORAC SURG, V60, P908, DOI 10.1016/0003-4975(95)00669-C; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COWEN D, 1995, RADIOTHER ONCOL, V34, P9, DOI 10.1016/0167-8140(94)01493-M; Giaccone G, 1996, J CLIN ONCOL, V14, P814, DOI 10.1200/JCO.1996.14.3.814; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1994, MOSS RAD ONCOLOGY RA, P320; LOEHRER PJ, 1990, ANN INTERN MED, V113, P520, DOI 10.7326/0003-4819-113-7-520; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164, DOI 10.1200/JCO.1994.12.6.1164; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093, DOI 10.1200/JCO.1997.15.9.3093; MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H; MAGGI G, 1986, CANCER-AM CANCER SOC, V58, P765, DOI 10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; MCCART JA, 1993, J SURG ONCOL, V54, P233, DOI 10.1002/jso.2930540409; PARK HS, 1994, CANCER-AM CANCER SOC, V73, P2491, DOI 10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6; REA F, 1993, J THORAC CARDIOV SUR, V106, P543; THOMAS C R JR, 1990, Current Opinion in Oncology, V2, P359; Uematsu M, 1996, INT J RADIAT ONCOL, V35, P357, DOI 10.1016/0360-3016(96)00086-7; VERLEY JM, 1985, CANCER, V55, P1074, DOI 10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T; Yang WI, 1996, HUM PATHOL, V27, P70, DOI 10.1016/S0046-8177(96)90140-9	20	92	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					100	104		10.7326/0003-4819-129-2-199807150-00006	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669967				2022-12-24	WOS:000074852000004
J	Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M				Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M			Reversal of lesions of diabetic nephropathy after pancreas transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR STRUCTURE; NORMAL KIDNEYS; IDDM PATIENTS; LONG-TERM; PROGRESSION; RECIPIENTS; MESANGIUM; MELLITUS; MEMBRANE; GLUCOSE	Background In patients with type 1 diabetes mellitus who do not have uremia and have not received a kidney transplant, pancreas transplantation does not ameliorate established lesions of diabetic nephropathy within five years after transplantation, but the effects of longer periods of normoglycemia are un known. Methods We studied kidney function and performed renal biopsies before pancreas transplantation and 5 and 10 years thereafter in eight patients with type 1 diabetes but without uremia who had mild to advanced lesions of diabetic nephropathy at the time of transplantation. The biopsy samples were analyzed morphometrically. Results All patients had persistently normal glycosylated hemoglobin values after transplantation. The median urinary albumin excretion rate was 103 mg per day before transplantation, 30 mg per day 5 years after transplantation, and 20 mg per day 10 years after transplantation (P=0.07 for the comparison of values at base line and at 5 years; P=0.11 for the comparison between base line and 10 years). The mean (+/-SD) creatinine clearance rate declined from 108+/-20 ml per minute per 1.73 m(2) of body-surface area at base line to 74+/-16 ml per minute per 1.73 m(2) at 5 years (P<0.001) and 74+/-14 ml per minute per 1.73 m(2) at 10 years (P<0.001). The thickness of the glomerular and tubular basement membranes was similar at 5 years (570+/-64 and 928+/-173 nm, respectively) and at base line (594+/-81 and 911+/-133 nm, respectively) but had decreased by 10 years (to 404+/-38 and 690+/-111 nm, respectively; P<0.001 and P=0.004 for the comparisons with the base-line values). The mesangial fractional volume (the proportion of the glomerulus occupied by the mesangium) increased from base line (0.33+/-0.07) to 5 years (0.39+/-0.10, P=0.02) but had decreased at 10 years (0,27+/-0.02, P=0.05 for the comparison with the baseline value and P=0.006 for the comparison with the value at 5 years), mostly because of a reduction in mesangial matrix. Conclusions Pancreas transplantation can reverse the lesions of diabetic nephropathy, but reversal requires more than five years of normoglycemia, (N Engl J Med 1998;339:69-75.) (C)1998, Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Pediat, UMHC, Minneapolis, MN 55455 USA; Univ Padua, Sch Med, Dept Internal Med, Padua, Italy; Univ Padua, Sch Med, Natl Res Council, Ctr Study Aging, Padua, Italy; Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Padua; University of Padua; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Mauer, M (corresponding author), Univ Minnesota, Sch Med, Dept Pediat, UMHC, Box 491,420 Delaware St SE, Minneapolis, MN 55455 USA.		Mauer, Michael/ABD-5415-2020; fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043605, P01DK013083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43605, DK13083] Funding Source: Medline; PHS HHS [MO1-KK00400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BARBOSA J, 1994, JAMA-J AM MED ASSOC, V272, P600, DOI 10.1001/jama.272.8.600; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; Brito PL, 1998, KIDNEY INT, V53, P754, DOI 10.1046/j.1523-1755.1998.00809.x; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; FIORETTO P, 1993, LANCET, V342, P1193, DOI 10.1016/0140-6736(93)92183-T; FIORETTO P, 1995, KIDNEY INT, V48, P1929, DOI 10.1038/ki.1995.493; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; FIORETTO P, 1995, KIDNEY INT, V48, P489, DOI 10.1038/ki.1995.318; FIORETTO P, 1992, AM J KIDNEY DIS, V20, P549, DOI 10.1016/S0272-6386(12)70217-2; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LUBEC G, 1980, Renal Physiology, V3, P4; MAUER SM, 1989, DIABETES, V38, P516, DOI 10.2337/diabetes.38.4.516; MAUER SM, 1983, DIABETES, V32, P948, DOI 10.2337/diabetes.32.10.948; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; Moriya Rika, 1996, Journal of the American Society of Nephrology, V7, P1362; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; OSTERBY R, 1991, DIABETOLOGIA, V34, P668, DOI 10.1007/BF00400997; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; STEFFES MW, 1985, NEW ENGL J MED, V312, P1282, DOI 10.1056/NEJM198505163122003; SUTHERLAND DER, 1993, AM J SURG, V166, P456, DOI 10.1016/S0002-9610(05)81142-0; SUTHERLAND DER, 1994, TRANSPL P, V26, P379; WEIBEL ER, 1962, J APPL PHYSIOL, V17, P343, DOI 10.1152/jappl.1962.17.2.343; 1994, AM J KIDNEY DIS S2, V24, pS48	33	823	849	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					69	75		10.1056/NEJM199807093390202	http://dx.doi.org/10.1056/NEJM199807093390202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654536	Bronze			2022-12-24	WOS:000074665300002
J	Cowie, LL; Songaila, A				Cowie, LL; Songaila, A			Heavy-element enrichment in low-density regions of the intergalactic medium	NATURE			English	Article							LYMAN-ALPHA FOREST; GRAVITATIONAL COLLAPSE; CLOUDS; MODEL; ABUNDANCE	Models for the composition of the diffuse intergalactic medium(1,2) predict that low-density intergalactic gas at high redshift should be very poor in heavy elements. This is because locations of early star formation land thus of heavy-element synthesis) and of gas delivery from such stars are located preferentially within higher-density regions of the intergalactic gas. Here we present a method for analysing carbon and oxygen absorption lines in quasar spectra that allows us to probe the heavy-element abundances at a redshift of three within low-density regions of intergalactic gas. We find that the ratio of triply ionized carbon to neutral hydrogen is roughly constant over a wide range of densities, and that, even as the density approaches zero, the ratio remains high. This unexpected enrichment of low-density gas in heavy elements suggests that early generations of small galaxies might be much more efficient at ejecting heavy elements into the intergalactic medium than has previously been thought.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of Hawaii System	Cowie, LL (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.			Cowie, Lennox/0000-0002-6319-1575; Cowie Songaila, Antoinette/0000-0001-9028-6978				Bi HG, 1997, ASTROPHYS J, V479, P523, DOI 10.1086/303908; CEN RY, 1994, ASTROPHYS J, V437, pL9, DOI 10.1086/187670; COWIE LL, 1995, ASTRON J, V109, P1522, DOI 10.1086/117381; Croft RAC, 1997, ASTROPHYS J, V488, P532, DOI 10.1086/304723; Dave R, 1997, ASTROPHYS J, V477, P21, DOI 10.1086/303712; Giroux ML, 1997, ASTRON J, V113, P1505, DOI 10.1086/118367; Gnedin NY, 1998, MON NOT R ASTRON SOC, V294, P407, DOI 10.1046/j.1365-8711.1998.01156.x; Gnedin NY, 1997, ASTROPHYS J, V486, P581, DOI 10.1086/304548; Haardt F, 1996, ASTROPHYS J, V461, P20, DOI 10.1086/177035; Haiman Z, 1997, ASTROPHYS J, V483, P21, DOI 10.1086/304238; Hellsten U, 1997, ASTROPHYS J, V487, P482, DOI 10.1086/304641; Hernquist L, 1996, ASTROPHYS J, V457, pL51, DOI 10.1086/309899; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; Hui L, 1997, MON NOT R ASTRON SOC, V292, P27, DOI 10.1093/mnras/292.1.27; LU LM, 1991, ASTROPHYS J, V379, P99, DOI 10.1086/170487; MEYER D, 1987, ASTROPHYS J, V315, pL8; MiraldaEscude J, 1996, ASTROPHYS J, V471, P582, DOI 10.1086/177992; MiraldaEscude J, 1997, ASTROPHYS J, V478, pL57, DOI 10.1086/310550; NORRIS J, 1983, ASTROPHYS J, V273, P450, DOI 10.1086/161383; PETITJEAN P, 1995, ASTRON ASTROPHYS, V295, pL9; Petitjean P., 1995, Science with VLT. Proceedings of the ESO Workshop, P339; Rauch M, 1997, ASTROPHYS J, V481, P601, DOI 10.1086/304085; SARGENT LL, ASTROPH9802189; Songaila A, 1997, ASTROPHYS J, V490, pL1, DOI 10.1086/311006; Songaila A, 1996, ASTRON J, V112, P335, DOI 10.1086/118018; SONGALILA A, IN PRESS ASTRON J; TYTLER D, 1994, ASTROPHYS J, V424, pL87, DOI 10.1086/187281; ZHANG Y, 1995, ASTROPHYS J, V453, pL57	28	131	132	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					44	46		10.1038/27845	http://dx.doi.org/10.1038/27845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665126				2022-12-24	WOS:000074579600041
J	Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G				Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G			Use of misoprostol during pregnancy and Mobius syndrome in infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOEBIUS SYNDROME; VASCULAR ETIOLOGY; ILLEGAL ABORTION; BRAZIL; TERATOGENICITY; MIFEPRISTONE; TRIMESTER	Background Patients with upper gastrointestinal ulceration may be treated with misoprostol, but it is not recommended for pregnant women because it may stimulate uterine contractions and cause vaginal bleeding and miscarriage. Recent data from Bra zil, where misoprostol is used orally and vaginally as an abortifacient, have suggested a relation between the use of misoprostol by women in an unsuccessful attempt to terminate pregnancy and Mobius' syndrome (congenital facial paralysis) in their infants. Methods We compared the frequency of misoprostol use during the first trimester by mothers of infants in whom Mobius' syndrome was diagnosed and mothers of infants with neural-tube defects in Brazil. All diagnoses in infants were made between January 16, 1990, and May 31, 1996, by clinical geneticists at seven hospitals who also interviewed the mothers and recorded information about the administration of misoprostol, among other data. Results We identified 96 infants with Mobius' syndrome and matched them with 96 infants with neural-tube defects. The mean age at the time of the diagnosis of Mobius' syndrome was 16 months (range, 0.5 to 78), and the diagnosis of neural-tube defects was made within 1 week of birth in most cases. Among the mothers of the 96 infants with Mobius' syndrome, 47 (49 percent) had used misoprostol in the first trimester of pregnancy, as compared with 3 (3 percent) of the mothers of the 96 infants with neural-tube defects (odds ratio, 29.7; 95 percent confidence interval, 11.6 to 76.0). Twenty of the mothers of the infants with Mobius' syndrome had taken misoprostol only orally (odds ratio, 38.8; 95 percent confidence interval, 9.5 to 159.4), 20 had taken misoprostol both orally and vaginally, 3 had taken the drug vaginally, and 4 did not report how they took the drug. Conclusions Attempted abortion with misoprostol is associated with an increased risk of Mobius' syndrome in infants. (N Engl J Med 1998;338:1881-5.) (C) 1998, Massachusetts Medical Society.	Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, Toronto, ON M5G 1X8, Canada; Univ Fed Rio Grande Sul, Dept Genet, Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Unidade Genet, Porto Alegre, RS, Brazil; Rede Hosp Sarah, Setor Genet, Brasilia, DF, Brazil; Rede Hosp Sarah, Setor Genet, Salvador, BA, Brazil; Hosp Univ Graffre Guinle, Setor Genet, Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Genet, Sao Paulo, Brazil; Hosp Serv Publ Estado Sao Paulo, Unidade Citogenet, Sao Paulo, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universidade Federal do Rio Grande do Sul; Universidade Federal de Sao Paulo (UNIFESP); Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE)	Pastuszak, AL (corresponding author), Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Meloni, Vera/O-8378-2015; SCHULER-FACCINI, LAVINIA/C-8309-2013; Schwartz, Ida/M-1422-2015; Brunoni, Decio/K-3155-2012; Vargas, Fernando/V-1934-2019; SCHULER-FACCINI, LAVINIA/K-2927-2016; Koren, Gideon/AAG-7726-2019	Meloni, Vera/0000-0003-4954-8766; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Schwartz, Ida/0000-0002-7933-6687; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Koren, Gideon/0000-0002-9234-0875				BAIRD DT, 1992, LANCET, V339, P313, DOI 10.1016/0140-6736(92)91392-L; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; CASTILLA EE, 1994, AM J MED GENET, V51, P161, DOI 10.1002/ajmg.1320510217; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; COSTA SH, 1993, LANCET, V341, P1486; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P189; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P213; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P167; Fonseca W, 1996, REV SAUDE PUBL, V30, P13, DOI 10.1590/S0034-89101996000100003; Genest D. R., 1994, Teratology, V49, P418; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KUMAR D, 1990, J MED GENET, V27, P122, DOI 10.1136/jmg.27.2.122; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; Lipson AH, 1996, EUR J PEDIATR, V155, P800, DOI 10.1007/BF02002911; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PAUMGARTTEN FJR, 1995, BRAZ J MED BIOL RES, V28, P355; SCHULER L, 1992, LANCET, V339, P437, DOI 10.1016/0140-6736(92)90131-L; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	24	149	160	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1881	1885		10.1056/NEJM199806253382604	http://dx.doi.org/10.1056/NEJM199806253382604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637807				2022-12-24	WOS:000074352800004
J	Ho, DD				Ho, DD			Toward HIV eradication or remission: The tasks ahead	SCIENCE			English	Editorial Material							LIFE-SPAN; IN-VIVO; T-CELLS; LYMPHOCYTES; TURNOVER; NAIVE		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org						Cao Y., UNPUB; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; HAVLIR DV, 1998, 5 C RETR OPP INF CHI, pLB16; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; MORRIS L, IN PRESS J EXP MED; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PERELSON AS, UNPUB; RAFFI F, 1998, 5 C RETR OPP INF CHI, pLB15; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; VESANEN M, 1997, INT WORKSH HIV DRUG; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	23	149	159	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1866	1867		10.1126/science.280.5371.1866	http://dx.doi.org/10.1126/science.280.5371.1866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669944				2022-12-24	WOS:000074323800040
J	Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM				Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM			An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BASEBALL; HEART	Background The syndrome of sudden death due to low-energy trauma to the chest wall (commotio cordis) has been described in young sports participants, but the mechanism is unknown. Methods We developed a swine model of commotio cordis in which a low-energy impact to the chest wall was produced by a wooden object the size and weight of a regulation baseball. This projectile was thrust at a velocity of 30 miles (48 km) per hour and was timed to the cardiac cycle. Results We first studied 18 young pigs, 6 subjected to multiple chest impacts and 12 to single impacts. Of the 10 impacts occurring within the window from 30 to 15 msec before the peak of the T wave on the electrocardiogram, 9 produced ventricular fibrillation. Ventricular fibrillation was not produced by impacts at any other time during the cardiac cycle. Of the 10 impacts sustained during the QRS complex, 4 resulted in transient complete heart block. We also studied whether the use of safety baseballs, which are softer than standard ones, would reduce the risk of arrhythmia. A total of 48 additional animals sustained up to three impacts during the T-wave window of vulnerability to ventricular fibrillation with a regulation baseball and safety baseballs of three degrees of hardness. We found that the likelihood of ventricular fibrillation was proportional to the hardness of the ball, with the softest balls associated with the lowest risk (two instances of ventricular fibrillation after 26 impacts, as compared with eight instances after 23 impacts with regulation baseballs). Conclusions This experimental model of commotio cordis closely resembles the clinical profile of this catastrophic event. Whether ventricular fibrillation occurred depended on the precise timing of the impact. Safety baseballs, as compared with regulation balls, may reduce the risk of commotio cordis. (C) 1998, Massachusetts Medical Society.	Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Boston, MA 02111 USA; EHS Christ Hosp & Med Ctr, Heart Inst Children, Maurice Lev Congenital Heart & Conduct Ctr, Oak Lawn, IL 60453 USA; Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN USA	Tufts Medical Center; Tufts University; Minneapolis Heart Institute Foundation	Link, MS (corresponding author), Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Box 197,750 Washington St, Boston, MA 02111 USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; Adler P, 1996, YOUTH BASEBALL PROTE, P1; BHARATI S, 1991, CHEST, V100, P207, DOI 10.1378/chest.100.1.207; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; HOWE BB, 1968, ACTA ANAT, V71, P13, DOI 10.1159/000143165; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KLEBER AG, 1978, CIRC RES, V42, P603, DOI 10.1161/01.RES.42.5.603; KYLE SB, 1996, YOUTH BASEBALL PROTE; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377, DOI 10.1152/ajplegacy.1974.226.2.377; LINK MS, IN PRESS CHEST; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1997, CIRCULATION S1, V96, P755; Morikawa M, 1996, CLIN CARDIOL, V19, P831; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Viano DC, 1992, CLIN J SPORT MED, V2, P166	19	235	242	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1805	1811		10.1056/NEJM199806183382504	http://dx.doi.org/10.1056/NEJM199806183382504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632447	Bronze			2022-12-24	WOS:000074197500004
J	Poulson, J				Poulson, J			Bitter pills to swallow	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada	University of Toronto	Poulson, J (corresponding author), Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada.								0	11	12	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1844	1846		10.1056/NEJM199806183382512	http://dx.doi.org/10.1056/NEJM199806183382512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632455				2022-12-24	WOS:000074197500012
J	Rosenberg, PS; Biggar, RJ				Rosenberg, PS; Biggar, RJ			Trends in HIV incidence among young adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJECTING DRUG-USERS; INCUBATION PERIOD; HOMOSEXUAL MEN; AIDS EPIDEMIC; INFECTION; MORTALITY; AGE	Context.-Behaviors that result in potential exposure to human immunodeficiency virus (HIV) usually begin in adolescence or young adulthood, but trends in HIV incidence in young people remain unclear. Objective.-To estimate trends in HIV incidence in teenagers and young adults. Design and Setting.-Back-calculation of past HIV incidence in persons born between 1960 and 1974 using US national acquired immunodeficiency syndrome (AIDS) incidence data and estimates of the distribution of times between HIV infection and AIDS. Main Outcome Measures.-Incidence and prevalence of HIV in 1988 and 1993 in persons aged 20 and 25 years, respectively, in each of those years. Results.-As of January 1993, about 22 000 men and 11 000 women aged 18 to 22 years were living with HIV infection in the United States. Homosexual contact was the leading route of infection among young men. Heterosexual contact was the leading route of infection among young women. The HIV incidence attributed to homosexual contact or injection drug use decreased among persons aged 20 and 25 years between 1988 and 1993, but HIV incidence attributed to heterosexual contact was stable or increasing. Notably, in men aged 20 and 25 years, HIV prevalence declined by about 50% in white men but was relatively stable in black and Hispanic men. In contrast, HIV prevalence in women aged 20 and 25 years rose by 36% and 45%, respectively, because of increasing heterosexual transmission. Overall, HIV prevalence in persons aged 20 and 25 years declined by only 14% between 1988 and 1993. Conclusions.-In young persons, HIV incidence in homosexual men and injection drug users was slowing by 1993; this favorable trend was offset by increasing heterosexual transmission, especially in minorities.	NCI, Biostat Branch, Bethesda, MD 20892 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, PS (corresponding author), NCI, Biostat Branch, 6130 Execut Blvd,EPN-403, Bethesda, MD 20892 USA.			Rosenberg, Philip/0000-0001-6349-9126	NIAID NIH HHS [U01-AI-35041, U01-AI-35040, U01-AI-35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035039, U01AI035040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1996, HIV AIDS SURV REP, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; CELUM C, 1997, 4 C RETR OPP INF JAN; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V18, P1; Cohen J, 1997, SCIENCE, V275, P615, DOI 10.1126/science.275.5300.615; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HOOVER DR, 1996, 11 INT C AIDS JUL 7; Institute of Medicine, 1997, HIDD EP CONFR SEX TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Karon JM, 1997, J ACQ IMMUN DEF SYND, V16, P116, DOI 10.1097/00042560-199710010-00007; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; McQuillan GM, 1997, J ACQ IMMUN DEF SYND, V14, P355, DOI 10.1097/00042560-199704010-00008; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Rosenberg PS, 1998, STAT MED, V17, P155, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;155::AID-SIM758&gt;3.0.CO;2-O; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; *US CENS BUR, 1997, OFF STAT; VANHAASTRECHT HJA, 1994, AIDS, V8, P363, DOI 10.1097/00002030-199403000-00011; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; ZACCARELLI M, 1994, AIDS, V8, P345, DOI 10.1097/00002030-199403000-00008	25	99	100	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1894	1899		10.1001/jama.279.23.1894	http://dx.doi.org/10.1001/jama.279.23.1894			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634261	Bronze			2022-12-24	WOS:000074109700037
J	Henry, JA; Hoffman, JR				Henry, JA; Hoffman, JR			Continuing controversy on gut decontamination	LANCET			English	Editorial Material							OVERDOSE		St Marys Hosp, Imperial Coll Sch Med, Dept Accid & Emergency Med, London W2 1NY, England; Univ Calif Los Angeles, Sch Med, Dept Med & Emergency Med, Los Angeles, CA 90024 USA	Imperial College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Henry, JA (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Accid & Emergency Med, Praed St, London W2 1NY, England.							*AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P699; CURTIS RA, 1984, ARCH INTERN MED, V144, P48, DOI 10.1001/archinte.144.1.48; KULIG K, 1985, ANN EMERG MED, V14, P562, DOI 10.1016/S0196-0644(85)80780-0; MERIGIAN KS, 1990, AM J EMERG MED, V8, P479, DOI 10.1016/0735-6757(90)90146-Q; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; WRIGHT N, 1980, J ROY COLL PHYS LOND, V14, P114	6	25	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					420	421		10.1016/S0140-6736(05)79183-2	http://dx.doi.org/10.1016/S0140-6736(05)79183-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708747				2022-12-24	WOS:000075252000006
J	Backstrom, BT; Muller, U; Hausmann, B; Palmer, E				Backstrom, BT; Muller, U; Hausmann, B; Palmer, E			Positive selection through a motif in the alpha beta T cell receptor	SCIENCE			English	Article							NEGATIVE SELECTION; CD4+8+ THYMOCYTES; TRANSGENIC MICE; ANTIGEN; CHAIN; THYMUS; TOLERANCE; MOLECULES; DELETION; IMMATURE	The two Lineages of T cells, alpha beta and gamma delta, differ in their developmental requirements: only alpha beta cells require major histocompatibility complex recognition, a process known as positive selection, The alpha beta T cell receptor (TCR), but not its gamma delta counterpart, contains a motif within the alpha-chain connecting peptide domain (alpha-CPM) that has been conserved over the Last 500 million years. In transgenic mice expressing an alpha beta TCR Lacking the alpha-CPM, thymocytes were blocked in positive selection but could undergo negative selection. Thus, the alpha-CPM seems to participate in the generation of signals required for positive selection.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Palmer, E (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.							AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BACKSTROM BT, UNPUB; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; COHN M, 1982, BEHRING I MITT, V70, P219; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; CURNOW SJ, 1994, CYTOMETRY, V16, P41, DOI 10.1002/cyto.990160107; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DIGIUSTO DL, 1994, MOL IMMUNOL, V31, P693, DOI 10.1016/0161-5890(94)90179-1; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGE DM, 1993, J IMMUNOL, V151, P1868; Partula S, 1996, J IMMUNOL, V157, P207; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033; SHIOHARA T, 1987, J IMMUNOL, V138, P1979; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	30	97	98	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					835	838		10.1126/science.281.5378.835	http://dx.doi.org/10.1126/science.281.5378.835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694657				2022-12-24	WOS:000075295600053
J	Hakem, R; Hakem, A; Duncan, GS; Henderson, JT; Woo, M; Soengas, MS; Elia, A; de la Pompa, JL; Kagi, D; Khoo, W; Potter, J; Yoshida, R; Kaufman, SA; Lowe, SW; Penninger, JM; Mak, TW				Hakem, R; Hakem, A; Duncan, GS; Henderson, JT; Woo, M; Soengas, MS; Elia, A; de la Pompa, JL; Kagi, D; Khoo, W; Potter, J; Yoshida, R; Kaufman, SA; Lowe, SW; Penninger, JM; Mak, TW			Differential requirement for Caspase 9 in apoptotic pathways in vivo	CELL			English	Article							PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; DEFICIENT MICE; MOUSE; THYMOCYTES; FAMILY; GENES; BCL-2; BAX	Mutation of Caspase 9 (Casp9) results in embryonic lethality and defective brain development associated with decreased apoptosis. Casp9 (-/-) embryonic stem cells and embryonic fibroblasts are resistant to several apoptotic stimuli, including UV and gamma irradiation. Casp9(-/-) thymocytes are also resistant to dexamethasone- and gamma irradiation-induced apoptosis, but are surprisingly sensitive to apoptosis induced by UV irradiation or anti-CD95. Resistance to apoptosis is accompanied by retention of the mitochondrial membrane potential in mutant cells. In addition, cytochrome c is translocated to the cytosol of Casp9(-/-) ES cells upon UV stimulation, suggesting that Casp9 acts downstream of cytochrome c. Caspase processing is inhibited in Casp9(-/-) ES cells but not in thymocytes or splenocytes. Comparison of the requirement for Casp9 and Casp3 in different apoptotic settings indicates the existence of at least four different apoptotic pathways in mammalian cells.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cold Spring Harbor Laboratory; Amgen	Mak, TW (corresponding author), Amgen Inst, Toronto, ON M5G 2C1, Canada.		Soengas, Maria S/H-6455-2015; Penninger, Josef M/I-6860-2013; Duncan, Gordon/AIE-7011-2022; De La Pompa, José Luis/F-9719-2014	Soengas, Maria S/0000-0003-0612-6299; Penninger, Josef M/0000-0002-8194-3777; De La Pompa, José Luis/0000-0001-6761-7265; Hakem, Razqallah/0000-0001-5948-7931	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	1122	1143	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					339	352		10.1016/S0092-8674(00)81477-4	http://dx.doi.org/10.1016/S0092-8674(00)81477-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708736	Bronze			2022-12-24	WOS:000075308400010
J	McMahon, SB; Van Buskirk, HA; Dugan, KA; Copeland, TD; Cole, MD				McMahon, SB; Van Buskirk, HA; Dugan, KA; Copeland, TD; Cole, MD			The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins	CELL			English	Article							NEOPLASTIC TRANSFORMATION; ATAXIA-TELANGIECTASIA; ONCOGENIC ACTIVITY; REPRESSOR SIN3; GENE-PRODUCT; LINEAR-SPACE; KINASE; TRANSCRIPTION; APOPTOSIS; BINDING	The c-Myc and E2F transcription factors are among the most potent regulators of cell cycle progression in higher eukaryotes. This report describes the isolation of a novel, highly conserved 434 kDa protein, designated TRRAP, which interacts specifically with the c-Myc N terminus and has homology to the ATM/PI3- kinase family. TRRAP also interacts specifically with the E2F-1 transactivation domain. Expression of transdominant mutants of the TRRAP protein or antisense RNA blocks c-Myc- and E1A-mediated oncogenic transformation. These data suggest that TRRAP is an essential cofactor for both the c-Myc and E1A/E2F oncogenic transcription factor pathways.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Princeton University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			McMahon, Steven/0000-0002-3405-1768				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Danska JS, 1996, MOL CELL BIOL, V16, P5507; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Lavin MF, 1996, CURR OPIN IMMUNOL, V8, P459, DOI 10.1016/S0952-7915(96)80030-6; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	52	518	533	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					363	374		10.1016/S0092-8674(00)81479-8	http://dx.doi.org/10.1016/S0092-8674(00)81479-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708738	Bronze			2022-12-24	WOS:000075308400012
J	Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT				Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT			Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis	SCIENCE			English	Article							SURFACE PROTEIN-A; BORRELIA-BURGDORFERI; RHEUMATOID-ARTHRITIS; ANTIGEN EXPRESSION; ASSOCIATION; DISEASE; PEPTIDE; RECOGNITION; PREDICTION; DISTINCT	Treatment-resistant Lyme arthritis is associated with immune reactivity to outer surface protein A (OspA) of Borrelia burgdorferi, the agent of Lyme disease, and the major histocompatibility complex class II allele DRB1*0401. The immunodominant epitope of OspA for T helper cells was identified. A homology search revealed a peptide from human leukocyte function-associated antigen-1 (hLFA-1) as a candidate autoantigen. Individuals with treatment-resistant Lyme arthritis, but not other forms of arthritis, generated responses to OspA, hLFA-1, and their highly related peptide epitopes. Identification of the initiating bacterial antigen and a cross-reactive autoantigen may provide a model for development of autoimmune disease.	Tufts Univ, Dept Pathol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Hoffmann La Roche Inc, Dept Immunol, Nutley, NJ 07110 USA; New England Med Ctr, Dept Rheumatol, Boston, MA 02111 USA	Tufts University; Case Western Reserve University; Roche Holding; Tufts Medical Center	Gross, DM (corresponding author), Tufts Univ, Dept Pathol, Boston, MA 02111 USA.		Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125; Steere, Allen/0000-0002-5268-9853	NIAMS NIH HHS [R01 AR20358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BRADLEY JF, 1994, ANN INTERN MED, V120, P487, DOI 10.7326/0003-4819-120-6-199403150-00007; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; FENG SL, 1995, J INFECT DIS, V172, P286, DOI 10.1093/infdis/172.1.286; Golde WT, 1998, INFECT MED, V15, P38; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Gross D., UNPUB; Gross DM, 1998, J IMMUNOL, V160, P1022; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kamradt T, 1996, INFECT IMMUN, V64, P1284, DOI 10.1128/IAI.64.4.1284-1289.1996; LAHESMAA R, 1993, J IMMUNOL, V150, P4125; LANCHBURY JSS, 1991, HUM IMMUNOL, V32, P56, DOI 10.1016/0198-8859(91)90117-R; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARSHALL KW, 1995, J IMMUNOL, V154, P5927; MORENO J, 1991, J IMMUNOL, V147, P3306; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, UNPUB; SZTEIN MB, 1984, J CLIN INVEST, V73, P556, DOI 10.1172/JCI111243; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6	28	371	408	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					703	706		10.1126/science.281.5377.703	http://dx.doi.org/10.1126/science.281.5377.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685265				2022-12-24	WOS:000075107900044
J	Madaule, P; Eda, M; Watanabe, N; Fujisawa, K; Matsuoka, T; Bito, H; Ishizaki, T; Narumiya, S				Madaule, P; Eda, M; Watanabe, N; Fujisawa, K; Matsuoka, T; Bito, H; Ishizaki, T; Narumiya, S			Role of citron kinase as a target of the small GTPase Rho in cytokinesis	NATURE			English	Article							BINDING PROTEIN-RHO; SERINE/THREONINE KINASE; CYTOSKELETON; CELLS	During mitosis, a ring containing actin and myosin appears beneath the equatorial surface of animal cells. This ring then contracts, forms a cleavage furrow and divides the cell(1-3), a step known as cytokinesis, The two daughter cells often remain connected by an intercellular bridge which contains a refringent structure known as the midbody(4,5). How the appearance of this ring is regulated is unclear, although the small GTPase Rho, which controls the formation of actin structures(6,7), is known to be essential(8-10). Protein kinases are also thought to participate in cytokinesis(8-10). We now show that a splice variant of a Rho target protein, named citron(13), contains a protein kinase domain that is related to the Rho-associated kinases ROCK14 and ROK15-17, which regulate myosin-based contractility(18-21). Citron kinase localizes to the cleavage furrow and midbody of HeLa cells; Rho is also localized in the midbody. We find that overexpression of citron mutants results in the production of multinucleate cells and that a kinase-active mutant causes abnormal contraction during cytokinesis, We propose that citron kinase regulates cytokinesis at a step after Rho in the contractile process.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ANDREASSEN PR, 1991, J CELL SCI, V99, P523; BYERS B, 1968, PROTOPLASMA, V66, P413, DOI 10.1007/BF01255868; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	28	329	345	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					491	494		10.1038/28873	http://dx.doi.org/10.1038/28873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697773				2022-12-24	WOS:000075080400055
J	Chou, JJ; Matsuo, H; Duan, H; Wagner, G				Chou, JJ; Matsuo, H; Duan, H; Wagner, G			Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment	CELL			English	Article							DEATH DOMAIN; PROTEINS; NMR; RESONANCE; FADD; C-13; FAS	Apoptosis requires recruitment of caspases by receptor-associated adaptors through homophilic interactions between the CARDs (caspase recruitment domains) of adaptor proteins and prodomains of caspases. We have solved the CARD structure of the RAIDD adaptor protein that recruits ICH-1/caspase-2. It consists of six tightly packed helices arranged in a topology homologous to the Fas death domain. The surface contains a basic and an acidic patch on opposite sides. This polarity is conserved in the ICH-1 CARD as indicated by homology modeling. Mutagenesis data suggest that these patches mediate CARD/CARD interaction between RAIDD and ICH-1. Subsequent modeling of the CARDs of Apaf-1 and caspase-9, as well as Ced-4 and Ced-3, showed that the basic/acidic surface polarity is highly conserved, suggesting a general mode for CARD/CARD interaction.	Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	Harvard University; Harvard University; Harvard Medical School; Pfizer	Wagner, G (corresponding author), Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA.		Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344	NIGMS NIH HHS [GM 47467, GM 38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467, R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SJ, 1996, ONCOGENE, V12, P1; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNGER AT, 1994, XPLOR 3851 SYSTEM XR; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou KC, 1997, FEBS LETT, V419, P49, DOI 10.1016/S0014-5793(97)01246-5; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DELRIOPORTILLA F, 1994, J MAGN RESON SER A, V111, P132, DOI 10.1006/jmra.1994.1238; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0 MOL; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Matsuo H, 1996, J MAGN RESON SER B, V110, P112, DOI 10.1006/jmrb.1996.0018; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	36	275	281	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					171	180		10.1016/S0092-8674(00)81417-8	http://dx.doi.org/10.1016/S0092-8674(00)81417-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695946	Bronze			2022-12-24	WOS:000075020100006
J	Hua, J; Meyerowitz, EM				Hua, J; Meyerowitz, EM			Ethylene responses are negatively regulated by a receptor gene family in Arabidopsis thaliana	CELL			English	Article							2-COMPONENT HISTIDINE KINASE; SIGNAL-TRANSDUCTION; PLANTS; PATHWAY; ETR1; INSENSITIVITY; DICTYOSTELIUM; PROTEINS; HOMOLOG; BINDING	A family of genes including ETR1, ETR2, EIN4, ERS1, and ERS2 is implicated in ethylene perception in Arabidopsis thaliana. As only dominant mutations were previously available for these genes, it was unclear whether all of them are components in the ethylene signaling pathway and whether they code for positive or negative regulators of ethylene responses. In this study, we have isolated loss-of-function mutations of four of these genes (ETR1, ETR2, EIN4, and ERS2) and identified an ethylene-independent role of ETR1 in promoting cell elongation. Quadruple mutants had constitutive ethylene responses, revealing that these proteins negatively regulate ethylene responses and that the induction of ethylene response in Arabidopsis is through inactivation rather than activation of these proteins.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009					Abeles F, 1992, ETHYLENE PLANT BIOL; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; HUA J, 1998, IN PRESS PLANT CELL; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUMAR PP, 1998, IN PRESS IN VITRO CE; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Neljubow D., 1901, BEIHEFTE ZUM BOT ZEN, V10, P128; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; ROMAN G, 1995, GENETICS, V139, P1393; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schuster SC, 1996, EMBO J, V15, P3880, DOI 10.1002/j.1460-2075.1996.tb00762.x; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; Zhou DB, 1996, PLANT MOL BIOL, V30, P1331, DOI 10.1007/BF00019564	40	789	877	7	145	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					261	271		10.1016/S0092-8674(00)81425-7	http://dx.doi.org/10.1016/S0092-8674(00)81425-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695954	Bronze			2022-12-24	WOS:000075020100014
J	Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T				Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T			An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy	NATURE			English	Article							LINKAGE-DISEQUILIBRIUM; GLYCOPROTEIN COMPLEX; LOCALIZATION; GENE; PROTEINS; FCMD	Fukuyama-type congenital muscular dystrophy (FCMD), one of the most common autosomal recessive disorders in Japan (incidence is 0.7-1.2 per 10,000 births), is characterized by congenital muscular dystrophy associated with brain malformation (micropolygria) due to a defect in the migration of neurons(1). We previously mapped the FCMD gene to a region of less than 100 kilobases which included the marker locus D9S2107 on chromosome 9q31 (refs 2-4). We have also described a haplotype that is shared by more than 80% of FCMD chromosomes, indicating that most chromosomes bearing the FCMD mutation could be derived hom a single ancestor(5). Here we report that there is a retrotransposal insertion of tandemly repeated sequences within this candidate-gene interval in all FCMD chromosomes carrying the founder haplotype (87%). The inserted sequence is about 3 kilobases long and is located in the 3' untranslated region of a gene encoding a new 461-amino-acid protein. This gene is expressed in various tissues in normal individuals, but not in FCMD patients who carry the insertion. Two independent point mutations confirm that mutation of this gene is responsible for FCMD. The predicted protein, which we term fukutin, contains an amino-terminal signal sequence, which together with results from transfection experiments suggests that fukutin is a secreted protein. To our knowledge, FCMD is the first human disease to be caused by an ancient retrotransposal integration.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Tokyo 1130033, Japan; Univ Tokushima, Sch Med, Dept Publ Hlth, Tokushima 7708503, Japan; Teikyo Univ, Sch Med, Dept Neurol, Tokyo 1738605, Japan; Tokyo Womens Med Coll, Dept Pediat, Tokyo 1628666, Japan; Segawa Neurol Clin Children, Tokyo 1010062, Japan; Kobe Gen Hosp, Dept Pediat, Kobe, Hyogo 6500046, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 3058576, Japan; Natl Inst Neurosci, NCNP, Dept Ultrastruct Res, Tokyo 1878502, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Tokushima University; Teikyo University; Tokyo Women's Medical University; Kobe City Medical Center General Hospital; University of Tsukuba; National Center for Neurology & Psychiatry - Japan	Toda, T (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	toda@ims.u-tokyo.ac.jp	Kobayashi, Kazuhiro/AAH-8638-2021	Kobayashi, Kazuhiro/0000-0001-7801-147X; Toda, Tatsushi/0000-0002-0717-1123; Saito, Kayoko/0000-0003-2632-0873				BANNAI M, 1994, EUR J IMMUNOGENET, V21, P1, DOI 10.1111/j.1744-313X.1994.tb00170.x; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HAYASHI YK, 1993, J NEUROL SCI, V119, P53, DOI 10.1016/0022-510X(93)90191-Z; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; KOBAYASHI K, IN PRESS HUM GENET; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakano I, 1996, ACTA NEUROPATHOL, V91, P313, DOI 10.1007/s004010050431; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; Toda T, 1996, AM J HUM GENET, V59, P1313; TODA T, 1994, AM J HUM GENET, V55, P946; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; [No title captured]	22	621	636	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					388	392		10.1038/28653	http://dx.doi.org/10.1038/28653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690476				2022-12-24	WOS:000074968800056
J	Griffin, BA; Adams, SR; Tsien, RY				Griffin, BA; Adams, SR; Tsien, RY			Specific covalent labeling of recombinant protein molecules inside live cells	SCIENCE			English	Article								Recombinant proteins containing four cysteines at the i, i + 1, i + 4, and i + 5 positions of an alpha helix were fluorescently labeled in Living cells by extracellular administration of 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluor This designed small Ligand is membrane-permeant and nonfluorescent until it binds with high affinity and specificity to the tetracysteine domain, Such in situ Labeling adds much Less mass than does green fluorescent protein and offers greater versatility in attachment sites as well as potential spectroscopic and chemical properties. This system provides a recipe for slightly modifying a target protein so that it can be singled out from the many other proteins inside Live cells and fluorescently stained by small nonfluorescent dye molecules added from outside the cells.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NCI NIH HHS [T32 CA09523] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHALFIE M, 1998, GFP GREEN FLUORESCEN; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; GRIFFIN BA, 1998, THESIS U CALIFORNIA; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Lowe WG, 1935, J AM CHEM SOC, V57, P1081, DOI 10.1021/ja01309a035; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; SPANG C, 1989, CHEM BER, V122, P1247, DOI 10.1002/cber.19891220706; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WEBB EC, 1947, BIOCHEM J, V41, P74, DOI 10.1042/bj0410074; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WHITTAKER VP, 1947, BIOCHEM J, V41, P56, DOI 10.1042/bj0410056; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	18	1200	1331	9	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					269	272		10.1126/science.281.5374.269	http://dx.doi.org/10.1126/science.281.5374.269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657724				2022-12-24	WOS:000074714200053
J	Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA				Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA		Eastern Cooperative Oncology Grp; N Cent Canc Treatment Grp; SW Oncology Grp	Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection	ANNALS OF INTERNAL MEDICINE			English	Article						surgical procedures, operative; colonic neoplasms; salvage therapy; outcome and process assessment (health care); disease-free survival	COLORECTAL-CARCINOMA; SURGICAL-TREATMENT; ADJUVANT THERAPY; POLYPS; FLUOROURACIL; LEVAMISOLE; METASTASES; LIVER	Background: Follow-up testing after surgery for colon cancer is recommended principally to identify resectable recurrences, but data on the efficacy of, outcomes of, and optimal strategies for this testing are limited. Objectives: To determine the relation between followup tests and salvage surgery, assess outcomes, and document surgical mortality. Design: Retrospective cohort study. Setting: A North American multi-institutional trial comparing postoperative chemotherapy plus follow-up with follow-up alone. Patients: 1247 patients with resected stage II and stage III colon cancer. Intervention: The protocol mandated follow-up testing that could be supplemented at the discretion of treating physicians. Indications of recurrent disease were documented. Measurements: Recurrence, resectable recurrence, surgical mortality, and survival were studied. Results: 548 patients had recurrence of colon cancer. Salvage surgery was attempted in 222 patients (41%). In 109 patients (20%), curative-intent surgery was done for hepatic recurrence (28 patients), pulmonary metastasis (20 patients), local recurrence (24 patients), or recurrence at other sites (37 patients). Most curative-intent surgical procedures were motivated by follow-up testing (36 patients), elevated carcinoembryonic antigen level (41 patients), or symptoms (27 patients). The median follow-up time after curative-intent surgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%. A solitary lesion was a favorable prognostic factor. The surgical mortality rate was 2%. Curative-intent resections were done in 15 patients with second primary colorectal cancer; 12 of these patients have survived disease-free. Conclusions: Second operations for colon cancer that are triggered by follow-up testing or symptoms are common and can result in long-term disease-free survival.	Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Grand Forks Clin Ltd, Grand Forks, ND 58201 USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Goldberg, RM (corresponding author), Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	goldberg.richard@mayo.edu	Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; 	NATIONAL CANCER INSTITUTE [U10CA025224, P01CA031224, U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-37404, CA-25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6; ECKARDT VF, 1988, CANCER, V61, P2552, DOI 10.1002/1097-0142(19880615)61:12<2552::AID-CNCR2820611227>3.0.CO;2-6; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; HUGHES KS, 1986, SURGERY, V100, P278; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCAFEE MK, 1992, ANN THORAC SURG, V53, P780, DOI 10.1016/0003-4975(92)91435-C; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; NELSON RL, 1993, CANCER-AM CANCER SOC, V71, P4298, DOI 10.1002/1097-0142(19930615)71:12+<4298::AID-CNCR2820711819>3.0.CO;2-9; NORFLEET RG, 1991, GASTROINTEST ENDOSC, V37, P531, DOI 10.1016/S0016-5107(91)70822-5; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; *SAS I INC, 1990, SAS STAT US GUID VER, P1027; STEELE G, 1993, CANCER, V71, P4225, DOI 10.1002/1097-0142(19930615)71:12+<4225::AID-CNCR2820711811>3.0.CO;2-C; TURK PS, 1993, CANCER-AM CANCER SOC, V71, P4267, DOI 10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>3.0.CO;2-O; WERNECKE K, 1991, AM J ROENTGENOL, V157, P731, DOI 10.2214/ajr.157.4.1892027; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301	19	226	229	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					27	+		10.7326/0003-4819-129-1-199807010-00007	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652996				2022-12-24	WOS:000074513300004
J	Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ				Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ			Arabidopsis LEAFY COTYLEDON1 is sufficient to induce embryo development in vegetative cells	CELL			English	Article							CCAAT-BINDING-FACTOR; MOSAIC VIRUS-35S PROMOTER; HAP3 TRANSCRIPTION FACTOR; GENE-EXPRESSION; NF-Y; LATE EMBRYOGENESIS; SEED DEVELOPMENT; ABSCISIC-ACID; DNA-BINDING; PROTEIN	The Arabidopsis LEAN COTYLEDON1 (LEC1) gene is required for the specification of cotyledon identity and the completion of embryo maturation. We isolated the LEC1 gene and showed that it functions at an early developmental stage to maintain embryonic cell fate. The LEC1 gene encodes a transcription factor homolog, the CCAAT box-binding factor HAP3 subunit. LEC1 RNA accumulates only during seed development in embryo cell types and in endosperm tissue. Ectopic postembryonic expression of the LEC I gene in vegetative cells induces the expression of embryo-specific genes and initiates formation of embryo-like structures. Our results suggest that LEC1 is an important regulator of embryo development that activates the transcription of genes required for both embryo morphogenesis and cellular differentiation.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Los Angeles	Harada, JJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA.			Lotan, Tamar/0000-0002-1679-4904				Albani D, 1995, GENE, V167, P209, DOI 10.1016/0378-1119(95)00680-X; BAUMLEIN H, 1994, PLANT J, V6, P379, DOI 10.1046/j.1365-313X.1994.06030379.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; Devic M, 1996, PLANT J, V9, P205, DOI 10.1046/j.1365-313X.1996.09020205.x; DIETRICH RA, 1989, PLANT CELL, V1, P73, DOI 10.1105/tpc.1.1.73; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; GUARENTE L, 1984, CELL, V32, P317; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; Harada JJ, 1997, ADV CELL MOL BIOL PL, V4, P545; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEITH K, 1994, PLANT CELL, V6, P589, DOI 10.1105/tpc.6.5.589; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEINKE DW, 1992, SCIENCE, V258, P1647, DOI 10.1126/science.258.5088.1647; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAMBARA E, 1992, PLANT J, V2, P435, DOI 10.1111/j.1365-313X.1992.00435.x; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; OLSEN LJ, 1993, PLANT CELL, V5, P941, DOI 10.1105/tpc.5.8.941; Papagiannopoulos P, 1996, MOL GEN GENET, V251, P412, DOI 10.1007/s004380050184; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Parcy F, 1997, PLANT CELL, V9, P1265, DOI 10.1105/tpc.9.8.1265; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SCHWARTZ BW, 1994, DEVELOPMENT, V120, P3235; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEEVES TA, 1983, CAN J BOT, V61, P3550, DOI 10.1139/b83-404; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; Tsugeki R, 1996, PLANT J, V10, P479, DOI 10.1046/j.1365-313X.1996.10030479.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WALBOT V, 1978, DORMANCY DEV ARREST, P113; WEST MAL, 1994, PLANT CELL, V6, P1731, DOI 10.1105/tpc.6.12.1731; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; YADEGARI R, 1994, PLANT CELL, V6, P1713, DOI 10.1105/tpc.6.12.1713	56	703	830	9	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1195	1205		10.1016/S0092-8674(00)81463-4	http://dx.doi.org/10.1016/S0092-8674(00)81463-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657152	Bronze			2022-12-24	WOS:000074491100014
J	Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R				Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R			Evidence for the shikimate pathway in apicomplexan parasites	NATURE			English	Article							CHORISMATE SYNTHASE; PLASMODIUM-FALCIPARUM; NEUROSPORA-CRASSA; CLONING; GENES; ACID; 3-PHOSPHATE; SULFADOXINE; GLYPHOSATE; MECHANISMS	Parasites of the phylum Apicomplexa cause substantial morbidity, mortality and economic losses, and new medicines to treat them are needed urgently(1,2). The shikimate pathway is an attractive target for herbicides and antimicrobial agents because it is essential in algae, higher plants, bacteria and fungi, but absent from mammals(3,4). Here we present biochemical, genetic and chemotherapeutic evidence for the presence of enzymes of the shikimate pathway in apicomplexan parasites. In vitro growth of Toxoplasma gondii, Plasmodium falciparum (malaria) and Cryptosporidium parvum was inhibited by the herbicide glyphosate, a well-characterized inhibitor(3) of the shikimate pathway enzyme 5-enolpyruvyl shikimate 3-phosphate synthase. This effect on T. gondii and P. falciparum was reversed by treatment with p-aminobenzoate, which suggests that the shikimate pathway supplies folate precursors for their growth. Glyphosate in combination with pyrimethamine limited T. gondii infection in mice. Four shikimate pathway enzymes were detected in extracts of I: gondii and glyphosate inhibited 5-enolpyruvyl shikimate 3-phosphate synthase activity. Genes encoding chorismate synthase, the final shikimate pathway enzyme, were cloned from T. gondii and P.falciparum This discovery of a functional shikimate pathway in apicomplexan parasites provides several targets for the development of new antiparasite agents.	Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA; Univ Chicago, Chicago, IL 60616 USA; Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Cent Florida, Orlando, FL 32816 USA	Michael Reese Hospital & Medical Center; University of Chicago; University of Strathclyde; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; University of Glasgow; Tufts University; University of Oxford; State University System of Florida; University of Central Florida	McLeod, R (corresponding author), Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA.	rmcleod@midway.uchicago.edu	Roberts, Craig William/B-8016-2008; Krell, Tino/G-7296-2015	Roberts, Craig William/0000-0002-0653-835X; Krell, Tino/0000-0002-9040-3166; Ferguson, David/0000-0001-5045-819X; Kyle, Dennis/0000-0002-0238-965X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANERJI S, 1995, J EUKARYOT MICROBIOL, V42, P675, DOI 10.1111/j.1550-7408.1995.tb01614.x; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; COGGINS JR, 1987, METHOD ENZYMOL, V142, P325; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DIECKMANN A, 1986, MOL BIOCHEM PARASIT, V19, P143, DOI 10.1016/0166-6851(86)90119-2; DUGGAN PJ, 1995, BIOORG MED CHEM LETT, V5, P2347, DOI 10.1016/0960-894X(95)00405-I; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GORLACH J, 1993, PLANT MOL BIOL, V23, P707, DOI 10.1007/BF00021526; HACKSTEIN JHP, 1995, PARASITOL RES, V81, P207; Haslam E., 1993, SHIKIMIC ACID METABO; HAUCKE V, 1997, CELL BIOL, V7, P103; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; MACK DG, 1984, ANTIMICROB AGENTS CH, V26, P26, DOI 10.1128/AAC.26.1.26; Marzabadi MR, 1996, BIOCHEMISTRY-US, V35, P4199, DOI 10.1021/bi9521349; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MILHOUS WK, 1985, ANTIMICROB AGENTS CH, V27, P525, DOI 10.1128/AAC.27.4.525; MOUSDALE DM, 1985, J CHROMATOGR, V329, P268, DOI 10.1016/S0021-9673(01)81929-4; ODUOLA AMJ, 1988, EXP PARASITOL, V66, P86, DOI 10.1016/0014-4894(88)90053-7; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; SCHMIDT J, 1993, J BIOL CHEM, V268, P27447; STEINRUCKEN HC, 1980, BIOCHEM BIOPH RES CO, V94, P1207, DOI 10.1016/0006-291X(80)90547-1; Tzipori S, 1998, ADV PARASIT, V40, P187, DOI 10.1016/S0065-308X(08)60121-9; WHITFIELD W, 1988, J ROYAL SOC HLTH, V1, P1; WILLIAMSON DH, 1994, MOL GEN GENET, V243, P249, DOI 10.1007/BF00280323	30	412	440	3	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					801	805		10.1038/31723	http://dx.doi.org/10.1038/31723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655396				2022-12-24	WOS:000074433100053
J	Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A				Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A			Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators	NATURE			English	Article							FACTOR-KAPPA-B; PHARMACOKINETIC PROPERTIES; THERAPEUTIC USE; EXPRESSION; CYCLOOXYGENASE-2; DYSLIPIDEMIA; SYNTHASE-2; RECEPTOR; ANGINA; SERUM	Peroxisome proliferator-activated receptors (PPARs) are key players in lipid and glucose metabolism and are implicated in metabolic disorders predisposing to atherosclerosis, such as dyslipidaemia and diabetes(1). Whereas PPAR gamma promotes Lipid storage by regulating adipocyte differentiation, PPAR alpha stimulates the beta-oxidative degradation of fatty acids. PPAR alpha-deficient mice show a prolonged response to inflammatory stimuli, suggesting that PPAR alpha is also a modulator of inflammation(2). Hypolipidaemic fibrate drugs are PPAR alpha ligands that inhibit the progressive formation of atherosclerotic lesions, which involves chronic inflammatory processes: even in the absence of their atherogenic lipoprotein-lowering effect(4,5). Here we show that PPAR alpha is expressed in human aortic smooth-muscle cells, which participate in plaque formation and post-angioplasty re-stenosis(3). In these smooth-muscle cells, we find that PPAR alpha ligands, and not PPAR gamma ligands, inhibit interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2. This inhibition of cyclooxygenase-2 induction occurs transcriptionally as a result of PPAR alpha repression of NF-kappa B signalling, In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. We conclude that activators of PPAR alpha inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins, indicating that PPAR alpha in the vascular wall may influence the process of atherosclerosis and re-stenosis.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany; INSERM, U348, F-75745 Paris 10, France; INSERM, U141, F-75745 Paris 10, France; IFR Circulat Lariboisiere, F-75745 Paris 10, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Ulm University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	chinetti, giulia/Q-6901-2016; Habib, Aida/H-8647-2019; Staels, Bart/N-9497-2016	chinetti, giulia/0000-0001-8048-8138; Habib, Aida/0000-0001-6027-0043; Staels, Bart/0000-0002-3784-1503				Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; HABIB A, 1993, J BIOL CHEM, V268, P23448; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TODD PA, 1988, DRUGS, V36, P314, DOI 10.2165/00003495-198836030-00004; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	30	973	1009	3	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					790	793		10.1038/31701	http://dx.doi.org/10.1038/31701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655393				2022-12-24	WOS:000074433100050
J	Perrin, L; Telenti, A				Perrin, L; Telenti, A			HIV treatment failure: Testing for HIV resistance in clinical practice	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; ZIDOVUDINE		CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.		Telenti, Amalio/AAY-1674-2021					Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1133, DOI 10.1126/science.279.5354.1133; DEEKS S, 1998, 5 C RETR OPP INF CHI; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; GERVAIX A, COMMUNICATION; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HAVLIR DV, 1998, 5 C RETR OPP INF CHI; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jellinger RM, 1997, J INFECT DIS, V175, P561, DOI 10.1093/infdis/175.3.561; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; MAYERS D, 1997, INT WORKSH HIV DRUG; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PERRIN L, UNPUB; Quigg M, 1997, AIDS, V11, P835; RAFFI R, 1998, 5 C RETR OPP INF CHI; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; Schinazi R. F., 1997, International Antiviral News, V5, P129; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; YERLY S, COMMUNICATION; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	38	172	179	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1871	1873		10.1126/science.280.5371.1871	http://dx.doi.org/10.1126/science.280.5371.1871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669946				2022-12-24	WOS:000074323800042
J	Britton, TC				Britton, TC			Torticollis - what is straight ahead?	LANCET			English	Editorial Material							SPASMODIC TORTICOLLIS		Univ London Kings Coll Hosp, Dept Neurol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Britton, TC (corresponding author), Univ London Kings Coll Hosp, Dept Neurol, Denmark Hill, London SE5 9RS, England.							Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P561, DOI 10.1002/mds.870120413; Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P709, DOI 10.1002/mds.870120514; Anastasopoulos D, 1998, BRAIN, V121, P91, DOI 10.1093/brain/121.1.91; Couch J R, 1976, Adv Neurol, V14, P245; Lekhel H, 1997, BRAIN, V120, P583, DOI 10.1093/brain/120.4.583; LEPLOW B, 1994, PERCEPT MOTOR SKILL, V78, P1363, DOI 10.2466/pms.1994.78.3c.1363; STELL R, 1989, J NEUROL NEUROSUR PS, V52, P57, DOI 10.1136/jnnp.52.1.57	7	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1223	1224		10.1016/S0140-6736(05)79313-2	http://dx.doi.org/10.1016/S0140-6736(05)79313-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643739				2022-12-24	WOS:000073283600005
J	van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG				van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG		Eur Union Collaborat Study Grp CJD	Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95	LANCET			English	Article							HUMAN GROWTH-HORMONE; PERSON TRANSMISSION; PRION DISEASES; HUMAN-BLOOD; EPIDEMIOLOGY; RECIPIENT; FRANCE; GENE	Background Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy. Genetic and iatrogenic forms have been recognised but most are sporadic and of unknown cause. We have studied risk factors for CJD as part of the 1993-95 European Union collaborative studies of CJD in Europe. Methods The 405 patients with definite or probable CJD who took part in our study had taken part in population-based studies done between 1993 and 1995 in Belgium, France, Germany, Italy, the Netherlands, and the UK. Data on putative risk factors from these patients were compared with data from 405 controls. Findings We found evidence for familiar aggregation of CJD with dementia due to causes other than CJD (relative risk [RR] 2.26, 95% CI 1.31-3.90). No significant increased risk of CJD in relation to a history of surgery and blood tranfusion was shown. There was no evidence for an association between the risk of CJD and the consumption of beef, veal, lamb, cheese, or milk. No association was found with occupational exposure to animals or leather. The few positive findings of the study include increased risk in relation to consumption of raw meat (RR 1.63 [95% CI 1.18-2.23]) and brain (1.68 [1.18-2.39]), frequent exposure to leather products (1.94 [1.13-3.33]), and exposure to fertiliser consisting of hoofs and horns (2.32 [138-2.91]). Additional analyses, for example stratification by country and of exposures pre-1985 and post-1985, suggest that these results should be interpreted with great caution. Interpretation Within the limits of the retrospective design of the study, our findings suggest that genetic factors other than the known CJD mutations may play an important part in CJD. latrogenic transmission of disease seems rare in this large population-based sample of patients with CJD. There is little evidence for an association between the risk of CJD and either animal exposure, or consumption of processed bovine meat or milk products for the period studied.	Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, NL-3000 DR Rotterdam, Netherlands; Hop La Pitie Salpetriere, INSERM, U360, Paris, France; Univ Cattolica Sacro Cuore, Dept Neurol, I-00168 Rome, Italy; Univ Gottingen, Neurol Klin, D-3400 Gottingen, Germany; Western Gen Hosp, CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Marien Hosp, Hamburg, Germany; Univ Naples Federico II, Dept Neurol, Naples, Italy; Univ Ferrara, Dept Neurol, I-44100 Ferrara, Italy	Erasmus University Rotterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Gottingen; University of Edinburgh; St. Marien Hospital; University of Naples Federico II; University of Ferrara	van Duijn, CM (corresponding author), Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Giese, Armin/F-3271-2010	Giese, Armin/0000-0002-8238-4102; Weber, Thomas/0000-0002-3833-6197; Granieri, Enrico/0000-0003-4038-3192				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BERNOULLI C, 1977, LANCET, V1, P478; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; *DEP EP POP SCI NA, 1995, 4 DEP EP POP SCI NAT; DUFFY P, 1974, NEW ENGL J MED, V290, P692; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; MANUELIDIS EE, 1985, LANCET, V2, P896; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; POWELLJACKSON J, 1985, LANCET, V2, P244; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; TATEISHI J, 1985, LANCET, V2, P1074; THADANI V, 1988, J NEUROSURG, V69, P766, DOI 10.3171/jns.1988.69.5.0766; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; Wientjens DPWM, 1996, NEUROLOGY, V46, P1287, DOI 10.1212/WNL.46.5.1287; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1982, J NEUROL NEUROSUR PS, V45, P235, DOI 10.1136/jnnp.45.3.235; WILL RG, IN PRESS ANN NEUROL; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204	27	151	151	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	1998	351	9109					1081	1085		10.1016/S0140-6736(97)09468-3	http://dx.doi.org/10.1016/S0140-6736(97)09468-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660576				2022-12-24	WOS:000073090200008
J	Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM				Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM			Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1	LANCET			English	Article							HISTOPROGNOSTIC GRADE; CARCINOMA; CARRIERS; LINKAGE; AGE	Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration. Methods We estimated disease-free adn overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis. Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001). Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.	Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, NL-3075 EA Rotterdam, Netherlands; Rotterdam Canc Inst, Dept Patient Registrat, Rotterdam, Netherlands; Acad Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC	Klijn, JGM (corresponding author), Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.		DEVILEE, PETER/ABR-2140-2022					Coebergh JWW, 1995, CANC INCIDENCE SURVI; CORNELIS RS, 1995, HUM GENET, V95, P539, DOI 10.1007/BF00223866; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisinger F, 1996, CANCER RES, V56, P471; FOEKENS JA, 1989, CANCER RES, V49, P5823; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Henderson IC, 1997, LANCET, V349, P1488, DOI 10.1016/S0140-6736(97)22021-0; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Jacquemier J, 1996, LANCET, V348, P1098, DOI 10.1016/S0140-6736(05)64441-8; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; KLIJN JGM, 1993, CANCER SURV, V18, P165; Klijn JGM, 1997, EUR J CANCER, V33, P2149, DOI 10.1016/S0959-8049(97)00360-2; Lakhani SR, 1997, LANCET, V349, P1505; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V246, P1197, DOI 10.1001/jama.246.11.1197; LYNCH HT, 1993, P ASCO, V12, P82; LYNCH HT, 1994, P ASCO, V13, P56; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sobol A, 1996, CANCER RES, V56, P3216; SOLIN LJ, 1996, J LIBBEY EUROTEXT, P351; WOBBES T, 1987, EUR J SURG ONCOL, V13, P119	30	367	374	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					316	321		10.1016/S0140-6736(97)07065-7	http://dx.doi.org/10.1016/S0140-6736(97)07065-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652611				2022-12-24	WOS:000071864000009
J	Nazerali, H; Hogerzeil, HV				Nazerali, H; Hogerzeil, HV			The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study	BRITISH MEDICAL JOURNAL			English	Article									WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland; Zimbabwe Essential Drugs Act Programme, Harare, Zimbabwe	World Health Organization	Hogerzeil, HV (corresponding author), WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland.							HOGERZEIL HV, 1992, BRIT MED J, V304, P210, DOI 10.1136/bmj.304.6821.210; Hogerzeil HV, 1996, EUR J OBSTET GYN R B, V69, P25, DOI 10.1016/0301-2115(95)02530-8; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; NAZERALI H, 1996, WHODAP9416; WALKER GJA, 1988, LANCET, V2, P393	5	32	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					512	513						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712597				2022-12-24	WOS:000075641400020
J	Marx, SO; Ondrias, K; Marks, AR				Marx, SO; Ondrias, K; Marks, AR			Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors)	SCIENCE			English	Article							II-III-LOOP; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTOR; REGIONS	Excitation-contraction coupling in skeletal muscle requires the release of intracellular calcium ions (Ca2+) through ryanodine receptor (RyR1) channels in the sarcoplasmic reticulum. Half of the RyR1 channels are activated by voltage-dependent Ca2+ channels in the plasma membrane, In planar Lipid bilayers, RyR1 channels exhibited simultaneous openings and closings, termed "coupled gating." Addition of the channel accessory protein FKBP12 induced coupled gating, and removal of FKBP12 uncoupled channels, Coupled gating provides a mechanism by which RyR1 channels that are not associated with voltage-dependent Ca2+ channels can be regulated.	Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Circulatory Physiol,Dept Med, New York, NY 10032 USA; Slovak Acad Sci, Inst Mol Physiol & Genet, SK-83334 Bratislava, Slovakia; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Slovak Academy of Sciences; Columbia University	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA.			Ondrias, Karol/0000-0001-8329-3563	FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00949] Funding Source: Medline; NHLBI NIH HHS [R01HL56180] Funding Source: Medline; PHS HHS [R01A139794] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MARX SO, UNPUB; MILLER C, 1986, ION CHANNL RECONSTIT, P3; Ondrias K, 1996, SOC GEN PHY, V51, P29; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0	20	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					818	821		10.1126/science.281.5378.818	http://dx.doi.org/10.1126/science.281.5378.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694652				2022-12-24	WOS:000075295600048
J	Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT				Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT			The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women	ANNALS OF INTERNAL MEDICINE			English	Article							MENSTRUAL-CYCLE; HEALTHY WOMEN; DIAGNOSIS; PROGESTERONE; POPULATION; ESTRADIOL	Background: Hormonal factors may play an important role in the pathophysiology of the Raynaud phenomenon. Experimental studies have shown an increased vasoconstrictor response to estrogen, a response that can be prevented by the addition of progesterone. Objective: To measure the association between estrogen replacement therapy (alone and with progesterone) and the Raynaud phenomenon. Design: Cross-sectional study. Setting: Framingham Offspring Study. Participants: 497 postmenopausal women. Measurements: Prevalence of the Raynaud phenomenon according to hormone use. Covariates measured included age, body mass index, smoking, alcohol consumption, and p-blocker use. Results: Forty-nine women were classified as having the Raynaud phenomenon (9.9%). The prevalence of this phenomenon was 8.4% among women who did not receive estrogen, 19.1% among women receiving estrogen alone, and 9.8% among women receiving estrogen plus progesterone. The adjusted odds ratio for the Raynaud phenomenon was 2.5 (95% CI, 1.2 to 5.3) for unopposed estrogen and 0.9 (CI, 0.3 to 2.6) for estrogen plus progesterone, with nonusers as the reference group. Conclusions: Unopposed estrogen therapy was associated with the Raynaud phenomenon in postmenopausal women. This association was not present in women who were receiving combined hormone therapy.	Boston Univ, Ctr Arthritis, Boston, MA 02118 USA; Boston Univ, Med Ctr, Boston, MA USA; NHLBI, Bethesda, MD USA	Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fraenkel, L (corresponding author), Boston Univ, Ctr Arthritis, A203,715 Albany St, Boston, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Chaisson, Christine/0000-0002-3207-9257; Zhang, Yuqing/0000-0001-7954-1149	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [AG09300] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTURA BM, 1975, J PHARMACOL EXP THER, V193, P403; BARTELINK ML, 1994, EUR J CLIN PHARMACOL, V46, P557, DOI 10.1007/BF00196115; BRENNAN P, 1993, BRIT J RHEUMATOL, V32, P357; COFFMAN JD, 1990, J VASC MED BIOL, V2; EASTCOTT HH, 1976, BRIT MED J, V2, P477, DOI 10.1136/bmj.2.6033.477-c; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; FELSON DT, 1995, AM J EPIDEMIOL, V142, P485, DOI 10.1093/oxfordjournals.aje.a117664; Greenstein D, 1996, ANGIOLOGY, V47, P427, DOI 10.1177/000331979604700501; HAMLET MA, 1980, AM J PHYSIOL, V239, pH450, DOI 10.1152/ajpheart.1980.239.4.H450; KEIL JE, 1991, INT J EPIDEMIOL, V20, P221, DOI 10.1093/ije/20.1.221; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE JD, 1989, BRAIN RES, V487, P143, DOI 10.1016/0006-8993(89)90949-9; MARICQ HR, 1988, J RHEUMATOL, V15, P454; OKEEFFE ST, 1992, J RHEUMATOL, V19, P1415; ROBERTS JM, 1977, NATURE, V270, P624, DOI 10.1038/270624a0; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; SOLERTE SB, 1988, BRIT J OBSTET GYNAEC, V95, P1305, DOI 10.1111/j.1471-0528.1988.tb06822.x; TERREGINO CA, 1985, ANGIOLOGY, V36, P88, DOI 10.1177/000331978503600204; Valter I, 1998, J RHEUMATOL, V25, P697; WILLIAMS LT, 1977, J CLIN INVEST, V60, P815, DOI 10.1172/JCI108835	20	43	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					208	211		10.7326/0003-4819-129-3-199808010-00009	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696729				2022-12-24	WOS:000075032700006
J	Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R				Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R			Identification of patients with atrial fibrillation in general practice: a study of screening methods	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England	Newcastle University - UK	Sudlow, M (corresponding author), Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Mark.Sudlow@ncl.ac.uk		Kenny, Rose Anne/0000-0002-9336-8124				Cuckle HS, 1984, ANTENATAL NEONATAL S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	5	51	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					327	328		10.1136/bmj.317.7154.327	http://dx.doi.org/10.1136/bmj.317.7154.327			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685281	Green Published			2022-12-24	WOS:000075409500025
J	Villers, D; Espaze, E; Coste-Burel, M; Giauffret, F; Ninin, E; Nicolas, F; Richet, H				Villers, D; Espaze, E; Coste-Burel, M; Giauffret, F; Ninin, E; Nicolas, F; Richet, H			Nosocomial Acinetobacter baumannii infections: Microbiological and clinical epidemiology	ANNALS OF INTERNAL MEDICINE			English	Article						Acinetobacter infections; drug resistance, multiple; opportunistic infections; cross infection; anti-infective agents, fluoroquinolone	QUINOLONE-RESISTANT MUTANTS; HOSPITAL OUTBREAKS; ESCHERICHIA-COLI; TYPING METHODS; RISK-FACTORS; IN-VITRO; STRAINS; DNA; CIPROFLOXACIN; PHARMACOKINETICS	Background: Acinetobacter baumannii is an important opportunistic pathogen that is rapidly evolving toward multidrug resistance and is involved in various nosocomial infections that are often severe. It is difficult to prevent A. baumannii infection because A. baumannii is ubiquitous and the epidemiology of the infections it causes is complex. Objective: To study the epidemiology of A. baumannii infections and assess the relation between fluoroquinolone use and the persistence of multidrug-resistant clones. Design: Three case-control studies and a retrospective cohort study. Setting: A 20-bed medical and surgical intensive care unit. Patients: Acinetobacter baumannii was isolated from 45 patients in urine (31%), the lower respiratory tract (26.7%), wounds (17.8%), blood (11.1%), skin (6.7%), cerebrospinal fluid (4.4%), and sinus specimens (2.2%). One death was due to A. baumannii infection. Measurements: Antimicrobial resistance pattern and molecular typing were used to characterize isolates. The incidence of A. baumannii infection and the use of fluoroquinolones were calculated annually. Results: Initially, 28 patients developed A. baumannii infection. Eleven isolates had the same antimicrobial susceptibility profile, genotypic profile, or both (epidemic cases), and 17 were heterogeneous (endemic cases). A surgical procedure done in an emergency operating room was the main risk factor for epidemic cases, whereas previous receipt of a fluoroquinolone was the only risk factor for endemic cases. The opening of a new operating room combined with the restriction of fluoroquinolone use contributed to a transitory reduction in the incidence of infection. When a third epidemiologic study was done, previous receipt of a fluoroquinolone was again an independent risk factor and a parallel was seen between the amount of intravenous fluoroquinolones prescribed and the incidence of endemic infection. Conclusion: Epidemic infections coexisted with endemic infections favored by the selection pressure of intravenous fluoroquinolones.	Hop Nantes, Bacteriol Lab, Inst Biol, F-44035 Nantes, France; Hop Hotel Dieu, Nantes, France	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Villers, D (corresponding author), CHU Nantes, Serv Reanimat Med, Hotel Dieu, F-44035 Nantes 01, France.							ANDREWS HJ, 1986, J HOSP INFECT, V7, P169, DOI 10.1016/0195-6701(86)90060-5; BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714; BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148, DOI 10.1128/CMR.9.2.148; BOUVET PJM, 1987, ANN INST PASTEUR MIC, V138, P569, DOI 10.1016/0769-2609(87)90042-1; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V26, P757, DOI 10.1128/AAC.26.5.757; CEFAI C, 1990, J HOSP INFECT, V15, P177, DOI 10.1016/0195-6701(90)90128-B; CHRISTIE C, 1995, INFECT CONT HOSP EP, V16, P590; DIJKSHOORN L, 1993, J CLIN MICROBIOL, V31, P702, DOI 10.1128/JCM.31.3.702-705.1993; DOLZANI L, 1995, J CLIN MICROBIOL, V33, P1108, DOI 10.1128/JCM.33.5.1108-1113.1995; Fung-Tomc J, 1990, ANTIMICROB NEWSLETT, V7, P17; GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7; GRUNDMANN H, 1995, J MED MICROBIOL, V43, P446, DOI 10.1099/00222615-43-6-446; HORREVORTS A, 1995, J CLIN MICROBIOL, V33, P1567, DOI 10.1128/JCM.33.6.1567-1572.1995; JOLYGUILLOU ML, 1990, J HOSP INFECT, V16, P49, DOI 10.1016/0195-6701(90)90048-S; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KROPEC A, 1993, J HOSP INFECT, V23, P133, DOI 10.1016/0195-6701(93)90017-T; Levin ASS, 1996, INFECT CONT HOSP EP, V17, P366, DOI 10.1086/647319; LORTHOLARY O, 1995, CLIN INFECT DIS, V20, P790, DOI 10.1093/clinids/20.4.790; MULIN B, 1995, EUR J CLIN MICROBIOL, V14, P569, DOI 10.1007/BF01690727; PETERSON LR, 1993, DIAGN MICR INFEC DIS, V17, P97, DOI 10.1016/0732-8893(93)90019-4; PIDDOCK LJV, 1991, J ANTIMICROB CHEMOTH, V28, P185, DOI 10.1093/jac/28.2.185; RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377; ROHWEDDER RW, 1990, DIAGN MICR INFEC DIS, V13, P127, DOI 10.1016/0732-8893(90)90095-D; SAMADPOUR M, 1988, J CLIN MICROBIOL, V26, P2319, DOI 10.1128/JCM.26.11.2319-2323.1988; SCERPELLA EG, 1995, INFECT CONT HOSP EP, V16, P92, DOI 10.1086/647063; SEIFERT H, 1994, INFECT CONT HOSP EP, V15, P520; SEIFERT H, 1995, J CLIN MICROBIOL, V33, P1402, DOI 10.1128/JCM.33.5.1402-1407.1995; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SOUSSY CJ, 1994, EUR J CLIN MICROBIOL, V13, P238, DOI 10.1007/BF01974543; STRUELENS MJ, 1993, J HOSP INFECT, V25, P15, DOI 10.1016/0195-6701(93)90005-K; TJERNBERG I, 1989, APMIS, V97, P595, DOI 10.1111/j.1699-0463.1989.tb00449.x; TRAUB WH, 1989, J CLIN MICROBIOL, V27, P2713, DOI 10.1128/JCM.27.12.2713-2716.1989; VANCEBRYAN K, 1990, CLIN PHARMACOKINET, V19, P434, DOI 10.2165/00003088-199019060-00003; VANDEECHOUTTE M, 1995, RES MICROBIOL, V146, P457; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; VILA J, 1989, J CLIN MICROBIOL, V27, P1086, DOI 10.1128/JCM.27.5.1086-1089.1989; VOLLAARD EJ, 1990, J ANTIMICROB CHEMOTH, V26, P847, DOI 10.1093/jac/26.6.847; WATANABE M, 1990, ANTIMICROB AGENTS CH, V34, P173, DOI 10.1128/AAC.34.1.173	39	169	185	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					182	+		10.7326/0003-4819-129-3-199808010-00003	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696725				2022-12-24	WOS:000075032700002
J	Smith, H; Gooding, S; Brown, R; Frew, A				Smith, H; Gooding, S; Brown, R; Frew, A			Evaluation of readability and accuracy of information leaflets in general practice for patients with asthma	BRITISH MEDICAL JOURNAL			English	Article									Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England; Wilton Hlth Ctr, Wilton SP2 0HT, England; Univ Med, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Smith, H (corresponding author), Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England.		Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124				*BAS SKILLS AG, 1992, MAK READ EAS; Carey S, 1997, ADULT LITERACY BRITA; ESTEY A, 1991, PATIENT EDUC COUNS, V18, P165, DOI 10.1016/0738-3991(91)90008-S; ESTEY A, 1996, PATIENT EDUC COUNS, V30, P205; MCLAUGHLIN GH, 1969, J READING, V12, P639; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	6	60	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					264	265		10.1136/bmj.317.7153.264	http://dx.doi.org/10.1136/bmj.317.7153.264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677221	Green Accepted, Green Published			2022-12-24	WOS:000075081900028
J	Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM				Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM			Distance modulation of neural activity in the visual cortex	SCIENCE			English	Article							RESPONSE PROPERTIES; PRESTRIATE CORTEX; VIEWING DISTANCE; EYE POSITION; NEURONS; MONKEY; AREA; DEPTH; SIZE; STEREOPSIS	Humans use distance information to scale the size of objects. Earlier studies demonstrated changes in neural response as a function of gaze direction and gaze distance in the dorsal visual cortical pathway to parietal cortex. These findings have been interpreted as evidence of the parietal pathway's role in spatial representation. Here, distance-dependent: changes in neural response were also found to be common in neurons in the ventral pathway leading to inferotemporal cortex of monkeys, This result implies that the information necessary for object and spatial scaling is common to all visual cortical areas.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ So Calif, Los Angeles, CA 90089 USA	California Institute of Technology; University of Southern California	Dobbins, AC (corresponding author), Univ Alabama, Dept Biomed Engn, Vis Sci Res Ctr, Birmingham, AL 35294 USA.		Fiser, József/A-2877-2009	Fiser, Jozsef/0000-0002-7064-0690				Aguirre GK, 1997, J NEUROSCI, V17, P2512; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARBUR JL, 1987, CLIN VISION SCI, V2, P131; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLLETT TS, 1991, PERCEPTION, V20, P733, DOI 10.1068/p200733; DOBBINS E, UNPUB; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280, DOI 10.1152/jn.1995.73.1.280; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Holway AH, 1941, AM J PSYCHOL, V54, P21, DOI 10.2307/1417790; HUMPHREY N, 1969, Q J EXP PSYCHOL, V21, P255; LEIBOWIT.H, 1966, J OPT SOC AM, V56, P1120, DOI 10.1364/JOSA.56.001120; Milner A. D., 1995, VISUAL BRAIN ACTION; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SAKATA H, 1980, J NEUROPHYSIOL, V43, P1654, DOI 10.1152/jn.1980.43.6.1654; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; UNGERLEIDER LG, 1977, EXP BRAIN RES, V27, P251; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; WALLACH H, 1963, AM J PSYCHOL, V76, P404, DOI 10.2307/1419781; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; WISE SP, 1988, SCIENCE, V242, P736, DOI 10.1126/science.3187520; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	27	86	86	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					552	555		10.1126/science.281.5376.552	http://dx.doi.org/10.1126/science.281.5376.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677196				2022-12-24	WOS:000075012300038
J	Wang, LY; Kaczmarek, LK				Wang, LY; Kaczmarek, LK			High-frequency firing helps replenish the readily releasable pool of synaptic vesicles	NATURE			English	Article							AUDITORY BRAIN-STEM; TRAPEZOID BODY; TRANSMITTER RELEASE; MEDIAL NUCLEUS; DEPRESSION; CELLS; ORGANIZATION; HIPPOCAMPUS; PARVALBUMIN; CALRETININ	Synapses in the central nervous system undergo various short- and long-term changes in their strength(1-3), but it is often difficult to distinguish whether presynaptic or postsynaptic mechanisms are responsible for these changes. Using patch-clamp recording from giant synapses in the mouse auditory brainstem(4-7), we show here that short-term synaptic depression can be largely attributed to rapid depletion of a readily releasable pool of vesicles. Replenishment of this pool is highly dependent on the recent history of synaptic activity. High-frequency stimulation of presynaptic terminals significantly enhances the rate of replenishment. Broadening the presynaptic action potential with the potassium-channel blocker tetraethylammonium, which increases Ca2+ entry, further enhances the rate of replenishment. As this increase can be suppressed by the Ca2+-channel blocker Cd2+ or by the Ca2+ buffer EGTA, we conclude that Ca2+ influx through voltage-gated Ca2+ channels is the key signal that dynamically regulates the refilling of che releasable pool of synaptic vesicles in response to different patterns of inputs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Toronto, Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada	Yale University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	Kaczmarek@Yale.edu						BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; BROWNELL WE, 1975, BRAIN RES, V94, P413, DOI 10.1016/0006-8993(75)90226-7; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; GUINAN JJ, 1972, INT J NEUROSCI, V4, P147, DOI 10.3109/00207457209164756; HANKEL AW, 1996, CURR OPIN NEUROBIOL, V6, P350; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Isaacson JS, 1996, J NEUROPHYSIOL, V76, P1566, DOI 10.1152/jn.1996.76.3.1566; KUSANO K, 1975, J PHYSIOL-LONDON, V245, P13, DOI 10.1113/jphysiol.1975.sp010832; KUWABARA N, 1991, J COMP NEUROL, V314, P684, DOI 10.1002/cne.903140405; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lohmann C, 1996, J COMP NEUROL, V367, P90, DOI 10.1002/(SICI)1096-9861(19960325)367:1<90::AID-CNE7>3.0.CO;2-E; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MOREST D K, 1968, Zeitschrift fuer Anatomie und Entwicklungsgeschichte, V127, P201, DOI 10.1007/BF00526129; PARKER D, 1995, J NEUROPHYSIOL, V74, P529, DOI 10.1152/jn.1995.74.2.529; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VATER M, 1994, J COMP NEUROL, V341, P534, DOI 10.1002/cne.903410409; vonGersdorff H, 1997, J NEUROSCI, V17, P8137; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WANG LY, 1997, SOC NEUR ABSTR, V25, P365; WU SH, 1993, HEARING RES, V68, P189, DOI 10.1016/0378-5955(93)90123-I; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	456	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					384	388		10.1038/28645	http://dx.doi.org/10.1038/28645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690475				2022-12-24	WOS:000074968800055
J	Nicoll, RA; Malenka, RC				Nicoll, RA; Malenka, RC			Neuroscience - A tale of two transmitters	SCIENCE			English	Editorial Material							GLYCINE; GABA; INHIBITION; TERMINALS		Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BOWERS CW, 1994, TRENDS NEUROSCI, V17, P315, DOI 10.1016/0166-2236(94)90168-6; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CHAUDHRY FA, IN PRESS J NEUROSCI; CULLHEIM S, 1981, J PHYSIOL-LONDON, V312, P209, DOI 10.1113/jphysiol.1981.sp013624; DALE HENRY, 1935, PROC ROY SOC MED, V28, P319; ECCLES JC, 1954, J PHYSIOL-LONDON, V126, P524, DOI 10.1113/jphysiol.1954.sp005226; EDWARDS RG, COMMUNICATION; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Nicoll R A, 1979, Int Rev Neurobiol, V21, P217; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; Ornung G, 1996, J COMP NEUROL, V365, P413; Ottersen O.P., 1990, GLYCINE NEUROTRANS, P303; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; TRILLER A, 1987, J CELL BIOL, V104, P947, DOI 10.1083/jcb.104.4.947; ZAFRA F, 1995, J NEUROSCI, V15, P3952	19	31	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					360	361		10.1126/science.281.5375.360	http://dx.doi.org/10.1126/science.281.5375.360			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705712				2022-12-24	WOS:000074918800034
J	Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P				Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P			Reduction of atherosclerosis in mice by inhibition of CD40 signalling	NATURE			English	Article							ENDOTHELIAL-CELLS; LIGAND INTERACTIONS; LYMPHOCYTES-T; GP39; HYPERCHOLESTEROLEMIA; PATHOGENESIS; MACROPHAGES; PREVENTION; EXPRESSION; LESIONS	Increasing amounts of evidence support the involvement of inflammation and immunity in atherogenesis(1-4), but mediators of communication between the major cell types in atherosclerotic plaques are poorly defined. Cells in human atherosclerotic lesions express the immune mediator CD40 and its ligand CD40L (also known as CD154 or gp39)(5). The interaction of CD40 with CD40L figures prominently in both humoral and cell-mediated immune responses(6). CD4OL-positive T cells accumulate in atheroma(5), and, by virtue of their early appearance, persistence and localization at sites of lesion growth and complication, activated T cells may coordinate important aspects of atherogenesis(7-9). Interruption of CD40L-CD40 signalling by administration of an anti-CD40L antibody Limits experimental autoimmune diseases such as collagen-induced arthritis, lupus nephritis, acute or chronic graft-versus-host disease, multiple sclerosis and thyroiditis(10-14). Ligation of CD40 on atheroma-associated cells in vitro activates functions related to atherogenesis, including induction of proinflammatory cytokines(5), matrix metalloproteinases(15,16), adhesion molecules(17-19) and tissue factor(16,20). However, the role of CD40 signalling in atherogenesis in vivo remains unknown. Here we determine whether interruption of CD40 signalling influences atherogenesis in vivo in hyperlipidaemic mice, Treatment with antibody against mouse CD40L limited atherosclerosis in mice lacking the receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks. This antibody reduces the size of aortic atherosclerotic lesions by 59% and their lipid content by 79%, Furthermore, atheroma of mice treated with anti-CD40L antibody contained significantly fewer macrophages (64%) and T lymphocytes (70%), and exhibited decreased expression of vascular cell adhesion molecule-1. These data support the involvement of inflammatory pathways in atherosclerosis and indicate a role for CD40 signalling during atherogenesis in hyperlipidaemic mice.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, 221 Longwood Ave, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X				Carayanniotis G, 1997, IMMUNOLOGY, V90, P421, DOI 10.1111/j.1365-2567.1997.00421.x; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; EMESON EE, 1988, AM J PATHOL, V130, P369; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; HANSSON GK, 1988, ATHEROSCLEROSIS, V72, P135, DOI 10.1016/0021-9150(88)90074-3; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lichtman A. H., 1997, FASEB Journal, V11, pA154; Lichtman AH, 1996, AM J PATHOL, V149, P351; Lu LN, 1997, TRANSPLANTATION, V64, P1808, DOI 10.1097/00007890-199712270-00031; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MACH F, IN PRESS ATHEROSCLER; MOHAN C, 1995, J IMMUNOL, V154, P1470; Roselaar SE, 1996, ARTERIOSCL THROM VAS, V16, P1013, DOI 10.1161/01.ATV.16.8.1013; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zhou XH, 1996, AM J PATHOL, V149, P359	29	723	784	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					200	203		10.1038/28204	http://dx.doi.org/10.1038/28204			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671306				2022-12-24	WOS:000074705900059
J	McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS				McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS			High-temperature silicate volcanism on Jupiter's moon Io	SCIENCE			English	Article							GALILEAN SATELLITES; INTERNAL STRUCTURE; TOPOGRAPHY; SPECTRA; SYSTEM	Infrared wavelength observations of lo by the Galileo spacecraft show that at Least 12 different vents are erupting lavas that are probably hotter than the highest temperature basaltic eruptions on Earth today. In at least one case, the eruption near Pillan Patera, two independent instruments on Galileo show that the lava temperature must have exceeded 1700 kelvin and may have reached 2000 kelvin. The most likely explanation is that these lavas are ultramafic (magnesium-rich) silicates, and this idea-is supported by the tentative identification of magnesium-rich orthopyroxene in Lava flows associated with these high-temperature hot spots.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Lowell Observ, Flagstaff, AZ 86001 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; US Geol Survey, Menlo Park, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA	University of Arizona; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Brown University; Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory	McEwen, AS (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.	mcewen@lplarizona.edu	Lopes, Rosaly M.C./D-1608-2016; Fagents, Sarah/B-3983-2014; Davies, Ashley/S-5588-2018	Lopes, Rosaly M.C./0000-0002-7928-3167; Davies, Ashley/0000-0003-1747-8142; Kestay, Laszlo/0000-0003-1879-4331				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; Bevington PR, 1969, DATA REDUCTION ERROR; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARR MH, 1986, J GEOPHYS RES-SOLID, V91, P3521, DOI 10.1029/JB091iB03p03521; CARR MH, IN PRESS ICARUS; DAVIES AG, 1998, LUNAR PLANET SCI, V29; GARCIA MO, 1995, GEOPHYS MONOGR SER, V92, P219; GASKELL RW, 1988, GEOPHYS RES LETT, V15, P581, DOI 10.1029/GL015i006p00581; Hall A, 1987, IGNEOUS PETROLOGY; HEAD JW, 1992, GEOCHIM COSMOCHIM AC, V56, P2155, DOI 10.1016/0016-7037(92)90183-J; HEIKEN G, 1991, LUNAR SORUCEBOOK USE; HERZBERG C, 1992, J GEOPHYS RES-SOL EA, V97, P4521, DOI 10.1029/91JB03066; Hess PC., 1989, ORIGINS IGNEOUS ROCK; JOHNSON ML, 1990, GEOPHYS RES LETT, V17, P981, DOI 10.1029/GL017i007p00981; JOHNSON TV, 1988, SCIENCE, V242, P1280, DOI 10.1126/science.242.4883.1280; Keszthelyi L, 1997, GEOPHYS RES LETT, V24, P2463, DOI 10.1029/97GL01368; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; KLAASEN KP, 1984, OPT ENG, V23, P334, DOI 10.1117/12.7973290; KLASSEN KP, 1997, OPT ENG, V36, P3001; LopesGautier R, 1997, GEOPHYS RES LETT, V24, P2439, DOI 10.1029/97GL02662; LUNINE JI, 1985, ICARUS, V64, P345, DOI 10.1016/0019-1035(85)90060-0; MATSON DL, 1998, LUNAR PLANET SCI, V29; McEwen AS, 1997, GEOPHYS RES LETT, V24, P2443, DOI 10.1029/97GL01956; MCEWEN AS, 1989, NASA SP494, P11; MCEWEN AS, IN PRESS ICARUS; Morse S. A., 1980, BASALTS PHASE DIAGRA; NASH DB, 1990, SATELLITES, P629; Pearl J.S., 1982, SATELLITES JUPITER, P724; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROSS MN, 1990, ICARUS, V85, P309, DOI 10.1016/0019-1035(90)90119-T; Rothery DA, 1996, J GEOPHYS RES-PLANET, V101, P26131, DOI 10.1029/96JE02864; SCHABER GG, 1982, SATELLITES JUPITER, P556; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2451, DOI 10.1029/97GL02591; Stansberry JA, 1997, GEOPHYS RES LETT, V24, P2455, DOI 10.1029/97GL02593; THOMAS PE, IN PRESS; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637	40	159	161	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					87	90		10.1126/science.281.5373.87	http://dx.doi.org/10.1126/science.281.5373.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651251				2022-12-24	WOS:000074685800043
J	DePace, AH; Santoso, A; Hillner, P; Weissman, JS				DePace, AH; Santoso, A; Hillner, P; Weissman, JS			A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROTEIN; PSI(+); URE3	The yeast [PSI+] factor propagates by a prion-like mechanism involving self-replicating Sup35p amyloids. We identified multiple Sup35p mutants that either are poorly recruited into, or cause curing of, wildtype amyloids in vivo. In vitro, these mutants showed markedly decreased rates of amyloid formation, strongly supporting the protein-only prion hypothesis. Kinetic analysis suggests that the prion state replicates by accelerating slow conformational changes rather than by providing stable nuclei. Strikingly, our mutations map exclusively within a short glutamine/asparagine-rich region of Sup35p, and all but one occur at polar residues. Even after replacement of this region with polyglutamine, Sup35p retains its ability to form amyloids. These and other considerations suggest similarities between the prion-like propagation of [PSI+] and polyglutamine-mediated pathogenesis of several neurodegenerative diseases.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.			Weissman, Jonathan/0000-0003-2445-670X				BRIEHL RW, 1980, NATURE, V288, P622, DOI 10.1038/288622a0; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; JAHLEM P, 1998, MOL CELL, V1, P595; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Moore DD, 1995, GLOB MOB SURV; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	38	326	329	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1241	1252		10.1016/S0092-8674(00)81467-1	http://dx.doi.org/10.1016/S0092-8674(00)81467-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657156	Bronze			2022-12-24	WOS:000074491100018
J	Nabarro, DN; Tayler, EM				Nabarro, DN; Tayler, EM			The "Roll Back Malaria" campaign	SCIENCE			English	Editorial Material									Dept Int Dev, London SW1E 5JL, England		Nabarro, DN (corresponding author), Dept Int Dev, 94 Victoria St, London SW1E 5JL, England.	d-nabarro@dfid.gtnet.gov.uk						Butler D, 1997, NATURE, V390, P209, DOI 10.1038/36663; Mons B, 1998, SCIENCE, V279, P498, DOI 10.1126/science.279.5350.498; *WHO HLTH ORG, 1993, GLOB STRAT MAL CONTR; *WHO HLTH ORG AFR, AFR IN MAL CONTR 21, P98	4	114	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2067	2068		10.1126/science.280.5372.2067	http://dx.doi.org/10.1126/science.280.5372.2067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9669961				2022-12-24	WOS:000074435900028
J	Nomura, M; Li, E				Nomura, M; Li, E			Smad2 role in mesoderm formation, left-right patterning and craniofacial development	NATURE			English	Article							SIGNALING PATHWAYS; NODAL EXPRESSION; GENE; MOUSE; GASTRULATION; PROTEINS; MUTATION; ACTIVIN	Signalling by the transforming growth factor-p (TGF-P) superfamily of proteins depends on the phosphorylation and activation of SMAD proteins by heteromeric complexes of ligand-specific type I and type II receptors with serine/threonine-kinase activity(1). The vertebrate SMAD family includes at least nine members, of which Smad2 has been shown to mediate signalling by activin and TGF-beta(2-5). In Xenopus, Smad2 can induce dorsal mesoderm, mimicking Vg-1, activin and nodal(2,4), Here we investigate the function of Smad2 in mammalian development by generating two independent Smad2 mutant alleles in mice by gene targeting, We show that homozygous mutant embryos fail to form an organized egg cylinder and lack mesoderm, like mutant mice lacking nodal(6,7) or ActRIB the gene encoding the activin type-I receptor(8). About 20 per cent of Smad2 heterozygous embryos have severe gastrulation defects and lack mandibles or eyes, indicating that the gene dosage of Smad2 is critical for signalling. Mice trans-heterozygous for both Smad2 and nodal mutations display a range of phenotypes, including gastrulation defects, complex craniofacial abnormalities such as cyclopia, and defects in left-right patterning, indicating that Smad2 may mediate nodal signalling in these developmental processes. Our results show that Smad2 function is essential for early development and for several patterning processes in mice.	Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Harvard University	Li, E (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOGAN B, 1994, MANIPULATING MOUSE E, P51; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JONES CM, 1995, DEVELOPMENT, V121, P3651; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIXATIO; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	497	521	4	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					786	790		10.1038/31693	http://dx.doi.org/10.1038/31693			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655392				2022-12-24	WOS:000074433100049
J	Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S		Swedish Hip Fracture Study Grp	Hormone replacement therapy and risk of hip fracture: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; BONE-DENSITY; ESTROGEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREVENTION; AGE	Objective: To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Design: Population based case-control study. Setting: Six counties in Sweden. Subjects: 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Main outcome measure: Use of hormone replacement therapy. Results: Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01), For every year of therapy the overall risk decreased by 6% (3% to 9%): 4%, (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously with a duration of use more than five years, was associated with all odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (-7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. Conclusions: Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can bt started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Stockholm Cty Council, Dept Epidemiol, S-17176 Stockholm, Sweden; Malmo Gen Hosp, Dept Orthopaed, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Karolinska Institutet; Stockholm County Council; Uppsala University; Uppsala University Hospital	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217; Magnusson, Cecilia/0000-0002-8567-6725	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1985, LANCET, V2, P800; Christiansen C, 1990, Osteoporos Int, V1, P7; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MELTON LJ, 1987, BONE MINER, V2, P321; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	28	201	206	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1858	1863						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632404				2022-12-24	WOS:000074686500016
J	Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R				Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R			Extended excretion of rotavirus after severe diarrhoea in young children	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSE; CELL-CULTURE; SERUM; INFECTION; GASTROENTERITIS; ENTERITIS	Background Rotaviruses are the major cause of severe childhood diarrhoea. Knowledge of the natural history of infection, including duration of intestinal virus shedding, is important in the understanding of transmission, sources of infection, and immune responses. Methods We carried out a study of rotavirus excretion in 37 children admitted to hospital with severe rotavirus diarrhoea. Sequential faecal specimens were collected from each child during 100 days of surveillance, and screened for rotavirus by EIA and by amplification of genome double-stranded RNA by reverse-transcription PCR. IgA coproantibody was estimated by EIA. Findings Duration of rotavirus excretion ranged from 4 to 57 days after onset of diarrhoea. Excretion ceased within 10 days in 16 (43%) children, and within 20 days in 26 (70%) children. Extended excretion was detected for 25-57 days in the remaining 11 (30%) children owing mainly to continued excretion of the primary infecting strain. Extended excretion was significantly associated with antirotavirus IgA coproantibody boosts during 100 days of surveillance (p=0.001, log-rank test), and with recurrence of mild diarrhoea symptoms during convalescence (p=0.006, Fisher's exact test). Interpretation Severe rotavirus disease in young children may be followed by extended excretion of rotavirus. The risk of transmission to others may be greater than previously believed. Extended excretion could also explain some cases of the postgastroenteritis syndrome.	Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Melbourne, Vic, Australia; Wellington Sch Med, Dept Paediat & Child Hlth, Wellington S, New Zealand	Royal Children's Hospital Melbourne; University of Otago	Bishop, R (corresponding author), Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Flemington Rd, Parkville, Vic 3052, Australia.	bishop@cryptic.rch.unimelb.edu.au	Palombo, Enzo/AAV-8632-2021; Grimwood, Keith/F-9334-2011; Gorrell, Rebecca/H-5259-2019; Gorrell, Rebecca/J-1454-2012	Palombo, Enzo/0000-0001-5889-1393; Gorrell, Rebecca/0000-0003-0728-3325; Grimwood, Keith/0000-0003-3174-9834				ALBERT MJ, 1984, J MED VIROL, V13, P377, DOI 10.1002/jmv.1890130409; BASS DM, 1991, DIARRHOEAL DIS, P139; BEARDS GM, 1984, J CLIN MICROBIOL, V19, P248, DOI 10.1128/JCM.19.2.248-254.1984; BISHOP R, 1990, MED VIROL, V9, P85; CHIARINI A, 1983, J GEN VIROL, V64, P1101, DOI 10.1099/0022-1317-64-5-1101; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; COULSON BS, 1987, J CLIN MICROBIOL, V25, P509, DOI 10.1128/JCM.25.3.509-515.1987; COULSON BS, 1989, J VIROL METHODS, V26, P53, DOI 10.1016/0166-0934(89)90074-8; DAVIDSON GP, 1975, LANCET, V1, P242; DAVIDSON GP, 1983, INFECT IMMUN, V40, P447, DOI 10.1128/IAI.40.2.447-452.1983; EIDEN JJ, 1988, PEDIATR INFECT DIS J, V7, P564; ESTES MK, 1980, ARCH VIROL, V65, P187, DOI 10.1007/BF01317330; GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRIMWOOD K, 1988, J CLIN MICROBIOL, V26, P732, DOI 10.1128/JCM.26.4.732-738.1988; GUARINO A, 1995, J PEDIATR GASTR NUTR, V20, P173, DOI 10.1097/00005176-199502000-00006; HJELT K, 1985, J PEDIATR GASTR NUTR, V4, P60, DOI 10.1097/00005176-198502000-00012; Kapikian A.Z., 1996, FIELDS VIROLOGY, P1657; KILBOURNE ED, 1973, J INFECT DIS, V128, P668, DOI 10.1093/infdis/128.5.668; KRAFT LISBETH M., 1961, PROC ANIMAL CARE PANEL, V11, P125; MISRA V, 1980, ICN UCLA S MOL CELL, V18, P727; NAGAYOSHI S, 1980, EUR J PEDIATR, V134, P99, DOI 10.1007/BF01846024; PALOMBO EA, 1993, ARCH VIROL, V133, P323, DOI 10.1007/BF01313772; RIEPENHOFFTALTY M, 1981, J MED VIROL, V8, P215, DOI 10.1002/jmv.1890080309; STALS F, 1984, J MED VIROL, V4, P333; VESIKARI T, 1981, ACTA PAEDIATR SCAND, V70, P717, DOI 10.1111/j.1651-2227.1981.tb05774.x; WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871; WARD RL, 1984, J CLIN MICROBIOL, V19, P748, DOI 10.1128/JCM.19.6.748-753.1984; WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L; WILDE J, 1992, J INFECT DIS, V166, P507, DOI 10.1093/infdis/166.3.507; XU L, 1990, J VIROL METHODS, V27, P29, DOI 10.1016/0166-0934(90)90143-4	31	95	100	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1844	1848		10.1016/S0140-6736(97)11257-0	http://dx.doi.org/10.1016/S0140-6736(97)11257-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652668				2022-12-24	WOS:000074347100011
J	Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L				Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L			Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; SERUM LEVELS; BONE-MARROW; IFN-GAMMA; IN-VITRO; CHILDREN; ANEMIA; IL-10; DISEASE	Background Severe anaemia is a major complication of malaria but little is known about its pathogenesis. Experimental models have implicated tumour necrosis factor (TNF) in induction of bone-marow suppression and eythrophagocytosis. Conversely, interleukin 10 (IL-10), which mediates feed-back regulation of TNF, stimulates bone-marrow function in vitro and counteracts anaemia in mice. We investigated the associations of these cytokines with malarial anaemia. Methods We enrolled 175 African children with malaria into two studies in 1995 and 1996. In the first study, children were classified as having severe anaemia (n=10), uncomplicated malaria (n=26), or cerebral anaemia (n=41). In the second study, patients were classified as having cerebral malaria (n=33) or being fully conscious (n=65), and the two groups were subdivided by measured haemoglobin as normal (>110 g/L), moderate anaemia (60-90 g/L), and severe anaemia (<50 g/L). IL-10 and TNF concentrations were measured by ELISA in plasma samples from all patients. Findings IL-10 concentrations were significantly lower in patients with severe anaemia than in all other groups. In 1995, geometric mean plasma IL-10 in patients with severe anaemia was 270 pg/mL (95% CI 152-482) compared with 725 pg/mL (465-1129) in uncomplicated malaria and 966 pg/mL (612-1526) in cerebral malaria (p<0.03). In 1996, fully conscious patients with severe anaemia also had significantly lower IL-10 concentrations than all other groups, including cerebral-malaria patients with severe anaemia and all patients with moderate anaemia (p<0.001). In both studies, TNF concentrations were significantly higher in cerebral malaria than in fully conscious patients (p<0.01). By contrast, the ratio of TNF to IL-10 was significantly higher in fully conscious patients with severe anaemia than in all other groups (p<0.001). Interpretation Our findings identify severe malarial anaemia as a distinct disorder in which insufficient IL-10 response to high TNF concentrations may have a central role.	Noguchi Mem Inst Med Res, Immunol Unit, Legon, Ghana; Korle Bu Teaching Hosp, Dept Child Hlth, Accra, Ghana; Copenhagen Univ Hosp, RHIMA Ctr, Ctr Medlocal Parisitol, Copenhagen, Denmark; Univ Copenhagen, Inst Med Microbiol & Immunol, DK-1168 Copenhagen, Denmark; Inst Pasteur, Unite Immunol Mol Parasites, CNRS, URA 1960, Paris, France	University of Ghana; University of Copenhagen; University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kurtzhals, JAL (corresponding author), Rigshosp, Dept M7641, DK-2200 Copenhagen N, Denmark.	jkcmp@ncs.com.gh	Kurtzhals, Jorgen AL/I-8921-2012; Kurtzhals, Jorgen/Y-3799-2019; Hviid, Lars/G-3705-2012	Kurtzhals, Jorgen/0000-0003-2760-8713; Hviid, Lars/0000-0002-1698-4927				ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x; CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x; Clark IA, 1996, ADV PARASIT, V37, P1, DOI 10.1016/S0065-308X(08)60218-3; DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776; ECKWALANGA M, 1994, P NATL ACAD SCI USA, V91, P8097, DOI 10.1073/pnas.91.17.8097; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; HO M, 1995, J INFECT DIS, V172, P838, DOI 10.1093/infdis/172.3.838; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; Jakobsen PH, 1996, CLIN EXP IMMUNOL, V105, P69, DOI 10.1046/j.1365-2249.1996.d01-718.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MALEFYT RD, 1991, J EXP MED, V174, P1209; McHugh S, 1996, EUR J IMMUNOL, V26, P1260, DOI 10.1002/eji.1830260612; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; MOLYNEUX ME, 1989, Q J MED, V71, P441; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; PEYRON F, 1994, CLIN EXP IMMUNOL, V95, P300, DOI 10.1111/j.1365-2249.1994.tb06527.x; PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; RALPH P, 1992, J IMMUNOL, V148, P808; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; TAVERNE J, 1994, IMMUNOLOGY, V82, P397; Tsukahara H, 1997, BLOOD, V90, P473; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; VANVLASSELAER P, 1995, CLIN ORTHOP RELAT R, P103; Wang CQ, 1996, J CELL PHYSIOL, V166, P305, DOI 10.1002/(SICI)1097-4652(199602)166:2<305::AID-JCP8>3.0.CO;2-T; Waruiru CM, 1996, T ROY SOC TROP MED H, V90, P152, DOI 10.1016/S0035-9203(96)90120-0; WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734; WENISCH C, 1995, CLIN IMMUNOL IMMUNOP, V74, P115, DOI 10.1006/clin.1995.1017; WICKRAMASINGHE SN, 1987, BRIT J HAEMATOL, V66, P295, DOI 10.1111/j.1365-2141.1987.tb06913.x; YAP GS, 1994, INFECT IMMUN, V62, P357, DOI 10.1128/IAI.62.2.357-362.1994	36	248	252	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1998	351	9118					1768	1772		10.1016/S0140-6736(97)09439-7	http://dx.doi.org/10.1016/S0140-6736(97)09439-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635949				2022-12-24	WOS:000074197600010
J	Arnsten, AFT				Arnsten, AFT			Research: Neuroscience - The biology of being frazzled	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX; DOPAMINE TURNOVER; AMYGDALA; MODULATION; STRESS; RAT		Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06520 USA	Yale University	Arnsten, AFT (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	amy_arnsten@qm.yale.edu						AGGLETON JP, 1992, AMYGDALA; Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; Arnsten AFT, 1997, PHARMACOL BIOCHEM BE, V58, P55, DOI 10.1016/S0091-3057(96)00477-7; Cahill L, 1997, ANN NY ACAD SCI, V821, P238, DOI 10.1111/j.1749-6632.1997.tb48283.x; CAHILL L, IN PRESS TRENDS NEUR; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Goldstein LE, 1996, J NEUROSCI, V16, P4787; LAMONT EW, IN PRESS BRAIN RES; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; MAZURE CM, 1995, DOES STRESS CUASE PS; Murphy BL, 1996, P NATL ACAD SCI USA, V93, P1325, DOI 10.1073/pnas.93.3.1325; PACKARD MG, 1994, P NATL ACAD SCI USA, V91, P8477, DOI 10.1073/pnas.91.18.8477; Stuss D.T., 1986, FRONTAL LOBES; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Yang CR, 1996, J NEUROSCI, V16, P1922; Zahrt J, 1997, J NEUROSCI, V17, P8528	19	207	210	6	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1711	1712		10.1126/science.280.5370.1711	http://dx.doi.org/10.1126/science.280.5370.1711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZU446	9660710				2022-12-24	WOS:000074197800028
J	Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG				Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG			Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence	NATURE			English	Article							ANTIGEN; RESISTANCE; SURVIVAL; LEPRAE; REPEAT; SEARCH; CELLS; GENES; DNA	Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus. The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve our understanding of the biology of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions. The genome comprises 4,411,529 base pairs, contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in the biased amino-acid content of the proteins. M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the production of enzymes involved in lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.	Sanger Ctr, Hinxton CB10 1SA, England; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Mol Levures, F-75724 Paris 15, France; NIAID, TB Res Unit, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark	Wellcome Trust Sanger Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Technical University of Denmark	Barrell, BG (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	stcole@pasteur.fr; barrell@sanger.ac.uk	Brosch, Roland/ABB-4108-2021; Choobkar, Saeed/AAA-3212-2020; Salami, Aysan/AAZ-6730-2020; Tekaia, Fredj/H-4553-2012; Quail, michael/ABE-6131-2020; Barry, III, Clifton/H-3839-2012; Parkhill, Julian/G-4703-2011; Barry, Clifton E/ABE-7992-2020; Brosch, Roland/AAZ-3850-2021; Azadbakht, Morteza/ABA-2569-2020; Krogh, Anders/M-1541-2014	Barry, III, Clifton/0000-0002-2927-270X; Parkhill, Julian/0000-0002-7069-5958; Barry, Clifton E/0000-0002-2927-270X; Brosch, Roland/0000-0003-2587-3863; Azadbakht, Morteza/0000-0001-8103-3506; Gordon, Stephen/0000-0002-4833-5542; Murphy, Lee/0000-0001-6467-7449; Davies, Robert/0000-0002-9983-1378; Tekaia, Fredj/0000-0003-1934-2396; Krogh, Anders/0000-0002-5147-6282	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1991, INFECT IMMUN, V59, P2712, DOI 10.1128/IAI.59.8.2712-2718.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; BARRY CE, IN PRESS PROG LIPID; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bloom Barry R., 1994, P531; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Brennan Patrick J., 1994, P271; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chan J, 1994, TUBERCULOSIS PATHOGE, P271; COLE ST, 1995, EUR RESPIR J, V8, pS701; COLE ST, 1994, FEMS MICROBIOL REV, V14, P139, DOI 10.1016/0168-6445(94)90003-5; Cole ST, 1998, NOVART FDN SYMP, V217, P160, DOI 10.1002/0470846526.ch12; Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; HERMANS PWM, 1992, J BACTERIOL, V174, P4157, DOI 10.1128/jb.174.12.4157-4165.1992; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; RATLEDGE CR, 1982, BIOL MYCOBACTERIA, P53; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; Smith DR, 1997, GENOME RES, V7, P802, DOI 10.1101/gr.7.8.802; SNIDER DE, 1994, TUBERCULOSIS PATHOGE, P2; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Wheeler Paul R., 1994, P353; YOUNG DB, 1997, NEW GENERATION VACCI, P631	50	6153	10749	16	703	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					537	+		10.1038/31159	http://dx.doi.org/10.1038/31159			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634230	Bronze			2022-12-24	WOS:000074150100041
J	Nightingale, SL				Nightingale, SL			New mammography screening aid approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-24	WOS:000075050200006
J	Nightingale, SL				Nightingale, SL			New prescribing information about standardized grass pollen extracts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-24	WOS:000075050200009
